1|BACKGROUND: Sporadic or late onset Alzheimer's disease (LOAD) is a multifactorial neurodegenerative disease with aging the most known risk factor|Alzheimer's disease|Alzheimer's disease|disease|35|mesh:D000544|LOAD|LOAD|disease|56|mesh:D010900
1|BACKGROUND: Sporadic or late onset Alzheimer's disease (LOAD) is a multifactorial neurodegenerative disease with aging the most known risk factor|Alzheimer's disease|Alzheimer's disease|disease|35|mesh:D000544|neurodegenerative disease|neurodegenerative disease|disease|82|mesh:D019636
1|BACKGROUND: Sporadic or late onset Alzheimer's disease (LOAD) is a multifactorial neurodegenerative disease with aging the most known risk factor|LOAD|LOAD|disease|56|mesh:D010900|neurodegenerative disease|neurodegenerative disease|disease|82|mesh:D019636
1|We applied biochemical assays to measure tau phosphorylation and  multiple signaling pathways indicated in AD|tau|tau|gene|41|NCBIGene:4137|AD|AD|disease|107|mesh:D000544
1|We applied biochemical assays to measure tau phosphorylation and  multiple signaling pathways indicated in AD|tau|tau|gene|41|NCBIGene:4137|Signal Transduction Pathways|signaling pathways|physiology|75|C0086982
1|We applied biochemical assays to measure tau phosphorylation and  multiple signaling pathways indicated in AD|tau|tau|gene|41|NCBIGene:4137|Phosphorylation|phosphorylation|physiology|45|C0031715
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|tau|tau|gene|141|NCBIGene:4137|AD|AD|disease|27|mesh:D000544
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP|AMP|compound|189|mesh:D000249|AD|AD|disease|27|mesh:D000544
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP-activated protein kinase|AMP-activated protein kinase|gene|189|NCBIGene:203|AD|AD|disease|27|mesh:D000544
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMPK|AMPK|gene|219|NCBIGene:5563|AD|AD|disease|27|mesh:D000544
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516|AD|AD|disease|27|mesh:D000544
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|PP2A|PP2A|gene|275|NCBIGene:5524|AD|AD|disease|27|mesh:D000544
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AD|AD|disease|27|mesh:D000544|Hippocampus (Brain)|hippocampus|anatomy|100|C0019564
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AD|AD|disease|27|mesh:D000544|Post-Synaptic Density|postsynaptic densities|anatomy|327|C1817671
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AD|AD|disease|27|mesh:D000544|Prefrontal Cortex|[|anatomy|66|C0162783
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AD|AD|disease|27|mesh:D000544|Mitochondria|mitochondrial|anatomy|297|C0026237
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP|AMP|compound|189|mesh:D000249|tau|tau|gene|141|NCBIGene:4137
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|tau|tau|gene|141|NCBIGene:4137|AMP-activated protein kinase|AMP-activated protein kinase|gene|189|NCBIGene:203
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|tau|tau|gene|141|NCBIGene:4137|AMPK|AMPK|gene|219|NCBIGene:5563
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|tau|tau|gene|141|NCBIGene:4137|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|tau|tau|gene|141|NCBIGene:4137|PP2A|PP2A|gene|275|NCBIGene:5524
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|tau|tau|gene|141|NCBIGene:4137|Hippocampus (Brain)|hippocampus|anatomy|100|C0019564
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|tau|tau|gene|141|NCBIGene:4137|Impairments:-:Point in time:^Patient:-|impairments|physiology|282|C2598156
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|tau|tau|gene|141|NCBIGene:4137|Post-Synaptic Density|postsynaptic densities|anatomy|327|C1817671
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|tau|tau|gene|141|NCBIGene:4137|Prefrontal Cortex|[|anatomy|66|C0162783
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|tau|tau|gene|141|NCBIGene:4137|Mitochondria|mitochondrial|anatomy|297|C0026237
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|tau|tau|gene|141|NCBIGene:4137|Like|like|physiology|30|C0870814
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP|AMP|compound|189|mesh:D000249|AMPK|AMPK|gene|219|NCBIGene:5563
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP|AMP|compound|189|mesh:D000249|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP|AMP|compound|189|mesh:D000249|PP2A|PP2A|gene|275|NCBIGene:5524
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP|AMP|compound|189|mesh:D000249|Hippocampus (Brain)|hippocampus|anatomy|100|C0019564
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP|AMP|compound|189|mesh:D000249|Post-Synaptic Density|postsynaptic densities|anatomy|327|C1817671
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP|AMP|compound|189|mesh:D000249|Prefrontal Cortex|[|anatomy|66|C0162783
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP|AMP|compound|189|mesh:D000249|Mitochondria|mitochondrial|anatomy|297|C0026237
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP-activated protein kinase|AMP-activated protein kinase|gene|189|NCBIGene:203|AMPK|AMPK|gene|219|NCBIGene:5563
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP-activated protein kinase|AMP-activated protein kinase|gene|189|NCBIGene:203|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP-activated protein kinase|AMP-activated protein kinase|gene|189|NCBIGene:203|PP2A|PP2A|gene|275|NCBIGene:5524
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP-activated protein kinase|AMP-activated protein kinase|gene|189|NCBIGene:203|Hippocampus (Brain)|hippocampus|anatomy|100|C0019564
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP-activated protein kinase|AMP-activated protein kinase|gene|189|NCBIGene:203|Impairments:-:Point in time:^Patient:-|impairments|physiology|282|C2598156
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP-activated protein kinase|AMP-activated protein kinase|gene|189|NCBIGene:203|Post-Synaptic Density|postsynaptic densities|anatomy|327|C1817671
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP-activated protein kinase|AMP-activated protein kinase|gene|189|NCBIGene:203|Prefrontal Cortex|[|anatomy|66|C0162783
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP-activated protein kinase|AMP-activated protein kinase|gene|189|NCBIGene:203|Mitochondria|mitochondrial|anatomy|297|C0026237
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMP-activated protein kinase|AMP-activated protein kinase|gene|189|NCBIGene:203|Like|like|physiology|30|C0870814
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMPK|AMPK|gene|219|NCBIGene:5563|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMPK|AMPK|gene|219|NCBIGene:5563|PP2A|PP2A|gene|275|NCBIGene:5524
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMPK|AMPK|gene|219|NCBIGene:5563|Hippocampus (Brain)|hippocampus|anatomy|100|C0019564
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMPK|AMPK|gene|219|NCBIGene:5563|Impairments:-:Point in time:^Patient:-|impairments|physiology|282|C2598156
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMPK|AMPK|gene|219|NCBIGene:5563|Post-Synaptic Density|postsynaptic densities|anatomy|327|C1817671
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMPK|AMPK|gene|219|NCBIGene:5563|Prefrontal Cortex|[|anatomy|66|C0162783
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMPK|AMPK|gene|219|NCBIGene:5563|Mitochondria|mitochondrial|anatomy|297|C0026237
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|AMPK|AMPK|gene|219|NCBIGene:5563|Like|like|physiology|30|C0870814
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516|PP2A|PP2A|gene|275|NCBIGene:5524
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516|Hippocampus (Brain)|hippocampus|anatomy|100|C0019564
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516|Impairments:-:Point in time:^Patient:-|impairments|physiology|282|C2598156
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516|Post-Synaptic Density|postsynaptic densities|anatomy|327|C1817671
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516|Prefrontal Cortex|[|anatomy|66|C0162783
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516|Mitochondria|mitochondrial|anatomy|297|C0026237
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|protein phosphatase 2A|protein phosphatase 2A|gene|251|NCBIGene:5516|Like|like|physiology|30|C0870814
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|PP2A|PP2A|gene|275|NCBIGene:5524|Hippocampus (Brain)|hippocampus|anatomy|100|C0019564
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|PP2A|PP2A|gene|275|NCBIGene:5524|Impairments:-:Point in time:^Patient:-|impairments|physiology|282|C2598156
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|PP2A|PP2A|gene|275|NCBIGene:5524|Post-Synaptic Density|postsynaptic densities|anatomy|327|C1817671
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|PP2A|PP2A|gene|275|NCBIGene:5524|Prefrontal Cortex|[|anatomy|66|C0162783
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|PP2A|PP2A|gene|275|NCBIGene:5524|Mitochondria|mitochondrial|anatomy|297|C0026237
1|RESULTS: We found multiple AD-like pathological alteration in the prefrontal cortex (but not in the hippocampus) of the older NHPs including tau hyperphosphorylation, increased activity of AMP-activated protein kinase (AMPK),  decreased expression of protein phosphatase 2A (PP2A), impairments in mitochondrial morphology, and postsynaptic densities formation|PP2A|PP2A|gene|275|NCBIGene:5524|Like|like|physiology|30|C0870814
2|From our screen, knockdown of a Mitochondrial Complex I (MCI) subunit  gene (ND-20L) lowered levels of NMJ neurotransmission|Mitochondrial Complex I (MCI) subunit  gene|Mitochondrial Complex I (MCI) subunit  gene|gene|32|NCBIGene:4717|ND-20L|ND-20L|gene|77|NCBIGene:91860
2|From our screen, knockdown of a Mitochondrial Complex I (MCI) subunit  gene (ND-20L) lowered levels of NMJ neurotransmission|Mitochondrial Complex I (MCI) subunit  gene|Mitochondrial Complex I (MCI) subunit  gene|gene|32|NCBIGene:4717|Neuromuscular Junction|NMJ|anatomy|103|C0027869
2|From our screen, knockdown of a Mitochondrial Complex I (MCI) subunit  gene (ND-20L) lowered levels of NMJ neurotransmission|Mitochondrial Complex I (MCI) subunit  gene|Mitochondrial Complex I (MCI) subunit  gene|gene|32|NCBIGene:4717|Synaptic Transmission|neurotransmission|physiology|107|C0027793
2|From our screen, knockdown of a Mitochondrial Complex I (MCI) subunit  gene (ND-20L) lowered levels of NMJ neurotransmission|ND-20L|ND-20L|gene|77|NCBIGene:91860|Neuromuscular Junction|NMJ|anatomy|103|C0027869
2|From our screen, knockdown of a Mitochondrial Complex I (MCI) subunit  gene (ND-20L) lowered levels of NMJ neurotransmission|ND-20L|ND-20L|gene|77|NCBIGene:91860|Synaptic Transmission|neurotransmission|physiology|107|C0027793
2|Knockdown of core MCI subunits concurrently in neurons and muscle led to impaired neurotransmission|core MCI subunits|core MCI subunits|gene|13|NCBIGene:345643|Muscle (organ)|muscle|anatomy|59|C4083049
2|Knockdown of core MCI subunits concurrently in neurons and muscle led to impaired neurotransmission|core MCI subunits|core MCI subunits|gene|13|NCBIGene:345643|Neurons|neurons|anatomy|47|C0027882
2|Knockdown of core MCI subunits concurrently in neurons and muscle led to impaired neurotransmission|core MCI subunits|core MCI subunits|gene|13|NCBIGene:345643|Synaptic Transmission|neurotransmission|physiology|82|C0027793
2|Finally, MCI subunit knockdowns or pharmacological inhibition led to profound cytological defects, including reduced NMJ growth and altered NMJ morphology|MCI subunit|MCI subunit|gene|9|NCBIGene:345643|Metabolic Inhibition|inhibition|physiology|51|C0021469
2|Impaired Mitochondrial Complex I subunits in humans are associated with  disorders such as Parkinson's disease, Leigh syndrome, and cardiomyopathy|Mitochondrial Complex I subunits|Mitochondrial Complex I subunits|gene|9|NCBIGene:4723|Parkinson's disease|Parkinson's disease|disease|91|mesh:D010300
2|Impaired Mitochondrial Complex I subunits in humans are associated with  disorders such as Parkinson's disease, Leigh syndrome, and cardiomyopathy|Mitochondrial Complex I subunits|Mitochondrial Complex I subunits|gene|9|NCBIGene:4723|Leigh syndrome|Leigh syndrome|disease|112|omim:256000
2|Impaired Mitochondrial Complex I subunits in humans are associated with  disorders such as Parkinson's disease, Leigh syndrome, and cardiomyopathy|Mitochondrial Complex I subunits|Mitochondrial Complex I subunits|gene|9|NCBIGene:4723|cardiomyopathy|cardiomyopathy|disease|132|mesh:D009202
2|Impaired Mitochondrial Complex I subunits in humans are associated with  disorders such as Parkinson's disease, Leigh syndrome, and cardiomyopathy|Parkinson's disease|Parkinson's disease|disease|91|mesh:D010300|Leigh syndrome|Leigh syndrome|disease|112|omim:256000
2|Impaired Mitochondrial Complex I subunits in humans are associated with  disorders such as Parkinson's disease, Leigh syndrome, and cardiomyopathy|Parkinson's disease|Parkinson's disease|disease|91|mesh:D010300|cardiomyopathy|cardiomyopathy|disease|132|mesh:D009202
2|Impaired Mitochondrial Complex I subunits in humans are associated with  disorders such as Parkinson's disease, Leigh syndrome, and cardiomyopathy|Leigh syndrome|Leigh syndrome|disease|112|omim:256000|cardiomyopathy|cardiomyopathy|disease|132|mesh:D009202
2|Together, our data present an analysis of Complex I in the context of synapse function and plasticity|Complex I|Complex I|gene|42|NCBIGene:4723|contextual factors|context|physiology|59|C0542559
2|Together, our data present an analysis of Complex I in the context of synapse function and plasticity|Complex I|Complex I|gene|42|NCBIGene:4723|Function Axis|function|physiology|78|C0700205
3|Germinal matrix hemorrhage (GMH) is a common complication in preterm infants and  is associated with high risk of adverse neurodevelopmental outcomes|Germinal matrix hemorrhage|Germinal matrix hemorrhage|disease|0|mesh:D020300|GMH|GMH|disease|28|mesh:C562602
3|We used a rat GMH model and performed RNA sequencing to investigate the signaling pathways  and biological processes following hemorrhage|GMH|GMH|disease|14|mesh:C562602|hemorrhage|hemorrhage|disease|127|mesh:D006474
3|GMH induced brain injury characterized by early hematoma and subsequent tissue loss|GMH|GMH|compound|0|mesh:D005839|brain injury|brain injury|disease|12|mesh:D001930
3|GMH induced brain injury characterized by early hematoma and subsequent tissue loss|GMH|GMH|compound|0|mesh:D005839|hematoma|hematoma|disease|48|mesh:D006406
3|GMH induced brain injury characterized by early hematoma and subsequent tissue loss|GMH|GMH|compound|0|mesh:D005839|Body tissue|tissue|anatomy|72|C0040300
3|GMH induced brain injury characterized by early hematoma and subsequent tissue loss|brain injury|brain injury|disease|12|mesh:D001930|hematoma|hematoma|disease|48|mesh:D006406
3|GMH induced brain injury characterized by early hematoma and subsequent tissue loss|brain injury|brain injury|disease|12|mesh:D001930|Body tissue|tissue|anatomy|72|C0040300
3|GMH induced brain injury characterized by early hematoma and subsequent tissue loss|hematoma|hematoma|disease|48|mesh:D006406|Body tissue|tissue|anatomy|72|C0040300
3|At 6 hours after GMH, gene expression indicated an increase in mitochondrial activity such as ATP metabolism and oxidative phosphorylation along with upregulation of cytoprotective pathways and heme metabolism|ATP|ATP|compound|94|CHEBI:30616|heme|heme|compound|194|mesh:D006418
3|At 6 hours after GMH, gene expression indicated an increase in mitochondrial activity such as ATP metabolism and oxidative phosphorylation along with upregulation of cytoprotective pathways and heme metabolism|ATP|ATP|compound|94|CHEBI:30616|Mitochondria|mitochondrial|anatomy|63|C0026237
3|At 6 hours after GMH, gene expression indicated an increase in mitochondrial activity such as ATP metabolism and oxidative phosphorylation along with upregulation of cytoprotective pathways and heme metabolism|heme|heme|compound|194|mesh:D006418|Mitochondria|mitochondrial|anatomy|63|C0026237
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|heme|heme|compound|43|mesh:D006418|Hemoglobin|Hemoglobin|gene|0|NCBIGene:114757
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Hemoglobin|Hemoglobin|gene|0|NCBIGene:114757|ferroptosis|ferroptosis|disease|63|mesh:D012806
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Hemoglobin|Hemoglobin|gene|0|NCBIGene:114757|Hmox1|Hmox1|gene|83|NCBIGene:3162
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Hemoglobin|Hemoglobin|gene|0|NCBIGene:114757|Alox15|Alox15|gene|90|NCBIGene:246
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Hemoglobin|Hemoglobin|gene|0|NCBIGene:114757|Alas2|Alas2|gene|102|NCBIGene:212
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Hemoglobin|Hemoglobin|gene|0|NCBIGene:114757|heme metabolic process|heme metabolism|physiology|43|C1158226
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Hemoglobin|Hemoglobin|gene|0|NCBIGene:114757|Ferroptosis|ferroptosis|physiology|63|C4236737
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|heme|heme|compound|43|mesh:D006418|ferroptosis|ferroptosis|disease|63|mesh:D012806
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|heme|heme|compound|43|mesh:D006418|Hmox1|Hmox1|gene|83|NCBIGene:3162
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|heme|heme|compound|43|mesh:D006418|Alox15|Alox15|gene|90|NCBIGene:246
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|heme|heme|compound|43|mesh:D006418|Alas2|Alas2|gene|102|NCBIGene:212
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Hmox1|Hmox1|gene|83|NCBIGene:3162|ferroptosis|ferroptosis|disease|63|mesh:D012806
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Alox15|Alox15|gene|90|NCBIGene:246|ferroptosis|ferroptosis|disease|63|mesh:D012806
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Alas2|Alas2|gene|102|NCBIGene:212|ferroptosis|ferroptosis|disease|63|mesh:D012806
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Hmox1|Hmox1|gene|83|NCBIGene:3162|Alox15|Alox15|gene|90|NCBIGene:246
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Hmox1|Hmox1|gene|83|NCBIGene:3162|Alas2|Alas2|gene|102|NCBIGene:212
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Hmox1|Hmox1|gene|83|NCBIGene:3162|heme metabolic process|heme metabolism|physiology|43|C1158226
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Hmox1|Hmox1|gene|83|NCBIGene:3162|Ferroptosis|ferroptosis|physiology|63|C4236737
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Alox15|Alox15|gene|90|NCBIGene:246|Alas2|Alas2|gene|102|NCBIGene:212
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Alox15|Alox15|gene|90|NCBIGene:246|heme metabolic process|heme metabolism|physiology|43|C1158226
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Alox15|Alox15|gene|90|NCBIGene:246|Ferroptosis|ferroptosis|physiology|63|C4236737
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Alas2|Alas2|gene|102|NCBIGene:212|heme metabolic process|heme metabolism|physiology|43|C1158226
3|Hemoglobin components and genes related to heme metabolism and ferroptosis such as Hmox1, Alox15, and Alas2 were among the most upregulated genes|Alas2|Alas2|gene|102|NCBIGene:212|Ferroptosis|ferroptosis|physiology|63|C4236737
3|We observed dysregulation of processes involved in development, mitochondrial function, cholesterol biosynthesis, and inflammation, all of which  contribute to neurodevelopmental deterioration following GMH|cholesterol|cholesterol|compound|88|mesh:D002784|neurodevelopmental deterioration|neurodevelopmental deterioration|disease|160|mesh:D065886
3|We observed dysregulation of processes involved in development, mitochondrial function, cholesterol biosynthesis, and inflammation, all of which  contribute to neurodevelopmental deterioration following GMH|cholesterol|cholesterol|compound|88|mesh:D002784|GMH|GMH|disease|203|mesh:C562602
3|We observed dysregulation of processes involved in development, mitochondrial function, cholesterol biosynthesis, and inflammation, all of which  contribute to neurodevelopmental deterioration following GMH|cholesterol|cholesterol|compound|88|mesh:D002784|bony process|processes|anatomy|29|C1184743
3|We observed dysregulation of processes involved in development, mitochondrial function, cholesterol biosynthesis, and inflammation, all of which  contribute to neurodevelopmental deterioration following GMH|neurodevelopmental deterioration|neurodevelopmental deterioration|disease|160|mesh:D065886|GMH|GMH|disease|203|mesh:C562602
3|We observed dysregulation of processes involved in development, mitochondrial function, cholesterol biosynthesis, and inflammation, all of which  contribute to neurodevelopmental deterioration following GMH|neurodevelopmental deterioration|neurodevelopmental deterioration|disease|160|mesh:D065886|bony process|processes|anatomy|29|C1184743
3|We observed dysregulation of processes involved in development, mitochondrial function, cholesterol biosynthesis, and inflammation, all of which  contribute to neurodevelopmental deterioration following GMH|GMH|GMH|disease|203|mesh:C562602|bony process|processes|anatomy|29|C1184743
3|This study is the first temporal transcriptome profile providing a comprehensive overview of the molecular mechanisms underlying brain injury following GMH, and it provides useful guidance in the search for therapeutic interventions|brain injury|brain injury|disease|129|mesh:D001930|GMH|GMH|disease|152|mesh:C562602
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|doublecortin|doublecortin|gene|6|NCBIGene:1641|brain malformations|brain malformations|disease|62|mesh:D001927
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|doublecortin|doublecortin|gene|6|NCBIGene:1641|heterotopia|heterotopia|disease|122|mesh:D002828
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|doublecortin|doublecortin|gene|6|NCBIGene:1641|intellectual disability|intellectual disability|disease|136|mesh:D008607
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|doublecortin|doublecortin|gene|6|NCBIGene:1641|epilepsy|epilepsy|disease|164|mesh:D004827
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|doublecortin|doublecortin|gene|6|NCBIGene:1641|Mutation|mutations|physiology|25|C0026882
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|doublecortin|doublecortin|gene|6|NCBIGene:1641|Neurons|neuron|anatomy|102|C0027882
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|DCX|DCX|gene|20|NCBIGene:1641|brain malformations|brain malformations|disease|62|mesh:D001927
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|DCX|DCX|gene|20|NCBIGene:1641|heterotopia|heterotopia|disease|122|mesh:D002828
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|DCX|DCX|gene|20|NCBIGene:1641|intellectual disability|intellectual disability|disease|136|mesh:D008607
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|DCX|DCX|gene|20|NCBIGene:1641|epilepsy|epilepsy|disease|164|mesh:D004827
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|DCX|DCX|gene|20|NCBIGene:1641|Mutation|mutations|physiology|25|C0026882
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|DCX|DCX|gene|20|NCBIGene:1641|Neurons|neuron|anatomy|102|C0027882
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|brain malformations|brain malformations|disease|62|mesh:D001927|heterotopia|heterotopia|disease|122|mesh:D002828
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|brain malformations|brain malformations|disease|62|mesh:D001927|intellectual disability|intellectual disability|disease|136|mesh:D008607
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|brain malformations|brain malformations|disease|62|mesh:D001927|epilepsy|epilepsy|disease|164|mesh:D004827
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|brain malformations|brain malformations|disease|62|mesh:D001927|Neurons|neuron|anatomy|102|C0027882
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|heterotopia|heterotopia|disease|122|mesh:D002828|intellectual disability|intellectual disability|disease|136|mesh:D008607
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|heterotopia|heterotopia|disease|122|mesh:D002828|epilepsy|epilepsy|disease|164|mesh:D004827
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|heterotopia|heterotopia|disease|122|mesh:D002828|Neurons|neuron|anatomy|102|C0027882
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|intellectual disability|intellectual disability|disease|136|mesh:D008607|epilepsy|epilepsy|disease|164|mesh:D004827
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|intellectual disability|intellectual disability|disease|136|mesh:D008607|Neurons|neuron|anatomy|102|C0027882
4|Human doublecortin (DCX) mutations are associated with severe brain malformations leading to aberrant neuron positioning (heterotopia), intellectual disability and epilepsy|epilepsy|epilepsy|disease|164|mesh:D004827|Neurons|neuron|anatomy|102|C0027882
4|DCX is a microtubule-associated protein which plays a key role during neurodevelopment in neuronal migration and differentiation|DCX|DCX|gene|0|NCBIGene:1641|Cell Differentiation process|differentiation|physiology|113|C0007589
4|DCX is a microtubule-associated protein which plays a key role during neurodevelopment in neuronal migration and differentiation|DCX|DCX|gene|0|NCBIGene:1641|neuron migration|neuronal migration|physiology|90|C1326504
4|DCX is a microtubule-associated protein which plays a key role during neurodevelopment in neuronal migration and differentiation|DCX|DCX|gene|0|NCBIGene:1641|neurodevelopment|neurodevelopment|physiology|70|C0599855
4|Dcx knockout (KO) mice show disorganized hippocampal pyramidal neurons|Dcx|Dcx|gene|0|NCBIGene:1641|Pyramidal Cells|pyramidal neurons|anatomy|53|C0206441
4|Dcx knockout (KO) mice show disorganized hippocampal pyramidal neurons|Dcx|Dcx|gene|0|NCBIGene:1641|Hippocampus (Brain)|hippocampal|anatomy|41|C0019564
4|The CA2/CA3 pyramidal cell  layer is present as two abnormal layers and disorganized CA3 KO pyramidal neurons are also more excitable than wild-type (WT) cells|CA3 KO|CA3 KO|gene|85|NCBIGene:761|Pyramidal Cells|pyramidal neurons|anatomy|92|C0206441
4|To further identify abnormalities, we characterized Dcx KO hippocampal neurons at subcellular, molecular and ultrastructural levels|Dcx|Dcx|gene|52|NCBIGene:1641|Neurons|neurons|anatomy|71|C0027882
4|To further identify abnormalities, we characterized Dcx KO hippocampal neurons at subcellular, molecular and ultrastructural levels|Dcx|Dcx|gene|52|NCBIGene:1641|Hippocampus (Brain)|hippocampal|anatomy|59|C0019564
4|To further identify abnormalities, we characterized Dcx KO hippocampal neurons at subcellular, molecular and ultrastructural levels|Dcx|Dcx|gene|52|NCBIGene:1641|KELL NULL|KO|anatomy|56|C1862225
4|Locomotor activity and fear memory of young and mature adults were also abnormal: Dcx KO mice consistently performed less well than WT littermates, with defects becoming more severe with age|Dcx|Dcx|gene|82|NCBIGene:1641|Locomotion|Locomotor activity|physiology|0|C0023946
4|Locomotor activity and fear memory of young and mature adults were also abnormal: Dcx KO mice consistently performed less well than WT littermates, with defects becoming more severe with age|Dcx|Dcx|gene|82|NCBIGene:1641|Memory|memory|physiology|28|C0025260
5|Lysosomal storage diseases (LSDs) are inherited metabolic diseases caused by deficiency of lysosomal enzymes, essential for the normal development of the brain and other organs|Lysosomal storage diseases|Lysosomal storage diseases|disease|0|mesh:D016464|inherited metabolic diseases|inherited metabolic diseases|disease|38|mesh:D008661
5|Lysosomal storage diseases (LSDs) are inherited metabolic diseases caused by deficiency of lysosomal enzymes, essential for the normal development of the brain and other organs|Lysosomal storage diseases|Lysosomal storage diseases|disease|0|mesh:D016464|Organ|organs|anatomy|170|C0178784
5|Lysosomal storage diseases (LSDs) are inherited metabolic diseases caused by deficiency of lysosomal enzymes, essential for the normal development of the brain and other organs|LSDs|LSDs|disease|28|mesh:D016464|inherited metabolic diseases|inherited metabolic diseases|disease|38|mesh:D008661
5|Lysosomal storage diseases (LSDs) are inherited metabolic diseases caused by deficiency of lysosomal enzymes, essential for the normal development of the brain and other organs|LSDs|LSDs|disease|28|mesh:D016464|Organ|organs|anatomy|170|C0178784
5|Lysosomal storage diseases (LSDs) are inherited metabolic diseases caused by deficiency of lysosomal enzymes, essential for the normal development of the brain and other organs|inherited metabolic diseases|inherited metabolic diseases|disease|38|mesh:D008661|deficiency of lysosomal enzymes|deficiency of lysosomal enzymes|disease|77|mesh:D016464
5|Lysosomal storage diseases (LSDs) are inherited metabolic diseases caused by deficiency of lysosomal enzymes, essential for the normal development of the brain and other organs|inherited metabolic diseases|inherited metabolic diseases|disease|38|mesh:D008661|Organ|organs|anatomy|170|C0178784
5|Lysosomal storage diseases (LSDs) are inherited metabolic diseases caused by deficiency of lysosomal enzymes, essential for the normal development of the brain and other organs|deficiency of lysosomal enzymes|deficiency of lysosomal enzymes|disease|77|mesh:D016464|Organ|organs|anatomy|170|C0178784
5|Approximately two-thirds of the patients suffering from LSD exhibit neurological deficits and impose an escalating challenge to the medical and scientific field|LSD|LSD|disease|56|mesh:D016464|neurological deficits|neurological deficits|disease|68|mesh:D009461
5|The advent of induced pluripotent stem cell (iPSC)  technology has aided researchers in efficiently generating functional neuronal and non-neuronal cells through directed differentiation protocols, as well as in  decoding the cellular, subcellular, and molecular defects associated with LSDs using two-dimensional cultures and cerebral organoid models|LSDs|LSDs|disease|287|mesh:D016464|Organoids|organoid|anatomy|336|C0029250
5|The advent of induced pluripotent stem cell (iPSC)  technology has aided researchers in efficiently generating functional neuronal and non-neuronal cells through directed differentiation protocols, as well as in  decoding the cellular, subcellular, and molecular defects associated with LSDs using two-dimensional cultures and cerebral organoid models|LSDs|LSDs|disease|287|mesh:D016464|Cells|cellular|anatomy|226|C0007634
5|The advent of induced pluripotent stem cell (iPSC)  technology has aided researchers in efficiently generating functional neuronal and non-neuronal cells through directed differentiation protocols, as well as in  decoding the cellular, subcellular, and molecular defects associated with LSDs using two-dimensional cultures and cerebral organoid models|LSDs|LSDs|disease|287|mesh:D016464|Induced Pluripotent Stem Cells|induced pluripotent stem cell|anatomy|14|C2717959
5|This review highlights the information assembled from patient-derived iPSCs on neurodevelopmental and neuropathological defects identified in LSDs|neurodevelopmental and neuropathological defects|neurodevelopmental and neuropathological defects|disease|79|mesh:D065886|LSDs|LSDs|disease|142|mesh:D016464
5|Multiple studies have identified neural progenitor cell migration and differentiation defects, substrate accumulation, axon growth and myelination defects, impaired calcium homeostasis, and altered electrophysiological properties, using patient-derived iPSCs|axon|axon|disease|119|mesh:D012183|myelination defects|myelination defects|disease|135|mesh:D003711
5|Multiple studies have identified neural progenitor cell migration and differentiation defects, substrate accumulation, axon growth and myelination defects, impaired calcium homeostasis, and altered electrophysiological properties, using patient-derived iPSCs|calcium|calcium|compound|165|mesh:D002118|axon|axon|disease|119|mesh:D012183
5|Multiple studies have identified neural progenitor cell migration and differentiation defects, substrate accumulation, axon growth and myelination defects, impaired calcium homeostasis, and altered electrophysiological properties, using patient-derived iPSCs|axon|axon|disease|119|mesh:D012183|Induced Pluripotent Stem Cells|iPSCs|anatomy|253|C2717959
5|Multiple studies have identified neural progenitor cell migration and differentiation defects, substrate accumulation, axon growth and myelination defects, impaired calcium homeostasis, and altered electrophysiological properties, using patient-derived iPSCs|calcium|calcium|compound|165|mesh:D002118|myelination defects|myelination defects|disease|135|mesh:D003711
5|Multiple studies have identified neural progenitor cell migration and differentiation defects, substrate accumulation, axon growth and myelination defects, impaired calcium homeostasis, and altered electrophysiological properties, using patient-derived iPSCs|myelination defects|myelination defects|disease|135|mesh:D003711|Induced Pluripotent Stem Cells|iPSCs|anatomy|253|C2717959
5|Multiple studies have identified neural progenitor cell migration and differentiation defects, substrate accumulation, axon growth and myelination defects, impaired calcium homeostasis, and altered electrophysiological properties, using patient-derived iPSCs|calcium|calcium|compound|165|mesh:D002118|Induced Pluripotent Stem Cells|iPSCs|anatomy|253|C2717959
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neuroinflammation|neuroinflammation|disease|196|mesh:D020078|blood-brain barrier dysfunction|blood-brain barrier dysfunction|disease|216|mesh:D001927
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neuroinflammation|neuroinflammation|disease|196|mesh:D020078|neurodegeneration|neurodegeneration|disease|249|mesh:D009410
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neuroinflammation|neuroinflammation|disease|196|mesh:D020078|gliosis|gliosis|disease|268|mesh:D005911
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neuroinflammation|neuroinflammation|disease|196|mesh:D020078|LSDs|LSDs|disease|307|mesh:D016464
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neuroinflammation|neuroinflammation|disease|196|mesh:D020078|Cellular Vesicle|vesicle|anatomy|134|C1622418
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neuroinflammation|neuroinflammation|disease|196|mesh:D020078|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|82|C0014239
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neuroinflammation|neuroinflammation|disease|196|mesh:D020078|Golgi Apparatus|Golgi complex|anatomy|105|C0018042
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neuroinflammation|neuroinflammation|disease|196|mesh:D020078|Mitochondria|mitochondria|anatomy|68|C0026237
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neuroinflammation|neuroinflammation|disease|196|mesh:D020078|Lysosomes|lysosomes|anatomy|57|C0024369
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|blood-brain barrier dysfunction|blood-brain barrier dysfunction|disease|216|mesh:D001927|neurodegeneration|neurodegeneration|disease|249|mesh:D009410
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|blood-brain barrier dysfunction|blood-brain barrier dysfunction|disease|216|mesh:D001927|gliosis|gliosis|disease|268|mesh:D005911
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|blood-brain barrier dysfunction|blood-brain barrier dysfunction|disease|216|mesh:D001927|LSDs|LSDs|disease|307|mesh:D016464
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|blood-brain barrier dysfunction|blood-brain barrier dysfunction|disease|216|mesh:D001927|Cellular Vesicle|vesicle|anatomy|134|C1622418
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|blood-brain barrier dysfunction|blood-brain barrier dysfunction|disease|216|mesh:D001927|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|82|C0014239
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|blood-brain barrier dysfunction|blood-brain barrier dysfunction|disease|216|mesh:D001927|Golgi Apparatus|Golgi complex|anatomy|105|C0018042
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|blood-brain barrier dysfunction|blood-brain barrier dysfunction|disease|216|mesh:D001927|Mitochondria|mitochondria|anatomy|68|C0026237
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|blood-brain barrier dysfunction|blood-brain barrier dysfunction|disease|216|mesh:D001927|Lysosomes|lysosomes|anatomy|57|C0024369
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neurodegeneration|neurodegeneration|disease|249|mesh:D009410|gliosis|gliosis|disease|268|mesh:D005911
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neurodegeneration|neurodegeneration|disease|249|mesh:D009410|LSDs|LSDs|disease|307|mesh:D016464
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neurodegeneration|neurodegeneration|disease|249|mesh:D009410|Cellular Vesicle|vesicle|anatomy|134|C1622418
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neurodegeneration|neurodegeneration|disease|249|mesh:D009410|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|82|C0014239
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neurodegeneration|neurodegeneration|disease|249|mesh:D009410|Golgi Apparatus|Golgi complex|anatomy|105|C0018042
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neurodegeneration|neurodegeneration|disease|249|mesh:D009410|Mitochondria|mitochondria|anatomy|68|C0026237
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|neurodegeneration|neurodegeneration|disease|249|mesh:D009410|Lysosomes|lysosomes|anatomy|57|C0024369
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|gliosis|gliosis|disease|268|mesh:D005911|LSDs|LSDs|disease|307|mesh:D016464
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|gliosis|gliosis|disease|268|mesh:D005911|Cellular Vesicle|vesicle|anatomy|134|C1622418
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|gliosis|gliosis|disease|268|mesh:D005911|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|82|C0014239
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|gliosis|gliosis|disease|268|mesh:D005911|Golgi Apparatus|Golgi complex|anatomy|105|C0018042
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|gliosis|gliosis|disease|268|mesh:D005911|Mitochondria|mitochondria|anatomy|68|C0026237
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|gliosis|gliosis|disease|268|mesh:D005911|Lysosomes|lysosomes|anatomy|57|C0024369
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|LSDs|LSDs|disease|307|mesh:D016464|Cellular Vesicle|vesicle|anatomy|134|C1622418
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|LSDs|LSDs|disease|307|mesh:D016464|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|82|C0014239
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|LSDs|LSDs|disease|307|mesh:D016464|Golgi Apparatus|Golgi complex|anatomy|105|C0018042
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|LSDs|LSDs|disease|307|mesh:D016464|Mitochondria|mitochondria|anatomy|68|C0026237
5|In addition, these studies have also uncovered defective lysosomes, mitochondria, endoplasmic reticulum, Golgi complex, autophagy and vesicle trafficking and signaling pathways, oxidative stress, neuroinflammation,  blood-brain barrier dysfunction, neurodegeneration, gliosis, and altered transcriptomes in LSDs|LSDs|LSDs|disease|307|mesh:D016464|Lysosomes|lysosomes|anatomy|57|C0024369
5|The review also discusses the therapeutic applications such as drug discovery, repurposing of drugs, synergistic effects of drugs, targeted molecular therapies, gene therapy, and transplantation applications of mutation-corrected lines identified using patient-derived iPSCs for different LSDs|LSDs|LSDs|disease|289|mesh:D016464|Induced Pluripotent Stem Cells|iPSCs|anatomy|269|C2717959
6|Broadband near-infrared spectroscopy (bNIRS) provides the opportunity to explore the relationship between cerebral energy metabolism and blood oxygenation/haemodynamics through the measurement of changes in the oxidation state of mitochondrial respiratory chain enzyme cytochrome-c-oxidase (ΔoxCCO) alongside haemodynamic changes|cytochrome-c-oxidase|cytochrome-c-oxidase|gene|269|NCBIGene:6775083|oxCCO|oxCCO|gene|291|NCBIGene:6261
6|Broadband near-infrared spectroscopy (bNIRS) provides the opportunity to explore the relationship between cerebral energy metabolism and blood oxygenation/haemodynamics through the measurement of changes in the oxidation state of mitochondrial respiratory chain enzyme cytochrome-c-oxidase (ΔoxCCO) alongside haemodynamic changes|cytochrome-c-oxidase|cytochrome-c-oxidase|gene|269|NCBIGene:6775083|Hemodynamics|haemodynamic|physiology|309|C0019010
6|Broadband near-infrared spectroscopy (bNIRS) provides the opportunity to explore the relationship between cerebral energy metabolism and blood oxygenation/haemodynamics through the measurement of changes in the oxidation state of mitochondrial respiratory chain enzyme cytochrome-c-oxidase (ΔoxCCO) alongside haemodynamic changes|cytochrome-c-oxidase|cytochrome-c-oxidase|gene|269|NCBIGene:6775083|Hemodynamics|haemodynamics|physiology|155|C0019010
6|Broadband near-infrared spectroscopy (bNIRS) provides the opportunity to explore the relationship between cerebral energy metabolism and blood oxygenation/haemodynamics through the measurement of changes in the oxidation state of mitochondrial respiratory chain enzyme cytochrome-c-oxidase (ΔoxCCO) alongside haemodynamic changes|cytochrome-c-oxidase|cytochrome-c-oxidase|gene|269|NCBIGene:6775083|Oxidation|oxidation|physiology|211|C0030011
6|Broadband near-infrared spectroscopy (bNIRS) provides the opportunity to explore the relationship between cerebral energy metabolism and blood oxygenation/haemodynamics through the measurement of changes in the oxidation state of mitochondrial respiratory chain enzyme cytochrome-c-oxidase (ΔoxCCO) alongside haemodynamic changes|cytochrome-c-oxidase|cytochrome-c-oxidase|gene|269|NCBIGene:6775083|Alveolar ventilation function|oxygenation|physiology|143|C0231940
6|Broadband near-infrared spectroscopy (bNIRS) provides the opportunity to explore the relationship between cerebral energy metabolism and blood oxygenation/haemodynamics through the measurement of changes in the oxidation state of mitochondrial respiratory chain enzyme cytochrome-c-oxidase (ΔoxCCO) alongside haemodynamic changes|oxCCO|oxCCO|gene|291|NCBIGene:6261|Hemodynamics|haemodynamic|physiology|309|C0019010
6|Broadband near-infrared spectroscopy (bNIRS) provides the opportunity to explore the relationship between cerebral energy metabolism and blood oxygenation/haemodynamics through the measurement of changes in the oxidation state of mitochondrial respiratory chain enzyme cytochrome-c-oxidase (ΔoxCCO) alongside haemodynamic changes|oxCCO|oxCCO|gene|291|NCBIGene:6261|Hemodynamics|haemodynamics|physiology|155|C0019010
6|Broadband near-infrared spectroscopy (bNIRS) provides the opportunity to explore the relationship between cerebral energy metabolism and blood oxygenation/haemodynamics through the measurement of changes in the oxidation state of mitochondrial respiratory chain enzyme cytochrome-c-oxidase (ΔoxCCO) alongside haemodynamic changes|oxCCO|oxCCO|gene|291|NCBIGene:6261|Oxidation|oxidation|physiology|211|C0030011
6|Broadband near-infrared spectroscopy (bNIRS) provides the opportunity to explore the relationship between cerebral energy metabolism and blood oxygenation/haemodynamics through the measurement of changes in the oxidation state of mitochondrial respiratory chain enzyme cytochrome-c-oxidase (ΔoxCCO) alongside haemodynamic changes|oxCCO|oxCCO|gene|291|NCBIGene:6261|Alveolar ventilation function|oxygenation|physiology|143|C0231940
7|Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for  the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain|Coenzyme|Coenzyme|compound|0|mesh:D003067|homologue of yeast coq8|homologue of yeast coq8|gene|25|NCBIGene:56997
7|Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for  the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain|Coenzyme|Coenzyme|compound|0|mesh:D003067|ATPase|ATPase|gene|53|NCBIGene:1769
7|Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for  the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain|Coenzyme|Coenzyme|compound|0|mesh:D003067|Coenzyme Q10|Coenzyme Q10|compound|102|mesh:C024989
7|Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for  the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain|Coenzyme Q8A|Coenzyme Q8A|gene|0|NCBIGene:56997|ATPase|ATPase|gene|53|NCBIGene:1769
7|Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for  the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain|Coenzyme Q10|Coenzyme Q10|compound|102|mesh:C024989|Coenzyme Q8A|Coenzyme Q8A|gene|0|NCBIGene:56997
7|Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for  the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain|Coenzyme Q8A|Coenzyme Q8A|gene|0|NCBIGene:56997|electron transport chain|electron transport chain|physiology|146|C2244392
7|Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for  the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain|homologue of yeast coq8|homologue of yeast coq8|gene|25|NCBIGene:56997|ATPase|ATPase|gene|53|NCBIGene:1769
7|Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for  the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain|Coenzyme Q10|Coenzyme Q10|compound|102|mesh:C024989|homologue of yeast coq8|homologue of yeast coq8|gene|25|NCBIGene:56997
7|Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for  the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain|homologue of yeast coq8|homologue of yeast coq8|gene|25|NCBIGene:56997|electron transport chain|electron transport chain|physiology|146|C2244392
7|Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for  the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain|Coenzyme Q10|Coenzyme Q10|compound|102|mesh:C024989|ATPase|ATPase|gene|53|NCBIGene:1769
7|Coenzyme Q8A encodes the homologue of yeast coq8, an ATPase that is required for  the biosynthesis of Coenzyme Q10, an essential component of the electron transport chain|ATPase|ATPase|gene|53|NCBIGene:1769|electron transport chain|electron transport chain|physiology|146|C2244392
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|COQ8A|COQ8A|gene|13|NCBIGene:56997|CoQ10 deficiency|CoQ10 deficiency|disease|39|mesh:C564403
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|CoQ10|CoQ10|compound|39|mesh:C024989|COQ8A|COQ8A|gene|13|NCBIGene:56997
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|COQ8A|COQ8A|gene|13|NCBIGene:56997|cerebellar ataxia|cerebellar ataxia|disease|108|mesh:D001259
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|COQ8A|COQ8A|gene|13|NCBIGene:56997|seizures|seizures|disease|127|mesh:D012640
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|COQ8A|COQ8A|gene|13|NCBIGene:56997|intellectual disability|intellectual disability|disease|140|mesh:D008607
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|COQ8A|COQ8A|gene|13|NCBIGene:56997|Mutation|Mutations|physiology|0|C0026882
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|COQ8A|COQ8A|gene|13|NCBIGene:56997|clinical aspects|clinical features|physiology|61|C0683325
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|CoQ10 deficiency|CoQ10 deficiency|disease|39|mesh:C564403|cerebellar ataxia|cerebellar ataxia|disease|108|mesh:D001259
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|CoQ10 deficiency|CoQ10 deficiency|disease|39|mesh:C564403|seizures|seizures|disease|127|mesh:D012640
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|CoQ10 deficiency|CoQ10 deficiency|disease|39|mesh:C564403|intellectual disability|intellectual disability|disease|140|mesh:D008607
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|CoQ10|CoQ10|compound|39|mesh:C024989|cerebellar ataxia|cerebellar ataxia|disease|108|mesh:D001259
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|CoQ10|CoQ10|compound|39|mesh:C024989|seizures|seizures|disease|127|mesh:D012640
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|CoQ10|CoQ10|compound|39|mesh:C024989|intellectual disability|intellectual disability|disease|140|mesh:D008607
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|cerebellar ataxia|cerebellar ataxia|disease|108|mesh:D001259|seizures|seizures|disease|127|mesh:D012640
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|cerebellar ataxia|cerebellar ataxia|disease|108|mesh:D001259|intellectual disability|intellectual disability|disease|140|mesh:D008607
7|Mutations in COQ8A in humans result in CoQ10 deficiency, the clinical features of which include early-onset cerebellar ataxia, seizures and intellectual disability|seizures|seizures|disease|127|mesh:D012640|intellectual disability|intellectual disability|disease|140|mesh:D008607
7|The rapid advancement of massively parallel sequencing has resulted in the identification of more than 40 new mutations in COQ8A and functional studies are required to confirm causality and to further research into determining the specific mechanisms through which the mutations result in loss of function|COQ8A|COQ8A|gene|123|NCBIGene:56997|Mutation|mutations|physiology|269|C0026882
7|The rapid advancement of massively parallel sequencing has resulted in the identification of more than 40 new mutations in COQ8A and functional studies are required to confirm causality and to further research into determining the specific mechanisms through which the mutations result in loss of function|COQ8A|COQ8A|gene|123|NCBIGene:56997|Function Axis|function|physiology|297|C0700205
7|The rapid advancement of massively parallel sequencing has resulted in the identification of more than 40 new mutations in COQ8A and functional studies are required to confirm causality and to further research into determining the specific mechanisms through which the mutations result in loss of function|COQ8A|COQ8A|gene|123|NCBIGene:56997|Identification (Psychology)|identification|physiology|75|C0020792
7|To that end, a Drosophila model of Coq8 deficiency was developed and characterized to determine its appropriateness as a model system to further explore the role of Coq8 in the brain, and for functional characterisation of Coq8 mutations|Coq8|Coq8|gene|165|NCBIGene:56997|Coq8 deficiency|Coq8 deficiency|disease|35|mesh:C564403
7|To that end, a Drosophila model of Coq8 deficiency was developed and characterized to determine its appropriateness as a model system to further explore the role of Coq8 in the brain, and for functional characterisation of Coq8 mutations|Coq8 mutations|Coq8 mutations|gene|223|NCBIGene:56997|Coq8 deficiency|Coq8 deficiency|disease|35|mesh:C564403
7|To that end, a Drosophila model of Coq8 deficiency was developed and characterized to determine its appropriateness as a model system to further explore the role of Coq8 in the brain, and for functional characterisation of Coq8 mutations|Coq8 deficiency|Coq8 deficiency|disease|35|mesh:C564403|Brain|brain|anatomy|177|C0006104
7|To that end, a Drosophila model of Coq8 deficiency was developed and characterized to determine its appropriateness as a model system to further explore the role of Coq8 in the brain, and for functional characterisation of Coq8 mutations|Coq8|Coq8|gene|35|NCBIGene:56997|Brain|brain|anatomy|177|C0006104
7|To that end, a Drosophila model of Coq8 deficiency was developed and characterized to determine its appropriateness as a model system to further explore the role of Coq8 in the brain, and for functional characterisation of Coq8 mutations|Coq8|Coq8|gene|35|NCBIGene:56997|Vendor model number:ID:Pt:{Device}:Nom|model|physiology|26|C3833412
7|To that end, a Drosophila model of Coq8 deficiency was developed and characterized to determine its appropriateness as a model system to further explore the role of Coq8 in the brain, and for functional characterisation of Coq8 mutations|Coq8|Coq8|gene|35|NCBIGene:56997|Mutation|mutations|physiology|228|C0026882
7|To that end, a Drosophila model of Coq8 deficiency was developed and characterized to determine its appropriateness as a model system to further explore the role of Coq8 in the brain, and for functional characterisation of Coq8 mutations|Coq8|Coq8|gene|165|NCBIGene:56997|Brain|brain|anatomy|177|C0006104
7|To that end, a Drosophila model of Coq8 deficiency was developed and characterized to determine its appropriateness as a model system to further explore the role of Coq8 in the brain, and for functional characterisation of Coq8 mutations|Coq8|Coq8|gene|165|NCBIGene:56997|Vendor model number:ID:Pt:{Device}:Nom|model|physiology|26|C3833412
7|To that end, a Drosophila model of Coq8 deficiency was developed and characterized to determine its appropriateness as a model system to further explore the role of Coq8 in the brain, and for functional characterisation of Coq8 mutations|Coq8|Coq8|gene|165|NCBIGene:56997|Mutation|mutations|physiology|228|C0026882
7|To that end, a Drosophila model of Coq8 deficiency was developed and characterized to determine its appropriateness as a model system to further explore the role of Coq8 in the brain, and for functional characterisation of Coq8 mutations|Coq8 mutations|Coq8 mutations|gene|223|NCBIGene:56997|Brain|brain|anatomy|177|C0006104
7|To that end, a Drosophila model of Coq8 deficiency was developed and characterized to determine its appropriateness as a model system to further explore the role of Coq8 in the brain, and for functional characterisation of Coq8 mutations|Coq8 mutations|Coq8 mutations|gene|223|NCBIGene:56997|Vendor model number:ID:Pt:{Device}:Nom|model|physiology|26|C3833412
7|Pan-neuronal RNAi knockdown of Coq8 was largely lethal, with female escapers displaying severe locomotor deficits|Coq8|Coq8|gene|31|NCBIGene:56997|Females|female|physiology|61|C0086287
7|Pan-neuronal RNAi knockdown of Coq8 was largely lethal, with female escapers displaying severe locomotor deficits|Coq8|Coq8|gene|31|NCBIGene:56997|RNA Interference|RNAi|physiology|13|C1136031
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|Coq8|Coq8|gene|13|NCBIGene:56997|degeneration of|degeneration of|disease|41|mesh:D019636
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|Coq8|Coq8|gene|13|NCBIGene:56997|progressive|progressive|disease|73|mesh:D018450
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|Coq8|Coq8|gene|13|NCBIGene:56997|necrosis|necrosis|disease|85|mesh:D009336
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|oxygen|oxygen|compound|131|mesh:D010100|Coq8|Coq8|gene|13|NCBIGene:56997
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|Coq8|Coq8|gene|13|NCBIGene:56997|Eye|eye|anatomy|25|C0015392
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|Coq8|Coq8|gene|13|NCBIGene:56997|Necrosis|necrosis|physiology|85|C0027540
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|degeneration of|degeneration of|disease|41|mesh:D019636|progressive|progressive|disease|73|mesh:D018450
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|degeneration of|degeneration of|disease|41|mesh:D019636|necrosis|necrosis|disease|85|mesh:D009336
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|oxygen|oxygen|compound|131|mesh:D010100|degeneration of|degeneration of|disease|41|mesh:D019636
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|degeneration of|degeneration of|disease|41|mesh:D019636|Eye|eye|anatomy|25|C0015392
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|progressive|progressive|disease|73|mesh:D018450|necrosis|necrosis|disease|85|mesh:D009336
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|oxygen|oxygen|compound|131|mesh:D010100|progressive|progressive|disease|73|mesh:D018450
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|progressive|progressive|disease|73|mesh:D018450|Eye|eye|anatomy|25|C0015392
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|oxygen|oxygen|compound|131|mesh:D010100|necrosis|necrosis|disease|85|mesh:D009336
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|necrosis|necrosis|disease|85|mesh:D009336|Eye|eye|anatomy|25|C0015392
7|Knockdown of Coq8 in the eye resulted in degeneration of photoreceptors, progressive necrosis and increased generation of reactive oxygen species|oxygen|oxygen|compound|131|mesh:D010100|Eye|eye|anatomy|25|C0015392
7|Reintroduction of wild-type Coq8 restored normal function, however expression of human wild-type COQ8A exacerbated the eye phenotype, suggesting it was acting as a dominant-negative|wild-type Coq8|wild-type Coq8|gene|18|NCBIGene:56997|Phenotype|phenotype|physiology|123|C0031437
7|Reintroduction of wild-type Coq8 restored normal function, however expression of human wild-type COQ8A exacerbated the eye phenotype, suggesting it was acting as a dominant-negative|wild-type Coq8|wild-type Coq8|gene|18|NCBIGene:56997|Eye|eye|anatomy|119|C0015392
7|Reintroduction of wild-type Coq8 restored normal function, however expression of human wild-type COQ8A exacerbated the eye phenotype, suggesting it was acting as a dominant-negative|human wild-type COQ8A|human wild-type COQ8A|gene|81|NCBIGene:56997|Phenotype|phenotype|physiology|123|C0031437
7|Reintroduction of wild-type Coq8 restored normal function, however expression of human wild-type COQ8A exacerbated the eye phenotype, suggesting it was acting as a dominant-negative|human wild-type COQ8A|human wild-type COQ8A|gene|81|NCBIGene:56997|Eye|eye|anatomy|119|C0015392
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|Drosophila Coq8|Drosophila Coq8|gene|70|NCBIGene:56997|Coq8 deficiency|Coq8 deficiency|disease|163|mesh:C564403
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|Drosophila Coq8|Drosophila Coq8|gene|70|NCBIGene:56997|Vendor model number:ID:Pt:{Device}:Nom|model|physiology|5|C3833412
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|Drosophila Coq8|Drosophila Coq8|gene|70|NCBIGene:56997|Mutation|mutations|physiology|108|C0026882
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|Drosophila Coq8|Drosophila Coq8|gene|70|NCBIGene:56997|Function Axis|function|physiology|58|C0700205
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|human COQ8A mutations|human COQ8A mutations|gene|96|NCBIGene:56997|Coq8 deficiency|Coq8 deficiency|disease|163|mesh:C564403
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|human COQ8A mutations|human COQ8A mutations|gene|96|NCBIGene:56997|Vendor model number:ID:Pt:{Device}:Nom|model|physiology|5|C3833412
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|human COQ8A mutations|human COQ8A mutations|gene|96|NCBIGene:56997|Function Axis|function|physiology|58|C0700205
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|hCOQ8A|hCOQ8A|gene|140|NCBIGene:56997|Coq8 deficiency|Coq8 deficiency|disease|163|mesh:C564403
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|hCOQ8A|hCOQ8A|gene|140|NCBIGene:56997|Vendor model number:ID:Pt:{Device}:Nom|model|physiology|5|C3833412
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|hCOQ8A|hCOQ8A|gene|140|NCBIGene:56997|Mutation|mutations|physiology|108|C0026882
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|hCOQ8A|hCOQ8A|gene|140|NCBIGene:56997|Function Axis|function|physiology|58|C0700205
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|Coq8|Coq8|gene|163|NCBIGene:56997|Vendor model number:ID:Pt:{Device}:Nom|model|physiology|5|C3833412
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|Coq8|Coq8|gene|163|NCBIGene:56997|Mutation|mutations|physiology|108|C0026882
7|This model is therefore informative for investigating the function of Drosophila Coq8, however  human COQ8A mutations cannot be assessed as hCOQ8A does not rescue Coq8 deficiency|Coq8|Coq8|gene|163|NCBIGene:56997|Function Axis|function|physiology|58|C0700205
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|aspartate|aspartate|compound|53|mesh:D001224|AGC1|AGC1|gene|0|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|glutamate|glutamate|compound|63|mesh:D018698|AGC1|AGC1|gene|0|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|NADH|NADH|compound|106|mesh:D009243|AGC1|AGC1|gene|0|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|malate-|malate-|compound|111|CHEBI:30797|AGC1|AGC1|gene|0|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|aspartate|aspartate|compound|118|mesh:D001224|AGC1|AGC1|gene|0|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|AGC1|AGC1|gene|0|NCBIGene:8604|Malate-Aspartate Shuttle Pathway|malate-aspartate shuttle|physiology|111|C1518158
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|AGC1|AGC1|gene|0|NCBIGene:8604|Mitochondria|mitochondria|anatomy|191|C0026237
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|AGC1|AGC1|gene|0|NCBIGene:8604|Oxidation-Reduction|redox|physiology|167|C0030012
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|aspartate|aspartate|compound|53|mesh:D001224|Aralar|Aralar|gene|5|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|glutamate|glutamate|compound|63|mesh:D018698|Aralar|Aralar|gene|5|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|NADH|NADH|compound|106|mesh:D009243|Aralar|Aralar|gene|5|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|malate-|malate-|compound|111|CHEBI:30797|Aralar|Aralar|gene|5|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|aspartate|aspartate|compound|118|mesh:D001224|Aralar|Aralar|gene|5|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|Aralar|Aralar|gene|5|NCBIGene:8604|Malate-Aspartate Shuttle Pathway|malate-aspartate shuttle|physiology|111|C1518158
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|Aralar|Aralar|gene|5|NCBIGene:8604|Mitochondria|mitochondria|anatomy|191|C0026237
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|Aralar|Aralar|gene|5|NCBIGene:8604|Oxidation-Reduction|redox|physiology|167|C0030012
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|aspartate|aspartate|compound|53|mesh:D001224|Slc25a12|Slc25a12|gene|12|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|glutamate|glutamate|compound|63|mesh:D018698|Slc25a12|Slc25a12|gene|12|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|NADH|NADH|compound|106|mesh:D009243|Slc25a12|Slc25a12|gene|12|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|malate-|malate-|compound|111|CHEBI:30797|Slc25a12|Slc25a12|gene|12|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|aspartate|aspartate|compound|118|mesh:D001224|Slc25a12|Slc25a12|gene|12|NCBIGene:8604
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|Slc25a12|Slc25a12|gene|12|NCBIGene:8604|Malate-Aspartate Shuttle Pathway|malate-aspartate shuttle|physiology|111|C1518158
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|Slc25a12|Slc25a12|gene|12|NCBIGene:8604|Mitochondria|mitochondria|anatomy|191|C0026237
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|Slc25a12|Slc25a12|gene|12|NCBIGene:8604|Oxidation-Reduction|redox|physiology|167|C0030012
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|aspartate|aspartate|compound|53|mesh:D001224|glutamate|glutamate|compound|63|mesh:D018698
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|aspartate|aspartate|compound|53|mesh:D001224|NADH|NADH|compound|106|mesh:D009243
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|aspartate|aspartate|compound|53|mesh:D001224|malate-|malate-|compound|111|CHEBI:30797
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|aspartate|aspartate|compound|53|mesh:D001224|Mitochondria|mitochondria|anatomy|191|C0026237
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|glutamate|glutamate|compound|63|mesh:D018698|NADH|NADH|compound|106|mesh:D009243
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|glutamate|glutamate|compound|63|mesh:D018698|malate-|malate-|compound|111|CHEBI:30797
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|glutamate|glutamate|compound|63|mesh:D018698|aspartate|aspartate|compound|118|mesh:D001224
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|glutamate|glutamate|compound|63|mesh:D018698|Mitochondria|mitochondria|anatomy|191|C0026237
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|NADH|NADH|compound|106|mesh:D009243|malate-|malate-|compound|111|CHEBI:30797
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|NADH|NADH|compound|106|mesh:D009243|aspartate|aspartate|compound|118|mesh:D001224
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|NADH|NADH|compound|106|mesh:D009243|Mitochondria|mitochondria|anatomy|191|C0026237
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|malate-|malate-|compound|111|CHEBI:30797|aspartate|aspartate|compound|118|mesh:D001224
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|malate-|malate-|compound|111|CHEBI:30797|Mitochondria|mitochondria|anatomy|191|C0026237
8|AGC1/Aralar/Slc25a12 is the mitochondrial carrier of aspartate-glutamate, the regulatory component of the NADH malate-aspartate shuttle (MAS) that transfers cytosolic redox power to neuronal mitochondria|aspartate|aspartate|compound|118|mesh:D001224|Mitochondria|mitochondria|anatomy|191|C0026237
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|deficiency in AGC1/Aralar|deficiency in AGC1/Aralar|disease|4|omim:207800|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|deficiency in AGC1/Aralar|deficiency in AGC1/Aralar|disease|4|omim:207800|EIEE 39|EIEE 39|disease|115|mesh:C567404
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|deficiency in AGC1/Aralar|deficiency in AGC1/Aralar|disease|4|omim:207800|epilepsy|epilepsy|disease|156|mesh:D004827
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|deficiency in AGC1/Aralar|deficiency in AGC1/Aralar|disease|4|omim:207800|hypotonia|hypotonia|disease|166|mesh:D009123
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|deficiency in AGC1/Aralar|deficiency in AGC1/Aralar|disease|4|omim:207800|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|deficiency in AGC1/Aralar|deficiency in AGC1/Aralar|disease|4|omim:207800|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|deficiency in AGC1/Aralar|deficiency in AGC1/Aralar|disease|4|omim:207800
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Asp|Asp|compound|272|CHEBI:17053|deficiency in AGC1/Aralar|deficiency in AGC1/Aralar|disease|4|omim:207800
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179|deficiency in AGC1/Aralar|deficiency in AGC1/Aralar|disease|4|omim:207800
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|NAA|NAA|compound|300|CHEBI:21547|deficiency in AGC1/Aralar|deficiency in AGC1/Aralar|disease|4|omim:207800
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|AGC1|AGC1|gene|18|NCBIGene:8604|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|AGC1|AGC1|gene|18|NCBIGene:8604|EIEE 39|EIEE 39|disease|115|mesh:C567404
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|AGC1|AGC1|gene|18|NCBIGene:8604|epilepsy|epilepsy|disease|156|mesh:D004827
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|AGC1|AGC1|gene|18|NCBIGene:8604|hypotonia|hypotonia|disease|166|mesh:D009123
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|AGC1|AGC1|gene|18|NCBIGene:8604|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|AGC1|AGC1|gene|18|NCBIGene:8604|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|AGC1|AGC1|gene|18|NCBIGene:8604
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Asp|Asp|compound|272|CHEBI:17053|AGC1|AGC1|gene|18|NCBIGene:8604
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179|AGC1|AGC1|gene|18|NCBIGene:8604
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|NAA|NAA|compound|300|CHEBI:21547|AGC1|AGC1|gene|18|NCBIGene:8604
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|AGC1|AGC1|gene|18|NCBIGene:8604|myelination|myelination|physiology|221|C0596991
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|AGC1|AGC1|gene|18|NCBIGene:8604|neurodevelopment|neurodevelopment|physiology|198|C0599855
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Aralar|Aralar|gene|23|NCBIGene:8604|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Aralar|Aralar|gene|23|NCBIGene:8604|EIEE 39|EIEE 39|disease|115|mesh:C567404
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Aralar|Aralar|gene|23|NCBIGene:8604|epilepsy|epilepsy|disease|156|mesh:D004827
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Aralar|Aralar|gene|23|NCBIGene:8604|hypotonia|hypotonia|disease|166|mesh:D009123
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Aralar|Aralar|gene|23|NCBIGene:8604|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Aralar|Aralar|gene|23|NCBIGene:8604|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|Aralar|Aralar|gene|23|NCBIGene:8604
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Asp|Asp|compound|272|CHEBI:17053|Aralar|Aralar|gene|23|NCBIGene:8604
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179|Aralar|Aralar|gene|23|NCBIGene:8604
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|NAA|NAA|compound|300|CHEBI:21547|Aralar|Aralar|gene|23|NCBIGene:8604
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Aralar|Aralar|gene|23|NCBIGene:8604|myelination|myelination|physiology|221|C0596991
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Aralar|Aralar|gene|23|NCBIGene:8604|neurodevelopment|neurodevelopment|physiology|198|C0599855
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088|EIEE 39|EIEE 39|disease|115|mesh:C567404
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088|epilepsy|epilepsy|disease|156|mesh:D004827
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088|hypotonia|hypotonia|disease|166|mesh:D009123
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Asp|Asp|compound|272|CHEBI:17053|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|NAA|NAA|compound|300|CHEBI:21547|early infantile epileptic encephalopathy 39|early infantile epileptic encephalopathy 39|disease|69|omim:300088
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|EIEE 39|EIEE 39|disease|115|mesh:C567404|epilepsy|epilepsy|disease|156|mesh:D004827
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|EIEE 39|EIEE 39|disease|115|mesh:C567404|hypotonia|hypotonia|disease|166|mesh:D009123
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|EIEE 39|EIEE 39|disease|115|mesh:C567404|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|EIEE 39|EIEE 39|disease|115|mesh:C567404|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|EIEE 39|EIEE 39|disease|115|mesh:C567404
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Asp|Asp|compound|272|CHEBI:17053|EIEE 39|EIEE 39|disease|115|mesh:C567404
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179|EIEE 39|EIEE 39|disease|115|mesh:C567404
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|NAA|NAA|compound|300|CHEBI:21547|EIEE 39|EIEE 39|disease|115|mesh:C567404
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|epilepsy|epilepsy|disease|156|mesh:D004827|hypotonia|hypotonia|disease|166|mesh:D009123
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|epilepsy|epilepsy|disease|156|mesh:D004827|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|epilepsy|epilepsy|disease|156|mesh:D004827|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|epilepsy|epilepsy|disease|156|mesh:D004827
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Asp|Asp|compound|272|CHEBI:17053|epilepsy|epilepsy|disease|156|mesh:D004827
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179|epilepsy|epilepsy|disease|156|mesh:D004827
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|NAA|NAA|compound|300|CHEBI:21547|epilepsy|epilepsy|disease|156|mesh:D004827
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|hypotonia|hypotonia|disease|166|mesh:D009123|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|hypotonia|hypotonia|disease|166|mesh:D009123|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|hypotonia|hypotonia|disease|166|mesh:D009123
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Asp|Asp|compound|272|CHEBI:17053|hypotonia|hypotonia|disease|166|mesh:D009123
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179|hypotonia|hypotonia|disease|166|mesh:D009123
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|NAA|NAA|compound|300|CHEBI:21547|hypotonia|hypotonia|disease|166|mesh:D009123
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Asp|Asp|compound|272|CHEBI:17053|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|NAA|NAA|compound|300|CHEBI:21547|arrested psychomotor neurodevelopment|arrested psychomotor neurodevelopment|disease|177|mesh:D011596
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Asp|Asp|compound|272|CHEBI:17053|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|NAA|NAA|compound|300|CHEBI:21547|hypo myelination|hypo myelination|disease|216|mesh:D003711
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|Asp|Asp|compound|272|CHEBI:17053
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|aspartate|aspartate|compound|261|mesh:D001224|NAA|NAA|compound|300|CHEBI:21547
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Asp|Asp|compound|272|CHEBI:17053|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|Asp|Asp|compound|272|CHEBI:17053|NAA|NAA|compound|300|CHEBI:21547
8|The deficiency in AGC1/Aralar leads to the human rare disease named "early infantile epileptic encephalopathy 39" (EIEE 39, OMIM # 612949) characterized by epilepsy, hypotonia, arrested psychomotor neurodevelopment, hypo myelination and a drastic drop in brain aspartate (Asp) and N-acetylaspartate (NAA)|N-acetylaspartate|N-acetylaspartate|compound|281|mesh:C000179|NAA|NAA|compound|300|CHEBI:21547
8|Current evidence suggest that neurons are the main brain cell type expressing Aralar|Aralar|Aralar|gene|78|NCBIGene:8604|Neurons|neurons|anatomy|30|C0027882
8|Current evidence suggest that neurons are the main brain cell type expressing Aralar|Aralar|Aralar|gene|78|NCBIGene:8604|brain cell|brain cell type|anatomy|51|C0596208
8|However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency|Glutamine|Glutamine|compound|59|mesh:D005973|Gln|Gln|compound|70|CHEBI:32668
8|However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency|Glutamine|Glutamine|compound|59|mesh:D005973|AGC1 deficiency|AGC1 deficiency|disease|110|omim:612949
8|However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency|Glutamine|Glutamine|compound|59|mesh:D005973|AGC1|AGC1|gene|110|NCBIGene:176
8|However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency|Glutamine|Glutamine|compound|59|mesh:D005973|Myelin|myelin|anatomy|48|C0026969
8|However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency|Gln|Gln|compound|70|CHEBI:32668|AGC1 deficiency|AGC1 deficiency|disease|110|omim:612949
8|However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency|Gln|Gln|compound|70|CHEBI:32668|AGC1|AGC1|gene|110|NCBIGene:176
8|However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency|Gln|Gln|compound|70|CHEBI:32668|Myelin|myelin|anatomy|48|C0026969
8|However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency|AGC1 deficiency|AGC1 deficiency|disease|110|omim:612949|Myelin|myelin|anatomy|48|C0026969
8|However, paradoxically, glial functions such as myelin and Glutamine (Gln) synthesis are markedly impaired in AGC1 deficiency|AGC1|AGC1|gene|110|NCBIGene:176|Myelin|myelin|anatomy|48|C0026969
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|AGC1|AGC1|gene|35|NCBIGene:8604|MAS|MAS|gene|47|NCBIGene:4142
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Asp|Asp|compound|89|CHEBI:17053|AGC1|AGC1|gene|35|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|NAA|NAA|compound|97|CHEBI:21547|AGC1|AGC1|gene|35|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|lactate|lactate|compound|112|mesh:D019344|AGC1|AGC1|gene|35|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|glucose|glucose|compound|140|CHEBI:42758|AGC1|AGC1|gene|35|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|glutamate|glutamate|compound|149|mesh:D018698|AGC1|AGC1|gene|35|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Glu|Glu|compound|160|CHEBI:46854|AGC1|AGC1|gene|35|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|AGC1|AGC1|gene|35|NCBIGene:8604|Oxidation|oxidation|physiology|165|C0030011
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|AGC1|AGC1|gene|35|NCBIGene:8604|Cell Respiration|respiration|physiology|125|C0282636
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Aralar|Aralar|gene|40|NCBIGene:8604|MAS|MAS|gene|47|NCBIGene:4142
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Asp|Asp|compound|89|CHEBI:17053|Aralar|Aralar|gene|40|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|NAA|NAA|compound|97|CHEBI:21547|Aralar|Aralar|gene|40|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|lactate|lactate|compound|112|mesh:D019344|Aralar|Aralar|gene|40|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|glucose|glucose|compound|140|CHEBI:42758|Aralar|Aralar|gene|40|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|glutamate|glutamate|compound|149|mesh:D018698|Aralar|Aralar|gene|40|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Glu|Glu|compound|160|CHEBI:46854|Aralar|Aralar|gene|40|NCBIGene:8604
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Aralar|Aralar|gene|40|NCBIGene:8604|Oxidation|oxidation|physiology|165|C0030011
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Aralar|Aralar|gene|40|NCBIGene:8604|Cell Respiration|respiration|physiology|125|C0282636
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Asp|Asp|compound|89|CHEBI:17053|MAS|MAS|gene|47|NCBIGene:4142
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|NAA|NAA|compound|97|CHEBI:21547|MAS|MAS|gene|47|NCBIGene:4142
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|lactate|lactate|compound|112|mesh:D019344|MAS|MAS|gene|47|NCBIGene:4142
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|glucose|glucose|compound|140|CHEBI:42758|MAS|MAS|gene|47|NCBIGene:4142
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|glutamate|glutamate|compound|149|mesh:D018698|MAS|MAS|gene|47|NCBIGene:4142
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Glu|Glu|compound|160|CHEBI:46854|MAS|MAS|gene|47|NCBIGene:4142
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|MAS|MAS|gene|47|NCBIGene:4142|Oxidation|oxidation|physiology|165|C0030011
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|MAS|MAS|gene|47|NCBIGene:4142|Cell Respiration|respiration|physiology|125|C0282636
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Asp|Asp|compound|89|CHEBI:17053|NAA|NAA|compound|97|CHEBI:21547
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Asp|Asp|compound|89|CHEBI:17053|lactate|lactate|compound|112|mesh:D019344
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Asp|Asp|compound|89|CHEBI:17053|glucose|glucose|compound|140|CHEBI:42758
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Asp|Asp|compound|89|CHEBI:17053|glutamate|glutamate|compound|149|mesh:D018698
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|Asp|Asp|compound|89|CHEBI:17053|Glu|Glu|compound|160|CHEBI:46854
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|NAA|NAA|compound|97|CHEBI:21547|lactate|lactate|compound|112|mesh:D019344
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|NAA|NAA|compound|97|CHEBI:21547|glucose|glucose|compound|140|CHEBI:42758
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|NAA|NAA|compound|97|CHEBI:21547|glutamate|glutamate|compound|149|mesh:D018698
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|NAA|NAA|compound|97|CHEBI:21547|Glu|Glu|compound|160|CHEBI:46854
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|lactate|lactate|compound|112|mesh:D019344|glucose|glucose|compound|140|CHEBI:42758
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|lactate|lactate|compound|112|mesh:D019344|glutamate|glutamate|compound|149|mesh:D018698
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|lactate|lactate|compound|112|mesh:D019344|Glu|Glu|compound|160|CHEBI:46854
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|glucose|glucose|compound|140|CHEBI:42758|glutamate|glutamate|compound|149|mesh:D018698
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|glucose|glucose|compound|140|CHEBI:42758|Glu|Glu|compound|160|CHEBI:46854
8|Herein, we discuss the role of the AGC1/Aralar-MAS pathway in neuronal functions such as Asp and NAA synthesis, lactate use, respiration on glucose, glutamate (Glu) oxidation and other neurometabolic aspects|glutamate|glutamate|compound|149|mesh:D018698|Glu|Glu|compound|160|CHEBI:46854
8|The possible mechanism triggering the pathophysiological findings in AGC1 deficiency, such as epilepsy and postnatal hypomyelination observed in humans and mice, are also included|AGC1 deficiency|AGC1 deficiency|disease|69|omim:612949|epilepsy|epilepsy|disease|94|mesh:D004827
8|The possible mechanism triggering the pathophysiological findings in AGC1 deficiency, such as epilepsy and postnatal hypomyelination observed in humans and mice, are also included|AGC1 deficiency|AGC1 deficiency|disease|69|omim:612949|postnatal hypomyelination|postnatal hypomyelination|disease|107|mesh:D003711
8|The possible mechanism triggering the pathophysiological findings in AGC1 deficiency, such as epilepsy and postnatal hypomyelination observed in humans and mice, are also included|AGC1|AGC1|gene|69|NCBIGene:176|epilepsy|epilepsy|disease|94|mesh:D004827
8|The possible mechanism triggering the pathophysiological findings in AGC1 deficiency, such as epilepsy and postnatal hypomyelination observed in humans and mice, are also included|AGC1|AGC1|gene|69|NCBIGene:176|postnatal hypomyelination|postnatal hypomyelination|disease|107|mesh:D003711
8|The possible mechanism triggering the pathophysiological findings in AGC1 deficiency, such as epilepsy and postnatal hypomyelination observed in humans and mice, are also included|AGC1|AGC1|gene|69|NCBIGene:176|Precipitating Factors|triggering|physiology|23|C0032930
8|The possible mechanism triggering the pathophysiological findings in AGC1 deficiency, such as epilepsy and postnatal hypomyelination observed in humans and mice, are also included|AGC1|AGC1|gene|69|NCBIGene:176|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|57|C2926606
8|The possible mechanism triggering the pathophysiological findings in AGC1 deficiency, such as epilepsy and postnatal hypomyelination observed in humans and mice, are also included|epilepsy|epilepsy|disease|94|mesh:D004827|postnatal hypomyelination|postnatal hypomyelination|disease|107|mesh:D003711
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|Gln|Gln|compound|169|CHEBI:32668|aralar|aralar|gene|53|NCBIGene:8604
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|dopamine|dopamine|compound|181|mesh:D004298|aralar|aralar|gene|53|NCBIGene:8604
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|aralar|aralar|gene|53|NCBIGene:8604|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|36|C2926606
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|aralar|aralar|gene|53|NCBIGene:8604|KELL NULL|KO|anatomy|60|C1862225
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|aralar|aralar|gene|53|NCBIGene:8604|Astrocytes|astroglial|anatomy|136|C0004112
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|aralar|aralar|gene|53|NCBIGene:8604|nigrostriatal system|nigrostriatal system|anatomy|214|C0815010
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|Gln|Gln|compound|169|CHEBI:32668|dopamine|dopamine|compound|181|mesh:D004298
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|Gln|Gln|compound|169|CHEBI:32668|KELL NULL|KO|anatomy|60|C1862225
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|Gln|Gln|compound|169|CHEBI:32668|Astrocytes|astroglial|anatomy|136|C0004112
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|Gln|Gln|compound|169|CHEBI:32668|nigrostriatal system|nigrostriatal system|anatomy|214|C0815010
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|dopamine|dopamine|compound|181|mesh:D004298|KELL NULL|KO|anatomy|60|C1862225
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|dopamine|dopamine|compound|181|mesh:D004298|Astrocytes|astroglial|anatomy|136|C0004112
8|Many of these mechanisms arise from findings  in the aralar-KO mice model that extensively recapitulate the human disease including the astroglial failure to synthesize Gln and the dopamine (DA) mishandling in the nigrostriatal system|dopamine|dopamine|compound|181|mesh:D004298|nigrostriatal system|nigrostriatal system|anatomy|214|C0815010
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|Epilepsy|Epilepsy|disease|0|mesh:D004827|DA mishandling|DA mishandling|disease|13|mesh:D003221
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|Epilepsy|Epilepsy|disease|0|mesh:D004827|AGC1/Aralar deficiency|AGC1/Aralar deficiency|disease|95|omim:612949
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|AGC1|AGC1|gene|95|NCBIGene:8604|Epilepsy|Epilepsy|disease|0|mesh:D004827
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|Aralar|Aralar|gene|100|NCBIGene:8604|Epilepsy|Epilepsy|disease|0|mesh:D004827
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|Epilepsy|Epilepsy|disease|0|mesh:D004827|Neurons|neurons|anatomy|80|C0027882
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|DA mishandling|DA mishandling|disease|13|mesh:D003221|AGC1/Aralar deficiency|AGC1/Aralar deficiency|disease|95|omim:612949
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|AGC1|AGC1|gene|95|NCBIGene:8604|DA mishandling|DA mishandling|disease|13|mesh:D003221
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|Aralar|Aralar|gene|100|NCBIGene:8604|DA mishandling|DA mishandling|disease|13|mesh:D003221
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|DA mishandling|DA mishandling|disease|13|mesh:D003221|Neurons|neurons|anatomy|80|C0027882
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|AGC1/Aralar deficiency|AGC1/Aralar deficiency|disease|95|omim:612949|Neurons|neurons|anatomy|80|C0027882
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|AGC1|AGC1|gene|95|NCBIGene:8604|Neurons|neurons|anatomy|80|C0027882
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|AGC1|AGC1|gene|95|NCBIGene:8604|Metabolic Process, Cellular|metabolic|physiology|60|C1524026
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|Aralar|Aralar|gene|100|NCBIGene:8604|Neurons|neurons|anatomy|80|C0027882
8|Epilepsy and DA mishandling are a direct consequence of the metabolic defect in neurons due to AGC1/Aralar deficiency|Aralar|Aralar|gene|100|NCBIGene:8604|Metabolic Process, Cellular|metabolic|physiology|60|C1524026
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|Gln|Gln|compound|36|CHEBI:32668|AGC1/|AGC1/|disease|117|omim:109200
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|Gln|Gln|compound|36|CHEBI:32668|AGC1|AGC1|gene|117|NCBIGene:8604
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|Gln|Gln|compound|36|CHEBI:32668|Aralar deficiency|Aralar deficiency|disease|122|mesh:C562618
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|Gln|Gln|compound|36|CHEBI:32668|Aralar|Aralar|gene|122|NCBIGene:8604
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|Gln|Gln|compound|36|CHEBI:32668|Neuroglia|[|anatomy|143|C0027836
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|Gln|Gln|compound|36|CHEBI:32668|Myelin|myelin|anatomy|25|C0026969
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|AGC1/|AGC1/|disease|117|omim:109200|Aralar deficiency|Aralar deficiency|disease|122|mesh:C562618
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|Aralar|Aralar|gene|122|NCBIGene:8604|AGC1/|AGC1/|disease|117|omim:109200
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|AGC1/|AGC1/|disease|117|omim:109200|Neuroglia|[|anatomy|143|C0027836
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|AGC1/|AGC1/|disease|117|omim:109200|Myelin|myelin|anatomy|25|C0026969
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|AGC1|AGC1|gene|117|NCBIGene:8604|Aralar deficiency|Aralar deficiency|disease|122|mesh:C562618
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|AGC1|AGC1|gene|117|NCBIGene:8604|Neuroglia|[|anatomy|143|C0027836
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|AGC1|AGC1|gene|117|NCBIGene:8604|Myelin|myelin|anatomy|25|C0026969
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|Aralar deficiency|Aralar deficiency|disease|122|mesh:C562618|Neuroglia|[|anatomy|143|C0027836
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|Aralar deficiency|Aralar deficiency|disease|122|mesh:C562618|Myelin|myelin|anatomy|25|C0026969
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|Aralar|Aralar|gene|122|NCBIGene:8604|Neuroglia|[|anatomy|143|C0027836
8|However, the deficits in myelin and Gln synthesis may be a consequence of neuronal affectation or a direct effect of AGC1/Aralar deficiency in glial cells|Aralar|Aralar|gene|122|NCBIGene:8604|Myelin|myelin|anatomy|25|C0026969
9|Transcriptional profiling of microglia with diverse metabolic profiles revealed an activation signature wherein the interleukin (IL)-33 signaling axis is associated with phagocytic activity|interleukin (IL)-33|interleukin (IL)-33|gene|116|NCBIGene:90865|Metabolic Profile|[|physiology|52|C3853758
9|Transcriptional profiling of microglia with diverse metabolic profiles revealed an activation signature wherein the interleukin (IL)-33 signaling axis is associated with phagocytic activity|interleukin (IL)-33|interleukin (IL)-33|gene|116|NCBIGene:90865|Axis vertebra|axis|anatomy|146|C0004457
9|Transcriptional profiling of microglia with diverse metabolic profiles revealed an activation signature wherein the interleukin (IL)-33 signaling axis is associated with phagocytic activity|interleukin (IL)-33|interleukin (IL)-33|gene|116|NCBIGene:90865|Microglia|microglia|anatomy|29|C0206116
9|Transcriptional profiling of microglia with diverse metabolic profiles revealed an activation signature wherein the interleukin (IL)-33 signaling axis is associated with phagocytic activity|interleukin (IL)-33|interleukin (IL)-33|gene|116|NCBIGene:90865|Transcription, Genetic|Transcriptional|physiology|0|C0040649
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|IL-33|IL-33|gene|24|NCBIGene:90865|ST2|ST2|gene|46|NCBIGene:6761
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|IL-33|IL-33|gene|24|NCBIGene:90865|microglial dystrophy|microglial dystrophy|disease|57|mesh:D058494
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|IL-33|IL-33|gene|24|NCBIGene:90865|behavioral abnormalities|behavioral abnormalities|disease|111|mesh:D001523
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|IL-33|IL-33|gene|24|NCBIGene:90865|Function Axis|function|physiology|97|C0700205
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|IL-33|IL-33|gene|24|NCBIGene:90865|microglial|microglial|anatomy|57|C0521398
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|ST2|ST2|gene|46|NCBIGene:6761|microglial dystrophy|microglial dystrophy|disease|57|mesh:D058494
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|ST2|ST2|gene|46|NCBIGene:6761|behavioral abnormalities|behavioral abnormalities|disease|111|mesh:D001523
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|ST2|ST2|gene|46|NCBIGene:6761|Function Axis|function|physiology|97|C0700205
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|ST2|ST2|gene|46|NCBIGene:6761|microglial|microglial|anatomy|57|C0521398
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|ST2|ST2|gene|46|NCBIGene:6761|interleukin-33 receptor binding|IL-33|physiology|24|C2248030
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|microglial dystrophy|microglial dystrophy|disease|57|mesh:D058494|behavioral abnormalities|behavioral abnormalities|disease|111|mesh:D001523
9|Genetic perturbation of IL-33 or its receptor ST2 led to microglial dystrophy, impaired synaptic function, and behavioral abnormalities|behavioral abnormalities|behavioral abnormalities|disease|111|mesh:D001523|microglial|microglial|anatomy|57|C0521398
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|Il33|Il33|gene|24|NCBIGene:90865|Il1rl1|Il1rl1|gene|48|NCBIGene:9173
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|Il33|Il33|gene|24|NCBIGene:90865|ST2|ST2|gene|65|NCBIGene:6761
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|Il33|Il33|gene|24|NCBIGene:90865|seizures|seizures|disease|111|mesh:D012640
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|Il33|Il33|gene|24|NCBIGene:90865|Astrocytes|astrocytes|anatomy|34|C0004112
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|Il33|Il33|gene|24|NCBIGene:90865|Microglia|microglia|anatomy|73|C0206116
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|Il33|Il33|gene|24|NCBIGene:90865|Disease susceptibility|susceptibility|physiology|93|C0012655
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|Il1rl1|Il1rl1|gene|48|NCBIGene:9173|ST2|ST2|gene|65|NCBIGene:6761
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|Il1rl1|Il1rl1|gene|48|NCBIGene:9173|seizures|seizures|disease|111|mesh:D012640
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|Il1rl1|Il1rl1|gene|48|NCBIGene:9173|Astrocytes|astrocytes|anatomy|34|C0004112
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|Il1rl1|Il1rl1|gene|48|NCBIGene:9173|Microglia|microglia|anatomy|73|C0206116
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|Il1rl1|Il1rl1|gene|48|NCBIGene:9173|Disease susceptibility|susceptibility|physiology|93|C0012655
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|ST2|ST2|gene|65|NCBIGene:6761|seizures|seizures|disease|111|mesh:D012640
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|ST2|ST2|gene|65|NCBIGene:6761|Astrocytes|astrocytes|anatomy|34|C0004112
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|ST2|ST2|gene|65|NCBIGene:6761|Microglia|microglia|anatomy|73|C0206116
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|ST2|ST2|gene|65|NCBIGene:6761|Disease susceptibility|susceptibility|physiology|93|C0012655
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|seizures|seizures|disease|111|mesh:D012640|Astrocytes|astrocytes|anatomy|34|C0004112
9|Conditional deletion of Il33 from astrocytes or Il1rl1, encoding ST2, in microglia increased susceptibility to seizures|seizures|seizures|disease|111|mesh:D012640|Microglia|microglia|anatomy|73|C0206116
9|Mechanistically, IL-33 promoted mitochondrial activity and phagocytosis in an AKT-dependent manner|IL-33|IL-33|gene|17|NCBIGene:90865|AKT|AKT|gene|78|NCBIGene:207
9|Mechanistically, IL-33 promoted mitochondrial activity and phagocytosis in an AKT-dependent manner|IL-33|IL-33|gene|17|NCBIGene:90865|Phagocytosis|phagocytosis|physiology|59|C0031308
9|Mechanistically, IL-33 promoted mitochondrial activity and phagocytosis in an AKT-dependent manner|AKT|AKT|gene|78|NCBIGene:207|Phagocytosis|phagocytosis|physiology|59|C0031308
9|Mitochondrial metabolism and AKT activity were temporally regulated in vivo|AKT|AKT|gene|29|NCBIGene:207|Metabolism|metabolism|physiology|14|C0025519
9|Mitochondrial metabolism and AKT activity were temporally regulated in vivo|AKT|AKT|gene|29|NCBIGene:207|Mitochondria|Mitochondrial|anatomy|0|C0026237
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|IL-33|IL-33|gene|52|NCBIGene:90865|ST2|ST2|gene|58|NCBIGene:6761
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|IL-33|IL-33|gene|52|NCBIGene:90865|AKT|AKT|gene|62|NCBIGene:207
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|IL-33|IL-33|gene|52|NCBIGene:90865|neurodevelopmental and neuropsychiatric disorders|neurodevelopmental and neuropsychiatric disorders|disease|194|mesh:D065886
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|IL-33|IL-33|gene|52|NCBIGene:90865|Acclimatization|adaptation|physiology|111|C0000934
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|IL-33|IL-33|gene|52|NCBIGene:90865|Function Axis|function|physiology|137|C0700205
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|IL-33|IL-33|gene|52|NCBIGene:90865|Axis vertebra|axis|anatomy|76|C0004457
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|IL-33|IL-33|gene|52|NCBIGene:90865|Astrocytes|astrocyte|anatomy|18|C0004112
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|IL-33|IL-33|gene|52|NCBIGene:90865|Metabolic Process, Cellular|metabolic|physiology|101|C1524026
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|IL-33|IL-33|gene|52|NCBIGene:90865|Microglia|microglia|anatomy|8|C0206116
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|IL-33|IL-33|gene|52|NCBIGene:90865|microglial|microglial|anatomy|90|C0521398
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|IL-33|IL-33|gene|52|NCBIGene:90865|neurodevelopment|neurodevelopmental|physiology|194|C0599855
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|ST2|ST2|gene|58|NCBIGene:6761|AKT|AKT|gene|62|NCBIGene:207
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|ST2|ST2|gene|58|NCBIGene:6761|neurodevelopmental and neuropsychiatric disorders|neurodevelopmental and neuropsychiatric disorders|disease|194|mesh:D065886
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|ST2|ST2|gene|58|NCBIGene:6761|Acclimatization|adaptation|physiology|111|C0000934
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|ST2|ST2|gene|58|NCBIGene:6761|interleukin-33 receptor binding|IL-33|physiology|52|C2248030
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|ST2|ST2|gene|58|NCBIGene:6761|Function Axis|function|physiology|137|C0700205
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|ST2|ST2|gene|58|NCBIGene:6761|Axis vertebra|axis|anatomy|76|C0004457
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|ST2|ST2|gene|58|NCBIGene:6761|Astrocytes|astrocyte|anatomy|18|C0004112
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|ST2|ST2|gene|58|NCBIGene:6761|Metabolic Process, Cellular|metabolic|physiology|101|C1524026
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|ST2|ST2|gene|58|NCBIGene:6761|Microglia|microglia|anatomy|8|C0206116
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|ST2|ST2|gene|58|NCBIGene:6761|microglial|microglial|anatomy|90|C0521398
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|ST2|ST2|gene|58|NCBIGene:6761|neurodevelopment|neurodevelopmental|physiology|194|C0599855
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|AKT|AKT|gene|62|NCBIGene:207|neurodevelopmental and neuropsychiatric disorders|neurodevelopmental and neuropsychiatric disorders|disease|194|mesh:D065886
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|AKT|AKT|gene|62|NCBIGene:207|Acclimatization|adaptation|physiology|111|C0000934
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|AKT|AKT|gene|62|NCBIGene:207|interleukin-33 receptor binding|IL-33|physiology|52|C2248030
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|AKT|AKT|gene|62|NCBIGene:207|Function Axis|function|physiology|137|C0700205
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|AKT|AKT|gene|62|NCBIGene:207|Axis vertebra|axis|anatomy|76|C0004457
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|AKT|AKT|gene|62|NCBIGene:207|Astrocytes|astrocyte|anatomy|18|C0004112
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|AKT|AKT|gene|62|NCBIGene:207|Metabolic Process, Cellular|metabolic|physiology|101|C1524026
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|AKT|AKT|gene|62|NCBIGene:207|Microglia|microglia|anatomy|8|C0206116
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|AKT|AKT|gene|62|NCBIGene:207|microglial|microglial|anatomy|90|C0521398
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|AKT|AKT|gene|62|NCBIGene:207|neurodevelopment|neurodevelopmental|physiology|194|C0599855
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|neurodevelopmental and neuropsychiatric disorders|neurodevelopmental and neuropsychiatric disorders|disease|194|mesh:D065886|Axis vertebra|axis|anatomy|76|C0004457
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|neurodevelopmental and neuropsychiatric disorders|neurodevelopmental and neuropsychiatric disorders|disease|194|mesh:D065886|Astrocytes|astrocyte|anatomy|18|C0004112
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|neurodevelopmental and neuropsychiatric disorders|neurodevelopmental and neuropsychiatric disorders|disease|194|mesh:D065886|Microglia|microglia|anatomy|8|C0206116
9|Thus, a microglia-astrocyte circuit mediated by the IL-33-ST2-AKT signaling axis supports microglial metabolic adaptation and phagocytic function during early development, with implications for neurodevelopmental and neuropsychiatric disorders|neurodevelopmental and neuropsychiatric disorders|neurodevelopmental and neuropsychiatric disorders|disease|194|mesh:D065886|microglial|microglial|anatomy|90|C0521398
10|In addition, alterations in dopamine signaling may be also involved in the pathophysiology of  psychiatric disorders|dopamine|dopamine|compound|28|mesh:D004298|psychiatric disorders|psychiatric disorders|disease|95|mesh:D001523
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|Hexokinase|Hexokinase|gene|0|NCBIGene:3098|HK|HK|gene|12|NCBIGene:479
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|Hexokinase|Hexokinase|gene|0|NCBIGene:3098|mt-HK|mt-HK|gene|56|NCBIGene:1760
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|Hexokinase|Hexokinase|gene|0|NCBIGene:3098|Mitochondria|mitochondria|anatomy|42|C0026237
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|Hexokinase|Hexokinase|gene|0|NCBIGene:3098|Mitochondria|mitochondrial|anatomy|107|C0026237
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|Hexokinase|Hexokinase|gene|0|NCBIGene:3098|Brain|brain|anatomy|132|C0006104
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|HK|HK|gene|12|NCBIGene:479|mt-HK|mt-HK|gene|56|NCBIGene:1760
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|HK|HK|gene|12|NCBIGene:479|Mitochondria|mitochondria|anatomy|42|C0026237
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|HK|HK|gene|12|NCBIGene:479|Mitochondria|mitochondrial|anatomy|107|C0026237
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|HK|HK|gene|12|NCBIGene:479|Brain|brain|anatomy|132|C0006104
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|mt-HK|mt-HK|gene|56|NCBIGene:1760|Mitochondria|mitochondria|anatomy|42|C0026237
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|mt-HK|mt-HK|gene|56|NCBIGene:1760|Mitochondria|mitochondrial|anatomy|107|C0026237
10|Hexokinase (HK), when associated with the mitochondria (mt-HK), is a potent modulator of the generation of mitochondrial ROS in the brain|mt-HK|mt-HK|gene|56|NCBIGene:1760|Brain|brain|anatomy|132|C0006104
10|In the present study, we investigated whether dopamine could affect both the activity and redox  function of mt-HK in human neural progenitor cells (NPCs)|dopamine|dopamine|compound|46|mesh:D004298|mt-HK|mt-HK|gene|109|NCBIGene:1760
10|In the present study, we investigated whether dopamine could affect both the activity and redox  function of mt-HK in human neural progenitor cells (NPCs)|dopamine|dopamine|compound|46|mesh:D004298|Neural Stem Cells|neural progenitor cells|anatomy|124|C1113654
10|In the present study, we investigated whether dopamine could affect both the activity and redox  function of mt-HK in human neural progenitor cells (NPCs)|mt-HK|mt-HK|gene|109|NCBIGene:1760|Affect (mental function)|affect|physiology|61|C0001721
10|In the present study, we investigated whether dopamine could affect both the activity and redox  function of mt-HK in human neural progenitor cells (NPCs)|mt-HK|mt-HK|gene|109|NCBIGene:1760|Neural Stem Cells|neural progenitor cells|anatomy|124|C1113654
10|In the present study, we investigated whether dopamine could affect both the activity and redox  function of mt-HK in human neural progenitor cells (NPCs)|mt-HK|mt-HK|gene|109|NCBIGene:1760|Function Axis|function|physiology|97|C0700205
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|dopamine|dopamine|compound|14|mesh:D004298|D1R|D1R|gene|37|NCBIGene:1812
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|dopamine|dopamine|compound|14|mesh:D004298|mt-HK|mt-HK|gene|51|NCBIGene:1760
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|dopamine|dopamine|compound|14|mesh:D004298|H2O2|H2O2|compound|140|mesh:D006861
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|dopamine|dopamine|compound|14|mesh:D004298|calcium|calcium|compound|163|mesh:D002118
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|dopamine|dopamine|compound|14|mesh:D004298|Mitochondria|mitochondria|anatomy|187|C0026237
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|D1R|D1R|gene|37|NCBIGene:1812|mt-HK|mt-HK|gene|51|NCBIGene:1760
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|H2O2|H2O2|compound|140|mesh:D006861|D1R|D1R|gene|37|NCBIGene:1812
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|calcium|calcium|compound|163|mesh:D002118|D1R|D1R|gene|37|NCBIGene:1812
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|D1R|D1R|gene|37|NCBIGene:1812|Mitochondria|mitochondria|anatomy|187|C0026237
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|D1R|D1R|gene|37|NCBIGene:1812|Signal Transduction|signaling|physiology|23|C0037083
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|H2O2|H2O2|compound|140|mesh:D006861|mt-HK|mt-HK|gene|51|NCBIGene:1760
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|calcium|calcium|compound|163|mesh:D002118|mt-HK|mt-HK|gene|51|NCBIGene:1760
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|mt-HK|mt-HK|gene|51|NCBIGene:1760|Mitochondria|mitochondria|anatomy|187|C0026237
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|mt-HK|mt-HK|gene|51|NCBIGene:1760|Signal Transduction|signaling|physiology|23|C0037083
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|H2O2|H2O2|compound|140|mesh:D006861|calcium|calcium|compound|163|mesh:D002118
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|H2O2|H2O2|compound|140|mesh:D006861|Mitochondria|mitochondria|anatomy|187|C0026237
10|We found that dopamine signaling via D1R decreases mt-HK activity and impairs ROS modulation, which is followed by an expressive release of H2O2 and impairment in calcium handling by the mitochondria|calcium|calcium|compound|163|mesh:D002118|Mitochondria|mitochondria|anatomy|187|C0026237
10|Nevertheless, mitochondrial respiration is not affected, suggesting specificity for dopamine on mt-HK function|dopamine|dopamine|compound|84|mesh:D004298|mt-HK|mt-HK|gene|96|NCBIGene:1760
10|Nevertheless, mitochondrial respiration is not affected, suggesting specificity for dopamine on mt-HK function|dopamine|dopamine|compound|84|mesh:D004298|Mitochondria|mitochondrial|anatomy|14|C0026237
10|Nevertheless, mitochondrial respiration is not affected, suggesting specificity for dopamine on mt-HK function|mt-HK|mt-HK|gene|96|NCBIGene:1760|Cell Respiration|respiration|physiology|28|C0282636
10|Nevertheless, mitochondrial respiration is not affected, suggesting specificity for dopamine on mt-HK function|mt-HK|mt-HK|gene|96|NCBIGene:1760|Function Axis|function|physiology|102|C0700205
10|Nevertheless, mitochondrial respiration is not affected, suggesting specificity for dopamine on mt-HK function|mt-HK|mt-HK|gene|96|NCBIGene:1760|Mitochondria|mitochondrial|anatomy|14|C0026237
10|In neural stem cells (NSCs) derived from induced-pluripotent stem cells (iPSCs) of schizophrenia patients, mt-HK is unable to decrease mitochondrial ROS, in contrast with NSCs derived from healthy individuals|mt-HK|mt-HK|gene|107|NCBIGene:1760|schizophrenia|schizophrenia|disease|83|omim:181500
10|In neural stem cells (NSCs) derived from induced-pluripotent stem cells (iPSCs) of schizophrenia patients, mt-HK is unable to decrease mitochondrial ROS, in contrast with NSCs derived from healthy individuals|schizophrenia|schizophrenia|disease|83|omim:181500|Neural Stem Cells|NSCs|anatomy|171|C1113654
10|In neural stem cells (NSCs) derived from induced-pluripotent stem cells (iPSCs) of schizophrenia patients, mt-HK is unable to decrease mitochondrial ROS, in contrast with NSCs derived from healthy individuals|schizophrenia|schizophrenia|disease|83|omim:181500|Neural Stem Cells|neural stem cells|anatomy|3|C1113654
10|In neural stem cells (NSCs) derived from induced-pluripotent stem cells (iPSCs) of schizophrenia patients, mt-HK is unable to decrease mitochondrial ROS, in contrast with NSCs derived from healthy individuals|schizophrenia|schizophrenia|disease|83|omim:181500|Induced Pluripotent Stem Cells|induced-pluripotent stem cells|anatomy|41|C2717959
10|In neural stem cells (NSCs) derived from induced-pluripotent stem cells (iPSCs) of schizophrenia patients, mt-HK is unable to decrease mitochondrial ROS, in contrast with NSCs derived from healthy individuals|schizophrenia|schizophrenia|disease|83|omim:181500|Mitochondria|mitochondrial|anatomy|135|C0026237
10|In neural stem cells (NSCs) derived from induced-pluripotent stem cells (iPSCs) of schizophrenia patients, mt-HK is unable to decrease mitochondrial ROS, in contrast with NSCs derived from healthy individuals|mt-HK|mt-HK|gene|107|NCBIGene:1760|Neural Stem Cells|NSCs|anatomy|171|C1113654
10|In neural stem cells (NSCs) derived from induced-pluripotent stem cells (iPSCs) of schizophrenia patients, mt-HK is unable to decrease mitochondrial ROS, in contrast with NSCs derived from healthy individuals|mt-HK|mt-HK|gene|107|NCBIGene:1760|Neural Stem Cells|neural stem cells|anatomy|3|C1113654
10|In neural stem cells (NSCs) derived from induced-pluripotent stem cells (iPSCs) of schizophrenia patients, mt-HK is unable to decrease mitochondrial ROS, in contrast with NSCs derived from healthy individuals|mt-HK|mt-HK|gene|107|NCBIGene:1760|Induced Pluripotent Stem Cells|induced-pluripotent stem cells|anatomy|41|C2717959
10|In neural stem cells (NSCs) derived from induced-pluripotent stem cells (iPSCs) of schizophrenia patients, mt-HK is unable to decrease mitochondrial ROS, in contrast with NSCs derived from healthy individuals|mt-HK|mt-HK|gene|107|NCBIGene:1760|Mitochondria|mitochondrial|anatomy|135|C0026237
10|Our data point to mitochondrial hexokinase as a novel target of dopaminergic signaling, as well as a redox modulator in human neural progenitor cells, which may be relevant to the pathophysiology of neurodevelopmental disorders such as schizophrenia|mitochondrial hexokinase|mitochondrial hexokinase|gene|18|NCBIGene:3099|neurodevelopmental disorders|neurodevelopmental disorders|disease|199|mesh:D065886
10|Our data point to mitochondrial hexokinase as a novel target of dopaminergic signaling, as well as a redox modulator in human neural progenitor cells, which may be relevant to the pathophysiology of neurodevelopmental disorders such as schizophrenia|mitochondrial hexokinase|mitochondrial hexokinase|gene|18|NCBIGene:3099|schizophrenia|schizophrenia|disease|236|omim:181500
10|Our data point to mitochondrial hexokinase as a novel target of dopaminergic signaling, as well as a redox modulator in human neural progenitor cells, which may be relevant to the pathophysiology of neurodevelopmental disorders such as schizophrenia|mitochondrial hexokinase|mitochondrial hexokinase|gene|18|NCBIGene:3099|Neural Stem Cells|neural progenitor cells|anatomy|126|C1113654
10|Our data point to mitochondrial hexokinase as a novel target of dopaminergic signaling, as well as a redox modulator in human neural progenitor cells, which may be relevant to the pathophysiology of neurodevelopmental disorders such as schizophrenia|mitochondrial hexokinase|mitochondrial hexokinase|gene|18|NCBIGene:3099|Signal Transduction|signaling|physiology|77|C0037083
10|Our data point to mitochondrial hexokinase as a novel target of dopaminergic signaling, as well as a redox modulator in human neural progenitor cells, which may be relevant to the pathophysiology of neurodevelopmental disorders such as schizophrenia|mitochondrial hexokinase|mitochondrial hexokinase|gene|18|NCBIGene:3099|Oxidation-Reduction|redox|physiology|101|C0030012
10|Our data point to mitochondrial hexokinase as a novel target of dopaminergic signaling, as well as a redox modulator in human neural progenitor cells, which may be relevant to the pathophysiology of neurodevelopmental disorders such as schizophrenia|neurodevelopmental disorders|neurodevelopmental disorders|disease|199|mesh:D065886|schizophrenia|schizophrenia|disease|236|omim:181500
10|Our data point to mitochondrial hexokinase as a novel target of dopaminergic signaling, as well as a redox modulator in human neural progenitor cells, which may be relevant to the pathophysiology of neurodevelopmental disorders such as schizophrenia|neurodevelopmental disorders|neurodevelopmental disorders|disease|199|mesh:D065886|Mitochondria|mitochondrial|anatomy|18|C0026237
10|Our data point to mitochondrial hexokinase as a novel target of dopaminergic signaling, as well as a redox modulator in human neural progenitor cells, which may be relevant to the pathophysiology of neurodevelopmental disorders such as schizophrenia|neurodevelopmental disorders|neurodevelopmental disorders|disease|199|mesh:D065886|Neural Stem Cells|neural progenitor cells|anatomy|126|C1113654
10|Our data point to mitochondrial hexokinase as a novel target of dopaminergic signaling, as well as a redox modulator in human neural progenitor cells, which may be relevant to the pathophysiology of neurodevelopmental disorders such as schizophrenia|schizophrenia|schizophrenia|disease|236|omim:181500|Mitochondria|mitochondrial|anatomy|18|C0026237
10|Our data point to mitochondrial hexokinase as a novel target of dopaminergic signaling, as well as a redox modulator in human neural progenitor cells, which may be relevant to the pathophysiology of neurodevelopmental disorders such as schizophrenia|schizophrenia|schizophrenia|disease|236|omim:181500|Neural Stem Cells|neural progenitor cells|anatomy|126|C1113654
11|Fragile X syndrome (FXS) is a genetic disorder that is characterized by a range of cognitive and behavioral deficits, including mild-moderate intellectual disability|Fragile X syndrome|Fragile X syndrome|disease|0|omim:300624|genetic disorder|genetic disorder|disease|30|mesh:D030342
11|Fragile X syndrome (FXS) is a genetic disorder that is characterized by a range of cognitive and behavioral deficits, including mild-moderate intellectual disability|Fragile X syndrome|Fragile X syndrome|disease|0|omim:300624|cognitive and behavioral deficits|cognitive and behavioral deficits|disease|83|mesh:D011618
11|Fragile X syndrome (FXS) is a genetic disorder that is characterized by a range of cognitive and behavioral deficits, including mild-moderate intellectual disability|Fragile X syndrome|Fragile X syndrome|disease|0|omim:300624|intellectual disability|intellectual disability|disease|142|mesh:D008607
11|Fragile X syndrome (FXS) is a genetic disorder that is characterized by a range of cognitive and behavioral deficits, including mild-moderate intellectual disability|FXS|FXS|disease|20|omim:300624|genetic disorder|genetic disorder|disease|30|mesh:D030342
11|Fragile X syndrome (FXS) is a genetic disorder that is characterized by a range of cognitive and behavioral deficits, including mild-moderate intellectual disability|FXS|FXS|disease|20|omim:300624|cognitive and behavioral deficits|cognitive and behavioral deficits|disease|83|mesh:D011618
11|Fragile X syndrome (FXS) is a genetic disorder that is characterized by a range of cognitive and behavioral deficits, including mild-moderate intellectual disability|FXS|FXS|disease|20|omim:300624|intellectual disability|intellectual disability|disease|142|mesh:D008607
11|Fragile X syndrome (FXS) is a genetic disorder that is characterized by a range of cognitive and behavioral deficits, including mild-moderate intellectual disability|genetic disorder|genetic disorder|disease|30|mesh:D030342|cognitive and behavioral deficits|cognitive and behavioral deficits|disease|83|mesh:D011618
11|Fragile X syndrome (FXS) is a genetic disorder that is characterized by a range of cognitive and behavioral deficits, including mild-moderate intellectual disability|genetic disorder|genetic disorder|disease|30|mesh:D030342|intellectual disability|intellectual disability|disease|142|mesh:D008607
11|Fragile X syndrome (FXS) is a genetic disorder that is characterized by a range of cognitive and behavioral deficits, including mild-moderate intellectual disability|cognitive and behavioral deficits|cognitive and behavioral deficits|disease|83|mesh:D011618|intellectual disability|intellectual disability|disease|142|mesh:D008607
11|The disease is characterized by an X-linked mutation of the Fmr1 gene, which causes silencing of the gene coding for fragile X mental retardation  protein (FMRP), a translational regulator integral for neurodevelopment|Fmr1 gene|Fmr1 gene|gene|60|NCBIGene:2332|fragile X mental retardation|fragile X mental retardation|disease|117|omim:300624
11|The disease is characterized by an X-linked mutation of the Fmr1 gene, which causes silencing of the gene coding for fragile X mental retardation  protein (FMRP), a translational regulator integral for neurodevelopment|Fmr1 gene|Fmr1 gene|gene|60|NCBIGene:2332|Genetic Translation Process|translational|physiology|165|C1519614
11|The disease is characterized by an X-linked mutation of the Fmr1 gene, which causes silencing of the gene coding for fragile X mental retardation  protein (FMRP), a translational regulator integral for neurodevelopment|Fmr1 gene|Fmr1 gene|gene|60|NCBIGene:2332|neurodevelopment|neurodevelopment|physiology|202|C0599855
11|The disease is characterized by an X-linked mutation of the Fmr1 gene, which causes silencing of the gene coding for fragile X mental retardation  protein (FMRP), a translational regulator integral for neurodevelopment|FMRP|FMRP|gene|156|NCBIGene:2332|fragile X mental retardation|fragile X mental retardation|disease|117|omim:300624
11|The disease is characterized by an X-linked mutation of the Fmr1 gene, which causes silencing of the gene coding for fragile X mental retardation  protein (FMRP), a translational regulator integral for neurodevelopment|fragile X mental retardation  protein|fragile X mental retardation  protein|gene|117|NCBIGene:2332|Genetic Translation Process|translational|physiology|165|C1519614
11|The disease is characterized by an X-linked mutation of the Fmr1 gene, which causes silencing of the gene coding for fragile X mental retardation  protein (FMRP), a translational regulator integral for neurodevelopment|fragile X mental retardation  protein|fragile X mental retardation  protein|gene|117|NCBIGene:2332|neurodevelopment|neurodevelopment|physiology|202|C0599855
11|The disease is characterized by an X-linked mutation of the Fmr1 gene, which causes silencing of the gene coding for fragile X mental retardation  protein (FMRP), a translational regulator integral for neurodevelopment|FMRP|FMRP|gene|156|NCBIGene:2332|Genetic Translation Process|translational|physiology|165|C1519614
11|The disease is characterized by an X-linked mutation of the Fmr1 gene, which causes silencing of the gene coding for fragile X mental retardation  protein (FMRP), a translational regulator integral for neurodevelopment|FMRP|FMRP|gene|156|NCBIGene:2332|neurodevelopment|neurodevelopment|physiology|202|C0599855
11|Mitochondrial dysfunction has been recently associated with FXS, with reports of  increases in oxidative stress markers, reactive oxygen species, and lipid peroxidation being present in the brain tissue|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|0|mesh:D028361|FXS|FXS|disease|60|omim:300624
11|Mitochondrial dysfunction has been recently associated with FXS, with reports of  increases in oxidative stress markers, reactive oxygen species, and lipid peroxidation being present in the brain tissue|oxygen|oxygen|compound|130|mesh:D010100|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|0|mesh:D028361
11|Mitochondrial dysfunction has been recently associated with FXS, with reports of  increases in oxidative stress markers, reactive oxygen species, and lipid peroxidation being present in the brain tissue|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|0|mesh:D028361|Brain tissue|brain tissue|anatomy|190|C0459385
11|Mitochondrial dysfunction has been recently associated with FXS, with reports of  increases in oxidative stress markers, reactive oxygen species, and lipid peroxidation being present in the brain tissue|oxygen|oxygen|compound|130|mesh:D010100|FXS|FXS|disease|60|omim:300624
11|Mitochondrial dysfunction has been recently associated with FXS, with reports of  increases in oxidative stress markers, reactive oxygen species, and lipid peroxidation being present in the brain tissue|FXS|FXS|disease|60|omim:300624|Brain tissue|brain tissue|anatomy|190|C0459385
11|Mitochondrial dysfunction has been recently associated with FXS, with reports of  increases in oxidative stress markers, reactive oxygen species, and lipid peroxidation being present in the brain tissue|oxygen|oxygen|compound|130|mesh:D010100|Brain tissue|brain tissue|anatomy|190|C0459385
11|Astrocytes, a prominent glial cell within the central nervous system (CNS), play a large role in regulating oxidative homeostasis within the developing brain and dysregulation of astrocyte  redox balance in FXS, which may contribute to oxidative stress|FXS|FXS|disease|207|omim:300624|Astrocytes|astrocyte|anatomy|179|C0004112
11|Astrocytes, a prominent glial cell within the central nervous system (CNS), play a large role in regulating oxidative homeostasis within the developing brain and dysregulation of astrocyte  redox balance in FXS, which may contribute to oxidative stress|FXS|FXS|disease|207|omim:300624|Astrocytes|Astrocytes|anatomy|0|C0004112
11|Astrocytes, a prominent glial cell within the central nervous system (CNS), play a large role in regulating oxidative homeostasis within the developing brain and dysregulation of astrocyte  redox balance in FXS, which may contribute to oxidative stress|FXS|FXS|disease|207|omim:300624|Brain|brain|anatomy|152|C0006104
11|Astrocyte function and mitochondrial bioenergetics are significantly influenced by oxygen availability and circulating sex hormones; yet, these parameters are rarely considered during in vitro experimentation|oxygen|oxygen|compound|83|mesh:D010100|Mitochondria|mitochondrial|anatomy|23|C0026237
11|Given that the brain normally develops in a range of hypoxic conditions and FXS is a sex-linked genetic disorder, we investigated how different oxygen levels (normoxic vs|FXS|FXS|disease|76|omim:300624|sex-linked genetic disorder|sex-linked genetic disorder|disease|85|mesh:D025064
11|Given that the brain normally develops in a range of hypoxic conditions and FXS is a sex-linked genetic disorder, we investigated how different oxygen levels (normoxic vs|oxygen|oxygen|compound|144|mesh:D010100|FXS|FXS|disease|76|omim:300624
11|Given that the brain normally develops in a range of hypoxic conditions and FXS is a sex-linked genetic disorder, we investigated how different oxygen levels (normoxic vs|FXS|FXS|disease|76|omim:300624|Brain|brain|anatomy|15|C0006104
11|Given that the brain normally develops in a range of hypoxic conditions and FXS is a sex-linked genetic disorder, we investigated how different oxygen levels (normoxic vs|oxygen|oxygen|compound|144|mesh:D010100|sex-linked genetic disorder|sex-linked genetic disorder|disease|85|mesh:D025064
11|Given that the brain normally develops in a range of hypoxic conditions and FXS is a sex-linked genetic disorder, we investigated how different oxygen levels (normoxic vs|sex-linked genetic disorder|sex-linked genetic disorder|disease|85|mesh:D025064|Brain|brain|anatomy|15|C0006104
11|Given that the brain normally develops in a range of hypoxic conditions and FXS is a sex-linked genetic disorder, we investigated how different oxygen levels (normoxic vs|oxygen|oxygen|compound|144|mesh:D010100|Brain|brain|anatomy|15|C0006104
11|hypoxic) and  biological sex affected mitochondrial bioenergetics of astrocytes in FXS|FXS|FXS|disease|83|omim:300624|Astrocytes|astrocytes|anatomy|69|C0004112
11|hypoxic) and  biological sex affected mitochondrial bioenergetics of astrocytes in FXS|FXS|FXS|disease|83|omim:300624|Mitochondria|mitochondrial|anatomy|38|C0026237
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|oxygen|oxygen|compound|82|mesh:D010100|Fmr1|Fmr1|gene|123|NCBIGene:2332
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|oxygen|oxygen|compound|82|mesh:D010100|Astrocytes|astrocytes|anatomy|140|C0004112
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|oxygen|oxygen|compound|82|mesh:D010100|Emission - Male genitalia finding|emission|anatomy|97|C0233929
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|oxygen|oxygen|compound|82|mesh:D010100|Mitochondria|mitochondrial|anatomy|34|C0026237
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|oxygen|oxygen|compound|216|mesh:D010100|Fmr1|Fmr1|gene|123|NCBIGene:2332
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|Fmr1|Fmr1|gene|123|NCBIGene:2332|Astrocytes|astrocytes|anatomy|140|C0004112
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|Fmr1|Fmr1|gene|123|NCBIGene:2332|Emission - Male genitalia finding|emission|anatomy|97|C0233929
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|Fmr1|Fmr1|gene|123|NCBIGene:2332|Cell Respiration|respiration|physiology|48|C0282636
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|Fmr1|Fmr1|gene|123|NCBIGene:2332|Mitochondria|mitochondrial|anatomy|34|C0026237
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|oxygen|oxygen|compound|216|mesh:D010100|Astrocytes|astrocytes|anatomy|140|C0004112
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|oxygen|oxygen|compound|216|mesh:D010100|Emission - Male genitalia finding|emission|anatomy|97|C0233929
11|Our results demonstrate that both mitochondrial respiration capacity and reactive oxygen species emission are altered with Fmr1 deletion in astrocytes and these changes were dependent upon both sexual dimorphism and oxygen availability|oxygen|oxygen|compound|216|mesh:D010100|Mitochondria|mitochondrial|anatomy|34|C0026237
12|The association between maternal immune activation (MIA) during pregnancy and risk for offspring neuropsychiatric disorders has been increasingly recognized over the past several years|maternal|maternal|disease|24|mesh:D063130|MIA|MIA|disease|52|mesh:C567832
12|The association between maternal immune activation (MIA) during pregnancy and risk for offspring neuropsychiatric disorders has been increasingly recognized over the past several years|maternal|maternal|disease|24|mesh:D063130|neuropsychiatric disorders|neuropsychiatric disorders|disease|97|mesh:D001523
12|The association between maternal immune activation (MIA) during pregnancy and risk for offspring neuropsychiatric disorders has been increasingly recognized over the past several years|MIA|MIA|disease|52|mesh:C567832|neuropsychiatric disorders|neuropsychiatric disorders|disease|97|mesh:D001523
12|Among the mechanistic pathways that have been described through which maternal inflammation during pregnancy may affect fetal brain development, the role of mitochondria has received little attention|maternal inflammation|maternal inflammation|disease|70|mesh:D002821|Mitochondria|mitochondria|anatomy|157|C0026237
12|In this review, the role of mitochondria as a potential mediator of the association  between MIA during pregnancy and offspring brain development and risk for psychiatric disorders will be proposed|psychiatric disorders|psychiatric disorders|disease|159|mesh:D001523|Mitochondria|mitochondria|anatomy|28|C0026237
12|As a basis for this postulation, convergent evidence is presented supporting the obligatory role of mitochondria in brain development, the role of mitochondria as mediators and initiators of inflammatory processes, and evidence of mitochondrial dysfunction in preclinical  MIA exposure models and human neurodevelopmental disorders|mitochondrial dysfunction|mitochondrial dysfunction|disease|231|mesh:D028361|neurodevelopmental disorders|neurodevelopmental disorders|disease|303|mesh:D065886
12|Elucidating the role  of mitochondria as a potential mediator of MIA-induced alterations in brain development and neurodevelopmental disease risk may not only provide new insight  into the pathophysiology of mental health disorders that have their origins in exposure to infection/immune activation during pregnancy but also offer new therapeutic targets|neurodevelopmental disease|neurodevelopmental disease|disease|114|mesh:D065886|mental health disorders|mental health disorders|disease|208|mesh:D001523
12|Elucidating the role  of mitochondria as a potential mediator of MIA-induced alterations in brain development and neurodevelopmental disease risk may not only provide new insight  into the pathophysiology of mental health disorders that have their origins in exposure to infection/immune activation during pregnancy but also offer new therapeutic targets|neurodevelopmental disease|neurodevelopmental disease|disease|114|mesh:D065886|Mitochondria|mitochondria|anatomy|25|C0026237
12|Elucidating the role  of mitochondria as a potential mediator of MIA-induced alterations in brain development and neurodevelopmental disease risk may not only provide new insight  into the pathophysiology of mental health disorders that have their origins in exposure to infection/immune activation during pregnancy but also offer new therapeutic targets|mental health disorders|mental health disorders|disease|208|mesh:D001523|Mitochondria|mitochondria|anatomy|25|C0026237
13|Background: Prader-Willi syndrome (PWS) is a neurodevelopmental disorder characterized by hormonal dysregulation, obesity, intellectual disability, and behavioral problems|Prader-Willi syndrome|Prader-Willi syndrome|disease|12|omim:176270|neurodevelopmental disorder|neurodevelopmental disorder|disease|45|mesh:D065886
13|Background: Prader-Willi syndrome (PWS) is a neurodevelopmental disorder characterized by hormonal dysregulation, obesity, intellectual disability, and behavioral problems|Prader-Willi syndrome|Prader-Willi syndrome|disease|12|omim:176270|obesity|obesity|disease|114|omim:601665
13|Background: Prader-Willi syndrome (PWS) is a neurodevelopmental disorder characterized by hormonal dysregulation, obesity, intellectual disability, and behavioral problems|Prader-Willi syndrome|Prader-Willi syndrome|disease|12|omim:176270|intellectual disability|intellectual disability|disease|123|mesh:D008607
13|Background: Prader-Willi syndrome (PWS) is a neurodevelopmental disorder characterized by hormonal dysregulation, obesity, intellectual disability, and behavioral problems|PWS|PWS|disease|35|omim:176270|neurodevelopmental disorder|neurodevelopmental disorder|disease|45|mesh:D065886
13|Background: Prader-Willi syndrome (PWS) is a neurodevelopmental disorder characterized by hormonal dysregulation, obesity, intellectual disability, and behavioral problems|PWS|PWS|disease|35|omim:176270|obesity|obesity|disease|114|omim:601665
13|Background: Prader-Willi syndrome (PWS) is a neurodevelopmental disorder characterized by hormonal dysregulation, obesity, intellectual disability, and behavioral problems|PWS|PWS|disease|35|omim:176270|intellectual disability|intellectual disability|disease|123|mesh:D008607
13|Background: Prader-Willi syndrome (PWS) is a neurodevelopmental disorder characterized by hormonal dysregulation, obesity, intellectual disability, and behavioral problems|neurodevelopmental disorder|neurodevelopmental disorder|disease|45|mesh:D065886|obesity|obesity|disease|114|omim:601665
13|Background: Prader-Willi syndrome (PWS) is a neurodevelopmental disorder characterized by hormonal dysregulation, obesity, intellectual disability, and behavioral problems|neurodevelopmental disorder|neurodevelopmental disorder|disease|45|mesh:D065886|intellectual disability|intellectual disability|disease|123|mesh:D008607
13|Background: Prader-Willi syndrome (PWS) is a neurodevelopmental disorder characterized by hormonal dysregulation, obesity, intellectual disability, and behavioral problems|obesity|obesity|disease|114|omim:601665|intellectual disability|intellectual disability|disease|123|mesh:D008607
13|Most PWS cases are caused by paternal interstitial deletions of 15q11|PWS|PWS|disease|5|omim:176270|interstitial|interstitial|anatomy|38|C0596790
13|1, while a smaller number of cases are caused by chromosome 15 maternal uniparental disomy (PW-UPD)|chromosome 15 maternal uniparental disomy|chromosome 15 maternal uniparental disomy|disease|49|mesh:C538037|PW-UPD|PW-UPD|disease|92|mesh:D020734
13|Children with PW-UPD are at higher risk for developing autism spectrum disorder (ASD) than the neurotypical population|PW-UPD|PW-UPD|disease|14|mesh:D020734|autism spectrum disorder|autism spectrum disorder|disease|55|mesh:D002659
13|Children with PW-UPD are at higher risk for developing autism spectrum disorder (ASD) than the neurotypical population|PW-UPD|PW-UPD|disease|14|mesh:D020734|ASD|ASD|disease|81|mesh:D006344
13|Children with PW-UPD are at higher risk for developing autism spectrum disorder (ASD) than the neurotypical population|autism spectrum disorder|autism spectrum disorder|disease|55|mesh:D002659|ASD|ASD|disease|81|mesh:D006344
13|In this study, we used expression analysis of PW-UPD neurons to try to identify the  molecular cause for increased autism risk|autism|autism|disease|115|omim:209850|Neurons|neurons|anatomy|53|C0027882
13|Methods: Dental pulp stem cells (DPSC) from neurotypical control and PWS subjects were differentiated to neurons for mRNA sequencing|PWS|PWS|disease|69|omim:176270|Neurons|neurons|anatomy|105|C0027882
13|1) that may contribute to core PWS phenotypes|PWS|PWS|disease|31|omim:176270|Core Specimen|core|anatomy|26|C3274653
13|Moreover, we discovered a global reduction in mitochondrial transcripts in the PW-UPD + ASD group|PW-UPD|PW-UPD|disease|79|mesh:D020734|ASD|ASD|disease|88|mesh:D006344
13|We also found decreased mitochondrial abundance along with mitochondrial aggregates in the cell body and neural projections of +ASD neurons|ASD|ASD|disease|128|mesh:D006344|Cell body of neuron|cell body|anatomy|91|C0599444
13|Importantly, we found a global reduction in mitochondrial transcripts in PW-UPD + ASD neurons versus control and other PWS subtypes|ASD|ASD|disease|82|mesh:D006344|PWS|PWS|disease|119|omim:176270
13|Importantly, we found a global reduction in mitochondrial transcripts in PW-UPD + ASD neurons versus control and other PWS subtypes|ASD|ASD|disease|82|mesh:D006344|Neurons|neurons|anatomy|86|C0027882
13|Importantly, we found a global reduction in mitochondrial transcripts in PW-UPD + ASD neurons versus control and other PWS subtypes|PWS|PWS|disease|119|omim:176270|Neurons|neurons|anatomy|86|C0027882
13|We then confirmed mitochondrial defects in neurons from individuals with PWS at the cellular level|PWS|PWS|disease|73|omim:176270|Cells|cellular|anatomy|84|C0007634
13|We then confirmed mitochondrial defects in neurons from individuals with PWS at the cellular level|PWS|PWS|disease|73|omim:176270|Mitochondria|mitochondrial|anatomy|18|C0026237
13|We then confirmed mitochondrial defects in neurons from individuals with PWS at the cellular level|PWS|PWS|disease|73|omim:176270|Neurons|neurons|anatomy|43|C0027882
13|Quantification of this phenotype supports our hypothesis that the increased incidence of ASD in PW-UPD subjects may arise from mitochondrial defects in developing neurons|ASD|ASD|disease|89|mesh:D006344|PW-UPD|PW-UPD|disease|96|mesh:D020734
13|Quantification of this phenotype supports our hypothesis that the increased incidence of ASD in PW-UPD subjects may arise from mitochondrial defects in developing neurons|ASD|ASD|disease|89|mesh:D006344|Neurons|neurons|anatomy|163|C0027882
13|Quantification of this phenotype supports our hypothesis that the increased incidence of ASD in PW-UPD subjects may arise from mitochondrial defects in developing neurons|ASD|ASD|disease|89|mesh:D006344|Mitochondria|mitochondrial|anatomy|127|C0026237
13|Quantification of this phenotype supports our hypothesis that the increased incidence of ASD in PW-UPD subjects may arise from mitochondrial defects in developing neurons|PW-UPD|PW-UPD|disease|96|mesh:D020734|Neurons|neurons|anatomy|163|C0027882
13|Quantification of this phenotype supports our hypothesis that the increased incidence of ASD in PW-UPD subjects may arise from mitochondrial defects in developing neurons|PW-UPD|PW-UPD|disease|96|mesh:D020734|Mitochondria|mitochondrial|anatomy|127|C0026237
14|A growing body of evidence has emerged demonstrating a pathological link between  oxidative stress and schizophrenia|schizophrenia|schizophrenia|disease|103|omim:181500|Adult human body|body|anatomy|10|C4082212
14|We focus on evidence supporting the crucial role of either redox dysregulation, N-methyl-D-aspartate receptor hypofunction, neuroinflammation or mitochondria bioenergetics dysfunction, initiating "vicious circles" centered on oxidative stress during neurodevelopment|N-methyl-D-aspartate|N-methyl-D-aspartate|compound|80|mesh:D016202|neuroinflammation|neuroinflammation|disease|124|mesh:D020078
14|We focus on evidence supporting the crucial role of either redox dysregulation, N-methyl-D-aspartate receptor hypofunction, neuroinflammation or mitochondria bioenergetics dysfunction, initiating "vicious circles" centered on oxidative stress during neurodevelopment|N-methyl-D-aspartate receptor|N-methyl-D-aspartate receptor|gene|80|NCBIGene:2902|neuroinflammation|neuroinflammation|disease|124|mesh:D020078
14|We focus on evidence supporting the crucial role of either redox dysregulation, N-methyl-D-aspartate receptor hypofunction, neuroinflammation or mitochondria bioenergetics dysfunction, initiating "vicious circles" centered on oxidative stress during neurodevelopment|N-methyl-D-aspartate receptor|N-methyl-D-aspartate receptor|gene|80|NCBIGene:2902|neurodevelopment|neurodevelopment|physiology|250|C0599855
14|We focus on evidence supporting the crucial role of either redox dysregulation, N-methyl-D-aspartate receptor hypofunction, neuroinflammation or mitochondria bioenergetics dysfunction, initiating "vicious circles" centered on oxidative stress during neurodevelopment|N-methyl-D-aspartate receptor|N-methyl-D-aspartate receptor|gene|80|NCBIGene:2902|Oxidation-Reduction|redox|physiology|59|C0030012
14|These processes would amplify one another in positive feed-forward loops, leading to persistent impairments of the maturation and function of local parvalbumin-GABAergic neurons microcircuits and myelinated fibers of long-range macrocircuitry|parvalbumin|parvalbumin|gene|148|NCBIGene:5816|bony process|processes|anatomy|6|C1184743
14|These processes would amplify one another in positive feed-forward loops, leading to persistent impairments of the maturation and function of local parvalbumin-GABAergic neurons microcircuits and myelinated fibers of long-range macrocircuitry|parvalbumin|parvalbumin|gene|148|NCBIGene:5816|Tissue fiber|fibers|anatomy|207|C1304649
14|These processes would amplify one another in positive feed-forward loops, leading to persistent impairments of the maturation and function of local parvalbumin-GABAergic neurons microcircuits and myelinated fibers of long-range macrocircuitry|parvalbumin|parvalbumin|gene|148|NCBIGene:5816|Anatomical maturation|maturation|physiology|115|C1254042
14|These processes would amplify one another in positive feed-forward loops, leading to persistent impairments of the maturation and function of local parvalbumin-GABAergic neurons microcircuits and myelinated fibers of long-range macrocircuitry|parvalbumin|parvalbumin|gene|148|NCBIGene:5816|Function Axis|function|physiology|130|C0700205
14|These processes would amplify one another in positive feed-forward loops, leading to persistent impairments of the maturation and function of local parvalbumin-GABAergic neurons microcircuits and myelinated fibers of long-range macrocircuitry|parvalbumin|parvalbumin|gene|148|NCBIGene:5816|Myelin Sheath|myelinated|anatomy|196|C0026973
14|This is at the basis of neural circuit synchronization impairments and cognitive, emotional, social and sensory deficits characteristic of schizophrenia|cognitive, emotional, social and sensory deficits|cognitive, emotional, social and sensory deficits|disease|71|mesh:D003072|schizophrenia|schizophrenia|disease|139|omim:181500
14|In order to improve early detection and increase the signal-to-noise ratio for adjunctive trials of antioxidant, anti-inflammatory and NMDAR modulator drugs, a reverse translation of validated circuitry approach  is needed|NMDAR|NMDAR|gene|135|NCBIGene:2902|Genetic Translation Process|translation|physiology|168|C1519614
15|Mitochondrial dysfunction is an underlying cause of childhood neurological disease secondary to the crucial role of mitochondria in proper neurodevelopment|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|0|mesh:D028361|childhood neurological disease|childhood neurological disease|disease|52|mesh:D002493
15|Mitochondrial dysfunction is an underlying cause of childhood neurological disease secondary to the crucial role of mitochondria in proper neurodevelopment|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|0|mesh:D028361|Mitochondria|mitochondria|anatomy|116|C0026237
15|Mitochondrial dysfunction is an underlying cause of childhood neurological disease secondary to the crucial role of mitochondria in proper neurodevelopment|childhood neurological disease|childhood neurological disease|disease|52|mesh:D002493|Mitochondria|mitochondria|anatomy|116|C0026237
15|We hypothesized that chronic intrauterine hypoxia (HPX) induces mitochondrial deficits by altering mitochondrial biogenesis and dynamics in the fetal brain|intrauterine hypoxia|intrauterine hypoxia|disease|29|mesh:D005311|mitochondrial deficits|mitochondrial deficits|disease|64|mesh:D028361
15|We hypothesized that chronic intrauterine hypoxia (HPX) induces mitochondrial deficits by altering mitochondrial biogenesis and dynamics in the fetal brain|intrauterine hypoxia|intrauterine hypoxia|disease|29|mesh:D005311|Fetal brain|fetal brain|anatomy|144|C0440731
15|We hypothesized that chronic intrauterine hypoxia (HPX) induces mitochondrial deficits by altering mitochondrial biogenesis and dynamics in the fetal brain|mitochondrial deficits|mitochondrial deficits|disease|64|mesh:D028361|Fetal brain|fetal brain|anatomy|144|C0440731
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|mitochondrial complex subunits I-V|mitochondrial complex subunits I-V|gene|14|NCBIGene:4540|CI-CV|CI-CV|gene|50|NCBIGene:341
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|mitochondrial complex subunits I-V|mitochondrial complex subunits I-V|gene|14|NCBIGene:4540|fission|fission|gene|58|NCBIGene:51024
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|mitochondrial complex subunits I-V|mitochondrial complex subunits I-V|gene|14|NCBIGene:4540|Drp-1|Drp-1|gene|67|NCBIGene:8562
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|mitochondrial complex subunits I-V|mitochondrial complex subunits I-V|gene|14|NCBIGene:4540|fusion|fusion|gene|79|NCBIGene:2522
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|mitochondrial complex subunits I-V|mitochondrial complex subunits I-V|gene|14|NCBIGene:4540|Mfn-2|Mfn-2|gene|87|NCBIGene:9927
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|mitochondrial complex subunits I-V|mitochondrial complex subunits I-V|gene|14|NCBIGene:4540|ciliary vesicle|CV|anatomy|53|C4318503
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|CI-CV|CI-CV|gene|50|NCBIGene:341|fission|fission|gene|58|NCBIGene:51024
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|CI-CV|CI-CV|gene|50|NCBIGene:341|Drp-1|Drp-1|gene|67|NCBIGene:8562
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|CI-CV|CI-CV|gene|50|NCBIGene:341|fusion|fusion|gene|79|NCBIGene:2522
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|CI-CV|CI-CV|gene|50|NCBIGene:341|Mfn-2|Mfn-2|gene|87|NCBIGene:9927
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|CI-CV|CI-CV|gene|50|NCBIGene:341|Mitochondria|mitochondrial|anatomy|14|C0026237
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|fission|fission|gene|58|NCBIGene:51024|Drp-1|Drp-1|gene|67|NCBIGene:8562
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|fission|fission|gene|58|NCBIGene:51024|fusion|fusion|gene|79|NCBIGene:2522
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|fission|fission|gene|58|NCBIGene:51024|Mfn-2|Mfn-2|gene|87|NCBIGene:9927
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|fission|fission|gene|58|NCBIGene:51024|ciliary vesicle|CV|anatomy|53|C4318503
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|fission|fission|gene|58|NCBIGene:51024|Mitochondria|mitochondrial|anatomy|14|C0026237
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|Drp-1|Drp-1|gene|67|NCBIGene:8562|fusion|fusion|gene|79|NCBIGene:2522
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|Drp-1|Drp-1|gene|67|NCBIGene:8562|Mfn-2|Mfn-2|gene|87|NCBIGene:9927
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|Drp-1|Drp-1|gene|67|NCBIGene:8562|ciliary vesicle|CV|anatomy|53|C4318503
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|Drp-1|Drp-1|gene|67|NCBIGene:8562|Mitochondria|mitochondrial|anatomy|14|C0026237
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|fusion|fusion|gene|79|NCBIGene:2522|Mfn-2|Mfn-2|gene|87|NCBIGene:9927
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|fusion|fusion|gene|79|NCBIGene:2522|ciliary vesicle|CV|anatomy|53|C4318503
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|fusion|fusion|gene|79|NCBIGene:2522|Mitochondria|mitochondrial|anatomy|14|C0026237
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|Mfn-2|Mfn-2|gene|87|NCBIGene:9927|ciliary vesicle|CV|anatomy|53|C4318503
15|Expression of mitochondrial complex subunits I-V (CI-CV), fission (Drp-1), and fusion (Mfn-2) proteins was measured by Western blot|Mfn-2|Mfn-2|gene|87|NCBIGene:9927|Mitochondria|mitochondrial|anatomy|14|C0026237
15|CI and CIV enzyme activities were measured by colorimetric assays|CI|CI|gene|0|NCBIGene:4712|CIV|CIV|gene|7|NCBIGene:346
15|CI and CIV enzyme activities were measured by colorimetric assays|CI|CI|gene|0|NCBIGene:4712|enzyme activity|enzyme activities|physiology|11|C0243102
15|CI and CIV enzyme activities were measured by colorimetric assays|CIV|CIV|gene|7|NCBIGene:346|enzyme activity|enzyme activities|physiology|11|C0243102
15|CV subunit levels were increased in EO-HPX males only and CII levels increased in LO-HPX females only compared to NMX|CII|CII|gene|58|NCBIGene:4712|EO-HPX|EO-HPX|disease|36|mesh:C562782
15|CV subunit levels were increased in EO-HPX males only and CII levels increased in LO-HPX females only compared to NMX|EO-HPX|EO-HPX|disease|36|mesh:C562782|NMX|NMX|disease|114|mesh:C536816
15|CV subunit levels were increased in EO-HPX males only and CII levels increased in LO-HPX females only compared to NMX|EO-HPX|EO-HPX|disease|36|mesh:C562782|ciliary vesicle|CV|anatomy|0|C4318503
15|CV subunit levels were increased in EO-HPX males only and CII levels increased in LO-HPX females only compared to NMX|CII|CII|gene|58|NCBIGene:4712|HPX|HPX|disease|85|mesh:C562782
15|CV subunit levels were increased in EO-HPX males only and CII levels increased in LO-HPX females only compared to NMX|CII|CII|gene|58|NCBIGene:4712|NMX|NMX|disease|114|mesh:C536816
15|CV subunit levels were increased in EO-HPX males only and CII levels increased in LO-HPX females only compared to NMX|CII|CII|gene|58|NCBIGene:4712|Females|females|physiology|89|C0086287
15|CV subunit levels were increased in EO-HPX males only and CII levels increased in LO-HPX females only compared to NMX|CII|CII|gene|58|NCBIGene:4712|Males|males|physiology|43|C0086582
15|CV subunit levels were increased in EO-HPX males only and CII levels increased in LO-HPX females only compared to NMX|CII|CII|gene|58|NCBIGene:4712|ciliary vesicle|CV|anatomy|0|C4318503
15|CV subunit levels were increased in EO-HPX males only and CII levels increased in LO-HPX females only compared to NMX|HPX|HPX|disease|85|mesh:C562782|NMX|NMX|disease|114|mesh:C536816
15|CV subunit levels were increased in EO-HPX males only and CII levels increased in LO-HPX females only compared to NMX|HPX|HPX|disease|85|mesh:C562782|ciliary vesicle|CV|anatomy|0|C4318503
15|CV subunit levels were increased in EO-HPX males only and CII levels increased in LO-HPX females only compared to NMX|NMX|NMX|disease|114|mesh:C536816|ciliary vesicle|CV|anatomy|0|C4318503
15|Both EO- and LO-HPX decreased CIV activity in both sexes but had no effect on CI activity|CIV|CIV|gene|30|NCBIGene:346|CI|CI|gene|78|NCBIGene:4712
15|EO-HPX increased Drp1 and decreased Mfn2 levels in males, while LO-HPX had no effect on either protein levels|Drp1|Drp1|gene|17|NCBIGene:8562|Mfn2|Mfn2|gene|36|NCBIGene:9927
15|EO-HPX increased Drp1 and decreased Mfn2 levels in males, while LO-HPX had no effect on either protein levels|Drp1|Drp1|gene|17|NCBIGene:8562|Males|males|physiology|51|C0086582
15|EO-HPX increased Drp1 and decreased Mfn2 levels in males, while LO-HPX had no effect on either protein levels|Mfn2|Mfn2|gene|36|NCBIGene:9927|Males|males|physiology|51|C0086582
15|In females, both EO-HPX and LO-HPX increased Drp1 but had no effect on Mfn2 levels|Drp1|Drp1|gene|45|NCBIGene:8562|Mfn2|Mfn2|gene|71|NCBIGene:9927
15|In females, both EO-HPX and LO-HPX increased Drp1 but had no effect on Mfn2 levels|Drp1|Drp1|gene|45|NCBIGene:8562|Females|females|physiology|3|C0086287
15|In females, both EO-HPX and LO-HPX increased Drp1 but had no effect on Mfn2 levels|Mfn2|Mfn2|gene|71|NCBIGene:9927|Females|females|physiology|3|C0086287
15|This may be an underlying mechanism of reduced respiratory efficiency leading to disrupted metabolism and increased vulnerability to a second neurological injury at the time of birth in HPX fetal brains|neurological injury|neurological injury|disease|142|mesh:D009410|HPX|HPX|disease|186|mesh:C562782
15|This may be an underlying mechanism of reduced respiratory efficiency leading to disrupted metabolism and increased vulnerability to a second neurological injury at the time of birth in HPX fetal brains|neurological injury|neurological injury|disease|142|mesh:D009410|Fetal brain|fetal brains|anatomy|190|C0440731
15|This may be an underlying mechanism of reduced respiratory efficiency leading to disrupted metabolism and increased vulnerability to a second neurological injury at the time of birth in HPX fetal brains|HPX|HPX|disease|186|mesh:C562782|Fetal brain|fetal brains|anatomy|190|C0440731
16|Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with extensive genetic and aetiological heterogeneity|Autism Spectrum Disorder|Autism Spectrum Disorder|disease|0|mesh:D002659|ASD|ASD|disease|26|mesh:D006344
16|Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with extensive genetic and aetiological heterogeneity|Autism Spectrum Disorder|Autism Spectrum Disorder|disease|0|mesh:D002659|neurodevelopmental disorder|neurodevelopmental disorder|disease|44|mesh:D065886
16|Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with extensive genetic and aetiological heterogeneity|ASD|ASD|disease|26|mesh:D006344|neurodevelopmental disorder|neurodevelopmental disorder|disease|44|mesh:D065886
16|We identify canonical pathways that are consistently implicated  in ASD molecular data and find an enrichment of pathways involved in mitochondrial metabolism and neurogenesis|ASD|ASD|disease|68|mesh:D006344|Mitochondria|mitochondrial|anatomy|134|C0026237
16|This review highlights how proteomics can uncover potential molecular mechanisms to explain a link between mitochondrial dysfunction and neurodevelopmental pathology|mitochondrial dysfunction|mitochondrial dysfunction|disease|107|mesh:D028361|neurodevelopmental|neurodevelopmental|disease|137|mesh:D065886
17|Hereditary spastic paraplegias are heterogeneous neurodegenerative disorders|Hereditary spastic paraplegias|Hereditary spastic paraplegias|disease|0|mesh:D015419|neurodegenerative disorders|neurodegenerative disorders|disease|49|mesh:D019636
17|We characterized a mouse model lacking the Cyp2u1 gene, loss of which is known to be involved in a complex form of these diseases in humans|Cyp2u1 gene|Cyp2u1 gene|gene|43|NCBIGene:113612|Form:Finding:Point in time:{Setting}:Document:{Role}|form|physiology|107|C4255237
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|vitamin B2|vitamin B2|compound|75|mesh:D012256|CYP2U1 enzyme|CYP2U1 enzyme|gene|108|NCBIGene:113612
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|vitamin B2|vitamin B2|compound|75|mesh:D012256|coenzyme Q|coenzyme Q|compound|134|mesh:D014451
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|vitamin B2|vitamin B2|compound|75|mesh:D012256|neopterin|neopterin|compound|146|mesh:D019798
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|vitamin B2|vitamin B2|compound|75|mesh:D012256|IFN- levels|IFN- levels|gene|161|NCBIGene:3439
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|vitamin B2|vitamin B2|compound|75|mesh:D012256|CYP2U1|CYP2U1|gene|251|NCBIGene:113612
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|vitamin B2|vitamin B2|compound|75|mesh:D012256|Body Fluids and Substances|fluids|anatomy|209|C1521806
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|coenzyme Q|coenzyme Q|compound|134|mesh:D014451|CYP2U1 enzyme|CYP2U1 enzyme|gene|108|NCBIGene:113612
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|neopterin|neopterin|compound|146|mesh:D019798|CYP2U1 enzyme|CYP2U1 enzyme|gene|108|NCBIGene:113612
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|CYP2U1 enzyme|CYP2U1 enzyme|gene|108|NCBIGene:113612|IFN- levels|IFN- levels|gene|161|NCBIGene:3439
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|CYP2U1 enzyme|CYP2U1 enzyme|gene|108|NCBIGene:113612|Body Fluids and Substances|fluids|anatomy|209|C1521806
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|coenzyme Q|coenzyme Q|compound|134|mesh:D014451|neopterin|neopterin|compound|146|mesh:D019798
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|coenzyme Q|coenzyme Q|compound|134|mesh:D014451|IFN- levels|IFN- levels|gene|161|NCBIGene:3439
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|coenzyme Q|coenzyme Q|compound|134|mesh:D014451|CYP2U1|CYP2U1|gene|251|NCBIGene:113612
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|coenzyme Q|coenzyme Q|compound|134|mesh:D014451|Body Fluids and Substances|fluids|anatomy|209|C1521806
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|neopterin|neopterin|compound|146|mesh:D019798|IFN- levels|IFN- levels|gene|161|NCBIGene:3439
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|neopterin|neopterin|compound|146|mesh:D019798|CYP2U1|CYP2U1|gene|251|NCBIGene:113612
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|neopterin|neopterin|compound|146|mesh:D019798|Body Fluids and Substances|fluids|anatomy|209|C1521806
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|IFN- levels|IFN- levels|gene|161|NCBIGene:3439|CYP2U1|CYP2U1|gene|251|NCBIGene:113612
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|IFN- levels|IFN- levels|gene|161|NCBIGene:3439|Body Fluids and Substances|fluids|anatomy|209|C1521806
17|Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far|CYP2U1|CYP2U1|gene|251|NCBIGene:113612|Body Fluids and Substances|fluids|anatomy|209|C1521806
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|folate|folate|compound|140|CHEBI:62501|CYP2U1 deficiency|CYP2U1 deficiency|disease|25|mesh:C535979
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|CYP2U1 deficiency|CYP2U1 deficiency|disease|25|mesh:C535979|neurodegenerative|neurodegenerative|disease|197|mesh:D009410
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|CYP2U1 deficiency|CYP2U1 deficiency|disease|25|mesh:C535979|Body tissue|tissues|anatomy|268|C0040300
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|CYP2U1 deficiency|CYP2U1 deficiency|disease|25|mesh:C535979|bony process|process|anatomy|215|C1184743
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|folate|folate|compound|140|CHEBI:62501|CYP2U1|CYP2U1|gene|25|NCBIGene:113612
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|CYP2U1|CYP2U1|gene|25|NCBIGene:113612|neurodegenerative|neurodegenerative|disease|197|mesh:D009410
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|CYP2U1|CYP2U1|gene|25|NCBIGene:113612|Body tissue|tissues|anatomy|268|C0040300
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|CYP2U1|CYP2U1|gene|25|NCBIGene:113612|Function Axis|function|physiology|66|C0700205
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|CYP2U1|CYP2U1|gene|25|NCBIGene:113612|neurodevelopment|neurodevelopment|physiology|94|C0599855
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|CYP2U1|CYP2U1|gene|25|NCBIGene:113612|bony process|process|anatomy|215|C1184743
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|folate|folate|compound|140|CHEBI:62501|neurodegenerative|neurodegenerative|disease|197|mesh:D009410
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|folate|folate|compound|140|CHEBI:62501|Body tissue|tissues|anatomy|268|C0040300
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|folate|folate|compound|140|CHEBI:62501|bony process|process|anatomy|215|C1184743
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|neurodegenerative|neurodegenerative|disease|197|mesh:D009410|Body tissue|tissues|anatomy|268|C0040300
17|Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues|neurodegenerative|neurodegenerative|disease|197|mesh:D009410|bony process|process|anatomy|215|C1184743
18|Trimethyltin (TMT) is an irreversible neurotoxicant|Trimethyltin|Trimethyltin|compound|0|CHEBI:63948|TMT|TMT|compound|14|CHEBI:74322
18|In behavioral testing of offspring at 5 weeks of age, the total times spent in the center, corner, or border zones in the male prenatal TMT-exposed mice were less than those of control unexposed mice in the open-field test|TMT|TMT|compound|136|CHEBI:74322|Test - temporal region|test|anatomy|218|C4318744
18|In behavioral testing of offspring at 5 weeks of age, the total times spent in the center, corner, or border zones in the male prenatal TMT-exposed mice were less than those of control unexposed mice in the open-field test|TMT|TMT|compound|136|CHEBI:74322|Anatomic Border|border|anatomy|102|C1522411
18|Female TMT-exposed mice scored lower on total numbers of arm entries and percentages of alternations than controls in the Y-maze test with lower body weight|TMT|TMT|compound|7|CHEBI:74322|Body Site Modifier - Lower|lower|anatomy|31|C1548802
18|We found that only TMT-exposed males had fewer copies of mtDNA in the hippocampus and prefrontal cortex region than controls|TMT|TMT|compound|19|CHEBI:74322|Hippocampus (Brain)|hippocampus|anatomy|70|C0019564
18|We found that only TMT-exposed males had fewer copies of mtDNA in the hippocampus and prefrontal cortex region than controls|TMT|TMT|compound|19|CHEBI:74322|Prefrontal Cortex|[|anatomy|86|C0162783
18|We found that only TMT-exposed males had fewer copies of mtDNA in the hippocampus and prefrontal cortex region than controls|TMT|TMT|compound|19|CHEBI:74322|mitochondrial DNA location|mtDNA|anatomy|57|C1819717
18|Additional epigenetic changes, including increased 5-methyl cytosine/5-hydroxymethyl cytosine levels in the male TMT hippocampus, were observed|5-methyl cytosine|5-methyl cytosine|compound|51|mesh:D044503|5-hydroxymethyl cytosine|5-hydroxymethyl cytosine|compound|69|mesh:C011865
18|Additional epigenetic changes, including increased 5-methyl cytosine/5-hydroxymethyl cytosine levels in the male TMT hippocampus, were observed|5-methyl cytosine|5-methyl cytosine|compound|51|mesh:D044503|TMT|TMT|disease|113|mesh:C564664
18|Additional epigenetic changes, including increased 5-methyl cytosine/5-hydroxymethyl cytosine levels in the male TMT hippocampus, were observed|5-methyl cytosine|5-methyl cytosine|compound|51|mesh:D044503|Hippocampus (Brain)|hippocampus|anatomy|117|C0019564
18|Additional epigenetic changes, including increased 5-methyl cytosine/5-hydroxymethyl cytosine levels in the male TMT hippocampus, were observed|5-hydroxymethyl cytosine|5-hydroxymethyl cytosine|compound|69|mesh:C011865|TMT|TMT|disease|113|mesh:C564664
18|Additional epigenetic changes, including increased 5-methyl cytosine/5-hydroxymethyl cytosine levels in the male TMT hippocampus, were observed|5-hydroxymethyl cytosine|5-hydroxymethyl cytosine|compound|69|mesh:C011865|Hippocampus (Brain)|hippocampus|anatomy|117|C0019564
18|Additional epigenetic changes, including increased 5-methyl cytosine/5-hydroxymethyl cytosine levels in the male TMT hippocampus, were observed|TMT|TMT|disease|113|mesh:C564664|Hippocampus (Brain)|hippocampus|anatomy|117|C0019564
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|methylation binding domain|methylation binding domain|gene|6|NCBIGene:4152|FoxO|FoxO|gene|133|NCBIGene:2309
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|methylation binding domain|methylation binding domain|gene|6|NCBIGene:4152|neurodevelopment|neurodevelopment|physiology|105|C0599855
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|methylation binding domain|methylation binding domain|gene|6|NCBIGene:4152|Signal Transduction Pathways|signaling pathways|physiology|60|C0086982
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|methylation binding domain|methylation binding domain|gene|6|NCBIGene:4152|Signal Transduction|signaling|physiology|138|C0037083
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|methylation binding domain|methylation binding domain|gene|6|NCBIGene:4152|Metabolism|metabolism|physiology|90|C0025519
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|MBD|MBD|gene|34|NCBIGene:4152|FoxO|FoxO|gene|133|NCBIGene:2309
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|MBD|MBD|gene|34|NCBIGene:4152|neurodevelopment|neurodevelopment|physiology|105|C0599855
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|MBD|MBD|gene|34|NCBIGene:4152|Signal Transduction Pathways|signaling pathways|physiology|60|C0086982
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|MBD|MBD|gene|34|NCBIGene:4152|Signal Transduction|signaling|physiology|138|C0037083
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|MBD|MBD|gene|34|NCBIGene:4152|Metabolism|metabolism|physiology|90|C0025519
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|FoxO|FoxO|gene|133|NCBIGene:2309|neurodevelopment|neurodevelopment|physiology|105|C0599855
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|FoxO|FoxO|gene|133|NCBIGene:2309|Signal Transduction Pathways|signaling pathways|physiology|60|C0086982
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|FoxO|FoxO|gene|133|NCBIGene:2309|Signal Transduction|signaling|physiology|138|C0037083
18|After methylation binding domain (MBD) sequencing, multiple signaling pathways related to metabolism and neurodevelopment, including FoxO signaling, were identified by pathway analysis for differentially methylated regions (DMRs)|FoxO|FoxO|gene|133|NCBIGene:2309|Metabolism|metabolism|physiology|90|C0025519
18|Increased FOXO3 and decreased ASCL1 expression were also observed in male TMT hippocampi|FOXO3|FOXO3|gene|10|NCBIGene:2309|ASCL1|ASCL1|gene|30|NCBIGene:429
18|Increased FOXO3 and decreased ASCL1 expression were also observed in male TMT hippocampi|FOXO3|FOXO3|gene|10|NCBIGene:2309|TMT|TMT|disease|74|mesh:C564664
18|Increased FOXO3 and decreased ASCL1 expression were also observed in male TMT hippocampi|FOXO3|FOXO3|gene|10|NCBIGene:2309|Hippocampus (Brain)|hippocampi|anatomy|78|C0019564
18|Increased FOXO3 and decreased ASCL1 expression were also observed in male TMT hippocampi|FOXO3|FOXO3|gene|10|NCBIGene:2309|Male, Self-Reported|male|physiology|69|C1706429
18|Increased FOXO3 and decreased ASCL1 expression were also observed in male TMT hippocampi|FOXO3|FOXO3|gene|10|NCBIGene:2309|thiol S-methyltransferase activity|TMT|physiology|74|C1152354
18|Increased FOXO3 and decreased ASCL1 expression were also observed in male TMT hippocampi|ASCL1|ASCL1|gene|30|NCBIGene:429|TMT|TMT|disease|74|mesh:C564664
18|Increased FOXO3 and decreased ASCL1 expression were also observed in male TMT hippocampi|ASCL1|ASCL1|gene|30|NCBIGene:429|Hippocampus (Brain)|hippocampi|anatomy|78|C0019564
18|Increased FOXO3 and decreased ASCL1 expression were also observed in male TMT hippocampi|ASCL1|ASCL1|gene|30|NCBIGene:429|Male, Self-Reported|male|physiology|69|C1706429
18|Increased FOXO3 and decreased ASCL1 expression were also observed in male TMT hippocampi|ASCL1|ASCL1|gene|30|NCBIGene:429|thiol S-methyltransferase activity|TMT|physiology|74|C1152354
18|Increased FOXO3 and decreased ASCL1 expression were also observed in male TMT hippocampi|TMT|TMT|disease|74|mesh:C564664|Hippocampus (Brain)|hippocampi|anatomy|78|C0019564
19|Genetic defects affecting cytoplasmic  translation perturb synapse development, neurotransmission, and are causative of  neurodevelopmental disorders, such as Fragile X syndrome|Genetic defects|Genetic defects|disease|0|mesh:D030342|neurodevelopmental disorders|neurodevelopmental disorders|disease|121|mesh:D065886
19|Genetic defects affecting cytoplasmic  translation perturb synapse development, neurotransmission, and are causative of  neurodevelopmental disorders, such as Fragile X syndrome|Genetic defects|Genetic defects|disease|0|mesh:D030342|Fragile X syndrome|Fragile X syndrome|disease|159|omim:300624
19|Genetic defects affecting cytoplasmic  translation perturb synapse development, neurotransmission, and are causative of  neurodevelopmental disorders, such as Fragile X syndrome|neurodevelopmental disorders|neurodevelopmental disorders|disease|121|mesh:D065886|Fragile X syndrome|Fragile X syndrome|disease|159|omim:300624
19|Here we focus on two genes deleted in a recurrent copy  number variation causing neurodevelopmental disorders, the 22q11|neurodevelopmental disorders|neurodevelopmental disorders|disease|81|mesh:D065886|22q11|22q11|anatomy|115|C1521101
19|We demonstrate that SLC25A1 and MRPL40, two genes present in the microdeleted segment and whose products localize to mitochondria, interact and are necessary for mitochondrial ribosomal integrity and proteostasis|SLC25A1|SLC25A1|gene|20|NCBIGene:6576|MRPL40|MRPL40|gene|32|NCBIGene:64976
19|We demonstrate that SLC25A1 and MRPL40, two genes present in the microdeleted segment and whose products localize to mitochondria, interact and are necessary for mitochondrial ribosomal integrity and proteostasis|SLC25A1|SLC25A1|gene|20|NCBIGene:6576|Proteostasis|proteostasis|physiology|200|C4505258
19|We demonstrate that SLC25A1 and MRPL40, two genes present in the microdeleted segment and whose products localize to mitochondria, interact and are necessary for mitochondrial ribosomal integrity and proteostasis|SLC25A1|SLC25A1|gene|20|NCBIGene:6576|Mitochondria|mitochondria|anatomy|117|C0026237
19|We demonstrate that SLC25A1 and MRPL40, two genes present in the microdeleted segment and whose products localize to mitochondria, interact and are necessary for mitochondrial ribosomal integrity and proteostasis|SLC25A1|SLC25A1|gene|20|NCBIGene:6576|Mitochondrial Ribosomes|mitochondrial ribosomal|anatomy|162|C1166893
19|We demonstrate that SLC25A1 and MRPL40, two genes present in the microdeleted segment and whose products localize to mitochondria, interact and are necessary for mitochondrial ribosomal integrity and proteostasis|MRPL40|MRPL40|gene|32|NCBIGene:64976|Proteostasis|proteostasis|physiology|200|C4505258
19|We demonstrate that SLC25A1 and MRPL40, two genes present in the microdeleted segment and whose products localize to mitochondria, interact and are necessary for mitochondrial ribosomal integrity and proteostasis|MRPL40|MRPL40|gene|32|NCBIGene:64976|Mitochondria|mitochondria|anatomy|117|C0026237
19|We demonstrate that SLC25A1 and MRPL40, two genes present in the microdeleted segment and whose products localize to mitochondria, interact and are necessary for mitochondrial ribosomal integrity and proteostasis|MRPL40|MRPL40|gene|32|NCBIGene:64976|Mitochondrial Ribosomes|mitochondrial ribosomal|anatomy|162|C1166893
19|We propose that mitochondrial proteostasis perturbations, either by genetic or environmental factors, are a pathogenic mechanism for neurodevelopmental disorders|neurodevelopmental disorders|neurodevelopmental disorders|disease|133|mesh:D065886|Mitochondria|mitochondrial|anatomy|16|C0026237
19|Proteostasis dependent on cytoplasmic  ribosomes is a well-established target of genetic defects that cause neurodevelopmental disorders, such as autism|genetic defects|genetic defects|disease|81|mesh:D030342|neurodevelopmental disorders|neurodevelopmental disorders|disease|108|mesh:D065886
19|Proteostasis dependent on cytoplasmic  ribosomes is a well-established target of genetic defects that cause neurodevelopmental disorders, such as autism|genetic defects|genetic defects|disease|81|mesh:D030342|autism|autism|disease|146|omim:209850
19|Proteostasis dependent on cytoplasmic  ribosomes is a well-established target of genetic defects that cause neurodevelopmental disorders, such as autism|neurodevelopmental disorders|neurodevelopmental disorders|disease|108|mesh:D065886|autism|autism|disease|146|omim:209850
19|We propose that defective mitochondrial proteostasis is a mechanism with the potential to contribute to neurodevelopmental disease|neurodevelopmental disease|neurodevelopmental disease|disease|104|mesh:D065886|Mitochondria|mitochondrial|anatomy|26|C0026237
20|BACKGROUND: Oxidative stress (OS) has been implicated in the pathophysiology of late-life depression (LLD)|late-life depression|late-life depression|disease|80|mesh:D009497|LLD|LLD|disease|102|mesh:C537267
20|METHODS: We evaluated the plasma levels of ccf-mtDNA in between 32 LLD and 21 never-depressed participants|ccf-mtDNA|ccf-mtDNA|gene|43|NCBIGene:100529251|LLD|LLD|disease|67|mesh:C537267
20|METHODS: We evaluated the plasma levels of ccf-mtDNA in between 32 LLD and 21 never-depressed participants|ccf-mtDNA|ccf-mtDNA|gene|43|NCBIGene:100529251|never|never|disease|78|mesh:D009066
20|METHODS: We evaluated the plasma levels of ccf-mtDNA in between 32 LLD and 21 never-depressed participants|ccf-mtDNA|ccf-mtDNA|gene|43|NCBIGene:100529251|Plasma|plasma|anatomy|26|C0032105
20|METHODS: We evaluated the plasma levels of ccf-mtDNA in between 32 LLD and 21 never-depressed participants|LLD|LLD|disease|67|mesh:C537267|never|never|disease|78|mesh:D009066
20|METHODS: We evaluated the plasma levels of ccf-mtDNA in between 32 LLD and 21 never-depressed participants|LLD|LLD|disease|67|mesh:C537267|Plasma|plasma|anatomy|26|C0032105
20|METHODS: We evaluated the plasma levels of ccf-mtDNA in between 32 LLD and 21 never-depressed participants|never|never|disease|78|mesh:D009066|Plasma|plasma|anatomy|26|C0032105
20|We also investigated the association between ccf-mtDNA and the severity of depressive episodes and cognition performance|ccf|ccf|gene|45|NCBIGene:5307|depressive episodes|depressive episodes|disease|75|mesh:D009497
20|We also investigated the association between ccf-mtDNA and the severity of depressive episodes and cognition performance|ccf|ccf|gene|45|NCBIGene:5307|Mental association|association|physiology|25|C0004083
20|We also investigated the association between ccf-mtDNA and the severity of depressive episodes and cognition performance|ccf|ccf|gene|45|NCBIGene:5307|Cognition|cognition|physiology|99|C0009240
20|RESULTS: We found a higher ccf-mtDNA level in LLD cases compared with controls (t = -2|ccf-mtDNA|ccf-mtDNA|gene|27|NCBIGene:100529251|LLD|LLD|disease|46|mesh:C537267
20|RESULTS: We found a higher ccf-mtDNA level in LLD cases compared with controls (t = -2|ccf-mtDNA|ccf-mtDNA|gene|27|NCBIGene:100529251|T prime|t|physiology|80|C2603360
20|RESULTS: We found a higher ccf-mtDNA level in LLD cases compared with controls (t = -2|LLD|LLD|disease|46|mesh:C537267|mitochondrial DNA location|mtDNA|anatomy|31|C1819717
20|Also, ccf-mtDNA was significantly correlated with the severity of depression (r = 0|ccf|ccf|gene|6|NCBIGene:5307|depression|depression|disease|66|mesh:D009497
20|Also, ccf-mtDNA was significantly correlated with the severity of depression (r = 0|ccf|ccf|gene|6|NCBIGene:5307|R prime|r|physiology|78|C2603358
20|Also, ccf-mtDNA was significantly correlated with the severity of depression (r = 0|ccf|ccf|gene|6|NCBIGene:5307|mitochondrial DNA location|mtDNA|anatomy|10|C1819717
20|Also, ccf-mtDNA was significantly correlated with the severity of depression (r = 0|depression|depression|disease|66|mesh:D009497|mitochondrial DNA location|mtDNA|anatomy|10|C1819717
20|There was no significant correlation between ccf-mtDNA and measures of cognitive decline|ccf-mtDNA|ccf-mtDNA|gene|45|NCBIGene:100529251|cognitive decline|cognitive decline|disease|71|mesh:D003072
20|There was no significant correlation between ccf-mtDNA and measures of cognitive decline|cognitive decline|cognitive decline|disease|71|mesh:D003072|mitochondrial DNA location|mtDNA|anatomy|49|C1819717
20|If validated, the measurement of ccf-mtDNA in LLD can guide the development of novel treatments focused on cytoprotection and reduction of mitochondrial dysfunction for this condition|ccf|ccf|gene|33|NCBIGene:5307|LLD|LLD|disease|46|mesh:C537267
20|If validated, the measurement of ccf-mtDNA in LLD can guide the development of novel treatments focused on cytoprotection and reduction of mitochondrial dysfunction for this condition|ccf|ccf|gene|33|NCBIGene:5307|mitochondrial dysfunction|mitochondrial dysfunction|disease|139|mesh:D028361
20|If validated, the measurement of ccf-mtDNA in LLD can guide the development of novel treatments focused on cytoprotection and reduction of mitochondrial dysfunction for this condition|ccf|ccf|gene|33|NCBIGene:5307|Condition:Find:Pt:^Patient:Nom|condition|physiology|174|C3864998
20|If validated, the measurement of ccf-mtDNA in LLD can guide the development of novel treatments focused on cytoprotection and reduction of mitochondrial dysfunction for this condition|ccf|ccf|gene|33|NCBIGene:5307|Cytoprotection|cytoprotection|physiology|107|C0524828
20|If validated, the measurement of ccf-mtDNA in LLD can guide the development of novel treatments focused on cytoprotection and reduction of mitochondrial dysfunction for this condition|ccf|ccf|gene|33|NCBIGene:5307|Biologic Development|development|physiology|64|C0678723
20|If validated, the measurement of ccf-mtDNA in LLD can guide the development of novel treatments focused on cytoprotection and reduction of mitochondrial dysfunction for this condition|ccf|ccf|gene|33|NCBIGene:5307|mitochondrial DNA location|mtDNA|anatomy|37|C1819717
20|If validated, the measurement of ccf-mtDNA in LLD can guide the development of novel treatments focused on cytoprotection and reduction of mitochondrial dysfunction for this condition|LLD|LLD|disease|46|mesh:C537267|mitochondrial dysfunction|mitochondrial dysfunction|disease|139|mesh:D028361
20|If validated, the measurement of ccf-mtDNA in LLD can guide the development of novel treatments focused on cytoprotection and reduction of mitochondrial dysfunction for this condition|LLD|LLD|disease|46|mesh:C537267|mitochondrial DNA location|mtDNA|anatomy|37|C1819717
20|If validated, the measurement of ccf-mtDNA in LLD can guide the development of novel treatments focused on cytoprotection and reduction of mitochondrial dysfunction for this condition|mitochondrial dysfunction|mitochondrial dysfunction|disease|139|mesh:D028361|mitochondrial DNA location|mtDNA|anatomy|37|C1819717
21|Autism spectrum disorder (ASD) pathophysiology is not completely understood; however, altered inflammatory response and glutamate signaling have been reported, leading to the investigation of molecules targeting the immune-glutamatergic system in ASD treatment|Autism spectrum disorder|Autism spectrum disorder|disease|0|mesh:D002659|ASD|ASD|disease|26|mesh:D006344
21|Autism spectrum disorder (ASD) pathophysiology is not completely understood; however, altered inflammatory response and glutamate signaling have been reported, leading to the investigation of molecules targeting the immune-glutamatergic system in ASD treatment|glutamate|glutamate|compound|120|mesh:D018698|Autism spectrum disorder|Autism spectrum disorder|disease|0|mesh:D002659
21|Autism spectrum disorder (ASD) pathophysiology is not completely understood; however, altered inflammatory response and glutamate signaling have been reported, leading to the investigation of molecules targeting the immune-glutamatergic system in ASD treatment|Autism spectrum disorder|Autism spectrum disorder|disease|0|mesh:D002659|ASD|ASD|disease|247|mesh:D006344
21|Autism spectrum disorder (ASD) pathophysiology is not completely understood; however, altered inflammatory response and glutamate signaling have been reported, leading to the investigation of molecules targeting the immune-glutamatergic system in ASD treatment|glutamate|glutamate|compound|120|mesh:D018698|ASD|ASD|disease|26|mesh:D006344
21|Autism spectrum disorder (ASD) pathophysiology is not completely understood; however, altered inflammatory response and glutamate signaling have been reported, leading to the investigation of molecules targeting the immune-glutamatergic system in ASD treatment|glutamate|glutamate|compound|120|mesh:D018698|ASD|ASD|disease|247|mesh:D006344
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|Palmitoylethanolamide|Palmitoylethanolamide|compound|0|mesh:C005958|PEA|PEA|compound|23|CHEBI:17553
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|Palmitoylethanolamide|Palmitoylethanolamide|compound|0|mesh:C005958|saturated N-acylethanolamine|saturated N-acylethanolamine|compound|53|mesh:C466089
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|Palmitoylethanolamide|Palmitoylethanolamide|compound|0|mesh:C005958|inflammation|inflammation|disease|130|mesh:D007249
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|Palmitoylethanolamide|Palmitoylethanolamide|compound|0|mesh:C005958|depression|depression|disease|144|mesh:D009497
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|Palmitoylethanolamide|Palmitoylethanolamide|compound|0|mesh:C005958|epilepsy|epilepsy|disease|156|mesh:D004827
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|Palmitoylethanolamide|Palmitoylethanolamide|compound|0|mesh:C005958|pain|pain|disease|170|mesh:D010146
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|Palmitoylethanolamide|Palmitoylethanolamide|compound|0|mesh:C005958|glutamate|glutamate|compound|224|mesh:D018698
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|PEA|PEA|compound|23|CHEBI:17553|saturated N-acylethanolamine|saturated N-acylethanolamine|compound|53|mesh:C466089
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|PEA|PEA|compound|23|CHEBI:17553|inflammation|inflammation|disease|130|mesh:D007249
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|PEA|PEA|compound|23|CHEBI:17553|depression|depression|disease|144|mesh:D009497
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|PEA|PEA|compound|23|CHEBI:17553|epilepsy|epilepsy|disease|156|mesh:D004827
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|PEA|PEA|compound|23|CHEBI:17553|pain|pain|disease|170|mesh:D010146
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|PEA|PEA|compound|23|CHEBI:17553|glutamate|glutamate|compound|224|mesh:D018698
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|saturated N-acylethanolamine|saturated N-acylethanolamine|compound|53|mesh:C466089|inflammation|inflammation|disease|130|mesh:D007249
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|saturated N-acylethanolamine|saturated N-acylethanolamine|compound|53|mesh:C466089|depression|depression|disease|144|mesh:D009497
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|saturated N-acylethanolamine|saturated N-acylethanolamine|compound|53|mesh:C466089|epilepsy|epilepsy|disease|156|mesh:D004827
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|saturated N-acylethanolamine|saturated N-acylethanolamine|compound|53|mesh:C466089|pain|pain|disease|170|mesh:D010146
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|saturated N-acylethanolamine|saturated N-acylethanolamine|compound|53|mesh:C466089|glutamate|glutamate|compound|224|mesh:D018698
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|inflammation|inflammation|disease|130|mesh:D007249|depression|depression|disease|144|mesh:D009497
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|inflammation|inflammation|disease|130|mesh:D007249|epilepsy|epilepsy|disease|156|mesh:D004827
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|inflammation|inflammation|disease|130|mesh:D007249|pain|pain|disease|170|mesh:D010146
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|glutamate|glutamate|compound|224|mesh:D018698|inflammation|inflammation|disease|130|mesh:D007249
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|depression|depression|disease|144|mesh:D009497|epilepsy|epilepsy|disease|156|mesh:D004827
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|depression|depression|disease|144|mesh:D009497|pain|pain|disease|170|mesh:D010146
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|glutamate|glutamate|compound|224|mesh:D018698|depression|depression|disease|144|mesh:D009497
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|epilepsy|epilepsy|disease|156|mesh:D004827|pain|pain|disease|170|mesh:D010146
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|glutamate|glutamate|compound|224|mesh:D018698|epilepsy|epilepsy|disease|156|mesh:D004827
21|Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective  in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity|glutamate|glutamate|compound|224|mesh:D018698|pain|pain|disease|170|mesh:D010146
21|Studies indicate altered serum/brain levels of PEA and other endocannabinoids (ECBs)/acylethanolamines (AEs) in ASD|PEA|PEA|compound|47|CHEBI:17553|acylethanolamines|acylethanolamines|compound|85|CHEBI:52640
21|Studies indicate altered serum/brain levels of PEA and other endocannabinoids (ECBs)/acylethanolamines (AEs) in ASD|PEA|PEA|compound|47|CHEBI:17553|ASD|ASD|disease|112|mesh:D006344
21|Studies indicate altered serum/brain levels of PEA and other endocannabinoids (ECBs)/acylethanolamines (AEs) in ASD|PEA|PEA|compound|47|CHEBI:17553|Brain|brain|anatomy|31|C0006104
21|Studies indicate altered serum/brain levels of PEA and other endocannabinoids (ECBs)/acylethanolamines (AEs) in ASD|acylethanolamines|acylethanolamines|compound|85|CHEBI:52640|ASD|ASD|disease|112|mesh:D006344
21|Studies indicate altered serum/brain levels of PEA and other endocannabinoids (ECBs)/acylethanolamines (AEs) in ASD|acylethanolamines|acylethanolamines|compound|85|CHEBI:52640|Brain|brain|anatomy|31|C0006104
21|Studies indicate altered serum/brain levels of PEA and other endocannabinoids (ECBs)/acylethanolamines (AEs) in ASD|ASD|ASD|disease|112|mesh:D006344|Brain|brain|anatomy|31|C0006104
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|PEA|PEA|compound|8|CHEBI:17553|peroxisome proliferator activated receptor-|peroxisome proliferator activated receptor-|gene|183|NCBIGene:5465
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|PEA|PEA|compound|8|CHEBI:17553|PPAR-|PPAR-|gene|228|NCBIGene:5465
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|PEA|PEA|compound|8|CHEBI:17553|cannabinoid receptor|cannabinoid receptor|gene|239|NCBIGene:1268
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|PEA|PEA|compound|8|CHEBI:17553|GPR55 mRNA|GPR55 mRNA|gene|267|NCBIGene:9290
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|PEA|PEA|compound|8|CHEBI:17553|Brain|brain|anatomy|280|C0006104
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|peroxisome proliferator activated receptor-|peroxisome proliferator activated receptor-|gene|183|NCBIGene:5465|cannabinoid receptor|cannabinoid receptor|gene|239|NCBIGene:1268
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|peroxisome proliferator activated receptor-|peroxisome proliferator activated receptor-|gene|183|NCBIGene:5465|GPR55 mRNA|GPR55 mRNA|gene|267|NCBIGene:9290
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|peroxisome proliferator activated receptor-|peroxisome proliferator activated receptor-|gene|183|NCBIGene:5465|Response (communication)|response|physiology|22|C2911692
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|peroxisome proliferator activated receptor-|peroxisome proliferator activated receptor-|gene|183|NCBIGene:5465|Down-Regulation|downregulation|physiology|161|C0013081
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|peroxisome proliferator activated receptor-|peroxisome proliferator activated receptor-|gene|183|NCBIGene:5465|Brain|brain|anatomy|280|C0006104
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|PPAR-|PPAR-|gene|228|NCBIGene:5465|cannabinoid receptor|cannabinoid receptor|gene|239|NCBIGene:1268
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|PPAR-|PPAR-|gene|228|NCBIGene:5465|GPR55 mRNA|GPR55 mRNA|gene|267|NCBIGene:9290
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|PPAR-|PPAR-|gene|228|NCBIGene:5465|Response (communication)|response|physiology|22|C2911692
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|PPAR-|PPAR-|gene|228|NCBIGene:5465|Down-Regulation|downregulation|physiology|161|C0013081
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|PPAR-|PPAR-|gene|228|NCBIGene:5465|Brain|brain|anatomy|280|C0006104
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|cannabinoid receptor|cannabinoid receptor|gene|239|NCBIGene:1268|GPR55 mRNA|GPR55 mRNA|gene|267|NCBIGene:9290
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|cannabinoid receptor|cannabinoid receptor|gene|239|NCBIGene:1268|Response (communication)|response|physiology|22|C2911692
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|cannabinoid receptor|cannabinoid receptor|gene|239|NCBIGene:1268|Down-Regulation|downregulation|physiology|161|C0013081
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|cannabinoid receptor|cannabinoid receptor|gene|239|NCBIGene:1268|Brain|brain|anatomy|280|C0006104
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|GPR55 mRNA|GPR55 mRNA|gene|267|NCBIGene:9290|Response (communication)|response|physiology|22|C2911692
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|GPR55 mRNA|GPR55 mRNA|gene|267|NCBIGene:9290|Down-Regulation|downregulation|physiology|161|C0013081
21|Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported|GPR55 mRNA|GPR55 mRNA|gene|267|NCBIGene:9290|Brain|brain|anatomy|280|C0006104
21|Stress and exposure to exogenous cannabinoids may modulate ECBs/AEs levels and expression of candidate genes for neuropsychiatric disorders, with implications for ASD|cannabinoids|cannabinoids|compound|33|mesh:D002186|neuropsychiatric disorders|neuropsychiatric disorders|disease|113|mesh:D001523
21|Stress and exposure to exogenous cannabinoids may modulate ECBs/AEs levels and expression of candidate genes for neuropsychiatric disorders, with implications for ASD|cannabinoids|cannabinoids|compound|33|mesh:D002186|ASD|ASD|disease|163|mesh:D006344
21|Stress and exposure to exogenous cannabinoids may modulate ECBs/AEs levels and expression of candidate genes for neuropsychiatric disorders, with implications for ASD|neuropsychiatric disorders|neuropsychiatric disorders|disease|113|mesh:D001523|ASD|ASD|disease|163|mesh:D006344
21|Limited research suggests that PEA supplementation reduces overall autism severity by improving language and social and nonsocial behaviors|PEA|PEA|compound|31|CHEBI:17553|autism|autism|disease|67|omim:209850
21|Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation|peroxisome proliferator-activated receptor|peroxisome proliferator-activated receptor|gene|238|NCBIGene:5465|neurodegeneration|neurodegeneration|disease|153|mesh:D009410
21|Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation|PPAR|PPAR|gene|283|NCBIGene:5465|neurodegeneration|neurodegeneration|disease|153|mesh:D009410
21|Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation|peroxisome proliferator-activated receptor|peroxisome proliferator-activated receptor|gene|238|NCBIGene:5465|Apoptosis|apoptosis|physiology|111|C0162638
21|Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation|peroxisome proliferator-activated receptor|peroxisome proliferator-activated receptor|gene|238|NCBIGene:5465|Neurogenesis|neurogenesis|physiology|122|C0814002
21|Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation|peroxisome proliferator-activated receptor|peroxisome proliferator-activated receptor|gene|238|NCBIGene:5465|Neuronal Plasticity|neuroplasticity|physiology|136|C0027880
21|Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation|peroxisome proliferator-activated receptor|peroxisome proliferator-activated receptor|gene|238|NCBIGene:5465|Function Axis|function|physiology|186|C0700205
21|Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation|PPAR|PPAR|gene|283|NCBIGene:5465|Apoptosis|apoptosis|physiology|111|C0162638
21|Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation|PPAR|PPAR|gene|283|NCBIGene:5465|Neurogenesis|neurogenesis|physiology|122|C0814002
21|Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation|PPAR|PPAR|gene|283|NCBIGene:5465|Neuronal Plasticity|neuroplasticity|physiology|136|C0027880
21|Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation|PPAR|PPAR|gene|283|NCBIGene:5465|Function Axis|function|physiology|186|C0700205
22|Tetrabromobisphenol A (TBBPA), one of the most common flame retardants, affects neurodevelopment, disrupts the endocrine system, and increases the possibility of tumorigenesis|Tetrabromobisphenol A|Tetrabromobisphenol A|compound|0|mesh:C020806|Endocrine system|endocrine system|anatomy|111|C0014136
22|Tetrabromobisphenol A (TBBPA), one of the most common flame retardants, affects neurodevelopment, disrupts the endocrine system, and increases the possibility of tumorigenesis|TBBPA|TBBPA|compound|23|mesh:C020806|Endocrine system|endocrine system|anatomy|111|C0014136
22|The cell exposure was measured by mimicking the residual TBBPA concentrations in human plasma, specifically in occupational populations|TBBPA|TBBPA|compound|57|mesh:C020806|Cells|cell|anatomy|4|C0007634
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|TBBPA|TBBPA|compound|23|mesh:C020806|oxygen|oxygen|compound|72|mesh:D010100
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|TBBPA|TBBPA|compound|23|mesh:C020806|Adenosine Monophosphate|Adenosine Monophosphate|compound|140|mesh:D000249
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|TBBPA|TBBPA|compound|23|mesh:C020806|Adenosine Monophosphate activated Protein kinase|Adenosine Monophosphate activated Protein kinase|gene|140|NCBIGene:203
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|TBBPA|TBBPA|compound|23|mesh:C020806|AMPK|AMPK|gene|190|NCBIGene:5563
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|TBBPA|TBBPA|compound|23|mesh:C020806|Mitochondria|mitochondria|anatomy|107|C0026237
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|oxygen|oxygen|compound|72|mesh:D010100|Adenosine Monophosphate|Adenosine Monophosphate|compound|140|mesh:D000249
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|oxygen|oxygen|compound|72|mesh:D010100|Adenosine Monophosphate activated Protein kinase|Adenosine Monophosphate activated Protein kinase|gene|140|NCBIGene:203
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|oxygen|oxygen|compound|72|mesh:D010100|AMPK|AMPK|gene|190|NCBIGene:5563
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|oxygen|oxygen|compound|72|mesh:D010100|Mitochondria|mitochondria|anatomy|107|C0026237
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|Adenosine Monophosphate|Adenosine Monophosphate|compound|140|mesh:D000249|AMPK|AMPK|gene|190|NCBIGene:5563
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|Adenosine Monophosphate|Adenosine Monophosphate|compound|140|mesh:D000249|Mitochondria|mitochondria|anatomy|107|C0026237
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|Adenosine Monophosphate activated Protein kinase|Adenosine Monophosphate activated Protein kinase|gene|140|NCBIGene:203|AMPK|AMPK|gene|190|NCBIGene:5563
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|Adenosine Monophosphate activated Protein kinase|Adenosine Monophosphate activated Protein kinase|gene|140|NCBIGene:203|Cell Proliferation|cellular proliferation|physiology|229|C0596290
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|Adenosine Monophosphate activated Protein kinase|Adenosine Monophosphate activated Protein kinase|gene|140|NCBIGene:203|Mitochondria|mitochondria|anatomy|107|C0026237
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|AMPK|AMPK|gene|190|NCBIGene:5563|Cell Proliferation|cellular proliferation|physiology|229|C0596290
22|Furthermore, long-term TBBPA exposure can double the levels of reactive oxygen species (ROS) released from mitochondria, thereby increasing Adenosine Monophosphate activated Protein kinase (AMPK) gene expression level to promote cellular proliferation|AMPK|AMPK|gene|190|NCBIGene:5563|Mitochondria|mitochondria|anatomy|107|C0026237
22|The RNA-seq analysis confirmed that the Ras signaling pathway was activated by the growth factor to mediate cell detoxification mechanism, increasing lipid and vitamin metabolic rate|Ras|Ras|gene|40|NCBIGene:6237|metabolic rates|metabolic rate|physiology|168|C0870882
22|The RNA-seq analysis confirmed that the Ras signaling pathway was activated by the growth factor to mediate cell detoxification mechanism, increasing lipid and vitamin metabolic rate|Ras|Ras|gene|40|NCBIGene:6237|cellular detoxification|cell detoxification|physiology|108|C4235382
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|TBBPA|TBBPA|compound|88|mesh:C020806|Ras|Ras|gene|127|NCBIGene:6237
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|TBBPA|TBBPA|compound|88|mesh:C020806|metabolic disorder|metabolic disorder|disease|176|mesh:D008659
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|TBBPA|TBBPA|compound|88|mesh:C020806|Plasma|plasma|anatomy|227|C0032105
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|TBBPA|TBBPA|compound|88|mesh:C020806|Cells|cellular|anatomy|20|C0007634
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|Ras|Ras|gene|127|NCBIGene:6237|metabolic disorder|metabolic disorder|disease|176|mesh:D008659
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|TBBPA|TBBPA|compound|234|mesh:C020806|Ras|Ras|gene|127|NCBIGene:6237
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|Ras|Ras|gene|127|NCBIGene:6237|Mental concentration|concentration|physiology|74|C0086045
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|Ras|Ras|gene|127|NCBIGene:6237|Plasma|plasma|anatomy|227|C0032105
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|Ras|Ras|gene|127|NCBIGene:6237|Cells|cellular|anatomy|20|C0007634
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|TBBPA|TBBPA|compound|234|mesh:C020806|metabolic disorder|metabolic disorder|disease|176|mesh:D008659
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|metabolic disorder|metabolic disorder|disease|176|mesh:D008659|Plasma|plasma|anatomy|227|C0032105
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|metabolic disorder|metabolic disorder|disease|176|mesh:D008659|Cells|cellular|anatomy|20|C0007634
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|TBBPA|TBBPA|compound|234|mesh:C020806|Plasma|plasma|anatomy|227|C0032105
22|Our work uncovers a cellular mechanism by which long-term exposure to low concentration TBBPA can induce the activation of the Ras signaling pathway and demonstrates potential metabolic disorder in the human hepatic cells upon plasma TBBPA exposure|TBBPA|TBBPA|compound|234|mesh:C020806|Cells|cellular|anatomy|20|C0007634
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|black|black|compound|57|CHEBI:38508|carbon|carbon|compound|63|mesh:D002244
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|black|black|compound|57|CHEBI:38508|ozone|ozone|compound|88|mesh:D010126
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|black|black|compound|57|CHEBI:38508|O3|O3|compound|95|CHEBI:25812
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|black|black|compound|57|CHEBI:38508|nitrogen dioxide|nitrogen dioxide|compound|101|mesh:D009585
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|black|black|compound|57|CHEBI:38508|NO2|NO2|compound|119|CHEBI:29785
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|black|black|compound|57|CHEBI:38508|carbon monoxide (|carbon monoxide (|compound|129|mesh:D002248
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|black|black|compound|57|CHEBI:38508|CO)|CO)|compound|146|mesh:D002248
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|carbon|carbon|compound|63|mesh:D002244|ozone|ozone|compound|88|mesh:D010126
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|carbon|carbon|compound|63|mesh:D002244|O3|O3|compound|95|CHEBI:25812
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|carbon|carbon|compound|63|mesh:D002244|nitrogen dioxide|nitrogen dioxide|compound|101|mesh:D009585
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|carbon|carbon|compound|63|mesh:D002244|NO2|NO2|compound|119|CHEBI:29785
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|carbon|carbon|compound|63|mesh:D002244|carbon monoxide (|carbon monoxide (|compound|129|mesh:D002248
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|carbon|carbon|compound|63|mesh:D002244|CO)|CO)|compound|146|mesh:D002248
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|ozone|ozone|compound|88|mesh:D010126|O3|O3|compound|95|CHEBI:25812
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|ozone|ozone|compound|88|mesh:D010126|nitrogen dioxide|nitrogen dioxide|compound|101|mesh:D009585
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|ozone|ozone|compound|88|mesh:D010126|NO2|NO2|compound|119|CHEBI:29785
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|ozone|ozone|compound|88|mesh:D010126|carbon monoxide (|carbon monoxide (|compound|129|mesh:D002248
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|ozone|ozone|compound|88|mesh:D010126|CO)|CO)|compound|146|mesh:D002248
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|O3|O3|compound|95|CHEBI:25812|nitrogen dioxide|nitrogen dioxide|compound|101|mesh:D009585
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|O3|O3|compound|95|CHEBI:25812|NO2|NO2|compound|119|CHEBI:29785
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|O3|O3|compound|95|CHEBI:25812|carbon monoxide (|carbon monoxide (|compound|129|mesh:D002248
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|O3|O3|compound|95|CHEBI:25812|CO)|CO)|compound|146|mesh:D002248
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|nitrogen dioxide|nitrogen dioxide|compound|101|mesh:D009585|NO2|NO2|compound|119|CHEBI:29785
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|nitrogen dioxide|nitrogen dioxide|compound|101|mesh:D009585|carbon monoxide (|carbon monoxide (|compound|129|mesh:D002248
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|nitrogen dioxide|nitrogen dioxide|compound|101|mesh:D009585|CO)|CO)|compound|146|mesh:D002248
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|NO2|NO2|compound|119|CHEBI:29785|carbon monoxide (|carbon monoxide (|compound|129|mesh:D002248
23|Air pollution comprises particulate matter (PM), metals, black carbon and gases such as ozone (O3 ), nitrogen dioxide (NO2 ) and carbon monoxide (CO)|NO2|NO2|compound|119|CHEBI:29785|CO)|CO)|compound|146|mesh:D002248
23|In addition to respiratory and cardiovascular disease,  PM exposure is linked with increased risk of neurodegeneration as well as neurodevelopmental impairments|respiratory and cardiovascular disease|respiratory and cardiovascular disease|disease|15|mesh:D012120|neurodegeneration|neurodegeneration|disease|101|mesh:D009410
23|In addition to respiratory and cardiovascular disease,  PM exposure is linked with increased risk of neurodegeneration as well as neurodevelopmental impairments|respiratory and cardiovascular disease|respiratory and cardiovascular disease|disease|15|mesh:D012120|neurodevelopmental impairments|neurodevelopmental impairments|disease|130|mesh:D065886
23|In addition to respiratory and cardiovascular disease,  PM exposure is linked with increased risk of neurodegeneration as well as neurodevelopmental impairments|neurodegeneration|neurodegeneration|disease|101|mesh:D009410|neurodevelopmental impairments|neurodevelopmental impairments|disease|130|mesh:D065886
23|Rodent models reveal that neuroinflammation, neurotransmitter imbalance and oxidative stress are triggered  following gestational/early life exposure to PM, and may be exacerbated by concomitant mitochondrial dysfunction|neuroinflammation|neuroinflammation|disease|26|mesh:D020078|mitochondrial dysfunction|mitochondrial dysfunction|disease|195|mesh:D028361
23|Gestational PM exposure (potentiated by mitochondrial impairment in the metabolically active neonatal brain) not only impacts neurodevelopment but may sensitise the brain to subsequent cognitive impairment|cognitive impairment|cognitive impairment|disease|185|mesh:D003072|Mitochondria|mitochondrial|anatomy|40|C0026237
24|Although the involvement of mitochondria in the pathogenesis and progression of neurodegenerative diseases and brain dysfunction  has been demonstrated, the precise role they play in cell life and death remains  unknown, compromising the development of new mitochondria-targeted approaches to  treat human diseases|neurodegenerative diseases|neurodegenerative diseases|disease|80|mesh:D019636|brain dysfunction|brain dysfunction|disease|111|mesh:D001927
24|Although the involvement of mitochondria in the pathogenesis and progression of neurodegenerative diseases and brain dysfunction  has been demonstrated, the precise role they play in cell life and death remains  unknown, compromising the development of new mitochondria-targeted approaches to  treat human diseases|neurodegenerative diseases|neurodegenerative diseases|disease|80|mesh:D019636|Mitochondria|mitochondria|anatomy|28|C0026237
24|Although the involvement of mitochondria in the pathogenesis and progression of neurodegenerative diseases and brain dysfunction  has been demonstrated, the precise role they play in cell life and death remains  unknown, compromising the development of new mitochondria-targeted approaches to  treat human diseases|brain dysfunction|brain dysfunction|disease|111|mesh:D001927|Mitochondria|mitochondria|anatomy|28|C0026237
25|Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway|autophagy|autophagy|gene|243|NCBIGene:8408|Block Specimens|block|anatomy|190|C1533157
25|Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway|autophagy|autophagy|gene|243|NCBIGene:8408|Biochemical Pathway|pathway|physiology|317|C1704259
25|Finally, several core components of the autophagy machinery have been implicated in distinct autophagic processes (canonical and noncanonical autophagy), implying that genetic approaches to block autophagy should rely on targeting two or more autophagy-related genes that ideally participate in distinct steps of the pathway|autophagy|autophagy|gene|243|NCBIGene:8408|bony process|processes|anatomy|104|C1184743
26|We treated male Wistar rat puppies (P) with rotenone (Rot), an inhibitor of mitochondrial complex I, from postnatal days 5 to 11 (P5-P11)|rotenone|rotenone|compound|44|mesh:D012402|Rot|Rot|compound|54|mesh:C010804
26|We treated male Wistar rat puppies (P) with rotenone (Rot), an inhibitor of mitochondrial complex I, from postnatal days 5 to 11 (P5-P11)|rotenone|rotenone|compound|44|mesh:D012402|mitochondrial complex I|mitochondrial complex I|gene|76|NCBIGene:4723
26|We treated male Wistar rat puppies (P) with rotenone (Rot), an inhibitor of mitochondrial complex I, from postnatal days 5 to 11 (P5-P11)|Rot|Rot|compound|54|mesh:C010804|mitochondrial complex I|mitochondrial complex I|gene|76|NCBIGene:4723
26|We treated male Wistar rat puppies (P) with rotenone (Rot), an inhibitor of mitochondrial complex I, from postnatal days 5 to 11 (P5-P11)|mitochondrial complex I|mitochondrial complex I|gene|76|NCBIGene:4723|P prime|P|physiology|36|C2603361
26|We treated male Wistar rat puppies (P) with rotenone (Rot), an inhibitor of mitochondrial complex I, from postnatal days 5 to 11 (P5-P11)|mitochondrial complex I|mitochondrial complex I|gene|76|NCBIGene:4723|Male, Self-Reported|male|physiology|11|C1706429
26|We demonstrated that at P60 and P120, Rot-treated animals showed hyperlocomotion and deficits in social interaction and aversive contextual memory, features observed  in animal models of schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder|Rot|Rot|gene|38|NCBIGene:64755|hyperlocomotion|hyperlocomotion|disease|65|mesh:D001289
26|We demonstrated that at P60 and P120, Rot-treated animals showed hyperlocomotion and deficits in social interaction and aversive contextual memory, features observed  in animal models of schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder|Rot|Rot|gene|38|NCBIGene:64755|schizophrenia|schizophrenia|disease|187|omim:181500
26|We demonstrated that at P60 and P120, Rot-treated animals showed hyperlocomotion and deficits in social interaction and aversive contextual memory, features observed  in animal models of schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder|Rot|Rot|gene|38|NCBIGene:64755|autism spectrum disorder|autism spectrum disorder|disease|202|mesh:D002659
26|We demonstrated that at P60 and P120, Rot-treated animals showed hyperlocomotion and deficits in social interaction and aversive contextual memory, features observed  in animal models of schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder|Rot|Rot|gene|38|NCBIGene:64755|attention deficit hyperactivity disorder|attention deficit hyperactivity disorder|disease|232|mesh:D001289
26|We demonstrated that at P60 and P120, Rot-treated animals showed hyperlocomotion and deficits in social interaction and aversive contextual memory, features observed  in animal models of schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder|Rot|Rot|gene|38|NCBIGene:64755|Memory|memory|physiology|140|C0025260
26|We demonstrated that at P60 and P120, Rot-treated animals showed hyperlocomotion and deficits in social interaction and aversive contextual memory, features observed  in animal models of schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder|hyperlocomotion|hyperlocomotion|disease|65|mesh:D001289|schizophrenia|schizophrenia|disease|187|omim:181500
26|We demonstrated that at P60 and P120, Rot-treated animals showed hyperlocomotion and deficits in social interaction and aversive contextual memory, features observed  in animal models of schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder|hyperlocomotion|hyperlocomotion|disease|65|mesh:D001289|autism spectrum disorder|autism spectrum disorder|disease|202|mesh:D002659
26|We demonstrated that at P60 and P120, Rot-treated animals showed hyperlocomotion and deficits in social interaction and aversive contextual memory, features observed  in animal models of schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder|schizophrenia|schizophrenia|disease|187|omim:181500|autism spectrum disorder|autism spectrum disorder|disease|202|mesh:D002659
26|We demonstrated that at P60 and P120, Rot-treated animals showed hyperlocomotion and deficits in social interaction and aversive contextual memory, features observed  in animal models of schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder|schizophrenia|schizophrenia|disease|187|omim:181500|attention deficit hyperactivity disorder|attention deficit hyperactivity disorder|disease|232|mesh:D001289
26|We demonstrated that at P60 and P120, Rot-treated animals showed hyperlocomotion and deficits in social interaction and aversive contextual memory, features observed  in animal models of schizophrenia, autism spectrum disorder, and attention deficit hyperactivity disorder|autism spectrum disorder|autism spectrum disorder|disease|202|mesh:D002659|attention deficit hyperactivity disorder|attention deficit hyperactivity disorder|disease|232|mesh:D001289
26|During adulthood, Rot-treated rodents also presented modifications in CBP and CREB levels in addition to a decrease in mitochondrial biogenesis and Nrf1 expression|Rot|Rot|compound|18|mesh:C010804|CBP|CBP|gene|70|NCBIGene:1387
26|During adulthood, Rot-treated rodents also presented modifications in CBP and CREB levels in addition to a decrease in mitochondrial biogenesis and Nrf1 expression|Rot|Rot|compound|18|mesh:C010804|CREB|CREB|gene|78|NCBIGene:1385
26|During adulthood, Rot-treated rodents also presented modifications in CBP and CREB levels in addition to a decrease in mitochondrial biogenesis and Nrf1 expression|Rot|Rot|compound|18|mesh:C010804|Nrf1|Nrf1|gene|148|NCBIGene:4899
26|During adulthood, Rot-treated rodents also presented modifications in CBP and CREB levels in addition to a decrease in mitochondrial biogenesis and Nrf1 expression|CBP|CBP|gene|70|NCBIGene:1387|CREB|CREB|gene|78|NCBIGene:1385
26|During adulthood, Rot-treated rodents also presented modifications in CBP and CREB levels in addition to a decrease in mitochondrial biogenesis and Nrf1 expression|CBP|CBP|gene|70|NCBIGene:1387|Nrf1|Nrf1|gene|148|NCBIGene:4899
26|During adulthood, Rot-treated rodents also presented modifications in CBP and CREB levels in addition to a decrease in mitochondrial biogenesis and Nrf1 expression|CBP|CBP|gene|70|NCBIGene:1387|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|119|C3494456
26|During adulthood, Rot-treated rodents also presented modifications in CBP and CREB levels in addition to a decrease in mitochondrial biogenesis and Nrf1 expression|CREB|CREB|gene|78|NCBIGene:1385|Nrf1|Nrf1|gene|148|NCBIGene:4899
26|During adulthood, Rot-treated rodents also presented modifications in CBP and CREB levels in addition to a decrease in mitochondrial biogenesis and Nrf1 expression|CREB|CREB|gene|78|NCBIGene:1385|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|119|C3494456
26|During adulthood, Rot-treated rodents also presented modifications in CBP and CREB levels in addition to a decrease in mitochondrial biogenesis and Nrf1 expression|Nrf1|Nrf1|gene|148|NCBIGene:4899|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|119|C3494456
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|NFE2L2|NFE2L2|gene|14|NCBIGene:4780|Rot|Rot|gene|51|NCBIGene:64755
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|NFE2L2|NFE2L2|gene|14|NCBIGene:4780|pNFE2L2|pNFE2L2|gene|104|NCBIGene:646309
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|NFE2L2|NFE2L2|gene|14|NCBIGene:4780|Transcriptional Activation|upregulation|physiology|88|C0162493
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|NFE2L2|NFE2L2|gene|14|NCBIGene:4780|Cerebral cortex|cortices|anatomy|145|C0007776
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|Rot|Rot|gene|51|NCBIGene:64755|pNFE2L2|pNFE2L2|gene|104|NCBIGene:646309
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|Rot|Rot|gene|51|NCBIGene:64755|NFE2L2|NFE2L2|gene|113|NCBIGene:4780
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|Rot|Rot|gene|51|NCBIGene:64755|Transcriptional Activation|upregulation|physiology|88|C0162493
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|Rot|Rot|gene|51|NCBIGene:64755|Cerebral cortex|cortices|anatomy|145|C0007776
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|pNFE2L2|pNFE2L2|gene|104|NCBIGene:646309|NFE2L2|NFE2L2|gene|113|NCBIGene:4780
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|pNFE2L2|pNFE2L2|gene|104|NCBIGene:646309|Transcriptional Activation|upregulation|physiology|88|C0162493
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|pNFE2L2|pNFE2L2|gene|104|NCBIGene:646309|Cerebral cortex|cortices|anatomy|145|C0007776
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|NFE2L2|NFE2L2|gene|113|NCBIGene:4780|Transcriptional Activation|upregulation|physiology|88|C0162493
26|Additionally, NFE2L2-activation was not altered in Rot-treated P60 and P120 animals; an upregulation of pNFE2L2/ NFE2L2 was only observed in P12 cortices|NFE2L2|NFE2L2|gene|113|NCBIGene:4780|Cerebral cortex|cortices|anatomy|145|C0007776
26|Curiously, ATP/ADP levels did not change in all ages evaluated|ATP|ATP|compound|11|CHEBI:30616|ADP|ADP|compound|15|CHEBI:73342
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Rot|Rot|gene|0|NCBIGene:64755|Rest|Rest|gene|68|NCBIGene:5978
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Rot|Rot|gene|0|NCBIGene:64755|Mecp2|Mecp2|gene|77|NCBIGene:4204
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Rot|Rot|gene|0|NCBIGene:64755|PSD-95|PSD-95|gene|134|NCBIGene:1742
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Rot|Rot|gene|0|NCBIGene:64755|Synaptotagmin-1|Synaptotagmin-1|gene|142|NCBIGene:6857
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Rot|Rot|gene|0|NCBIGene:64755|Synaptophysin|Synaptophysin|gene|163|NCBIGene:6855
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Rot|Rot|gene|0|NCBIGene:64755|site-specific telomere resolvase activity|Rest|physiology|68|C1622890
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Rest|Rest|gene|68|NCBIGene:5978|Mecp2|Mecp2|gene|77|NCBIGene:4204
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Rest|Rest|gene|68|NCBIGene:5978|PSD-95|PSD-95|gene|134|NCBIGene:1742
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Rest|Rest|gene|68|NCBIGene:5978|Synaptotagmin-1|Synaptotagmin-1|gene|142|NCBIGene:6857
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Rest|Rest|gene|68|NCBIGene:5978|Synaptophysin|Synaptophysin|gene|163|NCBIGene:6855
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Mecp2|Mecp2|gene|77|NCBIGene:4204|PSD-95|PSD-95|gene|134|NCBIGene:1742
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Mecp2|Mecp2|gene|77|NCBIGene:4204|Synaptotagmin-1|Synaptotagmin-1|gene|142|NCBIGene:6857
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Mecp2|Mecp2|gene|77|NCBIGene:4204|Synaptophysin|Synaptophysin|gene|163|NCBIGene:6855
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Mecp2|Mecp2|gene|77|NCBIGene:4204|site-specific telomere resolvase activity|Rest|physiology|68|C1622890
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|PSD-95|PSD-95|gene|134|NCBIGene:1742|Synaptotagmin-1|Synaptotagmin-1|gene|142|NCBIGene:6857
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|PSD-95|PSD-95|gene|134|NCBIGene:1742|Synaptophysin|Synaptophysin|gene|163|NCBIGene:6855
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|PSD-95|PSD-95|gene|134|NCBIGene:1742|site-specific telomere resolvase activity|Rest|physiology|68|C1622890
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Synaptotagmin-1|Synaptotagmin-1|gene|142|NCBIGene:6857|Synaptophysin|Synaptophysin|gene|163|NCBIGene:6855
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Synaptotagmin-1|Synaptotagmin-1|gene|142|NCBIGene:6857|site-specific telomere resolvase activity|Rest|physiology|68|C1622890
26|Rot administration in newborn rodents also promoted modification in Rest and Mecp2 expression, and in synaptic protein levels, named  PSD-95, Synaptotagmin-1, and Synaptophysin in the adult rats|Synaptophysin|Synaptophysin|gene|163|NCBIGene:6855|site-specific telomere resolvase activity|Rest|physiology|68|C1622890
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|Rot|Rot|gene|126|NCBIGene:64755|behavioral abnormalities|behavioral abnormalities|disease|35|mesh:D001523
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|CREB|CREB|gene|181|NCBIGene:1385|behavioral abnormalities|behavioral abnormalities|disease|35|mesh:D001523
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|Nrf1|Nrf1|gene|243|NCBIGene:4899|behavioral abnormalities|behavioral abnormalities|disease|35|mesh:D001523
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|Rot|Rot|gene|126|NCBIGene:64755|CREB|CREB|gene|181|NCBIGene:1385
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|Rot|Rot|gene|126|NCBIGene:64755|Nrf1|Nrf1|gene|243|NCBIGene:4899
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|Rot|Rot|gene|126|NCBIGene:64755|Biochemical Pathway|pathways|physiology|186|C1704259
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|Rot|Rot|gene|126|NCBIGene:64755|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|214|C3494456
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|CREB|CREB|gene|181|NCBIGene:1385|Nrf1|Nrf1|gene|243|NCBIGene:4899
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|CREB|CREB|gene|181|NCBIGene:1385|Biochemical Pathway|pathways|physiology|186|C1704259
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|CREB|CREB|gene|181|NCBIGene:1385|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|214|C3494456
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|Nrf1|Nrf1|gene|243|NCBIGene:4899|Biochemical Pathway|pathways|physiology|186|C1704259
26|Altogether, our data indicate that behavioral abnormalities and changes in synaptic proteins in adulthood induced by neonatal Rot administration might be a result of adjustments in CREB pathways and alterations in mitochondrial biogenesis and Nrf1 expression, rather than a direct deficiency of energy supply, as previously speculated|Nrf1|Nrf1|gene|243|NCBIGene:4899|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|214|C3494456
26|Consequently, Rot-induced psychiatric-like behavior would be an outcome of alterations in neuronal paths due to mitochondrial deregulation|Rot|Rot|compound|14|mesh:C010804|Mitochondria|mitochondrial|anatomy|112|C0026237
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|Autism spectrum disorders|Autism spectrum disorders|disease|0|mesh:D002659|ASDs|ASDs|disease|27|omim:209850
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|Autism spectrum disorders|Autism spectrum disorders|disease|0|mesh:D002659|neurodevelopmental disorders|neurodevelopmental disorders|disease|56|mesh:D065886
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|Autism spectrum disorders|Autism spectrum disorders|disease|0|mesh:D002659|autistic disorder|autistic disorder|disease|96|omim:209850
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|Autism spectrum disorders|Autism spectrum disorders|disease|0|mesh:D002659|Asperger's syndrome|Asperger's syndrome|disease|115|omim:608631
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|Autism spectrum disorders|Autism spectrum disorders|disease|0|mesh:D002659|childhood disintegrative disorder|childhood disintegrative disorder|disease|173|mesh:D012753
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|ASDs|ASDs|disease|27|omim:209850|neurodevelopmental disorders|neurodevelopmental disorders|disease|56|mesh:D065886
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|ASDs|ASDs|disease|27|omim:209850|Asperger's syndrome|Asperger's syndrome|disease|115|omim:608631
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|ASDs|ASDs|disease|27|omim:209850|pervasive developmental disorder|pervasive developmental disorder|disease|136|mesh:D002659
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|ASDs|ASDs|disease|27|omim:209850|childhood disintegrative disorder|childhood disintegrative disorder|disease|173|mesh:D012753
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|neurodevelopmental disorders|neurodevelopmental disorders|disease|56|mesh:D065886|autistic disorder|autistic disorder|disease|96|omim:209850
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|neurodevelopmental disorders|neurodevelopmental disorders|disease|56|mesh:D065886|Asperger's syndrome|Asperger's syndrome|disease|115|omim:608631
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|neurodevelopmental disorders|neurodevelopmental disorders|disease|56|mesh:D065886|pervasive developmental disorder|pervasive developmental disorder|disease|136|mesh:D002659
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|neurodevelopmental disorders|neurodevelopmental disorders|disease|56|mesh:D065886|childhood disintegrative disorder|childhood disintegrative disorder|disease|173|mesh:D012753
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|autistic disorder|autistic disorder|disease|96|omim:209850|Asperger's syndrome|Asperger's syndrome|disease|115|omim:608631
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|autistic disorder|autistic disorder|disease|96|omim:209850|pervasive developmental disorder|pervasive developmental disorder|disease|136|mesh:D002659
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|autistic disorder|autistic disorder|disease|96|omim:209850|childhood disintegrative disorder|childhood disintegrative disorder|disease|173|mesh:D012753
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|Asperger's syndrome|Asperger's syndrome|disease|115|omim:608631|pervasive developmental disorder|pervasive developmental disorder|disease|136|mesh:D002659
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|Asperger's syndrome|Asperger's syndrome|disease|115|omim:608631|childhood disintegrative disorder|childhood disintegrative disorder|disease|173|mesh:D012753
27|Autism spectrum disorders (ASDs) are a group of complex neurodevelopmental disorders, including autistic disorder, Asperger's syndrome, pervasive developmental disorder and childhood disintegrative disorder|pervasive developmental disorder|pervasive developmental disorder|disease|136|mesh:D002659|childhood disintegrative disorder|childhood disintegrative disorder|disease|173|mesh:D012753
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|ATP|ATP|compound|65|CHEBI:30616|calcium|calcium|compound|181|mesh:D002118
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|ATP|ATP|compound|65|CHEBI:30616|Ca2+|Ca2+|compound|194|CHEBI:29108
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|ATP|ATP|compound|65|CHEBI:30616|oxygen|oxygen|compound|226|mesh:D010100
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|ATP|ATP|compound|65|CHEBI:30616|Mitochondria|Mitochondria|anatomy|0|C0026237
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|ATP|ATP|compound|65|CHEBI:30616|Neurons|neurons|anatomy|30|C0027882
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|ATP|ATP|compound|65|CHEBI:30616|Protoplasm|intracellular|anatomy|167|C0175996
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|calcium|calcium|compound|181|mesh:D002118|Ca2+|Ca2+|compound|194|CHEBI:29108
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|calcium|calcium|compound|181|mesh:D002118|oxygen|oxygen|compound|226|mesh:D010100
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|calcium|calcium|compound|181|mesh:D002118|Mitochondria|Mitochondria|anatomy|0|C0026237
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|calcium|calcium|compound|181|mesh:D002118|Neurons|neurons|anatomy|30|C0027882
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|calcium|calcium|compound|181|mesh:D002118|Protoplasm|intracellular|anatomy|167|C0175996
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|Ca2+|Ca2+|compound|194|CHEBI:29108|oxygen|oxygen|compound|226|mesh:D010100
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|Ca2+|Ca2+|compound|194|CHEBI:29108|Mitochondria|Mitochondria|anatomy|0|C0026237
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|Ca2+|Ca2+|compound|194|CHEBI:29108|Neurons|neurons|anatomy|30|C0027882
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|Ca2+|Ca2+|compound|194|CHEBI:29108|Protoplasm|intracellular|anatomy|167|C0175996
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|oxygen|oxygen|compound|226|mesh:D010100|Mitochondria|Mitochondria|anatomy|0|C0026237
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|oxygen|oxygen|compound|226|mesh:D010100|Neurons|neurons|anatomy|30|C0027882
27|Mitochondria not only provide neurons with energy in the form of ATP to sustain neuron growth, proliferation and neurodevelopment, but also regulate neuron apoptosis, intracellular calcium ion (Ca2+) homeostasis, and reactive oxygen species (ROS) clearance|oxygen|oxygen|compound|226|mesh:D010100|Protoplasm|intracellular|anatomy|167|C0175996
27|Due to their postmitotic state and high energy-demanded feature, neurons are particularly prone to mitophagy and mitochondrial disfunction|mitochondrial disfunction|mitochondrial disfunction|disease|113|mesh:D028361|Neurons|neurons|anatomy|65|C0027882
27|Dysfunctional mitochondria and dysregulated mitophagy have been closely associated with the onset of ASDs|ASDs|ASDs|disease|101|omim:209850|Mitochondria|mitochondria|anatomy|14|C0026237
27|In this review, we summarize the mechanism of mitophagy and its role in neurons, and the consequence of mitophagy dysfunction in ASDs|ASDs|ASDs|disease|129|omim:209850|Neurons|neurons|anatomy|72|C0027882
28|The prevalence of autism spectrum disorder (ASD)-a type of neurodevelopmental disorder-is increasing and is around 2% in North America, Asia, and Europe|autism spectrum disorder|autism spectrum disorder|disease|18|mesh:D002659|ASD|ASD|disease|44|mesh:D006344
28|The prevalence of autism spectrum disorder (ASD)-a type of neurodevelopmental disorder-is increasing and is around 2% in North America, Asia, and Europe|autism spectrum disorder|autism spectrum disorder|disease|18|mesh:D002659|neurodevelopmental disorder|neurodevelopmental disorder|disease|59|mesh:D065886
28|The prevalence of autism spectrum disorder (ASD)-a type of neurodevelopmental disorder-is increasing and is around 2% in North America, Asia, and Europe|ASD|ASD|disease|44|mesh:D006344|neurodevelopmental disorder|neurodevelopmental disorder|disease|59|mesh:D065886
28|Although highly heterogeneous at the behavioral level, ASD comprises a set of core symptoms including impaired communication and social interaction skills as well as stereotyped and repetitive behaviors|ASD|ASD|disease|55|mesh:D006344|Core Specimen|core|anatomy|78|C3274653
28|This has led to the suggestion that a large part of the ASD phenotype  is caused by changes in a few and common set of signaling pathways, the identification of which is a fundamental aim of autism research|ASD|ASD|disease|56|mesh:D006344|autism|autism|disease|191|omim:209850
28|Cellular processes known to be impaired in ASD include gene regulation, synaptic transmission affecting the excitation/inhibition balance, neuronal Ca2+ signaling, development of short-/long-range connectivity (circuits  and networks), and mitochondrial function|Ca2+|Ca2+|compound|148|CHEBI:29108|ASD|ASD|disease|43|mesh:D006344
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|ASD|ASD|disease|35|mesh:D006344|schizophrenia|schizophrenia|disease|54|omim:181500
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|Ca2+|Ca2+|compound|93|CHEBI:29108|ASD|ASD|disease|35|mesh:D006344
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|Ca2+-binding protein parvalbumin|Ca2+-binding protein parvalbumin|gene|93|NCBIGene:5816|ASD|ASD|disease|35|mesh:D006344
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|PV|PV|gene|127|NCBIGene:83483|ASD|ASD|disease|35|mesh:D006344
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|ASD|ASD|disease|35|mesh:D006344|Neurons|neurons|anatomy|10|C0027882
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|Ca2+|Ca2+|compound|93|CHEBI:29108|schizophrenia|schizophrenia|disease|54|omim:181500
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|Ca2+-binding protein parvalbumin|Ca2+-binding protein parvalbumin|gene|93|NCBIGene:5816|schizophrenia|schizophrenia|disease|54|omim:181500
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|PV|PV|gene|127|NCBIGene:83483|schizophrenia|schizophrenia|disease|54|omim:181500
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|schizophrenia|schizophrenia|disease|54|omim:181500|Neurons|neurons|anatomy|10|C0027882
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|Ca2+|Ca2+|compound|93|CHEBI:29108|PV|PV|gene|127|NCBIGene:83483
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|Ca2+|Ca2+|compound|93|CHEBI:29108|Neurons|neurons|anatomy|10|C0027882
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|Ca2+-binding protein parvalbumin|Ca2+-binding protein parvalbumin|gene|93|NCBIGene:5816|PV|PV|gene|127|NCBIGene:83483
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|Ca2+-binding protein parvalbumin|Ca2+-binding protein parvalbumin|gene|93|NCBIGene:5816|Neurons|neurons|anatomy|10|C0027882
28|Among the neurons most affected in ASD as well  as in schizophrenia are those expressing the Ca2+-binding protein parvalbumin (PV)|PV|PV|gene|127|NCBIGene:83483|Neurons|neurons|anatomy|10|C0027882
28|PV expression is often reduced at both messenger  RNA (mRNA) and protein levels in human ASD brain samples and mouse ASD (and schizophrenia) models|PV|PV|gene|0|NCBIGene:83483|ASD|ASD|disease|89|mesh:D006344
28|PV expression is often reduced at both messenger  RNA (mRNA) and protein levels in human ASD brain samples and mouse ASD (and schizophrenia) models|PV|PV|gene|0|NCBIGene:83483|ASD|ASD|disease|117|mesh:D006344
28|PV expression is often reduced at both messenger  RNA (mRNA) and protein levels in human ASD brain samples and mouse ASD (and schizophrenia) models|PV|PV|gene|0|NCBIGene:83483|schizophrenia|schizophrenia|disease|126|omim:181500
28|PV expression is often reduced at both messenger  RNA (mRNA) and protein levels in human ASD brain samples and mouse ASD (and schizophrenia) models|PV|PV|gene|0|NCBIGene:83483|Vendor model number:ID:Pt:{Device}:Nom|models|physiology|141|C3833412
28|PV expression is often reduced at both messenger  RNA (mRNA) and protein levels in human ASD brain samples and mouse ASD (and schizophrenia) models|PV|PV|gene|0|NCBIGene:83483|Brain|brain|anatomy|93|C0006104
28|PV expression is often reduced at both messenger  RNA (mRNA) and protein levels in human ASD brain samples and mouse ASD (and schizophrenia) models|ASD|ASD|disease|89|mesh:D006344|schizophrenia|schizophrenia|disease|126|omim:181500
28|PV expression is often reduced at both messenger  RNA (mRNA) and protein levels in human ASD brain samples and mouse ASD (and schizophrenia) models|ASD|ASD|disease|89|mesh:D006344|Brain|brain|anatomy|93|C0006104
28|PV expression is often reduced at both messenger  RNA (mRNA) and protein levels in human ASD brain samples and mouse ASD (and schizophrenia) models|ASD|ASD|disease|117|mesh:D006344|schizophrenia|schizophrenia|disease|126|omim:181500
28|PV expression is often reduced at both messenger  RNA (mRNA) and protein levels in human ASD brain samples and mouse ASD (and schizophrenia) models|ASD|ASD|disease|117|mesh:D006344|Brain|brain|anatomy|93|C0006104
28|PV expression is often reduced at both messenger  RNA (mRNA) and protein levels in human ASD brain samples and mouse ASD (and schizophrenia) models|schizophrenia|schizophrenia|disease|126|omim:181500|Brain|brain|anatomy|93|C0006104
28|Although the human PVALB gene is not a high-ranking susceptibility/risk gene for either disorder and is currently only listed in the  SFARI Gene Archive, we propose and present supporting evidence for the Parvalbumin Hypothesis, which posits that decreased PV level is causally related  to the etiology of ASD (and possibly schizophrenia)|human PVALB gene|human PVALB gene|gene|13|NCBIGene:4151|Parvalbumin|Parvalbumin|gene|205|NCBIGene:5816
28|Although the human PVALB gene is not a high-ranking susceptibility/risk gene for either disorder and is currently only listed in the  SFARI Gene Archive, we propose and present supporting evidence for the Parvalbumin Hypothesis, which posits that decreased PV level is causally related  to the etiology of ASD (and possibly schizophrenia)|human PVALB gene|human PVALB gene|gene|13|NCBIGene:4151|PV|PV|gene|257|NCBIGene:83483
28|Although the human PVALB gene is not a high-ranking susceptibility/risk gene for either disorder and is currently only listed in the  SFARI Gene Archive, we propose and present supporting evidence for the Parvalbumin Hypothesis, which posits that decreased PV level is causally related  to the etiology of ASD (and possibly schizophrenia)|human PVALB gene|human PVALB gene|gene|13|NCBIGene:4151|ASD|ASD|disease|306|mesh:D006344
28|Although the human PVALB gene is not a high-ranking susceptibility/risk gene for either disorder and is currently only listed in the  SFARI Gene Archive, we propose and present supporting evidence for the Parvalbumin Hypothesis, which posits that decreased PV level is causally related  to the etiology of ASD (and possibly schizophrenia)|human PVALB gene|human PVALB gene|gene|13|NCBIGene:4151|schizophrenia|schizophrenia|disease|324|omim:181500
28|Although the human PVALB gene is not a high-ranking susceptibility/risk gene for either disorder and is currently only listed in the  SFARI Gene Archive, we propose and present supporting evidence for the Parvalbumin Hypothesis, which posits that decreased PV level is causally related  to the etiology of ASD (and possibly schizophrenia)|Parvalbumin|Parvalbumin|gene|205|NCBIGene:5816|PV|PV|gene|257|NCBIGene:83483
28|Although the human PVALB gene is not a high-ranking susceptibility/risk gene for either disorder and is currently only listed in the  SFARI Gene Archive, we propose and present supporting evidence for the Parvalbumin Hypothesis, which posits that decreased PV level is causally related  to the etiology of ASD (and possibly schizophrenia)|Parvalbumin|Parvalbumin|gene|205|NCBIGene:5816|ASD|ASD|disease|306|mesh:D006344
28|Although the human PVALB gene is not a high-ranking susceptibility/risk gene for either disorder and is currently only listed in the  SFARI Gene Archive, we propose and present supporting evidence for the Parvalbumin Hypothesis, which posits that decreased PV level is causally related  to the etiology of ASD (and possibly schizophrenia)|Parvalbumin|Parvalbumin|gene|205|NCBIGene:5816|schizophrenia|schizophrenia|disease|324|omim:181500
28|Although the human PVALB gene is not a high-ranking susceptibility/risk gene for either disorder and is currently only listed in the  SFARI Gene Archive, we propose and present supporting evidence for the Parvalbumin Hypothesis, which posits that decreased PV level is causally related  to the etiology of ASD (and possibly schizophrenia)|PV|PV|gene|257|NCBIGene:83483|ASD|ASD|disease|306|mesh:D006344
28|Although the human PVALB gene is not a high-ranking susceptibility/risk gene for either disorder and is currently only listed in the  SFARI Gene Archive, we propose and present supporting evidence for the Parvalbumin Hypothesis, which posits that decreased PV level is causally related  to the etiology of ASD (and possibly schizophrenia)|PV|PV|gene|257|NCBIGene:83483|schizophrenia|schizophrenia|disease|324|omim:181500
28|Although the human PVALB gene is not a high-ranking susceptibility/risk gene for either disorder and is currently only listed in the  SFARI Gene Archive, we propose and present supporting evidence for the Parvalbumin Hypothesis, which posits that decreased PV level is causally related  to the etiology of ASD (and possibly schizophrenia)|ASD|ASD|disease|306|mesh:D006344|schizophrenia|schizophrenia|disease|324|omim:181500
29|Therefore, we evaluated a 'Phase Zero' clinical study platform combining broadband Vis/near-infrared(NIR) spectroscopy and electrophysiology with studying E-I ratio based on the spectral exponent of local field potentials and bioenergetics based on the activity of mitochondrial Cytochrome-C Oxidase (CCO)|mitochondrial Cytochrome-C Oxidase|mitochondrial Cytochrome-C Oxidase|gene|265|NCBIGene:9377|CCO|CCO|gene|301|NCBIGene:6261
29|Therefore, we evaluated a 'Phase Zero' clinical study platform combining broadband Vis/near-infrared(NIR) spectroscopy and electrophysiology with studying E-I ratio based on the spectral exponent of local field potentials and bioenergetics based on the activity of mitochondrial Cytochrome-C Oxidase (CCO)|mitochondrial Cytochrome-C Oxidase|mitochondrial Cytochrome-C Oxidase|gene|265|NCBIGene:9377|Bioenergetics|bioenergetics|physiology|226|C0005486
29|Therefore, we evaluated a 'Phase Zero' clinical study platform combining broadband Vis/near-infrared(NIR) spectroscopy and electrophysiology with studying E-I ratio based on the spectral exponent of local field potentials and bioenergetics based on the activity of mitochondrial Cytochrome-C Oxidase (CCO)|CCO|CCO|gene|301|NCBIGene:6261|Bioenergetics|bioenergetics|physiology|226|C0005486
29|Therefore, we evaluated a 'Phase Zero' clinical study platform combining broadband Vis/near-infrared(NIR) spectroscopy and electrophysiology with studying E-I ratio based on the spectral exponent of local field potentials and bioenergetics based on the activity of mitochondrial Cytochrome-C Oxidase (CCO)|CCO|CCO|gene|301|NCBIGene:6261|Mitochondria|mitochondrial|anatomy|265|C0026237
29|We found a significant effect of the age of the healthy controls iPSC CO from 23 days to 3 months on the CCO activity (chi-square (2, N = 10) = 20, p = 4|CCO|CCO|gene|105|NCBIGene:6261|P prime|p|physiology|168|C2603361
29|We found a significant effect of the age of the healthy controls iPSC CO from 23 days to 3 months on the CCO activity (chi-square (2, N = 10) = 20, p = 4|CCO|CCO|gene|105|NCBIGene:6261|Age|age|physiology|37|C0001779
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|choline|choline|compound|37|CHEBI:133341|CHO|CHO|compound|46|CHEBI:42485
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|choline|choline|compound|37|CHEBI:133341|idebenone|idebenone|compound|53|mesh:C036619
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|choline|choline|compound|37|CHEBI:133341|IDB|IDB|compound|64|mesh:C053669
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|choline|choline|compound|37|CHEBI:133341|R-alpha-lipoic acid|R-alpha-lipoic acid|compound|70|mesh:D008063
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|choline|choline|compound|37|CHEBI:133341|acetyl-L-carnitine|acetyl-L-carnitine|compound|95|mesh:D000108
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|choline|choline|compound|37|CHEBI:133341|CCO|CCO|compound|139|CHEBI:47985
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|CHO|CHO|compound|46|CHEBI:42485|idebenone|idebenone|compound|53|mesh:C036619
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|CHO|CHO|compound|46|CHEBI:42485|IDB|IDB|compound|64|mesh:C053669
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|CHO|CHO|compound|46|CHEBI:42485|R-alpha-lipoic acid|R-alpha-lipoic acid|compound|70|mesh:D008063
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|CHO|CHO|compound|46|CHEBI:42485|acetyl-L-carnitine|acetyl-L-carnitine|compound|95|mesh:D000108
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|CHO|CHO|compound|46|CHEBI:42485|CCO|CCO|compound|139|CHEBI:47985
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|idebenone|idebenone|compound|53|mesh:C036619|IDB|IDB|compound|64|mesh:C053669
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|idebenone|idebenone|compound|53|mesh:C036619|R-alpha-lipoic acid|R-alpha-lipoic acid|compound|70|mesh:D008063
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|idebenone|idebenone|compound|53|mesh:C036619|acetyl-L-carnitine|acetyl-L-carnitine|compound|95|mesh:D000108
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|idebenone|idebenone|compound|53|mesh:C036619|CCO|CCO|compound|139|CHEBI:47985
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|IDB|IDB|compound|64|mesh:C053669|R-alpha-lipoic acid|R-alpha-lipoic acid|compound|70|mesh:D008063
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|IDB|IDB|compound|64|mesh:C053669|acetyl-L-carnitine|acetyl-L-carnitine|compound|95|mesh:D000108
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|IDB|IDB|compound|64|mesh:C053669|CCO|CCO|compound|139|CHEBI:47985
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|R-alpha-lipoic acid|R-alpha-lipoic acid|compound|70|mesh:D008063|acetyl-L-carnitine|acetyl-L-carnitine|compound|95|mesh:D000108
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|R-alpha-lipoic acid|R-alpha-lipoic acid|compound|70|mesh:D008063|CCO|CCO|compound|139|CHEBI:47985
29|Also, a significant effect of drugs, choline (CHO),  idebenone (IDB), R-alpha-lipoic acid plus acetyl-L-carnitine (LCLA), was found on the CCO activity (chi-square (3, N = 10) = 25|acetyl-L-carnitine|acetyl-L-carnitine|compound|95|mesh:D000108|CCO|CCO|compound|139|CHEBI:47985
30|We previously  suggested that mTor-dependent upregulation of mitochondrial function may be involved in such changes|mTor|mTor|gene|30|NCBIGene:2475|Transcriptional Activation|upregulation|physiology|45|C0162493
30|We previously  suggested that mTor-dependent upregulation of mitochondrial function may be involved in such changes|mTor|mTor|gene|30|NCBIGene:2475|Function Axis|function|physiology|75|C0700205
30|We previously  suggested that mTor-dependent upregulation of mitochondrial function may be involved in such changes|mTor|mTor|gene|30|NCBIGene:2475|Mitochondria|mitochondrial|anatomy|61|C0026237
30|5 % sevoflurane for 2 h followed by injection of rotenone, a mitochondrial complex I inhibitor|sevoflurane|sevoflurane|compound|4|mesh:D000077149|rotenone|rotenone|compound|48|mesh:D012402
30|5 % sevoflurane for 2 h followed by injection of rotenone, a mitochondrial complex I inhibitor|sevoflurane|sevoflurane|compound|4|mesh:D000077149|mitochondrial complex I|mitochondrial complex I|gene|60|NCBIGene:4723
30|5 % sevoflurane for 2 h followed by injection of rotenone, a mitochondrial complex I inhibitor|rotenone|rotenone|compound|48|mesh:D012402|mitochondrial complex I|mitochondrial complex I|gene|60|NCBIGene:4723
30|In postnatal day 17 (PND17) mice, intraperitoneal injection  of rotenone not only blocked sevoflurane-induced increases in mitochondrial function, it also prevented sevoflurane-induced changes in excitatory synaptic transmission|rotenone|rotenone|compound|64|mesh:D012402|sevoflurane|sevoflurane|compound|90|mesh:D000077149
30|In postnatal day 17 (PND17) mice, intraperitoneal injection  of rotenone not only blocked sevoflurane-induced increases in mitochondrial function, it also prevented sevoflurane-induced changes in excitatory synaptic transmission|rotenone|rotenone|compound|64|mesh:D012402|sevoflurane|sevoflurane|compound|165|mesh:D000077149
30|In postnatal day 17 (PND17) mice, intraperitoneal injection  of rotenone not only blocked sevoflurane-induced increases in mitochondrial function, it also prevented sevoflurane-induced changes in excitatory synaptic transmission|rotenone|rotenone|compound|64|mesh:D012402|Mitochondria|mitochondrial|anatomy|123|C0026237
30|In postnatal day 17 (PND17) mice, intraperitoneal injection  of rotenone not only blocked sevoflurane-induced increases in mitochondrial function, it also prevented sevoflurane-induced changes in excitatory synaptic transmission|sevoflurane|sevoflurane|compound|90|mesh:D000077149|Mitochondria|mitochondrial|anatomy|123|C0026237
30|In postnatal day 17 (PND17) mice, intraperitoneal injection  of rotenone not only blocked sevoflurane-induced increases in mitochondrial function, it also prevented sevoflurane-induced changes in excitatory synaptic transmission|sevoflurane|sevoflurane|compound|165|mesh:D000077149|Mitochondria|mitochondrial|anatomy|123|C0026237
30|Expression of UPRmt proteins, which help maintain protein-folding homeostasis and increase mitochondrial function, was increased 6 h after sevoflurane exposure|sevoflurane|sevoflurane|compound|138|mesh:D000077149|UPRmt proteins|UPRmt proteins|gene|14|NCBIGene:139596
30|Expression of UPRmt proteins, which help maintain protein-folding homeostasis and increase mitochondrial function, was increased 6 h after sevoflurane exposure|UPRmt proteins|UPRmt proteins|gene|14|NCBIGene:139596|Function Axis|function|physiology|105|C0700205
30|Our results show that a single, brief sevoflurane exposure  induces age-dependent changes in mitochondrial function that constitute an important mechanism for the increase in excitatory synaptic transmission in late  postnatal mice, and also suggest mitochondria and UPRmt as potential targets for  preventing anesthesia toxicity|sevoflurane|sevoflurane|compound|38|mesh:D000077149|Mitochondria|mitochondria|anatomy|250|C0026237
30|Our results show that a single, brief sevoflurane exposure  induces age-dependent changes in mitochondrial function that constitute an important mechanism for the increase in excitatory synaptic transmission in late  postnatal mice, and also suggest mitochondria and UPRmt as potential targets for  preventing anesthesia toxicity|sevoflurane|sevoflurane|compound|38|mesh:D000077149|Mitochondria|mitochondrial|anatomy|93|C0026237
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|aspartate|aspartate|compound|40|mesh:D001224|Aralar|Aralar|gene|0|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|glutamate|glutamate|compound|50|mesh:D018698|Aralar|Aralar|gene|0|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|NADH|NADH|compound|126|mesh:D009243|Aralar|Aralar|gene|0|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|malate-|malate-|compound|131|CHEBI:30797|Aralar|Aralar|gene|0|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|aspartate|aspartate|compound|138|mesh:D001224|Aralar|Aralar|gene|0|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|Aralar|Aralar|gene|0|NCBIGene:8604|Neurons|neurons|anatomy|82|C0027882
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|Aralar|Aralar|gene|0|NCBIGene:8604|Malate-Aspartate Shuttle Pathway|malate-aspartate shuttle|physiology|131|C1518158
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|aspartate|aspartate|compound|40|mesh:D001224|AGC1|AGC1|gene|7|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|glutamate|glutamate|compound|50|mesh:D018698|AGC1|AGC1|gene|7|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|NADH|NADH|compound|126|mesh:D009243|AGC1|AGC1|gene|7|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|malate-|malate-|compound|131|CHEBI:30797|AGC1|AGC1|gene|7|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|aspartate|aspartate|compound|138|mesh:D001224|AGC1|AGC1|gene|7|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|AGC1|AGC1|gene|7|NCBIGene:8604|Neurons|neurons|anatomy|82|C0027882
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|AGC1|AGC1|gene|7|NCBIGene:8604|Malate-Aspartate Shuttle Pathway|malate-aspartate shuttle|physiology|131|C1518158
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|aspartate|aspartate|compound|40|mesh:D001224|Slc25a12|Slc25a12|gene|12|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|glutamate|glutamate|compound|50|mesh:D018698|Slc25a12|Slc25a12|gene|12|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|NADH|NADH|compound|126|mesh:D009243|Slc25a12|Slc25a12|gene|12|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|malate-|malate-|compound|131|CHEBI:30797|Slc25a12|Slc25a12|gene|12|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|aspartate|aspartate|compound|138|mesh:D001224|Slc25a12|Slc25a12|gene|12|NCBIGene:8604
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|Slc25a12|Slc25a12|gene|12|NCBIGene:8604|Neurons|neurons|anatomy|82|C0027882
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|Slc25a12|Slc25a12|gene|12|NCBIGene:8604|Malate-Aspartate Shuttle Pathway|malate-aspartate shuttle|physiology|131|C1518158
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|aspartate|aspartate|compound|40|mesh:D001224|glutamate|glutamate|compound|50|mesh:D018698
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|aspartate|aspartate|compound|40|mesh:D001224|NADH|NADH|compound|126|mesh:D009243
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|aspartate|aspartate|compound|40|mesh:D001224|malate-|malate-|compound|131|CHEBI:30797
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|aspartate|aspartate|compound|40|mesh:D001224|Neurons|neurons|anatomy|82|C0027882
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|glutamate|glutamate|compound|50|mesh:D018698|NADH|NADH|compound|126|mesh:D009243
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|glutamate|glutamate|compound|50|mesh:D018698|malate-|malate-|compound|131|CHEBI:30797
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|glutamate|glutamate|compound|50|mesh:D018698|aspartate|aspartate|compound|138|mesh:D001224
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|glutamate|glutamate|compound|50|mesh:D018698|Neurons|neurons|anatomy|82|C0027882
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|NADH|NADH|compound|126|mesh:D009243|malate-|malate-|compound|131|CHEBI:30797
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|NADH|NADH|compound|126|mesh:D009243|aspartate|aspartate|compound|138|mesh:D001224
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|NADH|NADH|compound|126|mesh:D009243|Neurons|neurons|anatomy|82|C0027882
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|malate-|malate-|compound|131|CHEBI:30797|aspartate|aspartate|compound|138|mesh:D001224
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|malate-|malate-|compound|131|CHEBI:30797|Neurons|neurons|anatomy|82|C0027882
31|Aralar/AGC1/Slc25a12, the mitochondrial aspartate-glutamate carrier expressed in  neurons, is the regulatory component of the NADH malate-aspartate shuttle|aspartate|aspartate|compound|138|mesh:D001224|Neurons|neurons|anatomy|82|C0027882
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|AGC1 deficiency|AGC1 deficiency|disease|0|omim:612949|neuropediatric rare disease|neuropediatric rare disease|disease|21|mesh:D009422
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|AGC1 deficiency|AGC1 deficiency|disease|0|omim:612949|hypomyelination|hypomyelination|disease|66|mesh:D003711
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|AGC1 deficiency|AGC1 deficiency|disease|0|omim:612949|hypotonia|hypotonia|disease|83|mesh:D009123
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|AGC1 deficiency|AGC1 deficiency|disease|0|omim:612949|developmental arrest|developmental arrest|disease|94|mesh:D002658
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|AGC1 deficiency|AGC1 deficiency|disease|0|omim:612949|epilepsy|epilepsy|disease|120|mesh:D004827
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|AGC1|AGC1|gene|0|NCBIGene:176|neuropediatric rare disease|neuropediatric rare disease|disease|21|mesh:D009422
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|AGC1|AGC1|gene|0|NCBIGene:176|hypomyelination|hypomyelination|disease|66|mesh:D003711
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|AGC1|AGC1|gene|0|NCBIGene:176|hypotonia|hypotonia|disease|83|mesh:D009123
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|AGC1|AGC1|gene|0|NCBIGene:176|developmental arrest|developmental arrest|disease|94|mesh:D002658
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|AGC1|AGC1|gene|0|NCBIGene:176|epilepsy|epilepsy|disease|120|mesh:D004827
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|neuropediatric rare disease|neuropediatric rare disease|disease|21|mesh:D009422|hypomyelination|hypomyelination|disease|66|mesh:D003711
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|neuropediatric rare disease|neuropediatric rare disease|disease|21|mesh:D009422|hypotonia|hypotonia|disease|83|mesh:D009123
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|neuropediatric rare disease|neuropediatric rare disease|disease|21|mesh:D009422|developmental arrest|developmental arrest|disease|94|mesh:D002658
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|neuropediatric rare disease|neuropediatric rare disease|disease|21|mesh:D009422|epilepsy|epilepsy|disease|120|mesh:D004827
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|hypomyelination|hypomyelination|disease|66|mesh:D003711|hypotonia|hypotonia|disease|83|mesh:D009123
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|hypomyelination|hypomyelination|disease|66|mesh:D003711|developmental arrest|developmental arrest|disease|94|mesh:D002658
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|hypomyelination|hypomyelination|disease|66|mesh:D003711|epilepsy|epilepsy|disease|120|mesh:D004827
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|hypotonia|hypotonia|disease|83|mesh:D009123|developmental arrest|developmental arrest|disease|94|mesh:D002658
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|hypotonia|hypotonia|disease|83|mesh:D009123|epilepsy|epilepsy|disease|120|mesh:D004827
31|AGC1 deficiency is a neuropediatric rare disease characterized by hypomyelination, hypotonia, developmental arrest, and epilepsy|developmental arrest|developmental arrest|disease|94|mesh:D002658|epilepsy|epilepsy|disease|120|mesh:D004827
31|We have investigated whether β-hydroxybutyrate (βOHB), the main ketone body (KB) produced in ketogenic diet (KD), is neuroprotective in aralar-knock-out (KO) neurons and mice|whether|whether|compound|21|mesh:D016572|-hydroxybutyrate|-hydroxybutyrate|compound|29|CHEBI:17290
31|We have investigated whether β-hydroxybutyrate (βOHB), the main ketone body (KB) produced in ketogenic diet (KD), is neuroprotective in aralar-knock-out (KO) neurons and mice|whether|whether|compound|21|mesh:D016572|OHB|OHB|compound|47|CHEBI:32114
31|We have investigated whether β-hydroxybutyrate (βOHB), the main ketone body (KB) produced in ketogenic diet (KD), is neuroprotective in aralar-knock-out (KO) neurons and mice|-hydroxybutyrate|-hydroxybutyrate|compound|29|CHEBI:17290|OHB|OHB|compound|47|CHEBI:32114
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|OHB|OHB|compound|15|CHEBI:32114|aralar|aralar|gene|40|NCBIGene:8604
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|OHB|OHB|compound|15|CHEBI:32114|glutamate|glutamate|compound|96|mesh:D018698
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|OHB|OHB|compound|15|CHEBI:32114|glutamate|glutamate|compound|193|mesh:D018698
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|OHB|OHB|compound|15|CHEBI:32114|Neurons|neuron|anatomy|169|C0027882
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|OHB|OHB|compound|15|CHEBI:32114|Neurons|neurons|anatomy|51|C0027882
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|OHB|OHB|compound|15|CHEBI:32114|KELL NULL|KO|anatomy|48|C1862225
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|glutamate|glutamate|compound|96|mesh:D018698|aralar|aralar|gene|40|NCBIGene:8604
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|OHB|OHB|compound|148|CHEBI:32114|aralar|aralar|gene|40|NCBIGene:8604
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|glutamate|glutamate|compound|193|mesh:D018698|aralar|aralar|gene|40|NCBIGene:8604
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|aralar|aralar|gene|40|NCBIGene:8604|Neurons|neuron|anatomy|169|C0027882
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|aralar|aralar|gene|40|NCBIGene:8604|Neurons|neurons|anatomy|51|C0027882
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|aralar|aralar|gene|40|NCBIGene:8604|Recovery - healing process|recovers|physiology|32|C2004454
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|aralar|aralar|gene|40|NCBIGene:8604|Report:Finding:Point in time:{Setting}:Document:{Role}|report|physiology|3|C4255046
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|aralar|aralar|gene|40|NCBIGene:8604|Cell Respiration|respiration|physiology|118|C0282636
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|aralar|aralar|gene|40|NCBIGene:8604|KELL NULL|KO|anatomy|48|C1862225
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|glutamate|glutamate|compound|96|mesh:D018698|OHB|OHB|compound|148|CHEBI:32114
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|glutamate|glutamate|compound|96|mesh:D018698|Neurons|neuron|anatomy|169|C0027882
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|glutamate|glutamate|compound|96|mesh:D018698|Neurons|neurons|anatomy|51|C0027882
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|glutamate|glutamate|compound|96|mesh:D018698|KELL NULL|KO|anatomy|48|C1862225
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|OHB|OHB|compound|148|CHEBI:32114|glutamate|glutamate|compound|193|mesh:D018698
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|OHB|OHB|compound|148|CHEBI:32114|Neurons|neuron|anatomy|169|C0027882
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|OHB|OHB|compound|148|CHEBI:32114|Neurons|neurons|anatomy|51|C0027882
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|OHB|OHB|compound|148|CHEBI:32114|KELL NULL|KO|anatomy|48|C1862225
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|glutamate|glutamate|compound|193|mesh:D018698|Neurons|neuron|anatomy|169|C0027882
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|glutamate|glutamate|compound|193|mesh:D018698|Neurons|neurons|anatomy|51|C0027882
31|We report that βOHB efficiently recovers aralar-KO neurons from deficits in basal-stimulated and glutamate-stimulated respiration, effects requiring βOHB entry into the neuron, and protects from glutamate excitotoxicity|glutamate|glutamate|compound|193|mesh:D018698|KELL NULL|KO|anatomy|48|C1862225
31|Therefore, aralar-KO pups were treated without distinction of gender with daily intraperitoneal injections  of βOHB during 5 d|OHB|OHB|compound|111|CHEBI:32114|aralar|aralar|gene|11|NCBIGene:8604
31|Therefore, aralar-KO pups were treated without distinction of gender with daily intraperitoneal injections  of βOHB during 5 d|aralar|aralar|gene|11|NCBIGene:8604|Gender|gender|physiology|62|C0079399
31|Therefore, aralar-KO pups were treated without distinction of gender with daily intraperitoneal injections  of βOHB during 5 d|aralar|aralar|gene|11|NCBIGene:8604|KELL NULL|KO|anatomy|18|C1862225
31|Therefore, aralar-KO pups were treated without distinction of gender with daily intraperitoneal injections  of βOHB during 5 d|OHB|OHB|compound|111|CHEBI:32114|KELL NULL|KO|anatomy|18|C1862225
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|dopamine|dopamine|compound|96|mesh:D004298|3,4-dihydroxyphenylacetic acid|3,4-dihydroxyphenylacetic acid|compound|111|mesh:D015102
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|dopamine|dopamine|compound|96|mesh:D004298|DOPAC|DOPAC|compound|143|mesh:D015102
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|dopamine|dopamine|compound|96|mesh:D004298|vesicular monoamine transporter 2|vesicular monoamine transporter 2|gene|164|NCBIGene:6571
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|dopamine|dopamine|compound|96|mesh:D004298|monoamine|monoamine|compound|174|CHEBI:63534
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|dopamine|dopamine|compound|96|mesh:D004298|VMAT2|VMAT2|gene|199|NCBIGene:6571
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|3,4-dihydroxyphenylacetic acid|3,4-dihydroxyphenylacetic acid|compound|111|mesh:D015102|vesicular monoamine transporter 2|vesicular monoamine transporter 2|gene|164|NCBIGene:6571
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|3,4-dihydroxyphenylacetic acid|3,4-dihydroxyphenylacetic acid|compound|111|mesh:D015102|monoamine|monoamine|compound|174|CHEBI:63534
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|3,4-dihydroxyphenylacetic acid|3,4-dihydroxyphenylacetic acid|compound|111|mesh:D015102|VMAT2|VMAT2|gene|199|NCBIGene:6571
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|DOPAC|DOPAC|compound|143|mesh:D015102|vesicular monoamine transporter 2|vesicular monoamine transporter 2|gene|164|NCBIGene:6571
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|DOPAC|DOPAC|compound|143|mesh:D015102|monoamine|monoamine|compound|174|CHEBI:63534
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|DOPAC|DOPAC|compound|143|mesh:D015102|VMAT2|VMAT2|gene|199|NCBIGene:6571
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|vesicular monoamine transporter 2|vesicular monoamine transporter 2|gene|164|NCBIGene:6571|Recovery - healing process|recovery|physiology|29|C2004454
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|monoamine|monoamine|compound|174|CHEBI:63534|VMAT2|VMAT2|gene|199|NCBIGene:6571
31|This treatment resulted in a recovery of striatal markers of  the dopaminergic system including dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein|VMAT2|VMAT2|gene|199|NCBIGene:6571|Recovery - healing process|recovery|physiology|29|C2004454
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|myelin basic protein|myelin basic protein|gene|33|NCBIGene:4155|myelin-associated glycoprotein|myelin-associated glycoprotein|gene|64|NCBIGene:4099
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|myelin basic protein|myelin basic protein|gene|33|NCBIGene:4155|MAG|MAG|gene|96|NCBIGene:4099
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|OHB|OHB|compound|160|CHEBI:32114|myelin basic protein|myelin basic protein|gene|33|NCBIGene:4155
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|myelin basic protein|myelin basic protein|gene|33|NCBIGene:4155|aralar-|aralar-|gene|172|NCBIGene:8604
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|myelin basic protein|myelin basic protein|gene|33|NCBIGene:4155|myelination|myelination|physiology|20|C0596991
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|MBP|MBP|gene|55|NCBIGene:4155|myelin-associated glycoprotein|myelin-associated glycoprotein|gene|64|NCBIGene:4099
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|MBP|MBP|gene|55|NCBIGene:4155|MAG|MAG|gene|96|NCBIGene:4099
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|OHB|OHB|compound|160|CHEBI:32114|MBP|MBP|gene|55|NCBIGene:4155
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|MBP|MBP|gene|55|NCBIGene:4155|aralar-|aralar-|gene|172|NCBIGene:8604
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|MBP|MBP|gene|55|NCBIGene:4155|myelination|myelination|physiology|20|C0596991
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|OHB|OHB|compound|160|CHEBI:32114|myelin-associated glycoprotein|myelin-associated glycoprotein|gene|64|NCBIGene:4099
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|myelin-associated glycoprotein|myelin-associated glycoprotein|gene|64|NCBIGene:4099|aralar-|aralar-|gene|172|NCBIGene:8604
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|myelin-associated glycoprotein|myelin-associated glycoprotein|gene|64|NCBIGene:4099|myelination|myelination|physiology|20|C0596991
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|OHB|OHB|compound|160|CHEBI:32114|MAG|MAG|gene|96|NCBIGene:4099
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|MAG|MAG|gene|96|NCBIGene:4099|aralar-|aralar-|gene|172|NCBIGene:8604
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|MAG|MAG|gene|96|NCBIGene:4099|myelination|myelination|physiology|20|C0596991
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|OHB|OHB|compound|160|CHEBI:32114|aralar-|aralar-|gene|172|NCBIGene:8604
31|Regarding postnatal myelination, myelin basic protein (MBP) and myelin-associated glycoprotein (MAG) myelin proteins were markedly increased in the cortices of βOHB-treated aralar-KO mice|aralar-|aralar-|gene|172|NCBIGene:8604|myelination|myelination|physiology|20|C0596991
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|Asp|Asp|compound|15|CHEBI:17053|NAA|NAA|compound|23|CHEBI:21547
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|Asp|Asp|compound|15|CHEBI:17053|OHB|OHB|compound|53|CHEBI:32114
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|Asp|Asp|compound|15|CHEBI:17053|OHB|OHB|compound|79|CHEBI:32114
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|Asp|Asp|compound|15|CHEBI:17053|aralar|aralar|gene|96|NCBIGene:8604
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|Asp|Asp|compound|15|CHEBI:17053|NAA|NAA|compound|185|CHEBI:21547
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|Asp|Asp|compound|15|CHEBI:17053|Neurons|neurons|anatomy|129|C0027882
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|NAA|NAA|compound|23|CHEBI:21547|OHB|OHB|compound|53|CHEBI:32114
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|NAA|NAA|compound|23|CHEBI:21547|OHB|OHB|compound|79|CHEBI:32114
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|NAA|NAA|compound|23|CHEBI:21547|aralar|aralar|gene|96|NCBIGene:8604
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|NAA|NAA|compound|23|CHEBI:21547|Asp|Asp|compound|168|CHEBI:17053
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|NAA|NAA|compound|23|CHEBI:21547|Neurons|neurons|anatomy|129|C0027882
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|OHB|OHB|compound|53|CHEBI:32114|aralar|aralar|gene|96|NCBIGene:8604
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|OHB|OHB|compound|53|CHEBI:32114|Asp|Asp|compound|168|CHEBI:17053
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|OHB|OHB|compound|53|CHEBI:32114|NAA|NAA|compound|185|CHEBI:21547
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|OHB|OHB|compound|53|CHEBI:32114|Neurons|neurons|anatomy|129|C0027882
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|OHB|OHB|compound|79|CHEBI:32114|aralar|aralar|gene|96|NCBIGene:8604
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|OHB|OHB|compound|79|CHEBI:32114|Asp|Asp|compound|168|CHEBI:17053
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|OHB|OHB|compound|79|CHEBI:32114|NAA|NAA|compound|185|CHEBI:21547
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|OHB|OHB|compound|79|CHEBI:32114|Neurons|neurons|anatomy|129|C0027882
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|Asp|Asp|compound|168|CHEBI:17053|aralar|aralar|gene|96|NCBIGene:8604
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|NAA|NAA|compound|185|CHEBI:21547|aralar|aralar|gene|96|NCBIGene:8604
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|aralar|aralar|gene|96|NCBIGene:8604|Neurons|neurons|anatomy|129|C0027882
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|Asp|Asp|compound|168|CHEBI:17053|NAA|NAA|compound|185|CHEBI:21547
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|Asp|Asp|compound|168|CHEBI:17053|Neurons|neurons|anatomy|129|C0027882
31|Although brain Asp and NAA levels did not change by  βOHB administration, a 4-d βOHB treatment to aralar-KO, but not to control, neurons led to a substantial increase in Asp (3-fold) and NAA (4-fold) levels|NAA|NAA|compound|185|CHEBI:21547|Neurons|neurons|anatomy|129|C0027882
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|Asp|Asp|compound|57|CHEBI:17053|NAA|NAA|compound|65|CHEBI:21547
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|Asp|Asp|compound|57|CHEBI:17053|aralar|aralar|gene|123|NCBIGene:8604
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|Asp|Asp|compound|57|CHEBI:17053|NAA|NAA|compound|178|CHEBI:21547
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|Asp|Asp|compound|57|CHEBI:17053|Brain|brain|anatomy|133|C0006104
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|Asp|Asp|compound|57|CHEBI:17053|KELL NULL|KO|anatomy|130|C1862225
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|NAA|NAA|compound|65|CHEBI:21547|aralar|aralar|gene|123|NCBIGene:8604
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|NAA|NAA|compound|65|CHEBI:21547|Brain|brain|anatomy|133|C0006104
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|NAA|NAA|compound|65|CHEBI:21547|KELL NULL|KO|anatomy|130|C1862225
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|NAA|NAA|compound|178|CHEBI:21547|aralar|aralar|gene|123|NCBIGene:8604
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|aralar|aralar|gene|123|NCBIGene:8604|Brain|brain|anatomy|133|C0006104
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|aralar|aralar|gene|123|NCBIGene:8604|myelination|myelination|physiology|195|C0596991
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|aralar|aralar|gene|123|NCBIGene:8604|KELL NULL|KO|anatomy|130|C1862225
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|NAA|NAA|compound|178|CHEBI:21547|Brain|brain|anatomy|133|C0006104
31|These results suggest that the lack of increase in brain Asp and NAA is possibly  because of its active utilization by the aralar-KO brain and the likely involvement of neuronal NAA in postnatal myelination in these mice|NAA|NAA|compound|178|CHEBI:21547|KELL NULL|KO|anatomy|130|C1862225
31|The effectiveness of βOHB as a therapeutic treatment in AGC1 deficiency deserves further investigation|OHB|OHB|compound|21|CHEBI:32114|AGC1 deficiency|AGC1 deficiency|disease|55|omim:612949
31|The effectiveness of βOHB as a therapeutic treatment in AGC1 deficiency deserves further investigation|OHB|OHB|compound|21|CHEBI:32114|AGC1|AGC1|gene|55|NCBIGene:176
31|SIGNIFICANCE STATEMENT Aralar deficiency induces a fatal phenotype in humans and mice and is associated with impaired neurodevelopment, epilepsy, and hypomyelination|Aralar deficiency|Aralar deficiency|disease|23|mesh:C562618|impaired neurodevelopment|impaired neurodevelopment|disease|109|mesh:D002658
31|SIGNIFICANCE STATEMENT Aralar deficiency induces a fatal phenotype in humans and mice and is associated with impaired neurodevelopment, epilepsy, and hypomyelination|Aralar deficiency|Aralar deficiency|disease|23|mesh:C562618|epilepsy|epilepsy|disease|136|mesh:D004827
31|SIGNIFICANCE STATEMENT Aralar deficiency induces a fatal phenotype in humans and mice and is associated with impaired neurodevelopment, epilepsy, and hypomyelination|Aralar deficiency|Aralar deficiency|disease|23|mesh:C562618|hypomyelination|hypomyelination|disease|150|mesh:D003711
31|SIGNIFICANCE STATEMENT Aralar deficiency induces a fatal phenotype in humans and mice and is associated with impaired neurodevelopment, epilepsy, and hypomyelination|Aralar|Aralar|gene|23|NCBIGene:8604|impaired neurodevelopment|impaired neurodevelopment|disease|109|mesh:D002658
31|SIGNIFICANCE STATEMENT Aralar deficiency induces a fatal phenotype in humans and mice and is associated with impaired neurodevelopment, epilepsy, and hypomyelination|Aralar|Aralar|gene|23|NCBIGene:8604|epilepsy|epilepsy|disease|136|mesh:D004827
31|SIGNIFICANCE STATEMENT Aralar deficiency induces a fatal phenotype in humans and mice and is associated with impaired neurodevelopment, epilepsy, and hypomyelination|Aralar|Aralar|gene|23|NCBIGene:8604|hypomyelination|hypomyelination|disease|150|mesh:D003711
31|SIGNIFICANCE STATEMENT Aralar deficiency induces a fatal phenotype in humans and mice and is associated with impaired neurodevelopment, epilepsy, and hypomyelination|Aralar|Aralar|gene|23|NCBIGene:8604|neurodevelopment|neurodevelopment|physiology|118|C0599855
31|SIGNIFICANCE STATEMENT Aralar deficiency induces a fatal phenotype in humans and mice and is associated with impaired neurodevelopment, epilepsy, and hypomyelination|Aralar|Aralar|gene|23|NCBIGene:8604|Phenotype|phenotype|physiology|57|C0031437
31|SIGNIFICANCE STATEMENT Aralar deficiency induces a fatal phenotype in humans and mice and is associated with impaired neurodevelopment, epilepsy, and hypomyelination|impaired neurodevelopment|impaired neurodevelopment|disease|109|mesh:D002658|epilepsy|epilepsy|disease|136|mesh:D004827
31|SIGNIFICANCE STATEMENT Aralar deficiency induces a fatal phenotype in humans and mice and is associated with impaired neurodevelopment, epilepsy, and hypomyelination|impaired neurodevelopment|impaired neurodevelopment|disease|109|mesh:D002658|hypomyelination|hypomyelination|disease|150|mesh:D003711
31|SIGNIFICANCE STATEMENT Aralar deficiency induces a fatal phenotype in humans and mice and is associated with impaired neurodevelopment, epilepsy, and hypomyelination|epilepsy|epilepsy|disease|136|mesh:D004827|hypomyelination|hypomyelination|disease|150|mesh:D003711
31|In neurons, highly expressing aralar, its deficiency causes a metabolic blockade hampering mitochondrial energetics and respiration|aralar|aralar|gene|30|NCBIGene:8604|Cell Respiration|respiration|physiology|120|C0282636
31|In neurons, highly expressing aralar, its deficiency causes a metabolic blockade hampering mitochondrial energetics and respiration|aralar|aralar|gene|30|NCBIGene:8604|Neurons|neurons|anatomy|3|C0027882
31|In neurons, highly expressing aralar, its deficiency causes a metabolic blockade hampering mitochondrial energetics and respiration|aralar|aralar|gene|30|NCBIGene:8604|Metabolic Process, Cellular|metabolic|physiology|62|C1524026
31|In neurons, highly expressing aralar, its deficiency causes a metabolic blockade hampering mitochondrial energetics and respiration|aralar|aralar|gene|30|NCBIGene:8604|Mitochondria|mitochondrial|anatomy|91|C0026237
31|Here, we find that βOHB, the main metabolic product in KD, recovers  defective mitochondrial respiration bypassing the metabolic failure in aralar-deficient neurons|OHB|OHB|compound|19|CHEBI:32114|KD|KD|disease|54|mesh:D009080
31|Here, we find that βOHB, the main metabolic product in KD, recovers  defective mitochondrial respiration bypassing the metabolic failure in aralar-deficient neurons|OHB|OHB|compound|19|CHEBI:32114|aralar-deficient|aralar-deficient|disease|139|omim:102700
31|Here, we find that βOHB, the main metabolic product in KD, recovers  defective mitochondrial respiration bypassing the metabolic failure in aralar-deficient neurons|OHB|OHB|compound|19|CHEBI:32114|Mitochondria|mitochondrial|anatomy|79|C0026237
31|Here, we find that βOHB, the main metabolic product in KD, recovers  defective mitochondrial respiration bypassing the metabolic failure in aralar-deficient neurons|KD|KD|disease|54|mesh:D009080|aralar-deficient|aralar-deficient|disease|139|omim:102700
31|Here, we find that βOHB, the main metabolic product in KD, recovers  defective mitochondrial respiration bypassing the metabolic failure in aralar-deficient neurons|KD|KD|disease|54|mesh:D009080|Mitochondria|mitochondrial|anatomy|79|C0026237
31|Here, we find that βOHB, the main metabolic product in KD, recovers  defective mitochondrial respiration bypassing the metabolic failure in aralar-deficient neurons|aralar-deficient|aralar-deficient|disease|139|omim:102700|Mitochondria|mitochondrial|anatomy|79|C0026237
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|OHB|OHB|compound|0|CHEBI:32114|aspartate|aspartate|compound|65|mesh:D001224
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|OHB|OHB|compound|0|CHEBI:32114|Asp|Asp|compound|76|CHEBI:17053
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|OHB|OHB|compound|0|CHEBI:32114|NAA|NAA|compound|85|CHEBI:21547
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|OHB|OHB|compound|0|CHEBI:32114|aralar deficiency|aralar deficiency|disease|110|mesh:C562618
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|OHB|OHB|compound|0|CHEBI:32114|citrate|citrate|compound|148|mesh:D019343
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|OHB|OHB|compound|0|CHEBI:32114|malate|malate|compound|156|CHEBI:30797
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|OHB|OHB|compound|0|CHEBI:32114|Mitochondria|mitochondria|anatomy|18|C0026237
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|OHB|OHB|compound|0|CHEBI:32114|Cytoplasmic matrix|cytosolic|anatomy|56|C1383501
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|aspartate|aspartate|compound|65|mesh:D001224|Asp|Asp|compound|76|CHEBI:17053
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|aspartate|aspartate|compound|65|mesh:D001224|NAA|NAA|compound|85|CHEBI:21547
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|aspartate|aspartate|compound|65|mesh:D001224|aralar deficiency|aralar deficiency|disease|110|mesh:C562618
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|aspartate|aspartate|compound|65|mesh:D001224|citrate|citrate|compound|148|mesh:D019343
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|aspartate|aspartate|compound|65|mesh:D001224|malate|malate|compound|156|CHEBI:30797
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|aspartate|aspartate|compound|65|mesh:D001224|Mitochondria|mitochondria|anatomy|18|C0026237
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|aspartate|aspartate|compound|65|mesh:D001224|Cytoplasmic matrix|cytosolic|anatomy|56|C1383501
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|Asp|Asp|compound|76|CHEBI:17053|NAA|NAA|compound|85|CHEBI:21547
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|Asp|Asp|compound|76|CHEBI:17053|aralar deficiency|aralar deficiency|disease|110|mesh:C562618
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|Asp|Asp|compound|76|CHEBI:17053|citrate|citrate|compound|148|mesh:D019343
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|Asp|Asp|compound|76|CHEBI:17053|malate|malate|compound|156|CHEBI:30797
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|Asp|Asp|compound|76|CHEBI:17053|Mitochondria|mitochondria|anatomy|18|C0026237
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|Asp|Asp|compound|76|CHEBI:17053|Cytoplasmic matrix|cytosolic|anatomy|56|C1383501
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|NAA|NAA|compound|85|CHEBI:21547|aralar deficiency|aralar deficiency|disease|110|mesh:C562618
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|NAA|NAA|compound|85|CHEBI:21547|citrate|citrate|compound|148|mesh:D019343
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|NAA|NAA|compound|85|CHEBI:21547|malate|malate|compound|156|CHEBI:30797
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|NAA|NAA|compound|85|CHEBI:21547|Mitochondria|mitochondria|anatomy|18|C0026237
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|NAA|NAA|compound|85|CHEBI:21547|Cytoplasmic matrix|cytosolic|anatomy|56|C1383501
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|citrate|citrate|compound|148|mesh:D019343|aralar deficiency|aralar deficiency|disease|110|mesh:C562618
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|malate|malate|compound|156|CHEBI:30797|aralar deficiency|aralar deficiency|disease|110|mesh:C562618
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|aralar deficiency|aralar deficiency|disease|110|mesh:C562618|Mitochondria|mitochondria|anatomy|18|C0026237
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|aralar deficiency|aralar deficiency|disease|110|mesh:C562618|Cytoplasmic matrix|cytosolic|anatomy|56|C1383501
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|citrate|citrate|compound|148|mesh:D019343|malate|malate|compound|156|CHEBI:30797
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|citrate|citrate|compound|148|mesh:D019343|Mitochondria|mitochondria|anatomy|18|C0026237
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|citrate|citrate|compound|148|mesh:D019343|Cytoplasmic matrix|cytosolic|anatomy|56|C1383501
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|malate|malate|compound|156|CHEBI:30797|Mitochondria|mitochondria|anatomy|18|C0026237
31|βOHB oxidation in mitochondria boosts the synthesis of  cytosolic aspartate (Asp) and NAA, which is impeded by aralar deficiency, presumably through citrate-malate shuttle|malate|malate|compound|156|CHEBI:30797|Cytoplasmic matrix|cytosolic|anatomy|56|C1383501
31|In aralar-knock-out (KO) mice, βOHB recovers from the drastic drop in specific dopaminergic and myelin markers|OHB|OHB|compound|31|CHEBI:32114|Myelin|myelin|anatomy|96|C0026969
31|The βOHB-induced myelin synthesis occurring together with the marked increment in neuronal NAA synthesis supports the role of NAA as a lipid precursor during postnatal myelination|OHB|OHB|compound|4|CHEBI:32114|NAA|NAA|compound|90|CHEBI:21547
31|The βOHB-induced myelin synthesis occurring together with the marked increment in neuronal NAA synthesis supports the role of NAA as a lipid precursor during postnatal myelination|OHB|OHB|compound|4|CHEBI:32114|NAA|NAA|compound|125|CHEBI:21547
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|autism spectrum disorder|autism spectrum disorder|disease|206|mesh:D002659|ASD|ASD|disease|232|mesh:D006344
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|autism spectrum disorder|autism spectrum disorder|disease|206|mesh:D002659|neurodevelopmental regression|neurodevelopmental regression|disease|247|mesh:D065886
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|autism spectrum disorder|autism spectrum disorder|disease|206|mesh:D002659|NDR|NDR|disease|278|omim:310600
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|autism spectrum disorder|autism spectrum disorder|disease|206|mesh:D002659|Cytoplasmic organelle|organelle|anatomy|49|C1179962
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|autism spectrum disorder|autism spectrum disorder|disease|206|mesh:D002659|Mitochondria|mitochondrion|anatomy|31|C0026237
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|ASD|ASD|disease|232|mesh:D006344|neurodevelopmental regression|neurodevelopmental regression|disease|247|mesh:D065886
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|ASD|ASD|disease|232|mesh:D006344|NDR|NDR|disease|278|omim:310600
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|ASD|ASD|disease|232|mesh:D006344|Cytoplasmic organelle|organelle|anatomy|49|C1179962
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|ASD|ASD|disease|232|mesh:D006344|Mitochondria|mitochondrion|anatomy|31|C0026237
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|neurodevelopmental regression|neurodevelopmental regression|disease|247|mesh:D065886|NDR|NDR|disease|278|omim:310600
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|neurodevelopmental regression|neurodevelopmental regression|disease|247|mesh:D065886|Cytoplasmic organelle|organelle|anatomy|49|C1179962
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|neurodevelopmental regression|neurodevelopmental regression|disease|247|mesh:D065886|Mitochondria|mitochondrion|anatomy|31|C0026237
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|NDR|NDR|disease|278|omim:310600|Cytoplasmic organelle|organelle|anatomy|49|C1179962
33|We investigate the role of the mitochondrion, an organelle highly sensitive to environmental agents, in the influence of prenatal air pollution exposure on neurodevelopment and behavior in 96 children with autism spectrum disorder (ASD)  [45 with neurodevelopmental regression (NDR); 76% Male; mean (SD) age 10 y 9 m (3 y 9 m)]|NDR|NDR|disease|278|omim:310600|Mitochondria|mitochondrion|anatomy|31|C0026237
34|The study of the development of epilepsy and hyperexcitability states involves molecular, synaptic, and structural alterations of neuronal bioelectric activity|epilepsy|epilepsy|disease|32|mesh:D004827|hyperexcitability states|hyperexcitability states|disease|45|mesh:D001289
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|tau|tau|gene|104|NCBIGene:4137|neurodegenerative diseases|neurodegenerative diseases|disease|111|mesh:D019636
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|tau|tau|gene|104|NCBIGene:4137|epileptic|epileptic|disease|142|mesh:D004827
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|tau|tau|gene|104|NCBIGene:4137|epilepsy|epilepsy|disease|256|mesh:D004827
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|tau|tau|gene|104|NCBIGene:4137|Vendor model number:ID:Pt:{Device}:Nom|models|physiology|265|C3833412
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|tau|tau|gene|104|NCBIGene:4137|Microtubules|microtubule|anatomy|186|C0026046
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|tau|tau|gene|104|NCBIGene:4137|Cytoskeleton|cytoskeleton|anatomy|224|C0010853
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|neurodegenerative diseases|neurodegenerative diseases|disease|111|mesh:D019636|epileptic|epileptic|disease|142|mesh:D004827
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|neurodegenerative diseases|neurodegenerative diseases|disease|111|mesh:D019636|epilepsy|epilepsy|disease|256|mesh:D004827
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|neurodegenerative diseases|neurodegenerative diseases|disease|111|mesh:D019636|Microtubules|microtubule|anatomy|186|C0026046
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|neurodegenerative diseases|neurodegenerative diseases|disease|111|mesh:D019636|Cytoskeleton|cytoskeleton|anatomy|224|C0010853
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|epileptic|epileptic|disease|142|mesh:D004827|Microtubules|microtubule|anatomy|186|C0026046
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|epileptic|epileptic|disease|142|mesh:D004827|Cytoskeleton|cytoskeleton|anatomy|224|C0010853
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|epilepsy|epilepsy|disease|256|mesh:D004827|Microtubules|microtubule|anatomy|186|C0026046
34|Recent researches were reported on the phosphorylation state of microtubule-associated proteins such as tau in neurodegenerative diseases and epileptic states, but also on the effect of microtubule-active agents influencing cytoskeleton destabilization in epilepsy models|epilepsy|epilepsy|disease|256|mesh:D004827|Cytoskeleton|cytoskeleton|anatomy|224|C0010853
34|Otherwise, this can lead to cognitive deficits, hyperexcitability phenomena and neurodevelopmental disorders|cognitive deficits|cognitive deficits|disease|28|mesh:D003072|hyperexcitability|hyperexcitability|disease|48|mesh:D001289
34|Otherwise, this can lead to cognitive deficits, hyperexcitability phenomena and neurodevelopmental disorders|cognitive deficits|cognitive deficits|disease|28|mesh:D003072|neurodevelopmental disorders|neurodevelopmental disorders|disease|80|mesh:D065886
34|Otherwise, this can lead to cognitive deficits, hyperexcitability phenomena and neurodevelopmental disorders|hyperexcitability|hyperexcitability|disease|48|mesh:D001289|neurodevelopmental disorders|neurodevelopmental disorders|disease|80|mesh:D065886
35|Postnatal failure of oligodendrocyte maturation has been proposed as a cellular mechanism of diffuse white matter injury (WMI) in premature infants|white matter injury|white matter injury|disease|101|mesh:D056784|WMI|WMI|disease|122|mesh:C536690
35|Postnatal failure of oligodendrocyte maturation has been proposed as a cellular mechanism of diffuse white matter injury (WMI) in premature infants|white matter injury|white matter injury|disease|101|mesh:D056784|Cells|cellular|anatomy|71|C0007634
35|Postnatal failure of oligodendrocyte maturation has been proposed as a cellular mechanism of diffuse white matter injury (WMI) in premature infants|WMI|WMI|disease|122|mesh:C536690|Cells|cellular|anatomy|71|C0007634
35|In  neonatal mice and cultured differentiating oligodendrocytes, sublethal intermittent hypoxic (IH) stress activated cyclophilin D-dependent mitochondrial  proton leak and uncoupled mitochondrial respiration, leading to transient bioenergetic stress|cyclophilin D|cyclophilin D|gene|118|NCBIGene:5481|Cell Respiration|respiration|physiology|197|C0282636
35|In  neonatal mice and cultured differentiating oligodendrocytes, sublethal intermittent hypoxic (IH) stress activated cyclophilin D-dependent mitochondrial  proton leak and uncoupled mitochondrial respiration, leading to transient bioenergetic stress|cyclophilin D|cyclophilin D|gene|118|NCBIGene:5481|Oligodendroglia|oligodendrocytes|anatomy|47|C0028944
35|In  neonatal mice and cultured differentiating oligodendrocytes, sublethal intermittent hypoxic (IH) stress activated cyclophilin D-dependent mitochondrial  proton leak and uncoupled mitochondrial respiration, leading to transient bioenergetic stress|cyclophilin D|cyclophilin D|gene|118|NCBIGene:5481|Bioenergetics|bioenergetic|physiology|231|C0005486
35|In  neonatal mice and cultured differentiating oligodendrocytes, sublethal intermittent hypoxic (IH) stress activated cyclophilin D-dependent mitochondrial  proton leak and uncoupled mitochondrial respiration, leading to transient bioenergetic stress|cyclophilin D|cyclophilin D|gene|118|NCBIGene:5481|W stress|stress|physiology|244|C1718621
35|In  neonatal mice and cultured differentiating oligodendrocytes, sublethal intermittent hypoxic (IH) stress activated cyclophilin D-dependent mitochondrial  proton leak and uncoupled mitochondrial respiration, leading to transient bioenergetic stress|cyclophilin D|cyclophilin D|gene|118|NCBIGene:5481|Mitochondria|mitochondrial|anatomy|183|C0026237
35|This was associated with development of diffuse WMI: poor oligodendrocyte maturation, diffuse axonal hypomyelination, and permanent sensorimotor deficit|WMI|WMI|disease|48|mesh:C536690|axonal hypomyelination|axonal hypomyelination|disease|94|omim:605253
35|This was associated with development of diffuse WMI: poor oligodendrocyte maturation, diffuse axonal hypomyelination, and permanent sensorimotor deficit|WMI|WMI|disease|48|mesh:C536690|sensorimotor deficit|sensorimotor deficit|disease|132|mesh:D009461
35|This was associated with development of diffuse WMI: poor oligodendrocyte maturation, diffuse axonal hypomyelination, and permanent sensorimotor deficit|WMI|WMI|disease|48|mesh:C536690|Axon|axonal|anatomy|94|C0004461
35|This was associated with development of diffuse WMI: poor oligodendrocyte maturation, diffuse axonal hypomyelination, and permanent sensorimotor deficit|axonal hypomyelination|axonal hypomyelination|disease|94|omim:605253|sensorimotor deficit|sensorimotor deficit|disease|132|mesh:D009461
35|This was associated with development of diffuse WMI: poor oligodendrocyte maturation, diffuse axonal hypomyelination, and permanent sensorimotor deficit|sensorimotor deficit|sensorimotor deficit|disease|132|mesh:D009461|Axon|axonal|anatomy|94|C0004461
35|In normoxic mice and oligodendrocytes, exposure to a mitochondrial uncoupler recapitulated the phenotype of WMI, supporting the detrimental role of mitochondrial uncoupling in the pathogenesis of WMI|WMI|WMI|disease|108|mesh:C536690|Oligodendroglia|oligodendrocytes|anatomy|21|C0028944
35|In normoxic mice and oligodendrocytes, exposure to a mitochondrial uncoupler recapitulated the phenotype of WMI, supporting the detrimental role of mitochondrial uncoupling in the pathogenesis of WMI|WMI|WMI|disease|196|mesh:C536690|Oligodendroglia|oligodendrocytes|anatomy|21|C0028944
35|Compared with WT mice, cyclophilin D-knockout littermates did not develop bioenergetic stress in response to IH challenge and fully preserved oligodendrocyte maturation, axonal myelination, and neurofunction|cyclophilin D|cyclophilin D|gene|23|NCBIGene:5481|IH|IH|disease|109|omim:235000
35|Compared with WT mice, cyclophilin D-knockout littermates did not develop bioenergetic stress in response to IH challenge and fully preserved oligodendrocyte maturation, axonal myelination, and neurofunction|cyclophilin D|cyclophilin D|gene|23|NCBIGene:5481|Challenge:Type:Point in time:^Patient:Nominal|challenge|physiology|112|C0798503
35|Compared with WT mice, cyclophilin D-knockout littermates did not develop bioenergetic stress in response to IH challenge and fully preserved oligodendrocyte maturation, axonal myelination, and neurofunction|cyclophilin D|cyclophilin D|gene|23|NCBIGene:5481|myelination|myelination|physiology|177|C0596991
35|Compared with WT mice, cyclophilin D-knockout littermates did not develop bioenergetic stress in response to IH challenge and fully preserved oligodendrocyte maturation, axonal myelination, and neurofunction|cyclophilin D|cyclophilin D|gene|23|NCBIGene:5481|oligodendrocyte development|oligodendrocyte maturation|physiology|142|C1817605
35|Compared with WT mice, cyclophilin D-knockout littermates did not develop bioenergetic stress in response to IH challenge and fully preserved oligodendrocyte maturation, axonal myelination, and neurofunction|cyclophilin D|cyclophilin D|gene|23|NCBIGene:5481|Inspiration function|IH|physiology|109|C0004048
35|Compared with WT mice, cyclophilin D-knockout littermates did not develop bioenergetic stress in response to IH challenge and fully preserved oligodendrocyte maturation, axonal myelination, and neurofunction|cyclophilin D|cyclophilin D|gene|23|NCBIGene:5481|Axon|axonal|anatomy|170|C0004461
35|Compared with WT mice, cyclophilin D-knockout littermates did not develop bioenergetic stress in response to IH challenge and fully preserved oligodendrocyte maturation, axonal myelination, and neurofunction|cyclophilin D|cyclophilin D|gene|23|NCBIGene:5481|Bioenergetics|bioenergetic|physiology|74|C0005486
35|Compared with WT mice, cyclophilin D-knockout littermates did not develop bioenergetic stress in response to IH challenge and fully preserved oligodendrocyte maturation, axonal myelination, and neurofunction|IH|IH|disease|109|omim:235000|Axon|axonal|anatomy|170|C0004461
35|Our study identified the cyclophilin D-dependent mitochondrial proton leak and uncoupling as a potentially novel subcellular mechanism for the maturational failure of oligodendrocytes and  offers a potential therapeutic target for prevention of diffuse WMI in premature  infants experiencing chronic IH stress|cyclophilin D|cyclophilin D|gene|25|NCBIGene:5481|WMI|WMI|disease|253|mesh:C536690
35|Our study identified the cyclophilin D-dependent mitochondrial proton leak and uncoupling as a potentially novel subcellular mechanism for the maturational failure of oligodendrocytes and  offers a potential therapeutic target for prevention of diffuse WMI in premature  infants experiencing chronic IH stress|cyclophilin D|cyclophilin D|gene|25|NCBIGene:5481|IH|IH|disease|300|omim:235000
35|Our study identified the cyclophilin D-dependent mitochondrial proton leak and uncoupling as a potentially novel subcellular mechanism for the maturational failure of oligodendrocytes and  offers a potential therapeutic target for prevention of diffuse WMI in premature  infants experiencing chronic IH stress|cyclophilin D|cyclophilin D|gene|25|NCBIGene:5481|Experience|experiencing|physiology|279|C0596545
35|Our study identified the cyclophilin D-dependent mitochondrial proton leak and uncoupling as a potentially novel subcellular mechanism for the maturational failure of oligodendrocytes and  offers a potential therapeutic target for prevention of diffuse WMI in premature  infants experiencing chronic IH stress|cyclophilin D|cyclophilin D|gene|25|NCBIGene:5481|W stress|stress|physiology|303|C1718621
35|Our study identified the cyclophilin D-dependent mitochondrial proton leak and uncoupling as a potentially novel subcellular mechanism for the maturational failure of oligodendrocytes and  offers a potential therapeutic target for prevention of diffuse WMI in premature  infants experiencing chronic IH stress|cyclophilin D|cyclophilin D|gene|25|NCBIGene:5481|Inspiration function|IH|physiology|300|C0004048
35|Our study identified the cyclophilin D-dependent mitochondrial proton leak and uncoupling as a potentially novel subcellular mechanism for the maturational failure of oligodendrocytes and  offers a potential therapeutic target for prevention of diffuse WMI in premature  infants experiencing chronic IH stress|cyclophilin D|cyclophilin D|gene|25|NCBIGene:5481|Oligodendroglia|oligodendrocytes|anatomy|167|C0028944
35|Our study identified the cyclophilin D-dependent mitochondrial proton leak and uncoupling as a potentially novel subcellular mechanism for the maturational failure of oligodendrocytes and  offers a potential therapeutic target for prevention of diffuse WMI in premature  infants experiencing chronic IH stress|WMI|WMI|disease|253|mesh:C536690|IH|IH|disease|300|omim:235000
35|Our study identified the cyclophilin D-dependent mitochondrial proton leak and uncoupling as a potentially novel subcellular mechanism for the maturational failure of oligodendrocytes and  offers a potential therapeutic target for prevention of diffuse WMI in premature  infants experiencing chronic IH stress|WMI|WMI|disease|253|mesh:C536690|Oligodendroglia|oligodendrocytes|anatomy|167|C0028944
35|Our study identified the cyclophilin D-dependent mitochondrial proton leak and uncoupling as a potentially novel subcellular mechanism for the maturational failure of oligodendrocytes and  offers a potential therapeutic target for prevention of diffuse WMI in premature  infants experiencing chronic IH stress|IH|IH|disease|300|omim:235000|Oligodendroglia|oligodendrocytes|anatomy|167|C0028944
36|To better understand the potential toxic effects of SSRIs, we employed an ultra-low input RNA-sequencing method to identify potential pathways that are affected by early exposure to two SSRIs (fluoxetine and paroxetine)|fluoxetine|fluoxetine|compound|193|mesh:D005473|paroxetine|paroxetine|compound|208|mesh:D017374
36|We exposed wildtype zebrafish (Danio rerio) embryos  to 100 μg/L of either fluoxetine or paroxetine for 6 days before extracting and sequencing mRNA from individual larval brains|fluoxetine|fluoxetine|compound|74|mesh:D005473|paroxetine|paroxetine|compound|88|mesh:D017374
36|We exposed wildtype zebrafish (Danio rerio) embryos  to 100 μg/L of either fluoxetine or paroxetine for 6 days before extracting and sequencing mRNA from individual larval brains|fluoxetine|fluoxetine|compound|74|mesh:D005473|Embryo|embryos|anatomy|44|C0013935
36|We exposed wildtype zebrafish (Danio rerio) embryos  to 100 μg/L of either fluoxetine or paroxetine for 6 days before extracting and sequencing mRNA from individual larval brains|fluoxetine|fluoxetine|compound|74|mesh:D005473|Brain|brains|anatomy|172|C0006104
36|We exposed wildtype zebrafish (Danio rerio) embryos  to 100 μg/L of either fluoxetine or paroxetine for 6 days before extracting and sequencing mRNA from individual larval brains|paroxetine|paroxetine|compound|88|mesh:D017374|Embryo|embryos|anatomy|44|C0013935
36|We exposed wildtype zebrafish (Danio rerio) embryos  to 100 μg/L of either fluoxetine or paroxetine for 6 days before extracting and sequencing mRNA from individual larval brains|paroxetine|paroxetine|compound|88|mesh:D017374|Brain|brains|anatomy|172|C0006104
37|Here we found that treatment with triiodothyronine (T3) ameliorated the progression of neurological deficits in mice subjected to TBI|triiodothyronine|triiodothyronine|compound|34|mesh:D014284|neurological deficits|neurological deficits|disease|87|mesh:D009461
37|Here we found that treatment with triiodothyronine (T3) ameliorated the progression of neurological deficits in mice subjected to TBI|triiodothyronine|triiodothyronine|compound|34|mesh:D014284|TBI|TBI|disease|130|mesh:D001930
37|Here we found that treatment with triiodothyronine (T3) ameliorated the progression of neurological deficits in mice subjected to TBI|neurological deficits|neurological deficits|disease|87|mesh:D009461|TBI|TBI|disease|130|mesh:D001930
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|phosphatase and tensin homolog|phosphatase and tensin homolog|gene|54|NCBIGene:5728|TBI|TBI|disease|28|mesh:D001930
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|PTEN|PTEN|gene|86|NCBIGene:5728|TBI|TBI|disease|28|mesh:D001930
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|Pink1|Pink1|gene|119|NCBIGene:65018|TBI|TBI|disease|28|mesh:D001930
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|phosphatase and tensin homolog|phosphatase and tensin homolog|gene|54|NCBIGene:5728|Pink1|Pink1|gene|119|NCBIGene:65018
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|phosphatase and tensin homolog|phosphatase and tensin homolog|gene|54|NCBIGene:5728|Cell Death|cell death|physiology|40|C0007587
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|phosphatase and tensin homolog|phosphatase and tensin homolog|gene|54|NCBIGene:5728|Mitophagy|mitophagy|physiology|170|C1820119
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|PTEN|PTEN|gene|86|NCBIGene:5728|Pink1|Pink1|gene|119|NCBIGene:65018
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|PTEN|PTEN|gene|86|NCBIGene:5728|Cell Death|cell death|physiology|40|C0007587
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|PTEN|PTEN|gene|86|NCBIGene:5728|Mitophagy|mitophagy|physiology|170|C1820119
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|PTEN|PTEN|gene|86|NCBIGene:5728|phosphoric monoester hydrolase activity|phosphatase|physiology|54|C1149880
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|Pink1|Pink1|gene|119|NCBIGene:65018|Cell Death|cell death|physiology|40|C0007587
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|Pink1|Pink1|gene|119|NCBIGene:65018|Mitophagy|mitophagy|physiology|170|C1820119
37|However, T3 did not prevent TBI-induced cell death in phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (Pink1) knockout mice suggesting the involvement of mitophagy|Pink1|Pink1|gene|119|NCBIGene:65018|phosphoric monoester hydrolase activity|phosphatase|physiology|54|C1149880
37|Moreover, we also found that T3 promoted neurogenesis via crosstalk between mature neurons and neural stem cells (NSCs) after TBI|TBI|TBI|disease|126|mesh:D001930|Neural Stem Cells|neural stem cells|anatomy|95|C1113654
37|Moreover, we also found that T3 promoted neurogenesis via crosstalk between mature neurons and neural stem cells (NSCs) after TBI|TBI|TBI|disease|126|mesh:D001930|Neurons|neurons|anatomy|83|C0027882
37|In neuron cultures undergoing oxygen and glucose deprivation (OGD), conditioned neuron culture medium collected after T3 treatment enhanced the in vitro differentiation of NSCs into mature neurons, a process in which mitophagy was required|oxygen|oxygen|compound|30|mesh:D010100|glucose|glucose|compound|41|CHEBI:42758
37|In neuron cultures undergoing oxygen and glucose deprivation (OGD), conditioned neuron culture medium collected after T3 treatment enhanced the in vitro differentiation of NSCs into mature neurons, a process in which mitophagy was required|oxygen|oxygen|compound|30|mesh:D010100|bony process|process|anatomy|200|C1184743
37|In neuron cultures undergoing oxygen and glucose deprivation (OGD), conditioned neuron culture medium collected after T3 treatment enhanced the in vitro differentiation of NSCs into mature neurons, a process in which mitophagy was required|glucose|glucose|compound|41|CHEBI:42758|bony process|process|anatomy|200|C1184743
37|Taken together, these data suggested that T3 treatment could provide a  therapeutic approach for TBI by preventing neuronal death via mitophagy and promoting neurogenesis via neuron-NSC crosstalk|TBI|TBI|disease|97|mesh:D001930|Neurons|neuron|anatomy|175|C0027882
38|Exposure to benzo(a)pyrene (BaP) is associated with poor neurodevelopment in children and memory impairment in adults|benzo(a)pyrene|benzo(a)pyrene|compound|12|mesh:D001564|BaP|BaP|compound|28|CHEBI:29865
38|Exposure to benzo(a)pyrene (BaP) is associated with poor neurodevelopment in children and memory impairment in adults|benzo(a)pyrene|benzo(a)pyrene|compound|12|mesh:D001564|memory impairment|memory impairment|disease|90|mesh:D008569
38|Exposure to benzo(a)pyrene (BaP) is associated with poor neurodevelopment in children and memory impairment in adults|BaP|BaP|compound|28|CHEBI:29865|memory impairment|memory impairment|disease|90|mesh:D008569
38|Of interest, increasing evidence has suggested that resveratrol (RSV) can alleviate  nerve cell damage, however the exact mechanisms of biological activity in mitochondria are not fully understood|resveratrol|resveratrol|compound|52|mesh:D000077185|RSV|RSV|compound|65|mesh:D022261
38|Of interest, increasing evidence has suggested that resveratrol (RSV) can alleviate  nerve cell damage, however the exact mechanisms of biological activity in mitochondria are not fully understood|resveratrol|resveratrol|compound|52|mesh:D000077185|nerve|nerve|disease|85|mesh:D009422
38|Of interest, increasing evidence has suggested that resveratrol (RSV) can alleviate  nerve cell damage, however the exact mechanisms of biological activity in mitochondria are not fully understood|resveratrol|resveratrol|compound|52|mesh:D000077185|Mitochondria|mitochondria|anatomy|159|C0026237
38|Of interest, increasing evidence has suggested that resveratrol (RSV) can alleviate  nerve cell damage, however the exact mechanisms of biological activity in mitochondria are not fully understood|RSV|RSV|compound|65|mesh:D022261|nerve|nerve|disease|85|mesh:D009422
38|Of interest, increasing evidence has suggested that resveratrol (RSV) can alleviate  nerve cell damage, however the exact mechanisms of biological activity in mitochondria are not fully understood|RSV|RSV|compound|65|mesh:D022261|Mitochondria|mitochondria|anatomy|159|C0026237
38|Of interest, increasing evidence has suggested that resveratrol (RSV) can alleviate  nerve cell damage, however the exact mechanisms of biological activity in mitochondria are not fully understood|nerve|nerve|disease|85|mesh:D009422|Mitochondria|mitochondria|anatomy|159|C0026237
38|In the current study, Wistar rats were exposed to BaP (1, 2, 4 mg/kg) and/or RSV (15, 30 mg/kg) during embryonic development and adolescence, and learning and memory ability, mitochondrial damage, and the expression of proteins associated with mitochondrial biogenesis and mitophagy were evaluated|BaP|BaP|compound|50|CHEBI:29865|RSV|RSV|compound|77|mesh:D022261
38|However, pretreatment with 30 mg/kg RSV alleviated cell damage and the disorder of mitochondrial biogenesis by activating the AMPK/PGC-1α signaling pathway and promoting mitophagy|RSV|RSV|compound|36|mesh:D022261|AMPK|AMPK|gene|126|NCBIGene:5562
38|However, pretreatment with 30 mg/kg RSV alleviated cell damage and the disorder of mitochondrial biogenesis by activating the AMPK/PGC-1α signaling pathway and promoting mitophagy|RSV|RSV|compound|36|mesh:D022261|PGC-1|PGC-1|gene|131|NCBIGene:10891
38|However, pretreatment with 30 mg/kg RSV alleviated cell damage and the disorder of mitochondrial biogenesis by activating the AMPK/PGC-1α signaling pathway and promoting mitophagy|AMPK|AMPK|gene|126|NCBIGene:5562|PGC-1|PGC-1|gene|131|NCBIGene:10891
38|However, pretreatment with 30 mg/kg RSV alleviated cell damage and the disorder of mitochondrial biogenesis by activating the AMPK/PGC-1α signaling pathway and promoting mitophagy|AMPK|AMPK|gene|126|NCBIGene:5562|Mitophagy|mitophagy|physiology|170|C1820119
38|However, pretreatment with 30 mg/kg RSV alleviated cell damage and the disorder of mitochondrial biogenesis by activating the AMPK/PGC-1α signaling pathway and promoting mitophagy|AMPK|AMPK|gene|126|NCBIGene:5562|Signal Transduction|signaling pathway|physiology|138|C0037083
38|However, pretreatment with 30 mg/kg RSV alleviated cell damage and the disorder of mitochondrial biogenesis by activating the AMPK/PGC-1α signaling pathway and promoting mitophagy|AMPK|AMPK|gene|126|NCBIGene:5562|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|83|C3494456
38|However, pretreatment with 30 mg/kg RSV alleviated cell damage and the disorder of mitochondrial biogenesis by activating the AMPK/PGC-1α signaling pathway and promoting mitophagy|PGC-1|PGC-1|gene|131|NCBIGene:10891|Mitophagy|mitophagy|physiology|170|C1820119
38|However, pretreatment with 30 mg/kg RSV alleviated cell damage and the disorder of mitochondrial biogenesis by activating the AMPK/PGC-1α signaling pathway and promoting mitophagy|PGC-1|PGC-1|gene|131|NCBIGene:10891|Signal Transduction|signaling pathway|physiology|138|C0037083
38|However, pretreatment with 30 mg/kg RSV alleviated cell damage and the disorder of mitochondrial biogenesis by activating the AMPK/PGC-1α signaling pathway and promoting mitophagy|PGC-1|PGC-1|gene|131|NCBIGene:10891|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|83|C3494456
38|These findings suggested that RSV had utility in promoting mitochondrial homeostasis against BaP-induced nerve cell damage in the hippocampus of rats|RSV|RSV|compound|30|mesh:D022261|BaP|BaP|compound|93|CHEBI:29865
38|These findings suggested that RSV had utility in promoting mitochondrial homeostasis against BaP-induced nerve cell damage in the hippocampus of rats|RSV|RSV|compound|30|mesh:D022261|Mitochondria|mitochondrial|anatomy|59|C0026237
38|These findings suggested that RSV had utility in promoting mitochondrial homeostasis against BaP-induced nerve cell damage in the hippocampus of rats|RSV|RSV|compound|30|mesh:D022261|Hippocampus (Brain)|hippocampus|anatomy|130|C0019564
38|These findings suggested that RSV had utility in promoting mitochondrial homeostasis against BaP-induced nerve cell damage in the hippocampus of rats|BaP|BaP|compound|93|CHEBI:29865|Mitochondria|mitochondrial|anatomy|59|C0026237
38|These findings suggested that RSV had utility in promoting mitochondrial homeostasis against BaP-induced nerve cell damage in the hippocampus of rats|BaP|BaP|compound|93|CHEBI:29865|Hippocampus (Brain)|hippocampus|anatomy|130|C0019564
39|Mitochondria play a variety of roles in the cell, far beyond their widely recognized role in ATP generation|ATP|ATP|compound|93|CHEBI:30616|Cells|cell|anatomy|44|C0007634
39|Mitochondria play a variety of roles in the cell, far beyond their widely recognized role in ATP generation|ATP|ATP|compound|93|CHEBI:30616|Mitochondria|Mitochondria|anatomy|0|C0026237
39|One such role is the regulation and sequestration of calcium, which is done with the help of the mitochondrial calcium uniporter (MCU) and its regulators, MICU1 and MICU2|calcium|calcium|compound|53|mesh:D002118|mitochondrial calcium uniporter|mitochondrial calcium uniporter|gene|97|NCBIGene:90550
39|One such role is the regulation and sequestration of calcium, which is done with the help of the mitochondrial calcium uniporter (MCU) and its regulators, MICU1 and MICU2|calcium|calcium|compound|53|mesh:D002118|MCU|MCU|gene|130|NCBIGene:90550
39|One such role is the regulation and sequestration of calcium, which is done with the help of the mitochondrial calcium uniporter (MCU) and its regulators, MICU1 and MICU2|calcium|calcium|compound|53|mesh:D002118|MICU1|MICU1|gene|155|NCBIGene:10367
39|One such role is the regulation and sequestration of calcium, which is done with the help of the mitochondrial calcium uniporter (MCU) and its regulators, MICU1 and MICU2|mitochondrial calcium uniporter|mitochondrial calcium uniporter|gene|97|NCBIGene:90550|MICU1|MICU1|gene|155|NCBIGene:10367
39|One such role is the regulation and sequestration of calcium, which is done with the help of the mitochondrial calcium uniporter (MCU) and its regulators, MICU1 and MICU2|calcium|calcium|compound|111|mesh:D002118|MCU|MCU|gene|130|NCBIGene:90550
39|One such role is the regulation and sequestration of calcium, which is done with the help of the mitochondrial calcium uniporter (MCU) and its regulators, MICU1 and MICU2|calcium|calcium|compound|111|mesh:D002118|MICU1|MICU1|gene|155|NCBIGene:10367
39|One such role is the regulation and sequestration of calcium, which is done with the help of the mitochondrial calcium uniporter (MCU) and its regulators, MICU1 and MICU2|MCU|MCU|gene|130|NCBIGene:90550|MICU1|MICU1|gene|155|NCBIGene:10367
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|MICU1|MICU1|gene|22|NCBIGene:10367|MICU2|MICU2|gene|32|NCBIGene:221154
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|MICU1|MICU1|gene|22|NCBIGene:10367|myopathy|myopathy|disease|66|mesh:D009135
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|MICU1|MICU1|gene|22|NCBIGene:10367|developmental disability|developmental disability|disease|76|mesh:D002658
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|MICU1|MICU1|gene|22|NCBIGene:10367|neurological symptoms|neurological symptoms|disease|105|mesh:D009422
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|MICU1|MICU1|gene|22|NCBIGene:10367|mitochondrial disorders|mitochondrial disorders|disease|138|mesh:D028361
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|MICU2|MICU2|gene|32|NCBIGene:221154|myopathy|myopathy|disease|66|mesh:D009135
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|MICU2|MICU2|gene|32|NCBIGene:221154|developmental disability|developmental disability|disease|76|mesh:D002658
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|MICU2|MICU2|gene|32|NCBIGene:221154|neurological symptoms|neurological symptoms|disease|105|mesh:D009422
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|MICU2|MICU2|gene|32|NCBIGene:221154|mitochondrial disorders|mitochondrial disorders|disease|138|mesh:D028361
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|myopathy|myopathy|disease|66|mesh:D009135|developmental disability|developmental disability|disease|76|mesh:D002658
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|myopathy|myopathy|disease|66|mesh:D009135|neurological symptoms|neurological symptoms|disease|105|mesh:D009422
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|myopathy|myopathy|disease|66|mesh:D009135|mitochondrial disorders|mitochondrial disorders|disease|138|mesh:D028361
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|developmental disability|developmental disability|disease|76|mesh:D002658|neurological symptoms|neurological symptoms|disease|105|mesh:D009422
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|developmental disability|developmental disability|disease|76|mesh:D002658|mitochondrial disorders|mitochondrial disorders|disease|138|mesh:D028361
39|Genetic variations in MICU1 and MICU2 have been reported to cause myopathy, developmental disability and neurological symptoms typical of mitochondrial disorders|neurological symptoms|neurological symptoms|disease|105|mesh:D009422|mitochondrial disorders|mitochondrial disorders|disease|138|mesh:D028361
39|The symptoms of MICU1/2 deficiency have generally been attributed to calcium regulation in the metabolic and biochemical roles of mitochondria|calcium|calcium|compound|69|mesh:D002118|MICU1/2 deficiency|MICU1/2 deficiency|disease|16|omim:210210
39|The symptoms of MICU1/2 deficiency have generally been attributed to calcium regulation in the metabolic and biochemical roles of mitochondria|MICU1/2 deficiency|MICU1/2 deficiency|disease|16|omim:210210|Mitochondria|mitochondria|anatomy|130|C0026237
39|The symptoms of MICU1/2 deficiency have generally been attributed to calcium regulation in the metabolic and biochemical roles of mitochondria|calcium|calcium|compound|69|mesh:D002118|MICU1/2|MICU1/2|gene|16|NCBIGene:221154
39|The symptoms of MICU1/2 deficiency have generally been attributed to calcium regulation in the metabolic and biochemical roles of mitochondria|MICU1/2|MICU1/2|gene|16|NCBIGene:221154|Metabolic Process, Cellular|metabolic|physiology|95|C1524026
39|The symptoms of MICU1/2 deficiency have generally been attributed to calcium regulation in the metabolic and biochemical roles of mitochondria|MICU1/2|MICU1/2|gene|16|NCBIGene:221154|Mitochondria|mitochondria|anatomy|130|C0026237
39|The symptoms of MICU1/2 deficiency have generally been attributed to calcium regulation in the metabolic and biochemical roles of mitochondria|calcium|calcium|compound|69|mesh:D002118|Mitochondria|mitochondria|anatomy|130|C0026237
39|Here, we report a female child with heterozygous MICU1 variants and multiple congenital brain malformations on MRI|MICU1 variants|MICU1 variants|gene|49|NCBIGene:10367|congenital brain malformations|congenital brain malformations|disease|77|mesh:D009421
39|Here, we report a female child with heterozygous MICU1 variants and multiple congenital brain malformations on MRI|MICU1 variants|MICU1 variants|gene|49|NCBIGene:10367|Report:Finding:Point in time:{Setting}:Document:{Role}|report|physiology|9|C4255046
39|Here, we report a female child with heterozygous MICU1 variants and multiple congenital brain malformations on MRI|MICU1 variants|MICU1 variants|gene|49|NCBIGene:10367|Heterozygote|heterozygous|physiology|36|C0019425
39|Specifically, she shows anterior perisylvian polymicrogyria, dysmorphic basal ganglia, and cerebellar dysplasia in addition to white matter abnormalities|dysmorphic basal ganglia|dysmorphic basal ganglia|disease|61|mesh:D001480|cerebellar dysplasia|cerebellar dysplasia|disease|91|mesh:D002526
39|Specifically, she shows anterior perisylvian polymicrogyria, dysmorphic basal ganglia, and cerebellar dysplasia in addition to white matter abnormalities|dysmorphic basal ganglia|dysmorphic basal ganglia|disease|61|mesh:D001480|white matter abnormalities|white matter abnormalities|disease|127|mesh:D056784
39|Specifically, she shows anterior perisylvian polymicrogyria, dysmorphic basal ganglia, and cerebellar dysplasia in addition to white matter abnormalities|cerebellar dysplasia|cerebellar dysplasia|disease|91|mesh:D002526|white matter abnormalities|white matter abnormalities|disease|127|mesh:D056784
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|calcium|calcium|compound|134|mesh:D002118|MICU1|MICU1|gene|34|NCBIGene:10367
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|MICU1|MICU1|gene|34|NCBIGene:10367|Miro1|Miro1|gene|192|NCBIGene:55288
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|MICU1|MICU1|gene|34|NCBIGene:10367|MCU complex|MCU complex|gene|198|NCBIGene:90550
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|ATP|ATP|compound|256|CHEBI:30616|MICU1|MICU1|gene|34|NCBIGene:10367
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|MICU1|MICU1|gene|34|NCBIGene:10367|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|12|C2926606
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|MICU1|MICU1|gene|34|NCBIGene:10367|Movement|movement|physiology|233|C0026649
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|MICU1|MICU1|gene|34|NCBIGene:10367|Mitochondria|mitochondrial|anatomy|219|C0026237
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|MICU1|MICU1|gene|34|NCBIGene:10367|neurodevelopment|neurodevelopment|physiology|64|C0599855
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|calcium|calcium|compound|134|mesh:D002118|Miro1|Miro1|gene|192|NCBIGene:55288
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|calcium|calcium|compound|134|mesh:D002118|MCU complex|MCU complex|gene|198|NCBIGene:90550
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|calcium|calcium|compound|134|mesh:D002118|ATP|ATP|compound|256|CHEBI:30616
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|calcium|calcium|compound|134|mesh:D002118|Mitochondria|mitochondrial|anatomy|219|C0026237
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|Miro1|Miro1|gene|192|NCBIGene:55288|MCU complex|MCU complex|gene|198|NCBIGene:90550
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|ATP|ATP|compound|256|CHEBI:30616|Miro1|Miro1|gene|192|NCBIGene:55288
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|Miro1|Miro1|gene|192|NCBIGene:55288|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|12|C2926606
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|Miro1|Miro1|gene|192|NCBIGene:55288|Movement|movement|physiology|233|C0026649
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|Miro1|Miro1|gene|192|NCBIGene:55288|Mitochondria|mitochondrial|anatomy|219|C0026237
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|Miro1|Miro1|gene|192|NCBIGene:55288|neurodevelopment|neurodevelopment|physiology|64|C0599855
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|ATP|ATP|compound|256|CHEBI:30616|MCU complex|MCU complex|gene|198|NCBIGene:90550
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|MCU complex|MCU complex|gene|198|NCBIGene:90550|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|12|C2926606
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|MCU complex|MCU complex|gene|198|NCBIGene:90550|Movement|movement|physiology|233|C0026649
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|MCU complex|MCU complex|gene|198|NCBIGene:90550|Mitochondria|mitochondrial|anatomy|219|C0026237
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|MCU complex|MCU complex|gene|198|NCBIGene:90550|neurodevelopment|neurodevelopment|physiology|64|C0599855
39|These novel findings suggest that MICU1 is necessary for proper neurodevelopment through a variety of potential mechanisms, including calcium-mediated regulation of the neuronal cytoskeleton, Miro1-MCU complex-mediated mitochondrial movement, or enhancing ATP production|ATP|ATP|compound|256|CHEBI:30616|Mitochondria|mitochondrial|anatomy|219|C0026237
39|This case provides new insight into the molecular pathogenesis of MCU dysfunction and may represent a novel diagnostic feature of calcium-based mitochondrial disease|calcium|calcium|compound|130|mesh:D002118|MCU dysfunction|MCU dysfunction|disease|66|mesh:D000080343
39|This case provides new insight into the molecular pathogenesis of MCU dysfunction and may represent a novel diagnostic feature of calcium-based mitochondrial disease|MCU dysfunction|MCU dysfunction|disease|66|mesh:D000080343|mitochondrial disease|mitochondrial disease|disease|144|mesh:D028361
39|This case provides new insight into the molecular pathogenesis of MCU dysfunction and may represent a novel diagnostic feature of calcium-based mitochondrial disease|calcium|calcium|compound|130|mesh:D002118|MCU|MCU|gene|66|NCBIGene:90550
39|This case provides new insight into the molecular pathogenesis of MCU dysfunction and may represent a novel diagnostic feature of calcium-based mitochondrial disease|MCU|MCU|gene|66|NCBIGene:90550|mitochondrial disease|mitochondrial disease|disease|144|mesh:D028361
39|This case provides new insight into the molecular pathogenesis of MCU dysfunction and may represent a novel diagnostic feature of calcium-based mitochondrial disease|MCU|MCU|gene|66|NCBIGene:90550|Insight|insight|physiology|23|C0233820
39|This case provides new insight into the molecular pathogenesis of MCU dysfunction and may represent a novel diagnostic feature of calcium-based mitochondrial disease|calcium|calcium|compound|130|mesh:D002118|mitochondrial disease|mitochondrial disease|disease|144|mesh:D028361
40|Epilepsy, intellectual and cortical sensory deficits, and psychiatric manifestations are the most frequent manifestations of mitochondrial diseases|Epilepsy|Epilepsy|disease|0|mesh:D004827|intellectual and cortical sensory deficits|intellectual and cortical sensory deficits|disease|10|omim:611943
40|Epilepsy, intellectual and cortical sensory deficits, and psychiatric manifestations are the most frequent manifestations of mitochondrial diseases|Epilepsy|Epilepsy|disease|0|mesh:D004827|mitochondrial diseases|mitochondrial diseases|disease|125|mesh:D028361
40|Epilepsy, intellectual and cortical sensory deficits, and psychiatric manifestations are the most frequent manifestations of mitochondrial diseases|Epilepsy|Epilepsy|disease|0|mesh:D004827|Adrenal Cortex|cortical|anatomy|27|C0001613
40|Epilepsy, intellectual and cortical sensory deficits, and psychiatric manifestations are the most frequent manifestations of mitochondrial diseases|intellectual and cortical sensory deficits|intellectual and cortical sensory deficits|disease|10|omim:611943|mitochondrial diseases|mitochondrial diseases|disease|125|mesh:D028361
40|Epilepsy, intellectual and cortical sensory deficits, and psychiatric manifestations are the most frequent manifestations of mitochondrial diseases|mitochondrial diseases|mitochondrial diseases|disease|125|mesh:D028361|Adrenal Cortex|cortical|anatomy|27|C0001613
40|How mitochondrial dysfunction affects neural structure and function remains elusive, mostly because of a lack of proper in vitro neuronal model systems with  mitochondrial dysfunction|mitochondrial dysfunction|mitochondrial dysfunction|disease|4|mesh:D028361|Nerve|neural structure|anatomy|38|C0027740
40|How mitochondrial dysfunction affects neural structure and function remains elusive, mostly because of a lack of proper in vitro neuronal model systems with  mitochondrial dysfunction|mitochondrial dysfunction|mitochondrial dysfunction|disease|158|mesh:D028361|Nerve|neural structure|anatomy|38|C0027740
40|3243A  > G variant of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like  episodes (MELAS)|mitochondrial encephalomyopathy|mitochondrial encephalomyopathy|disease|22|mesh:D017237|lactic acidosis|lactic acidosis|disease|55|mesh:D000140
40|3243A  > G variant of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like  episodes (MELAS)|mitochondrial encephalomyopathy|mitochondrial encephalomyopathy|disease|22|mesh:D017237|stroke-like  episodes|stroke-like  episodes|disease|76|mesh:D020521
40|3243A  > G variant of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like  episodes (MELAS)|mitochondrial encephalomyopathy|mitochondrial encephalomyopathy|disease|22|mesh:D017237|MELAS|MELAS|disease|99|mesh:D017241
40|3243A  > G variant of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like  episodes (MELAS)|lactic acidosis|lactic acidosis|disease|55|mesh:D000140|stroke-like  episodes|stroke-like  episodes|disease|76|mesh:D020521
40|3243A  > G variant of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like  episodes (MELAS)|lactic acidosis|lactic acidosis|disease|55|mesh:D000140|MELAS|MELAS|disease|99|mesh:D017241
40|3243A  > G variant of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like  episodes (MELAS)|stroke-like  episodes|stroke-like  episodes|disease|76|mesh:D020521|MELAS|MELAS|disease|99|mesh:D017241
40|iNeurons with high heteroplasmy exhibited mitochondrial dysfunction, delayed neural maturation, reduced dendritic complexity, and fewer excitatory synapses|mitochondrial dysfunction|mitochondrial dysfunction|disease|42|mesh:D028361|Excitatory Synapse|excitatory synapses|anatomy|136|C1516988
40|Impaired neuronal energy metabolism and compromised structural and functional integrity of neurons and neural networks could be the primary drivers of increased susceptibility to neuropsychiatric manifestations of mitochondrial disease|mitochondrial disease|mitochondrial disease|disease|214|mesh:D028361|Neurons|neurons|anatomy|91|C0027882
41|Rationale: Potential adverse effects of fluoride on neurodevelopment has been extensively explored and mitochondria have been recognized as critical targets|fluoride|fluoride|compound|40|mesh:D005459|Mitochondria|mitochondria|anatomy|103|C0026237
41|Mitochondrial biogenesis serves a crucial role in maintaining mitochondrial homeostasis and salubrious properties of resveratrol (RSV) has been well-defined|resveratrol|resveratrol|compound|117|mesh:D000077185|RSV|RSV|compound|130|mesh:D022261
41|Methods: In vitro neuroblastoma SH-SY5Y cells and in vivo Sprague-Dawley rat model of developmental fluoride exposure were adopted|fluoride|fluoride|compound|100|mesh:D005459|neuroblastoma|neuroblastoma|disease|18|omim:256700
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|silent information regulator 1|silent information regulator 1|gene|192|NCBIGene:23089|SIRT1|SIRT1|gene|224|NCBIGene:23411
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|silent information regulator 1|silent information regulator 1|gene|192|NCBIGene:23089|peroxisome proliferator-activated receptor  coactivator-1|peroxisome proliferator-activated receptor  coactivator-1|gene|232|NCBIGene:84498
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|silent information regulator 1|silent information regulator 1|gene|192|NCBIGene:23089|PGC-1|PGC-1|gene|291|NCBIGene:10891
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|silent information regulator 1|silent information regulator 1|gene|192|NCBIGene:23089|nuclear respiratory factor 1|nuclear respiratory factor 1|gene|299|NCBIGene:4899
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|silent information regulator 1|silent information regulator 1|gene|192|NCBIGene:23089|NRF1|NRF1|gene|329|NCBIGene:4899
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|silent information regulator 1|silent information regulator 1|gene|192|NCBIGene:23089|mitochondrial transcription factor A|mitochondrial transcription factor A|gene|339|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|silent information regulator 1|silent information regulator 1|gene|192|NCBIGene:23089|TFAM|TFAM|gene|377|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|silent information regulator 1|silent information regulator 1|gene|192|NCBIGene:23089|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|68|C3494456
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|silent information regulator 1|silent information regulator 1|gene|192|NCBIGene:23089|protein expression|protein expression|physiology|114|C1171362
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|silent information regulator 1|silent information regulator 1|gene|192|NCBIGene:23089|receptor ligand activity|signaling molecules|physiology|161|C3154965
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|SIRT1|SIRT1|gene|224|NCBIGene:23411|peroxisome proliferator-activated receptor  coactivator-1|peroxisome proliferator-activated receptor  coactivator-1|gene|232|NCBIGene:84498
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|SIRT1|SIRT1|gene|224|NCBIGene:23411|PGC-1|PGC-1|gene|291|NCBIGene:10891
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|SIRT1|SIRT1|gene|224|NCBIGene:23411|nuclear respiratory factor 1|nuclear respiratory factor 1|gene|299|NCBIGene:4899
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|SIRT1|SIRT1|gene|224|NCBIGene:23411|NRF1|NRF1|gene|329|NCBIGene:4899
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|SIRT1|SIRT1|gene|224|NCBIGene:23411|mitochondrial transcription factor A|mitochondrial transcription factor A|gene|339|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|SIRT1|SIRT1|gene|224|NCBIGene:23411|TFAM|TFAM|gene|377|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|SIRT1|SIRT1|gene|224|NCBIGene:23411|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|68|C3494456
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|SIRT1|SIRT1|gene|224|NCBIGene:23411|protein expression|protein expression|physiology|114|C1171362
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|SIRT1|SIRT1|gene|224|NCBIGene:23411|receptor ligand activity|signaling molecules|physiology|161|C3154965
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|peroxisome proliferator-activated receptor  coactivator-1|peroxisome proliferator-activated receptor  coactivator-1|gene|232|NCBIGene:84498|PGC-1|PGC-1|gene|291|NCBIGene:10891
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|peroxisome proliferator-activated receptor  coactivator-1|peroxisome proliferator-activated receptor  coactivator-1|gene|232|NCBIGene:84498|nuclear respiratory factor 1|nuclear respiratory factor 1|gene|299|NCBIGene:4899
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|peroxisome proliferator-activated receptor  coactivator-1|peroxisome proliferator-activated receptor  coactivator-1|gene|232|NCBIGene:84498|NRF1|NRF1|gene|329|NCBIGene:4899
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|peroxisome proliferator-activated receptor  coactivator-1|peroxisome proliferator-activated receptor  coactivator-1|gene|232|NCBIGene:84498|mitochondrial transcription factor A|mitochondrial transcription factor A|gene|339|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|peroxisome proliferator-activated receptor  coactivator-1|peroxisome proliferator-activated receptor  coactivator-1|gene|232|NCBIGene:84498|TFAM|TFAM|gene|377|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|peroxisome proliferator-activated receptor  coactivator-1|peroxisome proliferator-activated receptor  coactivator-1|gene|232|NCBIGene:84498|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|68|C3494456
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|peroxisome proliferator-activated receptor  coactivator-1|peroxisome proliferator-activated receptor  coactivator-1|gene|232|NCBIGene:84498|protein expression|protein expression|physiology|114|C1171362
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|peroxisome proliferator-activated receptor  coactivator-1|peroxisome proliferator-activated receptor  coactivator-1|gene|232|NCBIGene:84498|receptor ligand activity|signaling molecules|physiology|161|C3154965
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|PGC-1|PGC-1|gene|291|NCBIGene:10891|nuclear respiratory factor 1|nuclear respiratory factor 1|gene|299|NCBIGene:4899
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|PGC-1|PGC-1|gene|291|NCBIGene:10891|NRF1|NRF1|gene|329|NCBIGene:4899
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|PGC-1|PGC-1|gene|291|NCBIGene:10891|mitochondrial transcription factor A|mitochondrial transcription factor A|gene|339|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|PGC-1|PGC-1|gene|291|NCBIGene:10891|TFAM|TFAM|gene|377|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|PGC-1|PGC-1|gene|291|NCBIGene:10891|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|68|C3494456
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|PGC-1|PGC-1|gene|291|NCBIGene:10891|protein expression|protein expression|physiology|114|C1171362
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|PGC-1|PGC-1|gene|291|NCBIGene:10891|receptor ligand activity|signaling molecules|physiology|161|C3154965
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|nuclear respiratory factor 1|nuclear respiratory factor 1|gene|299|NCBIGene:4899|mitochondrial transcription factor A|mitochondrial transcription factor A|gene|339|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|nuclear respiratory factor 1|nuclear respiratory factor 1|gene|299|NCBIGene:4899|TFAM|TFAM|gene|377|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|nuclear respiratory factor 1|nuclear respiratory factor 1|gene|299|NCBIGene:4899|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|68|C3494456
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|nuclear respiratory factor 1|nuclear respiratory factor 1|gene|299|NCBIGene:4899|protein expression|protein expression|physiology|114|C1171362
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|nuclear respiratory factor 1|nuclear respiratory factor 1|gene|299|NCBIGene:4899|receptor ligand activity|signaling molecules|physiology|161|C3154965
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|NRF1|NRF1|gene|329|NCBIGene:4899|mitochondrial transcription factor A|mitochondrial transcription factor A|gene|339|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|NRF1|NRF1|gene|329|NCBIGene:4899|TFAM|TFAM|gene|377|NCBIGene:7019
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|NRF1|NRF1|gene|329|NCBIGene:4899|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|68|C3494456
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|NRF1|NRF1|gene|329|NCBIGene:4899|protein expression|protein expression|physiology|114|C1171362
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|NRF1|NRF1|gene|329|NCBIGene:4899|receptor ligand activity|signaling molecules|physiology|161|C3154965
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|mitochondrial transcription factor A|mitochondrial transcription factor A|gene|339|NCBIGene:7019|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|68|C3494456
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|mitochondrial transcription factor A|mitochondrial transcription factor A|gene|339|NCBIGene:7019|protein expression|protein expression|physiology|114|C1171362
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|mitochondrial transcription factor A|mitochondrial transcription factor A|gene|339|NCBIGene:7019|receptor ligand activity|signaling molecules|physiology|161|C3154965
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|TFAM|TFAM|gene|377|NCBIGene:7019|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|68|C3494456
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|TFAM|TFAM|gene|377|NCBIGene:7019|protein expression|protein expression|physiology|114|C1171362
41|Biochemical methods included analysis of mitochondrial function and mitochondrial biogenesis, as well as mRNA and protein expression of mitochondrial biogenesis signaling molecules, including silent information regulator 1 (SIRT1), peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM)|TFAM|TFAM|gene|377|NCBIGene:7019|receptor ligand activity|signaling molecules|physiology|161|C3154965
41|Results: Both in vivo and in vitro experiments showed that sodium fluoride (NaF)  caused mitochondrial dysfunction and impaired mitochondrial biogenesis|sodium fluoride|sodium fluoride|compound|59|CHEBI:28741|mitochondrial dysfunction|mitochondrial dysfunction|disease|89|mesh:D028361
41|Results: Both in vivo and in vitro experiments showed that sodium fluoride (NaF)  caused mitochondrial dysfunction and impaired mitochondrial biogenesis|NaF|NaF|compound|76|CHEBI:28741|mitochondrial dysfunction|mitochondrial dysfunction|disease|89|mesh:D028361
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|NaF|NaF|compound|6|CHEBI:28741|SIRT1|SIRT1|gene|19|NCBIGene:23411
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|NaF|NaF|compound|6|CHEBI:28741|SIRT1|SIRT1|gene|47|NCBIGene:23411
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|NaF|NaF|compound|6|CHEBI:28741|PGC-1|PGC-1|gene|105|NCBIGene:10891
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|NaF|NaF|compound|6|CHEBI:28741|NRF1|NRF1|gene|112|NCBIGene:4899
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|NaF|NaF|compound|6|CHEBI:28741|TFAM|TFAM|gene|121|NCBIGene:7019
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|19|NCBIGene:23411|PGC-1|PGC-1|gene|105|NCBIGene:10891
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|19|NCBIGene:23411|NRF1|NRF1|gene|112|NCBIGene:4899
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|19|NCBIGene:23411|TFAM|TFAM|gene|121|NCBIGene:7019
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|19|NCBIGene:23411|deacetylase activity|deacetylase activity|physiology|53|C1149763
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|19|NCBIGene:23411|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|159|C3494456
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|19|NCBIGene:23411|receptor ligand activity|signaling molecules|physiology|184|C3154965
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|47|NCBIGene:23411|PGC-1|PGC-1|gene|105|NCBIGene:10891
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|47|NCBIGene:23411|NRF1|NRF1|gene|112|NCBIGene:4899
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|47|NCBIGene:23411|TFAM|TFAM|gene|121|NCBIGene:7019
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|47|NCBIGene:23411|deacetylase activity|deacetylase activity|physiology|53|C1149763
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|47|NCBIGene:23411|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|159|C3494456
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|SIRT1|SIRT1|gene|47|NCBIGene:23411|receptor ligand activity|signaling molecules|physiology|184|C3154965
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|PGC-1|PGC-1|gene|105|NCBIGene:10891|NRF1|NRF1|gene|112|NCBIGene:4899
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|PGC-1|PGC-1|gene|105|NCBIGene:10891|TFAM|TFAM|gene|121|NCBIGene:7019
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|PGC-1|PGC-1|gene|105|NCBIGene:10891|deacetylase activity|deacetylase activity|physiology|53|C1149763
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|PGC-1|PGC-1|gene|105|NCBIGene:10891|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|159|C3494456
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|PGC-1|PGC-1|gene|105|NCBIGene:10891|receptor ligand activity|signaling molecules|physiology|184|C3154965
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|NRF1|NRF1|gene|112|NCBIGene:4899|TFAM|TFAM|gene|121|NCBIGene:7019
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|NRF1|NRF1|gene|112|NCBIGene:4899|deacetylase activity|deacetylase activity|physiology|53|C1149763
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|NRF1|NRF1|gene|112|NCBIGene:4899|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|159|C3494456
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|NRF1|NRF1|gene|112|NCBIGene:4899|receptor ligand activity|signaling molecules|physiology|184|C3154965
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|TFAM|TFAM|gene|121|NCBIGene:7019|deacetylase activity|deacetylase activity|physiology|53|C1149763
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|TFAM|TFAM|gene|121|NCBIGene:7019|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|159|C3494456
41|Also, NaF elevated SIRT1 levels and suppressed SIRT1 deacetylase activity along with decreased levels of PGC-1α, NRF1 and TFAM, suggestive of dysregulation of mitochondrial biogenesis signaling molecules|TFAM|TFAM|gene|121|NCBIGene:7019|receptor ligand activity|signaling molecules|physiology|184|C3154965
41|Moreover, enhancement of mitochondrial biogenesis by TFAM overexpression alleviated NaF-induced neuronal death through improving mitochondrial function in vitro|NaF|NaF|compound|84|CHEBI:28741|TFAM|TFAM|gene|53|NCBIGene:7019
41|Moreover, enhancement of mitochondrial biogenesis by TFAM overexpression alleviated NaF-induced neuronal death through improving mitochondrial function in vitro|TFAM|TFAM|gene|53|NCBIGene:7019|Cessation of life|death|physiology|105|C0011065
41|Moreover, enhancement of mitochondrial biogenesis by TFAM overexpression alleviated NaF-induced neuronal death through improving mitochondrial function in vitro|TFAM|TFAM|gene|53|NCBIGene:7019|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|25|C3494456
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|fluoride|fluoride|compound|198|mesh:D005459|SIRT1|SIRT1|gene|76|NCBIGene:23411
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|76|NCBIGene:23411|PGC-1|PGC-1|gene|252|NCBIGene:10891
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|76|NCBIGene:23411|NRF1|NRF1|gene|258|NCBIGene:4899
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|76|NCBIGene:23411|TFAM|TFAM|gene|263|NCBIGene:7019
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|76|NCBIGene:23411|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|102|C3494456
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|76|NCBIGene:23411|Function Axis|function|physiology|156|C0700205
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|76|NCBIGene:23411|Signal Transduction|signaling pathway|physiology|269|C0037083
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|76|NCBIGene:23411|Biologic Development|developmental|physiology|184|C0678723
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|fluoride|fluoride|compound|198|mesh:D005459|SIRT1|SIRT1|gene|236|NCBIGene:23411
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|fluoride|fluoride|compound|198|mesh:D005459|PGC-1|PGC-1|gene|252|NCBIGene:10891
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|fluoride|fluoride|compound|198|mesh:D005459|NRF1|NRF1|gene|258|NCBIGene:4899
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|fluoride|fluoride|compound|198|mesh:D005459|TFAM|TFAM|gene|263|NCBIGene:7019
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|236|NCBIGene:23411|PGC-1|PGC-1|gene|252|NCBIGene:10891
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|236|NCBIGene:23411|NRF1|NRF1|gene|258|NCBIGene:4899
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|236|NCBIGene:23411|TFAM|TFAM|gene|263|NCBIGene:7019
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|236|NCBIGene:23411|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|102|C3494456
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|236|NCBIGene:23411|Function Axis|function|physiology|156|C0700205
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|236|NCBIGene:23411|Signal Transduction|signaling pathway|physiology|269|C0037083
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|SIRT1|SIRT1|gene|236|NCBIGene:23411|Biologic Development|developmental|physiology|184|C0678723
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|PGC-1|PGC-1|gene|252|NCBIGene:10891|NRF1|NRF1|gene|258|NCBIGene:4899
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|PGC-1|PGC-1|gene|252|NCBIGene:10891|TFAM|TFAM|gene|263|NCBIGene:7019
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|PGC-1|PGC-1|gene|252|NCBIGene:10891|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|102|C3494456
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|PGC-1|PGC-1|gene|252|NCBIGene:10891|Function Axis|function|physiology|156|C0700205
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|PGC-1|PGC-1|gene|252|NCBIGene:10891|Signal Transduction|signaling pathway|physiology|269|C0037083
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|PGC-1|PGC-1|gene|252|NCBIGene:10891|Biologic Development|developmental|physiology|184|C0678723
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|NRF1|NRF1|gene|258|NCBIGene:4899|TFAM|TFAM|gene|263|NCBIGene:7019
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|NRF1|NRF1|gene|258|NCBIGene:4899|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|102|C3494456
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|NRF1|NRF1|gene|258|NCBIGene:4899|Function Axis|function|physiology|156|C0700205
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|NRF1|NRF1|gene|258|NCBIGene:4899|Signal Transduction|signaling pathway|physiology|269|C0037083
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|NRF1|NRF1|gene|258|NCBIGene:4899|Biologic Development|developmental|physiology|184|C0678723
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|TFAM|TFAM|gene|263|NCBIGene:7019|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|102|C3494456
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|TFAM|TFAM|gene|263|NCBIGene:7019|Function Axis|function|physiology|156|C0700205
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|TFAM|TFAM|gene|263|NCBIGene:7019|Signal Transduction|signaling pathway|physiology|269|C0037083
41|Further in vivo and in vitro studies identified RSV, the strongest specific SIRT1 activator, improved mitochondrial biogenesis and subsequent mitochondrial function to protect against developmental fluoride neurotoxicity via activating SIRT1-dependent PGC-1α/NRF1/TFAM signaling pathway|TFAM|TFAM|gene|263|NCBIGene:7019|Biologic Development|developmental|physiology|184|C0678723
41|Noteworthy, epidemiological data indicated intimate correlations between disturbed circulating levels of mitochondrial biogenesis signaling molecules and fluoride-caused intellectual loss in children|fluoride|fluoride|compound|154|mesh:D005459|intellectual loss|intellectual loss|disease|170|mesh:D008607
41|Conclusions: Our data suggest the pivotal role of impaired mitochondrial biogenesis in developmental fluoride neurotoxicity and the underlying SIRT1 signaling dysfunction in such neurotoxic process, which emphasizes RSV as a potential therapeutic dietary agent for relieving developmental fluoride neurotoxicity|fluoride|fluoride|compound|101|mesh:D005459|SIRT1|SIRT1|gene|143|NCBIGene:23411
41|Conclusions: Our data suggest the pivotal role of impaired mitochondrial biogenesis in developmental fluoride neurotoxicity and the underlying SIRT1 signaling dysfunction in such neurotoxic process, which emphasizes RSV as a potential therapeutic dietary agent for relieving developmental fluoride neurotoxicity|fluoride|fluoride|compound|289|mesh:D005459|SIRT1|SIRT1|gene|143|NCBIGene:23411
41|Conclusions: Our data suggest the pivotal role of impaired mitochondrial biogenesis in developmental fluoride neurotoxicity and the underlying SIRT1 signaling dysfunction in such neurotoxic process, which emphasizes RSV as a potential therapeutic dietary agent for relieving developmental fluoride neurotoxicity|SIRT1|SIRT1|gene|143|NCBIGene:23411|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|59|C3494456
42|Fragile X syndrome (FXS) is the leading known inherited intellectual disability and the most common genetic cause of autism|Fragile X syndrome|Fragile X syndrome|disease|0|omim:300624|inherited intellectual disability|inherited intellectual disability|disease|46|mesh:D008607
42|Fragile X syndrome (FXS) is the leading known inherited intellectual disability and the most common genetic cause of autism|Fragile X syndrome|Fragile X syndrome|disease|0|omim:300624|autism|autism|disease|117|omim:209850
42|Fragile X syndrome (FXS) is the leading known inherited intellectual disability and the most common genetic cause of autism|FXS|FXS|disease|20|omim:300624|inherited intellectual disability|inherited intellectual disability|disease|46|mesh:D008607
42|Fragile X syndrome (FXS) is the leading known inherited intellectual disability and the most common genetic cause of autism|FXS|FXS|disease|20|omim:300624|autism|autism|disease|117|omim:209850
42|Fragile X syndrome (FXS) is the leading known inherited intellectual disability and the most common genetic cause of autism|inherited intellectual disability|inherited intellectual disability|disease|46|mesh:D008607|autism|autism|disease|117|omim:209850
42|The full mutation results in transcriptional silencing of the Fmr1 gene and loss of fragile X mental retardation protein (FMRP) expression|Fmr1 gene|Fmr1 gene|gene|62|NCBIGene:2332|fragile X mental retardation|fragile X mental retardation|disease|84|omim:300624
42|The full mutation results in transcriptional silencing of the Fmr1 gene and loss of fragile X mental retardation protein (FMRP) expression|Fmr1 gene|Fmr1 gene|gene|62|NCBIGene:2332|Mutation|mutation|physiology|9|C0026882
42|The full mutation results in transcriptional silencing of the Fmr1 gene and loss of fragile X mental retardation protein (FMRP) expression|FMRP|FMRP|gene|122|NCBIGene:2332|fragile X mental retardation|fragile X mental retardation|disease|84|omim:300624
42|The full mutation results in transcriptional silencing of the Fmr1 gene and loss of fragile X mental retardation protein (FMRP) expression|fragile X mental retardation protein|fragile X mental retardation protein|gene|84|NCBIGene:2332|Mutation|mutation|physiology|9|C0026882
42|The full mutation results in transcriptional silencing of the Fmr1 gene and loss of fragile X mental retardation protein (FMRP) expression|FMRP|FMRP|gene|122|NCBIGene:2332|Mutation|mutation|physiology|9|C0026882
42|Thus, we explored the integrity of forebrain mitochondria in Fmr1 knockout mice during the peak of synaptogenesis|Fmr1|Fmr1|gene|61|NCBIGene:2332|Mitochondria|mitochondria|anatomy|45|C0026237
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|Fmr1|Fmr1|gene|74|NCBIGene:2332|coenzyme Q (CoQ) deficiency|coenzyme Q (CoQ) deficiency|disease|105|mesh:C564403
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|coenzyme Q|coenzyme Q|compound|105|mesh:D014451|Fmr1|Fmr1|gene|74|NCBIGene:2332
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|CoQ|CoQ|compound|117|mesh:C024989|Fmr1|Fmr1|gene|74|NCBIGene:2332
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|cyclosporine|cyclosporine|compound|145|mesh:D016572|Fmr1|Fmr1|gene|74|NCBIGene:2332
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|Fmr1|Fmr1|gene|74|NCBIGene:2332|Mitochondria|mitochondria|anatomy|82|C0026237
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|Fmr1|Fmr1|gene|74|NCBIGene:2332|Cell Respiration|respiration|physiology|33|C0282636
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|Fmr1|Fmr1|gene|74|NCBIGene:2332|KELL NULL|KO|anatomy|79|C1862225
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|cyclosporine|cyclosporine|compound|145|mesh:D016572|coenzyme Q (CoQ) deficiency|coenzyme Q (CoQ) deficiency|disease|105|mesh:C564403
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|coenzyme Q (CoQ) deficiency|coenzyme Q (CoQ) deficiency|disease|105|mesh:C564403|Mitochondria|mitochondria|anatomy|82|C0026237
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|coenzyme Q (CoQ) deficiency|coenzyme Q (CoQ) deficiency|disease|105|mesh:C564403|KELL NULL|KO|anatomy|79|C1862225
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|coenzyme Q|coenzyme Q|compound|105|mesh:D014451|CoQ|CoQ|compound|117|mesh:C024989
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|coenzyme Q|coenzyme Q|compound|105|mesh:D014451|cyclosporine|cyclosporine|compound|145|mesh:D016572
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|coenzyme Q|coenzyme Q|compound|105|mesh:D014451|Mitochondria|mitochondria|anatomy|82|C0026237
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|coenzyme Q|coenzyme Q|compound|105|mesh:D014451|KELL NULL|KO|anatomy|79|C1862225
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|CoQ|CoQ|compound|117|mesh:C024989|cyclosporine|cyclosporine|compound|145|mesh:D016572
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|CoQ|CoQ|compound|117|mesh:C024989|Mitochondria|mitochondria|anatomy|82|C0026237
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|CoQ|CoQ|compound|117|mesh:C024989|KELL NULL|KO|anatomy|79|C1862225
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|cyclosporine|cyclosporine|compound|145|mesh:D016572|Mitochondria|mitochondria|anatomy|82|C0026237
42|We found inefficient thermogenic respiration due to futile proton leak in Fmr1 KO mitochondria caused by coenzyme Q (CoQ) deficiency and an open cyclosporine-sensitive channel|cyclosporine|cyclosporine|compound|145|mesh:D016572|KELL NULL|KO|anatomy|79|C1862225
42|Repletion of mitochondrial CoQ within the Fmr1 KO forebrain closed the channel, blocked the pathological proton leak, restored rates of protein synthesis during synaptogenesis, and normalized the key phenotypic features later in life|CoQ|CoQ|compound|27|mesh:C024989|Fmr1|Fmr1|gene|42|NCBIGene:2332
42|Repletion of mitochondrial CoQ within the Fmr1 KO forebrain closed the channel, blocked the pathological proton leak, restored rates of protein synthesis during synaptogenesis, and normalized the key phenotypic features later in life|CoQ|CoQ|compound|27|mesh:C024989|Prosencephalon|forebrain|anatomy|50|C0085140
42|Repletion of mitochondrial CoQ within the Fmr1 KO forebrain closed the channel, blocked the pathological proton leak, restored rates of protein synthesis during synaptogenesis, and normalized the key phenotypic features later in life|CoQ|CoQ|compound|27|mesh:C024989|KELL NULL|KO|anatomy|47|C1862225
42|Repletion of mitochondrial CoQ within the Fmr1 KO forebrain closed the channel, blocked the pathological proton leak, restored rates of protein synthesis during synaptogenesis, and normalized the key phenotypic features later in life|CoQ|CoQ|compound|27|mesh:C024989|Mitochondria|mitochondrial|anatomy|13|C0026237
42|Repletion of mitochondrial CoQ within the Fmr1 KO forebrain closed the channel, blocked the pathological proton leak, restored rates of protein synthesis during synaptogenesis, and normalized the key phenotypic features later in life|Fmr1|Fmr1|gene|42|NCBIGene:2332|synaptogenesis|synaptogenesis|physiology|161|C0597545
42|Repletion of mitochondrial CoQ within the Fmr1 KO forebrain closed the channel, blocked the pathological proton leak, restored rates of protein synthesis during synaptogenesis, and normalized the key phenotypic features later in life|Fmr1|Fmr1|gene|42|NCBIGene:2332|Prosencephalon|forebrain|anatomy|50|C0085140
42|Repletion of mitochondrial CoQ within the Fmr1 KO forebrain closed the channel, blocked the pathological proton leak, restored rates of protein synthesis during synaptogenesis, and normalized the key phenotypic features later in life|Fmr1|Fmr1|gene|42|NCBIGene:2332|KELL NULL|KO|anatomy|47|C1862225
42|Repletion of mitochondrial CoQ within the Fmr1 KO forebrain closed the channel, blocked the pathological proton leak, restored rates of protein synthesis during synaptogenesis, and normalized the key phenotypic features later in life|Fmr1|Fmr1|gene|42|NCBIGene:2332|Protein Biosynthesis|protein synthesis|physiology|136|C0597295
42|Repletion of mitochondrial CoQ within the Fmr1 KO forebrain closed the channel, blocked the pathological proton leak, restored rates of protein synthesis during synaptogenesis, and normalized the key phenotypic features later in life|Fmr1|Fmr1|gene|42|NCBIGene:2332|Mitochondria|mitochondrial|anatomy|13|C0026237
42|Repletion of mitochondrial CoQ within the Fmr1 KO forebrain closed the channel, blocked the pathological proton leak, restored rates of protein synthesis during synaptogenesis, and normalized the key phenotypic features later in life|Fmr1|Fmr1|gene|42|NCBIGene:2332|Phenotype|phenotypic|physiology|200|C0031437
42|The findings demonstrate that FMRP deficiency  results in inefficient oxidative phosphorylation during the neurodevelopment and  suggest that dysfunctional mitochondria may contribute to the FXS phenotype|FMRP deficiency|FMRP deficiency|disease|30|mesh:D005621|FXS|FXS|disease|191|omim:300624
42|The findings demonstrate that FMRP deficiency  results in inefficient oxidative phosphorylation during the neurodevelopment and  suggest that dysfunctional mitochondria may contribute to the FXS phenotype|FMRP deficiency|FMRP deficiency|disease|30|mesh:D005621|Mitochondria|mitochondria|anatomy|156|C0026237
42|The findings demonstrate that FMRP deficiency  results in inefficient oxidative phosphorylation during the neurodevelopment and  suggest that dysfunctional mitochondria may contribute to the FXS phenotype|FMRP|FMRP|gene|30|NCBIGene:57532|FXS|FXS|disease|191|omim:300624
42|The findings demonstrate that FMRP deficiency  results in inefficient oxidative phosphorylation during the neurodevelopment and  suggest that dysfunctional mitochondria may contribute to the FXS phenotype|FMRP|FMRP|gene|30|NCBIGene:57532|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|4|C2926606
42|The findings demonstrate that FMRP deficiency  results in inefficient oxidative phosphorylation during the neurodevelopment and  suggest that dysfunctional mitochondria may contribute to the FXS phenotype|FMRP|FMRP|gene|30|NCBIGene:57532|neurodevelopment|neurodevelopment|physiology|107|C0599855
42|The findings demonstrate that FMRP deficiency  results in inefficient oxidative phosphorylation during the neurodevelopment and  suggest that dysfunctional mitochondria may contribute to the FXS phenotype|FMRP|FMRP|gene|30|NCBIGene:57532|Mitochondria|mitochondria|anatomy|156|C0026237
42|The findings demonstrate that FMRP deficiency  results in inefficient oxidative phosphorylation during the neurodevelopment and  suggest that dysfunctional mitochondria may contribute to the FXS phenotype|FMRP|FMRP|gene|30|NCBIGene:57532|Oxidative Phosphorylation|oxidative phosphorylation|physiology|70|C0030013
42|The findings demonstrate that FMRP deficiency  results in inefficient oxidative phosphorylation during the neurodevelopment and  suggest that dysfunctional mitochondria may contribute to the FXS phenotype|FMRP|FMRP|gene|30|NCBIGene:57532|Phenotype|phenotype|physiology|195|C0031437
42|The findings demonstrate that FMRP deficiency  results in inefficient oxidative phosphorylation during the neurodevelopment and  suggest that dysfunctional mitochondria may contribute to the FXS phenotype|FXS|FXS|disease|191|omim:300624|Mitochondria|mitochondria|anatomy|156|C0026237
43|METHODS: Cerebral organoids were generated from iPSCs of eight bipolar disorder (BPI) patients and eight healthy control individuals|bipolar disorder|bipolar disorder|disease|63|mesh:D001714|Organoids|organoids|anatomy|18|C0029250
43|METHODS: Cerebral organoids were generated from iPSCs of eight bipolar disorder (BPI) patients and eight healthy control individuals|bipolar disorder|bipolar disorder|disease|63|mesh:D001714|Induced Pluripotent Stem Cells|iPSCs|anatomy|48|C2717959
43|METHODS: Cerebral organoids were generated from iPSCs of eight bipolar disorder (BPI) patients and eight healthy control individuals|BPI|BPI|disease|81|mesh:D001714|Organoids|organoids|anatomy|18|C0029250
43|METHODS: Cerebral organoids were generated from iPSCs of eight bipolar disorder (BPI) patients and eight healthy control individuals|BPI|BPI|disease|81|mesh:D001714|Induced Pluripotent Stem Cells|iPSCs|anatomy|48|C2717959
43|The central hub in the network analysis was neurocan (NCAN), which is located in a locus with evidence for genome-wide significant association in BPI|neurocan|neurocan|gene|44|NCBIGene:1463|BPI|BPI|disease|146|mesh:D001714
43|The central hub in the network analysis was neurocan (NCAN), which is located in a locus with evidence for genome-wide significant association in BPI|neurocan|neurocan|gene|44|NCBIGene:1463|Mental association|association|physiology|131|C0004083
43|The central hub in the network analysis was neurocan (NCAN), which is located in a locus with evidence for genome-wide significant association in BPI|NCAN|NCAN|gene|54|NCBIGene:1463|BPI|BPI|disease|146|mesh:D001714
43|The central hub in the network analysis was neurocan (NCAN), which is located in a locus with evidence for genome-wide significant association in BPI|NCAN|NCAN|gene|54|NCBIGene:1463|Mental association|association|physiology|131|C0004083
43|Gene ontology analyses suggested  deficits related to endoplasmic reticulum biology in BPI, which was supported by  cellular characterization of ER-mitochondria interactions|BPI|BPI|disease|87|mesh:D001714|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|54|C0014239
43|Gene ontology analyses suggested  deficits related to endoplasmic reticulum biology in BPI, which was supported by  cellular characterization of ER-mitochondria interactions|BPI|BPI|disease|87|mesh:D001714|Cells|cellular|anatomy|116|C0007634
43|Gene ontology analyses suggested  deficits related to endoplasmic reticulum biology in BPI, which was supported by  cellular characterization of ER-mitochondria interactions|BPI|BPI|disease|87|mesh:D001714|Mitochondria|mitochondria|anatomy|148|C0026237
43|Functional studies with microelectrode arrays revealed specific deficits in response to stimulation  and depolarization in BPI cerebral organoids|BPI|BPI|disease|123|mesh:D001714|Organoids|organoids|anatomy|136|C0029250
43|CONCLUSIONS: Our studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission|NCAN|NCAN|gene|222|NCBIGene:1463|bipolar disorder|bipolar disorder|disease|52|mesh:D001714
43|CONCLUSIONS: Our studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission|bipolar disorder|bipolar disorder|disease|52|mesh:D001714|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|148|C0014239
43|CONCLUSIONS: Our studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission|bipolar disorder|bipolar disorder|disease|52|mesh:D001714|Organoids|organoids|anatomy|37|C0029250
43|CONCLUSIONS: Our studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission|NCAN|NCAN|gene|222|NCBIGene:1463|BPI|BPI|disease|245|mesh:D001714
43|CONCLUSIONS: Our studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission|NCAN|NCAN|gene|222|NCBIGene:1463|Synaptic Transmission|neurotransmission|physiology|285|C0027793
43|CONCLUSIONS: Our studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission|NCAN|NCAN|gene|222|NCBIGene:1463|Cell Adhesion|cell adhesion|physiology|111|C0007577
43|CONCLUSIONS: Our studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission|NCAN|NCAN|gene|222|NCBIGene:1463|Signal Transduction|signaling|physiology|133|C0037083
43|CONCLUSIONS: Our studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission|NCAN|NCAN|gene|222|NCBIGene:1463|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|148|C0014239
43|CONCLUSIONS: Our studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission|NCAN|NCAN|gene|222|NCBIGene:1463|Organoids|organoids|anatomy|37|C0029250
43|CONCLUSIONS: Our studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission|BPI|BPI|disease|245|mesh:D001714|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|148|C0014239
43|CONCLUSIONS: Our studies in cerebral organoids from bipolar disorder showed dysregulation in genes involved in cell adhesion, immune signaling, and endoplasmic reticulum biology; implicated a central role for the GWAS hit NCAN in the biology of BPI; and showed evidence of deficits in neurotransmission|BPI|BPI|disease|245|mesh:D001714|Organoids|organoids|anatomy|37|C0029250
44|Advances in the understanding and management of bipolar disorder (BD) have been slow to emerge|bipolar disorder|bipolar disorder|disease|48|mesh:D001714|BD|BD|disease|66|mesh:D001528
45|Importance: Three-dimensional cerebral organoids generated from patient-derived induced pluripotent stem cells (iPSCs) may be used to interrogate cellular-molecular underpinnings of schizophrenia|schizophrenia|schizophrenia|disease|182|omim:181500|Induced Pluripotent Stem Cells|induced pluripotent stem cells|anatomy|80|C2717959
45|Importance: Three-dimensional cerebral organoids generated from patient-derived induced pluripotent stem cells (iPSCs) may be used to interrogate cellular-molecular underpinnings of schizophrenia|schizophrenia|schizophrenia|disease|182|omim:181500|Organoids|organoids|anatomy|39|C0029250
45|Importance: Three-dimensional cerebral organoids generated from patient-derived induced pluripotent stem cells (iPSCs) may be used to interrogate cellular-molecular underpinnings of schizophrenia|schizophrenia|schizophrenia|disease|182|omim:181500|Cells|cellular|anatomy|146|C0007634
45|Objective: To determine transcriptomic profiles and functional characteristics of cerebral organoids from patients with schizophrenia using gene expression studies, complemented with investigations of mitochondrial function through measurement of real-time oxygen consumption rate, and functional studies of neuronal firing with microelectrode arrays|oxygen|oxygen|compound|257|mesh:D010100|schizophrenia|schizophrenia|disease|120|omim:181500
45|Objective: To determine transcriptomic profiles and functional characteristics of cerebral organoids from patients with schizophrenia using gene expression studies, complemented with investigations of mitochondrial function through measurement of real-time oxygen consumption rate, and functional studies of neuronal firing with microelectrode arrays|schizophrenia|schizophrenia|disease|120|omim:181500|Mitochondria|mitochondrial|anatomy|201|C0026237
45|Objective: To determine transcriptomic profiles and functional characteristics of cerebral organoids from patients with schizophrenia using gene expression studies, complemented with investigations of mitochondrial function through measurement of real-time oxygen consumption rate, and functional studies of neuronal firing with microelectrode arrays|schizophrenia|schizophrenia|disease|120|omim:181500|Organoids|organoids|anatomy|91|C0029250
45|Objective: To determine transcriptomic profiles and functional characteristics of cerebral organoids from patients with schizophrenia using gene expression studies, complemented with investigations of mitochondrial function through measurement of real-time oxygen consumption rate, and functional studies of neuronal firing with microelectrode arrays|oxygen|oxygen|compound|257|mesh:D010100|Mitochondria|mitochondrial|anatomy|201|C0026237
45|Objective: To determine transcriptomic profiles and functional characteristics of cerebral organoids from patients with schizophrenia using gene expression studies, complemented with investigations of mitochondrial function through measurement of real-time oxygen consumption rate, and functional studies of neuronal firing with microelectrode arrays|oxygen|oxygen|compound|257|mesh:D010100|Organoids|organoids|anatomy|91|C0029250
45|Transcriptomic profiling of iPSC-derived cerebral organoids from 8 patients with schizophrenia and 8 healthy  control individuals was undertaken to identify cellular pathways that are aberrant in schizophrenia|schizophrenia|schizophrenia|disease|81|omim:181500|Cells|cellular|anatomy|157|C0007634
45|Transcriptomic profiling of iPSC-derived cerebral organoids from 8 patients with schizophrenia and 8 healthy  control individuals was undertaken to identify cellular pathways that are aberrant in schizophrenia|schizophrenia|schizophrenia|disease|81|omim:181500|Induced Pluripotent Stem Cells|iPSC|anatomy|28|C2717959
45|Transcriptomic profiling of iPSC-derived cerebral organoids from 8 patients with schizophrenia and 8 healthy  control individuals was undertaken to identify cellular pathways that are aberrant in schizophrenia|schizophrenia|schizophrenia|disease|81|omim:181500|Organoids|organoids|anatomy|50|C0029250
45|Transcriptomic profiling of iPSC-derived cerebral organoids from 8 patients with schizophrenia and 8 healthy  control individuals was undertaken to identify cellular pathways that are aberrant in schizophrenia|schizophrenia|schizophrenia|disease|196|omim:181500|Cells|cellular|anatomy|157|C0007634
45|Transcriptomic profiling of iPSC-derived cerebral organoids from 8 patients with schizophrenia and 8 healthy  control individuals was undertaken to identify cellular pathways that are aberrant in schizophrenia|schizophrenia|schizophrenia|disease|196|omim:181500|Induced Pluripotent Stem Cells|iPSC|anatomy|28|C2717959
45|Transcriptomic profiling of iPSC-derived cerebral organoids from 8 patients with schizophrenia and 8 healthy  control individuals was undertaken to identify cellular pathways that are aberrant in schizophrenia|schizophrenia|schizophrenia|disease|196|omim:181500|Organoids|organoids|anatomy|50|C0029250
45|Induced pluripotent stem cells and cerebral organoids  were generated from patients who had been diagnosed as having schizophrenia and from heathy control individuals|schizophrenia|schizophrenia|disease|117|omim:181500|Induced Pluripotent Stem Cells|Induced pluripotent stem cells|anatomy|0|C2717959
45|Induced pluripotent stem cells and cerebral organoids  were generated from patients who had been diagnosed as having schizophrenia and from heathy control individuals|schizophrenia|schizophrenia|disease|117|omim:181500|Organoids|organoids|anatomy|44|C0029250
45|RNA sequencing data from iPSC-derived cerebral organoids in schizophrenia showed differential expression of genes involved in synapses, in nervous system development, and in antigen processing|schizophrenia|schizophrenia|disease|60|omim:181500|Synapses|synapses|anatomy|126|C0039062
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|adenosine triphosphate|adenosine triphosphate|compound|74|mesh:D000255|oxygen|oxygen|compound|143|mesh:D010100
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|adenosine triphosphate|adenosine triphosphate|compound|74|mesh:D000255|schizophrenia|schizophrenia|disease|165|omim:181500
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|adenosine triphosphate|adenosine triphosphate|compound|74|mesh:D000255|Body Site Modifier - Lower|lower|anatomy|44|C1548802
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|adenosine triphosphate|adenosine triphosphate|compound|74|mesh:D000255|Mitochondria|mitochondrial|anatomy|11|C0026237
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|adenosine triphosphate|adenosine triphosphate|compound|74|mesh:D000255|Organoids|organoids|anatomy|188|C0029250
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|adenosine triphosphate|adenosine triphosphate|compound|74|mesh:D000255|Extracellular|extracellular|anatomy|231|C0521119
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|oxygen|oxygen|compound|143|mesh:D010100|schizophrenia|schizophrenia|disease|165|omim:181500
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|oxygen|oxygen|compound|143|mesh:D010100|Body Site Modifier - Lower|lower|anatomy|44|C1548802
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|oxygen|oxygen|compound|143|mesh:D010100|Mitochondria|mitochondrial|anatomy|11|C0026237
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|oxygen|oxygen|compound|143|mesh:D010100|Organoids|organoids|anatomy|188|C0029250
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|oxygen|oxygen|compound|143|mesh:D010100|Extracellular|extracellular|anatomy|231|C0521119
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|schizophrenia|schizophrenia|disease|165|omim:181500|Body Site Modifier - Lower|lower|anatomy|44|C1548802
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|schizophrenia|schizophrenia|disease|165|omim:181500|Mitochondria|mitochondrial|anatomy|11|C0026237
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|schizophrenia|schizophrenia|disease|165|omim:181500|Organoids|organoids|anatomy|188|C0029250
45|Studies of mitochondrial respiration showed lower basal consumption rate, adenosine triphosphate production, proton leak, and nonmitochondrial oxygen consumption in schizophrenia cerebral organoids, without  any differences in the extracellular acidification rate|schizophrenia|schizophrenia|disease|165|omim:181500|Extracellular|extracellular|anatomy|231|C0521119
45|Microelectrode array studies of cerebral organoids showed no differences in baseline electrical activity in schizophrenia but revealed a diminished response to stimulation and depolarization|schizophrenia|schizophrenia|disease|108|omim:181500|Organoids|organoids|anatomy|41|C0029250
45|Conclusions and Relevance: Investigations of patient-derived cerebral organoids in schizophrenia revealed gene expression patterns suggesting dysregulation of a  number of pathways in schizophrenia, delineated differences in mitochondrial function, and showed deficits in response to stimulation and depolarization in schizophrenia|schizophrenia|schizophrenia|disease|83|omim:181500|Mitochondria|mitochondrial|anatomy|225|C0026237
45|Conclusions and Relevance: Investigations of patient-derived cerebral organoids in schizophrenia revealed gene expression patterns suggesting dysregulation of a  number of pathways in schizophrenia, delineated differences in mitochondrial function, and showed deficits in response to stimulation and depolarization in schizophrenia|schizophrenia|schizophrenia|disease|83|omim:181500|Organoids|organoids|anatomy|70|C0029250
45|Conclusions and Relevance: Investigations of patient-derived cerebral organoids in schizophrenia revealed gene expression patterns suggesting dysregulation of a  number of pathways in schizophrenia, delineated differences in mitochondrial function, and showed deficits in response to stimulation and depolarization in schizophrenia|schizophrenia|schizophrenia|disease|184|omim:181500|Mitochondria|mitochondrial|anatomy|225|C0026237
45|Conclusions and Relevance: Investigations of patient-derived cerebral organoids in schizophrenia revealed gene expression patterns suggesting dysregulation of a  number of pathways in schizophrenia, delineated differences in mitochondrial function, and showed deficits in response to stimulation and depolarization in schizophrenia|schizophrenia|schizophrenia|disease|184|omim:181500|Organoids|organoids|anatomy|70|C0029250
45|Conclusions and Relevance: Investigations of patient-derived cerebral organoids in schizophrenia revealed gene expression patterns suggesting dysregulation of a  number of pathways in schizophrenia, delineated differences in mitochondrial function, and showed deficits in response to stimulation and depolarization in schizophrenia|schizophrenia|schizophrenia|disease|318|omim:181500|Mitochondria|mitochondrial|anatomy|225|C0026237
45|Conclusions and Relevance: Investigations of patient-derived cerebral organoids in schizophrenia revealed gene expression patterns suggesting dysregulation of a  number of pathways in schizophrenia, delineated differences in mitochondrial function, and showed deficits in response to stimulation and depolarization in schizophrenia|schizophrenia|schizophrenia|disease|318|omim:181500|Organoids|organoids|anatomy|70|C0029250
46|Chronic exposition to stressors operates as a risk factor for psychiatric diseases such as depression and posttraumatic stress disorder|psychiatric diseases|psychiatric diseases|disease|62|mesh:D001523|depression|depression|disease|91|mesh:D009497
46|Chronic exposition to stressors operates as a risk factor for psychiatric diseases such as depression and posttraumatic stress disorder|psychiatric diseases|psychiatric diseases|disease|62|mesh:D001523|posttraumatic stress disorder|posttraumatic stress disorder|disease|106|mesh:D013313
46|Chronic exposition to stressors operates as a risk factor for psychiatric diseases such as depression and posttraumatic stress disorder|depression|depression|disease|91|mesh:D009497|posttraumatic stress disorder|posttraumatic stress disorder|disease|106|mesh:D013313
46|Among the cellular alterations observed as a consequence of environmental stress, alterations to organelle function at the level of mitochondria and endoplasmic reticulum (ER) are emerging as possible factors contributing to neuronal dysfunction|neuronal dysfunction|neuronal dysfunction|disease|225|mesh:D009410|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|149|C0014239
46|Among the cellular alterations observed as a consequence of environmental stress, alterations to organelle function at the level of mitochondria and endoplasmic reticulum (ER) are emerging as possible factors contributing to neuronal dysfunction|neuronal dysfunction|neuronal dysfunction|disease|225|mesh:D009410|Cytoplasmic organelle|organelle|anatomy|97|C1179962
46|Among the cellular alterations observed as a consequence of environmental stress, alterations to organelle function at the level of mitochondria and endoplasmic reticulum (ER) are emerging as possible factors contributing to neuronal dysfunction|neuronal dysfunction|neuronal dysfunction|disease|225|mesh:D009410|Mitochondria|mitochondria|anatomy|132|C0026237
47|Over the past decade, human stem cell-derived brain organoids have emerged as a biologically relevant model system to study normal human brain development and neurological diseases|neurological diseases|neurological diseases|disease|159|mesh:D009422|Organoids|organoids|anatomy|52|C0029250
48|In this study, we investigate the role of miR-137, a brain-enriched miRNA, in determining the fate of human induced pluripotent stem cells-derived NSCs (hiNSCs)|miR-137|miR-137|gene|42|NCBIGene:406928|Brain|brain|anatomy|53|C0006104
48|We show that ectopic expression of miR-137 in hiNSCs reduces proliferation and accelerates neuronal differentiation and migration|miR-137|miR-137|gene|35|NCBIGene:406928|physiologic migration|migration|physiology|120|C1533574
48|We show that ectopic expression of miR-137 in hiNSCs reduces proliferation and accelerates neuronal differentiation and migration|miR-137|miR-137|gene|35|NCBIGene:406928|Ectopic Gene Expression|ectopic expression|physiology|13|C1512167
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|myocyte enhancer factor-2A|myocyte enhancer factor-2A|gene|34|NCBIGene:4205|peroxisome proliferator-activated receptor-gamma coactivator|peroxisome proliferator-activated receptor-gamma coactivator|gene|108|NCBIGene:23082
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|myocyte enhancer factor-2A|myocyte enhancer factor-2A|gene|34|NCBIGene:4205|PGC1|PGC1|gene|170|NCBIGene:10891
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|myocyte enhancer factor-2A|myocyte enhancer factor-2A|gene|34|NCBIGene:4205|miR-137|miR-137|gene|206|NCBIGene:406928
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|myocyte enhancer factor-2A|myocyte enhancer factor-2A|gene|34|NCBIGene:4205|Transcription, Genetic|transcription|physiology|177|C0040649
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|myocyte enhancer factor-2A|myocyte enhancer factor-2A|gene|34|NCBIGene:4205|transcription factor activity|transcription factor|physiology|72|C1148759
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|MEF2A|MEF2A|gene|62|NCBIGene:4205|peroxisome proliferator-activated receptor-gamma coactivator|peroxisome proliferator-activated receptor-gamma coactivator|gene|108|NCBIGene:23082
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|MEF2A|MEF2A|gene|62|NCBIGene:4205|PGC1|PGC1|gene|170|NCBIGene:10891
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|MEF2A|MEF2A|gene|62|NCBIGene:4205|miR-137|miR-137|gene|206|NCBIGene:406928
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|MEF2A|MEF2A|gene|62|NCBIGene:4205|Transcription, Genetic|transcription|physiology|177|C0040649
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|MEF2A|MEF2A|gene|62|NCBIGene:4205|transcription factor activity|transcription factor|physiology|72|C1148759
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|peroxisome proliferator-activated receptor-gamma coactivator|peroxisome proliferator-activated receptor-gamma coactivator|gene|108|NCBIGene:23082|PGC1|PGC1|gene|170|NCBIGene:10891
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|peroxisome proliferator-activated receptor-gamma coactivator|peroxisome proliferator-activated receptor-gamma coactivator|gene|108|NCBIGene:23082|miR-137|miR-137|gene|206|NCBIGene:406928
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|peroxisome proliferator-activated receptor-gamma coactivator|peroxisome proliferator-activated receptor-gamma coactivator|gene|108|NCBIGene:23082|Transcription, Genetic|transcription|physiology|177|C0040649
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|peroxisome proliferator-activated receptor-gamma coactivator|peroxisome proliferator-activated receptor-gamma coactivator|gene|108|NCBIGene:23082|transcription factor activity|transcription factor|physiology|72|C1148759
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|PGC1|PGC1|gene|170|NCBIGene:10891|miR-137|miR-137|gene|206|NCBIGene:406928
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|PGC1|PGC1|gene|170|NCBIGene:10891|Transcription, Genetic|transcription|physiology|177|C0040649
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|PGC1|PGC1|gene|170|NCBIGene:10891|transcription factor activity|transcription factor|physiology|72|C1148759
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|miR-137|miR-137|gene|206|NCBIGene:406928|Transcription, Genetic|transcription|physiology|177|C0040649
48|TargetScan and MicroT-CDS predict myocyte enhancer factor-2A (MEF2A), a transcription factor that regulates peroxisome proliferator-activated receptor-gamma coactivator (PGC1α) transcription, as a target of miR-137|miR-137|miR-137|gene|206|NCBIGene:406928|transcription factor activity|transcription factor|physiology|72|C1148759
48|Using a reporter assay, we validate MEF2A  as a downstream target of miR-137|MEF2A|MEF2A|gene|36|NCBIGene:4205|miR-137|miR-137|gene|69|NCBIGene:406928
48|Our results indicate that reduced levels of MEF2A reduce the transcription of PGC1α, which in turn impacts mitochondrial dynamics|MEF2A|MEF2A|gene|44|NCBIGene:4205|PGC1|PGC1|gene|78|NCBIGene:10891
48|Our results indicate that reduced levels of MEF2A reduce the transcription of PGC1α, which in turn impacts mitochondrial dynamics|MEF2A|MEF2A|gene|44|NCBIGene:4205|Mitochondrial Dynamics|mitochondrial dynamics|physiology|107|C3494415
48|Our results indicate that reduced levels of MEF2A reduce the transcription of PGC1α, which in turn impacts mitochondrial dynamics|MEF2A|MEF2A|gene|44|NCBIGene:4205|Transcription, Genetic|transcription|physiology|61|C0040649
48|Our results indicate that reduced levels of MEF2A reduce the transcription of PGC1α, which in turn impacts mitochondrial dynamics|PGC1|PGC1|gene|78|NCBIGene:10891|Mitochondrial Dynamics|mitochondrial dynamics|physiology|107|C3494415
48|Our results indicate that reduced levels of MEF2A reduce the transcription of PGC1α, which in turn impacts mitochondrial dynamics|PGC1|PGC1|gene|78|NCBIGene:10891|Transcription, Genetic|transcription|physiology|61|C0040649
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|miR-137|miR-137|gene|9|NCBIGene:406928|PGC1|PGC1|gene|59|NCBIGene:10891
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|miR-137|miR-137|gene|9|NCBIGene:406928|nuclear factor erythroid 2 (NFE2)-related factor 2|nuclear factor erythroid 2 (NFE2)-related factor 2|gene|99|NCBIGene:4780
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|miR-137|miR-137|gene|9|NCBIGene:406928|NRF2|NRF2|gene|151|NCBIGene:4780
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|miR-137|miR-137|gene|9|NCBIGene:406928|transcription factor A of mitochondria|transcription factor A of mitochondria|gene|161|NCBIGene:7019
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|miR-137|miR-137|gene|9|NCBIGene:406928|TFAM|TFAM|gene|201|NCBIGene:7019
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|miR-137|miR-137|gene|9|NCBIGene:406928|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|29|C3494456
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|miR-137|miR-137|gene|9|NCBIGene:406928|Mitochondria|mitochondria|anatomy|188|C0026237
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|PGC1|PGC1|gene|59|NCBIGene:10891|nuclear factor erythroid 2 (NFE2)-related factor 2|nuclear factor erythroid 2 (NFE2)-related factor 2|gene|99|NCBIGene:4780
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|PGC1|PGC1|gene|59|NCBIGene:10891|NRF2|NRF2|gene|151|NCBIGene:4780
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|PGC1|PGC1|gene|59|NCBIGene:10891|transcription factor A of mitochondria|transcription factor A of mitochondria|gene|161|NCBIGene:7019
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|PGC1|PGC1|gene|59|NCBIGene:10891|TFAM|TFAM|gene|201|NCBIGene:7019
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|PGC1|PGC1|gene|59|NCBIGene:10891|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|29|C3494456
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|PGC1|PGC1|gene|59|NCBIGene:10891|Mitochondria|mitochondria|anatomy|188|C0026237
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|nuclear factor erythroid 2 (NFE2)-related factor 2|nuclear factor erythroid 2 (NFE2)-related factor 2|gene|99|NCBIGene:4780|transcription factor A of mitochondria|transcription factor A of mitochondria|gene|161|NCBIGene:7019
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|nuclear factor erythroid 2 (NFE2)-related factor 2|nuclear factor erythroid 2 (NFE2)-related factor 2|gene|99|NCBIGene:4780|TFAM|TFAM|gene|201|NCBIGene:7019
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|nuclear factor erythroid 2 (NFE2)-related factor 2|nuclear factor erythroid 2 (NFE2)-related factor 2|gene|99|NCBIGene:4780|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|29|C3494456
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|nuclear factor erythroid 2 (NFE2)-related factor 2|nuclear factor erythroid 2 (NFE2)-related factor 2|gene|99|NCBIGene:4780|Mitochondria|mitochondria|anatomy|188|C0026237
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|NRF2|NRF2|gene|151|NCBIGene:4780|transcription factor A of mitochondria|transcription factor A of mitochondria|gene|161|NCBIGene:7019
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|NRF2|NRF2|gene|151|NCBIGene:4780|TFAM|TFAM|gene|201|NCBIGene:7019
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|NRF2|NRF2|gene|151|NCBIGene:4780|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|29|C3494456
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|NRF2|NRF2|gene|151|NCBIGene:4780|Mitochondria|mitochondria|anatomy|188|C0026237
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|transcription factor A of mitochondria|transcription factor A of mitochondria|gene|161|NCBIGene:7019|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|29|C3494456
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|TFAM|TFAM|gene|201|NCBIGene:7019|Mitochondrial Biogenesis|mitochondrial biogenesis|physiology|29|C3494456
48|Notably, miR-137 accelerates mitochondrial biogenesis in a PGC1α independent manner by upregulating nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) and transcription factor A of mitochondria (TFAM)|TFAM|TFAM|gene|201|NCBIGene:7019|Mitochondria|mitochondria|anatomy|188|C0026237
48|In addition, miR-137 modulates mitochondrial dynamics by inducing mitochondrial fusion and fission events, resulting in increased mitochondrial content and activation of oxidative phosphorylation (OXPHOS) and oxygen consumption rate|oxygen|oxygen|compound|209|mesh:D010100|miR-137|miR-137|gene|13|NCBIGene:406928
48|In addition, miR-137 modulates mitochondrial dynamics by inducing mitochondrial fusion and fission events, resulting in increased mitochondrial content and activation of oxidative phosphorylation (OXPHOS) and oxygen consumption rate|miR-137|miR-137|gene|13|NCBIGene:406928|positive regulation of oxidative phosphorylation|activation of oxidative phosphorylation|physiology|156|C3895352
48|In addition, miR-137 modulates mitochondrial dynamics by inducing mitochondrial fusion and fission events, resulting in increased mitochondrial content and activation of oxidative phosphorylation (OXPHOS) and oxygen consumption rate|miR-137|miR-137|gene|13|NCBIGene:406928|Oxygen Consumption|oxygen consumption|physiology|209|C0030055
48|In addition, miR-137 modulates mitochondrial dynamics by inducing mitochondrial fusion and fission events, resulting in increased mitochondrial content and activation of oxidative phosphorylation (OXPHOS) and oxygen consumption rate|miR-137|miR-137|gene|13|NCBIGene:406928|Mitochondrial Dynamics|mitochondrial dynamics|physiology|31|C3494415
48|In addition, miR-137 modulates mitochondrial dynamics by inducing mitochondrial fusion and fission events, resulting in increased mitochondrial content and activation of oxidative phosphorylation (OXPHOS) and oxygen consumption rate|miR-137|miR-137|gene|13|NCBIGene:406928|Feeling content|content|physiology|144|C0423896
48|In addition, miR-137 modulates mitochondrial dynamics by inducing mitochondrial fusion and fission events, resulting in increased mitochondrial content and activation of oxidative phosphorylation (OXPHOS) and oxygen consumption rate|miR-137|miR-137|gene|13|NCBIGene:406928|Mitochondria|mitochondrial|anatomy|130|C0026237
48|In addition, miR-137 modulates mitochondrial dynamics by inducing mitochondrial fusion and fission events, resulting in increased mitochondrial content and activation of oxidative phosphorylation (OXPHOS) and oxygen consumption rate|oxygen|oxygen|compound|209|mesh:D010100|Mitochondria|mitochondrial|anatomy|130|C0026237
48|Pluripotency transcription factors OCT4 and SOX2 are known to have binding sites in the promoter region of miR-137 gene|OCT4|OCT4|gene|35|NCBIGene:5460|SOX2|SOX2|gene|44|NCBIGene:6657
48|Pluripotency transcription factors OCT4 and SOX2 are known to have binding sites in the promoter region of miR-137 gene|OCT4|OCT4|gene|35|NCBIGene:5460|miR-137 gene|miR-137 gene|gene|107|NCBIGene:406928
48|Pluripotency transcription factors OCT4 and SOX2 are known to have binding sites in the promoter region of miR-137 gene|SOX2|SOX2|gene|44|NCBIGene:6657|miR-137 gene|miR-137 gene|gene|107|NCBIGene:406928
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|miR-137|miR-137|gene|22|NCBIGene:406928|OCT4|OCT4|gene|64|NCBIGene:5460
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|miR-137|miR-137|gene|22|NCBIGene:406928|SOX2|SOX2|gene|73|NCBIGene:6657
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|miR-137|miR-137|gene|22|NCBIGene:406928|OCT4|OCT4|gene|162|NCBIGene:5460
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|miR-137|miR-137|gene|22|NCBIGene:406928|SOX2|SOX2|gene|167|NCBIGene:6657
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|miR-137|miR-137|gene|22|NCBIGene:406928|Ectopic Gene Expression|Ectopic expression|physiology|0|C1512167
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|miR-137|miR-137|gene|22|NCBIGene:406928|regulatory loop|regulatory loop|physiology|126|C0678662
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|OCT4|OCT4|gene|64|NCBIGene:5460|SOX2|SOX2|gene|73|NCBIGene:6657
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|OCT4|OCT4|gene|64|NCBIGene:5460|miR-137|miR-137|gene|150|NCBIGene:406928
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|OCT4|OCT4|gene|64|NCBIGene:5460|SOX2|SOX2|gene|167|NCBIGene:6657
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|OCT4|OCT4|gene|64|NCBIGene:5460|Ectopic Gene Expression|Ectopic expression|physiology|0|C1512167
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|OCT4|OCT4|gene|64|NCBIGene:5460|regulatory loop|regulatory loop|physiology|126|C0678662
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|SOX2|SOX2|gene|73|NCBIGene:6657|miR-137|miR-137|gene|150|NCBIGene:406928
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|SOX2|SOX2|gene|73|NCBIGene:6657|OCT4|OCT4|gene|162|NCBIGene:5460
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|SOX2|SOX2|gene|73|NCBIGene:6657|Ectopic Gene Expression|Ectopic expression|physiology|0|C1512167
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|SOX2|SOX2|gene|73|NCBIGene:6657|regulatory loop|regulatory loop|physiology|126|C0678662
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|miR-137|miR-137|gene|150|NCBIGene:406928|OCT4|OCT4|gene|162|NCBIGene:5460
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|miR-137|miR-137|gene|150|NCBIGene:406928|SOX2|SOX2|gene|167|NCBIGene:6657
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|miR-137|miR-137|gene|150|NCBIGene:406928|Ectopic Gene Expression|Ectopic expression|physiology|0|C1512167
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|miR-137|miR-137|gene|150|NCBIGene:406928|regulatory loop|regulatory loop|physiology|126|C0678662
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|OCT4|OCT4|gene|162|NCBIGene:5460|SOX2|SOX2|gene|167|NCBIGene:6657
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|OCT4|OCT4|gene|162|NCBIGene:5460|Ectopic Gene Expression|Ectopic expression|physiology|0|C1512167
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|OCT4|OCT4|gene|162|NCBIGene:5460|regulatory loop|regulatory loop|physiology|126|C0678662
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|SOX2|SOX2|gene|167|NCBIGene:6657|Ectopic Gene Expression|Ectopic expression|physiology|0|C1512167
48|Ectopic expression of miR-137 elevates the expression levels of OCT4 and SOX2 in hiNSCs which establishes a feed-forward self-regulatory loop between miR-137 and OCT4/SOX2|SOX2|SOX2|gene|167|NCBIGene:6657|regulatory loop|regulatory loop|physiology|126|C0678662
48|Our study provides novel molecular insights into NSC fate determination by miR-137|miR-137|miR-137|gene|75|NCBIGene:406928|Insight|insights|physiology|35|C0233820
49|Alteration of lipid metabolism has been demonstrated in many neurological disorders and neurodegenerative diseases|neurological disorders|neurological disorders|disease|61|mesh:D009422|neurodegenerative diseases|neurodegenerative diseases|disease|88|mesh:D019636
49|It has been shown that GM has strong potency in neuroprotective activity and GM reduces the production of reactive oxygen species by regulating glucose metabolism, which protects neurons against oxidative stress-induced cell death|oxygen|oxygen|compound|115|mesh:D010100|glucose|glucose|compound|144|CHEBI:42758
49|MATERIALS AND METHODS: Using a glutamate-induced oxidative toxicity model in mouse hippocampal neuronal cell line (HT-22 cells), we investigated the effect of GM on glutamate-induced lipid peroxidation, lipotoxicity and mitochondrial dysfunction|glutamate|glutamate|compound|31|mesh:D018698|lipotoxicity|lipotoxicity|disease|203|mesh:D006949
49|MATERIALS AND METHODS: Using a glutamate-induced oxidative toxicity model in mouse hippocampal neuronal cell line (HT-22 cells), we investigated the effect of GM on glutamate-induced lipid peroxidation, lipotoxicity and mitochondrial dysfunction|glutamate|glutamate|compound|31|mesh:D018698|mitochondrial dysfunction|mitochondrial dysfunction|disease|220|mesh:D028361
49|MATERIALS AND METHODS: Using a glutamate-induced oxidative toxicity model in mouse hippocampal neuronal cell line (HT-22 cells), we investigated the effect of GM on glutamate-induced lipid peroxidation, lipotoxicity and mitochondrial dysfunction|glutamate|glutamate|compound|31|mesh:D018698|Cells|cells|anatomy|121|C0007634
49|MATERIALS AND METHODS: Using a glutamate-induced oxidative toxicity model in mouse hippocampal neuronal cell line (HT-22 cells), we investigated the effect of GM on glutamate-induced lipid peroxidation, lipotoxicity and mitochondrial dysfunction|glutamate|glutamate|compound|165|mesh:D018698|lipotoxicity|lipotoxicity|disease|203|mesh:D006949
49|MATERIALS AND METHODS: Using a glutamate-induced oxidative toxicity model in mouse hippocampal neuronal cell line (HT-22 cells), we investigated the effect of GM on glutamate-induced lipid peroxidation, lipotoxicity and mitochondrial dysfunction|glutamate|glutamate|compound|165|mesh:D018698|mitochondrial dysfunction|mitochondrial dysfunction|disease|220|mesh:D028361
49|MATERIALS AND METHODS: Using a glutamate-induced oxidative toxicity model in mouse hippocampal neuronal cell line (HT-22 cells), we investigated the effect of GM on glutamate-induced lipid peroxidation, lipotoxicity and mitochondrial dysfunction|glutamate|glutamate|compound|165|mesh:D018698|Cells|cells|anatomy|121|C0007634
49|MATERIALS AND METHODS: Using a glutamate-induced oxidative toxicity model in mouse hippocampal neuronal cell line (HT-22 cells), we investigated the effect of GM on glutamate-induced lipid peroxidation, lipotoxicity and mitochondrial dysfunction|lipotoxicity|lipotoxicity|disease|203|mesh:D006949|mitochondrial dysfunction|mitochondrial dysfunction|disease|220|mesh:D028361
49|MATERIALS AND METHODS: Using a glutamate-induced oxidative toxicity model in mouse hippocampal neuronal cell line (HT-22 cells), we investigated the effect of GM on glutamate-induced lipid peroxidation, lipotoxicity and mitochondrial dysfunction|lipotoxicity|lipotoxicity|disease|203|mesh:D006949|Cells|cells|anatomy|121|C0007634
49|MATERIALS AND METHODS: Using a glutamate-induced oxidative toxicity model in mouse hippocampal neuronal cell line (HT-22 cells), we investigated the effect of GM on glutamate-induced lipid peroxidation, lipotoxicity and mitochondrial dysfunction|mitochondrial dysfunction|mitochondrial dysfunction|disease|220|mesh:D028361|Cells|cells|anatomy|121|C0007634
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|glutamate|glutamate|compound|44|mesh:D018698|fatty acids|fatty acids|compound|146|mesh:D005227
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|glutamate|glutamate|compound|44|mesh:D018698|triacylglycerol|triacylglycerol|compound|164|mesh:D014280
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|glutamate|glutamate|compound|44|mesh:D018698|sphingomyelin|sphingomyelin|compound|186|mesh:D013109
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|glutamate|glutamate|compound|44|mesh:D018698|cardiolipin|cardiolipin|compound|206|mesh:D002308
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|glutamate|glutamate|compound|44|mesh:D018698|lysophosphatidylcholines|lysophosphatidylcholines|compound|224|mesh:D008244
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|glutamate|glutamate|compound|44|mesh:D018698|LPC|LPC|compound|250|CHEBI:11502
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|fatty acids|fatty acids|compound|146|mesh:D005227|triacylglycerol|triacylglycerol|compound|164|mesh:D014280
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|fatty acids|fatty acids|compound|146|mesh:D005227|sphingomyelin|sphingomyelin|compound|186|mesh:D013109
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|fatty acids|fatty acids|compound|146|mesh:D005227|cardiolipin|cardiolipin|compound|206|mesh:D002308
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|fatty acids|fatty acids|compound|146|mesh:D005227|lysophosphatidylcholines|lysophosphatidylcholines|compound|224|mesh:D008244
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|fatty acids|fatty acids|compound|146|mesh:D005227|LPC|LPC|compound|250|CHEBI:11502
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|triacylglycerol|triacylglycerol|compound|164|mesh:D014280|sphingomyelin|sphingomyelin|compound|186|mesh:D013109
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|triacylglycerol|triacylglycerol|compound|164|mesh:D014280|cardiolipin|cardiolipin|compound|206|mesh:D002308
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|triacylglycerol|triacylglycerol|compound|164|mesh:D014280|lysophosphatidylcholines|lysophosphatidylcholines|compound|224|mesh:D008244
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|triacylglycerol|triacylglycerol|compound|164|mesh:D014280|LPC|LPC|compound|250|CHEBI:11502
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|sphingomyelin|sphingomyelin|compound|186|mesh:D013109|cardiolipin|cardiolipin|compound|206|mesh:D002308
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|sphingomyelin|sphingomyelin|compound|186|mesh:D013109|lysophosphatidylcholines|lysophosphatidylcholines|compound|224|mesh:D008244
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|sphingomyelin|sphingomyelin|compound|186|mesh:D013109|LPC|LPC|compound|250|CHEBI:11502
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|cardiolipin|cardiolipin|compound|206|mesh:D002308|lysophosphatidylcholines|lysophosphatidylcholines|compound|224|mesh:D008244
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|cardiolipin|cardiolipin|compound|206|mesh:D002308|LPC|LPC|compound|250|CHEBI:11502
49|Overall,  lipidomics analysis revealed that glutamate treatment resulted in different extents of changes in a wide range of lipid classes such as fatty acids (FA), triacylglycerol (TG), sphingomyelin (SM), cardiolipin (CL), lysophosphatidylcholines (LPC)|lysophosphatidylcholines|lysophosphatidylcholines|compound|224|mesh:D008244|LPC|LPC|compound|250|CHEBI:11502
49|However, GM treatment can significantly reverse glutamate-induced lipids disorder to the homeostasis level|glutamate|glutamate|compound|48|mesh:D018698|lipids disorder|lipids disorder|disease|66|mesh:D052439
49|CONCLUSION: These findings clearly demonstrated a novel protective mechanism of GM against glutamate-induced oxidative toxicity in neurons via regulating lipid metabolism|glutamate|glutamate|compound|91|mesh:D018698|Neurons|neurons|anatomy|131|C0027882
50|Polybrominated diphenyl ethers (PBDEs)-induced neurotoxicity is closely associated with mitochondrial abnormalities|Polybrominated diphenyl ethers|Polybrominated diphenyl ethers|compound|0|mesh:D055768|neurotoxicity|neurotoxicity|disease|47|mesh:D020258
50|Polybrominated diphenyl ethers (PBDEs)-induced neurotoxicity is closely associated with mitochondrial abnormalities|Polybrominated diphenyl ethers|Polybrominated diphenyl ethers|compound|0|mesh:D055768|mitochondrial abnormalities|mitochondrial abnormalities|disease|88|mesh:D028361
50|Polybrominated diphenyl ethers (PBDEs)-induced neurotoxicity is closely associated with mitochondrial abnormalities|PBDEs|PBDEs|compound|32|mesh:D055768|neurotoxicity|neurotoxicity|disease|47|mesh:D020258
50|Polybrominated diphenyl ethers (PBDEs)-induced neurotoxicity is closely associated with mitochondrial abnormalities|PBDEs|PBDEs|compound|32|mesh:D055768|mitochondrial abnormalities|mitochondrial abnormalities|disease|88|mesh:D028361
50|Polybrominated diphenyl ethers (PBDEs)-induced neurotoxicity is closely associated with mitochondrial abnormalities|neurotoxicity|neurotoxicity|disease|47|mesh:D020258|mitochondrial abnormalities|mitochondrial abnormalities|disease|88|mesh:D028361
50|Methods: We investigated the effects of 2, 2', 4, 4'-tetrabromodiphenyl ether (PBDE-47), the dominant congener in human samples, on mitochondrial fusion and fission dynamics using PC12 cells, a well-defined in vitro neurodevelopmental model|2, 2', 4, 4'-tetrabromodiphenyl ether|2, 2', 4, 4'-tetrabromodiphenyl ether|compound|40|mesh:C511295|PC12 Cells|PC12 cells|anatomy|180|C0085262
50|Methods: We investigated the effects of 2, 2', 4, 4'-tetrabromodiphenyl ether (PBDE-47), the dominant congener in human samples, on mitochondrial fusion and fission dynamics using PC12 cells, a well-defined in vitro neurodevelopmental model|2, 2', 4, 4'-tetrabromodiphenyl ether|2, 2', 4, 4'-tetrabromodiphenyl ether|compound|40|mesh:C511295|Biospecimen|samples|anatomy|120|C2347026
50|Methods: We investigated the effects of 2, 2', 4, 4'-tetrabromodiphenyl ether (PBDE-47), the dominant congener in human samples, on mitochondrial fusion and fission dynamics using PC12 cells, a well-defined in vitro neurodevelopmental model|PBDE-47|PBDE-47|compound|79|mesh:C511295|PC12 Cells|PC12 cells|anatomy|180|C0085262
50|Methods: We investigated the effects of 2, 2', 4, 4'-tetrabromodiphenyl ether (PBDE-47), the dominant congener in human samples, on mitochondrial fusion and fission dynamics using PC12 cells, a well-defined in vitro neurodevelopmental model|PBDE-47|PBDE-47|compound|79|mesh:C511295|Biospecimen|samples|anatomy|120|C2347026
50|We also evaluated the effects of  perinatal low-dose PBDE-47 exposure on hippocampal mitochondrial dynamics and its association with neurobehavioral changes in adult Sprague-Dawley rats|PBDE-47|PBDE-47|compound|53|mesh:C511295|Hippocampus (Brain)|hippocampal|anatomy|73|C0019564
50|Results: In vitro, PBDE-47 disrupted mitochondrial dynamics by inhibiting mitochondrial fusion and fission simultaneously, accompanied by mitochondrial fragmentation, membrane potential dissipation, ATP loss, and apoptosis activation|PBDE-47|PBDE-47|compound|19|mesh:C511295|ATP|ATP|compound|199|CHEBI:30616
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|PBDE-47|PBDE-47|compound|138|mesh:C511295|mitofusin 2|mitofusin 2|gene|96|NCBIGene:9927
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|mitofusin 2|mitofusin 2|gene|96|NCBIGene:9927|functional impairments|functional impairments|disease|194|mesh:D000073496
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|mitofusin 2|mitofusin 2|gene|96|NCBIGene:9927|Nerve Cell Survival|neuronal survival|physiology|265|C1514121
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|mitofusin 2|mitofusin 2|gene|96|NCBIGene:9927|Apoptosis|apoptosis|physiology|242|C0162638
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|mitofusin 2|mitofusin 2|gene|96|NCBIGene:9927|Impairments:-:Point in time:^Patient:-|impairments|physiology|205|C2598156
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|mitofusin 2|mitofusin 2|gene|96|NCBIGene:9927|Mitochondrial Fusion|mitochondrial fusion|physiology|24|C1156067
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|mitofusin 2|mitofusin 2|gene|96|NCBIGene:9927|Mitochondrial Dynamics|mitochondrial dynamic|physiology|153|C3494415
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|PBDE-47|PBDE-47|compound|138|mesh:C511295|Mfn2|Mfn2|gene|109|NCBIGene:9927
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|Mfn2|Mfn2|gene|109|NCBIGene:9927|functional impairments|functional impairments|disease|194|mesh:D000073496
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|Mfn2|Mfn2|gene|109|NCBIGene:9927|Nerve Cell Survival|neuronal survival|physiology|265|C1514121
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|Mfn2|Mfn2|gene|109|NCBIGene:9927|Apoptosis|apoptosis|physiology|242|C0162638
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|Mfn2|Mfn2|gene|109|NCBIGene:9927|Impairments:-:Point in time:^Patient:-|impairments|physiology|205|C2598156
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|Mfn2|Mfn2|gene|109|NCBIGene:9927|Mitochondrial Fusion|mitochondrial fusion|physiology|24|C1156067
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|Mfn2|Mfn2|gene|109|NCBIGene:9927|Mitochondrial Dynamics|mitochondrial dynamic|physiology|153|C3494415
50|Specifically, enhancing mitochondrial fusion by the chemical promoter M1 or adenovirus-mediated mitofusin 2 (Mfn2) overexpression rescued PBDE-47-caused mitochondrial dynamic, morphological and functional impairments, prevented the resultant apoptosis and promoted neuronal survival|PBDE-47|PBDE-47|compound|138|mesh:C511295|functional impairments|functional impairments|disease|194|mesh:D000073496
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|fission protein 1|fission protein 1|gene|78|NCBIGene:51024|mitochondrial division inhibitor-1|mitochondrial division inhibitor-1|gene|162|NCBIGene:4096
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|fission protein 1|fission protein 1|gene|78|NCBIGene:51024|Mdivi|Mdivi|gene|198|NCBIGene:4096
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|PBDE-47|PBDE-47|compound|244|mesh:C511295|fission protein 1|fission protein 1|gene|78|NCBIGene:51024
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|fission protein 1|fission protein 1|gene|78|NCBIGene:51024|Protein Overexpression|overexpression|physiology|103|C1514559
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|fission protein 1|fission protein 1|gene|78|NCBIGene:51024|neuron death|neuronal death|physiology|285|C2754100
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|Fis1|Fis1|gene|97|NCBIGene:51024|mitochondrial division inhibitor-1|mitochondrial division inhibitor-1|gene|162|NCBIGene:4096
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|Fis1|Fis1|gene|97|NCBIGene:51024|Mdivi|Mdivi|gene|198|NCBIGene:4096
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|PBDE-47|PBDE-47|compound|244|mesh:C511295|Fis1|Fis1|gene|97|NCBIGene:51024
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|Fis1|Fis1|gene|97|NCBIGene:51024|Protein Overexpression|overexpression|physiology|103|C1514559
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|Fis1|Fis1|gene|97|NCBIGene:51024|neuron death|neuronal death|physiology|285|C2754100
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|PBDE-47|PBDE-47|compound|244|mesh:C511295|mitochondrial division inhibitor-1|mitochondrial division inhibitor-1|gene|162|NCBIGene:4096
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|mitochondrial division inhibitor-1|mitochondrial division inhibitor-1|gene|162|NCBIGene:4096|Protein Overexpression|overexpression|physiology|103|C1514559
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|mitochondrial division inhibitor-1|mitochondrial division inhibitor-1|gene|162|NCBIGene:4096|neuron death|neuronal death|physiology|285|C2754100
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|PBDE-47|PBDE-47|compound|244|mesh:C511295|Mdivi|Mdivi|gene|198|NCBIGene:4096
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|Mdivi|Mdivi|gene|198|NCBIGene:4096|Protein Overexpression|overexpression|physiology|103|C1514559
50|Unexpectedly, either stimulating mitochondrial fission by adenovirus-mediated fission protein 1 (Fis1) overexpression or suppressing mitochondrial fission by the mitochondrial division inhibitor-1 (Mdivi-1) failed to reverse whereas aggravated PBDE-47-induced mitochondrial damage and neuronal death|Mdivi|Mdivi|gene|198|NCBIGene:4096|neuron death|neuronal death|physiology|285|C2754100
50|Importantly, promoting mitochondrial fusion by Mfn2 overexpression neutralized the detrimental effects elicited by Fis1 overexpression after PBDE-47 treatment|Mfn2|Mfn2|gene|47|NCBIGene:9927|Fis1|Fis1|gene|115|NCBIGene:51024
50|Importantly, promoting mitochondrial fusion by Mfn2 overexpression neutralized the detrimental effects elicited by Fis1 overexpression after PBDE-47 treatment|PBDE-47|PBDE-47|compound|141|mesh:C511295|Mfn2|Mfn2|gene|47|NCBIGene:9927
50|Importantly, promoting mitochondrial fusion by Mfn2 overexpression neutralized the detrimental effects elicited by Fis1 overexpression after PBDE-47 treatment|Mfn2|Mfn2|gene|47|NCBIGene:9927|Mitochondrial Fusion|mitochondrial fusion|physiology|23|C1156067
50|Importantly, promoting mitochondrial fusion by Mfn2 overexpression neutralized the detrimental effects elicited by Fis1 overexpression after PBDE-47 treatment|Mfn2|Mfn2|gene|47|NCBIGene:9927|Protein Overexpression|overexpression|physiology|120|C1514559
50|Importantly, promoting mitochondrial fusion by Mfn2 overexpression neutralized the detrimental effects elicited by Fis1 overexpression after PBDE-47 treatment|PBDE-47|PBDE-47|compound|141|mesh:C511295|Fis1|Fis1|gene|115|NCBIGene:51024
50|Importantly, promoting mitochondrial fusion by Mfn2 overexpression neutralized the detrimental effects elicited by Fis1 overexpression after PBDE-47 treatment|Fis1|Fis1|gene|115|NCBIGene:51024|Mitochondrial Fusion|mitochondrial fusion|physiology|23|C1156067
50|Importantly, promoting mitochondrial fusion by Mfn2 overexpression neutralized the detrimental effects elicited by Fis1 overexpression after PBDE-47 treatment|Fis1|Fis1|gene|115|NCBIGene:51024|Protein Overexpression|overexpression|physiology|120|C1514559
50|Finally, perinatal oral administration of PBDE-47 elicited neurobehavioral deficits and hippocampal neuronal loss via apoptosis in adult rats, which were associated with mitochondrial dynamics alterations manifested as a fragmented phenotype|PBDE-47|PBDE-47|compound|42|mesh:C511295|Hippocampus (Brain)|hippocampal|anatomy|88|C0019564
50|Conclusion: Our results suggest that PBDE-47 disrupts mitochondrial dynamics to induce mitochondrial abnormalities, triggering apoptosis and thus contributing to neuronal loss and subsequent neurobehavioral deficits|PBDE-47|PBDE-47|compound|37|mesh:C511295|mitochondrial abnormalities|mitochondrial abnormalities|disease|87|mesh:D028361
50|Conclusion: Our results suggest that PBDE-47 disrupts mitochondrial dynamics to induce mitochondrial abnormalities, triggering apoptosis and thus contributing to neuronal loss and subsequent neurobehavioral deficits|PBDE-47|PBDE-47|compound|37|mesh:C511295|neurobehavioral deficits|neurobehavioral deficits|disease|191|mesh:D019954
50|Conclusion: Our results suggest that PBDE-47 disrupts mitochondrial dynamics to induce mitochondrial abnormalities, triggering apoptosis and thus contributing to neuronal loss and subsequent neurobehavioral deficits|mitochondrial abnormalities|mitochondrial abnormalities|disease|87|mesh:D028361|neurobehavioral deficits|neurobehavioral deficits|disease|191|mesh:D019954
52|Studies in animal models have shown that the short-chain fatty acid, propionic acid (PPA), interferes with mitochondrial metabolism leading to mitochondrial dysfunction and behavioral abnormalities|fatty acid|fatty acid|compound|57|mesh:D005227|propionic acid|propionic acid|compound|69|mesh:C029658
52|Studies in animal models have shown that the short-chain fatty acid, propionic acid (PPA), interferes with mitochondrial metabolism leading to mitochondrial dysfunction and behavioral abnormalities|fatty acid|fatty acid|compound|57|mesh:D005227|PPA|PPA|compound|85|mesh:D010665
52|Studies in animal models have shown that the short-chain fatty acid, propionic acid (PPA), interferes with mitochondrial metabolism leading to mitochondrial dysfunction and behavioral abnormalities|fatty acid|fatty acid|compound|57|mesh:D005227|mitochondrial dysfunction|mitochondrial dysfunction|disease|143|mesh:D028361
52|Studies in animal models have shown that the short-chain fatty acid, propionic acid (PPA), interferes with mitochondrial metabolism leading to mitochondrial dysfunction and behavioral abnormalities|fatty acid|fatty acid|compound|57|mesh:D005227|Mitochondria|mitochondrial|anatomy|107|C0026237
52|Studies in animal models have shown that the short-chain fatty acid, propionic acid (PPA), interferes with mitochondrial metabolism leading to mitochondrial dysfunction and behavioral abnormalities|propionic acid|propionic acid|compound|69|mesh:C029658|PPA|PPA|compound|85|mesh:D010665
52|Studies in animal models have shown that the short-chain fatty acid, propionic acid (PPA), interferes with mitochondrial metabolism leading to mitochondrial dysfunction and behavioral abnormalities|propionic acid|propionic acid|compound|69|mesh:C029658|mitochondrial dysfunction|mitochondrial dysfunction|disease|143|mesh:D028361
52|Studies in animal models have shown that the short-chain fatty acid, propionic acid (PPA), interferes with mitochondrial metabolism leading to mitochondrial dysfunction and behavioral abnormalities|propionic acid|propionic acid|compound|69|mesh:C029658|Mitochondria|mitochondrial|anatomy|107|C0026237
52|Studies in animal models have shown that the short-chain fatty acid, propionic acid (PPA), interferes with mitochondrial metabolism leading to mitochondrial dysfunction and behavioral abnormalities|PPA|PPA|compound|85|mesh:D010665|mitochondrial dysfunction|mitochondrial dysfunction|disease|143|mesh:D028361
52|Studies in animal models have shown that the short-chain fatty acid, propionic acid (PPA), interferes with mitochondrial metabolism leading to mitochondrial dysfunction and behavioral abnormalities|PPA|PPA|compound|85|mesh:D010665|Mitochondria|mitochondrial|anatomy|107|C0026237
52|Studies in animal models have shown that the short-chain fatty acid, propionic acid (PPA), interferes with mitochondrial metabolism leading to mitochondrial dysfunction and behavioral abnormalities|mitochondrial dysfunction|mitochondrial dysfunction|disease|143|mesh:D028361|Mitochondria|mitochondrial|anatomy|107|C0026237
52|The aim of this study was to investigate the effects of PPA on mitochondrial function and gene expression in neuronal cells|PPA|PPA|compound|56|mesh:D010665|Cells|cells|anatomy|118|C0007634
52|SH-SY5Y cells and normal human neural progenitor (NHNP) cells were exposed to 1, 5 mM PPA for 4 or 24 h and we found that the mitochondrial potential measured in SH-SY5Y cells decreased in a dose-dependent manner after PPA treatment|PPA|PPA|compound|85|mesh:D010665|Mitochondria|mitochondrial|anatomy|136|C0026237
52|SH-SY5Y cells and normal human neural progenitor (NHNP) cells were exposed to 1, 5 mM PPA for 4 or 24 h and we found that the mitochondrial potential measured in SH-SY5Y cells decreased in a dose-dependent manner after PPA treatment|PPA|PPA|compound|217|mesh:D010665|Mitochondria|mitochondrial|anatomy|136|C0026237
52|A dose-dependent  increase in the mitochondrial DNA copy number was observed in the PPA-treated cells|PPA|PPA|compound|84|mesh:D010665|Cells|cells|anatomy|96|C0007634
52|A dose-dependent  increase in the mitochondrial DNA copy number was observed in the PPA-treated cells|PPA|PPA|compound|84|mesh:D010665|mitochondrial DNA location|mitochondrial DNA|anatomy|34|C1819717
52|The expression of the mitochondrial biogenesis-related proteins PGC-1α, TFAM, SIRT3, and COX4 was significantly increased after PPA treatment|PGC-1|PGC-1|gene|64|NCBIGene:10891|TFAM|TFAM|gene|71|NCBIGene:7019
52|The expression of the mitochondrial biogenesis-related proteins PGC-1α, TFAM, SIRT3, and COX4 was significantly increased after PPA treatment|PGC-1|PGC-1|gene|64|NCBIGene:10891|SIRT3|SIRT3|gene|77|NCBIGene:23410
52|The expression of the mitochondrial biogenesis-related proteins PGC-1α, TFAM, SIRT3, and COX4 was significantly increased after PPA treatment|PGC-1|PGC-1|gene|64|NCBIGene:10891|COX4|COX4|gene|88|NCBIGene:1327
52|The expression of the mitochondrial biogenesis-related proteins PGC-1α, TFAM, SIRT3, and COX4 was significantly increased after PPA treatment|PPA|PPA|compound|127|mesh:D010665|PGC-1|PGC-1|gene|64|NCBIGene:10891
52|The expression of the mitochondrial biogenesis-related proteins PGC-1α, TFAM, SIRT3, and COX4 was significantly increased after PPA treatment|TFAM|TFAM|gene|71|NCBIGene:7019|SIRT3|SIRT3|gene|77|NCBIGene:23410
52|The expression of the mitochondrial biogenesis-related proteins PGC-1α, TFAM, SIRT3, and COX4 was significantly increased after PPA treatment|TFAM|TFAM|gene|71|NCBIGene:7019|COX4|COX4|gene|88|NCBIGene:1327
52|The expression of the mitochondrial biogenesis-related proteins PGC-1α, TFAM, SIRT3, and COX4 was significantly increased after PPA treatment|PPA|PPA|compound|127|mesh:D010665|TFAM|TFAM|gene|71|NCBIGene:7019
52|The expression of the mitochondrial biogenesis-related proteins PGC-1α, TFAM, SIRT3, and COX4 was significantly increased after PPA treatment|SIRT3|SIRT3|gene|77|NCBIGene:23410|COX4|COX4|gene|88|NCBIGene:1327
52|The expression of the mitochondrial biogenesis-related proteins PGC-1α, TFAM, SIRT3, and COX4 was significantly increased after PPA treatment|PPA|PPA|compound|127|mesh:D010665|SIRT3|SIRT3|gene|77|NCBIGene:23410
52|The expression of the mitochondrial biogenesis-related proteins PGC-1α, TFAM, SIRT3, and COX4 was significantly increased after PPA treatment|PPA|PPA|compound|127|mesh:D010665|COX4|COX4|gene|88|NCBIGene:1327
52|Transcriptome analysis revealed that mRNA expression in the notch signaling-related genes ASCL1 and LFNG changed after PPA treatment and the positive correlated protein expression changes were also observed|notch signaling|notch signaling|gene|60|NCBIGene:4851|ASCL1|ASCL1|gene|90|NCBIGene:429
52|Transcriptome analysis revealed that mRNA expression in the notch signaling-related genes ASCL1 and LFNG changed after PPA treatment and the positive correlated protein expression changes were also observed|notch signaling|notch signaling|gene|60|NCBIGene:4851|LFNG|LFNG|gene|100|NCBIGene:3955
52|Transcriptome analysis revealed that mRNA expression in the notch signaling-related genes ASCL1 and LFNG changed after PPA treatment and the positive correlated protein expression changes were also observed|PPA|PPA|compound|119|mesh:D010665|notch signaling|notch signaling|gene|60|NCBIGene:4851
52|Transcriptome analysis revealed that mRNA expression in the notch signaling-related genes ASCL1 and LFNG changed after PPA treatment and the positive correlated protein expression changes were also observed|notch signaling|notch signaling|gene|60|NCBIGene:4851|mRNA Expression|mRNA expression|physiology|37|C1515670
52|Transcriptome analysis revealed that mRNA expression in the notch signaling-related genes ASCL1 and LFNG changed after PPA treatment and the positive correlated protein expression changes were also observed|ASCL1|ASCL1|gene|90|NCBIGene:429|LFNG|LFNG|gene|100|NCBIGene:3955
52|Transcriptome analysis revealed that mRNA expression in the notch signaling-related genes ASCL1 and LFNG changed after PPA treatment and the positive correlated protein expression changes were also observed|PPA|PPA|compound|119|mesh:D010665|ASCL1|ASCL1|gene|90|NCBIGene:429
52|Transcriptome analysis revealed that mRNA expression in the notch signaling-related genes ASCL1 and LFNG changed after PPA treatment and the positive correlated protein expression changes were also observed|ASCL1|ASCL1|gene|90|NCBIGene:429|mRNA Expression|mRNA expression|physiology|37|C1515670
52|Transcriptome analysis revealed that mRNA expression in the notch signaling-related genes ASCL1 and LFNG changed after PPA treatment and the positive correlated protein expression changes were also observed|PPA|PPA|compound|119|mesh:D010665|LFNG|LFNG|gene|100|NCBIGene:3955
52|Transcriptome analysis revealed that mRNA expression in the notch signaling-related genes ASCL1 and LFNG changed after PPA treatment and the positive correlated protein expression changes were also observed|LFNG|LFNG|gene|100|NCBIGene:3955|mRNA Expression|mRNA expression|physiology|37|C1515670
52|These results  revealed that PPA treatment may affect neurodevelopment by altering mitochondrial function and notch signaling-related gene expression|PPA|PPA|compound|29|mesh:D010665|notch|notch|gene|110|NCBIGene:4851
52|These results  revealed that PPA treatment may affect neurodevelopment by altering mitochondrial function and notch signaling-related gene expression|PPA|PPA|compound|29|mesh:D010665|Mitochondria|mitochondrial|anatomy|83|C0026237
52|These results  revealed that PPA treatment may affect neurodevelopment by altering mitochondrial function and notch signaling-related gene expression|notch|notch|gene|110|NCBIGene:4851|Affect (mental function)|affect|physiology|47|C0001721
52|These results  revealed that PPA treatment may affect neurodevelopment by altering mitochondrial function and notch signaling-related gene expression|notch|notch|gene|110|NCBIGene:4851|neurodevelopment|neurodevelopment|physiology|54|C0599855
52|These results  revealed that PPA treatment may affect neurodevelopment by altering mitochondrial function and notch signaling-related gene expression|notch|notch|gene|110|NCBIGene:4851|Function Axis|function|physiology|97|C0700205
52|These results  revealed that PPA treatment may affect neurodevelopment by altering mitochondrial function and notch signaling-related gene expression|notch|notch|gene|110|NCBIGene:4851|Mitochondria|mitochondrial|anatomy|83|C0026237
53|As antiretroviral therapy (ART) becomes increasingly affordable and accessible to women of childbearing age across the globe, the number of children who are exposed to Human Immunodeficiency Viruses (HIV) but remain uninfected is on the rise, almost all of whom were also exposed to ART perinatally|Human Immunodeficiency|Human Immunodeficiency|disease|168|omim:609423|Eye|globe|anatomy|119|C0015392
56|We used existing sequencing-based methylation data, which assayed the majority of all 28 million CpGs in the human genome, to perform an MWAS for schizophrenia in blood, while controlling for cell-type heterogeneity with a recently generated platform-specific reference panel|schizophrenia|schizophrenia|disease|146|omim:181500|Blood|blood|anatomy|163|C0005767
56|We used existing sequencing-based methylation data, which assayed the majority of all 28 million CpGs in the human genome, to perform an MWAS for schizophrenia in blood, while controlling for cell-type heterogeneity with a recently generated platform-specific reference panel|schizophrenia|schizophrenia|disease|146|omim:181500|Cells|cell-type|anatomy|192|C0007634
56|Next, we compared the MWAS results with findings from 3 existing large-scale array-based schizophrenia methylation studies in blood that assayed up to ~450 000 CpGs|CpGs|CpGs|compound|160|mesh:C408982|schizophrenia|schizophrenia|disease|89|omim:181500
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|Ca2+|Ca2+|compound|67|CHEBI:29108|MFN2|MFN2|gene|20|NCBIGene:9927
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|MFN2|MFN2|gene|20|NCBIGene:9927|DISC1|DISC1|gene|149|NCBIGene:27185
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|MFN2|MFN2|gene|20|NCBIGene:9927|Mitochondria|mitochondria|anatomy|116|C0026237
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|MFN2|MFN2|gene|20|NCBIGene:9927|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|91|C0014239
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|Ca2+|Ca2+|compound|67|CHEBI:29108|mitofusin-2|mitofusin-2|gene|40|NCBIGene:9927
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|mitofusin-2|mitofusin-2|gene|40|NCBIGene:9927|DISC1|DISC1|gene|149|NCBIGene:27185
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|mitofusin-2|mitofusin-2|gene|40|NCBIGene:9927|Mitochondria|mitochondria|anatomy|116|C0026237
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|mitofusin-2|mitofusin-2|gene|40|NCBIGene:9927|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|91|C0014239
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|Ca2+|Ca2+|compound|67|CHEBI:29108|DISC1|DISC1|gene|149|NCBIGene:27185
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|Ca2+|Ca2+|compound|67|CHEBI:29108|Mitochondria|mitochondria|anatomy|116|C0026237
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|Ca2+|Ca2+|compound|67|CHEBI:29108|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|91|C0014239
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|DISC1|DISC1|gene|149|NCBIGene:27185|Mitochondria|mitochondria|anatomy|116|C0026237
56|001) was located in MFN2, which encodes mitofusin-2 that regulates Ca2+ transfer from  the endoplasmic reticulum to mitochondria in cooperation with DISC1|DISC1|DISC1|gene|149|NCBIGene:27185|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|91|C0014239
56|013) was located in ALDH1A2, which encodes an enzyme for astrocyte-derived retinoic acid-a key neuronal morphogen with relevance for schizophrenia|retinoic acid|retinoic acid|compound|75|CHEBI:26536|ALDH1A2|ALDH1A2|gene|20|NCBIGene:8854
56|013) was located in ALDH1A2, which encodes an enzyme for astrocyte-derived retinoic acid-a key neuronal morphogen with relevance for schizophrenia|ALDH1A2|ALDH1A2|gene|20|NCBIGene:8854|schizophrenia|schizophrenia|disease|133|omim:181500
56|013) was located in ALDH1A2, which encodes an enzyme for astrocyte-derived retinoic acid-a key neuronal morphogen with relevance for schizophrenia|ALDH1A2|ALDH1A2|gene|20|NCBIGene:8854|Astrocytes|astrocyte|anatomy|57|C0004112
56|013) was located in ALDH1A2, which encodes an enzyme for astrocyte-derived retinoic acid-a key neuronal morphogen with relevance for schizophrenia|retinoic acid|retinoic acid|compound|75|CHEBI:26536|schizophrenia|schizophrenia|disease|133|omim:181500
56|013) was located in ALDH1A2, which encodes an enzyme for astrocyte-derived retinoic acid-a key neuronal morphogen with relevance for schizophrenia|retinoic acid|retinoic acid|compound|75|CHEBI:26536|Astrocytes|astrocyte|anatomy|57|C0004112
56|013) was located in ALDH1A2, which encodes an enzyme for astrocyte-derived retinoic acid-a key neuronal morphogen with relevance for schizophrenia|schizophrenia|schizophrenia|disease|133|omim:181500|Astrocytes|astrocyte|anatomy|57|C0004112
57|Emerging evidence suggests that Parkinson's disease (PD), besides being an age-associated disorder, might also have a neurodevelopment component|Parkinson's disease|Parkinson's disease|disease|32|mesh:D010300|PD|PD|disease|53|omim:168600
57|Here, we show that PD patient-specific human neuroepithelial stem cells (NESCs), carrying the LRRK2-G2019S mutation, recapitulate key mitochondrial defects previously described only in differentiated dopaminergic neurons|LRRK2-G2019S mutation|LRRK2-G2019S mutation|gene|94|NCBIGene:100131905|PD|PD|disease|19|omim:168600
57|Here, we show that PD patient-specific human neuroepithelial stem cells (NESCs), carrying the LRRK2-G2019S mutation, recapitulate key mitochondrial defects previously described only in differentiated dopaminergic neurons|PD|PD|disease|19|omim:168600|Stem cells|stem cells|anatomy|61|C0038250
57|Here, we show that PD patient-specific human neuroepithelial stem cells (NESCs), carrying the LRRK2-G2019S mutation, recapitulate key mitochondrial defects previously described only in differentiated dopaminergic neurons|PD|PD|disease|19|omim:168600|Mitochondria|mitochondrial|anatomy|134|C0026237
57|Here, we show that PD patient-specific human neuroepithelial stem cells (NESCs), carrying the LRRK2-G2019S mutation, recapitulate key mitochondrial defects previously described only in differentiated dopaminergic neurons|LRRK2-G2019S mutation|LRRK2-G2019S mutation|gene|94|NCBIGene:100131905|Stem cells|stem cells|anatomy|61|C0038250
57|Here, we show that PD patient-specific human neuroepithelial stem cells (NESCs), carrying the LRRK2-G2019S mutation, recapitulate key mitochondrial defects previously described only in differentiated dopaminergic neurons|LRRK2-G2019S mutation|LRRK2-G2019S mutation|gene|94|NCBIGene:100131905|dopaminergic neuron differentiation|differentiated dopaminergic neurons|physiology|185|C2754748
57|Here, we show that PD patient-specific human neuroepithelial stem cells (NESCs), carrying the LRRK2-G2019S mutation, recapitulate key mitochondrial defects previously described only in differentiated dopaminergic neurons|LRRK2-G2019S mutation|LRRK2-G2019S mutation|gene|94|NCBIGene:100131905|Mitochondria|mitochondrial|anatomy|134|C0026237
57|By combining high-content imaging approaches, 3D image analysis, and functional mitochondrial readouts we show that LRRK2-G2019S mutation causes aberrations in mitochondrial morphology and functionality compared with isogenic controls|LRRK2-G2019S|LRRK2-G2019S|gene|116|NCBIGene:100131905|Mutation|mutation|physiology|129|C0026882
57|By combining high-content imaging approaches, 3D image analysis, and functional mitochondrial readouts we show that LRRK2-G2019S mutation causes aberrations in mitochondrial morphology and functionality compared with isogenic controls|LRRK2-G2019S|LRRK2-G2019S|gene|116|NCBIGene:100131905|Feeling content|content|physiology|18|C0423896
57|LRRK2-G2019S NESCs display an increased number of mitochondria compared with isogenic control lines|LRRK2-G2019S|LRRK2-G2019S|gene|0|NCBIGene:100131905|Mitochondria|mitochondria|anatomy|50|C0026237
57|Functional alterations in LRRK2-G2019S cultures are also accompanied by a reduced mitophagic clearance via lysosomes|LRRK2|LRRK2|gene|26|NCBIGene:120892|Lysosomes|lysosomes|anatomy|107|C0024369
57|Functional alterations in LRRK2-G2019S cultures are also accompanied by a reduced mitophagic clearance via lysosomes|LRRK2|LRRK2|gene|26|NCBIGene:120892|Clearance of substance|clearance|physiology|93|C1382187
57|These findings support the hypothesis that preceding mitochondrial developmental  defects contribute to the manifestation of the PD pathology later in life|mitochondrial developmental  defects|mitochondrial developmental  defects|disease|53|mesh:D028361|PD|PD|disease|129|omim:168600
57|These findings support the hypothesis that preceding mitochondrial developmental  defects contribute to the manifestation of the PD pathology later in life|PD|PD|disease|129|omim:168600|Mitochondria|mitochondrial|anatomy|53|C0026237
58|The activating molecule in Beclin-1-regulated autophagy (Ambra1) is a highly intrinsically disordered protein best known for its role as a mediator in autophagy, by favoring the formation of autophagosomes|Beclin-1|Beclin-1|gene|27|NCBIGene:8678|Ambra1|Ambra1|gene|57|NCBIGene:55626
58|The activating molecule in Beclin-1-regulated autophagy (Ambra1) is a highly intrinsically disordered protein best known for its role as a mediator in autophagy, by favoring the formation of autophagosomes|Beclin-1|Beclin-1|gene|27|NCBIGene:8678|Autophagy|autophagy|physiology|151|C0004391
58|The activating molecule in Beclin-1-regulated autophagy (Ambra1) is a highly intrinsically disordered protein best known for its role as a mediator in autophagy, by favoring the formation of autophagosomes|Ambra1|Ambra1|gene|57|NCBIGene:55626|Autophagy|autophagy|physiology|151|C0004391
58|Additional studies have revealed that Ambra1 is able to coordinate cell responses to stress conditions such as starvation, and it actively participates in cell proliferation, cytoskeletal modification, apoptosis, mitochondria removal, and cell cycle downregulation|Ambra1|Ambra1|gene|38|NCBIGene:55626|Ability|able|physiology|48|C0085732
58|Additional studies have revealed that Ambra1 is able to coordinate cell responses to stress conditions such as starvation, and it actively participates in cell proliferation, cytoskeletal modification, apoptosis, mitochondria removal, and cell cycle downregulation|Ambra1|Ambra1|gene|38|NCBIGene:55626|Apoptosis|apoptosis|physiology|202|C0162638
58|Additional studies have revealed that Ambra1 is able to coordinate cell responses to stress conditions such as starvation, and it actively participates in cell proliferation, cytoskeletal modification, apoptosis, mitochondria removal, and cell cycle downregulation|Ambra1|Ambra1|gene|38|NCBIGene:55626|Cellular Stress Response|cell responses to stress|physiology|67|C1516374
58|Additional studies have revealed that Ambra1 is able to coordinate cell responses to stress conditions such as starvation, and it actively participates in cell proliferation, cytoskeletal modification, apoptosis, mitochondria removal, and cell cycle downregulation|Ambra1|Ambra1|gene|38|NCBIGene:55626|Cell Proliferation|cell proliferation|physiology|155|C0596290
58|Additional studies have revealed that Ambra1 is able to coordinate cell responses to stress conditions such as starvation, and it actively participates in cell proliferation, cytoskeletal modification, apoptosis, mitochondria removal, and cell cycle downregulation|Ambra1|Ambra1|gene|38|NCBIGene:55626|Down-Regulation|downregulation|physiology|250|C0013081
58|Additional studies have revealed that Ambra1 is able to coordinate cell responses to stress conditions such as starvation, and it actively participates in cell proliferation, cytoskeletal modification, apoptosis, mitochondria removal, and cell cycle downregulation|Ambra1|Ambra1|gene|38|NCBIGene:55626|Condition:Find:Pt:^Patient:Nom|conditions|physiology|92|C3864998
58|Additional studies have revealed that Ambra1 is able to coordinate cell responses to stress conditions such as starvation, and it actively participates in cell proliferation, cytoskeletal modification, apoptosis, mitochondria removal, and cell cycle downregulation|Ambra1|Ambra1|gene|38|NCBIGene:55626|Cell Cycle|cell cycle|physiology|239|C0007586
58|All these functions highlight the importance of Ambra1 in crucial physiological events, including metabolism, cell death, and cell division|Ambra1|Ambra1|gene|48|NCBIGene:55626|Cell Death|cell death|physiology|110|C0007587
58|All these functions highlight the importance of Ambra1 in crucial physiological events, including metabolism, cell death, and cell division|Ambra1|Ambra1|gene|48|NCBIGene:55626|Cell division|cell division|physiology|126|C0007590
58|All these functions highlight the importance of Ambra1 in crucial physiological events, including metabolism, cell death, and cell division|Ambra1|Ambra1|gene|48|NCBIGene:55626|Metabolism|metabolism|physiology|98|C0025519
58|Importantly, Ambra1 is also crucial for proper embryonic development, and its complete absence in knock-out animal models leads to severe brain morphology defects|Ambra1|Ambra1|gene|13|NCBIGene:55626|brain morphology defects|brain morphology defects|disease|138|mesh:D001927
58|Importantly, Ambra1 is also crucial for proper embryonic development, and its complete absence in knock-out animal models leads to severe brain morphology defects|Ambra1|Ambra1|gene|13|NCBIGene:55626|Embryonic Development|embryonic development|physiology|47|C0013936
58|In line with this, it has recently been implicated in neurodevelopmental disorders affecting humans, particularly autism spectrum disorders and schizophrenia|neurodevelopmental disorders|neurodevelopmental disorders|disease|54|mesh:D065886|autism spectrum disorders|autism spectrum disorders|disease|114|mesh:D002659
58|In line with this, it has recently been implicated in neurodevelopmental disorders affecting humans, particularly autism spectrum disorders and schizophrenia|neurodevelopmental disorders|neurodevelopmental disorders|disease|54|mesh:D065886|schizophrenia|schizophrenia|disease|144|omim:181500
58|In line with this, it has recently been implicated in neurodevelopmental disorders affecting humans, particularly autism spectrum disorders and schizophrenia|autism spectrum disorders|autism spectrum disorders|disease|114|mesh:D002659|schizophrenia|schizophrenia|disease|144|omim:181500
58|Here, we discuss the recent links between Ambra1 and neurodevelopment, particularly focusing on its role during the maturation of hippocampal parvalbumin interneurons and its importance for maintaining a proper  excitation/inhibition balance in the brain|Ambra1|Ambra1|gene|42|NCBIGene:55626|neurodevelopment|neurodevelopment|physiology|53|C0599855
58|Here, we discuss the recent links between Ambra1 and neurodevelopment, particularly focusing on its role during the maturation of hippocampal parvalbumin interneurons and its importance for maintaining a proper  excitation/inhibition balance in the brain|Ambra1|Ambra1|gene|42|NCBIGene:55626|Visual Accommodation|focusing|physiology|84|C0000936
58|Here, we discuss the recent links between Ambra1 and neurodevelopment, particularly focusing on its role during the maturation of hippocampal parvalbumin interneurons and its importance for maintaining a proper  excitation/inhibition balance in the brain|Ambra1|Ambra1|gene|42|NCBIGene:55626|Anatomical maturation|maturation|physiology|116|C1254042
58|Here, we discuss the recent links between Ambra1 and neurodevelopment, particularly focusing on its role during the maturation of hippocampal parvalbumin interneurons and its importance for maintaining a proper  excitation/inhibition balance in the brain|Ambra1|Ambra1|gene|42|NCBIGene:55626|Equilibrium|balance|physiology|234|C0014653
59|This included impaired performance in prepulse inhibition as well as hyperlocomotion in the open field and elevated plus maze tests|hyperlocomotion|hyperlocomotion|disease|69|mesh:D001289|Test - temporal region|tests|anatomy|126|C4318744
59|Knocking out a mitochondria-related gene, UCP-2, blocked cellular and behavioral adaptations induced by surgical delivery|UCP-2|UCP-2|gene|42|NCBIGene:7351|Cells|cellular|anatomy|57|C0007634
59|Knocking out a mitochondria-related gene, UCP-2, blocked cellular and behavioral adaptations induced by surgical delivery|UCP-2|UCP-2|gene|42|NCBIGene:7351|Acclimatization|adaptations|physiology|81|C0000934
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNAP29|SNAP29|gene|24|NCBIGene:9342|SNARE protein|SNARE protein|gene|43|NCBIGene:10652
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNAP29|SNAP29|gene|24|NCBIGene:9342|CEDNIK|CEDNIK|disease|99|mesh:C537943
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNAP29|SNAP29|gene|24|NCBIGene:9342|Cerebral Dysgenesis,|Cerebral Dysgenesis,|disease|107|mesh:D054220
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNAP29|SNAP29|gene|24|NCBIGene:9342|Neuropathy|Neuropathy|disease|128|mesh:D009422
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNAP29|SNAP29|gene|24|NCBIGene:9342|Ichthyosis|Ichthyosis|disease|140|mesh:D007057
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNAP29|SNAP29|gene|24|NCBIGene:9342|Keratoderma|Keratoderma|disease|155|mesh:D007642
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNAP29|SNAP29|gene|24|NCBIGene:9342|congenital neurocutaneous syndrome|congenital neurocutaneous syndrome|disease|176|mesh:D020752
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNAP29|SNAP29|gene|24|NCBIGene:9342|SNAP receptor activity|SNARE|physiology|43|C1153540
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNAP29|SNAP29|gene|24|NCBIGene:9342|Membrane Fusion|membrane fusion|physiology|76|C0025246
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNAP29|SNAP29|gene|24|NCBIGene:9342|Mutation|mutations|physiology|11|C0026882
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNAP29|SNAP29|gene|24|NCBIGene:9342|Homozygote|Homozygous|physiology|0|C0019904
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNARE protein|SNARE protein|gene|43|NCBIGene:10652|CEDNIK|CEDNIK|disease|99|mesh:C537943
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNARE protein|SNARE protein|gene|43|NCBIGene:10652|Cerebral Dysgenesis,|Cerebral Dysgenesis,|disease|107|mesh:D054220
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNARE protein|SNARE protein|gene|43|NCBIGene:10652|Neuropathy|Neuropathy|disease|128|mesh:D009422
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNARE protein|SNARE protein|gene|43|NCBIGene:10652|Ichthyosis|Ichthyosis|disease|140|mesh:D007057
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNARE protein|SNARE protein|gene|43|NCBIGene:10652|Keratoderma|Keratoderma|disease|155|mesh:D007642
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNARE protein|SNARE protein|gene|43|NCBIGene:10652|congenital neurocutaneous syndrome|congenital neurocutaneous syndrome|disease|176|mesh:D020752
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNARE protein|SNARE protein|gene|43|NCBIGene:10652|Membrane Fusion|membrane fusion|physiology|76|C0025246
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNARE protein|SNARE protein|gene|43|NCBIGene:10652|Mutation|mutations|physiology|11|C0026882
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|SNARE protein|SNARE protein|gene|43|NCBIGene:10652|Homozygote|Homozygous|physiology|0|C0019904
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|CEDNIK|CEDNIK|disease|99|mesh:C537943|Cerebral Dysgenesis,|Cerebral Dysgenesis,|disease|107|mesh:D054220
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|CEDNIK|CEDNIK|disease|99|mesh:C537943|Neuropathy|Neuropathy|disease|128|mesh:D009422
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|CEDNIK|CEDNIK|disease|99|mesh:C537943|Ichthyosis|Ichthyosis|disease|140|mesh:D007057
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|CEDNIK|CEDNIK|disease|99|mesh:C537943|Keratoderma|Keratoderma|disease|155|mesh:D007642
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|CEDNIK|CEDNIK|disease|99|mesh:C537943|congenital neurocutaneous syndrome|congenital neurocutaneous syndrome|disease|176|mesh:D020752
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|Cerebral Dysgenesis,|Cerebral Dysgenesis,|disease|107|mesh:D054220|Neuropathy|Neuropathy|disease|128|mesh:D009422
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|Cerebral Dysgenesis,|Cerebral Dysgenesis,|disease|107|mesh:D054220|Ichthyosis|Ichthyosis|disease|140|mesh:D007057
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|Cerebral Dysgenesis,|Cerebral Dysgenesis,|disease|107|mesh:D054220|Keratoderma|Keratoderma|disease|155|mesh:D007642
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|Cerebral Dysgenesis,|Cerebral Dysgenesis,|disease|107|mesh:D054220|congenital neurocutaneous syndrome|congenital neurocutaneous syndrome|disease|176|mesh:D020752
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|Neuropathy|Neuropathy|disease|128|mesh:D009422|Ichthyosis|Ichthyosis|disease|140|mesh:D007057
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|Neuropathy|Neuropathy|disease|128|mesh:D009422|Keratoderma|Keratoderma|disease|155|mesh:D007642
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|Neuropathy|Neuropathy|disease|128|mesh:D009422|congenital neurocutaneous syndrome|congenital neurocutaneous syndrome|disease|176|mesh:D020752
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|Ichthyosis|Ichthyosis|disease|140|mesh:D007057|Keratoderma|Keratoderma|disease|155|mesh:D007642
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|Ichthyosis|Ichthyosis|disease|140|mesh:D007057|congenital neurocutaneous syndrome|congenital neurocutaneous syndrome|disease|176|mesh:D020752
60|Homozygous mutations in SNAP29, encoding a SNARE protein mainly involved in membrane fusion, cause CEDNIK (Cerebral Dysgenesis, Neuropathy, Ichthyosis and Keratoderma), a rare congenital neurocutaneous syndrome associated with short life expectancy, whose pathogenesis is unclear|Keratoderma|Keratoderma|disease|155|mesh:D007642|congenital neurocutaneous syndrome|congenital neurocutaneous syndrome|disease|176|mesh:D020752
60|Here, we report the analysis of the first genetic model of CEDNIK in zebrafish|CEDNIK|CEDNIK|gene|59|NCBIGene:9342|Report:Finding:Point in time:{Setting}:Document:{Role}|report|physiology|9|C4255046
60|Strikingly, homozygous snap29 mutant larvae display CEDNIK-like features, such as microcephaly and skin defects|snap29 mutant|snap29 mutant|gene|23|NCBIGene:9342|CEDNIK|CEDNIK|disease|52|mesh:C537943
60|Strikingly, homozygous snap29 mutant larvae display CEDNIK-like features, such as microcephaly and skin defects|snap29 mutant|snap29 mutant|gene|23|NCBIGene:9342|microcephaly|microcephaly|disease|82|mesh:D008831
60|Strikingly, homozygous snap29 mutant larvae display CEDNIK-like features, such as microcephaly and skin defects|snap29 mutant|snap29 mutant|gene|23|NCBIGene:9342|skin defects|skin defects|disease|99|mesh:D012871
60|Strikingly, homozygous snap29 mutant larvae display CEDNIK-like features, such as microcephaly and skin defects|snap29 mutant|snap29 mutant|gene|23|NCBIGene:9342|Skin|skin|anatomy|99|C1123023
60|Strikingly, homozygous snap29 mutant larvae display CEDNIK-like features, such as microcephaly and skin defects|snap29 mutant|snap29 mutant|gene|23|NCBIGene:9342|Homozygote|homozygous|physiology|12|C0019904
60|Strikingly, homozygous snap29 mutant larvae display CEDNIK-like features, such as microcephaly and skin defects|CEDNIK|CEDNIK|disease|52|mesh:C537943|microcephaly|microcephaly|disease|82|mesh:D008831
60|Strikingly, homozygous snap29 mutant larvae display CEDNIK-like features, such as microcephaly and skin defects|CEDNIK|CEDNIK|disease|52|mesh:C537943|skin defects|skin defects|disease|99|mesh:D012871
60|Strikingly, homozygous snap29 mutant larvae display CEDNIK-like features, such as microcephaly and skin defects|CEDNIK|CEDNIK|disease|52|mesh:C537943|Skin|skin|anatomy|99|C1123023
60|Strikingly, homozygous snap29 mutant larvae display CEDNIK-like features, such as microcephaly and skin defects|microcephaly|microcephaly|disease|82|mesh:D008831|skin defects|skin defects|disease|99|mesh:D012871
60|Strikingly, homozygous snap29 mutant larvae display CEDNIK-like features, such as microcephaly and skin defects|microcephaly|microcephaly|disease|82|mesh:D008831|Skin|skin|anatomy|99|C1123023
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|Snap29|Snap29|gene|16|NCBIGene:9342|p62|p62|gene|114|NCBIGene:23636
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|Snap29|Snap29|gene|16|NCBIGene:9342|LC3|LC3|gene|122|NCBIGene:84557
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|Snap29|Snap29|gene|16|NCBIGene:9342|Mitochondria|mitochondria|anatomy|182|C0026237
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|Snap29|Snap29|gene|16|NCBIGene:9342|Membrane Fusion|membrane fusion|physiology|31|C0025246
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|Snap29|Snap29|gene|16|NCBIGene:9342|Organelles|organelles|anatomy|167|C0029219
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|p62|p62|gene|114|NCBIGene:23636|LC3|LC3|gene|122|NCBIGene:84557
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|p62|p62|gene|114|NCBIGene:23636|Mitochondria|mitochondria|anatomy|182|C0026237
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|p62|p62|gene|114|NCBIGene:23636|Membrane Fusion|membrane fusion|physiology|31|C0025246
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|p62|p62|gene|114|NCBIGene:23636|Organelles|organelles|anatomy|167|C0029219
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|LC3|LC3|gene|122|NCBIGene:84557|Mitochondria|mitochondria|anatomy|182|C0026237
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|LC3|LC3|gene|122|NCBIGene:84557|Membrane Fusion|membrane fusion|physiology|31|C0025246
60|Consistent with Snap29 role in membrane fusion during autophagy, we observe accumulation of the autophagy markers p62 and LC3, and formation of aberrant multilamellar organelles and mitochondria|LC3|LC3|gene|122|NCBIGene:84557|Organelles|organelles|anatomy|167|C0029219
60|Importantly, we find high levels of apoptotic cell death during early development that might play a yet uncharacterized role in CEDNIK pathogenesis|CEDNIK|CEDNIK|gene|128|NCBIGene:9342|Biologic Development|development|physiology|70|C0678723
60|Importantly, we find high levels of apoptotic cell death during early development that might play a yet uncharacterized role in CEDNIK pathogenesis|CEDNIK|CEDNIK|gene|128|NCBIGene:9342|Apoptosis|apoptotic cell death|physiology|36|C0162638
60|Since the paralog Snap25 is known to promote axonal branching, Snap29 might act in opposition with, or modulate Snap25 activity during neurodevelopment|Snap25|Snap25|gene|18|NCBIGene:6616|Snap29|Snap29|gene|63|NCBIGene:9342
60|Since the paralog Snap25 is known to promote axonal branching, Snap29 might act in opposition with, or modulate Snap25 activity during neurodevelopment|Snap25|Snap25|gene|18|NCBIGene:6616|SNAP-25 activity|Snap25 activity|physiology|112|C1817242
60|Since the paralog Snap25 is known to promote axonal branching, Snap29 might act in opposition with, or modulate Snap25 activity during neurodevelopment|Snap25|Snap25|gene|18|NCBIGene:6616|axon branching|axonal branching|physiology|45|C3546325
60|Since the paralog Snap25 is known to promote axonal branching, Snap29 might act in opposition with, or modulate Snap25 activity during neurodevelopment|Snap29|Snap29|gene|63|NCBIGene:9342|Snap25|Snap25|gene|112|NCBIGene:6616
60|Since the paralog Snap25 is known to promote axonal branching, Snap29 might act in opposition with, or modulate Snap25 activity during neurodevelopment|Snap29|Snap29|gene|63|NCBIGene:9342|SNAP-25 activity|Snap25|physiology|18|C1817242
60|Since the paralog Snap25 is known to promote axonal branching, Snap29 might act in opposition with, or modulate Snap25 activity during neurodevelopment|Snap29|Snap29|gene|63|NCBIGene:9342|SNAP-25 activity|Snap25 activity|physiology|112|C1817242
60|Since the paralog Snap25 is known to promote axonal branching, Snap29 might act in opposition with, or modulate Snap25 activity during neurodevelopment|Snap29|Snap29|gene|63|NCBIGene:9342|axon branching|axonal branching|physiology|45|C3546325
60|Since the paralog Snap25 is known to promote axonal branching, Snap29 might act in opposition with, or modulate Snap25 activity during neurodevelopment|Snap25|Snap25|gene|112|NCBIGene:6616|SNAP-25 activity|Snap25|physiology|18|C1817242
60|Since the paralog Snap25 is known to promote axonal branching, Snap29 might act in opposition with, or modulate Snap25 activity during neurodevelopment|Snap25|Snap25|gene|112|NCBIGene:6616|axon branching|axonal branching|physiology|45|C3546325
60|Our vertebrate genetic model of CEDNIK extends the description in vivo of the multisystem defects due to loss of Snap29 and could provide the base to test compounds that might ameliorate traits of the disease|Snap29|Snap29|gene|113|NCBIGene:9342|CEDNIK|CEDNIK|disease|32|mesh:C537943
60|Our vertebrate genetic model of CEDNIK extends the description in vivo of the multisystem defects due to loss of Snap29 and could provide the base to test compounds that might ameliorate traits of the disease|CEDNIK|CEDNIK|disease|32|mesh:C537943|Structure of base of prostate|base|anatomy|142|C0227958
60|Our vertebrate genetic model of CEDNIK extends the description in vivo of the multisystem defects due to loss of Snap29 and could provide the base to test compounds that might ameliorate traits of the disease|CEDNIK|CEDNIK|disease|32|mesh:C537943|Test - temporal region|test|anatomy|150|C4318744
60|Our vertebrate genetic model of CEDNIK extends the description in vivo of the multisystem defects due to loss of Snap29 and could provide the base to test compounds that might ameliorate traits of the disease|Snap29|Snap29|gene|113|NCBIGene:9342|Structure of base of prostate|base|anatomy|142|C0227958
60|Our vertebrate genetic model of CEDNIK extends the description in vivo of the multisystem defects due to loss of Snap29 and could provide the base to test compounds that might ameliorate traits of the disease|Snap29|Snap29|gene|113|NCBIGene:9342|Test - temporal region|test|anatomy|150|C4318744
60|Our vertebrate genetic model of CEDNIK extends the description in vivo of the multisystem defects due to loss of Snap29 and could provide the base to test compounds that might ameliorate traits of the disease|Snap29|Snap29|gene|113|NCBIGene:9342|Trait|traits|physiology|187|C0599883
61|Fluoride neurotoxicity is associated with mitochondrial disruption|Fluoride|Fluoride|compound|0|mesh:D005459|Mitochondria|mitochondrial|anatomy|42|C0026237
61|Mitochondrial fission/fusion dynamics is crucial to maintain functional mitochondria, yet little is known about how fluoride perturbs this dynamics and whether such perturbation contributes to impaired neurodevelopment|fluoride|fluoride|compound|116|mesh:D005459|Mitochondria|mitochondria|anatomy|72|C0026237
61|Here in human neuroblastoma SH-SY5Y cells treated with sodium fluoride (NaF, 20, 40 and 60 mg/L), mitochondrial fission suppression exerted a central role in NaF-induced mitochondrial abnormalities and the resulting autophagy deficiency, apoptosis augmentation, and compromised neuronal survival|sodium fluoride|sodium fluoride|compound|55|CHEBI:28741|neuroblastoma|neuroblastoma|disease|14|omim:256700
61|Here in human neuroblastoma SH-SY5Y cells treated with sodium fluoride (NaF, 20, 40 and 60 mg/L), mitochondrial fission suppression exerted a central role in NaF-induced mitochondrial abnormalities and the resulting autophagy deficiency, apoptosis augmentation, and compromised neuronal survival|NaF|NaF|compound|72|CHEBI:28741|neuroblastoma|neuroblastoma|disease|14|omim:256700
61|Here in human neuroblastoma SH-SY5Y cells treated with sodium fluoride (NaF, 20, 40 and 60 mg/L), mitochondrial fission suppression exerted a central role in NaF-induced mitochondrial abnormalities and the resulting autophagy deficiency, apoptosis augmentation, and compromised neuronal survival|NaF|NaF|compound|158|CHEBI:28741|neuroblastoma|neuroblastoma|disease|14|omim:256700
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|NaF|NaF|compound|67|CHEBI:28741|fluoride|fluoride|compound|238|mesh:D005459
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|NaF|NaF|compound|67|CHEBI:28741|learning and memory impairments|learning and memory impairments|disease|254|mesh:D008569
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|NaF|NaF|compound|67|CHEBI:28741|excessive|excessive|disease|445|mesh:D006963
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|NaF|NaF|compound|67|CHEBI:28741|neuronal loss|neuronal loss|disease|469|mesh:D009410
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|NaF|NaF|compound|67|CHEBI:28741|Hippocampus (Brain)|hippocampal|anatomy|302|C0019564
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|fluoride|fluoride|compound|238|mesh:D005459|learning and memory impairments|learning and memory impairments|disease|254|mesh:D008569
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|fluoride|fluoride|compound|238|mesh:D005459|excessive|excessive|disease|445|mesh:D006963
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|fluoride|fluoride|compound|238|mesh:D005459|neuronal loss|neuronal loss|disease|469|mesh:D009410
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|fluoride|fluoride|compound|238|mesh:D005459|Hippocampus (Brain)|hippocampal|anatomy|302|C0019564
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|learning and memory impairments|learning and memory impairments|disease|254|mesh:D008569|excessive|excessive|disease|445|mesh:D006963
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|learning and memory impairments|learning and memory impairments|disease|254|mesh:D008569|neuronal loss|neuronal loss|disease|469|mesh:D009410
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|learning and memory impairments|learning and memory impairments|disease|254|mesh:D008569|Hippocampus (Brain)|hippocampal|anatomy|302|C0019564
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|excessive|excessive|disease|445|mesh:D006963|neuronal loss|neuronal loss|disease|469|mesh:D009410
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|excessive|excessive|disease|445|mesh:D006963|Hippocampus (Brain)|hippocampal|anatomy|302|C0019564
61|Consistently, using Sprague-Dawley rats developmentally exposed to NaF (10, 50, and 100 mg/L) from pre-pregnancy until 2 months of delivery to mimic human exposure, we showed  that perinatal exposure to environmentally relevant levels of fluoride caused learning and memory impairments, accompanied by hippocampal mitochondrial morphological alterations manifested as fission suppression and fusion acceleration, along with defective autophagy, excessive apoptosis and neuronal loss|neuronal loss|neuronal loss|disease|469|mesh:D009410|Hippocampus (Brain)|hippocampal|anatomy|302|C0019564
61|Intriguingly, the disturbed circulating levels of identified mitochondrial  fission/fusion molecules were closely associated with intellectual loss in children under long-term environmental drinking water fluoride exposure|fluoride|fluoride|compound|205|mesh:D005459|intellectual loss|intellectual loss|disease|130|mesh:D008607
61|Collectively, our results suggest that mitochondrial fission inhibition induces mitochondrial abnormalities, triggering abnormal autophagy and apoptosis, thus contributing to neuronal death, and that the mitochondrial dynamics molecules may act as promising indicators for developmental fluoride neurotoxicity|fluoride|fluoride|compound|287|mesh:D005459|mitochondrial abnormalities|mitochondrial abnormalities|disease|80|mesh:D028361
62|Inherited mutations and accumulated damage to mitochondria over the course of ageing serve as key factors underlying cognitive defects in neurodevelopmental disorders and neurodegenerative diseases, respectively|cognitive defects|cognitive defects|disease|117|mesh:D003072|neurodevelopmental disorders|neurodevelopmental disorders|disease|138|mesh:D065886
62|Inherited mutations and accumulated damage to mitochondria over the course of ageing serve as key factors underlying cognitive defects in neurodevelopmental disorders and neurodegenerative diseases, respectively|cognitive defects|cognitive defects|disease|117|mesh:D003072|neurodegenerative diseases|neurodegenerative diseases|disease|171|mesh:D019636
62|Inherited mutations and accumulated damage to mitochondria over the course of ageing serve as key factors underlying cognitive defects in neurodevelopmental disorders and neurodegenerative diseases, respectively|neurodevelopmental disorders|neurodevelopmental disorders|disease|138|mesh:D065886|neurodegenerative diseases|neurodegenerative diseases|disease|171|mesh:D019636
62|In this respect, mitochondria may serve as targets for stem-cell-based therapies and interventions for cognitive defects|cognitive defects|cognitive defects|disease|103|mesh:D003072|Mitochondria|mitochondria|anatomy|17|C0026237
63|Schizophrenia (SCZ) is a devastating mental disorder that is characterized by distortions in thinking, perception, emotion, language, sense of self, and behavior|Schizophrenia|Schizophrenia|disease|0|omim:181500|mental disorder|mental disorder|disease|37|mesh:D001523
63|Schizophrenia (SCZ) is a devastating mental disorder that is characterized by distortions in thinking, perception, emotion, language, sense of self, and behavior|SCZ|SCZ|disease|15|omim:181500|mental disorder|mental disorder|disease|37|mesh:D001523
63|Since iPSCs capture each donor's genotype, comparison between neuronal cells derived from healthy and diseased individuals can provide  important insights into the molecular and cellular basis of SCZ|SCZ|SCZ|compound|196|mesh:C034739|Cells|cells|anatomy|71|C0007634
63|Since iPSCs capture each donor's genotype, comparison between neuronal cells derived from healthy and diseased individuals can provide  important insights into the molecular and cellular basis of SCZ|SCZ|SCZ|compound|196|mesh:C034739|Cells|cellular|anatomy|178|C0007634
63|Since iPSCs capture each donor's genotype, comparison between neuronal cells derived from healthy and diseased individuals can provide  important insights into the molecular and cellular basis of SCZ|SCZ|SCZ|compound|196|mesh:C034739|Induced Pluripotent Stem Cells|iPSCs|anatomy|6|C2717959
63|In this review,  we discuss results from an increasing number of iPSC-based SCZ/control studies that highlight alterations in neuronal differentiation, maturation, and neurotransmission in addition to perturbed mitochondrial function and micro-RNA expression|SCZ|SCZ|disease|76|omim:181500|Mitochondria|mitochondrial|anatomy|211|C0026237
64|We established a CS exposure rat model to determine how maternal CS exposure induces oxidative stress and mitochondrial dysfunction in parafacial respiratory group (pFRG) essential to central chemoreceptive regulation of normal breathing|mitochondrial dysfunction|mitochondrial dysfunction|disease|106|mesh:D028361|Condylion superiore|CS|anatomy|65|C4085345
64|Our data showed that maternal CS exposure resulted in elevated accumulation of ROS, which left a footprint on DNA and lipid with increases in 8-hydroxy-2'-deoxyguanosine and malondialdehyde contents|8-hydroxy-2'-deoxyguanosine|8-hydroxy-2'-deoxyguanosine|compound|142|mesh:D000080242|malondialdehyde|malondialdehyde|compound|174|mesh:D008315
64|Our data showed that maternal CS exposure resulted in elevated accumulation of ROS, which left a footprint on DNA and lipid with increases in 8-hydroxy-2'-deoxyguanosine and malondialdehyde contents|8-hydroxy-2'-deoxyguanosine|8-hydroxy-2'-deoxyguanosine|compound|142|mesh:D000080242|Condylion superiore|CS|anatomy|30|C4085345
64|Our data showed that maternal CS exposure resulted in elevated accumulation of ROS, which left a footprint on DNA and lipid with increases in 8-hydroxy-2'-deoxyguanosine and malondialdehyde contents|malondialdehyde|malondialdehyde|compound|174|mesh:D008315|Condylion superiore|CS|anatomy|30|C4085345
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|manganese|manganese|compound|55|mesh:D008345|superoxide|superoxide|compound|65|mesh:D013481
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|manganese|manganese|compound|55|mesh:D008345|catalase|catalase|gene|87|NCBIGene:847
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|manganese|manganese|compound|55|mesh:D008345|glutathione|glutathione|compound|100|CHEBI:57925
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|manganese|manganese|compound|55|mesh:D008345|glutathione reductase|glutathione reductase|gene|100|NCBIGene:2936
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|manganese|manganese|compound|55|mesh:D008345|glutathione|glutathione|compound|158|CHEBI:57925
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|manganese superoxide dismutase|manganese superoxide dismutase|gene|55|NCBIGene:6648|catalase|catalase|gene|87|NCBIGene:847
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|glutathione|glutathione|compound|100|CHEBI:57925|manganese superoxide dismutase|manganese superoxide dismutase|gene|55|NCBIGene:6648
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|manganese superoxide dismutase|manganese superoxide dismutase|gene|55|NCBIGene:6648|glutathione reductase|glutathione reductase|gene|100|NCBIGene:2936
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|glutathione|glutathione|compound|158|CHEBI:57925|manganese superoxide dismutase|manganese superoxide dismutase|gene|55|NCBIGene:6648
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|manganese superoxide dismutase|manganese superoxide dismutase|gene|55|NCBIGene:6648|glutathione-disulfide reductase activity|glutathione reductase activities|physiology|100|C1148566
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|superoxide|superoxide|compound|65|mesh:D013481|catalase|catalase|gene|87|NCBIGene:847
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|superoxide|superoxide|compound|65|mesh:D013481|glutathione|glutathione|compound|100|CHEBI:57925
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|superoxide|superoxide|compound|65|mesh:D013481|glutathione reductase|glutathione reductase|gene|100|NCBIGene:2936
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|superoxide|superoxide|compound|65|mesh:D013481|glutathione|glutathione|compound|158|CHEBI:57925
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|glutathione|glutathione|compound|100|CHEBI:57925|catalase|catalase|gene|87|NCBIGene:847
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|catalase|catalase|gene|87|NCBIGene:847|glutathione reductase|glutathione reductase|gene|100|NCBIGene:2936
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|glutathione|glutathione|compound|158|CHEBI:57925|catalase|catalase|gene|87|NCBIGene:847
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|catalase|catalase|gene|87|NCBIGene:847|glutathione-disulfide reductase activity|glutathione reductase activities|physiology|100|C1148566
64|Furthermore, maternal CS exposure induced decreases in manganese superoxide dismutase, catalase and glutathione reductase activities as well as reduction in  glutathione content in pFRG in the offspring|glutathione|glutathione|compound|158|CHEBI:57925|glutathione reductase|glutathione reductase|gene|100|NCBIGene:2936
64|Moreover, maternal exposure to CS led to mitochondrial ultrastructure changes, mitochondrial swelling, reduction in ATP generation, loss of mitochondrial membrane potential and increase in mitochondrial DNA copy number|ATP|ATP|compound|116|CHEBI:30616|Mitochondria|mitochondrial|anatomy|41|C0026237
64|Moreover, maternal exposure to CS led to mitochondrial ultrastructure changes, mitochondrial swelling, reduction in ATP generation, loss of mitochondrial membrane potential and increase in mitochondrial DNA copy number|ATP|ATP|compound|116|CHEBI:30616|mitochondrial DNA location|mitochondrial DNA|anatomy|189|C1819717
64|Moreover, maternal exposure to CS led to mitochondrial ultrastructure changes, mitochondrial swelling, reduction in ATP generation, loss of mitochondrial membrane potential and increase in mitochondrial DNA copy number|ATP|ATP|compound|116|CHEBI:30616|Condylion superiore|CS|anatomy|31|C4085345
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|WD repeat and FYVE domain-containing 3|WD repeat and FYVE domain-containing 3|gene|0|NCBIGene:23001|intellectual disability|intellectual disability|disease|109|mesh:D008607
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|WD repeat and FYVE domain-containing 3|WD repeat and FYVE domain-containing 3|gene|0|NCBIGene:23001|developmental delay|developmental delay|disease|134|mesh:D002658
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|WD repeat and FYVE domain-containing 3|WD repeat and FYVE domain-containing 3|gene|0|NCBIGene:23001|autism|autism|disease|158|omim:209850
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|WD repeat and FYVE domain-containing 3|WD repeat and FYVE domain-containing 3|gene|0|NCBIGene:23001|Autophagy|Autophagy|physiology|61|C0004391
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|WDFY3|WDFY3|gene|40|NCBIGene:23001|intellectual disability|intellectual disability|disease|109|mesh:D008607
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|WDFY3|WDFY3|gene|40|NCBIGene:23001|developmental delay|developmental delay|disease|134|mesh:D002658
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|WDFY3|WDFY3|gene|40|NCBIGene:23001|autism|autism|disease|158|omim:209850
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|WDFY3|WDFY3|gene|40|NCBIGene:23001|Autophagy|Autophagy|physiology|61|C0004391
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|Autophagy-Linked FYVE|Autophagy-Linked FYVE|gene|61|NCBIGene:23001|intellectual disability|intellectual disability|disease|109|mesh:D008607
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|Autophagy-Linked FYVE|Autophagy-Linked FYVE|gene|61|NCBIGene:23001|developmental delay|developmental delay|disease|134|mesh:D002658
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|Autophagy-Linked FYVE|Autophagy-Linked FYVE|gene|61|NCBIGene:23001|autism|autism|disease|158|omim:209850
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|Alfy|Alfy|gene|86|NCBIGene:23001|intellectual disability|intellectual disability|disease|109|mesh:D008607
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|Alfy|Alfy|gene|86|NCBIGene:23001|developmental delay|developmental delay|disease|134|mesh:D002658
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|Alfy|Alfy|gene|86|NCBIGene:23001|autism|autism|disease|158|omim:209850
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|Alfy|Alfy|gene|86|NCBIGene:23001|Autophagy|Autophagy|physiology|61|C0004391
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|intellectual disability|intellectual disability|disease|109|mesh:D008607|developmental delay|developmental delay|disease|134|mesh:D002658
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|intellectual disability|intellectual disability|disease|109|mesh:D008607|autism|autism|disease|158|omim:209850
65|WD repeat and FYVE domain-containing 3 (WDFY3; also known as Autophagy-Linked FYVE or Alfy) is an identified intellectual disability, developmental delay and autism risk gene|developmental delay|developmental delay|disease|134|mesh:D002658|autism|autism|disease|158|omim:209850
65|This gene encodes for a scaffolding protein that is expressed in both the developing and adult central nervous system and required for autophagy and aggrephagy with yet unexplored roles in mitophagy|scaffolding protein|scaffolding protein|gene|24|NCBIGene:1951|Mitophagy|mitophagy|physiology|189|C1820119
65|This gene encodes for a scaffolding protein that is expressed in both the developing and adult central nervous system and required for autophagy and aggrephagy with yet unexplored roles in mitophagy|scaffolding protein|scaffolding protein|gene|24|NCBIGene:1951|Central Nervous System|central nervous system|anatomy|95|C3714787
65|This gene encodes for a scaffolding protein that is expressed in both the developing and adult central nervous system and required for autophagy and aggrephagy with yet unexplored roles in mitophagy|scaffolding protein|scaffolding protein|gene|24|NCBIGene:1951|Autophagy|autophagy|physiology|135|C0004391
65|This gene encodes for a scaffolding protein that is expressed in both the developing and adult central nervous system and required for autophagy and aggrephagy with yet unexplored roles in mitophagy|scaffolding protein|scaffolding protein|gene|24|NCBIGene:1951|Aggrephagy|aggrephagy|physiology|149|C3271453
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3|Wdfy3|gene|123|NCBIGene:23001|neurodevelopmental anomalies|neurodevelopmental anomalies|disease|231|mesh:D065886
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3|Wdfy3|gene|123|NCBIGene:23001|Mitochondria|mitochondrial|anatomy|11|C0026237
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3|Wdfy3|gene|123|NCBIGene:23001|trafficking|trafficking|physiology|25|C0599896
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3|Wdfy3|gene|123|NCBIGene:23001|Bioenergetics|bioenergetics|physiology|138|C0005486
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3|Wdfy3|gene|123|NCBIGene:23001|Neuronal Plasticity|synaptic plasticity|physiology|80|C0027880
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3|Wdfy3|gene|123|NCBIGene:23001|Brain|brain|anatomy|132|C0006104
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3+/lacZ|Wdfy3+/lacZ|gene|161|NCBIGene:23001|neurodevelopmental anomalies|neurodevelopmental anomalies|disease|231|mesh:D065886
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3+/lacZ|Wdfy3+/lacZ|gene|161|NCBIGene:23001|Mitochondria|mitochondrial|anatomy|11|C0026237
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3+/lacZ|Wdfy3+/lacZ|gene|161|NCBIGene:23001|trafficking|trafficking|physiology|25|C0599896
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3+/lacZ|Wdfy3+/lacZ|gene|161|NCBIGene:23001|Bioenergetics|bioenergetics|physiology|138|C0005486
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3+/lacZ|Wdfy3+/lacZ|gene|161|NCBIGene:23001|Neuronal Plasticity|synaptic plasticity|physiology|80|C0027880
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3+/lacZ|Wdfy3+/lacZ|gene|161|NCBIGene:23001|Brain|brain|anatomy|132|C0006104
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3 mutant|Wdfy3 mutant|gene|194|NCBIGene:23001|neurodevelopmental anomalies|neurodevelopmental anomalies|disease|231|mesh:D065886
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3 mutant|Wdfy3 mutant|gene|194|NCBIGene:23001|Mitochondria|mitochondrial|anatomy|11|C0026237
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3 mutant|Wdfy3 mutant|gene|194|NCBIGene:23001|trafficking|trafficking|physiology|25|C0599896
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3 mutant|Wdfy3 mutant|gene|194|NCBIGene:23001|Bioenergetics|bioenergetics|physiology|138|C0005486
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3 mutant|Wdfy3 mutant|gene|194|NCBIGene:23001|Neuronal Plasticity|synaptic plasticity|physiology|80|C0027880
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|Wdfy3 mutant|Wdfy3 mutant|gene|194|NCBIGene:23001|Brain|brain|anatomy|132|C0006104
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|neurodevelopmental anomalies|neurodevelopmental anomalies|disease|231|mesh:D065886|Mitochondria|mitochondrial|anatomy|11|C0026237
65|Given that mitochondrial trafficking, dynamics and remodeling have key roles in synaptic plasticity, we tested the role of Wdfy3 on brain bioenergetics by using Wdfy3+/lacZ mice, the only known Wdfy3 mutant animal model with overt neurodevelopmental anomalies that survive to adulthood|neurodevelopmental anomalies|neurodevelopmental anomalies|disease|231|mesh:D065886|Brain|brain|anatomy|132|C0006104
65|We found that Wdfy3 is required for sustaining brain bioenergetics and morphology via mitophagy|Wdfy3|Wdfy3|gene|14|NCBIGene:23001|Bioenergetics|bioenergetics|physiology|53|C0005486
65|We found that Wdfy3 is required for sustaining brain bioenergetics and morphology via mitophagy|Wdfy3|Wdfy3|gene|14|NCBIGene:23001|Brain|brain|anatomy|47|C0006104
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|semaphorin|semaphorin|gene|218|NCBIGene:7869|Robo|Robo|gene|230|NCBIGene:6091
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|semaphorin|semaphorin|gene|218|NCBIGene:7869|L1cam|L1cam|gene|236|NCBIGene:3897
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|semaphorin|semaphorin|gene|218|NCBIGene:7869|Eph|Eph|gene|246|NCBIGene:2041
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|semaphorin|semaphorin|gene|218|NCBIGene:7869|ephrin|ephrin|gene|250|NCBIGene:1942
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|semaphorin|semaphorin|gene|218|NCBIGene:7869|mitochondrial transport|mitochondrial transport|physiology|172|C0678851
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|semaphorin|semaphorin|gene|218|NCBIGene:7869|Axon Guidance|axon guidance|physiology|200|C2984268
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|semaphorin|semaphorin|gene|218|NCBIGene:7869|Signal Transduction|signaling|physiology|257|C0037083
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|semaphorin|semaphorin|gene|218|NCBIGene:7869|Mitophagy|mitophagy|physiology|161|C1820119
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|semaphorin|semaphorin|gene|218|NCBIGene:7869|Adrenal Cortex|cortical|anatomy|82|C0001613
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Robo|Robo|gene|230|NCBIGene:6091|L1cam|L1cam|gene|236|NCBIGene:3897
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Robo|Robo|gene|230|NCBIGene:6091|Eph|Eph|gene|246|NCBIGene:2041
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Robo|Robo|gene|230|NCBIGene:6091|ephrin|ephrin|gene|250|NCBIGene:1942
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Robo|Robo|gene|230|NCBIGene:6091|mitochondrial transport|mitochondrial transport|physiology|172|C0678851
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Robo|Robo|gene|230|NCBIGene:6091|Axon Guidance|axon guidance|physiology|200|C2984268
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Robo|Robo|gene|230|NCBIGene:6091|Signal Transduction|signaling|physiology|257|C0037083
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Robo|Robo|gene|230|NCBIGene:6091|Mitophagy|mitophagy|physiology|161|C1820119
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Robo|Robo|gene|230|NCBIGene:6091|Adrenal Cortex|cortical|anatomy|82|C0001613
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|L1cam|L1cam|gene|236|NCBIGene:3897|Eph|Eph|gene|246|NCBIGene:2041
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|L1cam|L1cam|gene|236|NCBIGene:3897|ephrin|ephrin|gene|250|NCBIGene:1942
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|L1cam|L1cam|gene|236|NCBIGene:3897|mitochondrial transport|mitochondrial transport|physiology|172|C0678851
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|L1cam|L1cam|gene|236|NCBIGene:3897|Axon Guidance|axon guidance|physiology|200|C2984268
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|L1cam|L1cam|gene|236|NCBIGene:3897|Signal Transduction|signaling|physiology|257|C0037083
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|L1cam|L1cam|gene|236|NCBIGene:3897|Mitophagy|mitophagy|physiology|161|C1820119
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|L1cam|L1cam|gene|236|NCBIGene:3897|Adrenal Cortex|cortical|anatomy|82|C0001613
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Eph|Eph|gene|246|NCBIGene:2041|ephrin|ephrin|gene|250|NCBIGene:1942
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Eph|Eph|gene|246|NCBIGene:2041|mitochondrial transport|mitochondrial transport|physiology|172|C0678851
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Eph|Eph|gene|246|NCBIGene:2041|Axon Guidance|axon guidance|physiology|200|C2984268
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Eph|Eph|gene|246|NCBIGene:2041|Signal Transduction|signaling|physiology|257|C0037083
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Eph|Eph|gene|246|NCBIGene:2041|Mitophagy|mitophagy|physiology|161|C1820119
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|Eph|Eph|gene|246|NCBIGene:2041|Adrenal Cortex|cortical|anatomy|82|C0001613
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|ephrin|ephrin|gene|250|NCBIGene:1942|mitochondrial transport|mitochondrial transport|physiology|172|C0678851
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|ephrin|ephrin|gene|250|NCBIGene:1942|Axon Guidance|axon guidance|physiology|200|C2984268
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|ephrin|ephrin|gene|250|NCBIGene:1942|Signal Transduction|signaling|physiology|257|C0037083
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|ephrin|ephrin|gene|250|NCBIGene:1942|Mitophagy|mitophagy|physiology|161|C1820119
65|These observations, extended  through proteomic analysis of mitochondria-enriched cortical fractions, showed significant enrichment for pathways associated with mitophagy, mitochondrial transport and axon guidance via semaphorin, Robo, L1cam and Eph-ephrin signaling|ephrin|ephrin|gene|250|NCBIGene:1942|Adrenal Cortex|cortical|anatomy|82|C0001613
65|Collectively, our findings support a critical role for Wdfy3 in mitochondrial homeostasis with implications for neuron differentiation, neurodevelopment and age-dependent neurodegeneration|Wdfy3|Wdfy3|gene|55|NCBIGene:23001|age-dependent neurodegeneration|age-dependent neurodegeneration|disease|157|mesh:D019636
65|Collectively, our findings support a critical role for Wdfy3 in mitochondrial homeostasis with implications for neuron differentiation, neurodevelopment and age-dependent neurodegeneration|Wdfy3|Wdfy3|gene|55|NCBIGene:23001|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|18|C2926606
65|Collectively, our findings support a critical role for Wdfy3 in mitochondrial homeostasis with implications for neuron differentiation, neurodevelopment and age-dependent neurodegeneration|Wdfy3|Wdfy3|gene|55|NCBIGene:23001|neural cell differentiation|neuron differentiation|physiology|112|C2755962
65|Collectively, our findings support a critical role for Wdfy3 in mitochondrial homeostasis with implications for neuron differentiation, neurodevelopment and age-dependent neurodegeneration|Wdfy3|Wdfy3|gene|55|NCBIGene:23001|neurodevelopment|neurodevelopment|physiology|136|C0599855
65|Collectively, our findings support a critical role for Wdfy3 in mitochondrial homeostasis with implications for neuron differentiation, neurodevelopment and age-dependent neurodegeneration|Wdfy3|Wdfy3|gene|55|NCBIGene:23001|Age|age|physiology|157|C0001779
65|Collectively, our findings support a critical role for Wdfy3 in mitochondrial homeostasis with implications for neuron differentiation, neurodevelopment and age-dependent neurodegeneration|Wdfy3|Wdfy3|gene|55|NCBIGene:23001|Mitochondria|mitochondrial|anatomy|64|C0026237
65|Collectively, our findings support a critical role for Wdfy3 in mitochondrial homeostasis with implications for neuron differentiation, neurodevelopment and age-dependent neurodegeneration|age-dependent neurodegeneration|age-dependent neurodegeneration|disease|157|mesh:D019636|Mitochondria|mitochondrial|anatomy|64|C0026237
66|Preterm infants often require prolonged oxygen supplementation and are at high risk of neurodevelopmental impairment|oxygen|oxygen|compound|40|mesh:D010100|neurodevelopmental impairment|neurodevelopmental impairment|disease|87|mesh:D065886
66|We evaluated C57BL/6 mouse pups at P14, exposed to either 85% oxygen or air from P2 to 14|oxygen|oxygen|compound|62|mesh:D010100|Bone structure of middle phalanx|P2|anatomy|81|C3669031
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mGLU7|mGLU7|gene|32|NCBIGene:2917|TrkB|TrkB|gene|40|NCBIGene:4915
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mGLU7|mGLU7|gene|32|NCBIGene:2917|AKT|AKT|gene|46|NCBIGene:207
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mGLU7|mGLU7|gene|32|NCBIGene:2917|ERK2|ERK2|gene|51|NCBIGene:5594
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mGLU7|mGLU7|gene|32|NCBIGene:2917|mTORC1|mTORC1|gene|57|NCBIGene:2475
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mGLU7|mGLU7|gene|32|NCBIGene:2917|RPS6|RPS6|gene|65|NCBIGene:6194
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mGLU7|mGLU7|gene|32|NCBIGene:2917|EIF4E|EIF4E|gene|75|NCBIGene:1977
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mGLU7|mGLU7|gene|32|NCBIGene:2917|GABAA receptor|GABAA receptor|gene|119|NCBIGene:2550
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mGLU7|mGLU7|gene|32|NCBIGene:2917|PTEN proteins|PTEN proteins|gene|138|NCBIGene:5728
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mGLU7|mGLU7|gene|32|NCBIGene:2917|MAP kinase activity|ERK2|physiology|51|C1150579
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mGLU7|mGLU7|gene|32|NCBIGene:2917|TOR complex 1|mTORC1|anatomy|57|C3152111
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mGLU7|mGLU7|gene|32|NCBIGene:2917|Hippocampus (Brain)|hippocampal|anatomy|20|C0019564
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|TrkB|TrkB|gene|40|NCBIGene:4915|AKT|AKT|gene|46|NCBIGene:207
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|TrkB|TrkB|gene|40|NCBIGene:4915|ERK2|ERK2|gene|51|NCBIGene:5594
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|TrkB|TrkB|gene|40|NCBIGene:4915|mTORC1|mTORC1|gene|57|NCBIGene:2475
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|TrkB|TrkB|gene|40|NCBIGene:4915|RPS6|RPS6|gene|65|NCBIGene:6194
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|TrkB|TrkB|gene|40|NCBIGene:4915|EIF4E|EIF4E|gene|75|NCBIGene:1977
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|TrkB|TrkB|gene|40|NCBIGene:4915|GABAA receptor|GABAA receptor|gene|119|NCBIGene:2550
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|TrkB|TrkB|gene|40|NCBIGene:4915|PTEN proteins|PTEN proteins|gene|138|NCBIGene:5728
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|TrkB|TrkB|gene|40|NCBIGene:4915|MAP kinase activity|ERK2|physiology|51|C1150579
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|TrkB|TrkB|gene|40|NCBIGene:4915|TOR complex 1|mTORC1|anatomy|57|C3152111
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|TrkB|TrkB|gene|40|NCBIGene:4915|Hippocampus (Brain)|hippocampal|anatomy|20|C0019564
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|AKT|AKT|gene|46|NCBIGene:207|ERK2|ERK2|gene|51|NCBIGene:5594
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|AKT|AKT|gene|46|NCBIGene:207|mTORC1|mTORC1|gene|57|NCBIGene:2475
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|AKT|AKT|gene|46|NCBIGene:207|RPS6|RPS6|gene|65|NCBIGene:6194
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|AKT|AKT|gene|46|NCBIGene:207|EIF4E|EIF4E|gene|75|NCBIGene:1977
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|AKT|AKT|gene|46|NCBIGene:207|GABAA receptor|GABAA receptor|gene|119|NCBIGene:2550
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|AKT|AKT|gene|46|NCBIGene:207|PTEN proteins|PTEN proteins|gene|138|NCBIGene:5728
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|AKT|AKT|gene|46|NCBIGene:207|MAP kinase activity|ERK2|physiology|51|C1150579
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|AKT|AKT|gene|46|NCBIGene:207|TOR complex 1|mTORC1|anatomy|57|C3152111
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|AKT|AKT|gene|46|NCBIGene:207|Hippocampus (Brain)|hippocampal|anatomy|20|C0019564
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|ERK2|ERK2|gene|51|NCBIGene:5594|mTORC1|mTORC1|gene|57|NCBIGene:2475
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|ERK2|ERK2|gene|51|NCBIGene:5594|RPS6|RPS6|gene|65|NCBIGene:6194
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|ERK2|ERK2|gene|51|NCBIGene:5594|EIF4E|EIF4E|gene|75|NCBIGene:1977
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|ERK2|ERK2|gene|51|NCBIGene:5594|GABAA receptor|GABAA receptor|gene|119|NCBIGene:2550
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|ERK2|ERK2|gene|51|NCBIGene:5594|PTEN proteins|PTEN proteins|gene|138|NCBIGene:5728
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|ERK2|ERK2|gene|51|NCBIGene:5594|TOR complex 1|mTORC1|anatomy|57|C3152111
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|ERK2|ERK2|gene|51|NCBIGene:5594|Hippocampus (Brain)|hippocampal|anatomy|20|C0019564
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mTORC1|mTORC1|gene|57|NCBIGene:2475|RPS6|RPS6|gene|65|NCBIGene:6194
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mTORC1|mTORC1|gene|57|NCBIGene:2475|EIF4E|EIF4E|gene|75|NCBIGene:1977
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mTORC1|mTORC1|gene|57|NCBIGene:2475|GABAA receptor|GABAA receptor|gene|119|NCBIGene:2550
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mTORC1|mTORC1|gene|57|NCBIGene:2475|PTEN proteins|PTEN proteins|gene|138|NCBIGene:5728
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mTORC1|mTORC1|gene|57|NCBIGene:2475|MAP kinase activity|ERK2|physiology|51|C1150579
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|mTORC1|mTORC1|gene|57|NCBIGene:2475|Hippocampus (Brain)|hippocampal|anatomy|20|C0019564
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|RPS6|RPS6|gene|65|NCBIGene:6194|EIF4E|EIF4E|gene|75|NCBIGene:1977
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|RPS6|RPS6|gene|65|NCBIGene:6194|GABAA receptor|GABAA receptor|gene|119|NCBIGene:2550
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|RPS6|RPS6|gene|65|NCBIGene:6194|PTEN proteins|PTEN proteins|gene|138|NCBIGene:5728
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|RPS6|RPS6|gene|65|NCBIGene:6194|MAP kinase activity|ERK2|physiology|51|C1150579
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|RPS6|RPS6|gene|65|NCBIGene:6194|TOR complex 1|mTORC1|anatomy|57|C3152111
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|RPS6|RPS6|gene|65|NCBIGene:6194|Hippocampus (Brain)|hippocampal|anatomy|20|C0019564
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|EIF4E|EIF4E|gene|75|NCBIGene:1977|GABAA receptor|GABAA receptor|gene|119|NCBIGene:2550
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|EIF4E|EIF4E|gene|75|NCBIGene:1977|PTEN proteins|PTEN proteins|gene|138|NCBIGene:5728
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|EIF4E|EIF4E|gene|75|NCBIGene:1977|MAP kinase activity|ERK2|physiology|51|C1150579
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|EIF4E|EIF4E|gene|75|NCBIGene:1977|TOR complex 1|mTORC1|anatomy|57|C3152111
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|EIF4E|EIF4E|gene|75|NCBIGene:1977|Hippocampus (Brain)|hippocampal|anatomy|20|C0019564
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|GABAA receptor|GABAA receptor|gene|119|NCBIGene:2550|PTEN proteins|PTEN proteins|gene|138|NCBIGene:5728
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|GABAA receptor|GABAA receptor|gene|119|NCBIGene:2550|MAP kinase activity|ERK2|physiology|51|C1150579
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|GABAA receptor|GABAA receptor|gene|119|NCBIGene:2550|TOR complex 1|mTORC1|anatomy|57|C3152111
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|GABAA receptor|GABAA receptor|gene|119|NCBIGene:2550|Hippocampus (Brain)|hippocampal|anatomy|20|C0019564
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|PTEN proteins|PTEN proteins|gene|138|NCBIGene:5728|MAP kinase activity|ERK2|physiology|51|C1150579
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|PTEN proteins|PTEN proteins|gene|138|NCBIGene:5728|TOR complex 1|mTORC1|anatomy|57|C3152111
66|Hyperoxia decreased hippocampal mGLU7,  TrkB, AKT, ERK2, mTORC1, RPS6, and EIF4E and increased α3, α5, and ɤ2 subunits of GABAA receptor and PTEN proteins, although changes in gene expression were not always concordant|PTEN proteins|PTEN proteins|gene|138|NCBIGene:5728|Hippocampus (Brain)|hippocampal|anatomy|20|C0019564
66|In conclusion, supraphysiological oxygen exposure reduced proteins necessary for hippocampus-dependent memory formation and may adversely impact hippocampal mitochondrial function and global protein synthesis|oxygen|oxygen|compound|34|mesh:D010100|Hippocampus (Brain)|hippocampus|anatomy|81|C0019564
66|These early hippocampal changes may account for memory deficits seen in preterm survivors following prolonged oxygen supplementation|oxygen|oxygen|compound|110|mesh:D010100|Hippocampus (Brain)|hippocampal|anatomy|12|C0019564
67|Hence we examined the hypothesis if inulin (IN) supplements during pregnancy in rats possess the potential to alleviate brain oxidative response and mitochondrial deficits employing a developmental model of rotenone (ROT) neurotoxicity|inulin|inulin|gene|36|NCBIGene:84844|mitochondrial deficits|mitochondrial deficits|disease|149|mesh:D028361
67|Hence we examined the hypothesis if inulin (IN) supplements during pregnancy in rats possess the potential to alleviate brain oxidative response and mitochondrial deficits employing a developmental model of rotenone (ROT) neurotoxicity|rotenone|rotenone|compound|207|mesh:D012402|inulin|inulin|gene|36|NCBIGene:84844
67|Hence we examined the hypothesis if inulin (IN) supplements during pregnancy in rats possess the potential to alleviate brain oxidative response and mitochondrial deficits employing a developmental model of rotenone (ROT) neurotoxicity|ROT|ROT|compound|217|mesh:C010804|inulin|inulin|gene|36|NCBIGene:84844
67|Hence we examined the hypothesis if inulin (IN) supplements during pregnancy in rats possess the potential to alleviate brain oxidative response and mitochondrial deficits employing a developmental model of rotenone (ROT) neurotoxicity|inulin|inulin|gene|36|NCBIGene:84844|Response (communication)|response|physiology|136|C2911692
67|Hence we examined the hypothesis if inulin (IN) supplements during pregnancy in rats possess the potential to alleviate brain oxidative response and mitochondrial deficits employing a developmental model of rotenone (ROT) neurotoxicity|inulin|inulin|gene|36|NCBIGene:84844|Pregnancy|pregnancy|physiology|67|C0032961
67|Hence we examined the hypothesis if inulin (IN) supplements during pregnancy in rats possess the potential to alleviate brain oxidative response and mitochondrial deficits employing a developmental model of rotenone (ROT) neurotoxicity|inulin|inulin|gene|36|NCBIGene:84844|Mitochondria|mitochondrial|anatomy|149|C0026237
67|Hence we examined the hypothesis if inulin (IN) supplements during pregnancy in rats possess the potential to alleviate brain oxidative response and mitochondrial deficits employing a developmental model of rotenone (ROT) neurotoxicity|rotenone|rotenone|compound|207|mesh:D012402|mitochondrial deficits|mitochondrial deficits|disease|149|mesh:D028361
67|Hence we examined the hypothesis if inulin (IN) supplements during pregnancy in rats possess the potential to alleviate brain oxidative response and mitochondrial deficits employing a developmental model of rotenone (ROT) neurotoxicity|ROT|ROT|compound|217|mesh:C010804|mitochondrial deficits|mitochondrial deficits|disease|149|mesh:D028361
67|Hence we examined the hypothesis if inulin (IN) supplements during pregnancy in rats possess the potential to alleviate brain oxidative response and mitochondrial deficits employing a developmental model of rotenone (ROT) neurotoxicity|rotenone|rotenone|compound|207|mesh:D012402|ROT|ROT|compound|217|mesh:C010804
67|Hence we examined the hypothesis if inulin (IN) supplements during pregnancy in rats possess the potential to alleviate brain oxidative response and mitochondrial deficits employing a developmental model of rotenone (ROT) neurotoxicity|rotenone|rotenone|compound|207|mesh:D012402|Mitochondria|mitochondrial|anatomy|149|C0026237
67|Hence we examined the hypothesis if inulin (IN) supplements during pregnancy in rats possess the potential to alleviate brain oxidative response and mitochondrial deficits employing a developmental model of rotenone (ROT) neurotoxicity|ROT|ROT|compound|217|mesh:C010804|Mitochondria|mitochondrial|anatomy|149|C0026237
67|Initially, pregnant Sprague-Dawley rats were gavaged during gestational days (GDs) 6-19 with 0 (control), 10 (low), 30 (mid) or 50 (high) mg/kg bw/day of ROT to recapitulate developmental effects on general fetotoxicity (assessed by the number of fetuses, fetal body and placental weights), markers of oxidative stress and cholinergic activities in maternal brain regions and whole fetal-brain|ROT|ROT|compound|154|mesh:C010804|Adult human body|body|anatomy|262|C4082212
67|IN supplements increased maternal cecal bacterial numbers that significantly corresponded with improved exploratory-related behavior among ROT administered rats|ROT|ROT|compound|139|mesh:C010804|Cecum|cecal|anatomy|34|C0007531
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|oxygen|oxygen|compound|57|mesh:D010100|cholinesterase|cholinesterase|gene|127|NCBIGene:590
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|oxygen|oxygen|compound|57|mesh:D010100|Cerebellum|cerebellum|anatomy|186|C0007765
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|oxygen|oxygen|compound|57|mesh:D010100|Cerebral cortex|cortex|anatomy|178|C0007776
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|oxygen|oxygen|compound|57|mesh:D010100|Corpus striatum structure|striatum|anatomy|202|C0010097
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|oxygen|oxygen|compound|57|mesh:D010100|Fetal brain|fetal brain|anatomy|216|C0440731
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|oxygen|oxygen|compound|57|mesh:D010100|Brain region|brain regions|anatomy|163|C1273723
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|cholinesterase|cholinesterase|gene|127|NCBIGene:590|Cerebellum|cerebellum|anatomy|186|C0007765
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|cholinesterase|cholinesterase|gene|127|NCBIGene:590|Cerebral cortex|cortex|anatomy|178|C0007776
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|cholinesterase|cholinesterase|gene|127|NCBIGene:590|Corpus striatum structure|striatum|anatomy|202|C0010097
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|cholinesterase|cholinesterase|gene|127|NCBIGene:590|Fetal brain|fetal brain|anatomy|216|C0440731
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|cholinesterase|cholinesterase|gene|127|NCBIGene:590|Biological Markers|biomarkers|physiology|111|C0005516
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|cholinesterase|cholinesterase|gene|127|NCBIGene:590|Lipid Peroxidation|lipid peroxidation|physiology|92|C0023775
67|IN diminished gestational ROT-induced increased reactive oxygen species levels, protein and lipid peroxidation biomarkers, and cholinesterase activity in maternal brain regions (cortex, cerebellum, and striatum) and fetal brain|cholinesterase|cholinesterase|gene|127|NCBIGene:590|Brain region|brain regions|anatomy|163|C1273723
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|ROT|ROT|compound|89|mesh:C010804|NADH|NADH|compound|114|mesh:D009243
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|ROT|ROT|compound|89|mesh:C010804|NADH cytochrome c oxidoreductase|NADH cytochrome c oxidoreductase|gene|114|NCBIGene:4717
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|ROT|ROT|compound|89|mesh:C010804|ATPase|ATPase|gene|151|NCBIGene:1769
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|ROT|ROT|compound|89|mesh:C010804|Cerebral cortex|cortex|anatomy|26|C0007776
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|ROT|ROT|compound|89|mesh:C010804|Mitochondria|mitochondrial|anatomy|34|C0026237
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|NADH|NADH|compound|114|mesh:D009243|ATPase|ATPase|gene|151|NCBIGene:1769
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|NADH|NADH|compound|114|mesh:D009243|Cerebral cortex|cortex|anatomy|26|C0007776
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|NADH|NADH|compound|114|mesh:D009243|Mitochondria|mitochondrial|anatomy|34|C0026237
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|NADH cytochrome c oxidoreductase|NADH cytochrome c oxidoreductase|gene|114|NCBIGene:4717|ATPase|ATPase|gene|151|NCBIGene:1769
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|NADH cytochrome c oxidoreductase|NADH cytochrome c oxidoreductase|gene|114|NCBIGene:4717|adenosinetriphosphatase activity|ATPase activities|physiology|151|C1148926
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|NADH cytochrome c oxidoreductase|NADH cytochrome c oxidoreductase|gene|114|NCBIGene:4717|Cerebral cortex|cortex|anatomy|26|C0007776
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|NADH cytochrome c oxidoreductase|NADH cytochrome c oxidoreductase|gene|114|NCBIGene:4717|Mitochondria|mitochondrial|anatomy|34|C0026237
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|ATPase|ATPase|gene|151|NCBIGene:1769|Cerebral cortex|cortex|anatomy|26|C0007776
67|Moreover, in the maternal cortex, mitochondrial assessment revealed IN protected against ROT-induced reduction in NADH cytochrome c oxidoreductase and ATPase activities|ATPase|ATPase|gene|151|NCBIGene:1769|Mitochondria|mitochondrial|anatomy|34|C0026237
68|Mitochondria-associated endoplasmic reticulum membranes (MAMs) regulate important cellular functions including calcium signaling, bioenergetics, and apoptosis during neurodevelopment and carcinogenesis, but its function in male reproduction and spermatogenesis remains enigmatic because the field lacks a complete understanding of the proteome within testis MAMs|calcium|calcium|compound|111|mesh:D002118|Endoplasmic reticulum, membrane|endoplasmic reticulum membranes|anatomy|24|C0230770
68|Mitochondria-associated endoplasmic reticulum membranes (MAMs) regulate important cellular functions including calcium signaling, bioenergetics, and apoptosis during neurodevelopment and carcinogenesis, but its function in male reproduction and spermatogenesis remains enigmatic because the field lacks a complete understanding of the proteome within testis MAMs|calcium|calcium|compound|111|mesh:D002118|Tissue membrane|MAMs|anatomy|358|C0025255
68|Mitochondria-associated endoplasmic reticulum membranes (MAMs) regulate important cellular functions including calcium signaling, bioenergetics, and apoptosis during neurodevelopment and carcinogenesis, but its function in male reproduction and spermatogenesis remains enigmatic because the field lacks a complete understanding of the proteome within testis MAMs|calcium|calcium|compound|111|mesh:D002118|Testis|testis|anatomy|351|C0039597
68|To better understand the biological processes and molecular functions of MAM in testes, a global mass spectrometry-based proteomic evaluation of MAM proteins from human and mouse testes are reported here, respectively|MAM|MAM|compound|73|mesh:C014659|MAM proteins|MAM proteins|gene|145|NCBIGene:6445
68|To better understand the biological processes and molecular functions of MAM in testes, a global mass spectrometry-based proteomic evaluation of MAM proteins from human and mouse testes are reported here, respectively|MAM|MAM|compound|73|mesh:C014659|Inferior Colliculus|testes|anatomy|80|C0021358
68|To better understand the biological processes and molecular functions of MAM in testes, a global mass spectrometry-based proteomic evaluation of MAM proteins from human and mouse testes are reported here, respectively|MAM|MAM|compound|73|mesh:C014659|Mouse Testis|mouse testes|anatomy|173|C1515315
68|To better understand the biological processes and molecular functions of MAM in testes, a global mass spectrometry-based proteomic evaluation of MAM proteins from human and mouse testes are reported here, respectively|MAM proteins|MAM proteins|gene|145|NCBIGene:6445|Comprehension|understand|physiology|10|C0162340
68|To better understand the biological processes and molecular functions of MAM in testes, a global mass spectrometry-based proteomic evaluation of MAM proteins from human and mouse testes are reported here, respectively|MAM proteins|MAM proteins|gene|145|NCBIGene:6445|Inferior Colliculus|testes|anatomy|80|C0021358
68|To better understand the biological processes and molecular functions of MAM in testes, a global mass spectrometry-based proteomic evaluation of MAM proteins from human and mouse testes are reported here, respectively|MAM proteins|MAM proteins|gene|145|NCBIGene:6445|Mouse Testis|mouse testes|anatomy|173|C1515315
68|To better understand the biological processes and molecular functions of MAM in testes, a global mass spectrometry-based proteomic evaluation of MAM proteins from human and mouse testes are reported here, respectively|MAM proteins|MAM proteins|gene|145|NCBIGene:6445|molecular_function|molecular functions|physiology|50|C1148560
68|To better understand the biological processes and molecular functions of MAM in testes, a global mass spectrometry-based proteomic evaluation of MAM proteins from human and mouse testes are reported here, respectively|MAM proteins|MAM proteins|gene|145|NCBIGene:6445|ER-mitochondrion membrane contact site|MAM|anatomy|73|C2752526
68|The evaluation and analysis showed that the components of MAM were highly conserved not only between different species (human and mouse) but also between different tissues (testes and brains)|MAM|MAM|compound|58|mesh:C014659|Brain|brains|anatomy|184|C0006104
68|The evaluation and analysis showed that the components of MAM were highly conserved not only between different species (human and mouse) but also between different tissues (testes and brains)|MAM|MAM|compound|58|mesh:C014659|Inferior Colliculus|testes|anatomy|173|C0021358
68|The evaluation and analysis showed that the components of MAM were highly conserved not only between different species (human and mouse) but also between different tissues (testes and brains)|MAM|MAM|compound|58|mesh:C014659|Body tissue|tissues|anatomy|164|C0040300
68|Bioinformatics interrogation of these MAM protein catalogues uncovered that 815 new potential linkages specifically existed in mouse testes compared with mouse brains|MAM protein|MAM protein|gene|38|NCBIGene:6445|CNS - Brain (MMHCC)|mouse brains|anatomy|154|C1521713
68|Bioinformatics interrogation of these MAM protein catalogues uncovered that 815 new potential linkages specifically existed in mouse testes compared with mouse brains|MAM protein|MAM protein|gene|38|NCBIGene:6445|Mouse Testis|mouse testes|anatomy|127|C1515315
68|Bioinformatics interrogation of these MAM protein catalogues uncovered that 815 new potential linkages specifically existed in mouse testes compared with mouse brains|MAM protein|MAM protein|gene|38|NCBIGene:6445|genetic linkage|linkages|physiology|94|C0023745
68|Furthermore, functional analysis revealed that testis-specific MAM proteins were related to spermatogenesis, male gamete generation, as well as sexual reproduction|testis-specific MAM proteins|testis-specific MAM proteins|gene|47|NCBIGene:6445|male gamete generation|male gamete generation|physiology|109|C1326808
68|Furthermore, functional analysis revealed that testis-specific MAM proteins were related to spermatogenesis, male gamete generation, as well as sexual reproduction|testis-specific MAM proteins|testis-specific MAM proteins|gene|47|NCBIGene:6445|sexual reproduction|sexual reproduction|physiology|144|C0871354
68|Furthermore, functional analysis revealed that testis-specific MAM proteins were related to spermatogenesis, male gamete generation, as well as sexual reproduction|testis-specific MAM proteins|testis-specific MAM proteins|gene|47|NCBIGene:6445|Spermatogenesis|spermatogenesis|physiology|92|C0037864
68|The data identified, for the first time, numerous MAM proteins in mouse and human testes, which provide a possibility to define the relationship between testis MAM proteins and reproductive diseases|MAM proteins|MAM proteins|gene|50|NCBIGene:6445|reproductive diseases|reproductive diseases|disease|177|mesh:D005831
68|The data identified, for the first time, numerous MAM proteins in mouse and human testes, which provide a possibility to define the relationship between testis MAM proteins and reproductive diseases|MAM proteins|MAM proteins|gene|50|NCBIGene:6445|Inferior Colliculus|testes|anatomy|82|C0021358
68|The data identified, for the first time, numerous MAM proteins in mouse and human testes, which provide a possibility to define the relationship between testis MAM proteins and reproductive diseases|testis MAM proteins|testis MAM proteins|gene|153|NCBIGene:6445|reproductive diseases|reproductive diseases|disease|177|mesh:D005831
68|The data identified, for the first time, numerous MAM proteins in mouse and human testes, which provide a possibility to define the relationship between testis MAM proteins and reproductive diseases|testis MAM proteins|testis MAM proteins|gene|153|NCBIGene:6445|Inferior Colliculus|testes|anatomy|82|C0021358
68|The data identified, for the first time, numerous MAM proteins in mouse and human testes, which provide a possibility to define the relationship between testis MAM proteins and reproductive diseases|reproductive diseases|reproductive diseases|disease|177|mesh:D005831|Inferior Colliculus|testes|anatomy|82|C0021358
69|While the insulin receptor (IR) was found in the CNS decades ago, the brain was long considered to be an insulin-insensitive organ|insulin receptor|insulin receptor|gene|10|NCBIGene:3643|insulin|insulin|gene|105|NCBIGene:3630
69|While the insulin receptor (IR) was found in the CNS decades ago, the brain was long considered to be an insulin-insensitive organ|insulin receptor|insulin receptor|gene|10|NCBIGene:3643|Brain|brain|anatomy|70|C0006104
69|While the insulin receptor (IR) was found in the CNS decades ago, the brain was long considered to be an insulin-insensitive organ|insulin receptor|insulin receptor|gene|10|NCBIGene:3643|Organ|organ|anatomy|125|C0178784
69|While the insulin receptor (IR) was found in the CNS decades ago, the brain was long considered to be an insulin-insensitive organ|insulin receptor|insulin receptor|gene|10|NCBIGene:3643|Central Nervous System|CNS|anatomy|49|C3714787
69|While the insulin receptor (IR) was found in the CNS decades ago, the brain was long considered to be an insulin-insensitive organ|IR|IR|gene|28|NCBIGene:3643|insulin|insulin|gene|105|NCBIGene:3630
69|While the insulin receptor (IR) was found in the CNS decades ago, the brain was long considered to be an insulin-insensitive organ|IR|IR|gene|28|NCBIGene:3643|Brain|brain|anatomy|70|C0006104
69|While the insulin receptor (IR) was found in the CNS decades ago, the brain was long considered to be an insulin-insensitive organ|IR|IR|gene|28|NCBIGene:3643|Organ|organ|anatomy|125|C0178784
69|While the insulin receptor (IR) was found in the CNS decades ago, the brain was long considered to be an insulin-insensitive organ|IR|IR|gene|28|NCBIGene:3643|Central Nervous System|CNS|anatomy|49|C3714787
69|While the insulin receptor (IR) was found in the CNS decades ago, the brain was long considered to be an insulin-insensitive organ|insulin|insulin|gene|105|NCBIGene:3630|Brain|brain|anatomy|70|C0006104
69|While the insulin receptor (IR) was found in the CNS decades ago, the brain was long considered to be an insulin-insensitive organ|insulin|insulin|gene|105|NCBIGene:3630|Organ|organ|anatomy|125|C0178784
69|While the insulin receptor (IR) was found in the CNS decades ago, the brain was long considered to be an insulin-insensitive organ|insulin|insulin|gene|105|NCBIGene:3630|Central Nervous System|CNS|anatomy|49|C3714787
69|This view is currently revisited, given emerging evidence of critical roles of IR-mediated signaling in  development, neuroprotection, metabolism, and plasticity in the brain|IR|IR|gene|79|NCBIGene:3643|Biologic Development|development|physiology|105|C0678723
69|This view is currently revisited, given emerging evidence of critical roles of IR-mediated signaling in  development, neuroprotection, metabolism, and plasticity in the brain|IR|IR|gene|79|NCBIGene:3643|Metabolism|metabolism|physiology|135|C0025519
69|This view is currently revisited, given emerging evidence of critical roles of IR-mediated signaling in  development, neuroprotection, metabolism, and plasticity in the brain|IR|IR|gene|79|NCBIGene:3643|Neuroprotection|neuroprotection|physiology|118|C0598958
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|41|NCBIGene:3643|Cells|cellular|anatomy|14|C0007634
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|41|NCBIGene:3643|Body tissue|tissues|anatomy|110|C0040300
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|41|NCBIGene:3643|Function Axis|functions|physiology|86|C0700205
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|41|NCBIGene:3643|Metabolic Process, Cellular|metabolic|physiology|73|C1524026
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|83|NCBIGene:3643|Cells|cellular|anatomy|14|C0007634
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|83|NCBIGene:3643|Body tissue|tissues|anatomy|110|C0040300
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|83|NCBIGene:3643|Function Axis|functions|physiology|86|C0700205
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|83|NCBIGene:3643|Metabolic Process, Cellular|metabolic|physiology|73|C1524026
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|159|NCBIGene:3643|Cells|cellular|anatomy|14|C0007634
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|159|NCBIGene:3643|Body tissue|tissues|anatomy|110|C0040300
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|159|NCBIGene:3643|Function Axis|functions|physiology|86|C0700205
69|These diverse cellular and physiological IR activities are distinct from metabolic IR functions in peripheral tissues, thus highlighting region specificity of IR properties|IR|IR|gene|159|NCBIGene:3643|Metabolic Process, Cellular|metabolic|physiology|73|C1524026
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|IR isoforms|IR isoforms|gene|45|NCBIGene:3645|A|A|gene|58|NCBIGene:7003
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|IR isoforms|IR isoforms|gene|45|NCBIGene:3645|IR-A|IR-A|gene|184|NCBIGene:3643
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|IR isoforms|IR isoforms|gene|45|NCBIGene:3645|Brain|brain|anatomy|109|C0006104
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|IR isoforms|IR isoforms|gene|45|NCBIGene:3645|Neurons|neurons|anatomy|156|C0027882
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|IR isoforms|IR isoforms|gene|45|NCBIGene:3645|Body tissue|tissues|anatomy|129|C0040300
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|A|A|gene|58|NCBIGene:7003|IR-A|IR-A|gene|184|NCBIGene:3643
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|A|A|gene|58|NCBIGene:7003|Brain|brain|anatomy|109|C0006104
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|A|A|gene|58|NCBIGene:7003|Neurons|neurons|anatomy|156|C0027882
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|A|A|gene|58|NCBIGene:7003|Body tissue|tissues|anatomy|129|C0040300
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|IR-A|IR-A|gene|184|NCBIGene:3643|Brain|brain|anatomy|109|C0006104
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|IR-A|IR-A|gene|184|NCBIGene:3643|Neurons|neurons|anatomy|156|C0027882
69|This particularly concerns the fact that two IR isoforms, A and B, are predominantly expressed in either the brain or peripheral tissues, respectively, and neurons express exclusively IR-A|IR-A|IR-A|gene|184|NCBIGene:3643|Body tissue|tissues|anatomy|129|C0040300
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IR-B|IR-B|gene|33|NCBIGene:107133510|IR-A|IR-A|gene|39|NCBIGene:3643
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IR-B|IR-B|gene|33|NCBIGene:107133510|insulin-like growth factor-2|insulin-like growth factor-2|gene|122|NCBIGene:3481
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IR-B|IR-B|gene|33|NCBIGene:107133510|IGF-2|IGF-2|gene|152|NCBIGene:3481
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IR-B|IR-B|gene|33|NCBIGene:107133510|bony process|processes|anatomy|251|C1184743
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IR-B|IR-B|gene|33|NCBIGene:107133510|Binding (Molecular Function)|binding|physiology|58|C1167622
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IR-B|IR-B|gene|33|NCBIGene:107133510|Neuronal Plasticity|neuronal plasticity|physiology|175|C0027880
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IR-A|IR-A|gene|39|NCBIGene:3643|insulin-like growth factor-2|insulin-like growth factor-2|gene|122|NCBIGene:3481
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IR-A|IR-A|gene|39|NCBIGene:3643|IGF-2|IGF-2|gene|152|NCBIGene:3481
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IR-A|IR-A|gene|39|NCBIGene:3643|bony process|processes|anatomy|251|C1184743
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IR-A|IR-A|gene|39|NCBIGene:3643|Binding (Molecular Function)|binding|physiology|58|C1167622
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IR-A|IR-A|gene|39|NCBIGene:3643|Neuronal Plasticity|neuronal plasticity|physiology|175|C0027880
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|insulin-like growth factor-2|insulin-like growth factor-2|gene|122|NCBIGene:3481|bony process|processes|anatomy|251|C1184743
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|insulin-like growth factor-2|insulin-like growth factor-2|gene|122|NCBIGene:3481|Binding (Molecular Function)|binding|physiology|58|C1167622
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|insulin-like growth factor-2|insulin-like growth factor-2|gene|122|NCBIGene:3481|Neuronal Plasticity|neuronal plasticity|physiology|175|C0027880
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IGF-2|IGF-2|gene|152|NCBIGene:3481|bony process|processes|anatomy|251|C1184743
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IGF-2|IGF-2|gene|152|NCBIGene:3481|Binding (Molecular Function)|binding|physiology|58|C1167622
69|Intriguingly, in comparison with IR-B, IR-A displays high binding affinity and is also activated by low concentrations of insulin-like growth factor-2 (IGF-2), a regulator of neuronal plasticity, whose dysregulation is associated with neuropathologic processes|IGF-2|IGF-2|gene|152|NCBIGene:3481|Neuronal Plasticity|neuronal plasticity|physiology|175|C0027880
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|16|NCBIGene:3643|insulin|insulin|gene|31|NCBIGene:3630
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|16|NCBIGene:3643|brain disorders|brain disorders|disease|171|mesh:D001927
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|16|NCBIGene:3643|neurodevelopmental syndromes|neurodevelopmental syndromes|disease|198|mesh:D065886
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|16|NCBIGene:3643|neoplasms|neoplasms|disease|228|mesh:D009369
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|16|NCBIGene:3643|neurodegenerative conditions|neurodegenerative conditions|disease|239|mesh:D019636
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|16|NCBIGene:3643|depression|depression|disease|273|mesh:D009497
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|16|NCBIGene:3643|neurodevelopment|neurodevelopmental|physiology|198|C0599855
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|insulin|insulin|gene|31|NCBIGene:3630|IR|IR|gene|68|NCBIGene:3643
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|insulin|insulin|gene|31|NCBIGene:3630|IR|IR|gene|113|NCBIGene:3643
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|insulin|insulin|gene|31|NCBIGene:3630|brain disorders|brain disorders|disease|171|mesh:D001927
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|insulin|insulin|gene|31|NCBIGene:3630|neurodevelopmental syndromes|neurodevelopmental syndromes|disease|198|mesh:D065886
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|insulin|insulin|gene|31|NCBIGene:3630|neoplasms|neoplasms|disease|228|mesh:D009369
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|insulin|insulin|gene|31|NCBIGene:3630|neurodegenerative conditions|neurodegenerative conditions|disease|239|mesh:D019636
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|insulin|insulin|gene|31|NCBIGene:3630|depression|depression|disease|273|mesh:D009497
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|insulin|insulin|gene|31|NCBIGene:3630|neurodevelopment|neurodevelopmental|physiology|198|C0599855
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|68|NCBIGene:3643|brain disorders|brain disorders|disease|171|mesh:D001927
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|68|NCBIGene:3643|neurodevelopmental syndromes|neurodevelopmental syndromes|disease|198|mesh:D065886
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|68|NCBIGene:3643|neoplasms|neoplasms|disease|228|mesh:D009369
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|68|NCBIGene:3643|neurodegenerative conditions|neurodegenerative conditions|disease|239|mesh:D019636
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|68|NCBIGene:3643|depression|depression|disease|273|mesh:D009497
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|68|NCBIGene:3643|neurodevelopment|neurodevelopmental|physiology|198|C0599855
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|113|NCBIGene:3643|brain disorders|brain disorders|disease|171|mesh:D001927
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|113|NCBIGene:3643|neurodevelopmental syndromes|neurodevelopmental syndromes|disease|198|mesh:D065886
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|113|NCBIGene:3643|neoplasms|neoplasms|disease|228|mesh:D009369
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|113|NCBIGene:3643|neurodegenerative conditions|neurodegenerative conditions|disease|239|mesh:D019636
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|113|NCBIGene:3643|depression|depression|disease|273|mesh:D009497
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|IR|IR|gene|113|NCBIGene:3643|neurodevelopment|neurodevelopmental|physiology|198|C0599855
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|brain disorders|brain disorders|disease|171|mesh:D001927|neurodevelopmental syndromes|neurodevelopmental syndromes|disease|198|mesh:D065886
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|brain disorders|brain disorders|disease|171|mesh:D001927|neoplasms|neoplasms|disease|228|mesh:D009369
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|brain disorders|brain disorders|disease|171|mesh:D001927|neurodegenerative conditions|neurodegenerative conditions|disease|239|mesh:D019636
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|brain disorders|brain disorders|disease|171|mesh:D001927|depression|depression|disease|273|mesh:D009497
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|neurodevelopmental syndromes|neurodevelopmental syndromes|disease|198|mesh:D065886|neoplasms|neoplasms|disease|228|mesh:D009369
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|neurodevelopmental syndromes|neurodevelopmental syndromes|disease|198|mesh:D065886|neurodegenerative conditions|neurodegenerative conditions|disease|239|mesh:D019636
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|neurodevelopmental syndromes|neurodevelopmental syndromes|disease|198|mesh:D065886|depression|depression|disease|273|mesh:D009497
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|neoplasms|neoplasms|disease|228|mesh:D009369|neurodegenerative conditions|neurodegenerative conditions|disease|239|mesh:D019636
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|neoplasms|neoplasms|disease|228|mesh:D009369|depression|depression|disease|273|mesh:D009497
69|Deficiencies in IR activation, insulin availability, and downstream IR-related mechanisms may result in aberrant IR-mediated functions and, subsequently, a broad range of brain disorders, including neurodevelopmental syndromes, neoplasms, neurodegenerative conditions, and depression|neurodegenerative conditions|neurodegenerative conditions|disease|239|mesh:D019636|depression|depression|disease|273|mesh:D009497
69|Here, we discuss findings on the brain-specific features of IR-mediated signaling with focus on mechanisms of primary receptor activation and their roles in the neuropathology|IR|IR|gene|60|NCBIGene:3643|Receptor Activation Process|receptor activation|physiology|118|C1514758
69|Here, we discuss findings on the brain-specific features of IR-mediated signaling with focus on mechanisms of primary receptor activation and their roles in the neuropathology|IR|IR|gene|60|NCBIGene:3643|Signal Transduction|signaling|physiology|72|C0037083
70|However, both HIV antiretroviral therapy and autism spectrum disorder (ASD) have been associated with mitochondrial alterations|HIV|HIV|disease|14|mesh:D000163|autism spectrum disorder|autism spectrum disorder|disease|45|mesh:D002659
70|However, both HIV antiretroviral therapy and autism spectrum disorder (ASD) have been associated with mitochondrial alterations|HIV|HIV|disease|14|mesh:D000163|ASD|ASD|disease|71|mesh:D006344
70|However, both HIV antiretroviral therapy and autism spectrum disorder (ASD) have been associated with mitochondrial alterations|autism spectrum disorder|autism spectrum disorder|disease|45|mesh:D002659|ASD|ASD|disease|71|mesh:D006344
70|Leukocyte mitochondrial DNA (mtDNA) content can serve as a marker for mitochondrial dysfunction|mitochondrial dysfunction|mitochondrial dysfunction|disease|70|mesh:D028361|mitochondrial DNA location|mitochondrial DNA|anatomy|10|C1819717
70|Leukocyte mitochondrial DNA (mtDNA) content can serve as a marker for mitochondrial dysfunction|mitochondrial dysfunction|mitochondrial dysfunction|disease|70|mesh:D028361|mitochondrial DNA location|mtDNA|anatomy|29|C1819717
70|HEU children without ASD and HUU children with ASD had higher mtDNA content than HUU controls|ASD|ASD|disease|21|mesh:D006344|mitochondrial DNA location|mtDNA|anatomy|62|C1819717
70|HEU children without ASD and HUU children with ASD had higher mtDNA content than HUU controls|ASD|ASD|disease|47|mesh:D006344|mitochondrial DNA location|mtDNA|anatomy|62|C1819717
70|HEU children with ASD had significantly higher mtDNA content than all other study groups|ASD|ASD|disease|18|mesh:D006344|mitochondrial DNA location|mtDNA|anatomy|47|C1819717
70|Our results suggest a clear association between elevated leukocyte mtDNA  content and both HEU and ASD status|HEU|HEU|disease|91|mesh:D006463|ASD|ASD|disease|99|mesh:D006344
70|This may implicate mitochondrial dysfunction as a contributor to the high ASD prevalence observed in our cohort|mitochondrial dysfunction|mitochondrial dysfunction|disease|19|mesh:D028361|ASD|ASD|disease|74|mesh:D006344
71|Recent research has uncovered an important role of thyroid hormone in the regulation of fatty acid oxidation (FAO), an energetic process essential for neurodevelopment that continues to support brain metabolism during adulthood|fatty acid|fatty acid|compound|88|mesh:D005227|bony process|process|anatomy|129|C1184743
71|Thyroid hormone stimulation of FAO has been shown to be protective in astrocytes and mouse models of brain injury, yet a clear mechanism of this relationship has not been elucidated|FAO|FAO|gene|31|NCBIGene:51|brain injury|brain injury|disease|101|mesh:D001930
71|Thyroid hormone stimulation of FAO has been shown to be protective in astrocytes and mouse models of brain injury, yet a clear mechanism of this relationship has not been elucidated|FAO|FAO|gene|31|NCBIGene:51|Astrocytes|astrocytes|anatomy|70|C0004112
71|Thyroid hormone stimulation of FAO has been shown to be protective in astrocytes and mouse models of brain injury, yet a clear mechanism of this relationship has not been elucidated|brain injury|brain injury|disease|101|mesh:D001930|Astrocytes|astrocytes|anatomy|70|C0004112
72|The brain is dependent on glucose and other metabolites for proper function and is spared from metabolic deficits even during starvation|glucose|glucose|compound|26|CHEBI:42758|metabolic deficits|metabolic deficits|disease|95|mesh:D008659
72|The brain is dependent on glucose and other metabolites for proper function and is spared from metabolic deficits even during starvation|glucose|glucose|compound|26|CHEBI:42758|starvation|starvation|disease|126|mesh:D013217
72|The brain is dependent on glucose and other metabolites for proper function and is spared from metabolic deficits even during starvation|glucose|glucose|compound|26|CHEBI:42758|Brain|brain|anatomy|4|C0006104
72|The brain is dependent on glucose and other metabolites for proper function and is spared from metabolic deficits even during starvation|metabolic deficits|metabolic deficits|disease|95|mesh:D008659|starvation|starvation|disease|126|mesh:D013217
72|The brain is dependent on glucose and other metabolites for proper function and is spared from metabolic deficits even during starvation|metabolic deficits|metabolic deficits|disease|95|mesh:D008659|Brain|brain|anatomy|4|C0006104
72|The brain is dependent on glucose and other metabolites for proper function and is spared from metabolic deficits even during starvation|starvation|starvation|disease|126|mesh:D013217|Brain|brain|anatomy|4|C0006104
72|In this review, we outline how the nutrient-sensitive nucleocytoplasmic post-translational modification O-linked N-acetylglucosamine (O-GlcNAc) regulates protein homeostasis|O|O|compound|104|CHEBI:29354|N-acetylglucosamine|N-acetylglucosamine|compound|113|CHEBI:59640
72|In this review, we outline how the nutrient-sensitive nucleocytoplasmic post-translational modification O-linked N-acetylglucosamine (O-GlcNAc) regulates protein homeostasis|N-acetylglucosamine|N-acetylglucosamine|compound|113|CHEBI:59640|O|O|compound|134|CHEBI:29354
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|O-GlcNAc|O-GlcNAc|compound|4|CHEBI:59521|proteopathies|proteopathies|disease|91|mesh:D057165
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|O-GlcNAc|O-GlcNAc|compound|4|CHEBI:59521|neurodegenerative diseases|neurodegenerative diseases|disease|116|mesh:D019636
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|O-GlcNAc|O-GlcNAc|compound|4|CHEBI:59521|Alzheimer's|Alzheimer's|disease|151|mesh:D000544
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|O-GlcNAc|O-GlcNAc|compound|4|CHEBI:59521|Huntington's|Huntington's|disease|181|mesh:D006816
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|O-GlcNAc|O-GlcNAc|compound|4|CHEBI:59521|Brain|brain|anatomy|62|C0006104
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|proteopathies|proteopathies|disease|91|mesh:D057165|neurodegenerative diseases|neurodegenerative diseases|disease|116|mesh:D019636
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|proteopathies|proteopathies|disease|91|mesh:D057165|Alzheimer's|Alzheimer's|disease|151|mesh:D000544
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|proteopathies|proteopathies|disease|91|mesh:D057165|Huntington's|Huntington's|disease|181|mesh:D006816
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|proteopathies|proteopathies|disease|91|mesh:D057165|Brain|brain|anatomy|62|C0006104
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|neurodegenerative diseases|neurodegenerative diseases|disease|116|mesh:D019636|Alzheimer's|Alzheimer's|disease|151|mesh:D000544
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|neurodegenerative diseases|neurodegenerative diseases|disease|116|mesh:D019636|Huntington's|Huntington's|disease|181|mesh:D006816
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|neurodegenerative diseases|neurodegenerative diseases|disease|116|mesh:D019636|Brain|brain|anatomy|62|C0006104
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|Alzheimer's|Alzheimer's|disease|151|mesh:D000544|Huntington's|Huntington's|disease|181|mesh:D006816
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|Alzheimer's|Alzheimer's|disease|151|mesh:D000544|Brain|brain|anatomy|62|C0006104
72|The O-GlcNAc modification is highly abundant in the mammalian brain and has been linked to proteopathies, including neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's|Huntington's|Huntington's|disease|181|mesh:D006816|Brain|brain|anatomy|62|C0006104
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|O-GlcNAc transferase-|O-GlcNAc transferase-|gene|48|NCBIGene:8473|O-GlcNAcase-knockout alleles|O-GlcNAcase-knockout alleles|gene|74|NCBIGene:10724
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|O-GlcNAc|O-GlcNAc|compound|131|CHEBI:59521|O-GlcNAc transferase-|O-GlcNAc transferase-|gene|48|NCBIGene:8473
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|O-GlcNAc transferase-|O-GlcNAc transferase-|gene|48|NCBIGene:8473|age|age|disease|172|mesh:C535608
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|O-GlcNAc transferase-|O-GlcNAc transferase-|gene|48|NCBIGene:8473|Biologic Development|development|physiology|149|C0678723
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|O-GlcNAc transferase-|O-GlcNAc transferase-|gene|48|NCBIGene:8473|Age|age|physiology|172|C0001779
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|GlcNAc|GlcNAc|compound|50|CHEBI:73685|O-GlcNAcase-knockout alleles|O-GlcNAcase-knockout alleles|gene|74|NCBIGene:10724
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|GlcNAc|GlcNAc|compound|50|CHEBI:73685|O-GlcNAc|O-GlcNAc|compound|131|CHEBI:59521
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|GlcNAc|GlcNAc|compound|50|CHEBI:73685|age|age|disease|172|mesh:C535608
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|O-GlcNAc|O-GlcNAc|compound|131|CHEBI:59521|O-GlcNAcase-knockout alleles|O-GlcNAcase-knockout alleles|gene|74|NCBIGene:10724
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|O-GlcNAcase-knockout alleles|O-GlcNAcase-knockout alleles|gene|74|NCBIGene:10724|age|age|disease|172|mesh:C535608
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|O-GlcNAcase-knockout alleles|O-GlcNAcase-knockout alleles|gene|74|NCBIGene:10724|protein O-GlcNAc transferase activity|O-GlcNAc transferase|physiology|48|C3541201
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|O-GlcNAcase-knockout alleles|O-GlcNAcase-knockout alleles|gene|74|NCBIGene:10724|Biologic Development|development|physiology|149|C0678723
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|O-GlcNAcase-knockout alleles|O-GlcNAcase-knockout alleles|gene|74|NCBIGene:10724|Age|age|physiology|172|C0001779
72|elegans, Drosophila, and mouse models harboring O-GlcNAc transferase- and O-GlcNAcase-knockout alleles have helped define the role O-GlcNAc plays in development as well as age-associated neurodegenerative disease|O-GlcNAc|O-GlcNAc|compound|131|CHEBI:59521|age|age|disease|172|mesh:C535608
72|These enzymes add and remove the single monosaccharide from protein serine and threonine residues, respectively|monosaccharide|monosaccharide|compound|40|mesh:D009005|serine|serine|compound|68|mesh:D012694
72|These enzymes add and remove the single monosaccharide from protein serine and threonine residues, respectively|monosaccharide|monosaccharide|compound|40|mesh:D009005|threonine|threonine|compound|79|mesh:D013912
72|These enzymes add and remove the single monosaccharide from protein serine and threonine residues, respectively|serine|serine|compound|68|mesh:D012694|threonine|threonine|compound|79|mesh:D013912
72|Like the quality control system in the endoplasmic reticulum which uses a 'mannose timer' to monitor protein folding, we propose that cytoplasmic proteostasis relies on an 'O-GlcNAc timer' to help regulate the lifetime and fate of nuclear and cytoplasmic proteins|mannose|mannose|compound|75|mesh:D008358|O-GlcNAc|O-GlcNAc|compound|173|CHEBI:59521
72|Like the quality control system in the endoplasmic reticulum which uses a 'mannose timer' to monitor protein folding, we propose that cytoplasmic proteostasis relies on an 'O-GlcNAc timer' to help regulate the lifetime and fate of nuclear and cytoplasmic proteins|mannose|mannose|compound|75|mesh:D008358|Cytoplasm|cytoplasmic|anatomy|134|C0010834
72|Like the quality control system in the endoplasmic reticulum which uses a 'mannose timer' to monitor protein folding, we propose that cytoplasmic proteostasis relies on an 'O-GlcNAc timer' to help regulate the lifetime and fate of nuclear and cytoplasmic proteins|O-GlcNAc|O-GlcNAc|compound|173|CHEBI:59521|Cytoplasm|cytoplasmic|anatomy|134|C0010834
72|Brain-selective knockout mouse models will be  an important tool for understanding the role of O-GlcNAc in the physiology of the brain and its susceptibility to neurodegenerative injury|O-GlcNAc|O-GlcNAc|compound|95|CHEBI:59521|neurodegenerative|neurodegenerative|disease|161|mesh:D009410
72|Brain-selective knockout mouse models will be  an important tool for understanding the role of O-GlcNAc in the physiology of the brain and its susceptibility to neurodegenerative injury|O-GlcNAc|O-GlcNAc|compound|95|CHEBI:59521|injury|injury|disease|179|mesh:D014947
72|Brain-selective knockout mouse models will be  an important tool for understanding the role of O-GlcNAc in the physiology of the brain and its susceptibility to neurodegenerative injury|neurodegenerative|neurodegenerative|disease|161|mesh:D009410|injury|injury|disease|179|mesh:D014947
73|Hypoxic ischemic encephalopathy (HIE) leads to significant morbidity and mortality|Hypoxic ischemic encephalopathy|Hypoxic ischemic encephalopathy|disease|0|mesh:D020925|HIE|HIE|disease|33|omim:243700
73|Thalamic lactate/N-Acetylasperate (Lac/NAA) peak area ratio of > 0|lactate|lactate|compound|9|mesh:D019344|N-Acetylasperate|N-Acetylasperate|compound|17|mesh:D009536
73|Thalamic lactate/N-Acetylasperate (Lac/NAA) peak area ratio of > 0|lactate|lactate|compound|9|mesh:D019344|Lac|Lac|compound|35|CHEBI:17716
73|Thalamic lactate/N-Acetylasperate (Lac/NAA) peak area ratio of > 0|lactate|lactate|compound|9|mesh:D019344|NAA|NAA|compound|39|CHEBI:21547
73|Thalamic lactate/N-Acetylasperate (Lac/NAA) peak area ratio of > 0|lactate|lactate|compound|9|mesh:D019344|Thalamic structure|Thalamic|anatomy|0|C0039729
73|Thalamic lactate/N-Acetylasperate (Lac/NAA) peak area ratio of > 0|N-Acetylasperate|N-Acetylasperate|compound|17|mesh:D009536|Lac|Lac|compound|35|CHEBI:17716
73|Thalamic lactate/N-Acetylasperate (Lac/NAA) peak area ratio of > 0|N-Acetylasperate|N-Acetylasperate|compound|17|mesh:D009536|NAA|NAA|compound|39|CHEBI:21547
73|Thalamic lactate/N-Acetylasperate (Lac/NAA) peak area ratio of > 0|N-Acetylasperate|N-Acetylasperate|compound|17|mesh:D009536|Thalamic structure|Thalamic|anatomy|0|C0039729
73|Thalamic lactate/N-Acetylasperate (Lac/NAA) peak area ratio of > 0|Lac|Lac|compound|35|CHEBI:17716|NAA|NAA|compound|39|CHEBI:21547
73|Thalamic lactate/N-Acetylasperate (Lac/NAA) peak area ratio of > 0|Lac|Lac|compound|35|CHEBI:17716|Thalamic structure|Thalamic|anatomy|0|C0039729
73|Thalamic lactate/N-Acetylasperate (Lac/NAA) peak area ratio of > 0|NAA|NAA|compound|39|CHEBI:21547|Thalamic structure|Thalamic|anatomy|0|C0039729
73|3 on proton (1H) magnetic resonance spectroscopy (MRS) is associated with poor neurodevelopment outcome following HIE|1H|1H|compound|13|CHEBI:49637|HIE|HIE|disease|114|omim:243700
73|Cytochrome-c-oxidase (CCO) plays a central role in mitochondrial oxidative metabolism and ATP synthesis|Cytochrome-c-oxidase|Cytochrome-c-oxidase|gene|0|NCBIGene:6775083|CCO|CCO|gene|22|NCBIGene:6261
73|Cytochrome-c-oxidase (CCO) plays a central role in mitochondrial oxidative metabolism and ATP synthesis|ATP|ATP|compound|90|CHEBI:30616|Cytochrome-c-oxidase|Cytochrome-c-oxidase|gene|0|NCBIGene:6775083
73|Cytochrome-c-oxidase (CCO) plays a central role in mitochondrial oxidative metabolism and ATP synthesis|Cytochrome-c-oxidase|Cytochrome-c-oxidase|gene|0|NCBIGene:6775083|ATP biosynthesis|ATP synthesis|physiology|90|C1157223
73|Cytochrome-c-oxidase (CCO) plays a central role in mitochondrial oxidative metabolism and ATP synthesis|Cytochrome-c-oxidase|Cytochrome-c-oxidase|gene|0|NCBIGene:6775083|Cell Respiration|oxidative metabolism|physiology|65|C0282636
73|Cytochrome-c-oxidase (CCO) plays a central role in mitochondrial oxidative metabolism and ATP synthesis|ATP|ATP|compound|90|CHEBI:30616|CCO|CCO|gene|22|NCBIGene:6261
73|Cytochrome-c-oxidase (CCO) plays a central role in mitochondrial oxidative metabolism and ATP synthesis|CCO|CCO|gene|22|NCBIGene:6261|ATP biosynthesis|ATP synthesis|physiology|90|C1157223
73|Cytochrome-c-oxidase (CCO) plays a central role in mitochondrial oxidative metabolism and ATP synthesis|CCO|CCO|gene|22|NCBIGene:6261|Cell Respiration|oxidative metabolism|physiology|65|C0282636
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|haemoglobin|haemoglobin|gene|129|NCBIGene:114757|HbD|HbD|gene|153|NCBIGene:100187828
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|haemoglobin|haemoglobin|gene|129|NCBIGene:114757|HbT|HbT|gene|205|NCBIGene:6506
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|haemoglobin|haemoglobin|gene|129|NCBIGene:114757|HIE|HIE|disease|241|omim:243700
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|haemoglobin|haemoglobin|gene|129|NCBIGene:114757|Alveolar ventilation function|oxygenation|physiology|116|C0231940
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|haemoglobin|haemoglobin|gene|129|NCBIGene:114757|Cerebral Blood Volume|cerebral blood volume|physiology|163|C4277714
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|haemoglobin|haemoglobin|gene|129|NCBIGene:114757|Metabolism|metabolism|physiology|98|C0025519
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|HbD|HbD|gene|153|NCBIGene:100187828|haemoglobin|haemoglobin|gene|192|NCBIGene:114757
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|HbD|HbD|gene|153|NCBIGene:100187828|HbT|HbT|gene|205|NCBIGene:6506
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|HbD|HbD|gene|153|NCBIGene:100187828|HIE|HIE|disease|241|omim:243700
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|HbD|HbD|gene|153|NCBIGene:100187828|Alveolar ventilation function|oxygenation|physiology|116|C0231940
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|HbD|HbD|gene|153|NCBIGene:100187828|Cerebral Blood Volume|cerebral blood volume|physiology|163|C4277714
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|HbD|HbD|gene|153|NCBIGene:100187828|Metabolism|metabolism|physiology|98|C0025519
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|haemoglobin|haemoglobin|gene|192|NCBIGene:114757|HbT|HbT|gene|205|NCBIGene:6506
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|haemoglobin|haemoglobin|gene|192|NCBIGene:114757|HIE|HIE|disease|241|omim:243700
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|haemoglobin|haemoglobin|gene|192|NCBIGene:114757|Alveolar ventilation function|oxygenation|physiology|116|C0231940
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|haemoglobin|haemoglobin|gene|192|NCBIGene:114757|Cerebral Blood Volume|cerebral blood volume|physiology|163|C4277714
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|haemoglobin|haemoglobin|gene|192|NCBIGene:114757|Metabolism|metabolism|physiology|98|C0025519
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|HbT|HbT|gene|205|NCBIGene:6506|HIE|HIE|disease|241|omim:243700
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|HbT|HbT|gene|205|NCBIGene:6506|Alveolar ventilation function|oxygenation|physiology|116|C0231940
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|HbT|HbT|gene|205|NCBIGene:6506|Cerebral Blood Volume|cerebral blood volume|physiology|163|C4277714
73|Using a novel broadband NIRS system, we investigated the impact of pressure passivity of cerebral metabolism (CCO), oxygenation (haemoglobin difference (HbD)) and cerebral blood volume (total haemoglobin (HbT)) in 23 term  infants following HIE during therapeutic hypothermia (HT)|HbT|HbT|gene|205|NCBIGene:6506|Metabolism|metabolism|physiology|98|C0025519
73|Wavelet semblance (a measure of phase difference) was calculated to compare reactivity between mean arterial blood pressure (MABP) with oxCCO, HbD and HbT|HbD|HbD|gene|143|NCBIGene:100187828|HbT|HbT|gene|151|NCBIGene:6506
73|Wavelet semblance (a measure of phase difference) was calculated to compare reactivity between mean arterial blood pressure (MABP) with oxCCO, HbD and HbT|HbD|HbD|gene|143|NCBIGene:100187828|Intravascular mean:Pressure:Point in time:Arterial system:Quantitative|mean arterial blood pressure|physiology|95|C0488053
73|Wavelet semblance (a measure of phase difference) was calculated to compare reactivity between mean arterial blood pressure (MABP) with oxCCO, HbD and HbT|HbT|HbT|gene|151|NCBIGene:6506|Intravascular mean:Pressure:Point in time:Arterial system:Quantitative|mean arterial blood pressure|physiology|95|C0488053
73|OxCCO-MABP semblance correlated with thalamic Lac/NAA ( r = 0|Lac|Lac|compound|46|CHEBI:17716|NAA|NAA|compound|50|CHEBI:21547
73|OxCCO-MABP semblance correlated with thalamic Lac/NAA ( r = 0|Lac|Lac|compound|46|CHEBI:17716|Thalamic structure|thalamic|anatomy|37|C0039729
73|OxCCO-MABP semblance correlated with thalamic Lac/NAA ( r = 0|NAA|NAA|compound|50|CHEBI:21547|Thalamic structure|thalamic|anatomy|37|C0039729
73|04), thalamic Lac/NAA ( p = 0|Lac|Lac|compound|14|CHEBI:17716|NAA|NAA|compound|18|CHEBI:21547
73|04), thalamic Lac/NAA ( p = 0|Lac|Lac|compound|14|CHEBI:17716|Thalamic structure|thalamic|anatomy|5|C0039729
73|04), thalamic Lac/NAA ( p = 0|NAA|NAA|compound|18|CHEBI:21547|Thalamic structure|thalamic|anatomy|5|C0039729
73|Pressure passive changes in cerebral metabolism were associated with injury severity indicated by thalamic Lac/NAA, MRI scores and neurodevelopmental assessment at one year of age|Lac|Lac|compound|107|CHEBI:17716|NAA|NAA|compound|111|CHEBI:21547
73|Pressure passive changes in cerebral metabolism were associated with injury severity indicated by thalamic Lac/NAA, MRI scores and neurodevelopmental assessment at one year of age|Lac|Lac|compound|107|CHEBI:17716|Thalamic structure|thalamic|anatomy|98|C0039729
73|Pressure passive changes in cerebral metabolism were associated with injury severity indicated by thalamic Lac/NAA, MRI scores and neurodevelopmental assessment at one year of age|NAA|NAA|compound|111|CHEBI:21547|Thalamic structure|thalamic|anatomy|98|C0039729
75|Idebenone, the synthetic analog of coenzyme Q10 can improve electron transport in mitochondria|Idebenone|Idebenone|compound|0|mesh:C036619|coenzyme Q10|coenzyme Q10|compound|35|mesh:C024989
75|Therefore, it is used in the treatment of Alzheimer's disease and other cognitive impairments|Alzheimer's disease|Alzheimer's disease|disease|42|mesh:D000544|cognitive impairments|cognitive impairments|disease|72|mesh:D019954
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|idebenone|idebenone|compound|29|mesh:C036619|MAP2|MAP2|gene|174|NCBIGene:4133
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|idebenone|idebenone|compound|29|mesh:C036619|GFAP|GFAP|gene|193|NCBIGene:2670
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|idebenone|idebenone|compound|29|mesh:C036619|MAP2|MAP2|gene|267|NCBIGene:4133
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|idebenone|idebenone|compound|29|mesh:C036619|astrocytic|astrocytic|anatomy|181|C0521395
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|idebenone|idebenone|compound|29|mesh:C036619|Neural Stem Cells|neural stem cells|anatomy|79|C1113654
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|174|NCBIGene:4133|GFAP|GFAP|gene|193|NCBIGene:2670
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|174|NCBIGene:4133|Tumor stage|stage|physiology|121|C1300072
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|174|NCBIGene:4133|Tumor stage|stages|physiology|229|C1300072
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|174|NCBIGene:4133|Decision|decision|physiology|102|C0679006
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|174|NCBIGene:4133|Report:Finding:Point in time:{Setting}:Document:{Role}|report|physiology|16|C4255046
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|174|NCBIGene:4133|astrocyte differentiation|astrocyte differentiation|physiology|307|C1657435
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|174|NCBIGene:4133|astrocytic|astrocytic|anatomy|181|C0521395
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|174|NCBIGene:4133|Biological Markers|markers|physiology|199|C0005516
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|174|NCBIGene:4133|Down-Regulation|down-regulation|physiology|248|C0013081
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|174|NCBIGene:4133|Neural Stem Cells|neural stem cells|anatomy|79|C1113654
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|GFAP|GFAP|gene|193|NCBIGene:2670|MAP2|MAP2|gene|267|NCBIGene:4133
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|GFAP|GFAP|gene|193|NCBIGene:2670|Tumor stage|stage|physiology|121|C1300072
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|GFAP|GFAP|gene|193|NCBIGene:2670|Tumor stage|stages|physiology|229|C1300072
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|GFAP|GFAP|gene|193|NCBIGene:2670|Decision|decision|physiology|102|C0679006
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|GFAP|GFAP|gene|193|NCBIGene:2670|Report:Finding:Point in time:{Setting}:Document:{Role}|report|physiology|16|C4255046
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|GFAP|GFAP|gene|193|NCBIGene:2670|astrocyte differentiation|astrocyte differentiation|physiology|307|C1657435
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|GFAP|GFAP|gene|193|NCBIGene:2670|astrocytic|astrocytic|anatomy|181|C0521395
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|GFAP|GFAP|gene|193|NCBIGene:2670|Biological Markers|markers|physiology|199|C0005516
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|GFAP|GFAP|gene|193|NCBIGene:2670|Down-Regulation|down-regulation|physiology|248|C0013081
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|GFAP|GFAP|gene|193|NCBIGene:2670|Neural Stem Cells|neural stem cells|anatomy|79|C1113654
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|267|NCBIGene:4133|Tumor stage|stage|physiology|121|C1300072
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|267|NCBIGene:4133|Tumor stage|stages|physiology|229|C1300072
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|267|NCBIGene:4133|Decision|decision|physiology|102|C0679006
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|267|NCBIGene:4133|Report:Finding:Point in time:{Setting}:Document:{Role}|report|physiology|16|C4255046
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|267|NCBIGene:4133|astrocyte differentiation|astrocyte differentiation|physiology|307|C1657435
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|267|NCBIGene:4133|astrocytic|astrocytic|anatomy|181|C0521395
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|267|NCBIGene:4133|Biological Markers|markers|physiology|199|C0005516
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|267|NCBIGene:4133|Down-Regulation|down-regulation|physiology|248|C0013081
75|In addition, we report novel idebenone properties  in a possible regulation of neural stem cells fate decision: only eNP stage responded with up-regulation of both neuronal (MAP2), astrocytic (GFAP) markers,  while at NSC and NP stages significant down-regulation of MAP2 expression was observed, promoting astrocyte differentiation|MAP2|MAP2|gene|267|NCBIGene:4133|Neural Stem Cells|neural stem cells|anatomy|79|C1113654
75|Thus, idebenone targets specific stages of hiPSC differentiation and may influence the neural stem cell fate decision|idebenone|idebenone|compound|6|mesh:C036619|Neural Stem Cells|neural stem cell|anatomy|87|C1113654
76|Chlorpyrifos (CPF) is an extensively used organophosphorus pesticide that has recently come under increasing scrutiny due to environmental health concerns particularly its association with neurodevelopmental defects|Chlorpyrifos|Chlorpyrifos|compound|0|mesh:D004390|CPF|CPF|compound|14|CHEBI:23501
76|Chlorpyrifos (CPF) is an extensively used organophosphorus pesticide that has recently come under increasing scrutiny due to environmental health concerns particularly its association with neurodevelopmental defects|Chlorpyrifos|Chlorpyrifos|compound|0|mesh:D004390|organophosphorus|organophosphorus|compound|42|mesh:D010755
76|Chlorpyrifos (CPF) is an extensively used organophosphorus pesticide that has recently come under increasing scrutiny due to environmental health concerns particularly its association with neurodevelopmental defects|Chlorpyrifos|Chlorpyrifos|compound|0|mesh:D004390|neurodevelopmental defects|neurodevelopmental defects|disease|189|mesh:D065886
76|Chlorpyrifos (CPF) is an extensively used organophosphorus pesticide that has recently come under increasing scrutiny due to environmental health concerns particularly its association with neurodevelopmental defects|CPF|CPF|compound|14|CHEBI:23501|organophosphorus|organophosphorus|compound|42|mesh:D010755
76|Chlorpyrifos (CPF) is an extensively used organophosphorus pesticide that has recently come under increasing scrutiny due to environmental health concerns particularly its association with neurodevelopmental defects|CPF|CPF|compound|14|CHEBI:23501|neurodevelopmental defects|neurodevelopmental defects|disease|189|mesh:D065886
76|Chlorpyrifos (CPF) is an extensively used organophosphorus pesticide that has recently come under increasing scrutiny due to environmental health concerns particularly its association with neurodevelopmental defects|organophosphorus|organophosphorus|compound|42|mesh:D010755|neurodevelopmental defects|neurodevelopmental defects|disease|189|mesh:D065886
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|53|CHEBI:23501|oxon|oxon|compound|79|mesh:C038620
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|53|CHEBI:23501|CPO|CPO|compound|96|CHEBI:45129
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|53|CHEBI:23501|acetylcholinesterase|acetylcholinesterase|gene|148|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|53|CHEBI:23501|AChE|AChE|gene|170|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|53|CHEBI:23501|CPO|CPO|compound|217|CHEBI:45129
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|53|CHEBI:23501|organophosphates|organophosphates|compound|232|mesh:D010755
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|53|CHEBI:23501|AChE|AChE|gene|337|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|53|CHEBI:23501|bony process|processes|anatomy|294|C1184743
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|53|CHEBI:23501|Block Specimens|inhibits|anatomy|116|C1533157
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|oxon|oxon|compound|79|mesh:C038620|CPO|CPO|compound|96|CHEBI:45129
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|oxon|oxon|compound|79|mesh:C038620|acetylcholinesterase|acetylcholinesterase|gene|148|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|oxon|oxon|compound|79|mesh:C038620|AChE|AChE|gene|170|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|oxon|oxon|compound|79|mesh:C038620|CPF|CPF|compound|212|CHEBI:23501
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|oxon|oxon|compound|79|mesh:C038620|CPO|CPO|compound|217|CHEBI:45129
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|oxon|oxon|compound|79|mesh:C038620|organophosphates|organophosphates|compound|232|mesh:D010755
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|oxon|oxon|compound|79|mesh:C038620|AChE|AChE|gene|337|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|oxon|oxon|compound|79|mesh:C038620|bony process|processes|anatomy|294|C1184743
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|oxon|oxon|compound|79|mesh:C038620|Block Specimens|inhibits|anatomy|116|C1533157
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|96|CHEBI:45129|acetylcholinesterase|acetylcholinesterase|gene|148|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|96|CHEBI:45129|AChE|AChE|gene|170|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|96|CHEBI:45129|CPF|CPF|compound|212|CHEBI:23501
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|96|CHEBI:45129|organophosphates|organophosphates|compound|232|mesh:D010755
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|96|CHEBI:45129|AChE|AChE|gene|337|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|96|CHEBI:45129|bony process|processes|anatomy|294|C1184743
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|96|CHEBI:45129|Block Specimens|inhibits|anatomy|116|C1533157
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|212|CHEBI:23501|acetylcholinesterase|acetylcholinesterase|gene|148|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|217|CHEBI:45129|acetylcholinesterase|acetylcholinesterase|gene|148|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|organophosphates|organophosphates|compound|232|mesh:D010755|acetylcholinesterase|acetylcholinesterase|gene|148|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|acetylcholinesterase|acetylcholinesterase|gene|148|NCBIGene:43|Affect (mental function)|affect|physiology|253|C0001721
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|acetylcholinesterase|acetylcholinesterase|gene|148|NCBIGene:43|bony process|processes|anatomy|294|C1184743
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|acetylcholinesterase|acetylcholinesterase|gene|148|NCBIGene:43|Block Specimens|inhibits|anatomy|116|C1533157
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|212|CHEBI:23501|AChE|AChE|gene|170|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|217|CHEBI:45129|AChE|AChE|gene|170|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|organophosphates|organophosphates|compound|232|mesh:D010755|AChE|AChE|gene|170|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|AChE|AChE|gene|170|NCBIGene:43|Affect (mental function)|affect|physiology|253|C0001721
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|AChE|AChE|gene|170|NCBIGene:43|bony process|processes|anatomy|294|C1184743
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|AChE|AChE|gene|170|NCBIGene:43|Block Specimens|inhibits|anatomy|116|C1533157
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|212|CHEBI:23501|CPO|CPO|compound|217|CHEBI:45129
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|212|CHEBI:23501|organophosphates|organophosphates|compound|232|mesh:D010755
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|212|CHEBI:23501|AChE|AChE|gene|337|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|212|CHEBI:23501|bony process|processes|anatomy|294|C1184743
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPF|CPF|compound|212|CHEBI:23501|Block Specimens|inhibits|anatomy|116|C1533157
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|217|CHEBI:45129|organophosphates|organophosphates|compound|232|mesh:D010755
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|217|CHEBI:45129|AChE|AChE|gene|337|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|217|CHEBI:45129|bony process|processes|anatomy|294|C1184743
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|CPO|CPO|compound|217|CHEBI:45129|Block Specimens|inhibits|anatomy|116|C1533157
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|organophosphates|organophosphates|compound|232|mesh:D010755|AChE|AChE|gene|337|NCBIGene:43
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|organophosphates|organophosphates|compound|232|mesh:D010755|bony process|processes|anatomy|294|C1184743
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|organophosphates|organophosphates|compound|232|mesh:D010755|Block Specimens|inhibits|anatomy|116|C1533157
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|AChE|AChE|gene|337|NCBIGene:43|Affect (mental function)|affect|physiology|253|C0001721
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|AChE|AChE|gene|337|NCBIGene:43|bony process|processes|anatomy|294|C1184743
76|While the insecticidal actions and acute toxicity of CPF are attributed to its oxon metabolite (CPO) which potently inhibits the cholinergic enzyme acetylcholinesterase (AChE), there is significant evidence that CPF, CPO, and other organophosphates may affect a variety of neuronal targets and processes that are not directly related to AChE|AChE|AChE|gene|337|NCBIGene:43|Block Specimens|inhibits|anatomy|116|C1533157
76|Previously, in adult rat sciatic nerves ex vivo and postnatal neurons from rats in vitro we observed that CPF and CPO impaired the movements of vesicles and mitochondria in axons|CPF|CPF|compound|106|CHEBI:23501|CPO|CPO|compound|114|CHEBI:45129
76|Previously, in adult rat sciatic nerves ex vivo and postnatal neurons from rats in vitro we observed that CPF and CPO impaired the movements of vesicles and mitochondria in axons|CPF|CPF|compound|106|CHEBI:23501|Structure of sciatic nerve|sciatic nerves|anatomy|25|C0036394
76|Previously, in adult rat sciatic nerves ex vivo and postnatal neurons from rats in vitro we observed that CPF and CPO impaired the movements of vesicles and mitochondria in axons|CPF|CPF|compound|106|CHEBI:23501|Mitochondria|mitochondria|anatomy|157|C0026237
76|Previously, in adult rat sciatic nerves ex vivo and postnatal neurons from rats in vitro we observed that CPF and CPO impaired the movements of vesicles and mitochondria in axons|CPF|CPF|compound|106|CHEBI:23501|Neurons|neurons|anatomy|62|C0027882
76|Previously, in adult rat sciatic nerves ex vivo and postnatal neurons from rats in vitro we observed that CPF and CPO impaired the movements of vesicles and mitochondria in axons|CPF|CPF|compound|106|CHEBI:23501|Axon|axons|anatomy|173|C0004461
76|Previously, in adult rat sciatic nerves ex vivo and postnatal neurons from rats in vitro we observed that CPF and CPO impaired the movements of vesicles and mitochondria in axons|CPO|CPO|compound|114|CHEBI:45129|Structure of sciatic nerve|sciatic nerves|anatomy|25|C0036394
76|Previously, in adult rat sciatic nerves ex vivo and postnatal neurons from rats in vitro we observed that CPF and CPO impaired the movements of vesicles and mitochondria in axons|CPO|CPO|compound|114|CHEBI:45129|Mitochondria|mitochondria|anatomy|157|C0026237
76|Previously, in adult rat sciatic nerves ex vivo and postnatal neurons from rats in vitro we observed that CPF and CPO impaired the movements of vesicles and mitochondria in axons|CPO|CPO|compound|114|CHEBI:45129|Neurons|neurons|anatomy|62|C0027882
76|Previously, in adult rat sciatic nerves ex vivo and postnatal neurons from rats in vitro we observed that CPF and CPO impaired the movements of vesicles and mitochondria in axons|CPO|CPO|compound|114|CHEBI:45129|Axon|axons|anatomy|173|C0004461
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPF|CPF|compound|80|CHEBI:23501|CPO|CPO|compound|88|CHEBI:45129
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPF|CPF|compound|80|CHEBI:23501|amyloid precursor protein|amyloid precursor protein|gene|230|NCBIGene:351
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPF|CPF|compound|80|CHEBI:23501|APP|APP|gene|257|NCBIGene:351
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPF|CPF|compound|80|CHEBI:23501|Dendra2|Dendra2|gene|298|NCBIGene:6442
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPF|CPF|compound|80|CHEBI:23501|APPDendra2|APPDendra2|gene|307|NCBIGene:7512
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPF|CPF|compound|80|CHEBI:23501|Neurons|neurons|anatomy|20|C0027882
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPF|CPF|compound|80|CHEBI:23501|Embryo|embryonic|anatomy|9|C0013935
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPO|CPO|compound|88|CHEBI:45129|amyloid precursor protein|amyloid precursor protein|gene|230|NCBIGene:351
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPO|CPO|compound|88|CHEBI:45129|APP|APP|gene|257|NCBIGene:351
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPO|CPO|compound|88|CHEBI:45129|Dendra2|Dendra2|gene|298|NCBIGene:6442
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPO|CPO|compound|88|CHEBI:45129|APPDendra2|APPDendra2|gene|307|NCBIGene:7512
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPO|CPO|compound|88|CHEBI:45129|Neurons|neurons|anatomy|20|C0027882
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|CPO|CPO|compound|88|CHEBI:45129|Embryo|embryonic|anatomy|9|C0013935
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|amyloid precursor protein|amyloid precursor protein|gene|230|NCBIGene:351|Dendra2|Dendra2|gene|298|NCBIGene:6442
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|amyloid precursor protein|amyloid precursor protein|gene|230|NCBIGene:351|APPDendra2|APPDendra2|gene|307|NCBIGene:7512
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|amyloid precursor protein|amyloid precursor protein|gene|230|NCBIGene:351|fast axonal transport|fast axonal transport|physiology|153|C0598954
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|amyloid precursor protein|amyloid precursor protein|gene|230|NCBIGene:351|Biological Markers|marker|physiology|290|C0005516
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|amyloid precursor protein|amyloid precursor protein|gene|230|NCBIGene:351|Mental concentration|concentrations|physiology|123|C0086045
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|amyloid precursor protein|amyloid precursor protein|gene|230|NCBIGene:351|Neurons|neurons|anatomy|20|C0027882
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|amyloid precursor protein|amyloid precursor protein|gene|230|NCBIGene:351|Embryo|embryonic|anatomy|9|C0013935
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|amyloid precursor protein|amyloid precursor protein|gene|230|NCBIGene:351|Binding (Molecular Function)|bound|physiology|187|C1167622
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APP|APP|gene|257|NCBIGene:351|Dendra2|Dendra2|gene|298|NCBIGene:6442
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APP|APP|gene|257|NCBIGene:351|APPDendra2|APPDendra2|gene|307|NCBIGene:7512
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APP|APP|gene|257|NCBIGene:351|fast axonal transport|fast axonal transport|physiology|153|C0598954
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APP|APP|gene|257|NCBIGene:351|Biological Markers|marker|physiology|290|C0005516
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APP|APP|gene|257|NCBIGene:351|Mental concentration|concentrations|physiology|123|C0086045
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APP|APP|gene|257|NCBIGene:351|Neurons|neurons|anatomy|20|C0027882
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APP|APP|gene|257|NCBIGene:351|Embryo|embryonic|anatomy|9|C0013935
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APP|APP|gene|257|NCBIGene:351|Binding (Molecular Function)|bound|physiology|187|C1167622
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|Dendra2|Dendra2|gene|298|NCBIGene:6442|APPDendra2|APPDendra2|gene|307|NCBIGene:7512
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|Dendra2|Dendra2|gene|298|NCBIGene:6442|fast axonal transport|fast axonal transport|physiology|153|C0598954
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|Dendra2|Dendra2|gene|298|NCBIGene:6442|Biological Markers|marker|physiology|290|C0005516
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|Dendra2|Dendra2|gene|298|NCBIGene:6442|Mental concentration|concentrations|physiology|123|C0086045
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|Dendra2|Dendra2|gene|298|NCBIGene:6442|Neurons|neurons|anatomy|20|C0027882
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|Dendra2|Dendra2|gene|298|NCBIGene:6442|Embryo|embryonic|anatomy|9|C0013935
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|Dendra2|Dendra2|gene|298|NCBIGene:6442|Binding (Molecular Function)|bound|physiology|187|C1167622
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APPDendra2|APPDendra2|gene|307|NCBIGene:7512|fast axonal transport|fast axonal transport|physiology|153|C0598954
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APPDendra2|APPDendra2|gene|307|NCBIGene:7512|Biological Markers|marker|physiology|290|C0005516
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APPDendra2|APPDendra2|gene|307|NCBIGene:7512|Mental concentration|concentrations|physiology|123|C0086045
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APPDendra2|APPDendra2|gene|307|NCBIGene:7512|Neurons|neurons|anatomy|20|C0027882
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APPDendra2|APPDendra2|gene|307|NCBIGene:7512|Embryo|embryonic|anatomy|9|C0013935
76|Here, in embryonic  neurons from rats in culture, we evaluated 24h exposures to CPF and CPO across picomolar to micromolar concentrations for effects on fast axonal transport of membrane bound organelles (MBOs) that contained the amyloid precursor protein (APP) tagged with the fluorescent marker, Dendra2 (APPDendra2)|APPDendra2|APPDendra2|gene|307|NCBIGene:7512|Binding (Molecular Function)|bound|physiology|187|C1167622
76|These effects occurred at concentrations that did not significantly inhibit AChE activity, they were not blocked by cholinergic receptor antagonists, and they were not associated with compromised cell viability|AChE|AChE|gene|76|NCBIGene:43|cholinergic receptor|cholinergic receptor|gene|116|NCBIGene:1134
76|These effects occurred at concentrations that did not significantly inhibit AChE activity, they were not blocked by cholinergic receptor antagonists, and they were not associated with compromised cell viability|AChE|AChE|gene|76|NCBIGene:43|Block Specimens|inhibit|anatomy|68|C1533157
76|These effects occurred at concentrations that did not significantly inhibit AChE activity, they were not blocked by cholinergic receptor antagonists, and they were not associated with compromised cell viability|AChE|AChE|gene|76|NCBIGene:43|Cell Survival|[|physiology|196|C0007620
76|These effects occurred at concentrations that did not significantly inhibit AChE activity, they were not blocked by cholinergic receptor antagonists, and they were not associated with compromised cell viability|AChE|AChE|gene|76|NCBIGene:43|Mental concentration|concentrations|physiology|26|C0086045
76|These effects occurred at concentrations that did not significantly inhibit AChE activity, they were not blocked by cholinergic receptor antagonists, and they were not associated with compromised cell viability|cholinergic receptor|cholinergic receptor|gene|116|NCBIGene:1134|Block Specimens|inhibit|anatomy|68|C1533157
76|These effects occurred at concentrations that did not significantly inhibit AChE activity, they were not blocked by cholinergic receptor antagonists, and they were not associated with compromised cell viability|cholinergic receptor|cholinergic receptor|gene|116|NCBIGene:1134|Cell Survival|[|physiology|196|C0007620
76|These effects occurred at concentrations that did not significantly inhibit AChE activity, they were not blocked by cholinergic receptor antagonists, and they were not associated with compromised cell viability|cholinergic receptor|cholinergic receptor|gene|116|NCBIGene:1134|Mental concentration|concentrations|physiology|26|C0086045
76|These effects of CPF and CPO may be significant given the importance of axonal transport to neuronal development as well the function of fully developed neurons|CPF|CPF|compound|17|CHEBI:23501|CPO|CPO|compound|25|CHEBI:45129
77|First described over 50 years ago, Rett syndrome (RTT) is a neurodevelopmental disorder caused primarily by mutations of the X-linked MECP2 gene|Rett syndrome|Rett syndrome|disease|35|mesh:D015518|neurodevelopmental disorder|neurodevelopmental disorder|disease|60|mesh:D065886
77|First described over 50 years ago, Rett syndrome (RTT) is a neurodevelopmental disorder caused primarily by mutations of the X-linked MECP2 gene|X-linked MECP2 gene|X-linked MECP2 gene|gene|125|NCBIGene:4204|Rett syndrome|Rett syndrome|disease|35|mesh:D015518
77|First described over 50 years ago, Rett syndrome (RTT) is a neurodevelopmental disorder caused primarily by mutations of the X-linked MECP2 gene|RTT|RTT|disease|50|mesh:D015518|neurodevelopmental disorder|neurodevelopmental disorder|disease|60|mesh:D065886
77|First described over 50 years ago, Rett syndrome (RTT) is a neurodevelopmental disorder caused primarily by mutations of the X-linked MECP2 gene|X-linked MECP2 gene|X-linked MECP2 gene|gene|125|NCBIGene:4204|RTT|RTT|disease|50|mesh:D015518
77|First described over 50 years ago, Rett syndrome (RTT) is a neurodevelopmental disorder caused primarily by mutations of the X-linked MECP2 gene|X-linked MECP2 gene|X-linked MECP2 gene|gene|125|NCBIGene:4204|neurodevelopmental disorder|neurodevelopmental disorder|disease|60|mesh:D065886
77|RTT affects predominantly females, and has a prevalence of roughly 1 in every 10,000 female births|RTT|RTT|disease|0|mesh:D015518|Female genitalia|[|anatomy|85|C0017421
77|Prior to the discovery that mutations of MECP2 are the leading cause of RTT, there were suggestions that RTT could be a mitochondrial disease|MECP2|MECP2|gene|41|NCBIGene:4204|RTT|RTT|disease|72|mesh:D015518
77|Prior to the discovery that mutations of MECP2 are the leading cause of RTT, there were suggestions that RTT could be a mitochondrial disease|MECP2|MECP2|gene|41|NCBIGene:4204|RTT|RTT|disease|105|mesh:D015518
77|Prior to the discovery that mutations of MECP2 are the leading cause of RTT, there were suggestions that RTT could be a mitochondrial disease|MECP2|MECP2|gene|41|NCBIGene:4204|mitochondrial disease|mitochondrial disease|disease|120|mesh:D028361
77|Prior to the discovery that mutations of MECP2 are the leading cause of RTT, there were suggestions that RTT could be a mitochondrial disease|MECP2|MECP2|gene|41|NCBIGene:4204|Mutation|mutations|physiology|28|C0026882
77|Prior to the discovery that mutations of MECP2 are the leading cause of RTT, there were suggestions that RTT could be a mitochondrial disease|RTT|RTT|disease|72|mesh:D015518|mitochondrial disease|mitochondrial disease|disease|120|mesh:D028361
77|Prior to the discovery that mutations of MECP2 are the leading cause of RTT, there were suggestions that RTT could be a mitochondrial disease|RTT|RTT|disease|105|mesh:D015518|mitochondrial disease|mitochondrial disease|disease|120|mesh:D028361
77|In fact, several reports documented altered mitochondrial structure, and deficiencies in mitochondrial enzyme activity in different cells or tissues derived from RTT patients|RTT|RTT|disease|162|mesh:D015518|Body tissue|tissues|anatomy|141|C0040300
77|In fact, several reports documented altered mitochondrial structure, and deficiencies in mitochondrial enzyme activity in different cells or tissues derived from RTT patients|RTT|RTT|disease|162|mesh:D015518|Somatostatin-Secreting Cells|different cells|anatomy|122|C0524984
77|In fact, several reports documented altered mitochondrial structure, and deficiencies in mitochondrial enzyme activity in different cells or tissues derived from RTT patients|RTT|RTT|disease|162|mesh:D015518|Mitochondria|mitochondrial structure|anatomy|44|C0026237
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MECP2|MECP2|gene|27|NCBIGene:4204|Affect (mental function)|affects|physiology|157|C0001721
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MECP2|MECP2|gene|27|NCBIGene:4204|Brain|brain|anatomy|130|C0006104
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MECP2|MECP2|gene|27|NCBIGene:4204|Interested|interest|physiology|53|C0543488
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MECP2|MECP2|gene|27|NCBIGene:4204|Neurophysiology - biologic function|neurophysiology|physiology|190|C0700630
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MECP2|MECP2|gene|27|NCBIGene:4204|neurodevelopment|neurodevelopment|physiology|169|C0599855
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MECP2|MECP2|gene|27|NCBIGene:4204|Identification (Psychology)|identification|physiology|9|C0020792
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MeCP2|MeCP2|gene|117|NCBIGene:4204|Affect (mental function)|affects|physiology|157|C0001721
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MeCP2|MeCP2|gene|117|NCBIGene:4204|Brain|brain|anatomy|130|C0006104
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MeCP2|MeCP2|gene|117|NCBIGene:4204|Interested|interest|physiology|53|C0543488
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MeCP2|MeCP2|gene|117|NCBIGene:4204|Neurophysiology - biologic function|neurophysiology|physiology|190|C0700630
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MeCP2|MeCP2|gene|117|NCBIGene:4204|neurodevelopment|neurodevelopment|physiology|169|C0599855
77|With the identification of MECP2 as the causal gene, interest largely shifted toward defining the normal function of MeCP2 in the brain, and how its absence affects the neurodevelopment and neurophysiology|MeCP2|MeCP2|gene|117|NCBIGene:4204|Identification (Psychology)|identification|physiology|9|C0020792
77|Recently, though, interest in studying mitochondrial function in RTT has been reignited, at least in part due to observations suggesting systemic oxidative stress does play a contributing role in RTT pathogenesis|RTT|RTT|disease|65|mesh:D015518|Mitochondria|mitochondrial|anatomy|39|C0026237
77|Recently, though, interest in studying mitochondrial function in RTT has been reignited, at least in part due to observations suggesting systemic oxidative stress does play a contributing role in RTT pathogenesis|RTT|RTT|disease|196|mesh:D015518|Mitochondria|mitochondrial|anatomy|39|C0026237
77|Here we review data relating to mitochondrial alterations at the structural and functional levels in RTT patients and model systems, and present a hypothesis for how the absence of MeCP2 could lead to altered mitochondrial function and elevated levels of cellular oxidative  stress|MeCP2|MeCP2|gene|181|NCBIGene:4204|RTT|RTT|disease|101|mesh:D015518
77|Here we review data relating to mitochondrial alterations at the structural and functional levels in RTT patients and model systems, and present a hypothesis for how the absence of MeCP2 could lead to altered mitochondrial function and elevated levels of cellular oxidative  stress|MeCP2|MeCP2|gene|181|NCBIGene:4204|Function Axis|function|physiology|223|C0700205
77|Finally, we discuss the prospects for treating RTT using interventions that target specific aspects of mitochondrial dysfunction and/or oxidative stress|RTT|RTT|disease|47|mesh:D015518|mitochondrial dysfunction|mitochondrial dysfunction|disease|103|mesh:D028361
78|BACKGROUND: Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency affects ketone body and isoleucine catabolism|acetoacetyl-CoA|acetoacetyl-CoA|compound|26|mesh:C010667|T2|T2|gene|52|NCBIGene:292
78|BACKGROUND: Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency affects ketone body and isoleucine catabolism|acetoacetyl-CoA|acetoacetyl-CoA|compound|26|mesh:C010667|isoleucine|isoleucine|compound|91|mesh:D007532
78|BACKGROUND: Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency affects ketone body and isoleucine catabolism|acetoacetyl-CoA thiolase|acetoacetyl-CoA thiolase|gene|26|NCBIGene:38|T2|T2|gene|52|NCBIGene:292
78|BACKGROUND: Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency affects ketone body and isoleucine catabolism|isoleucine|isoleucine|compound|91|mesh:D007532|acetoacetyl-CoA thiolase|acetoacetyl-CoA thiolase|gene|26|NCBIGene:38
78|BACKGROUND: Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency affects ketone body and isoleucine catabolism|acetoacetyl-CoA thiolase|acetoacetyl-CoA thiolase|gene|26|NCBIGene:38|Affect (mental function)|affects|physiology|67|C0001721
78|BACKGROUND: Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency affects ketone body and isoleucine catabolism|acetoacetyl-CoA thiolase|acetoacetyl-CoA thiolase|gene|26|NCBIGene:38|isoleucine catabolic process|isoleucine catabolism|physiology|91|C1156698
78|BACKGROUND: Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency affects ketone body and isoleucine catabolism|isoleucine|isoleucine|compound|91|mesh:D007532|T2|T2|gene|52|NCBIGene:292
78|BACKGROUND: Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency affects ketone body and isoleucine catabolism|T2|T2|gene|52|NCBIGene:292|Affect (mental function)|affects|physiology|67|C0001721
78|BACKGROUND: Mitochondrial acetoacetyl-CoA thiolase (T2) deficiency affects ketone body and isoleucine catabolism|T2|T2|gene|52|NCBIGene:292|isoleucine catabolic process|isoleucine catabolism|physiology|91|C1156698
78|Neurological impairment may occur secondary to ketoacidotic episodes|Neurological impairment|Neurological impairment|disease|0|mesh:D009422|ketoacidotic episodes|ketoacidotic episodes|disease|47|mesh:D007662
78|However, we observed neuromotor abnormalities without ketoacidotic events in two T2-deficient families|neuromotor abnormalities|neuromotor abnormalities|disease|21|mesh:D000068079|ketoacidotic|ketoacidotic|disease|54|mesh:D007662
78|However, we observed neuromotor abnormalities without ketoacidotic events in two T2-deficient families|neuromotor abnormalities|neuromotor abnormalities|disease|21|mesh:D000068079|T2-deficient|T2-deficient|disease|81|mesh:C535434
78|However, we observed neuromotor abnormalities without ketoacidotic events in two T2-deficient families|T2|T2|gene|81|NCBIGene:292|neuromotor abnormalities|neuromotor abnormalities|disease|21|mesh:D000068079
78|However, we observed neuromotor abnormalities without ketoacidotic events in two T2-deficient families|ketoacidotic|ketoacidotic|disease|54|mesh:D007662|T2-deficient|T2-deficient|disease|81|mesh:C535434
78|However, we observed neuromotor abnormalities without ketoacidotic events in two T2-deficient families|T2|T2|gene|81|NCBIGene:292|ketoacidotic|ketoacidotic|disease|54|mesh:D007662
78|We hypothesized that the neurological signs were related to the genetic defect and may occur independently of ketoacidotic episodes|genetic defect|genetic defect|disease|64|mesh:D030342|ketoacidotic|ketoacidotic|disease|110|mesh:D007662
78|We therefore conducted a retrospective review on a French T2-deficient patient series searching for neuromotor impairment|T2-deficient|T2-deficient|disease|58|mesh:C535434|neuromotor impairment|neuromotor impairment|disease|100|mesh:D000068079
78|We therefore conducted a retrospective review on a French T2-deficient patient series searching for neuromotor impairment|T2|T2|gene|58|NCBIGene:292|neuromotor impairment|neuromotor impairment|disease|100|mesh:D000068079
78|Among these, two had never experienced ketoacidotic episodes, though they developed extrapyramidal signs with putamen involvement|ketoacidotic episodes|ketoacidotic episodes|disease|39|mesh:D007662|extrapyramidal signs|extrapyramidal signs|disease|84|mesh:D001480
78|Two of the other four patients developed neurological abnormalities before the first ketoacidotic crisis, with putamen involvement in one case|neurological abnormalities|neurological abnormalities|disease|41|mesh:D009410|ketoacidotic crisis|ketoacidotic crisis|disease|85|mesh:D007662
78|Two of the other four patients developed neurological abnormalities before the first ketoacidotic crisis, with putamen involvement in one case|neurological abnormalities|neurological abnormalities|disease|41|mesh:D009410|Structure of putamen|putamen|anatomy|111|C0034169
78|Two of the other four patients developed neurological abnormalities before the first ketoacidotic crisis, with putamen involvement in one case|ketoacidotic crisis|ketoacidotic crisis|disease|85|mesh:D007662|Structure of putamen|putamen|anatomy|111|C0034169
78|The third patient developed extrapyramidal symptoms more than 10 years after the initial decompensation with globus pallidus involvement|extrapyramidal symptoms|extrapyramidal symptoms|disease|28|mesh:D001480|globus pallidus involvement|globus pallidus involvement|disease|109|mesh:C538104
78|The third patient developed extrapyramidal symptoms more than 10 years after the initial decompensation with globus pallidus involvement|extrapyramidal symptoms|extrapyramidal symptoms|disease|28|mesh:D001480|Globus Pallidus|globus pallidus|anatomy|109|C0017651
78|The last patient developed extrapyramidal signs immediately after a  severe ketoacidotic crisis with putaminal lesions|extrapyramidal|extrapyramidal|disease|27|mesh:D001480|ketoacidotic crisis|ketoacidotic crisis|disease|76|mesh:D007662
78|The last patient developed extrapyramidal signs immediately after a  severe ketoacidotic crisis with putaminal lesions|extrapyramidal|extrapyramidal|disease|27|mesh:D001480|putaminal lesions|putaminal lesions|disease|101|mesh:D001927
78|The last patient developed extrapyramidal signs immediately after a  severe ketoacidotic crisis with putaminal lesions|ketoacidotic crisis|ketoacidotic crisis|disease|76|mesh:D007662|putaminal lesions|putaminal lesions|disease|101|mesh:D001927
78|However, on account of the role of T2 in isoleucine catabolism, these patients are potentially exposed to accumulation of toxic isoleucine-derived metabolites,  which may contribute to neurological impairment|isoleucine|isoleucine|compound|41|mesh:D007532|neurological impairment|neurological impairment|disease|185|mesh:D009422
78|However, on account of the role of T2 in isoleucine catabolism, these patients are potentially exposed to accumulation of toxic isoleucine-derived metabolites,  which may contribute to neurological impairment|isoleucine|isoleucine|compound|128|mesh:D007532|neurological impairment|neurological impairment|disease|185|mesh:D009422
78|Our findings confirm previous observations that neurological symptoms in T2 deficiency may occur unrelated to ketoacidosis|neurological|neurological|disease|48|mesh:D009422|T2 deficiency|T2 deficiency|disease|73|mesh:C535434
78|Our findings confirm previous observations that neurological symptoms in T2 deficiency may occur unrelated to ketoacidosis|neurological|neurological|disease|48|mesh:D009422|ketoacidosis|ketoacidosis|disease|110|mesh:D007662
78|Our findings confirm previous observations that neurological symptoms in T2 deficiency may occur unrelated to ketoacidosis|T2 deficiency|T2 deficiency|disease|73|mesh:C535434|ketoacidosis|ketoacidosis|disease|110|mesh:D007662
79|Autism is a neurodevelopmental disease that presents in early life|Autism|Autism|disease|0|omim:209850|neurodevelopmental disease|neurodevelopmental disease|disease|12|mesh:D065886
79|Vitamin D is an active neurosteroid and  plays crucial neuroprotective roles in the developing brain|Vitamin D|Vitamin D|compound|0|mesh:D014807|Brain|brain|anatomy|95|C0006104
79|Here we review the potential neurobiological mechanisms linking prenatal vitamin D deficiency and autism and also discuss what future research targets must now be addressed|prenatal vitamin D deficiency|prenatal vitamin D deficiency|disease|64|mesh:D014808|autism|autism|disease|98|omim:209850
79|Here we review the potential neurobiological mechanisms linking prenatal vitamin D deficiency and autism and also discuss what future research targets must now be addressed|vitamin D|vitamin D|compound|73|mesh:D014807|autism|autism|disease|98|omim:209850
80|The authors, therefore, evaluated whether changes in synaptic transmission after dendritic spine formation induced  by sevoflurane were associated with long-term behavioral changes|sevoflurane|sevoflurane|compound|119|mesh:D000077149|Dendritic Spines|dendritic spine|anatomy|81|C0872341
80|CONCLUSIONS: Sevoflurane exposure during the critical period induces mitochondrial hyperactivity and transient imbalance of excitatory/inhibitory synaptic transmission, without long-lasting behavioral consequences|Sevoflurane|Sevoflurane|compound|13|mesh:D000077149|Mitochondria|mitochondrial|anatomy|69|C0026237
81|Extensive reviews have discussed the protective effects of polyphenols against a series of diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders|polyphenols|polyphenols|compound|59|mesh:D059808|cancer|cancer|disease|108|mesh:D009369
81|Extensive reviews have discussed the protective effects of polyphenols against a series of diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders|polyphenols|polyphenols|compound|59|mesh:D059808|cardiovascular diseases|cardiovascular diseases|disease|116|mesh:D002318
81|Extensive reviews have discussed the protective effects of polyphenols against a series of diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders|polyphenols|polyphenols|compound|59|mesh:D059808|diabetes|diabetes|disease|141|mesh:D003920
81|Extensive reviews have discussed the protective effects of polyphenols against a series of diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders|polyphenols|polyphenols|compound|59|mesh:D059808|neurodegenerative disorders|neurodegenerative disorders|disease|155|mesh:D019636
81|Extensive reviews have discussed the protective effects of polyphenols against a series of diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders|cancer|cancer|disease|108|mesh:D009369|cardiovascular diseases|cardiovascular diseases|disease|116|mesh:D002318
81|Extensive reviews have discussed the protective effects of polyphenols against a series of diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders|cancer|cancer|disease|108|mesh:D009369|diabetes|diabetes|disease|141|mesh:D003920
81|Extensive reviews have discussed the protective effects of polyphenols against a series of diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders|cancer|cancer|disease|108|mesh:D009369|neurodegenerative disorders|neurodegenerative disorders|disease|155|mesh:D019636
81|Extensive reviews have discussed the protective effects of polyphenols against a series of diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders|cardiovascular diseases|cardiovascular diseases|disease|116|mesh:D002318|diabetes|diabetes|disease|141|mesh:D003920
81|Extensive reviews have discussed the protective effects of polyphenols against a series of diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders|cardiovascular diseases|cardiovascular diseases|disease|116|mesh:D002318|neurodegenerative disorders|neurodegenerative disorders|disease|155|mesh:D019636
81|Extensive reviews have discussed the protective effects of polyphenols against a series of diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders|diabetes|diabetes|disease|141|mesh:D003920|neurodegenerative disorders|neurodegenerative disorders|disease|155|mesh:D019636
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|neurodevelopmental disorders|neurodevelopmental disorders|disease|98|mesh:D065886|intellectual disability|intellectual disability|disease|143|mesh:D008607
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|neurodevelopmental disorders|neurodevelopmental disorders|disease|98|mesh:D065886|Down syndrome|Down syndrome|disease|176|omim:190685
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|neurodevelopmental disorders|neurodevelopmental disorders|disease|98|mesh:D065886|DS|DS|disease|191|mesh:D009958
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|neurodevelopmental disorders|neurodevelopmental disorders|disease|98|mesh:D065886|mitochondrial dysfunctions|mitochondrial dysfunctions|disease|206|mesh:D028361
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|neurodevelopmental disorders|neurodevelopmental disorders|disease|98|mesh:D065886|deleterious symptoms|deleterious symptoms|disease|291|mesh:D010900
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|neurodevelopmental disorders|neurodevelopmental disorders|disease|98|mesh:D065886|cognitive decline|cognitive decline|disease|316|mesh:D003072
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|intellectual disability|intellectual disability|disease|143|mesh:D008607|Down syndrome|Down syndrome|disease|176|omim:190685
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|intellectual disability|intellectual disability|disease|143|mesh:D008607|DS|DS|disease|191|mesh:D009958
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|intellectual disability|intellectual disability|disease|143|mesh:D008607|mitochondrial dysfunctions|mitochondrial dysfunctions|disease|206|mesh:D028361
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|intellectual disability|intellectual disability|disease|143|mesh:D008607|deleterious symptoms|deleterious symptoms|disease|291|mesh:D010900
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|intellectual disability|intellectual disability|disease|143|mesh:D008607|cognitive decline|cognitive decline|disease|316|mesh:D003072
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|Down syndrome|Down syndrome|disease|176|omim:190685|DS|DS|disease|191|mesh:D009958
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|Down syndrome|Down syndrome|disease|176|omim:190685|mitochondrial dysfunctions|mitochondrial dysfunctions|disease|206|mesh:D028361
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|Down syndrome|Down syndrome|disease|176|omim:190685|deleterious symptoms|deleterious symptoms|disease|291|mesh:D010900
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|Down syndrome|Down syndrome|disease|176|omim:190685|cognitive decline|cognitive decline|disease|316|mesh:D003072
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|DS|DS|disease|191|mesh:D009958|mitochondrial dysfunctions|mitochondrial dysfunctions|disease|206|mesh:D028361
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|DS|DS|disease|191|mesh:D009958|deleterious symptoms|deleterious symptoms|disease|291|mesh:D010900
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|DS|DS|disease|191|mesh:D009958|cognitive decline|cognitive decline|disease|316|mesh:D003072
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|mitochondrial dysfunctions|mitochondrial dysfunctions|disease|206|mesh:D028361|deleterious symptoms|deleterious symptoms|disease|291|mesh:D010900
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|mitochondrial dysfunctions|mitochondrial dysfunctions|disease|206|mesh:D028361|cognitive decline|cognitive decline|disease|316|mesh:D003072
81|Limited studies have investigated the potential therapeutic effects of these natural compounds on neurodevelopmental disorders associated with intellectual disability, such as Down syndrome (DS), for which mitochondrial dysfunctions and  oxidative stress are hallmarks and contribute to the deleterious symptoms and cognitive decline|deleterious symptoms|deleterious symptoms|disease|291|mesh:D010900|cognitive decline|cognitive decline|disease|316|mesh:D003072
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|polyphenols|polyphenols|compound|99|mesh:D059808|epigallocatechin-3-gallate|epigallocatechin-3-gallate|compound|225|mesh:C045651
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|polyphenols|polyphenols|compound|99|mesh:D059808|resveratrol|resveratrol|compound|253|mesh:D000077185
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|polyphenols|polyphenols|compound|99|mesh:D059808|hydroxytyrosol|hydroxytyrosol|compound|269|mesh:C005975
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|polyphenols|polyphenols|compound|99|mesh:D059808|DS|DS|disease|371|mesh:D009958
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|polyphenols|polyphenols|compound|99|mesh:D059808|Mitochondria|mitochondrial|anatomy|298|C0026237
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|epigallocatechin-3-gallate|epigallocatechin-3-gallate|compound|225|mesh:C045651|resveratrol|resveratrol|compound|253|mesh:D000077185
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|epigallocatechin-3-gallate|epigallocatechin-3-gallate|compound|225|mesh:C045651|hydroxytyrosol|hydroxytyrosol|compound|269|mesh:C005975
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|epigallocatechin-3-gallate|epigallocatechin-3-gallate|compound|225|mesh:C045651|DS|DS|disease|371|mesh:D009958
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|epigallocatechin-3-gallate|epigallocatechin-3-gallate|compound|225|mesh:C045651|Mitochondria|mitochondrial|anatomy|298|C0026237
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|resveratrol|resveratrol|compound|253|mesh:D000077185|hydroxytyrosol|hydroxytyrosol|compound|269|mesh:C005975
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|resveratrol|resveratrol|compound|253|mesh:D000077185|DS|DS|disease|371|mesh:D009958
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|resveratrol|resveratrol|compound|253|mesh:D000077185|Mitochondria|mitochondrial|anatomy|298|C0026237
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|hydroxytyrosol|hydroxytyrosol|compound|269|mesh:C005975|DS|DS|disease|371|mesh:D009958
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|hydroxytyrosol|hydroxytyrosol|compound|269|mesh:C005975|Mitochondria|mitochondrial|anatomy|298|C0026237
81|This review, starting from the structure, source, bioavailability and pharmacokinetics of relevant polyphenols, highlights recent studies on the effect and potential molecular mechanism(s) of action of the phenolic compounds epigallocatechin-3-gallate, resveratrol and hydroxytyrosol in  restoring mitochondrial energy deficit and in reversing phenotypical alteration in DS|DS|DS|disease|371|mesh:D009958|Mitochondria|mitochondrial|anatomy|298|C0026237
81|The clinical implications of plant polyphenol dietary supplements as therapeutic tools in managing DS and other intellectual disability-related diseases, is also discussed|polyphenol|polyphenol|compound|35|mesh:D059808|DS|DS|disease|99|mesh:D009958
81|The clinical implications of plant polyphenol dietary supplements as therapeutic tools in managing DS and other intellectual disability-related diseases, is also discussed|polyphenol|polyphenol|compound|35|mesh:D059808|intellectual disability|intellectual disability|disease|112|mesh:D008607
81|The clinical implications of plant polyphenol dietary supplements as therapeutic tools in managing DS and other intellectual disability-related diseases, is also discussed|DS|DS|disease|99|mesh:D009958|intellectual disability|intellectual disability|disease|112|mesh:D008607
82|The mechanisms underlying Zika virus (ZIKV)-related microcephaly and other neurodevelopment defects remain poorly understood|Zika virus|Zika virus|disease|26|mesh:D000071243|microcephaly|microcephaly|disease|52|mesh:D008831
82|The mechanisms underlying Zika virus (ZIKV)-related microcephaly and other neurodevelopment defects remain poorly understood|Zika virus|Zika virus|disease|26|mesh:D000071243|neurodevelopment defects|neurodevelopment defects|disease|75|mesh:D065886
82|The mechanisms underlying Zika virus (ZIKV)-related microcephaly and other neurodevelopment defects remain poorly understood|microcephaly|microcephaly|disease|52|mesh:D008831|neurodevelopment defects|neurodevelopment defects|disease|75|mesh:D065886
82|By analyzing human NES cells, organotypic fetal brain slices, and a ZIKV-infected micrencephalic brain,  we show that ZIKV infects both neocortical and spinal NES cells as well as their  fetal homolog, radial glial cells (RGCs), causing disrupted mitoses, supernumerary centrosomes, structural disorganization, and cell death|ZIKV-infected micrencephalic|ZIKV-infected micrencephalic|disease|68|mesh:D000071243|Radial Glial Cells|radial glial cells|anatomy|202|C3661481
82|By analyzing human NES cells, organotypic fetal brain slices, and a ZIKV-infected micrencephalic brain,  we show that ZIKV infects both neocortical and spinal NES cells as well as their  fetal homolog, radial glial cells (RGCs), causing disrupted mitoses, supernumerary centrosomes, structural disorganization, and cell death|ZIKV-infected micrencephalic|ZIKV-infected micrencephalic|disease|68|mesh:D000071243|Centrosome|centrosomes|anatomy|270|C0242608
82|By analyzing human NES cells, organotypic fetal brain slices, and a ZIKV-infected micrencephalic brain,  we show that ZIKV infects both neocortical and spinal NES cells as well as their  fetal homolog, radial glial cells (RGCs), causing disrupted mitoses, supernumerary centrosomes, structural disorganization, and cell death|ZIKV-infected micrencephalic|ZIKV-infected micrencephalic|disease|68|mesh:D000071243|Cells|cells|anatomy|163|C0007634
82|By analyzing human NES cells, organotypic fetal brain slices, and a ZIKV-infected micrencephalic brain,  we show that ZIKV infects both neocortical and spinal NES cells as well as their  fetal homolog, radial glial cells (RGCs), causing disrupted mitoses, supernumerary centrosomes, structural disorganization, and cell death|ZIKV-infected micrencephalic|ZIKV-infected micrencephalic|disease|68|mesh:D000071243|Brain|brain|anatomy|97|C0006104
82|By analyzing human NES cells, organotypic fetal brain slices, and a ZIKV-infected micrencephalic brain,  we show that ZIKV infects both neocortical and spinal NES cells as well as their  fetal homolog, radial glial cells (RGCs), causing disrupted mitoses, supernumerary centrosomes, structural disorganization, and cell death|ZIKV-infected micrencephalic|ZIKV-infected micrencephalic|disease|68|mesh:D000071243|Fetal brain|fetal brain|anatomy|42|C0440731
82|By analyzing human NES cells, organotypic fetal brain slices, and a ZIKV-infected micrencephalic brain,  we show that ZIKV infects both neocortical and spinal NES cells as well as their  fetal homolog, radial glial cells (RGCs), causing disrupted mitoses, supernumerary centrosomes, structural disorganization, and cell death|ZIKV-infected micrencephalic|ZIKV-infected micrencephalic|disease|68|mesh:D000071243|Fetus|fetal|anatomy|187|C0015965
82|ZIKV infection of NES cells and RGCs causes centrosomal depletion and mitochondrial sequestration of phospho-TBK1 during mitosis|phospho-TBK1|phospho-TBK1|gene|101|NCBIGene:29110|Mitosis|mitosis|physiology|121|C0026255
82|ZIKV infection of NES cells and RGCs causes centrosomal depletion and mitochondrial sequestration of phospho-TBK1 during mitosis|phospho-TBK1|phospho-TBK1|gene|101|NCBIGene:29110|Cells|cells|anatomy|22|C0007634
82|ZIKV infection of NES cells and RGCs causes centrosomal depletion and mitochondrial sequestration of phospho-TBK1 during mitosis|phospho-TBK1|phospho-TBK1|gene|101|NCBIGene:29110|Mitochondria|mitochondrial|anatomy|70|C0026237
82|We also found that nucleoside analogs inhibit ZIKV replication in NES cells, protecting them from ZIKV-induced  pTBK1 relocalization and cell death|nucleoside|nucleoside|compound|19|mesh:D009705|pTBK1|pTBK1|gene|112|NCBIGene:5725
82|We also found that nucleoside analogs inhibit ZIKV replication in NES cells, protecting them from ZIKV-induced  pTBK1 relocalization and cell death|nucleoside|nucleoside|compound|19|mesh:D009705|Block Specimens|inhibit|anatomy|38|C1533157
82|We also found that nucleoside analogs inhibit ZIKV replication in NES cells, protecting them from ZIKV-induced  pTBK1 relocalization and cell death|pTBK1|pTBK1|gene|112|NCBIGene:5725|Cell Death|cell death|physiology|137|C0007587
82|We also found that nucleoside analogs inhibit ZIKV replication in NES cells, protecting them from ZIKV-induced  pTBK1 relocalization and cell death|pTBK1|pTBK1|gene|112|NCBIGene:5725|Block Specimens|inhibit|anatomy|38|C1533157
82|We established a model system of human neural stem cells to reveal cellular and molecular mechanisms underlying neurodevelopmental defects associated with ZIKV infection and its potential treatment|neurodevelopmental defects|neurodevelopmental defects|disease|112|mesh:D065886|ZIKV|ZIKV|disease|155|mesh:D000071243
82|We established a model system of human neural stem cells to reveal cellular and molecular mechanisms underlying neurodevelopmental defects associated with ZIKV infection and its potential treatment|neurodevelopmental defects|neurodevelopmental defects|disease|112|mesh:D065886|Cells|cellular|anatomy|67|C0007634
82|We established a model system of human neural stem cells to reveal cellular and molecular mechanisms underlying neurodevelopmental defects associated with ZIKV infection and its potential treatment|ZIKV|ZIKV|disease|155|mesh:D000071243|Cells|cellular|anatomy|67|C0007634
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|neurodevelopmental disorder|neurodevelopmental disorder|disease|82|mesh:D065886|pontocerebellar hypoplasia|pontocerebellar hypoplasia|disease|127|mesh:C580383
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|neurodevelopmental disorder|neurodevelopmental disorder|disease|82|mesh:D065886|apnoea|apnoea|disease|158|mesh:D001049
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|SLC25A46 gene|SLC25A46 gene|gene|230|NCBIGene:91137|neurodevelopmental disorder|neurodevelopmental disorder|disease|82|mesh:D065886
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|neurodevelopmental disorder|neurodevelopmental disorder|disease|82|mesh:D065886|optic atrophy spectrum disorder|optic atrophy spectrum disorder|disease|300|mesh:D009896
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|pontocerebellar hypoplasia|pontocerebellar hypoplasia|disease|127|mesh:C580383|apnoea|apnoea|disease|158|mesh:D001049
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|SLC25A46 gene|SLC25A46 gene|gene|230|NCBIGene:91137|pontocerebellar hypoplasia|pontocerebellar hypoplasia|disease|127|mesh:C580383
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|pontocerebellar hypoplasia|pontocerebellar hypoplasia|disease|127|mesh:C580383|optic atrophy spectrum disorder|optic atrophy spectrum disorder|disease|300|mesh:D009896
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|SLC25A46 gene|SLC25A46 gene|gene|230|NCBIGene:91137|apnoea|apnoea|disease|158|mesh:D001049
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|apnoea|apnoea|disease|158|mesh:D001049|optic atrophy spectrum disorder|optic atrophy spectrum disorder|disease|300|mesh:D009896
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|SLC25A46 gene|SLC25A46 gene|gene|230|NCBIGene:91137|optic atrophy spectrum disorder|optic atrophy spectrum disorder|disease|300|mesh:D009896
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|SLC25A46 gene|SLC25A46 gene|gene|230|NCBIGene:91137|Cessation of life|died|physiology|44|C0011065
83|In siblings from two unrelated families who died soon after birth with a profound neurodevelopmental disorder characterized by pontocerebellar hypoplasia and apnoea, we discovered a missense mutation and an exonic deletion in the SLC25A46 gene encoding a mitochondrial protein recently implicated in optic atrophy spectrum disorder|SLC25A46 gene|SLC25A46 gene|gene|230|NCBIGene:91137|Missense Mutation|missense mutation|physiology|182|C0599155
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|slc24a46|slc24a46|gene|13|NCBIGene:91137|brain malformation|brain malformation|disease|61|mesh:D001927
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|slc24a46|slc24a46|gene|13|NCBIGene:91137|spinal motor|spinal motor|disease|81|mesh:D013122
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|slc24a46|slc24a46|gene|13|NCBIGene:91137|poor motility|poor motility|disease|111|mesh:D020820
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|slc24a46|slc24a46|gene|13|NCBIGene:91137|Embryo|embryos|anatomy|46|C0013935
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|slc24a46|slc24a46|gene|13|NCBIGene:91137|cell motility|motility|physiology|116|C0007608
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|slc24a46|slc24a46|gene|13|NCBIGene:91137|Motor Neurons|motor neuron|anatomy|88|C0026609
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|brain malformation|brain malformation|disease|61|mesh:D001927|spinal motor|spinal motor|disease|81|mesh:D013122
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|brain malformation|brain malformation|disease|61|mesh:D001927|poor motility|poor motility|disease|111|mesh:D020820
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|brain malformation|brain malformation|disease|61|mesh:D001927|Embryo|embryos|anatomy|46|C0013935
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|brain malformation|brain malformation|disease|61|mesh:D001927|Motor Neurons|motor neuron|anatomy|88|C0026609
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|spinal motor|spinal motor|disease|81|mesh:D013122|poor motility|poor motility|disease|111|mesh:D020820
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|spinal motor|spinal motor|disease|81|mesh:D013122|Embryo|embryos|anatomy|46|C0013935
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|poor motility|poor motility|disease|111|mesh:D020820|Embryo|embryos|anatomy|46|C0013935
83|Knockdown of slc24a46 expression in zebrafish embryos caused brain malformation, spinal motor neuron loss, and poor motility|poor motility|poor motility|disease|111|mesh:D020820|Motor Neurons|motor neuron|anatomy|88|C0026609
83|At the cellular level, we observed abnormally elongated mitochondria, which was rescued by co-injection  of the wild-type but not the mutant slc25a46 mRNA|mutant slc25a46 mRNA|mutant slc25a46 mRNA|gene|134|NCBIGene:91137|Mitochondria|mitochondria|anatomy|56|C0026237
83|At the cellular level, we observed abnormally elongated mitochondria, which was rescued by co-injection  of the wild-type but not the mutant slc25a46 mRNA|mutant slc25a46 mRNA|mutant slc25a46 mRNA|gene|134|NCBIGene:91137|Cells|cellular|anatomy|7|C0007634
83|In contrast to mutations causing non-lethal optic atrophy, missense mutations causing lethal congenital pontocerebellar hypoplasia markedly  destabilize the protein|optic atrophy|optic atrophy|disease|44|mesh:D009896|congenital pontocerebellar hypoplasia|congenital pontocerebellar hypoplasia|disease|93|mesh:C580383
83|This genotype-phenotype correlation underscores the importance of SLC25A46 and fine tuning of mitochondrial fission and fusion in pontocerebellar hypoplasia and central neurodevelopment in addition to optic and peripheral neuropathy across the life span|SLC25A46|SLC25A46|gene|66|NCBIGene:91137|pontocerebellar hypoplasia|pontocerebellar hypoplasia|disease|130|mesh:C580383
83|This genotype-phenotype correlation underscores the importance of SLC25A46 and fine tuning of mitochondrial fission and fusion in pontocerebellar hypoplasia and central neurodevelopment in addition to optic and peripheral neuropathy across the life span|SLC25A46|SLC25A46|gene|66|NCBIGene:91137|neuropathy|neuropathy|disease|222|mesh:D009422
83|This genotype-phenotype correlation underscores the importance of SLC25A46 and fine tuning of mitochondrial fission and fusion in pontocerebellar hypoplasia and central neurodevelopment in addition to optic and peripheral neuropathy across the life span|SLC25A46|SLC25A46|gene|66|NCBIGene:91137|Mitochondrial Fission|mitochondrial fission|physiology|94|C0230871
83|This genotype-phenotype correlation underscores the importance of SLC25A46 and fine tuning of mitochondrial fission and fusion in pontocerebellar hypoplasia and central neurodevelopment in addition to optic and peripheral neuropathy across the life span|SLC25A46|SLC25A46|gene|66|NCBIGene:91137|neurodevelopment|neurodevelopment|physiology|169|C0599855
83|This genotype-phenotype correlation underscores the importance of SLC25A46 and fine tuning of mitochondrial fission and fusion in pontocerebellar hypoplasia and central neurodevelopment in addition to optic and peripheral neuropathy across the life span|SLC25A46|SLC25A46|gene|66|NCBIGene:91137|Eye|optic|anatomy|201|C0015392
83|This genotype-phenotype correlation underscores the importance of SLC25A46 and fine tuning of mitochondrial fission and fusion in pontocerebellar hypoplasia and central neurodevelopment in addition to optic and peripheral neuropathy across the life span|pontocerebellar hypoplasia|pontocerebellar hypoplasia|disease|130|mesh:C580383|neuropathy|neuropathy|disease|222|mesh:D009422
83|This genotype-phenotype correlation underscores the importance of SLC25A46 and fine tuning of mitochondrial fission and fusion in pontocerebellar hypoplasia and central neurodevelopment in addition to optic and peripheral neuropathy across the life span|pontocerebellar hypoplasia|pontocerebellar hypoplasia|disease|130|mesh:C580383|Eye|optic|anatomy|201|C0015392
83|This genotype-phenotype correlation underscores the importance of SLC25A46 and fine tuning of mitochondrial fission and fusion in pontocerebellar hypoplasia and central neurodevelopment in addition to optic and peripheral neuropathy across the life span|neuropathy|neuropathy|disease|222|mesh:D009422|Eye|optic|anatomy|201|C0015392
84|Mitochondria are key players in the generation and regulation of cellular bioenergetics, producing the majority of adenosine triphosphate molecules by the  oxidative phosphorylation system (OXPHOS)|adenosine triphosphate|adenosine triphosphate|compound|115|mesh:D000255|Mitochondria|Mitochondria|anatomy|0|C0026237
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|general|general|disease|86|mesh:D009494|schizophrenia|schizophrenia|disease|132|omim:181500
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|general|general|disease|86|mesh:D009494|SCZ|SCZ|disease|147|omim:181500
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|general|general|disease|86|mesh:D009494|chronic,|chronic,|disease|163|mesh:D002908
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|general|general|disease|86|mesh:D009494|debilitating illness|debilitating illness|disease|172|mesh:D002908
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|general|general|disease|86|mesh:D009494|Mitochondria|mitochondrial|anatomy|29|C0026237
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|schizophrenia|schizophrenia|disease|132|omim:181500|chronic,|chronic,|disease|163|mesh:D002908
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|schizophrenia|schizophrenia|disease|132|omim:181500|debilitating illness|debilitating illness|disease|172|mesh:D002908
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|schizophrenia|schizophrenia|disease|132|omim:181500|Mitochondria|mitochondrial|anatomy|29|C0026237
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|SCZ|SCZ|disease|147|omim:181500|chronic,|chronic,|disease|163|mesh:D002908
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|SCZ|SCZ|disease|147|omim:181500|debilitating illness|debilitating illness|disease|172|mesh:D002908
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|SCZ|SCZ|disease|147|omim:181500|Mitochondria|mitochondrial|anatomy|29|C0026237
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|chronic,|chronic,|disease|163|mesh:D002908|Mitochondria|mitochondrial|anatomy|29|C0026237
84|Impairments  in a variety of mitochondrial functions have been described in different general  and psychiatric disorders, including schizophrenia (SCZ), a severe, chronic, debilitating illness that heavily affects the lives of patients and their families|debilitating illness|debilitating illness|disease|172|mesh:D002908|Mitochondria|mitochondrial|anatomy|29|C0026237
84|Abnormalities have been reported in high-energy phosphates generated by the OXPHOS, in the activity of its complexes and gene expression, primarily of complex I (CoI)|phosphates|phosphates|compound|48|mesh:D010710|complex I|complex I|gene|151|NCBIGene:4723
84|Abnormalities have been reported in high-energy phosphates generated by the OXPHOS, in the activity of its complexes and gene expression, primarily of complex I (CoI)|phosphates|phosphates|compound|48|mesh:D010710|CoI|CoI|gene|162|NCBIGene:4512
84|Abnormalities have been reported in high-energy phosphates generated by the OXPHOS, in the activity of its complexes and gene expression, primarily of complex I (CoI)|phosphates|phosphates|compound|48|mesh:D010710|NADH dehydrogenase complex location|complex I|anatomy|151|C2245017
84|Abnormalities have been reported in high-energy phosphates generated by the OXPHOS, in the activity of its complexes and gene expression, primarily of complex I (CoI)|complex I|complex I|gene|151|NCBIGene:4723|CoI|CoI|gene|162|NCBIGene:4512
84|Abnormalities have been reported in high-energy phosphates generated by the OXPHOS, in the activity of its complexes and gene expression, primarily of complex I (CoI)|complex I|complex I|gene|151|NCBIGene:4723|Gene Expression|gene expression|physiology|121|C0017262
84|Abnormalities have been reported in high-energy phosphates generated by the OXPHOS, in the activity of its complexes and gene expression, primarily of complex I (CoI)|CoI|CoI|gene|162|NCBIGene:4512|Gene Expression|gene expression|physiology|121|C0017262
84|Abnormalities have been reported in high-energy phosphates generated by the OXPHOS, in the activity of its complexes and gene expression, primarily of complex I (CoI)|CoI|CoI|gene|162|NCBIGene:4512|NADH dehydrogenase complex location|complex I|anatomy|151|C2245017
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|cAMP|cAMP|compound|40|mesh:D000242|protein kinase A|protein kinase A|gene|45|NCBIGene:5566
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|cAMP|cAMP|compound|40|mesh:D000242|PKA|PKA|gene|63|NCBIGene:5566
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|cAMP|cAMP|compound|40|mesh:D000242|Ca(+2)|Ca(+2)|compound|72|CHEBI:29108
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|cAMP|cAMP|compound|40|mesh:D000242|SCZ|SCZ|disease|202|omim:181500
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|cAMP|cAMP|compound|40|mesh:D000242|Hippocampus Proper|Ca|anatomy|72|C3887642
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|Ca(+2)|Ca(+2)|compound|72|CHEBI:29108|protein kinase A|protein kinase A|gene|45|NCBIGene:5566
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|protein kinase A|protein kinase A|gene|45|NCBIGene:5566|SCZ|SCZ|disease|202|omim:181500
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|protein kinase A|protein kinase A|gene|45|NCBIGene:5566|Hippocampus Proper|Ca|anatomy|72|C3887642
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|protein kinase A|protein kinase A|gene|45|NCBIGene:5566|neuron development|neuronal development|physiology|80|C1657987
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|protein kinase A|protein kinase A|gene|45|NCBIGene:5566|Function Axis|function|physiology|158|C0700205
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|Ca(+2)|Ca(+2)|compound|72|CHEBI:29108|PKA|PKA|gene|63|NCBIGene:5566
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|PKA|PKA|gene|63|NCBIGene:5566|SCZ|SCZ|disease|202|omim:181500
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|PKA|PKA|gene|63|NCBIGene:5566|Hippocampus Proper|Ca|anatomy|72|C3887642
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|PKA|PKA|gene|63|NCBIGene:5566|neuron development|neuronal development|physiology|80|C1657987
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|PKA|PKA|gene|63|NCBIGene:5566|Function Axis|function|physiology|158|C0700205
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|Ca(+2)|Ca(+2)|compound|72|CHEBI:29108|SCZ|SCZ|disease|202|omim:181500
84|In addition, cellular signaling such as cAMP/protein kinase A (PKA) and Ca(+2), neuronal development, connectivity, and plasticity have been linked to OXPHOS function and are reported to be impaired in SCZ|SCZ|SCZ|disease|202|omim:181500|Hippocampus Proper|Ca|anatomy|72|C3887642
84|Finally, CoI has been shown as a site of interaction for both dopamine (DA)  and antipsychotic drugs, further substantiating its role in the pathology of SCZ|dopamine|dopamine|compound|62|mesh:D004298|SCZ|SCZ|disease|154|omim:181500
84|Understanding the role of mitochondria and the OXPHOS in particular may encourage new insights into the pathophysiology and etiology of this debilitating disorder|debilitating disorder|debilitating disorder|disease|141|mesh:D010900|Mitochondria|mitochondria|anatomy|26|C0026237
86|Autism is a neurodevelopment disorder|Autism|Autism|disease|0|omim:209850|neurodevelopment disorder|neurodevelopment disorder|disease|12|mesh:D065886
86|Microglia plays an important role in neurodevelopment, neuropsychiatric and neurodegenerative disorders|neuropsychiatric and neurodegenerative disorders|neuropsychiatric and neurodegenerative disorders|disease|55|mesh:D019636|Microglia|Microglia|anatomy|0|C0206116
86|The present study has been designed to investigate the role of minocycline in prenatal valproic acid induced autism in rats|minocycline|minocycline|compound|63|mesh:D008911|valproic acid|valproic acid|compound|87|CHEBI:39867
86|The present study has been designed to investigate the role of minocycline in prenatal valproic acid induced autism in rats|minocycline|minocycline|compound|63|mesh:D008911|autism|autism|disease|109|omim:209850
86|The present study has been designed to investigate the role of minocycline in prenatal valproic acid induced autism in rats|valproic acid|valproic acid|compound|87|CHEBI:39867|autism|autism|disease|109|omim:209850
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|valproic acid|valproic acid|compound|22|CHEBI:39867|serotonin|serotonin|compound|207|CHEBI:350546
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|valproic acid|valproic acid|compound|22|CHEBI:39867|complexes I, II, IV|complexes I, II, IV|gene|316|NCBIGene:1537
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|valproic acid|valproic acid|compound|22|CHEBI:39867|ileum|ileum|anatomy|255|C0020885
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|valproic acid|valproic acid|compound|22|CHEBI:39867|NADH dehydrogenase complex location|complexes I|anatomy|316|C2245017
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|valproic acid|valproic acid|compound|22|CHEBI:39867|Prefrontal Cortex|[|anatomy|233|C0162783
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|valproic acid|valproic acid|compound|22|CHEBI:39867|Test - temporal region|test|anatomy|179|C4318744
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|valproic acid|valproic acid|compound|22|CHEBI:39867|Anatomical Apparatus|apparatus|anatomy|100|C1947951
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|valproic acid|valproic acid|compound|22|CHEBI:39867|Chamber (anatomical)|chamber|anatomy|75|C0935616
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|serotonin|serotonin|compound|207|CHEBI:350546|complexes I, II, IV|complexes I, II, IV|gene|316|NCBIGene:1537
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|serotonin|serotonin|compound|207|CHEBI:350546|ileum|ileum|anatomy|255|C0020885
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|serotonin|serotonin|compound|207|CHEBI:350546|NADH dehydrogenase complex location|complexes I|anatomy|316|C2245017
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|serotonin|serotonin|compound|207|CHEBI:350546|Prefrontal Cortex|[|anatomy|233|C0162783
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|serotonin|serotonin|compound|207|CHEBI:350546|Test - temporal region|test|anatomy|179|C4318744
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|serotonin|serotonin|compound|207|CHEBI:350546|Anatomical Apparatus|apparatus|anatomy|100|C1947951
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|serotonin|serotonin|compound|207|CHEBI:350546|Chamber (anatomical)|chamber|anatomy|75|C0935616
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|complexes I, II, IV|complexes I, II, IV|gene|316|NCBIGene:1537|Intestinal Motility|intestinal motility|physiology|186|C0021838
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|complexes I, II, IV|complexes I, II, IV|gene|316|NCBIGene:1537|Reduced social interaction|reduced social interaction|physiology|41|C1718267
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|complexes I, II, IV|complexes I, II, IV|gene|316|NCBIGene:1537|ileum|ileum|anatomy|255|C0020885
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|complexes I, II, IV|complexes I, II, IV|gene|316|NCBIGene:1537|Prefrontal Cortex|[|anatomy|233|C0162783
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|complexes I, II, IV|complexes I, II, IV|gene|316|NCBIGene:1537|Test - temporal region|test|anatomy|179|C4318744
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|complexes I, II, IV|complexes I, II, IV|gene|316|NCBIGene:1537|Anatomical Apparatus|apparatus|anatomy|100|C1947951
86|Animals with prenatal valproic acid have reduced social interaction (three chamber social behaviour apparatus),  spontaneous alteration (Y-Maze), exploratory activity (Hole board test), intestinal motility, serotonin levels (both in prefrontal cortex and ileum) and prefrontal cortex mitochondrial complex activity (complexes I, II, IV)|complexes I, II, IV|complexes I, II, IV|gene|316|NCBIGene:1537|Chamber (anatomical)|chamber|anatomy|75|C0935616
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|anxiety|anxiety|disease|107|mesh:D001008
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|glutathione|glutathione|compound|199|CHEBI:57925
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|catalase|catalase|gene|212|NCBIGene:847
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|nitrosative|nitrosative|disease|223|mesh:D000860
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|nitrite|nitrite|compound|243|CHEBI:16301
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|nitrate|nitrate|compound|251|mesh:D009566
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|inflammation|inflammation|disease|261|mesh:D007249
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|calcium|calcium|compound|326|mesh:D002118
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|Blood - brain barrier anatomy|blood brain barrier|anatomy|338|C0005854
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|22|CHEBI:39867|Brain|brain|anatomy|283|C0006104
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684|anxiety|anxiety|disease|107|mesh:D001008
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|glutathione|glutathione|compound|199|CHEBI:57925|anxiety|anxiety|disease|107|mesh:D001008
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|catalase|catalase|gene|212|NCBIGene:847|anxiety|anxiety|disease|107|mesh:D001008
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|anxiety|anxiety|disease|107|mesh:D001008|nitrosative|nitrosative|disease|223|mesh:D000860
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrite|nitrite|compound|243|CHEBI:16301|anxiety|anxiety|disease|107|mesh:D001008
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrate|nitrate|compound|251|mesh:D009566|anxiety|anxiety|disease|107|mesh:D001008
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|anxiety|anxiety|disease|107|mesh:D001008|inflammation|inflammation|disease|261|mesh:D007249
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353|anxiety|anxiety|disease|107|mesh:D001008
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|calcium|calcium|compound|326|mesh:D002118|anxiety|anxiety|disease|107|mesh:D001008
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|anxiety|anxiety|disease|107|mesh:D001008|Blood - brain barrier anatomy|blood brain barrier|anatomy|338|C0005854
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|anxiety|anxiety|disease|107|mesh:D001008|Brain|brain|anatomy|283|C0006104
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684|glutathione|glutathione|compound|199|CHEBI:57925
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684|catalase|catalase|gene|212|NCBIGene:847
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684|nitrosative|nitrosative|disease|223|mesh:D000860
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684|nitrite|nitrite|compound|243|CHEBI:16301
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684|nitrate|nitrate|compound|251|mesh:D009566
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684|inflammation|inflammation|disease|261|mesh:D007249
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684|calcium|calcium|compound|326|mesh:D002118
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684|Blood - brain barrier anatomy|blood brain barrier|anatomy|338|C0005854
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|thiobarbituric acid|thiobarbituric acid|compound|161|mesh:C029684|Brain|brain|anatomy|283|C0006104
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|glutathione|glutathione|compound|199|CHEBI:57925|catalase|catalase|gene|212|NCBIGene:847
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|glutathione|glutathione|compound|199|CHEBI:57925|nitrosative|nitrosative|disease|223|mesh:D000860
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|glutathione|glutathione|compound|199|CHEBI:57925|nitrite|nitrite|compound|243|CHEBI:16301
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|glutathione|glutathione|compound|199|CHEBI:57925|nitrate|nitrate|compound|251|mesh:D009566
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|glutathione|glutathione|compound|199|CHEBI:57925|inflammation|inflammation|disease|261|mesh:D007249
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|glutathione|glutathione|compound|199|CHEBI:57925|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|glutathione|glutathione|compound|199|CHEBI:57925|calcium|calcium|compound|326|mesh:D002118
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|glutathione|glutathione|compound|199|CHEBI:57925|Blood - brain barrier anatomy|blood brain barrier|anatomy|338|C0005854
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|glutathione|glutathione|compound|199|CHEBI:57925|Brain|brain|anatomy|283|C0006104
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|catalase|catalase|gene|212|NCBIGene:847|nitrosative|nitrosative|disease|223|mesh:D000860
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrite|nitrite|compound|243|CHEBI:16301|catalase|catalase|gene|212|NCBIGene:847
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrate|nitrate|compound|251|mesh:D009566|catalase|catalase|gene|212|NCBIGene:847
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|catalase|catalase|gene|212|NCBIGene:847|inflammation|inflammation|disease|261|mesh:D007249
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|catalase|catalase|gene|212|NCBIGene:847|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|calcium|calcium|compound|326|mesh:D002118|catalase|catalase|gene|212|NCBIGene:847
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|catalase|catalase|gene|212|NCBIGene:847|Blood - brain barrier anatomy|blood brain barrier|anatomy|338|C0005854
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|catalase|catalase|gene|212|NCBIGene:847|peroxidase activity|myeloperoxidase activity|physiology|299|C1151518
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|catalase|catalase|gene|212|NCBIGene:847|Brain|brain|anatomy|283|C0006104
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|catalase|catalase|gene|212|NCBIGene:847|Locomotion|locomotion|physiology|78|C0023946
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrite|nitrite|compound|243|CHEBI:16301|nitrosative|nitrosative|disease|223|mesh:D000860
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrate|nitrate|compound|251|mesh:D009566|nitrosative|nitrosative|disease|223|mesh:D000860
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrosative|nitrosative|disease|223|mesh:D000860|inflammation|inflammation|disease|261|mesh:D007249
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353|nitrosative|nitrosative|disease|223|mesh:D000860
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|calcium|calcium|compound|326|mesh:D002118|nitrosative|nitrosative|disease|223|mesh:D000860
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrosative|nitrosative|disease|223|mesh:D000860|Blood - brain barrier anatomy|blood brain barrier|anatomy|338|C0005854
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrosative|nitrosative|disease|223|mesh:D000860|Brain|brain|anatomy|283|C0006104
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrite|nitrite|compound|243|CHEBI:16301|nitrate|nitrate|compound|251|mesh:D009566
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrite|nitrite|compound|243|CHEBI:16301|inflammation|inflammation|disease|261|mesh:D007249
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrite|nitrite|compound|243|CHEBI:16301|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrite|nitrite|compound|243|CHEBI:16301|calcium|calcium|compound|326|mesh:D002118
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrite|nitrite|compound|243|CHEBI:16301|Blood - brain barrier anatomy|blood brain barrier|anatomy|338|C0005854
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrite|nitrite|compound|243|CHEBI:16301|Brain|brain|anatomy|283|C0006104
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrate|nitrate|compound|251|mesh:D009566|inflammation|inflammation|disease|261|mesh:D007249
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrate|nitrate|compound|251|mesh:D009566|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrate|nitrate|compound|251|mesh:D009566|calcium|calcium|compound|326|mesh:D002118
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrate|nitrate|compound|251|mesh:D009566|Blood - brain barrier anatomy|blood brain barrier|anatomy|338|C0005854
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|nitrate|nitrate|compound|251|mesh:D009566|Brain|brain|anatomy|283|C0006104
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353|inflammation|inflammation|disease|261|mesh:D007249
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|calcium|calcium|compound|326|mesh:D002118|inflammation|inflammation|disease|261|mesh:D007249
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|inflammation|inflammation|disease|261|mesh:D007249|Blood - brain barrier anatomy|blood brain barrier|anatomy|338|C0005854
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|inflammation|inflammation|disease|261|mesh:D007249|Brain|brain|anatomy|283|C0006104
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|calcium|calcium|compound|326|mesh:D002118|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353|Blood - brain barrier anatomy|blood brain barrier|anatomy|338|C0005854
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353|Brain|brain|anatomy|283|C0006104
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|myeloperoxidase|myeloperoxidase|gene|299|NCBIGene:4353|Locomotion|locomotion|physiology|78|C0023946
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|calcium|calcium|compound|326|mesh:D002118|Blood - brain barrier anatomy|blood brain barrier|anatomy|338|C0005854
86|Furthermore, prenatal valproic acid treated animals have shown an increase in locomotion (actophotometer), anxiety (elevated plus maze), brain oxidative stress (thiobarbituric acid reactive species, glutathione, catalase), nitrosative stress (nitrite/nitrate), inflammation (both in brain and ileum myeloperoxidase activity), calcium and blood brain barrier permeability|calcium|calcium|compound|326|mesh:D002118|Brain|brain|anatomy|283|C0006104
86|Treatment with minocycline significantly attenuated prenatal valproic acid induced reduction in  social interaction, spontaneous alteration, exploratory activity intestinal motility, serotonin levels and prefrontal cortex mitochondrial complex activity|minocycline|minocycline|compound|15|mesh:D008911|valproic acid|valproic acid|compound|61|CHEBI:39867
86|Treatment with minocycline significantly attenuated prenatal valproic acid induced reduction in  social interaction, spontaneous alteration, exploratory activity intestinal motility, serotonin levels and prefrontal cortex mitochondrial complex activity|minocycline|minocycline|compound|15|mesh:D008911|serotonin|serotonin|compound|183|CHEBI:350546
86|Treatment with minocycline significantly attenuated prenatal valproic acid induced reduction in  social interaction, spontaneous alteration, exploratory activity intestinal motility, serotonin levels and prefrontal cortex mitochondrial complex activity|valproic acid|valproic acid|compound|61|CHEBI:39867|serotonin|serotonin|compound|183|CHEBI:350546
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|minocycline|minocycline|compound|13|mesh:D008911|valproic acid|valproic acid|compound|54|CHEBI:39867
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|minocycline|minocycline|compound|13|mesh:D008911|anxiety|anxiety|disease|100|mesh:D001008
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|minocycline|minocycline|compound|13|mesh:D008911|inflammation|inflammation|disease|149|mesh:D007249
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|minocycline|minocycline|compound|13|mesh:D008911|calcium|calcium|compound|163|mesh:D002118
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|minocycline|minocycline|compound|13|mesh:D008911|Brain|brain|anatomy|109|C0006104
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|minocycline|minocycline|compound|13|mesh:D008911|Blood - brain barrier anatomy|blood brain barrier|anatomy|175|C0005854
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|54|CHEBI:39867|anxiety|anxiety|disease|100|mesh:D001008
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|54|CHEBI:39867|inflammation|inflammation|disease|149|mesh:D007249
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|54|CHEBI:39867|calcium|calcium|compound|163|mesh:D002118
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|54|CHEBI:39867|Brain|brain|anatomy|109|C0006104
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|valproic acid|valproic acid|compound|54|CHEBI:39867|Blood - brain barrier anatomy|blood brain barrier|anatomy|175|C0005854
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|anxiety|anxiety|disease|100|mesh:D001008|inflammation|inflammation|disease|149|mesh:D007249
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|calcium|calcium|compound|163|mesh:D002118|anxiety|anxiety|disease|100|mesh:D001008
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|anxiety|anxiety|disease|100|mesh:D001008|Brain|brain|anatomy|109|C0006104
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|anxiety|anxiety|disease|100|mesh:D001008|Blood - brain barrier anatomy|blood brain barrier|anatomy|175|C0005854
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|calcium|calcium|compound|163|mesh:D002118|inflammation|inflammation|disease|149|mesh:D007249
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|inflammation|inflammation|disease|149|mesh:D007249|Brain|brain|anatomy|109|C0006104
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|inflammation|inflammation|disease|149|mesh:D007249|Blood - brain barrier anatomy|blood brain barrier|anatomy|175|C0005854
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|calcium|calcium|compound|163|mesh:D002118|Brain|brain|anatomy|109|C0006104
86|Furthermore, minocycline has also attenuated prenatal valproic acid induced increase in locomotion, anxiety, brain oxidative and nitrosative stress, inflammation, calcium and blood brain barrier permeability|calcium|calcium|compound|163|mesh:D002118|Blood - brain barrier anatomy|blood brain barrier|anatomy|175|C0005854
86|Thus, it may be concluded that prenatal valproic acid has induced autistic behaviour, biochemistry and blood brain barrier impairment in animals, which were significantly attenuated by minocycline|valproic acid|valproic acid|compound|40|CHEBI:39867|autistic|autistic|disease|66|omim:209850
86|Thus, it may be concluded that prenatal valproic acid has induced autistic behaviour, biochemistry and blood brain barrier impairment in animals, which were significantly attenuated by minocycline|valproic acid|valproic acid|compound|40|CHEBI:39867|minocycline|minocycline|compound|185|mesh:D008911
86|Thus, it may be concluded that prenatal valproic acid has induced autistic behaviour, biochemistry and blood brain barrier impairment in animals, which were significantly attenuated by minocycline|valproic acid|valproic acid|compound|40|CHEBI:39867|Blood - brain barrier anatomy|blood brain barrier|anatomy|103|C0005854
86|Thus, it may be concluded that prenatal valproic acid has induced autistic behaviour, biochemistry and blood brain barrier impairment in animals, which were significantly attenuated by minocycline|minocycline|minocycline|compound|185|mesh:D008911|autistic|autistic|disease|66|omim:209850
86|Thus, it may be concluded that prenatal valproic acid has induced autistic behaviour, biochemistry and blood brain barrier impairment in animals, which were significantly attenuated by minocycline|autistic|autistic|disease|66|omim:209850|Blood - brain barrier anatomy|blood brain barrier|anatomy|103|C0005854
86|Thus, it may be concluded that prenatal valproic acid has induced autistic behaviour, biochemistry and blood brain barrier impairment in animals, which were significantly attenuated by minocycline|minocycline|minocycline|compound|185|mesh:D008911|Blood - brain barrier anatomy|blood brain barrier|anatomy|103|C0005854
86|Minocycline should be explored further for its therapeutic benefits in autism|Minocycline|Minocycline|compound|0|mesh:D008911|autism|autism|disease|71|omim:209850
87|We showed that the expression of the protein-coding mitochondrial-encoded gene MT-ND2 was positively associated with indices of maternal psychosocial stress in pregnancy including Prenatal Perceived Stress (β = 0|mitochondrial-encoded gene MT-ND2|mitochondrial-encoded gene MT-ND2|gene|52|NCBIGene:4536|Pregnancy|pregnancy|physiology|160|C0032961
87|We showed that the expression of the protein-coding mitochondrial-encoded gene MT-ND2 was positively associated with indices of maternal psychosocial stress in pregnancy including Prenatal Perceived Stress (β = 0|mitochondrial-encoded gene MT-ND2|mitochondrial-encoded gene MT-ND2|gene|52|NCBIGene:4536|Perception|Perceived|physiology|189|C0030971
88|Apaf1 has been studied hitherto for its key role in regulating the formation of the apoptotic core machinery, the apoptosome, to induce programmed cell death|Apaf1|Apaf1|gene|0|NCBIGene:317|Apoptosis|programmed cell death|physiology|136|C0162638
88|Apaf1 has been studied hitherto for its key role in regulating the formation of the apoptotic core machinery, the apoptosome, to induce programmed cell death|Apaf1|Apaf1|gene|0|NCBIGene:317|Apoptosomes|apoptosome|anatomy|114|C1657248
88|In this review, we aim to highlight the origin of Apaf1 discoveries and how findings, mainly based on the analysis of knock-out mouse models, have led us to  consider Apaf1 as a master player in fine-tuning apoptosis during embryonic development|Apaf1|Apaf1|gene|50|NCBIGene:317|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|76|C2926606
88|In this review, we aim to highlight the origin of Apaf1 discoveries and how findings, mainly based on the analysis of knock-out mouse models, have led us to  consider Apaf1 as a master player in fine-tuning apoptosis during embryonic development|Apaf1|Apaf1|gene|50|NCBIGene:317|Apoptosis|apoptosis|physiology|207|C0162638
88|In this review, we aim to highlight the origin of Apaf1 discoveries and how findings, mainly based on the analysis of knock-out mouse models, have led us to  consider Apaf1 as a master player in fine-tuning apoptosis during embryonic development|Apaf1|Apaf1|gene|50|NCBIGene:317|Embryonic Development|embryonic development|physiology|224|C0013936
88|In this review, we aim to highlight the origin of Apaf1 discoveries and how findings, mainly based on the analysis of knock-out mouse models, have led us to  consider Apaf1 as a master player in fine-tuning apoptosis during embryonic development|Apaf1|Apaf1|gene|167|NCBIGene:317|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|76|C2926606
88|In this review, we aim to highlight the origin of Apaf1 discoveries and how findings, mainly based on the analysis of knock-out mouse models, have led us to  consider Apaf1 as a master player in fine-tuning apoptosis during embryonic development|Apaf1|Apaf1|gene|167|NCBIGene:317|Apoptosis|apoptosis|physiology|207|C0162638
88|In this review, we aim to highlight the origin of Apaf1 discoveries and how findings, mainly based on the analysis of knock-out mouse models, have led us to  consider Apaf1 as a master player in fine-tuning apoptosis during embryonic development|Apaf1|Apaf1|gene|167|NCBIGene:317|Embryonic Development|embryonic development|physiology|224|C0013936
88|Likewise, we also attempt to establish how Apaf1 function is locally time-dependent in regulating neurodevelopment and becomes dispensable during neuron maturation|Apaf1|Apaf1|gene|43|NCBIGene:317|neurodevelopment|neurodevelopment|physiology|98|C0599855
88|Likewise, we also attempt to establish how Apaf1 function is locally time-dependent in regulating neurodevelopment and becomes dispensable during neuron maturation|Apaf1|Apaf1|gene|43|NCBIGene:317|Function Axis|function|physiology|49|C0700205
88|Likewise, we also attempt to establish how Apaf1 function is locally time-dependent in regulating neurodevelopment and becomes dispensable during neuron maturation|Apaf1|Apaf1|gene|43|NCBIGene:317|neuron maturation|neuron maturation|physiology|146|C1623343
88|Hence, by presenting clear indications on the pro-survival roles of Apaf1, this review seeks to provide novel and more complex insights into Apaf1 involvement in nervous system development|Apaf1|Apaf1|gene|68|NCBIGene:317|Nervous System Development|nervous system development|physiology|162|C0598282
88|Hence, by presenting clear indications on the pro-survival roles of Apaf1, this review seeks to provide novel and more complex insights into Apaf1 involvement in nervous system development|Apaf1|Apaf1|gene|68|NCBIGene:317|Insight|insights|physiology|127|C0233820
88|Hence, by presenting clear indications on the pro-survival roles of Apaf1, this review seeks to provide novel and more complex insights into Apaf1 involvement in nervous system development|Apaf1|Apaf1|gene|68|NCBIGene:317|pro-survival|pro-survival|physiology|46|C3544385
88|Hence, by presenting clear indications on the pro-survival roles of Apaf1, this review seeks to provide novel and more complex insights into Apaf1 involvement in nervous system development|Apaf1|Apaf1|gene|141|NCBIGene:317|Nervous System Development|nervous system development|physiology|162|C0598282
88|Hence, by presenting clear indications on the pro-survival roles of Apaf1, this review seeks to provide novel and more complex insights into Apaf1 involvement in nervous system development|Apaf1|Apaf1|gene|141|NCBIGene:317|Insight|insights|physiology|127|C0233820
88|Hence, by presenting clear indications on the pro-survival roles of Apaf1, this review seeks to provide novel and more complex insights into Apaf1 involvement in nervous system development|Apaf1|Apaf1|gene|141|NCBIGene:317|pro-survival|pro-survival|physiology|46|C3544385
89|Cells can respond to environmental  stressors in many ways: inducing oxidative stress/inflammation, changes in energy production and epigenetic alterations|inflammation|inflammation|disease|86|mesh:D007249|Cells|Cells|anatomy|0|C0007634
90|Rett syndrome (RTT, MIM 312750) is a rare and orphan progressive neurodevelopmental disorder affecting girls almost exclusively, with a frequency  of 1/15,000 live births of girls|Rett syndrome|Rett syndrome|disease|0|mesh:D015518|progressive neurodevelopmental disorder|progressive neurodevelopmental disorder|disease|53|mesh:D065886
90|Rett syndrome (RTT, MIM 312750) is a rare and orphan progressive neurodevelopmental disorder affecting girls almost exclusively, with a frequency  of 1/15,000 live births of girls|RTT|RTT|disease|15|mesh:D015518|progressive neurodevelopmental disorder|progressive neurodevelopmental disorder|disease|53|mesh:D065886
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|MECP2|MECP2|gene|139|NCBIGene:4204|RTT|RTT|disease|0|mesh:D015518
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|methyl|methyl|compound|160|CHEBI:32875|RTT|RTT|disease|0|mesh:D015518
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|methyl-CpG binding protein 2|methyl-CpG binding protein 2|gene|160|NCBIGene:4204|RTT|RTT|disease|0|mesh:D015518
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|MeCP2|MeCP2|gene|190|NCBIGene:4204|RTT|RTT|disease|0|mesh:D015518
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|methyl|methyl|compound|160|CHEBI:32875|MECP2|MECP2|gene|139|NCBIGene:4204
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|MECP2|MECP2|gene|139|NCBIGene:4204|Ability|able|physiology|216|C0085732
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|MECP2|MECP2|gene|139|NCBIGene:4204|Gene Expression|gene expression|physiology|233|C0017262
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|MECP2|MECP2|gene|139|NCBIGene:4204|Mutation|mutations|physiology|83|C0026882
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|MECP2|MECP2|gene|139|NCBIGene:4204|Function Axis|function|physiology|74|C0700205
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|methyl|methyl|compound|160|CHEBI:32875|MeCP2|MeCP2|gene|190|NCBIGene:4204
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|methyl-CpG binding protein 2|methyl-CpG binding protein 2|gene|160|NCBIGene:4204|Ability|able|physiology|216|C0085732
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|methyl-CpG binding protein 2|methyl-CpG binding protein 2|gene|160|NCBIGene:4204|Gene Expression|gene expression|physiology|233|C0017262
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|methyl-CpG binding protein 2|methyl-CpG binding protein 2|gene|160|NCBIGene:4204|Mutation|mutations|physiology|83|C0026882
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|methyl-CpG binding protein 2|methyl-CpG binding protein 2|gene|160|NCBIGene:4204|Function Axis|function|physiology|74|C0700205
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|MeCP2|MeCP2|gene|190|NCBIGene:4204|Ability|able|physiology|216|C0085732
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|MeCP2|MeCP2|gene|190|NCBIGene:4204|Gene Expression|gene expression|physiology|233|C0017262
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|MeCP2|MeCP2|gene|190|NCBIGene:4204|Mutation|mutations|physiology|83|C0026882
90|RTT is known to be caused in 95% of the cases by sporadic de novo loss-of-function mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene encoding methyl-CpG binding protein 2 (MeCP2), a nuclear protein able to regulate gene expression|MeCP2|MeCP2|gene|190|NCBIGene:4204|Function Axis|function|physiology|74|C0700205
90|Despite almost two decades of research into the functions and role of MeCP2, little is known about the mechanisms leading from MECP2 mutation to the disease|MeCP2|MeCP2|gene|70|NCBIGene:4204|Mutation|mutation|physiology|133|C0026882
90|Despite almost two decades of research into the functions and role of MeCP2, little is known about the mechanisms leading from MECP2 mutation to the disease|MECP2|MECP2|gene|127|NCBIGene:4204|Mutation|mutation|physiology|133|C0026882
90|The link between MECP2 mutation and the redox imbalance found in RTT is not clear|MECP2|MECP2|gene|17|NCBIGene:4204|RTT|RTT|disease|65|mesh:D015518
90|The link between MECP2 mutation and the redox imbalance found in RTT is not clear|MECP2|MECP2|gene|17|NCBIGene:4204|Oxidation-Reduction|redox|physiology|40|C0030012
90|The link between MECP2 mutation and the redox imbalance found in RTT is not clear|MECP2|MECP2|gene|17|NCBIGene:4204|Mutation|mutation|physiology|23|C0026882
90|Animal studies have suggested a possible direct correlation between Mecp2 mutation and increased OS levels|Mecp2|Mecp2|gene|68|NCBIGene:4204|OS|OS|disease|97|mesh:C567932
90|Animal studies have suggested a possible direct correlation between Mecp2 mutation and increased OS levels|Mecp2|Mecp2|gene|68|NCBIGene:4204|Left eye structure|OS|anatomy|97|C0229090
90|Animal studies have suggested a possible direct correlation between Mecp2 mutation and increased OS levels|Mecp2|Mecp2|gene|68|NCBIGene:4204|Mutation|mutation|physiology|74|C0026882
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2|Mecp2|gene|32|NCBIGene:4204|oxidative brain damage|oxidative brain damage|disease|272|mesh:D002534
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2|Mecp2|gene|32|NCBIGene:4204|Astrocytes|astrocytes|anatomy|50|C0004112
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2|Mecp2|gene|32|NCBIGene:4204|Biologic Development|developmental|physiology|88|C0678723
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2|Mecp2|gene|114|NCBIGene:4204|oxidative brain damage|oxidative brain damage|disease|272|mesh:D002534
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2|Mecp2|gene|114|NCBIGene:4204|Astrocytes|astrocytes|anatomy|50|C0004112
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2|Mecp2|gene|114|NCBIGene:4204|Biologic Development|developmental|physiology|88|C0678723
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2 gene|Mecp2 gene|gene|150|NCBIGene:4204|oxidative brain damage|oxidative brain damage|disease|272|mesh:D002534
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2 gene|Mecp2 gene|gene|150|NCBIGene:4204|Astrocytes|astrocytes|anatomy|50|C0004112
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2 gene|Mecp2 gene|gene|150|NCBIGene:4204|Biologic Development|developmental|physiology|88|C0678723
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2|Mecp2|gene|230|NCBIGene:4204|oxidative brain damage|oxidative brain damage|disease|272|mesh:D002534
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2|Mecp2|gene|230|NCBIGene:4204|Astrocytes|astrocytes|anatomy|50|C0004112
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|Mecp2|Mecp2|gene|230|NCBIGene:4204|Biologic Development|developmental|physiology|88|C0678723
90|In addition, the restoration of Mecp2 function in astrocytes significantly improves the developmental outcome of  Mecp2-null mice and reexpression of Mecp2 gene in the brain of null mice restored oxidative damage, suggesting that Mecp2 loss of function can be involved in oxidative brain damage|oxidative brain damage|oxidative brain damage|disease|272|mesh:D002534|Astrocytes|astrocytes|anatomy|50|C0004112
90|Starting from the evidence that oxidative damage in the brain of Mecp2-null mice precedes the onset of symptoms, we evaluated whether, based on the current literature, the dysfunctions described in RTT could be a consequence or, in contrast, could be caused by OS|Mecp2|Mecp2|gene|65|NCBIGene:4204|RTT|RTT|disease|198|mesh:D015518
90|Starting from the evidence that oxidative damage in the brain of Mecp2-null mice precedes the onset of symptoms, we evaluated whether, based on the current literature, the dysfunctions described in RTT could be a consequence or, in contrast, could be caused by OS|Mecp2|Mecp2|gene|65|NCBIGene:4204|OS|OS|disease|261|mesh:C567932
90|Starting from the evidence that oxidative damage in the brain of Mecp2-null mice precedes the onset of symptoms, we evaluated whether, based on the current literature, the dysfunctions described in RTT could be a consequence or, in contrast, could be caused by OS|Mecp2|Mecp2|gene|65|NCBIGene:4204|Left eye structure|OS|anatomy|261|C0229090
90|Starting from the evidence that oxidative damage in the brain of Mecp2-null mice precedes the onset of symptoms, we evaluated whether, based on the current literature, the dysfunctions described in RTT could be a consequence or, in contrast, could be caused by OS|RTT|RTT|disease|198|mesh:D015518|OS|OS|disease|261|mesh:C567932
90|Starting from the evidence that oxidative damage in the brain of Mecp2-null mice precedes the onset of symptoms, we evaluated whether, based on the current literature, the dysfunctions described in RTT could be a consequence or, in contrast, could be caused by OS|RTT|RTT|disease|198|mesh:D015518|Left eye structure|OS|anatomy|261|C0229090
90|We also analyzed whether therapies that at least partially treated some RTT symptoms can play a role in defense against OS|RTT|RTT|disease|72|mesh:D015518|OS|OS|disease|120|mesh:C567932
90|We also analyzed whether therapies that at least partially treated some RTT symptoms can play a role in defense against OS|RTT|RTT|disease|72|mesh:D015518|Left eye structure|OS|anatomy|120|C0229090
90|At this stage we can propose that OS could be one of the main causes of the dysfunctions observed in RTT|OS|OS|disease|34|mesh:C567932|RTT|RTT|disease|101|mesh:D015518
90|At this stage we can propose that OS could be one of the main causes of the dysfunctions observed in RTT|RTT|RTT|disease|101|mesh:D015518|Left eye structure|OS|anatomy|34|C0229090
90|In addition, the major part of the therapies recommended to alleviate RTT symptoms have been shown to interfere with oxidative homeostasis, suggesting that MeCP2 could somehow be involved in the protection of the brain from OS|MeCP2|MeCP2|gene|156|NCBIGene:4204|RTT|RTT|disease|70|mesh:D015518
90|In addition, the major part of the therapies recommended to alleviate RTT symptoms have been shown to interfere with oxidative homeostasis, suggesting that MeCP2 could somehow be involved in the protection of the brain from OS|RTT|RTT|disease|70|mesh:D015518|Left eye structure|OS|anatomy|224|C0229090
90|In addition, the major part of the therapies recommended to alleviate RTT symptoms have been shown to interfere with oxidative homeostasis, suggesting that MeCP2 could somehow be involved in the protection of the brain from OS|RTT|RTT|disease|70|mesh:D015518|Brain|brain|anatomy|213|C0006104
90|In addition, the major part of the therapies recommended to alleviate RTT symptoms have been shown to interfere with oxidative homeostasis, suggesting that MeCP2 could somehow be involved in the protection of the brain from OS|MeCP2|MeCP2|gene|156|NCBIGene:4204|Left eye structure|OS|anatomy|224|C0229090
90|In addition, the major part of the therapies recommended to alleviate RTT symptoms have been shown to interfere with oxidative homeostasis, suggesting that MeCP2 could somehow be involved in the protection of the brain from OS|MeCP2|MeCP2|gene|156|NCBIGene:4204|Brain|brain|anatomy|213|C0006104
91|At high concentrations, manganese (Mn) promotes cellular neurodevelopment but causes toxicity|manganese|manganese|compound|24|mesh:D008345|Mn|Mn|compound|35|CHEBI:18291
91|At high concentrations, manganese (Mn) promotes cellular neurodevelopment but causes toxicity|manganese|manganese|compound|24|mesh:D008345|Cells|cellular|anatomy|48|C0007634
91|At high concentrations, manganese (Mn) promotes cellular neurodevelopment but causes toxicity|Mn|Mn|compound|35|CHEBI:18291|Cells|cellular|anatomy|48|C0007634
91|Here, we report that Mn ion at high concentrations can be delivered to pheochromocytoma 12 (PC12) cells using gold nanoparticles (AuNPs) to enhance cellular neurodevelopment without toxicity|Mn|Mn|compound|21|CHEBI:18291|Cells|cells|anatomy|98|C0007634
91|Here, we report that Mn ion at high concentrations can be delivered to pheochromocytoma 12 (PC12) cells using gold nanoparticles (AuNPs) to enhance cellular neurodevelopment without toxicity|Mn|Mn|compound|21|CHEBI:18291|Cells|cellular|anatomy|148|C0007634
91|Mn(2+) release from AuNPs was designed to be pH-responsive so that low pH condition of the cell endosomes can trigger in situ release of Mn(2+) from AuNPs after cellular uptake of Mn-incorporated AuNPs (MnAuNPs)|Mn(2+)|Mn(2+)|compound|0|CHEBI:29035|Mn|Mn|compound|180|CHEBI:18291
91|Mn(2+) release from AuNPs was designed to be pH-responsive so that low pH condition of the cell endosomes can trigger in situ release of Mn(2+) from AuNPs after cellular uptake of Mn-incorporated AuNPs (MnAuNPs)|Mn(2+)|Mn(2+)|compound|0|CHEBI:29035|MnAuNPs|MnAuNPs|compound|203|mesh:C025340
91|Mn(2+) release from AuNPs was designed to be pH-responsive so that low pH condition of the cell endosomes can trigger in situ release of Mn(2+) from AuNPs after cellular uptake of Mn-incorporated AuNPs (MnAuNPs)|Mn(2+)|Mn(2+)|compound|0|CHEBI:29035|Cells|cellular|anatomy|161|C0007634
91|Mn(2+) release from AuNPs was designed to be pH-responsive so that low pH condition of the cell endosomes can trigger in situ release of Mn(2+) from AuNPs after cellular uptake of Mn-incorporated AuNPs (MnAuNPs)|Mn(2+)|Mn(2+)|compound|137|CHEBI:29035|Mn|Mn|compound|180|CHEBI:18291
91|Mn(2+) release from AuNPs was designed to be pH-responsive so that low pH condition of the cell endosomes can trigger in situ release of Mn(2+) from AuNPs after cellular uptake of Mn-incorporated AuNPs (MnAuNPs)|Mn(2+)|Mn(2+)|compound|137|CHEBI:29035|MnAuNPs|MnAuNPs|compound|203|mesh:C025340
91|Mn(2+) release from AuNPs was designed to be pH-responsive so that low pH condition of the cell endosomes can trigger in situ release of Mn(2+) from AuNPs after cellular uptake of Mn-incorporated AuNPs (MnAuNPs)|Mn(2+)|Mn(2+)|compound|137|CHEBI:29035|Cells|cellular|anatomy|161|C0007634
91|Mn(2+) release from AuNPs was designed to be pH-responsive so that low pH condition of the cell endosomes can trigger in situ release of Mn(2+) from AuNPs after cellular uptake of Mn-incorporated AuNPs (MnAuNPs)|Mn|Mn|compound|180|CHEBI:18291|MnAuNPs|MnAuNPs|compound|203|mesh:C025340
91|Mn(2+) release from AuNPs was designed to be pH-responsive so that low pH condition of the cell endosomes can trigger in situ release of Mn(2+) from AuNPs after cellular uptake of Mn-incorporated AuNPs (MnAuNPs)|Mn|Mn|compound|180|CHEBI:18291|Cells|cellular|anatomy|161|C0007634
91|Mn(2+) release from AuNPs was designed to be pH-responsive so that low pH condition of the cell endosomes can trigger in situ release of Mn(2+) from AuNPs after cellular uptake of Mn-incorporated AuNPs (MnAuNPs)|MnAuNPs|MnAuNPs|compound|203|mesh:C025340|Cells|cellular|anatomy|161|C0007634
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Mn|Mn|compound|50|CHEBI:18291|Au|Au|compound|57|CHEBI:49482
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Mn|Mn|compound|50|CHEBI:18291|Au|Au|compound|96|CHEBI:49482
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Mn|Mn|compound|50|CHEBI:18291|MnAuNPs|MnAuNPs|compound|120|mesh:C025340
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Mn|Mn|compound|50|CHEBI:18291|Cells|cells|anatomy|145|C0007634
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Au|Au|compound|57|CHEBI:49482|Mn|Mn|compound|66|CHEBI:18291
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Au|Au|compound|57|CHEBI:49482|MnAuNPs|MnAuNPs|compound|120|mesh:C025340
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Au|Au|compound|57|CHEBI:49482|Cells|cells|anatomy|145|C0007634
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Mn|Mn|compound|66|CHEBI:18291|Au|Au|compound|96|CHEBI:49482
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Mn|Mn|compound|66|CHEBI:18291|MnAuNPs|MnAuNPs|compound|120|mesh:C025340
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Mn|Mn|compound|66|CHEBI:18291|Cells|cells|anatomy|145|C0007634
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Au|Au|compound|96|CHEBI:49482|MnAuNPs|MnAuNPs|compound|120|mesh:C025340
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|Au|Au|compound|96|CHEBI:49482|Cells|cells|anatomy|145|C0007634
91|Due to the differences in reduction potentials of Mn and Au, only Mn ionized and released while Au remained intact when MnAuNPs  were uptaken by cells|MnAuNPs|MnAuNPs|compound|120|mesh:C025340|Cells|cells|anatomy|145|C0007634
91|Compared to PC12 cells treated with a high concentration of free Mn(2+), PC12 cells treated with an equal concentration of MnAuNPs resulted in significantly enhanced cellular neurodevelopment with decreased apoptosis and necrosis|Mn(2+)|Mn(2+)|compound|65|CHEBI:29035|MnAuNPs|MnAuNPs|compound|123|mesh:C025340
91|Compared to PC12 cells treated with a high concentration of free Mn(2+), PC12 cells treated with an equal concentration of MnAuNPs resulted in significantly enhanced cellular neurodevelopment with decreased apoptosis and necrosis|Mn(2+)|Mn(2+)|compound|65|CHEBI:29035|necrosis|necrosis|disease|221|mesh:D009336
91|Compared to PC12 cells treated with a high concentration of free Mn(2+), PC12 cells treated with an equal concentration of MnAuNPs resulted in significantly enhanced cellular neurodevelopment with decreased apoptosis and necrosis|MnAuNPs|MnAuNPs|compound|123|mesh:C025340|necrosis|necrosis|disease|221|mesh:D009336
91|Compared to PC12 cells treated with a high concentration of free Mn(2+), PC12 cells treated with an equal concentration of MnAuNPs resulted in significantly enhanced cellular neurodevelopment with decreased apoptosis and necrosis|MnAuNPs|MnAuNPs|compound|123|mesh:C025340|MNSs Blood-Group System|Mn|anatomy|65|C0026327
91|Compared to PC12 cells treated with a high concentration of free Mn(2+), PC12 cells treated with an equal concentration of MnAuNPs resulted in significantly enhanced cellular neurodevelopment with decreased apoptosis and necrosis|necrosis|necrosis|disease|221|mesh:D009336|MNSs Blood-Group System|Mn|anatomy|65|C0026327
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|Mn(2+)|Mn(2+)|compound|44|CHEBI:29035|ATP|ATP|compound|101|CHEBI:30616
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|Mn(2+)|Mn(2+)|compound|44|CHEBI:29035|mitochondrial|mitochondrial|disease|199|mesh:D028361
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|Mn(2+)|Mn(2+)|compound|44|CHEBI:29035|Protoplasm|intracellular|anatomy|239|C0175996
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|ATP|ATP|compound|101|CHEBI:30616|Mn(2+)|Mn(2+)|compound|140|CHEBI:29035
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|ATP|ATP|compound|101|CHEBI:30616|mitochondrial|mitochondrial|disease|199|mesh:D028361
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|ATP|ATP|compound|101|CHEBI:30616|Mn(2+)|Mn(2+)|compound|270|CHEBI:29035
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|ATP|ATP|compound|101|CHEBI:30616|Protoplasm|intracellular|anatomy|239|C0175996
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|Mn(2+)|Mn(2+)|compound|140|CHEBI:29035|mitochondrial|mitochondrial|disease|199|mesh:D028361
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|Mn(2+)|Mn(2+)|compound|140|CHEBI:29035|Protoplasm|intracellular|anatomy|239|C0175996
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|Mn(2+)|Mn(2+)|compound|270|CHEBI:29035|mitochondrial|mitochondrial|disease|199|mesh:D028361
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|mitochondrial|mitochondrial|disease|199|mesh:D028361|Protoplasm|intracellular|anatomy|239|C0175996
91|Treatment with a high concentration of free Mn(2+) led to an abrupt consumption of a large amount of ATP for the intracellular transport of Mn(2+) through the ion channel of the cell membrane and to mitochondrial damage caused by the high intracellular concentration of Mn(2+), both of which resulted  in cell necrosis and apoptosis|Mn(2+)|Mn(2+)|compound|270|CHEBI:29035|Protoplasm|intracellular|anatomy|239|C0175996
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|MnAuNP|MnAuNP|compound|13|mesh:C424102|ATP|ATP|compound|66|CHEBI:30616
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|MnAuNP|MnAuNP|compound|13|mesh:C424102|MnAuNPs|MnAuNPs|compound|105|mesh:C025340
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|MnAuNP|MnAuNP|compound|13|mesh:C424102|Mn(2+)|Mn(2+)|compound|171|CHEBI:29035
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|MnAuNP|MnAuNP|compound|13|mesh:C424102|MnAuNPs|MnAuNPs|compound|187|mesh:C025340
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|MnAuNP|MnAuNP|compound|13|mesh:C424102|ATP|ATP|compound|275|CHEBI:30616
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|MnAuNP|MnAuNP|compound|13|mesh:C424102|Endosomes|endosomes|anatomy|202|C0034850
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|ATP|ATP|compound|66|CHEBI:30616|MnAuNPs|MnAuNPs|compound|105|mesh:C025340
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|ATP|ATP|compound|66|CHEBI:30616|Mn(2+)|Mn(2+)|compound|171|CHEBI:29035
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|ATP|ATP|compound|66|CHEBI:30616|MnAuNPs|MnAuNPs|compound|187|mesh:C025340
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|ATP|ATP|compound|66|CHEBI:30616|Endosomes|endosomes|anatomy|202|C0034850
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|MnAuNPs|MnAuNPs|compound|105|mesh:C025340|Mn(2+)|Mn(2+)|compound|171|CHEBI:29035
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|MnAuNPs|MnAuNPs|compound|105|mesh:C025340|ATP|ATP|compound|275|CHEBI:30616
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|MnAuNPs|MnAuNPs|compound|105|mesh:C025340|Endosomes|endosomes|anatomy|202|C0034850
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|Mn(2+)|Mn(2+)|compound|171|CHEBI:29035|MnAuNPs|MnAuNPs|compound|187|mesh:C025340
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|Mn(2+)|Mn(2+)|compound|171|CHEBI:29035|ATP|ATP|compound|275|CHEBI:30616
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|Mn(2+)|Mn(2+)|compound|171|CHEBI:29035|Endosomes|endosomes|anatomy|202|C0034850
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|MnAuNPs|MnAuNPs|compound|187|mesh:C025340|ATP|ATP|compound|275|CHEBI:30616
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|MnAuNPs|MnAuNPs|compound|187|mesh:C025340|Endosomes|endosomes|anatomy|202|C0034850
91|In contrast, MnAuNP-treated cells consumed much smaller amount of ATP for the intracellular transport of MnAuNPs by endocytosis and showed pH-triggered in situ release of Mn(2+) from the MnAuNPs in the endosomes of the cells, both of which prevented the cell death caused by ATP depletion and mitochondrial damage|ATP|ATP|compound|275|CHEBI:30616|Endosomes|endosomes|anatomy|202|C0034850
94|Recent studies showed that microcystins (MCs) can be transferred to offspring from their adults and exert notable neurotoxicity, but the exact mechanism is little known|microcystins|microcystins|gene|27|NCBIGene:9033|Exertion|exert|physiology|100|C0015264
94|In order to better understand cellular responses in brain tissues disrupted by prenatal transfer of MCs, this work mainly focuses on brain impairments of rat offspring|brain impairments|brain impairments|disease|133|mesh:D001927|brain tissue surgical material|brain tissues|anatomy|52|C0440746
94|Pregnant SD rats were infused exposed to microcystin-LR (MCLR) at 10μg/kg body weight (BW)/day or saline solution from gestational day 8 (GD8) to postnatal day 15 (PD15) of lactation|microcystin-LR|microcystin-LR|compound|41|mesh:C057862|MCLR|MCLR|compound|57|CHEBI:6925
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|MCLR|MCLR|compound|0|CHEBI:6925|malondialdehyde|malondialdehyde|compound|33|mesh:D008315
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|MCLR|MCLR|compound|0|CHEBI:6925|MDA|MDA|compound|50|CHEBI:32506
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|MCLR|MCLR|compound|0|CHEBI:6925|acetylcholine|acetylcholine|compound|59|mesh:D000109
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|MCLR|MCLR|compound|0|CHEBI:6925|acetylcholine esterase|acetylcholine esterase|gene|59|NCBIGene:43
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|MCLR|MCLR|compound|0|CHEBI:6925|AChE|AChE|gene|83|NCBIGene:43
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|malondialdehyde|malondialdehyde|compound|33|mesh:D008315|MDA|MDA|compound|50|CHEBI:32506
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|malondialdehyde|malondialdehyde|compound|33|mesh:D008315|acetylcholine|acetylcholine|compound|59|mesh:D000109
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|malondialdehyde|malondialdehyde|compound|33|mesh:D008315|acetylcholine esterase|acetylcholine esterase|gene|59|NCBIGene:43
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|malondialdehyde|malondialdehyde|compound|33|mesh:D008315|AChE|AChE|gene|83|NCBIGene:43
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|MDA|MDA|compound|50|CHEBI:32506|acetylcholine|acetylcholine|compound|59|mesh:D000109
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|MDA|MDA|compound|50|CHEBI:32506|acetylcholine esterase|acetylcholine esterase|gene|59|NCBIGene:43
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|MDA|MDA|compound|50|CHEBI:32506|AChE|AChE|gene|83|NCBIGene:43
94|MCLR accumulation, the levels of malondialdehyde (MDA) and acetylcholine esterase (AChE) activity were detected|acetylcholine|acetylcholine|compound|59|mesh:D000109|AChE|AChE|gene|83|NCBIGene:43
94|The results showed that MCLR enhanced toxin accumulation and MDA, but decreased GSH and the level of AChE activity in the brains of rat offspring|MDA|MDA|compound|61|CHEBI:32506|GSH|GSH|compound|80|mesh:D005978
94|The results showed that MCLR enhanced toxin accumulation and MDA, but decreased GSH and the level of AChE activity in the brains of rat offspring|MDA|MDA|compound|61|CHEBI:32506|AChE|AChE|gene|101|NCBIGene:43
94|The results showed that MCLR enhanced toxin accumulation and MDA, but decreased GSH and the level of AChE activity in the brains of rat offspring|GSH|GSH|compound|80|mesh:D005978|AChE|AChE|gene|101|NCBIGene:43
94|MCLR also caused changes to cerebrum ultrastructure, showing a sparse structure, distention of endoplasmic reticulum and swelling mitochondria|MCLR|MCLR|compound|0|CHEBI:6925|Mitochondria|mitochondria|anatomy|130|C0026237
94|MCLR also caused changes to cerebrum ultrastructure, showing a sparse structure, distention of endoplasmic reticulum and swelling mitochondria|MCLR|MCLR|compound|0|CHEBI:6925|Endoplasmic Reticulum|endoplasmic reticulum|anatomy|95|C0014239
94|MCLR also caused changes to cerebrum ultrastructure, showing a sparse structure, distention of endoplasmic reticulum and swelling mitochondria|MCLR|MCLR|compound|0|CHEBI:6925|Cerebral hemisphere structure (body structure)|cerebrum|anatomy|28|C0228174
95|However, mitochondrial impairment may affect bioenergetics in the developing brain and alter critical neuronal processes leading to neurodevelopmental abnormalities|mitochondrial impairment|mitochondrial impairment|disease|9|mesh:D028361|neurodevelopmental abnormalities|neurodevelopmental abnormalities|disease|132|mesh:D065886
95|However, mitochondrial impairment may affect bioenergetics in the developing brain and alter critical neuronal processes leading to neurodevelopmental abnormalities|mitochondrial impairment|mitochondrial impairment|disease|9|mesh:D028361|Neurites|neuronal processes|anatomy|102|C0085103
95|However, mitochondrial impairment may affect bioenergetics in the developing brain and alter critical neuronal processes leading to neurodevelopmental abnormalities|mitochondrial impairment|mitochondrial impairment|disease|9|mesh:D028361|Brain|brain|anatomy|77|C0006104
95|However, mitochondrial impairment may affect bioenergetics in the developing brain and alter critical neuronal processes leading to neurodevelopmental abnormalities|neurodevelopmental abnormalities|neurodevelopmental abnormalities|disease|132|mesh:D065886|Neurites|neuronal processes|anatomy|102|C0085103
95|However, mitochondrial impairment may affect bioenergetics in the developing brain and alter critical neuronal processes leading to neurodevelopmental abnormalities|neurodevelopmental abnormalities|neurodevelopmental abnormalities|disease|132|mesh:D065886|Mitochondria|mitochondrial|anatomy|9|C0026237
95|However, mitochondrial impairment may affect bioenergetics in the developing brain and alter critical neuronal processes leading to neurodevelopmental abnormalities|neurodevelopmental abnormalities|neurodevelopmental abnormalities|disease|132|mesh:D065886|Brain|brain|anatomy|77|C0006104
95|Schizophrenia is a chronic and severe neuropsychiatric disorder of neurodevelopmental origin|Schizophrenia|Schizophrenia|disease|0|omim:181500|neuropsychiatric disorder|neuropsychiatric disorder|disease|38|mesh:D001523
95|Recent understanding reveals that  perturbation of mitochondrial network dynamics might lead to various nervous system disorders with inflammatory pathologies|nervous system disorders|nervous system disorders|disease|104|mesh:D009422|inflammatory pathologies|inflammatory pathologies|disease|134|mesh:D007249
95|Mitochondrial deficit, altered redox balance and chronic low-grade inflammation are evident in schizophrenia|Mitochondrial deficit|Mitochondrial deficit|disease|0|mesh:D028361|schizophrenia|schizophrenia|disease|95|omim:181500
95|Mitochondrial deficit, altered redox balance and chronic low-grade inflammation are evident in schizophrenia|schizophrenia|schizophrenia|disease|95|omim:181500|Mitochondria|Mitochondrial|anatomy|0|C0026237
95|It is hypothesized that oxidative/nitrosative stress responses due to mitochondrial  dysfunctions might activate immuno-inflammatory pathways and subsequently lead to neuroprogressive changes in schizophrenia|mitochondrial  dysfunctions|mitochondrial  dysfunctions|disease|70|mesh:D028361|schizophrenia|schizophrenia|disease|195|omim:181500
95|Herein, we summarise the current understanding of molecular links between mitochondrial dysfunctions and pathogenesis of schizophrenia based on evidence from genomics, proteomics and imaging studies, which together support a role for mitochondrial impairment in the pathogenetic pathways of schizophrenia|mitochondrial dysfunctions|mitochondrial dysfunctions|disease|74|mesh:D028361|schizophrenia|schizophrenia|disease|121|omim:181500
95|Herein, we summarise the current understanding of molecular links between mitochondrial dysfunctions and pathogenesis of schizophrenia based on evidence from genomics, proteomics and imaging studies, which together support a role for mitochondrial impairment in the pathogenetic pathways of schizophrenia|mitochondrial dysfunctions|mitochondrial dysfunctions|disease|74|mesh:D028361|schizophrenia|schizophrenia|disease|291|omim:181500
95|Herein, we summarise the current understanding of molecular links between mitochondrial dysfunctions and pathogenesis of schizophrenia based on evidence from genomics, proteomics and imaging studies, which together support a role for mitochondrial impairment in the pathogenetic pathways of schizophrenia|mitochondrial dysfunctions|mitochondrial dysfunctions|disease|74|mesh:D028361|Mitochondria|mitochondrial|anatomy|234|C0026237
95|Herein, we summarise the current understanding of molecular links between mitochondrial dysfunctions and pathogenesis of schizophrenia based on evidence from genomics, proteomics and imaging studies, which together support a role for mitochondrial impairment in the pathogenetic pathways of schizophrenia|schizophrenia|schizophrenia|disease|121|omim:181500|Mitochondria|mitochondrial|anatomy|234|C0026237
95|Herein, we summarise the current understanding of molecular links between mitochondrial dysfunctions and pathogenesis of schizophrenia based on evidence from genomics, proteomics and imaging studies, which together support a role for mitochondrial impairment in the pathogenetic pathways of schizophrenia|schizophrenia|schizophrenia|disease|291|omim:181500|Mitochondria|mitochondrial|anatomy|234|C0026237
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O|O|compound|25|CHEBI:29354|OGT|OGT|gene|47|NCBIGene:8473
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O|O|compound|25|CHEBI:29354|OGT|OGT|gene|134|NCBIGene:8473
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O|O|compound|25|CHEBI:29354|Body Site Modifier - Lower|lower|anatomy|150|C1548802
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O|O|compound|25|CHEBI:29354|Body tissue|tissue|anatomy|185|C0040300
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O|O|compound|25|CHEBI:29354|Placenta|placental|anatomy|57|C0032043
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O-GlcNAc transferase|O-GlcNAc transferase|gene|25|NCBIGene:8473|maternal stress|maternal stress|physiology|229|C0746432
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O-GlcNAc transferase|O-GlcNAc transferase|gene|25|NCBIGene:8473|Body Site Modifier - Lower|lower|anatomy|150|C1548802
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O-GlcNAc transferase|O-GlcNAc transferase|gene|25|NCBIGene:8473|Body tissue|tissue|anatomy|185|C0040300
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O-GlcNAc transferase|O-GlcNAc transferase|gene|25|NCBIGene:8473|Females|female|physiology|178|C0086287
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O-GlcNAc transferase|O-GlcNAc transferase|gene|25|NCBIGene:8473|Male, Self-Reported|male|physiology|159|C1706429
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O-GlcNAc transferase|O-GlcNAc transferase|gene|25|NCBIGene:8473|Biological Markers|biomarker|physiology|67|C0005516
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|O-GlcNAc transferase|O-GlcNAc transferase|gene|25|NCBIGene:8473|Placenta|placental|anatomy|57|C0032043
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|47|NCBIGene:8473|maternal stress|maternal stress|physiology|229|C0746432
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|47|NCBIGene:8473|Body Site Modifier - Lower|lower|anatomy|150|C1548802
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|47|NCBIGene:8473|Body tissue|tissue|anatomy|185|C0040300
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|47|NCBIGene:8473|Females|female|physiology|178|C0086287
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|47|NCBIGene:8473|Male, Self-Reported|male|physiology|159|C1706429
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|47|NCBIGene:8473|Biological Markers|biomarker|physiology|67|C0005516
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|47|NCBIGene:8473|Placenta|placental|anatomy|57|C0032043
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|134|NCBIGene:8473|maternal stress|maternal stress|physiology|229|C0746432
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|134|NCBIGene:8473|Body Site Modifier - Lower|lower|anatomy|150|C1548802
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|134|NCBIGene:8473|Body tissue|tissue|anatomy|185|C0040300
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|134|NCBIGene:8473|Females|female|physiology|178|C0086287
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|134|NCBIGene:8473|Male, Self-Reported|male|physiology|159|C1706429
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|134|NCBIGene:8473|Biological Markers|biomarker|physiology|67|C0005516
96|We previously identified O-GlcNAc transferase (OGT) as a placental biomarker in our mouse model of early prenatal stress (EPS), where OGT levels were lower in male compared with female tissue and were further decreased following maternal stress|OGT|OGT|gene|134|NCBIGene:8473|Placenta|placental|anatomy|57|C0032043
96|However, the function of placental OGT in programming the developing brain has not been determined|placental OGT|placental OGT|gene|25|NCBIGene:8473|Brain|brain|anatomy|69|C0006104
96|Therefore, we generated a transgenic mouse with targeted placental disruption of  Ogt (Pl-OGT) and examined offspring for recapitulation of the adult EPS phenotype|Ogt|Ogt|gene|82|NCBIGene:8473|EPS|EPS|disease|150|mesh:C538012
96|Therefore, we generated a transgenic mouse with targeted placental disruption of  Ogt (Pl-OGT) and examined offspring for recapitulation of the adult EPS phenotype|Ogt|Ogt|gene|82|NCBIGene:8473|Phenotype|phenotype|physiology|154|C0031437
96|Therefore, we generated a transgenic mouse with targeted placental disruption of  Ogt (Pl-OGT) and examined offspring for recapitulation of the adult EPS phenotype|Ogt|Ogt|gene|82|NCBIGene:8473|Placenta|placental|anatomy|57|C0032043
96|Therefore, we generated a transgenic mouse with targeted placental disruption of  Ogt (Pl-OGT) and examined offspring for recapitulation of the adult EPS phenotype|Pl-OGT|Pl-OGT|gene|87|NCBIGene:8473|EPS|EPS|disease|150|mesh:C538012
96|Therefore, we generated a transgenic mouse with targeted placental disruption of  Ogt (Pl-OGT) and examined offspring for recapitulation of the adult EPS phenotype|Pl-OGT|Pl-OGT|gene|87|NCBIGene:8473|Phenotype|phenotype|physiology|154|C0031437
96|Therefore, we generated a transgenic mouse with targeted placental disruption of  Ogt (Pl-OGT) and examined offspring for recapitulation of the adult EPS phenotype|Pl-OGT|Pl-OGT|gene|87|NCBIGene:8473|Placenta|placental|anatomy|57|C0032043
96|Therefore, we generated a transgenic mouse with targeted placental disruption of  Ogt (Pl-OGT) and examined offspring for recapitulation of the adult EPS phenotype|EPS|EPS|disease|150|mesh:C538012|Placenta|placental|anatomy|57|C0032043
96|Pl-OGT hemizygous and EPS male placentas showed similar robust changes in gene expression patterns suggestive of an altered ability to respond to endocrine and inflammatory signals, supporting placental OGT as an important mediator of EPS effects|Pl-OGT|Pl-OGT|gene|0|NCBIGene:8473|EPS|EPS|disease|22|mesh:C538012
96|Pl-OGT hemizygous and EPS male placentas showed similar robust changes in gene expression patterns suggestive of an altered ability to respond to endocrine and inflammatory signals, supporting placental OGT as an important mediator of EPS effects|Pl-OGT|Pl-OGT|gene|0|NCBIGene:8473|Placenta|placental|anatomy|193|C0032043
96|Pl-OGT hemizygous and EPS male placentas showed similar robust changes in gene expression patterns suggestive of an altered ability to respond to endocrine and inflammatory signals, supporting placental OGT as an important mediator of EPS effects|Pl-OGT|Pl-OGT|gene|0|NCBIGene:8473|Placenta|placentas|anatomy|31|C0032043
96|Pl-OGT hemizygous and EPS male placentas showed similar robust changes in gene expression patterns suggestive of an altered ability to respond to endocrine and inflammatory signals, supporting placental OGT as an important mediator of EPS effects|Pl-OGT|Pl-OGT|gene|0|NCBIGene:8473|Endocrine system|endocrine|anatomy|146|C0014136
96|Pl-OGT hemizygous and EPS male placentas showed similar robust changes in gene expression patterns suggestive of an altered ability to respond to endocrine and inflammatory signals, supporting placental OGT as an important mediator of EPS effects|Pl-OGT|Pl-OGT|gene|0|NCBIGene:8473|Male, Self-Reported|male|physiology|26|C1706429
96|Pl-OGT hemizygous and EPS male placentas showed similar robust changes in gene expression patterns suggestive of an altered ability to respond to endocrine and inflammatory signals, supporting placental OGT as an important mediator of EPS effects|Pl-OGT|Pl-OGT|gene|0|NCBIGene:8473|Ability|ability|physiology|124|C0085732
96|Pl-OGT hemizygous and EPS male placentas showed similar robust changes in gene expression patterns suggestive of an altered ability to respond to endocrine and inflammatory signals, supporting placental OGT as an important mediator of EPS effects|EPS|EPS|disease|22|mesh:C538012|Placenta|placental|anatomy|193|C0032043
96|Pl-OGT hemizygous and EPS male placentas showed similar robust changes in gene expression patterns suggestive of an altered ability to respond to endocrine and inflammatory signals, supporting placental OGT as an important mediator of EPS effects|EPS|EPS|disease|22|mesh:C538012|Placenta|placentas|anatomy|31|C0032043
96|Pl-OGT hemizygous and EPS male placentas showed similar robust changes in gene expression patterns suggestive of an altered ability to respond to endocrine and inflammatory signals, supporting placental OGT as an important mediator of EPS effects|EPS|EPS|disease|22|mesh:C538012|Endocrine system|endocrine|anatomy|146|C0014136
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|O-GlcNAc|O-GlcNAc|compound|17|CHEBI:59521|17 beta hydroxysteroid|17 beta hydroxysteroid|compound|46|CHEBI:35343
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|O-GlcNAc|O-GlcNAc|compound|17|CHEBI:59521|17 beta hydroxysteroid dehydrogenase-3|17 beta hydroxysteroid dehydrogenase-3|gene|46|NCBIGene:3293
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|O-GlcNAc|O-GlcNAc|compound|17|CHEBI:59521|Hsd17b3|Hsd17b3|gene|86|NCBIGene:3293
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|O-GlcNAc|O-GlcNAc|compound|17|CHEBI:59521|EPS|EPS|disease|109|mesh:C538012
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|O-GlcNAc|O-GlcNAc|compound|17|CHEBI:59521|Hsd17b3|Hsd17b3|gene|161|NCBIGene:3293
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|O-GlcNAc|O-GlcNAc|compound|17|CHEBI:59521|testosterone|testosterone|compound|203|mesh:D013739
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|O-GlcNAc|O-GlcNAc|compound|17|CHEBI:59521|Placenta|placentas|anatomy|113|C0032043
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|17 beta hydroxysteroid|17 beta hydroxysteroid|compound|46|CHEBI:35343|Hsd17b3|Hsd17b3|gene|86|NCBIGene:3293
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|17 beta hydroxysteroid|17 beta hydroxysteroid|compound|46|CHEBI:35343|EPS|EPS|disease|109|mesh:C538012
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|17 beta hydroxysteroid|17 beta hydroxysteroid|compound|46|CHEBI:35343|Hsd17b3|Hsd17b3|gene|161|NCBIGene:3293
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|17 beta hydroxysteroid|17 beta hydroxysteroid|compound|46|CHEBI:35343|testosterone|testosterone|compound|203|mesh:D013739
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|17 beta hydroxysteroid|17 beta hydroxysteroid|compound|46|CHEBI:35343|Placenta|placentas|anatomy|113|C0032043
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|17 beta hydroxysteroid dehydrogenase-3|17 beta hydroxysteroid dehydrogenase-3|gene|46|NCBIGene:3293|EPS|EPS|disease|109|mesh:C538012
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|testosterone|testosterone|compound|203|mesh:D013739|17 beta hydroxysteroid dehydrogenase-3|17 beta hydroxysteroid dehydrogenase-3|gene|46|NCBIGene:3293
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|17 beta hydroxysteroid dehydrogenase-3|17 beta hydroxysteroid dehydrogenase-3|gene|46|NCBIGene:3293|Male, Self-Reported|male|physiology|104|C1706429
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|17 beta hydroxysteroid dehydrogenase-3|17 beta hydroxysteroid dehydrogenase-3|gene|46|NCBIGene:3293|Placenta|placentas|anatomy|113|C0032043
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|Hsd17b3|Hsd17b3|gene|86|NCBIGene:3293|EPS|EPS|disease|109|mesh:C538012
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|testosterone|testosterone|compound|203|mesh:D013739|Hsd17b3|Hsd17b3|gene|86|NCBIGene:3293
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|Hsd17b3|Hsd17b3|gene|86|NCBIGene:3293|Male, Self-Reported|male|physiology|104|C1706429
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|Hsd17b3|Hsd17b3|gene|86|NCBIGene:3293|Placenta|placentas|anatomy|113|C0032043
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|Hsd17b3|Hsd17b3|gene|161|NCBIGene:3293|EPS|EPS|disease|109|mesh:C538012
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|testosterone|testosterone|compound|203|mesh:D013739|EPS|EPS|disease|109|mesh:C538012
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|EPS|EPS|disease|109|mesh:C538012|Placenta|placentas|anatomy|113|C0032043
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|testosterone|testosterone|compound|203|mesh:D013739|Hsd17b3|Hsd17b3|gene|161|NCBIGene:3293
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|Hsd17b3|Hsd17b3|gene|161|NCBIGene:3293|Male, Self-Reported|male|physiology|104|C1706429
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|Hsd17b3|Hsd17b3|gene|161|NCBIGene:3293|Placenta|placentas|anatomy|113|C0032043
96|ChIP-Seq for the O-GlcNAc mark identified the 17 beta hydroxysteroid dehydrogenase-3 (Hsd17b3) locus in male EPS placentas, which correlated with a reduction in Hsd17b3 expression and concordant reduced testosterone conversion|testosterone|testosterone|compound|203|mesh:D013739|Placenta|placentas|anatomy|113|C0032043
96|Further, hypothalamic microarray gene-set enrichment analyses identified reduced mitochondrial function in both Pl-OGT and EPS males|Pl-OGT|Pl-OGT|disease|112|mesh:C536329|EPS|EPS|disease|123|mesh:C538012
96|Further, hypothalamic microarray gene-set enrichment analyses identified reduced mitochondrial function in both Pl-OGT and EPS males|Pl-OGT|Pl-OGT|disease|112|mesh:C536329|Mitochondria|mitochondrial|anatomy|81|C0026237
96|Further, hypothalamic microarray gene-set enrichment analyses identified reduced mitochondrial function in both Pl-OGT and EPS males|EPS|EPS|disease|123|mesh:C538012|Mitochondria|mitochondrial|anatomy|81|C0026237
96|Cytochrome c oxidase activity assays verified this finding, linking reduced placental OGT with critical brain programming|Cytochrome c oxidase|Cytochrome c oxidase|gene|0|NCBIGene:6775083|Brain|brain|anatomy|104|C0006104
96|Cytochrome c oxidase activity assays verified this finding, linking reduced placental OGT with critical brain programming|Cytochrome c oxidase|Cytochrome c oxidase|gene|0|NCBIGene:6775083|Placenta|placental|anatomy|76|C0032043
96|Together, these studies confirm OGT as in important placental biomarker of maternal stress and demonstrate the profound impact a single placental gene has on long-term metabolic and neurodevelopmental programming that may be related to an increased risk for neurodevelopmental disorders|OGT|OGT|gene|32|NCBIGene:8473|neurodevelopmental disorders|neurodevelopmental disorders|disease|258|mesh:D065886
96|Together, these studies confirm OGT as in important placental biomarker of maternal stress and demonstrate the profound impact a single placental gene has on long-term metabolic and neurodevelopmental programming that may be related to an increased risk for neurodevelopmental disorders|OGT|OGT|gene|32|NCBIGene:8473|maternal stress|maternal stress|physiology|75|C0746432
96|Together, these studies confirm OGT as in important placental biomarker of maternal stress and demonstrate the profound impact a single placental gene has on long-term metabolic and neurodevelopmental programming that may be related to an increased risk for neurodevelopmental disorders|OGT|OGT|gene|32|NCBIGene:8473|Metabolic Process, Cellular|metabolic|physiology|168|C1524026
96|Together, these studies confirm OGT as in important placental biomarker of maternal stress and demonstrate the profound impact a single placental gene has on long-term metabolic and neurodevelopmental programming that may be related to an increased risk for neurodevelopmental disorders|OGT|OGT|gene|32|NCBIGene:8473|Biological Markers|biomarker|physiology|62|C0005516
96|Together, these studies confirm OGT as in important placental biomarker of maternal stress and demonstrate the profound impact a single placental gene has on long-term metabolic and neurodevelopmental programming that may be related to an increased risk for neurodevelopmental disorders|OGT|OGT|gene|32|NCBIGene:8473|neurodevelopment|neurodevelopmental|physiology|182|C0599855
97|Friedreich ataxia is considered a neurodegenerative disorder involving both the peripheral and central nervous systems|Friedreich ataxia|Friedreich ataxia|disease|0|mesh:D005621|neurodegenerative disorder|neurodegenerative disorder|disease|34|mesh:D019636
97|Friedreich ataxia is considered a neurodegenerative disorder involving both the peripheral and central nervous systems|Friedreich ataxia|Friedreich ataxia|disease|0|mesh:D005621|Central Nervous System|[|anatomy|95|C3714787
97|Friedreich ataxia is considered a neurodegenerative disorder involving both the peripheral and central nervous systems|neurodegenerative disorder|neurodegenerative disorder|disease|34|mesh:D019636|Central Nervous System|[|anatomy|95|C3714787
97|This neuropathy is caused by mutations in the FXN gene  that encodes frataxin|FXN gene|FXN gene|gene|46|NCBIGene:2395|neuropathy|neuropathy|disease|5|mesh:D009422
97|This neuropathy is caused by mutations in the FXN gene  that encodes frataxin|frataxin|frataxin|gene|69|NCBIGene:2395|neuropathy|neuropathy|disease|5|mesh:D009422
97|This neuropathy is caused by mutations in the FXN gene  that encodes frataxin|FXN gene|FXN gene|gene|46|NCBIGene:2395|Mutation|mutations|physiology|29|C0026882
97|This neuropathy is caused by mutations in the FXN gene  that encodes frataxin|frataxin|frataxin|gene|69|NCBIGene:2395|Mutation|mutations|physiology|29|C0026882
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|frataxin|frataxin|gene|65|NCBIGene:2395|neurological diseases|neurological diseases|disease|242|mesh:D009422
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|frataxin|frataxin|gene|65|NCBIGene:2395|Mitochondria|mitochondrial|anatomy|26|C0026237
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|frataxin|frataxin|gene|65|NCBIGene:2395|Cultured Cell Line|cell line|anatomy|172|C0007600
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|frataxin|frataxin|gene|65|NCBIGene:2395|Vendor model number:ID:Pt:{Device}:Nom|model|physiology|98|C3833412
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|frataxin|frataxin|gene|65|NCBIGene:2395|Cells|cell|anatomy|44|C0007634
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|frataxin|frataxin|gene|113|NCBIGene:2395|neurological diseases|neurological diseases|disease|242|mesh:D009422
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|frataxin|frataxin|gene|113|NCBIGene:2395|Mitochondria|mitochondrial|anatomy|26|C0026237
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|frataxin|frataxin|gene|113|NCBIGene:2395|Cultured Cell Line|cell line|anatomy|172|C0007600
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|frataxin|frataxin|gene|113|NCBIGene:2395|Vendor model number:ID:Pt:{Device}:Nom|model|physiology|98|C3833412
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|frataxin|frataxin|gene|113|NCBIGene:2395|Cells|cell|anatomy|44|C0007634
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|neurological diseases|neurological diseases|disease|242|mesh:D009422|Mitochondria|mitochondrial|anatomy|26|C0026237
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|neurological diseases|neurological diseases|disease|242|mesh:D009422|Cultured Cell Line|cell line|anatomy|172|C0007600
97|Here, we investigated the mitochondrial and cell consequences of frataxin depletion in a cellular model based on frataxin silencing in SH-SY5Y human neuroblastoma cells, a cell line that has been used widely as in vitro models for studies on neurological diseases|neurological diseases|neurological diseases|disease|242|mesh:D009422|Cells|cell|anatomy|44|C0007634
97|We showed that the reduction of frataxin induced mitochondrial dysfunction due to a bioenergetic deficit and abnormal Ca(2+) homeostasis in the mitochondria that were associated  with oxidative and endoplasmic reticulum stresses|frataxin|frataxin|gene|32|NCBIGene:2395|mitochondrial dysfunction|mitochondrial dysfunction|disease|49|mesh:D028361
97|We showed that the reduction of frataxin induced mitochondrial dysfunction due to a bioenergetic deficit and abnormal Ca(2+) homeostasis in the mitochondria that were associated  with oxidative and endoplasmic reticulum stresses|Ca(2+)|Ca(2+)|compound|118|CHEBI:29108|frataxin|frataxin|gene|32|NCBIGene:2395
97|We showed that the reduction of frataxin induced mitochondrial dysfunction due to a bioenergetic deficit and abnormal Ca(2+) homeostasis in the mitochondria that were associated  with oxidative and endoplasmic reticulum stresses|frataxin|frataxin|gene|32|NCBIGene:2395|Hippocampus Proper|Ca|anatomy|118|C3887642
97|We showed that the reduction of frataxin induced mitochondrial dysfunction due to a bioenergetic deficit and abnormal Ca(2+) homeostasis in the mitochondria that were associated  with oxidative and endoplasmic reticulum stresses|frataxin|frataxin|gene|32|NCBIGene:2395|Mitochondria|mitochondria|anatomy|144|C0026237
97|We showed that the reduction of frataxin induced mitochondrial dysfunction due to a bioenergetic deficit and abnormal Ca(2+) homeostasis in the mitochondria that were associated  with oxidative and endoplasmic reticulum stresses|frataxin|frataxin|gene|32|NCBIGene:2395|Bioenergetics|bioenergetic|physiology|84|C0005486
97|We showed that the reduction of frataxin induced mitochondrial dysfunction due to a bioenergetic deficit and abnormal Ca(2+) homeostasis in the mitochondria that were associated  with oxidative and endoplasmic reticulum stresses|Ca(2+)|Ca(2+)|compound|118|CHEBI:29108|mitochondrial dysfunction|mitochondrial dysfunction|disease|49|mesh:D028361
97|We showed that the reduction of frataxin induced mitochondrial dysfunction due to a bioenergetic deficit and abnormal Ca(2+) homeostasis in the mitochondria that were associated  with oxidative and endoplasmic reticulum stresses|mitochondrial dysfunction|mitochondrial dysfunction|disease|49|mesh:D028361|Hippocampus Proper|Ca|anatomy|118|C3887642
97|We showed that the reduction of frataxin induced mitochondrial dysfunction due to a bioenergetic deficit and abnormal Ca(2+) homeostasis in the mitochondria that were associated  with oxidative and endoplasmic reticulum stresses|mitochondrial dysfunction|mitochondrial dysfunction|disease|49|mesh:D028361|Mitochondria|mitochondria|anatomy|144|C0026237
97|We showed that the reduction of frataxin induced mitochondrial dysfunction due to a bioenergetic deficit and abnormal Ca(2+) homeostasis in the mitochondria that were associated  with oxidative and endoplasmic reticulum stresses|Ca(2+)|Ca(2+)|compound|118|CHEBI:29108|Mitochondria|mitochondria|anatomy|144|C0026237
97|The depletion of frataxin did  not cause cell death but increased autophagy, which may have a cytoprotective effect against cellular insults such as oxidative stress|frataxin|frataxin|gene|17|NCBIGene:2395|Cell Death|cell death|physiology|41|C0007587
97|The depletion of frataxin did  not cause cell death but increased autophagy, which may have a cytoprotective effect against cellular insults such as oxidative stress|frataxin|frataxin|gene|17|NCBIGene:2395|Autophagy|autophagy|physiology|66|C0004391
97|The depletion of frataxin did  not cause cell death but increased autophagy, which may have a cytoprotective effect against cellular insults such as oxidative stress|frataxin|frataxin|gene|17|NCBIGene:2395|Cells|cellular|anatomy|124|C0007634
97|Frataxin silencing provoked slow cell growth associated with cellular senescence, as demonstrated by increased SA-βgal activity and cell cycle arrest at the G1 phase|Frataxin|Frataxin|gene|0|NCBIGene:2395|SA-gal|SA-gal|gene|111|NCBIGene:2717
97|Frataxin silencing provoked slow cell growth associated with cellular senescence, as demonstrated by increased SA-βgal activity and cell cycle arrest at the G1 phase|Frataxin|Frataxin|gene|0|NCBIGene:2395|Cellular Senescence|cellular senescence|physiology|61|C0007581
97|Frataxin silencing provoked slow cell growth associated with cellular senescence, as demonstrated by increased SA-βgal activity and cell cycle arrest at the G1 phase|Frataxin|Frataxin|gene|0|NCBIGene:2395|Cell Growth|cell growth|physiology|33|C0007595
97|Frataxin silencing provoked slow cell growth associated with cellular senescence, as demonstrated by increased SA-βgal activity and cell cycle arrest at the G1 phase|SA-gal|SA-gal|gene|111|NCBIGene:2717|Cellular Senescence|cellular senescence|physiology|61|C0007581
97|Frataxin silencing provoked slow cell growth associated with cellular senescence, as demonstrated by increased SA-βgal activity and cell cycle arrest at the G1 phase|SA-gal|SA-gal|gene|111|NCBIGene:2717|Cell Growth|cell growth|physiology|33|C0007595
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|formate|formate|compound|43|CHEBI:52343|one|one|compound|56|CHEBI:58972
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|formate|formate|compound|43|CHEBI:52343|carbon|carbon|compound|60|mesh:D002244
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|formate|formate|compound|43|CHEBI:52343|serine|serine|compound|82|mesh:D012694
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|formate|formate|compound|43|CHEBI:52343|glycine|glycine|compound|90|mesh:D005998
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|formate|formate|compound|43|CHEBI:52343|sarcosine|sarcosine|compound|103|mesh:D012521
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|formate|formate|compound|43|CHEBI:52343|Mitochondria|mitochondria|anatomy|10|C0026237
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|one|one|compound|56|CHEBI:58972|carbon|carbon|compound|60|mesh:D002244
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|one|one|compound|56|CHEBI:58972|serine|serine|compound|82|mesh:D012694
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|one|one|compound|56|CHEBI:58972|glycine|glycine|compound|90|mesh:D005998
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|one|one|compound|56|CHEBI:58972|sarcosine|sarcosine|compound|103|mesh:D012521
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|one|one|compound|56|CHEBI:58972|Mitochondria|mitochondria|anatomy|10|C0026237
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|carbon|carbon|compound|60|mesh:D002244|serine|serine|compound|82|mesh:D012694
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|carbon|carbon|compound|60|mesh:D002244|glycine|glycine|compound|90|mesh:D005998
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|carbon|carbon|compound|60|mesh:D002244|sarcosine|sarcosine|compound|103|mesh:D012521
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|carbon|carbon|compound|60|mesh:D002244|Mitochondria|mitochondria|anatomy|10|C0026237
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|serine|serine|compound|82|mesh:D012694|glycine|glycine|compound|90|mesh:D005998
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|serine|serine|compound|82|mesh:D012694|sarcosine|sarcosine|compound|103|mesh:D012521
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|serine|serine|compound|82|mesh:D012694|Mitochondria|mitochondria|anatomy|10|C0026237
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|glycine|glycine|compound|90|mesh:D005998|sarcosine|sarcosine|compound|103|mesh:D012521
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|glycine|glycine|compound|90|mesh:D005998|Mitochondria|mitochondria|anatomy|10|C0026237
98|Mammalian mitochondria are able to produce formate from one-carbon donors such as serine, glycine, and sarcosine|sarcosine|sarcosine|compound|103|mesh:D012521|Mitochondria|mitochondria|anatomy|10|C0026237
98|This pathway relies on the mitochondrial pool of  tetrahydrofolate (THF) and several folate-interconverting enzymes in the mitochondrial matrix|tetrahydrofolate|tetrahydrofolate|compound|50|mesh:C030371|THF|THF|compound|68|CHEBI:20506
98|This pathway relies on the mitochondrial pool of  tetrahydrofolate (THF) and several folate-interconverting enzymes in the mitochondrial matrix|tetrahydrofolate|tetrahydrofolate|compound|50|mesh:C030371|folate|folate|compound|85|CHEBI:62501
98|This pathway relies on the mitochondrial pool of  tetrahydrofolate (THF) and several folate-interconverting enzymes in the mitochondrial matrix|tetrahydrofolate|tetrahydrofolate|compound|50|mesh:C030371|Mitochondria|mitochondrial|anatomy|27|C0026237
98|This pathway relies on the mitochondrial pool of  tetrahydrofolate (THF) and several folate-interconverting enzymes in the mitochondrial matrix|THF|THF|compound|68|CHEBI:20506|folate|folate|compound|85|CHEBI:62501
98|This pathway relies on the mitochondrial pool of  tetrahydrofolate (THF) and several folate-interconverting enzymes in the mitochondrial matrix|THF|THF|compound|68|CHEBI:20506|Mitochondria|mitochondrial|anatomy|27|C0026237
98|This pathway relies on the mitochondrial pool of  tetrahydrofolate (THF) and several folate-interconverting enzymes in the mitochondrial matrix|folate|folate|compound|85|CHEBI:62501|Mitochondria|mitochondrial|anatomy|27|C0026237
98|We recently identified MTHFD2L as the enzyme that catalyzes the oxidation of 5,10-methylenetetrahydrofolate (CH2-THF) in adult mammalian mitochondria|5,10-methylenetetrahydrofolate|5,10-methylenetetrahydrofolate|compound|77|mesh:C013123|MTHFD2L|MTHFD2L|gene|23|NCBIGene:441024
98|We recently identified MTHFD2L as the enzyme that catalyzes the oxidation of 5,10-methylenetetrahydrofolate (CH2-THF) in adult mammalian mitochondria|CH2-THF|CH2-THF|compound|109|mesh:C005984|MTHFD2L|MTHFD2L|gene|23|NCBIGene:441024
98|We recently identified MTHFD2L as the enzyme that catalyzes the oxidation of 5,10-methylenetetrahydrofolate (CH2-THF) in adult mammalian mitochondria|MTHFD2L|MTHFD2L|gene|23|NCBIGene:441024|Mitochondria|mitochondria|anatomy|137|C0026237
98|We recently identified MTHFD2L as the enzyme that catalyzes the oxidation of 5,10-methylenetetrahydrofolate (CH2-THF) in adult mammalian mitochondria|MTHFD2L|MTHFD2L|gene|23|NCBIGene:441024|Oxidation|oxidation|physiology|64|C0030011
98|We recently identified MTHFD2L as the enzyme that catalyzes the oxidation of 5,10-methylenetetrahydrofolate (CH2-THF) in adult mammalian mitochondria|5,10-methylenetetrahydrofolate|5,10-methylenetetrahydrofolate|compound|77|mesh:C013123|CH2-THF|CH2-THF|compound|109|mesh:C005984
98|We recently identified MTHFD2L as the enzyme that catalyzes the oxidation of 5,10-methylenetetrahydrofolate (CH2-THF) in adult mammalian mitochondria|5,10-methylenetetrahydrofolate|5,10-methylenetetrahydrofolate|compound|77|mesh:C013123|Mitochondria|mitochondria|anatomy|137|C0026237
98|We recently identified MTHFD2L as the enzyme that catalyzes the oxidation of 5,10-methylenetetrahydrofolate (CH2-THF) in adult mammalian mitochondria|CH2-THF|CH2-THF|compound|109|mesh:C005984|Mitochondria|mitochondria|anatomy|137|C0026237
98|We show here that the MTHFD2L enzyme is bifunctional, possessing both CH2-THF dehydrogenase and 5,10-methenyl-THF cyclohydrolase activities|CH2-THF|CH2-THF|compound|70|mesh:C005984|MTHFD2L enzyme|MTHFD2L enzyme|gene|22|NCBIGene:441024
98|We show here that the MTHFD2L enzyme is bifunctional, possessing both CH2-THF dehydrogenase and 5,10-methenyl-THF cyclohydrolase activities|MTHFD2L enzyme|MTHFD2L enzyme|gene|22|NCBIGene:441024|CH2-THF dehydrogenase|CH2-THF dehydrogenase|gene|70|NCBIGene:10797
98|We show here that the MTHFD2L enzyme is bifunctional, possessing both CH2-THF dehydrogenase and 5,10-methenyl-THF cyclohydrolase activities|5,10-methenyl-THF|5,10-methenyl-THF|compound|96|CHEBI:1989|MTHFD2L enzyme|MTHFD2L enzyme|gene|22|NCBIGene:441024
98|We show here that the MTHFD2L enzyme is bifunctional, possessing both CH2-THF dehydrogenase and 5,10-methenyl-THF cyclohydrolase activities|MTHFD2L enzyme|MTHFD2L enzyme|gene|22|NCBIGene:441024|5,10-methenyl-THF cyclohydrolase|5,10-methenyl-THF cyclohydrolase|gene|96|NCBIGene:10797
98|We show here that the MTHFD2L enzyme is bifunctional, possessing both CH2-THF dehydrogenase and 5,10-methenyl-THF cyclohydrolase activities|MTHFD2L enzyme|MTHFD2L enzyme|gene|22|NCBIGene:441024|cyclohydrolase activity|cyclohydrolase activities|physiology|114|C1149723
98|We show here that the MTHFD2L enzyme is bifunctional, possessing both CH2-THF dehydrogenase and 5,10-methenyl-THF cyclohydrolase activities|CH2-THF|CH2-THF|compound|70|mesh:C005984|5,10-methenyl-THF|5,10-methenyl-THF|compound|96|CHEBI:1989
98|We show here that the MTHFD2L enzyme is bifunctional, possessing both CH2-THF dehydrogenase and 5,10-methenyl-THF cyclohydrolase activities|CH2-THF|CH2-THF|compound|70|mesh:C005984|5,10-methenyl-THF cyclohydrolase|5,10-methenyl-THF cyclohydrolase|gene|96|NCBIGene:10797
98|We show here that the MTHFD2L enzyme is bifunctional, possessing both CH2-THF dehydrogenase and 5,10-methenyl-THF cyclohydrolase activities|5,10-methenyl-THF|5,10-methenyl-THF|compound|96|CHEBI:1989|CH2-THF dehydrogenase|CH2-THF dehydrogenase|gene|70|NCBIGene:10797
98|We show here that the MTHFD2L enzyme is bifunctional, possessing both CH2-THF dehydrogenase and 5,10-methenyl-THF cyclohydrolase activities|CH2-THF dehydrogenase|CH2-THF dehydrogenase|gene|70|NCBIGene:10797|cyclohydrolase activity|cyclohydrolase activities|physiology|114|C1149723
98|The dehydrogenase activity can use either NAD(+) or NADP(+) but requires both phosphate and Mg(2+) when using NAD(+)|NAD(+)|NAD(+)|compound|42|CHEBI:15846|NADP(+)|NADP(+)|compound|52|mesh:D009249
98|The dehydrogenase activity can use either NAD(+) or NADP(+) but requires both phosphate and Mg(2+) when using NAD(+)|NAD(+)|NAD(+)|compound|42|CHEBI:15846|phosphate|phosphate|compound|78|mesh:D010710
98|The dehydrogenase activity can use either NAD(+) or NADP(+) but requires both phosphate and Mg(2+) when using NAD(+)|NAD(+)|NAD(+)|compound|42|CHEBI:15846|Mg(2+)|Mg(2+)|compound|92|CHEBI:18420
98|The dehydrogenase activity can use either NAD(+) or NADP(+) but requires both phosphate and Mg(2+) when using NAD(+)|NADP(+)|NADP(+)|compound|52|mesh:D009249|phosphate|phosphate|compound|78|mesh:D010710
98|The dehydrogenase activity can use either NAD(+) or NADP(+) but requires both phosphate and Mg(2+) when using NAD(+)|NADP(+)|NADP(+)|compound|52|mesh:D009249|Mg(2+)|Mg(2+)|compound|92|CHEBI:18420
98|The dehydrogenase activity can use either NAD(+) or NADP(+) but requires both phosphate and Mg(2+) when using NAD(+)|NADP(+)|NADP(+)|compound|52|mesh:D009249|NAD(+|NAD(+|compound|110|CHEBI:15846
98|The dehydrogenase activity can use either NAD(+) or NADP(+) but requires both phosphate and Mg(2+) when using NAD(+)|phosphate|phosphate|compound|78|mesh:D010710|Mg(2+)|Mg(2+)|compound|92|CHEBI:18420
98|The dehydrogenase activity can use either NAD(+) or NADP(+) but requires both phosphate and Mg(2+) when using NAD(+)|phosphate|phosphate|compound|78|mesh:D010710|NAD(+|NAD(+|compound|110|CHEBI:15846
98|The dehydrogenase activity can use either NAD(+) or NADP(+) but requires both phosphate and Mg(2+) when using NAD(+)|Mg(2+)|Mg(2+)|compound|92|CHEBI:18420|NAD(+|NAD(+|compound|110|CHEBI:15846
98|The NADP(+)-dependent dehydrogenase activity is inhibited by inorganic phosphate|NADP(+)|NADP(+)|compound|4|mesh:D009249|inorganic phosphate|inorganic phosphate|compound|61|mesh:D010710
98|The NADP(+)-dependent dehydrogenase activity is inhibited by inorganic phosphate|inorganic phosphate|inorganic phosphate|compound|61|mesh:D010710|NADP(+)-dependent dehydrogenase|NADP(+)-dependent dehydrogenase|gene|4|NCBIGene:2232
98|MTHFD2L uses the mono- and polyglutamylated forms of CH2-THF with similar catalytic efficiencies|CH2-THF|CH2-THF|compound|53|mesh:C005984|MTHFD2L|MTHFD2L|gene|0|NCBIGene:441024
98|Expression of the MTHFD2L transcript is low in early mouse embryos but begins to increase at embryonic day 10|MTHFD2L transcript|MTHFD2L transcript|gene|18|NCBIGene:441024|Embryo|embryonic|anatomy|93|C0013935
98|In adults, MTHFD2L is expressed in all tissues examined, with the highest levels observed in brain and  lung|MTHFD2L|MTHFD2L|gene|11|NCBIGene:441024|Lung|lung|anatomy|104|C0024109
98|In adults, MTHFD2L is expressed in all tissues examined, with the highest levels observed in brain and  lung|MTHFD2L|MTHFD2L|gene|11|NCBIGene:441024|Brain|brain|anatomy|93|C0006104
98|In adults, MTHFD2L is expressed in all tissues examined, with the highest levels observed in brain and  lung|MTHFD2L|MTHFD2L|gene|11|NCBIGene:441024|Body tissue|tissues|anatomy|39|C0040300
99|Chlorpyrifos (CPF) is one of the most widely used organophosphate insecticides with several harmful effects, including neurotoxicity|Chlorpyrifos|Chlorpyrifos|compound|0|mesh:D004390|CPF|CPF|compound|14|CHEBI:23501
99|Chlorpyrifos (CPF) is one of the most widely used organophosphate insecticides with several harmful effects, including neurotoxicity|Chlorpyrifos|Chlorpyrifos|compound|0|mesh:D004390|organophosphate|organophosphate|compound|50|mesh:D010755
99|Chlorpyrifos (CPF) is one of the most widely used organophosphate insecticides with several harmful effects, including neurotoxicity|Chlorpyrifos|Chlorpyrifos|compound|0|mesh:D004390|neurotoxicity|neurotoxicity|disease|119|mesh:D020258
99|Chlorpyrifos (CPF) is one of the most widely used organophosphate insecticides with several harmful effects, including neurotoxicity|CPF|CPF|compound|14|CHEBI:23501|organophosphate|organophosphate|compound|50|mesh:D010755
99|Chlorpyrifos (CPF) is one of the most widely used organophosphate insecticides with several harmful effects, including neurotoxicity|CPF|CPF|compound|14|CHEBI:23501|neurotoxicity|neurotoxicity|disease|119|mesh:D020258
99|Chlorpyrifos (CPF) is one of the most widely used organophosphate insecticides with several harmful effects, including neurotoxicity|organophosphate|organophosphate|compound|50|mesh:D010755|neurotoxicity|neurotoxicity|disease|119|mesh:D020258
99|Although many studies have addressed the neurotoxicity induced by CPF, most data on neurodevelopmental damage was obtained from animal models|CPF|CPF|compound|66|CHEBI:23501|neurodevelopmental|neurodevelopmental|disease|84|mesh:D065886
99|We are the first group to use human neural precursor cells (hNPCs) derived from human embryonic stem cells (hESCs) as a developing neuron model to evaluate the mechanisms involved in CPF-induced neurotoxicity|CPF|CPF|compound|183|CHEBI:23501|Human Embryonic Stem Cells|human embryonic stem cells|anatomy|80|C1171346
99|CPF was cytotoxic to these cells in a concentration-dependent manner, as shown by decreased cell viability and increased lactate dehydrogenase  release|CPF|CPF|compound|0|CHEBI:23501|lactate|lactate|compound|121|mesh:D019344
99|CPF was cytotoxic to these cells in a concentration-dependent manner, as shown by decreased cell viability and increased lactate dehydrogenase  release|CPF|CPF|compound|0|CHEBI:23501|lactate dehydrogenase|lactate dehydrogenase|gene|121|NCBIGene:3939
99|CPF was cytotoxic to these cells in a concentration-dependent manner, as shown by decreased cell viability and increased lactate dehydrogenase  release|lactate dehydrogenase|lactate dehydrogenase|gene|121|NCBIGene:3939|Cell Survival|[|physiology|92|C0007620
99|CPF was cytotoxic to these cells in a concentration-dependent manner, as shown by decreased cell viability and increased lactate dehydrogenase  release|lactate dehydrogenase|lactate dehydrogenase|gene|121|NCBIGene:3939|Mental concentration|concentration|physiology|38|C0086045
99|Furthermore, CPF reduced the expression of AKT and ERK proteins which are involved in intracellular survival pathways|CPF|CPF|compound|13|CHEBI:23501|AKT|AKT|gene|43|NCBIGene:207
99|Furthermore, CPF reduced the expression of AKT and ERK proteins which are involved in intracellular survival pathways|CPF|CPF|compound|13|CHEBI:23501|ERK proteins|ERK proteins|gene|51|NCBIGene:5594
99|Furthermore, CPF reduced the expression of AKT and ERK proteins which are involved in intracellular survival pathways|CPF|CPF|compound|13|CHEBI:23501|Protoplasm|intracellular|anatomy|86|C0175996
99|Furthermore, CPF reduced the expression of AKT and ERK proteins which are involved in intracellular survival pathways|AKT|AKT|gene|43|NCBIGene:207|ERK proteins|ERK proteins|gene|51|NCBIGene:5594
99|Furthermore, CPF reduced the expression of AKT and ERK proteins which are involved in intracellular survival pathways|AKT|AKT|gene|43|NCBIGene:207|Protoplasm|intracellular|anatomy|86|C0175996
99|Furthermore, CPF reduced the expression of AKT and ERK proteins which are involved in intracellular survival pathways|ERK proteins|ERK proteins|gene|51|NCBIGene:5594|Protoplasm|intracellular|anatomy|86|C0175996
99|Exposure of hNPCs to CPF led to  the production of reactive oxygen species (ROS), and the antioxidant N-acetyl-cystein (NAC) attenuated ROS production induced by CPF|oxygen|oxygen|compound|60|mesh:D010100|N-acetyl-cystein|N-acetyl-cystein|compound|102|mesh:C030905
99|Exposure of hNPCs to CPF led to  the production of reactive oxygen species (ROS), and the antioxidant N-acetyl-cystein (NAC) attenuated ROS production induced by CPF|oxygen|oxygen|compound|60|mesh:D010100|NAC|NAC|compound|120|CHEBI:33192
99|Exposure of hNPCs to CPF led to  the production of reactive oxygen species (ROS), and the antioxidant N-acetyl-cystein (NAC) attenuated ROS production induced by CPF|oxygen|oxygen|compound|60|mesh:D010100|CPF|CPF|compound|162|CHEBI:23501
99|Exposure of hNPCs to CPF led to  the production of reactive oxygen species (ROS), and the antioxidant N-acetyl-cystein (NAC) attenuated ROS production induced by CPF|N-acetyl-cystein|N-acetyl-cystein|compound|102|mesh:C030905|NAC|NAC|compound|120|CHEBI:33192
99|Exposure of hNPCs to CPF led to  the production of reactive oxygen species (ROS), and the antioxidant N-acetyl-cystein (NAC) attenuated ROS production induced by CPF|N-acetyl-cystein|N-acetyl-cystein|compound|102|mesh:C030905|CPF|CPF|compound|162|CHEBI:23501
99|Exposure of hNPCs to CPF led to  the production of reactive oxygen species (ROS), and the antioxidant N-acetyl-cystein (NAC) attenuated ROS production induced by CPF|NAC|NAC|compound|120|CHEBI:33192|CPF|CPF|compound|162|CHEBI:23501
99|In addition, CPF increased cytochrome c release into the cytosol and activated caspase-9 and -3, indicating that cell death induced by CPF was due to apoptosis in hNPCs|CPF|CPF|compound|13|CHEBI:23501|cytochrome c|cytochrome c|gene|27|NCBIGene:54205
99|In addition, CPF increased cytochrome c release into the cytosol and activated caspase-9 and -3, indicating that cell death induced by CPF was due to apoptosis in hNPCs|CPF|CPF|compound|13|CHEBI:23501|caspase-9 and -3|caspase-9 and -3|gene|79|NCBIGene:842
99|In addition, CPF increased cytochrome c release into the cytosol and activated caspase-9 and -3, indicating that cell death induced by CPF was due to apoptosis in hNPCs|cytochrome c|cytochrome c|gene|27|NCBIGene:54205|caspase-9 and -3|caspase-9 and -3|gene|79|NCBIGene:842
99|In addition, CPF increased cytochrome c release into the cytosol and activated caspase-9 and -3, indicating that cell death induced by CPF was due to apoptosis in hNPCs|CPF|CPF|compound|135|CHEBI:23501|cytochrome c|cytochrome c|gene|27|NCBIGene:54205
99|In addition, CPF increased cytochrome c release into the cytosol and activated caspase-9 and -3, indicating that cell death induced by CPF was due to apoptosis in hNPCs|cytochrome c|cytochrome c|gene|27|NCBIGene:54205|Cell Death|cell death|physiology|113|C0007587
99|In addition, CPF increased cytochrome c release into the cytosol and activated caspase-9 and -3, indicating that cell death induced by CPF was due to apoptosis in hNPCs|cytochrome c|cytochrome c|gene|27|NCBIGene:54205|Apoptosis|apoptosis|physiology|150|C0162638
99|In addition, CPF increased cytochrome c release into the cytosol and activated caspase-9 and -3, indicating that cell death induced by CPF was due to apoptosis in hNPCs|CPF|CPF|compound|135|CHEBI:23501|caspase-9 and -3|caspase-9 and -3|gene|79|NCBIGene:842
99|In addition, CPF increased cytochrome c release into the cytosol and activated caspase-9 and -3, indicating that cell death induced by CPF was due to apoptosis in hNPCs|caspase-9 and -3|caspase-9 and -3|gene|79|NCBIGene:842|Cell Death|cell death|physiology|113|C0007587
99|In addition, CPF increased cytochrome c release into the cytosol and activated caspase-9 and -3, indicating that cell death induced by CPF was due to apoptosis in hNPCs|caspase-9 and -3|caspase-9 and -3|gene|79|NCBIGene:842|Apoptosis|apoptosis|physiology|150|C0162638
99|Consistent with these findings, CPF treatment reduced the level of Bcl-2 protein  and increased the level of Bax protein|CPF|CPF|compound|32|CHEBI:23501|Bcl-2 protein|Bcl-2 protein|gene|67|NCBIGene:596
99|Consistent with these findings, CPF treatment reduced the level of Bcl-2 protein  and increased the level of Bax protein|CPF|CPF|compound|32|CHEBI:23501|Bax protein|Bax protein|gene|109|NCBIGene:581
99|Consistent with these findings, CPF treatment reduced the level of Bcl-2 protein  and increased the level of Bax protein|Bcl-2 protein|Bcl-2 protein|gene|67|NCBIGene:596|Bax protein|Bax protein|gene|109|NCBIGene:581
99|Consistent with these findings, CPF treatment reduced the level of Bcl-2 protein  and increased the level of Bax protein|Bcl-2 protein|Bcl-2 protein|gene|67|NCBIGene:596|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|22|C2926606
99|Consistent with these findings, CPF treatment reduced the level of Bcl-2 protein  and increased the level of Bax protein|Bax protein|Bax protein|gene|109|NCBIGene:581|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|22|C2926606
99|Especially, CPF increased the translocation of BAX into the mitochondria|CPF|CPF|compound|12|CHEBI:23501|BAX|BAX|gene|47|NCBIGene:581
99|Especially, CPF increased the translocation of BAX into the mitochondria|CPF|CPF|compound|12|CHEBI:23501|Mitochondria|mitochondria|anatomy|60|C0026237
99|Especially, CPF increased the translocation of BAX into the mitochondria|BAX|BAX|gene|47|NCBIGene:581|Mitochondria|mitochondria|anatomy|60|C0026237
99|CPF also induced nuclear accumulation of NF-κB and p53 proteins in a concentration-dependent manner, and their inhibitors attenuated CPF-induced cytotoxicity|CPF|CPF|compound|0|CHEBI:23501|NF-B|NF-B|gene|41|NCBIGene:4781
99|CPF also induced nuclear accumulation of NF-κB and p53 proteins in a concentration-dependent manner, and their inhibitors attenuated CPF-induced cytotoxicity|CPF|CPF|compound|0|CHEBI:23501|p53 proteins|p53 proteins|gene|50|NCBIGene:7157
99|CPF also induced nuclear accumulation of NF-κB and p53 proteins in a concentration-dependent manner, and their inhibitors attenuated CPF-induced cytotoxicity|NF-B|NF-B|gene|41|NCBIGene:4781|p53 proteins|p53 proteins|gene|50|NCBIGene:7157
99|CPF also induced nuclear accumulation of NF-κB and p53 proteins in a concentration-dependent manner, and their inhibitors attenuated CPF-induced cytotoxicity|CPF|CPF|compound|132|CHEBI:23501|NF-B|NF-B|gene|41|NCBIGene:4781
99|CPF also induced nuclear accumulation of NF-κB and p53 proteins in a concentration-dependent manner, and their inhibitors attenuated CPF-induced cytotoxicity|CPF|CPF|compound|132|CHEBI:23501|p53 proteins|p53 proteins|gene|50|NCBIGene:7157
99|In addition, an inhibitor of NF-κB nuclear translocation blocked the increase of p53 in CPF-treated hNPCs|NF-B|NF-B|gene|29|NCBIGene:4781|p53|p53|gene|80|NCBIGene:7157
99|In addition, an inhibitor of NF-κB nuclear translocation blocked the increase of p53 in CPF-treated hNPCs|NF-B|NF-B|gene|29|NCBIGene:4781|Nuclear Translocation|nuclear translocation|physiology|35|C1518440
99|In addition, an inhibitor of NF-κB nuclear translocation blocked the increase of p53 in CPF-treated hNPCs|p53|p53|gene|80|NCBIGene:7157|Nuclear Translocation|nuclear translocation|physiology|35|C1518440
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|CPF|CPF|compound|25|CHEBI:23501|NF-B|NF-B|gene|65|NCBIGene:4781
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|CPF|CPF|compound|25|CHEBI:23501|p53|p53|gene|129|NCBIGene:7157
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|CPF|CPF|compound|25|CHEBI:23501|Bcl-2|Bcl-2|gene|138|NCBIGene:596
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|CPF|CPF|compound|25|CHEBI:23501|Bax|Bax|gene|148|NCBIGene:581
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|CPF|CPF|compound|25|CHEBI:23501|cytochrome c|cytochrome c|gene|178|NCBIGene:54205
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|NF-B|NF-B|gene|65|NCBIGene:4781|p53|p53|gene|129|NCBIGene:7157
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|NF-B|NF-B|gene|65|NCBIGene:4781|Bcl-2|Bcl-2|gene|138|NCBIGene:596
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|NF-B|NF-B|gene|65|NCBIGene:4781|Bax|Bax|gene|148|NCBIGene:581
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|NF-B|NF-B|gene|65|NCBIGene:4781|cytochrome c|cytochrome c|gene|178|NCBIGene:54205
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|NF-B|NF-B|gene|65|NCBIGene:4781|Enabling|enabling|physiology|102|C1171285
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|NF-B|NF-B|gene|65|NCBIGene:4781|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|6|C2926606
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|NF-B|NF-B|gene|65|NCBIGene:4781|Cessation of life|death|physiology|43|C0011065
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|p53|p53|gene|129|NCBIGene:7157|Bcl-2|Bcl-2|gene|138|NCBIGene:596
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|p53|p53|gene|129|NCBIGene:7157|Bax|Bax|gene|148|NCBIGene:581
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|p53|p53|gene|129|NCBIGene:7157|cytochrome c|cytochrome c|gene|178|NCBIGene:54205
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|p53|p53|gene|129|NCBIGene:7157|Enabling|enabling|physiology|102|C1171285
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|p53|p53|gene|129|NCBIGene:7157|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|6|C2926606
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|p53|p53|gene|129|NCBIGene:7157|positive regulation of NF-kappaB transcription factor activity|NF-kappaB activation|physiology|65|C1523116
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|p53|p53|gene|129|NCBIGene:7157|Cessation of life|death|physiology|43|C0011065
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|Bcl-2|Bcl-2|gene|138|NCBIGene:596|Bax|Bax|gene|148|NCBIGene:581
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|Bcl-2|Bcl-2|gene|138|NCBIGene:596|cytochrome c|cytochrome c|gene|178|NCBIGene:54205
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|Bcl-2|Bcl-2|gene|138|NCBIGene:596|Enabling|enabling|physiology|102|C1171285
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|Bcl-2|Bcl-2|gene|138|NCBIGene:596|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|6|C2926606
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|Bcl-2|Bcl-2|gene|138|NCBIGene:596|positive regulation of NF-kappaB transcription factor activity|NF-kappaB activation|physiology|65|C1523116
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|Bcl-2|Bcl-2|gene|138|NCBIGene:596|Cessation of life|death|physiology|43|C0011065
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|Bax|Bax|gene|148|NCBIGene:581|cytochrome c|cytochrome c|gene|178|NCBIGene:54205
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|Bax|Bax|gene|148|NCBIGene:581|Enabling|enabling|physiology|102|C1171285
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|Bax|Bax|gene|148|NCBIGene:581|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|6|C2926606
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|Bax|Bax|gene|148|NCBIGene:581|positive regulation of NF-kappaB transcription factor activity|NF-kappaB activation|physiology|65|C1523116
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|Bax|Bax|gene|148|NCBIGene:581|Cessation of life|death|physiology|43|C0011065
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|cytochrome c|cytochrome c|gene|178|NCBIGene:54205|Enabling|enabling|physiology|102|C1171285
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|cytochrome c|cytochrome c|gene|178|NCBIGene:54205|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|6|C2926606
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|cytochrome c|cytochrome c|gene|178|NCBIGene:54205|positive regulation of NF-kappaB transcription factor activity|NF-kappaB activation|physiology|65|C1523116
99|These findings show that CPF induced hNPCs death in part through NF-κB activation via ROS generation, enabling the interaction of p53 with Bcl-2 and Bax and subsequent release of cytochrome c|cytochrome c|cytochrome c|gene|178|NCBIGene:54205|Cessation of life|death|physiology|43|C0011065
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|Zellweger syndrome|Zellweger syndrome|disease|0|mesh:D015211|neonatal-lethal genetic disease|neonatal-lethal genetic disease|disease|29|mesh:D007232
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|Zellweger syndrome|Zellweger syndrome|disease|0|mesh:D015211|developmental defects|developmental defects|disease|137|mesh:D002658
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|Zellweger syndrome|Zellweger syndrome|disease|0|mesh:D015211|neurodegeneration|neurodegeneration|disease|171|mesh:D009410
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|Zellweger syndrome|Zellweger syndrome|disease|0|mesh:D015211|Body tissue|tissues|anatomy|78|C0040300
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|ZS|ZS|disease|20|mesh:D015211|neonatal-lethal genetic disease|neonatal-lethal genetic disease|disease|29|mesh:D007232
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|ZS|ZS|disease|20|mesh:D015211|developmental defects|developmental defects|disease|137|mesh:D002658
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|ZS|ZS|disease|20|mesh:D015211|neurodegeneration|neurodegeneration|disease|171|mesh:D009410
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|ZS|ZS|disease|20|mesh:D015211|Body tissue|tissues|anatomy|78|C0040300
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|neonatal-lethal genetic disease|neonatal-lethal genetic disease|disease|29|mesh:D007232|developmental defects|developmental defects|disease|137|mesh:D002658
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|neonatal-lethal genetic disease|neonatal-lethal genetic disease|disease|29|mesh:D007232|neurodegeneration|neurodegeneration|disease|171|mesh:D009410
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|neonatal-lethal genetic disease|neonatal-lethal genetic disease|disease|29|mesh:D007232|Body tissue|tissues|anatomy|78|C0040300
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|developmental defects|developmental defects|disease|137|mesh:D002658|neurodegeneration|neurodegeneration|disease|171|mesh:D009410
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|developmental defects|developmental defects|disease|137|mesh:D002658|Body tissue|tissues|anatomy|78|C0040300
100|Zellweger syndrome (ZS) is a neonatal-lethal genetic disease that affects all tissues, and features neuropathology that involves primary developmental defects  as well as neurodegeneration|neurodegeneration|neurodegeneration|disease|171|mesh:D009410|Body tissue|tissues|anatomy|78|C0040300
100|Neuropathological changes include abnormal neuronal migration affecting the cerebral hemispheres, cerebellum and inferior olivary complex, abnormal Purkinje cell arborisation, demyelination and post-developmental neuronal degeneration|demyelination|demyelination|disease|176|mesh:D003711|post-developmental neuronal degeneration|post-developmental neuronal degeneration|disease|194|mesh:D009410
100|Neuropathological changes include abnormal neuronal migration affecting the cerebral hemispheres, cerebellum and inferior olivary complex, abnormal Purkinje cell arborisation, demyelination and post-developmental neuronal degeneration|demyelination|demyelination|disease|176|mesh:D003711|Cerebellum|cerebellum|anatomy|98|C0007765
100|Neuropathological changes include abnormal neuronal migration affecting the cerebral hemispheres, cerebellum and inferior olivary complex, abnormal Purkinje cell arborisation, demyelination and post-developmental neuronal degeneration|demyelination|demyelination|disease|176|mesh:D003711|Cerebral hemisphere structure (body structure)|cerebral hemispheres|anatomy|76|C0228174
100|Neuropathological changes include abnormal neuronal migration affecting the cerebral hemispheres, cerebellum and inferior olivary complex, abnormal Purkinje cell arborisation, demyelination and post-developmental neuronal degeneration|demyelination|demyelination|disease|176|mesh:D003711|Inferior olivary nucleus|inferior olivary complex|anatomy|113|C0228540
100|Neuropathological changes include abnormal neuronal migration affecting the cerebral hemispheres, cerebellum and inferior olivary complex, abnormal Purkinje cell arborisation, demyelination and post-developmental neuronal degeneration|post-developmental neuronal degeneration|post-developmental neuronal degeneration|disease|194|mesh:D009410|Cerebellum|cerebellum|anatomy|98|C0007765
100|Neuropathological changes include abnormal neuronal migration affecting the cerebral hemispheres, cerebellum and inferior olivary complex, abnormal Purkinje cell arborisation, demyelination and post-developmental neuronal degeneration|post-developmental neuronal degeneration|post-developmental neuronal degeneration|disease|194|mesh:D009410|Cerebral hemisphere structure (body structure)|cerebral hemispheres|anatomy|76|C0228174
100|Neuropathological changes include abnormal neuronal migration affecting the cerebral hemispheres, cerebellum and inferior olivary complex, abnormal Purkinje cell arborisation, demyelination and post-developmental neuronal degeneration|post-developmental neuronal degeneration|post-developmental neuronal degeneration|disease|194|mesh:D009410|Inferior olivary nucleus|inferior olivary complex|anatomy|113|C0228540
100|ZS is caused by mutations in peroxisome biogenesis, or PEX, genes which lead to defective peroxisome biogenesis and the resultant loss of peroxisomal metabolic function|PEX|PEX|gene|55|NCBIGene:5251|ZS|ZS|disease|0|mesh:D015211
100|ZS is caused by mutations in peroxisome biogenesis, or PEX, genes which lead to defective peroxisome biogenesis and the resultant loss of peroxisomal metabolic function|PEX|PEX|gene|55|NCBIGene:5251|Mutation|mutations|physiology|16|C0026882
100|ZS is caused by mutations in peroxisome biogenesis, or PEX, genes which lead to defective peroxisome biogenesis and the resultant loss of peroxisomal metabolic function|PEX|PEX|gene|55|NCBIGene:5251|Function Axis|function|physiology|160|C0700205
100|ZS is caused by mutations in peroxisome biogenesis, or PEX, genes which lead to defective peroxisome biogenesis and the resultant loss of peroxisomal metabolic function|PEX|PEX|gene|55|NCBIGene:5251|Metabolic Process, Cellular|metabolic|physiology|150|C1524026
100|The molecular and cellular bases of ZS neuropathology are still not completely understood|ZS|ZS|disease|36|mesh:D015211|Basal Cell|cellular bases|anatomy|18|C0596155
100|Attempts to explain the neuropathogenesis have implicated peroxisomal metabolic dysfunction,  and more specifically the loss of peroxisomal products, such as plasmalogens and  docosahexaenoic, and the accumulation of peroxisomal substrates, such as very-long-chain-fatty acids|docosahexaenoic|docosahexaenoic|compound|176|mesh:D004281|peroxisomal metabolic dysfunction|peroxisomal metabolic dysfunction|disease|58|mesh:D018901
100|Attempts to explain the neuropathogenesis have implicated peroxisomal metabolic dysfunction,  and more specifically the loss of peroxisomal products, such as plasmalogens and  docosahexaenoic, and the accumulation of peroxisomal substrates, such as very-long-chain-fatty acids|very-long-chain-fatty acids|very-long-chain-fatty acids|compound|249|CHEBI:27283|peroxisomal metabolic dysfunction|peroxisomal metabolic dysfunction|disease|58|mesh:D018901
100|Attempts to explain the neuropathogenesis have implicated peroxisomal metabolic dysfunction,  and more specifically the loss of peroxisomal products, such as plasmalogens and  docosahexaenoic, and the accumulation of peroxisomal substrates, such as very-long-chain-fatty acids|docosahexaenoic|docosahexaenoic|compound|176|mesh:D004281|very-long-chain-fatty acids|very-long-chain-fatty acids|compound|249|CHEBI:27283
100|In this review, consideration is also given to recent findings that implicate other candidate pathogenetic factors, such as mitochondrial dysfunction, oxidative stress, protein misfolding, aberrant cell signalling, and inflammation - factors that have also been identified as important in the pathogenesis of other neurological diseases|mitochondrial dysfunction|mitochondrial dysfunction|disease|124|mesh:D028361|neurological diseases|neurological diseases|disease|315|mesh:D009422
101|Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized primarily by the selective death of dopaminergic (DA) neurons in the substantia nigra pars compacta of the midbrain|Parkinson's disease|Parkinson's disease|disease|0|mesh:D010300|PD|PD|disease|21|omim:168600
101|Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized primarily by the selective death of dopaminergic (DA) neurons in the substantia nigra pars compacta of the midbrain|Parkinson's disease|Parkinson's disease|disease|0|mesh:D010300|debilitating neurodegenerative disease|debilitating neurodegenerative disease|disease|30|mesh:D019636
101|Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized primarily by the selective death of dopaminergic (DA) neurons in the substantia nigra pars compacta of the midbrain|Parkinson's disease|Parkinson's disease|disease|0|mesh:D010300|Pars Compacta|substantia nigra pars compacta|anatomy|152|C0175412
101|Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized primarily by the selective death of dopaminergic (DA) neurons in the substantia nigra pars compacta of the midbrain|Parkinson's disease|Parkinson's disease|disease|0|mesh:D010300|Midbrain structure|midbrain|anatomy|190|C0025462
101|Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized primarily by the selective death of dopaminergic (DA) neurons in the substantia nigra pars compacta of the midbrain|PD|PD|disease|21|omim:168600|debilitating neurodegenerative disease|debilitating neurodegenerative disease|disease|30|mesh:D019636
101|Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized primarily by the selective death of dopaminergic (DA) neurons in the substantia nigra pars compacta of the midbrain|PD|PD|disease|21|omim:168600|Pars Compacta|substantia nigra pars compacta|anatomy|152|C0175412
101|Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized primarily by the selective death of dopaminergic (DA) neurons in the substantia nigra pars compacta of the midbrain|PD|PD|disease|21|omim:168600|Midbrain structure|midbrain|anatomy|190|C0025462
101|Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized primarily by the selective death of dopaminergic (DA) neurons in the substantia nigra pars compacta of the midbrain|debilitating neurodegenerative disease|debilitating neurodegenerative disease|disease|30|mesh:D019636|Pars Compacta|substantia nigra pars compacta|anatomy|152|C0175412
101|Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized primarily by the selective death of dopaminergic (DA) neurons in the substantia nigra pars compacta of the midbrain|debilitating neurodegenerative disease|debilitating neurodegenerative disease|disease|30|mesh:D019636|Midbrain structure|midbrain|anatomy|190|C0025462
101|Although their role in PD pathogenesis is still a very active area of investigation, several seminal studies have contributed significantly to our understanding of the roles these small non-coding RNAs play in the disease process|PD|PD|disease|23|omim:168600|bony process|process|anatomy|222|C1184743
101|Among these are studies which  have demonstrated specific miRNAs that target and down-regulate the expression of PD-related genes as well as those demonstrating a reciprocal relationship in which PD-related genes act to regulate miRNA processing machinery|PD|PD|gene|196|NCBIGene:54704|PD|PD|disease|113|omim:168600
101|Among these are studies which  have demonstrated specific miRNAs that target and down-regulate the expression of PD-related genes as well as those demonstrating a reciprocal relationship in which PD-related genes act to regulate miRNA processing machinery|PD|PD|disease|113|omim:168600|Lanugo|down|anatomy|81|C0423866
101|Among these are studies which  have demonstrated specific miRNAs that target and down-regulate the expression of PD-related genes as well as those demonstrating a reciprocal relationship in which PD-related genes act to regulate miRNA processing machinery|PD|PD|gene|196|NCBIGene:54704|Lanugo|down|anatomy|81|C0423866
101|Among these are studies which  have demonstrated specific miRNAs that target and down-regulate the expression of PD-related genes as well as those demonstrating a reciprocal relationship in which PD-related genes act to regulate miRNA processing machinery|PD|PD|gene|196|NCBIGene:54704|production of miRNAs involved in gene silencing by miRNA|miRNA processing|physiology|229|C1523645
101|Concurrently,  a wealth of knowledge has become available regarding the molecular mechanisms that unify the underlying etiology of genetic and sporadic PD pathogenesis, including dysregulated protein quality control by the ubiquitin-proteasome system and autophagy pathway, activation of programmed cell death, mitochondrial damage  and aberrant DA neurodevelopment and maintenance|ubiquitin|ubiquitin|gene|223|NCBIGene:10537|PD|PD|disease|152|omim:168600
101|Concurrently,  a wealth of knowledge has become available regarding the molecular mechanisms that unify the underlying etiology of genetic and sporadic PD pathogenesis, including dysregulated protein quality control by the ubiquitin-proteasome system and autophagy pathway, activation of programmed cell death, mitochondrial damage  and aberrant DA neurodevelopment and maintenance|PD|PD|disease|152|omim:168600|DA|DA|disease|346|mesh:D000544
101|Concurrently,  a wealth of knowledge has become available regarding the molecular mechanisms that unify the underlying etiology of genetic and sporadic PD pathogenesis, including dysregulated protein quality control by the ubiquitin-proteasome system and autophagy pathway, activation of programmed cell death, mitochondrial damage  and aberrant DA neurodevelopment and maintenance|ubiquitin|ubiquitin|gene|223|NCBIGene:10537|DA|DA|disease|346|mesh:D000544
101|Concurrently,  a wealth of knowledge has become available regarding the molecular mechanisms that unify the underlying etiology of genetic and sporadic PD pathogenesis, including dysregulated protein quality control by the ubiquitin-proteasome system and autophagy pathway, activation of programmed cell death, mitochondrial damage  and aberrant DA neurodevelopment and maintenance|ubiquitin|ubiquitin|gene|223|NCBIGene:10537|activation of programmed cell death|activation of programmed cell death|physiology|274|C2248385
101|Concurrently,  a wealth of knowledge has become available regarding the molecular mechanisms that unify the underlying etiology of genetic and sporadic PD pathogenesis, including dysregulated protein quality control by the ubiquitin-proteasome system and autophagy pathway, activation of programmed cell death, mitochondrial damage  and aberrant DA neurodevelopment and maintenance|ubiquitin|ubiquitin|gene|223|NCBIGene:10537|Biochemical Pathway|pathway|physiology|265|C1704259
101|Concurrently,  a wealth of knowledge has become available regarding the molecular mechanisms that unify the underlying etiology of genetic and sporadic PD pathogenesis, including dysregulated protein quality control by the ubiquitin-proteasome system and autophagy pathway, activation of programmed cell death, mitochondrial damage  and aberrant DA neurodevelopment and maintenance|ubiquitin|ubiquitin|gene|223|NCBIGene:10537|neurodevelopment|neurodevelopment|physiology|349|C0599855
101|Concurrently,  a wealth of knowledge has become available regarding the molecular mechanisms that unify the underlying etiology of genetic and sporadic PD pathogenesis, including dysregulated protein quality control by the ubiquitin-proteasome system and autophagy pathway, activation of programmed cell death, mitochondrial damage  and aberrant DA neurodevelopment and maintenance|ubiquitin|ubiquitin|gene|223|NCBIGene:10537|Autophagy|autophagy|physiology|255|C0004391
102|Explanatory models support a potential role for neurotransmitter systems, inflammation, oxidative and nitrosative stress, mitochondrial dysfunction, neurotrophins and neurogenesis, and epigenetic effects, in anxiety pathogenesis|inflammation|inflammation|disease|74|mesh:D007249|mitochondrial dysfunction|mitochondrial dysfunction|disease|122|mesh:D028361
102|Explanatory models support a potential role for neurotransmitter systems, inflammation, oxidative and nitrosative stress, mitochondrial dysfunction, neurotrophins and neurogenesis, and epigenetic effects, in anxiety pathogenesis|neurotrophins|neurotrophins|gene|149|NCBIGene:627|inflammation|inflammation|disease|74|mesh:D007249
102|Explanatory models support a potential role for neurotransmitter systems, inflammation, oxidative and nitrosative stress, mitochondrial dysfunction, neurotrophins and neurogenesis, and epigenetic effects, in anxiety pathogenesis|inflammation|inflammation|disease|74|mesh:D007249|anxiety|anxiety|disease|208|mesh:D001008
102|Explanatory models support a potential role for neurotransmitter systems, inflammation, oxidative and nitrosative stress, mitochondrial dysfunction, neurotrophins and neurogenesis, and epigenetic effects, in anxiety pathogenesis|neurotrophins|neurotrophins|gene|149|NCBIGene:627|mitochondrial dysfunction|mitochondrial dysfunction|disease|122|mesh:D028361
102|Explanatory models support a potential role for neurotransmitter systems, inflammation, oxidative and nitrosative stress, mitochondrial dysfunction, neurotrophins and neurogenesis, and epigenetic effects, in anxiety pathogenesis|mitochondrial dysfunction|mitochondrial dysfunction|disease|122|mesh:D028361|anxiety|anxiety|disease|208|mesh:D001008
102|Explanatory models support a potential role for neurotransmitter systems, inflammation, oxidative and nitrosative stress, mitochondrial dysfunction, neurotrophins and neurogenesis, and epigenetic effects, in anxiety pathogenesis|neurotrophins|neurotrophins|gene|149|NCBIGene:627|anxiety|anxiety|disease|208|mesh:D001008
102|Explanatory models support a potential role for neurotransmitter systems, inflammation, oxidative and nitrosative stress, mitochondrial dysfunction, neurotrophins and neurogenesis, and epigenetic effects, in anxiety pathogenesis|neurotrophins|neurotrophins|gene|149|NCBIGene:627|Neurogenesis|neurogenesis|physiology|167|C0814002
102|A large heterogenous literature was reviewed that detailed the association  between cigarette smoking and anxiety symptoms and disorders with structural brain changes, inflammation, and cell-mediated immune markers, markers of oxidative and nitrosative stress, mitochondrial function, neurotransmitter systems, neurotrophins and neurogenesis|anxiety|anxiety|disease|106|mesh:D001008|inflammation|inflammation|disease|168|mesh:D007249
102|A large heterogenous literature was reviewed that detailed the association  between cigarette smoking and anxiety symptoms and disorders with structural brain changes, inflammation, and cell-mediated immune markers, markers of oxidative and nitrosative stress, mitochondrial function, neurotransmitter systems, neurotrophins and neurogenesis|neurotrophins|neurotrophins|gene|311|NCBIGene:627|anxiety|anxiety|disease|106|mesh:D001008
102|A large heterogenous literature was reviewed that detailed the association  between cigarette smoking and anxiety symptoms and disorders with structural brain changes, inflammation, and cell-mediated immune markers, markers of oxidative and nitrosative stress, mitochondrial function, neurotransmitter systems, neurotrophins and neurogenesis|anxiety|anxiety|disease|106|mesh:D001008|Cells|cell|anatomy|186|C0007634
102|A large heterogenous literature was reviewed that detailed the association  between cigarette smoking and anxiety symptoms and disorders with structural brain changes, inflammation, and cell-mediated immune markers, markers of oxidative and nitrosative stress, mitochondrial function, neurotransmitter systems, neurotrophins and neurogenesis|neurotrophins|neurotrophins|gene|311|NCBIGene:627|inflammation|inflammation|disease|168|mesh:D007249
102|A large heterogenous literature was reviewed that detailed the association  between cigarette smoking and anxiety symptoms and disorders with structural brain changes, inflammation, and cell-mediated immune markers, markers of oxidative and nitrosative stress, mitochondrial function, neurotransmitter systems, neurotrophins and neurogenesis|inflammation|inflammation|disease|168|mesh:D007249|Cells|cell|anatomy|186|C0007634
102|A large heterogenous literature was reviewed that detailed the association  between cigarette smoking and anxiety symptoms and disorders with structural brain changes, inflammation, and cell-mediated immune markers, markers of oxidative and nitrosative stress, mitochondrial function, neurotransmitter systems, neurotrophins and neurogenesis|neurotrophins|neurotrophins|gene|311|NCBIGene:627|Neurogenesis|neurogenesis|physiology|329|C0814002
102|A large heterogenous literature was reviewed that detailed the association  between cigarette smoking and anxiety symptoms and disorders with structural brain changes, inflammation, and cell-mediated immune markers, markers of oxidative and nitrosative stress, mitochondrial function, neurotransmitter systems, neurotrophins and neurogenesis|neurotrophins|neurotrophins|gene|311|NCBIGene:627|Function Axis|function|physiology|275|C0700205
102|A large heterogenous literature was reviewed that detailed the association  between cigarette smoking and anxiety symptoms and disorders with structural brain changes, inflammation, and cell-mediated immune markers, markers of oxidative and nitrosative stress, mitochondrial function, neurotransmitter systems, neurotrophins and neurogenesis|neurotrophins|neurotrophins|gene|311|NCBIGene:627|Mental association|association|physiology|63|C0004083
102|A large heterogenous literature was reviewed that detailed the association  between cigarette smoking and anxiety symptoms and disorders with structural brain changes, inflammation, and cell-mediated immune markers, markers of oxidative and nitrosative stress, mitochondrial function, neurotransmitter systems, neurotrophins and neurogenesis|neurotrophins|neurotrophins|gene|311|NCBIGene:627|Biological Markers|markers|physiology|216|C0005516
102|A large heterogenous literature was reviewed that detailed the association  between cigarette smoking and anxiety symptoms and disorders with structural brain changes, inflammation, and cell-mediated immune markers, markers of oxidative and nitrosative stress, mitochondrial function, neurotransmitter systems, neurotrophins and neurogenesis|neurotrophins|neurotrophins|gene|311|NCBIGene:627|Cells|cell|anatomy|186|C0007634
102|Further research into the specific actions of nicotine and other cigarette components on these pathways, and how these pathways interact, may provide insights that lead to new treatment for anxiety and a greater understanding of anxiety pathogenesis|nicotine|nicotine|compound|46|mesh:D009538|anxiety|anxiety|disease|190|mesh:D001008
102|Further research into the specific actions of nicotine and other cigarette components on these pathways, and how these pathways interact, may provide insights that lead to new treatment for anxiety and a greater understanding of anxiety pathogenesis|nicotine|nicotine|compound|46|mesh:D009538|anxiety|anxiety|disease|229|mesh:D001008
103|One of the prevailing hypotheses suggests schizophrenia as a neurodevelopmental disorder, involving dysfunction of dopaminergic and glutamatergic systems|schizophrenia|schizophrenia|disease|42|omim:181500|neurodevelopmental disorder|neurodevelopmental disorder|disease|61|mesh:D065886
103|One of the prevailing hypotheses suggests schizophrenia as a neurodevelopmental disorder, involving dysfunction of dopaminergic and glutamatergic systems|schizophrenia|schizophrenia|disease|42|omim:181500|dysfunction of dopaminergic and glutamatergic systems|dysfunction of dopaminergic and glutamatergic systems|disease|100|mesh:D011618
103|One of the prevailing hypotheses suggests schizophrenia as a neurodevelopmental disorder, involving dysfunction of dopaminergic and glutamatergic systems|neurodevelopmental disorder|neurodevelopmental disorder|disease|61|mesh:D065886|dysfunction of dopaminergic and glutamatergic systems|dysfunction of dopaminergic and glutamatergic systems|disease|100|mesh:D011618
103|Accumulating evidence suggests mitochondria as an additional pathological factor  in schizophrenia|schizophrenia|schizophrenia|disease|85|omim:181500|Mitochondria|mitochondria|anatomy|31|C0026237
103|An attractive model to study processes related to neurodevelopment in schizophrenia is reprogramming of somatic cells into induced  pluripotent stem cells (iPSCs) and differentiating them into different neuronal lineages|schizophrenia|schizophrenia|disease|70|omim:181500|bony process|processes|anatomy|29|C1184743
103|An attractive model to study processes related to neurodevelopment in schizophrenia is reprogramming of somatic cells into induced  pluripotent stem cells (iPSCs) and differentiating them into different neuronal lineages|schizophrenia|schizophrenia|disease|70|omim:181500|Diploid Cell|somatic cells|anatomy|104|C1257909
103|iPSCs from three schizophrenia patients and from two controls were reprogrammed from hair follicle keratinocytes, because of their accessibility and common ectodermal origin with neurons|schizophrenia|schizophrenia|disease|17|omim:181500|Hair follicle structure|hair follicle|anatomy|85|C0221971
103|iPSCs from three schizophrenia patients and from two controls were reprogrammed from hair follicle keratinocytes, because of their accessibility and common ectodermal origin with neurons|schizophrenia|schizophrenia|disease|17|omim:181500|keratinocyte|keratinocytes|anatomy|99|C0022567
103|iPSCs from three schizophrenia patients and from two controls were reprogrammed from hair follicle keratinocytes, because of their accessibility and common ectodermal origin with neurons|schizophrenia|schizophrenia|disease|17|omim:181500|Induced Pluripotent Stem Cells|iPSCs|anatomy|0|C2717959
103|iPSCs from three schizophrenia patients and from two controls were reprogrammed from hair follicle keratinocytes, because of their accessibility and common ectodermal origin with neurons|schizophrenia|schizophrenia|disease|17|omim:181500|Ectoderm|ectodermal|anatomy|156|C0013574
103|iPSCs from three schizophrenia patients and from two controls were reprogrammed from hair follicle keratinocytes, because of their accessibility and common ectodermal origin with neurons|schizophrenia|schizophrenia|disease|17|omim:181500|Neurons|neurons|anatomy|179|C0027882
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Pax6|Pax6|gene|31|NCBIGene:5080|Nestin|Nestin|gene|39|NCBIGene:10763
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Pax6|Pax6|gene|31|NCBIGene:5080|3-Tubulin|3-Tubulin|gene|104|NCBIGene:10381
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|tyrosine|tyrosine|compound|117|mesh:D014443|Pax6|Pax6|gene|31|NCBIGene:5080
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Pax6|Pax6|gene|31|NCBIGene:5080|tyrosine hydroxylase|tyrosine hydroxylase|gene|117|NCBIGene:7054
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Pax6|Pax6|gene|31|NCBIGene:5080|DAT|DAT|gene|141|NCBIGene:6531
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Pax6|Pax6|gene|31|NCBIGene:5080|Dopaminergic Neurons|dopaminergic neurons|anatomy|149|C1512035
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Pax6|Pax6|gene|31|NCBIGene:5080|Induced Pluripotent Stem Cells|iPSCs|anatomy|0|C2717959
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Pax6|Pax6|gene|31|NCBIGene:5080|tubulin location|Tubulin|anatomy|107|C2937342
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Nestin|Nestin|gene|39|NCBIGene:10763|3-Tubulin|3-Tubulin|gene|104|NCBIGene:10381
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|tyrosine|tyrosine|compound|117|mesh:D014443|Nestin|Nestin|gene|39|NCBIGene:10763
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Nestin|Nestin|gene|39|NCBIGene:10763|tyrosine hydroxylase|tyrosine hydroxylase|gene|117|NCBIGene:7054
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Nestin|Nestin|gene|39|NCBIGene:10763|DAT|DAT|gene|141|NCBIGene:6531
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Nestin|Nestin|gene|39|NCBIGene:10763|Dopaminergic Neurons|dopaminergic neurons|anatomy|149|C1512035
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Nestin|Nestin|gene|39|NCBIGene:10763|Induced Pluripotent Stem Cells|iPSCs|anatomy|0|C2717959
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|Nestin|Nestin|gene|39|NCBIGene:10763|tubulin location|Tubulin|anatomy|107|C2937342
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|tyrosine|tyrosine|compound|117|mesh:D014443|3-Tubulin|3-Tubulin|gene|104|NCBIGene:10381
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|3-Tubulin|3-Tubulin|gene|104|NCBIGene:10381|tyrosine hydroxylase|tyrosine hydroxylase|gene|117|NCBIGene:7054
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|3-Tubulin|3-Tubulin|gene|104|NCBIGene:10381|DAT|DAT|gene|141|NCBIGene:6531
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|3-Tubulin|3-Tubulin|gene|104|NCBIGene:10381|Dopaminergic Neurons|dopaminergic neurons|anatomy|149|C1512035
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|3-Tubulin|3-Tubulin|gene|104|NCBIGene:10381|Induced Pluripotent Stem Cells|iPSCs|anatomy|0|C2717959
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|tyrosine|tyrosine|compound|117|mesh:D014443|DAT|DAT|gene|141|NCBIGene:6531
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|tyrosine|tyrosine|compound|117|mesh:D014443|Dopaminergic Neurons|dopaminergic neurons|anatomy|149|C1512035
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|tyrosine|tyrosine|compound|117|mesh:D014443|Induced Pluripotent Stem Cells|iPSCs|anatomy|0|C2717959
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|tyrosine|tyrosine|compound|117|mesh:D014443|tubulin location|Tubulin|anatomy|107|C2937342
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|tyrosine hydroxylase|tyrosine hydroxylase|gene|117|NCBIGene:7054|DAT|DAT|gene|141|NCBIGene:6531
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|tyrosine hydroxylase|tyrosine hydroxylase|gene|117|NCBIGene:7054|Dopaminergic Neurons|dopaminergic neurons|anatomy|149|C1512035
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|tyrosine hydroxylase|tyrosine hydroxylase|gene|117|NCBIGene:7054|Induced Pluripotent Stem Cells|iPSCs|anatomy|0|C2717959
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|tyrosine hydroxylase|tyrosine hydroxylase|gene|117|NCBIGene:7054|tubulin location|Tubulin|anatomy|107|C2937342
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|DAT|DAT|gene|141|NCBIGene:6531|Dopaminergic Neurons|dopaminergic neurons|anatomy|149|C1512035
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|DAT|DAT|gene|141|NCBIGene:6531|Induced Pluripotent Stem Cells|iPSCs|anatomy|0|C2717959
103|iPSCs were differentiated into Pax6(+)/Nestin(+) neural precursors and then further differentiated into β3-Tubulin(+)/tyrosine hydroxylase(+)/DAT(+) dopaminergic neurons|DAT|DAT|gene|141|NCBIGene:6531|tubulin location|Tubulin|anatomy|107|C2937342
103|In addition, iPSCs were differentiated through embryonic bodies into β3-Tubulin(+)/Tbox brain1(+) glutamatergic neurons|3-Tubulin|3-Tubulin|gene|69|NCBIGene:10381|Tbox brain1|Tbox brain1|gene|82|NCBIGene:10716
103|In addition, iPSCs were differentiated through embryonic bodies into β3-Tubulin(+)/Tbox brain1(+) glutamatergic neurons|3-Tubulin|3-Tubulin|gene|69|NCBIGene:10381|Induced Pluripotent Stem Cells|iPSCs|anatomy|13|C2717959
103|In addition, iPSCs were differentiated through embryonic bodies into β3-Tubulin(+)/Tbox brain1(+) glutamatergic neurons|3-Tubulin|3-Tubulin|gene|69|NCBIGene:10381|Neurons|neurons|anatomy|112|C0027882
103|In addition, iPSCs were differentiated through embryonic bodies into β3-Tubulin(+)/Tbox brain1(+) glutamatergic neurons|3-Tubulin|3-Tubulin|gene|69|NCBIGene:10381|Embryoid Bodies|embryonic bodies|anatomy|47|C2936498
103|In addition, iPSCs were differentiated through embryonic bodies into β3-Tubulin(+)/Tbox brain1(+) glutamatergic neurons|3-Tubulin|3-Tubulin|gene|69|NCBIGene:10381|Cell Differentiation process|differentiated|physiology|24|C0007589
103|In addition, iPSCs were differentiated through embryonic bodies into β3-Tubulin(+)/Tbox brain1(+) glutamatergic neurons|Tbox brain1|Tbox brain1|gene|82|NCBIGene:10716|Induced Pluripotent Stem Cells|iPSCs|anatomy|13|C2717959
103|In addition, iPSCs were differentiated through embryonic bodies into β3-Tubulin(+)/Tbox brain1(+) glutamatergic neurons|Tbox brain1|Tbox brain1|gene|82|NCBIGene:10716|Neurons|neurons|anatomy|112|C0027882
103|In addition, iPSCs were differentiated through embryonic bodies into β3-Tubulin(+)/Tbox brain1(+) glutamatergic neurons|Tbox brain1|Tbox brain1|gene|82|NCBIGene:10716|tubulin location|Tubulin|anatomy|72|C2937342
103|In addition, iPSCs were differentiated through embryonic bodies into β3-Tubulin(+)/Tbox brain1(+) glutamatergic neurons|Tbox brain1|Tbox brain1|gene|82|NCBIGene:10716|Embryoid Bodies|embryonic bodies|anatomy|47|C2936498
103|In addition, iPSCs were differentiated through embryonic bodies into β3-Tubulin(+)/Tbox brain1(+) glutamatergic neurons|Tbox brain1|Tbox brain1|gene|82|NCBIGene:10716|Cell Differentiation process|differentiated|physiology|24|C0007589
103|Schizophrenia-derived dopaminergic cells showed  severely impaired ability to differentiate, whereas glutamatergic cells were unable to maturate|Schizophrenia|Schizophrenia|disease|0|omim:181500|Cells|cells|anatomy|115|C0007634
103|Schizophrenia-derived dopaminergic cells showed  severely impaired ability to differentiate, whereas glutamatergic cells were unable to maturate|Schizophrenia|Schizophrenia|disease|0|omim:181500|Dopaminergic Neurons|dopaminergic cells|anatomy|22|C1512035
103|Mitochondrial respiration and its sensitivity to dopamine-induced inhibition were impaired in schizophrenia-derived keratinocytes  and iPSCs|dopamine|dopamine|compound|49|mesh:D004298|schizophrenia|schizophrenia|disease|94|omim:181500
103|Mitochondrial respiration and its sensitivity to dopamine-induced inhibition were impaired in schizophrenia-derived keratinocytes  and iPSCs|dopamine|dopamine|compound|49|mesh:D004298|Induced Pluripotent Stem Cells|iPSCs|anatomy|135|C2717959
103|Mitochondrial respiration and its sensitivity to dopamine-induced inhibition were impaired in schizophrenia-derived keratinocytes  and iPSCs|dopamine|dopamine|compound|49|mesh:D004298|keratinocyte|keratinocytes|anatomy|116|C0022567
103|Mitochondrial respiration and its sensitivity to dopamine-induced inhibition were impaired in schizophrenia-derived keratinocytes  and iPSCs|dopamine|dopamine|compound|49|mesh:D004298|Mitochondria|Mitochondrial|anatomy|0|C0026237
103|Mitochondrial respiration and its sensitivity to dopamine-induced inhibition were impaired in schizophrenia-derived keratinocytes  and iPSCs|schizophrenia|schizophrenia|disease|94|omim:181500|Induced Pluripotent Stem Cells|iPSCs|anatomy|135|C2717959
103|Mitochondrial respiration and its sensitivity to dopamine-induced inhibition were impaired in schizophrenia-derived keratinocytes  and iPSCs|schizophrenia|schizophrenia|disease|94|omim:181500|keratinocyte|keratinocytes|anatomy|116|C0022567
103|Mitochondrial respiration and its sensitivity to dopamine-induced inhibition were impaired in schizophrenia-derived keratinocytes  and iPSCs|schizophrenia|schizophrenia|disease|94|omim:181500|Mitochondria|Mitochondrial|anatomy|0|C0026237
104|BACKGROUND: Autism spectrum disorders (ASDs) are relatively common neurodevelopmental conditions whose biological basis has been incompletely determined|Autism spectrum disorders|Autism spectrum disorders|disease|12|mesh:D002659|ASDs|ASDs|disease|39|omim:209850
104|BACKGROUND: Autism spectrum disorders (ASDs) are relatively common neurodevelopmental conditions whose biological basis has been incompletely determined|Autism spectrum disorders|Autism spectrum disorders|disease|12|mesh:D002659|neurodevelopmental conditions|neurodevelopmental conditions|disease|67|mesh:D065886
104|BACKGROUND: Autism spectrum disorders (ASDs) are relatively common neurodevelopmental conditions whose biological basis has been incompletely determined|ASDs|ASDs|disease|39|omim:209850|neurodevelopmental conditions|neurodevelopmental conditions|disease|67|mesh:D065886
104|METHODS: We analyzed the metabolic profile of lymphoblastoid cell lines from 137  patients with neurodevelopmental disorders with or without ASDs and 78 normal individuals, using Biolog Phenotype MicroArrays|neurodevelopmental disorders|neurodevelopmental disorders|disease|96|mesh:D065886|ASDs|ASDs|disease|141|omim:209850
104|METHODS: We analyzed the metabolic profile of lymphoblastoid cell lines from 137  patients with neurodevelopmental disorders with or without ASDs and 78 normal individuals, using Biolog Phenotype MicroArrays|neurodevelopmental disorders|neurodevelopmental disorders|disease|96|mesh:D065886|lymphoblastoid cell line|lymphoblastoid cell lines|anatomy|46|C0682526
104|METHODS: We analyzed the metabolic profile of lymphoblastoid cell lines from 137  patients with neurodevelopmental disorders with or without ASDs and 78 normal individuals, using Biolog Phenotype MicroArrays|ASDs|ASDs|disease|141|omim:209850|lymphoblastoid cell line|lymphoblastoid cell lines|anatomy|46|C0682526
104|RESULTS: Metabolic profiling of lymphoblastoid cells revealed that the 87 patients with ASD as a clinical feature, as compared to the 78 controls, exhibited on average reduced generation of NADH when tryptophan was the sole energy source|NADH|NADH|compound|190|mesh:D009243|ASD|ASD|disease|88|mesh:D006344
104|RESULTS: Metabolic profiling of lymphoblastoid cells revealed that the 87 patients with ASD as a clinical feature, as compared to the 78 controls, exhibited on average reduced generation of NADH when tryptophan was the sole energy source|tryptophan|tryptophan|compound|200|mesh:D014364|ASD|ASD|disease|88|mesh:D006344
104|RESULTS: Metabolic profiling of lymphoblastoid cells revealed that the 87 patients with ASD as a clinical feature, as compared to the 78 controls, exhibited on average reduced generation of NADH when tryptophan was the sole energy source|ASD|ASD|disease|88|mesh:D006344|Cells|cells|anatomy|47|C0007634
104|RESULTS: Metabolic profiling of lymphoblastoid cells revealed that the 87 patients with ASD as a clinical feature, as compared to the 78 controls, exhibited on average reduced generation of NADH when tryptophan was the sole energy source|NADH|NADH|compound|190|mesh:D009243|tryptophan|tryptophan|compound|200|mesh:D014364
104|RESULTS: Metabolic profiling of lymphoblastoid cells revealed that the 87 patients with ASD as a clinical feature, as compared to the 78 controls, exhibited on average reduced generation of NADH when tryptophan was the sole energy source|NADH|NADH|compound|190|mesh:D009243|Cells|cells|anatomy|47|C0007634
104|RESULTS: Metabolic profiling of lymphoblastoid cells revealed that the 87 patients with ASD as a clinical feature, as compared to the 78 controls, exhibited on average reduced generation of NADH when tryptophan was the sole energy source|tryptophan|tryptophan|compound|200|mesh:D014364|Cells|cells|anatomy|47|C0007634
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|NADH|NADH|compound|17|mesh:D009243|tryptophan|tryptophan|compound|52|mesh:D014364
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|NADH|NADH|compound|17|mesh:D009243|ASD|ASD|disease|103|mesh:D006344
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|NADH|NADH|compound|17|mesh:D009243|intellectual disability|intellectual disability|disease|121|mesh:D008607
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|NADH|NADH|compound|17|mesh:D009243|schizophrenia|schizophrenia|disease|146|omim:181500
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|NADH|NADH|compound|17|mesh:D009243|autism|autism|disease|221|omim:209850
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|NADH|NADH|compound|17|mesh:D009243|Cultured Cell Line|cell lines|anatomy|83|C0007600
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|tryptophan|tryptophan|compound|52|mesh:D014364|ASD|ASD|disease|103|mesh:D006344
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|tryptophan|tryptophan|compound|52|mesh:D014364|intellectual disability|intellectual disability|disease|121|mesh:D008607
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|tryptophan|tryptophan|compound|52|mesh:D014364|schizophrenia|schizophrenia|disease|146|omim:181500
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|tryptophan|tryptophan|compound|52|mesh:D014364|autism|autism|disease|221|omim:209850
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|tryptophan|tryptophan|compound|52|mesh:D014364|Cultured Cell Line|cell lines|anatomy|83|C0007600
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|ASD|ASD|disease|103|mesh:D006344|intellectual disability|intellectual disability|disease|121|mesh:D008607
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|ASD|ASD|disease|103|mesh:D006344|schizophrenia|schizophrenia|disease|146|omim:181500
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|ASD|ASD|disease|103|mesh:D006344|autism|autism|disease|221|omim:209850
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|ASD|ASD|disease|103|mesh:D006344|Cultured Cell Line|cell lines|anatomy|83|C0007600
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|intellectual disability|intellectual disability|disease|121|mesh:D008607|schizophrenia|schizophrenia|disease|146|omim:181500
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|intellectual disability|intellectual disability|disease|121|mesh:D008607|autism|autism|disease|221|omim:209850
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|intellectual disability|intellectual disability|disease|121|mesh:D008607|Cultured Cell Line|cell lines|anatomy|83|C0007600
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|schizophrenia|schizophrenia|disease|146|omim:181500|autism|autism|disease|221|omim:209850
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|schizophrenia|schizophrenia|disease|146|omim:181500|Cultured Cell Line|cell lines|anatomy|83|C0007600
104|The low level of NADH generation in the presence of tryptophan was not observed in cell lines from non-ASD patients with intellectual disability, schizophrenia or conditions exhibiting several similarities with syndromal autism except for the behavioral traits|autism|autism|disease|221|omim:209850|Cultured Cell Line|cell lines|anatomy|83|C0007600
104|CONCLUSIONS: Tryptophan is a precursor of important compounds, such as serotonin, quinolinic acid, and kynurenic acid, which are involved in neurodevelopment and synaptogenesis|Tryptophan|Tryptophan|compound|13|mesh:D014364|serotonin|serotonin|compound|71|CHEBI:350546
104|CONCLUSIONS: Tryptophan is a precursor of important compounds, such as serotonin, quinolinic acid, and kynurenic acid, which are involved in neurodevelopment and synaptogenesis|Tryptophan|Tryptophan|compound|13|mesh:D014364|quinolinic acid|quinolinic acid|compound|82|mesh:D017378
104|CONCLUSIONS: Tryptophan is a precursor of important compounds, such as serotonin, quinolinic acid, and kynurenic acid, which are involved in neurodevelopment and synaptogenesis|Tryptophan|Tryptophan|compound|13|mesh:D014364|kynurenic acid|kynurenic acid|compound|103|mesh:D007736
104|CONCLUSIONS: Tryptophan is a precursor of important compounds, such as serotonin, quinolinic acid, and kynurenic acid, which are involved in neurodevelopment and synaptogenesis|serotonin|serotonin|compound|71|CHEBI:350546|quinolinic acid|quinolinic acid|compound|82|mesh:D017378
104|CONCLUSIONS: Tryptophan is a precursor of important compounds, such as serotonin, quinolinic acid, and kynurenic acid, which are involved in neurodevelopment and synaptogenesis|serotonin|serotonin|compound|71|CHEBI:350546|kynurenic acid|kynurenic acid|compound|103|mesh:D007736
104|CONCLUSIONS: Tryptophan is a precursor of important compounds, such as serotonin, quinolinic acid, and kynurenic acid, which are involved in neurodevelopment and synaptogenesis|quinolinic acid|quinolinic acid|compound|82|mesh:D017378|kynurenic acid|kynurenic acid|compound|103|mesh:D007736
104|In addition, quinolinic acid is the structural precursor of NAD+, a critical energy carrier in mitochondria|quinolinic acid|quinolinic acid|compound|13|mesh:D017378|NAD+|NAD+|compound|60|CHEBI:15846
104|Also, the serotonin branch of the tryptophan metabolic pathway generates NADH|serotonin|serotonin|compound|10|CHEBI:350546|tryptophan|tryptophan|compound|34|mesh:D014364
104|Also, the serotonin branch of the tryptophan metabolic pathway generates NADH|serotonin|serotonin|compound|10|CHEBI:350546|NADH|NADH|compound|73|mesh:D009243
104|Also, the serotonin branch of the tryptophan metabolic pathway generates NADH|tryptophan|tryptophan|compound|34|mesh:D014364|NADH|NADH|compound|73|mesh:D009243
104|Lastly, the levels of quinolinic and kynurenic acid are strongly influenced by the activity of the immune system|quinolinic and kynurenic acid|quinolinic and kynurenic acid|compound|22|CHEBI:18344|Immune system|immune system|anatomy|99|C0020962
104|Our finding of decreased tryptophan metabolism appears to provide a unifying biochemical basis for ASDs and perhaps an initial step in the development of a diagnostic assay for ASDs|tryptophan|tryptophan|compound|25|mesh:D014364|ASDs|ASDs|disease|99|omim:209850
104|Our finding of decreased tryptophan metabolism appears to provide a unifying biochemical basis for ASDs and perhaps an initial step in the development of a diagnostic assay for ASDs|tryptophan|tryptophan|compound|25|mesh:D014364|ASDs|ASDs|disease|177|omim:209850
105|BACKGROUND: Mitochondrial dysfunction (MtD) has been observed in approximately five percent of children with autism spectrum disorders (ASD)|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|12|mesh:D028361|MtD|MtD|disease|39|omim:239100
105|BACKGROUND: Mitochondrial dysfunction (MtD) has been observed in approximately five percent of children with autism spectrum disorders (ASD)|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|12|mesh:D028361|autism spectrum disorders|autism spectrum disorders|disease|109|mesh:D002659
105|BACKGROUND: Mitochondrial dysfunction (MtD) has been observed in approximately five percent of children with autism spectrum disorders (ASD)|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|12|mesh:D028361|ASD|ASD|disease|136|mesh:D006344
105|BACKGROUND: Mitochondrial dysfunction (MtD) has been observed in approximately five percent of children with autism spectrum disorders (ASD)|MtD|MtD|disease|39|omim:239100|autism spectrum disorders|autism spectrum disorders|disease|109|mesh:D002659
105|BACKGROUND: Mitochondrial dysfunction (MtD) has been observed in approximately five percent of children with autism spectrum disorders (ASD)|MtD|MtD|disease|39|omim:239100|ASD|ASD|disease|136|mesh:D006344
105|BACKGROUND: Mitochondrial dysfunction (MtD) has been observed in approximately five percent of children with autism spectrum disorders (ASD)|autism spectrum disorders|autism spectrum disorders|disease|109|mesh:D002659|ASD|ASD|disease|136|mesh:D006344
105|MtD could impair highly energy-dependent processes such as neurodevelopment, thereby contributing  to autism|MtD|MtD|disease|0|omim:239100|autism|autism|disease|102|omim:209850
105|MtD could impair highly energy-dependent processes such as neurodevelopment, thereby contributing  to autism|MtD|MtD|disease|0|omim:239100|bony process|processes|anatomy|41|C1184743
105|MtD could impair highly energy-dependent processes such as neurodevelopment, thereby contributing  to autism|autism|autism|disease|102|omim:209850|bony process|processes|anatomy|41|C1184743
105|Most of the previous studies of MtD in autism have been restricted to  the biomarkers of energy metabolism, while most of the genetic studies have been  based on mutations in the mitochondrial DNA (mtDNA)|autism|autism|disease|39|omim:209850|mitochondrial DNA location|mitochondrial DNA|anatomy|179|C1819717
105|Most of the previous studies of MtD in autism have been restricted to  the biomarkers of energy metabolism, while most of the genetic studies have been  based on mutations in the mitochondrial DNA (mtDNA)|autism|autism|disease|39|omim:209850|mitochondrial DNA location|mtDNA|anatomy|198|C1819717
105|METHODS: For gene expression analysis, postmortem brain tissues (anterior cingulate gyrus (ACG), motor cortex (MC) and thalamus (THL)) from autism patients (n=8) and controls (n=10) were obtained from the Autism Tissue Program (Princeton, NJ, USA)|autism|autism|disease|140|omim:209850|Gyrus Cinguli|anterior cingulate gyrus|anatomy|65|C0018427
105|METHODS: For gene expression analysis, postmortem brain tissues (anterior cingulate gyrus (ACG), motor cortex (MC) and thalamus (THL)) from autism patients (n=8) and controls (n=10) were obtained from the Autism Tissue Program (Princeton, NJ, USA)|autism|autism|disease|140|omim:209850|Motor Cortex|motor cortex|anatomy|97|C0026607
105|METHODS: For gene expression analysis, postmortem brain tissues (anterior cingulate gyrus (ACG), motor cortex (MC) and thalamus (THL)) from autism patients (n=8) and controls (n=10) were obtained from the Autism Tissue Program (Princeton, NJ, USA)|autism|autism|disease|140|omim:209850|Thalamic structure|thalamus|anatomy|119|C0039729
105|METHODS: For gene expression analysis, postmortem brain tissues (anterior cingulate gyrus (ACG), motor cortex (MC) and thalamus (THL)) from autism patients (n=8) and controls (n=10) were obtained from the Autism Tissue Program (Princeton, NJ, USA)|autism|autism|disease|140|omim:209850|brain tissue surgical material|brain tissues|anatomy|50|C0440746
105|METHODS: For gene expression analysis, postmortem brain tissues (anterior cingulate gyrus (ACG), motor cortex (MC) and thalamus (THL)) from autism patients (n=8) and controls (n=10) were obtained from the Autism Tissue Program (Princeton, NJ, USA)|autism|autism|disease|140|omim:209850|Body tissue|Tissue|anatomy|212|C0040300
105|METHODS: For gene expression analysis, postmortem brain tissues (anterior cingulate gyrus (ACG), motor cortex (MC) and thalamus (THL)) from autism patients (n=8) and controls (n=10) were obtained from the Autism Tissue Program (Princeton, NJ, USA)|Autism|Autism|disease|205|omim:209850|Gyrus Cinguli|anterior cingulate gyrus|anatomy|65|C0018427
105|METHODS: For gene expression analysis, postmortem brain tissues (anterior cingulate gyrus (ACG), motor cortex (MC) and thalamus (THL)) from autism patients (n=8) and controls (n=10) were obtained from the Autism Tissue Program (Princeton, NJ, USA)|Autism|Autism|disease|205|omim:209850|Motor Cortex|motor cortex|anatomy|97|C0026607
105|METHODS: For gene expression analysis, postmortem brain tissues (anterior cingulate gyrus (ACG), motor cortex (MC) and thalamus (THL)) from autism patients (n=8) and controls (n=10) were obtained from the Autism Tissue Program (Princeton, NJ, USA)|Autism|Autism|disease|205|omim:209850|Thalamic structure|thalamus|anatomy|119|C0039729
105|METHODS: For gene expression analysis, postmortem brain tissues (anterior cingulate gyrus (ACG), motor cortex (MC) and thalamus (THL)) from autism patients (n=8) and controls (n=10) were obtained from the Autism Tissue Program (Princeton, NJ, USA)|Autism|Autism|disease|205|omim:209850|brain tissue surgical material|brain tissues|anatomy|50|C0440746
105|METHODS: For gene expression analysis, postmortem brain tissues (anterior cingulate gyrus (ACG), motor cortex (MC) and thalamus (THL)) from autism patients (n=8) and controls (n=10) were obtained from the Autism Tissue Program (Princeton, NJ, USA)|Autism|Autism|disease|205|omim:209850|Body tissue|Tissue|anatomy|212|C0040300
105|RESULTS: Several genes showed brain region-specific expression alterations in autism patients compared to controls|autism|autism|disease|78|omim:209850|Brain region|brain region|anatomy|30|C1273723
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|Metaxin 2|Metaxin 2|gene|0|NCBIGene:10651|neurofilament, light polypeptide|neurofilament, light polypeptide|gene|18|NCBIGene:4747
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|Metaxin 2|Metaxin 2|gene|0|NCBIGene:10651|NEFL|NEFL|gene|52|NCBIGene:4747
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|Metaxin 2|Metaxin 2|gene|0|NCBIGene:10651|solute carrier family 25, member 27|solute carrier family 25, member 27|gene|62|NCBIGene:9481
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|Metaxin 2|Metaxin 2|gene|0|NCBIGene:10651|SLC25A27|SLC25A27|gene|99|NCBIGene:9481
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|Metaxin 2|Metaxin 2|gene|0|NCBIGene:10651|autism|autism|disease|174|omim:209850
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|Metaxin 2|Metaxin 2|gene|0|NCBIGene:10651|Neurofilaments|neurofilament|anatomy|18|C0027834
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|MTX2|MTX2|gene|11|NCBIGene:10651|neurofilament, light polypeptide|neurofilament, light polypeptide|gene|18|NCBIGene:4747
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|MTX2|MTX2|gene|11|NCBIGene:10651|NEFL|NEFL|gene|52|NCBIGene:4747
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|MTX2|MTX2|gene|11|NCBIGene:10651|solute carrier family 25, member 27|solute carrier family 25, member 27|gene|62|NCBIGene:9481
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|MTX2|MTX2|gene|11|NCBIGene:10651|SLC25A27|SLC25A27|gene|99|NCBIGene:9481
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|MTX2|MTX2|gene|11|NCBIGene:10651|autism|autism|disease|174|omim:209850
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|MTX2|MTX2|gene|11|NCBIGene:10651|Neurofilaments|neurofilament|anatomy|18|C0027834
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|neurofilament, light polypeptide|neurofilament, light polypeptide|gene|18|NCBIGene:4747|solute carrier family 25, member 27|solute carrier family 25, member 27|gene|62|NCBIGene:9481
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|neurofilament, light polypeptide|neurofilament, light polypeptide|gene|18|NCBIGene:4747|SLC25A27|SLC25A27|gene|99|NCBIGene:9481
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|neurofilament, light polypeptide|neurofilament, light polypeptide|gene|18|NCBIGene:4747|autism|autism|disease|174|omim:209850
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|NEFL|NEFL|gene|52|NCBIGene:4747|solute carrier family 25, member 27|solute carrier family 25, member 27|gene|62|NCBIGene:9481
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|NEFL|NEFL|gene|52|NCBIGene:4747|SLC25A27|SLC25A27|gene|99|NCBIGene:9481
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|NEFL|NEFL|gene|52|NCBIGene:4747|autism|autism|disease|174|omim:209850
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|NEFL|NEFL|gene|52|NCBIGene:4747|Neurofilaments|neurofilament|anatomy|18|C0027834
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|solute carrier family 25, member 27|solute carrier family 25, member 27|gene|62|NCBIGene:9481|autism|autism|disease|174|omim:209850
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|solute carrier family 25, member 27|solute carrier family 25, member 27|gene|62|NCBIGene:9481|Neurofilaments|neurofilament|anatomy|18|C0027834
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|SLC25A27|SLC25A27|gene|99|NCBIGene:9481|autism|autism|disease|174|omim:209850
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|SLC25A27|SLC25A27|gene|99|NCBIGene:9481|Neurofilaments|neurofilament|anatomy|18|C0027834
105|Metaxin 2 (MTX2), neurofilament, light polypeptide (NEFL) and solute carrier family 25, member 27 (SLC25A27) showed consistently reduced expression in the ACG, MC and THL of autism patients|autism|autism|disease|174|omim:209850|Neurofilaments|neurofilament|anatomy|18|C0027834
105|066) and SLC25A27 (P = 0|SLC25A27|SLC25A27|gene|9|NCBIGene:9481|P prime|P|physiology|19|C2603361
105|990) showed genetic association with autism in Caucasian and Japanese samples, respectively|autism|autism|disease|37|omim:209850|Biospecimen|samples|anatomy|70|C2347026
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNAJC19|DNAJC19|gene|18|NCBIGene:131118|DNM1L|DNM1L|gene|27|NCBIGene:10059
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNAJC19|DNAJC19|gene|18|NCBIGene:131118|LRPPRC|LRPPRC|gene|34|NCBIGene:10128
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNAJC19|DNAJC19|gene|18|NCBIGene:131118|SLC25A12|SLC25A12|gene|42|NCBIGene:8604
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNAJC19|DNAJC19|gene|18|NCBIGene:131118|SLC25A14|SLC25A14|gene|52|NCBIGene:9016
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNAJC19|DNAJC19|gene|18|NCBIGene:131118|SLC25A24|SLC25A24|gene|62|NCBIGene:29957
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNAJC19|DNAJC19|gene|18|NCBIGene:131118|TOMM20|TOMM20|gene|75|NCBIGene:9804
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNAJC19|DNAJC19|gene|18|NCBIGene:131118|autism|autism|disease|135|omim:209850
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNAJC19|DNAJC19|gene|18|NCBIGene:131118|Brain region|brain regions|anatomy|118|C1273723
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNM1L|DNM1L|gene|27|NCBIGene:10059|LRPPRC|LRPPRC|gene|34|NCBIGene:10128
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNM1L|DNM1L|gene|27|NCBIGene:10059|SLC25A12|SLC25A12|gene|42|NCBIGene:8604
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNM1L|DNM1L|gene|27|NCBIGene:10059|SLC25A14|SLC25A14|gene|52|NCBIGene:9016
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNM1L|DNM1L|gene|27|NCBIGene:10059|SLC25A24|SLC25A24|gene|62|NCBIGene:29957
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNM1L|DNM1L|gene|27|NCBIGene:10059|TOMM20|TOMM20|gene|75|NCBIGene:9804
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNM1L|DNM1L|gene|27|NCBIGene:10059|autism|autism|disease|135|omim:209850
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|DNM1L|DNM1L|gene|27|NCBIGene:10059|Brain region|brain regions|anatomy|118|C1273723
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|LRPPRC|LRPPRC|gene|34|NCBIGene:10128|SLC25A12|SLC25A12|gene|42|NCBIGene:8604
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|LRPPRC|LRPPRC|gene|34|NCBIGene:10128|SLC25A14|SLC25A14|gene|52|NCBIGene:9016
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|LRPPRC|LRPPRC|gene|34|NCBIGene:10128|SLC25A24|SLC25A24|gene|62|NCBIGene:29957
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|LRPPRC|LRPPRC|gene|34|NCBIGene:10128|TOMM20|TOMM20|gene|75|NCBIGene:9804
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|LRPPRC|LRPPRC|gene|34|NCBIGene:10128|autism|autism|disease|135|omim:209850
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|LRPPRC|LRPPRC|gene|34|NCBIGene:10128|Brain region|brain regions|anatomy|118|C1273723
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A12|SLC25A12|gene|42|NCBIGene:8604|SLC25A14|SLC25A14|gene|52|NCBIGene:9016
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A12|SLC25A12|gene|42|NCBIGene:8604|SLC25A24|SLC25A24|gene|62|NCBIGene:29957
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A12|SLC25A12|gene|42|NCBIGene:8604|TOMM20|TOMM20|gene|75|NCBIGene:9804
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A12|SLC25A12|gene|42|NCBIGene:8604|autism|autism|disease|135|omim:209850
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A12|SLC25A12|gene|42|NCBIGene:8604|Brain region|brain regions|anatomy|118|C1273723
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A14|SLC25A14|gene|52|NCBIGene:9016|SLC25A24|SLC25A24|gene|62|NCBIGene:29957
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A14|SLC25A14|gene|52|NCBIGene:9016|TOMM20|TOMM20|gene|75|NCBIGene:9804
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A14|SLC25A14|gene|52|NCBIGene:9016|autism|autism|disease|135|omim:209850
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A14|SLC25A14|gene|52|NCBIGene:9016|Brain region|brain regions|anatomy|118|C1273723
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A24|SLC25A24|gene|62|NCBIGene:29957|TOMM20|TOMM20|gene|75|NCBIGene:9804
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A24|SLC25A24|gene|62|NCBIGene:29957|autism|autism|disease|135|omim:209850
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|SLC25A24|SLC25A24|gene|62|NCBIGene:29957|Brain region|brain regions|anatomy|118|C1273723
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|TOMM20|TOMM20|gene|75|NCBIGene:9804|autism|autism|disease|135|omim:209850
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|TOMM20|TOMM20|gene|75|NCBIGene:9804|Brain region|brain regions|anatomy|118|C1273723
105|The expression of DNAJC19, DNM1L, LRPPRC, SLC25A12, SLC25A14, SLC25A24 and TOMM20 were reduced in at least two of the brain regions of autism patients|autism|autism|disease|135|omim:209850|Brain region|brain regions|anatomy|118|C1273723
105|CONCLUSIONS: Our study, though preliminary, brings to light some new genes associated with MtD in autism|MtD|MtD|disease|91|omim:239100|autism|autism|disease|98|omim:209850
106|Retinoid-associated signaling which plays an  essential role in neurodevelopment appears to remain active in the adult central  nervous system (CNS), thus assuming a high significance in the context of neurodegeneration, and indeed retinoid analogs are thought to be promising therapeutic agents for the treatment of neurodegenerative disorders|Retinoid|Retinoid|compound|0|CHEBI:4913|neurodegeneration|neurodegeneration|disease|202|mesh:D009410
106|Retinoid-associated signaling which plays an  essential role in neurodevelopment appears to remain active in the adult central  nervous system (CNS), thus assuming a high significance in the context of neurodegeneration, and indeed retinoid analogs are thought to be promising therapeutic agents for the treatment of neurodegenerative disorders|Retinoid|Retinoid|compound|0|CHEBI:4913|neurodegenerative disorders|neurodegenerative disorders|disease|317|mesh:D019636
106|Retinoid-associated signaling which plays an  essential role in neurodevelopment appears to remain active in the adult central  nervous system (CNS), thus assuming a high significance in the context of neurodegeneration, and indeed retinoid analogs are thought to be promising therapeutic agents for the treatment of neurodegenerative disorders|retinoid|retinoid|compound|232|CHEBI:4913|neurodegeneration|neurodegeneration|disease|202|mesh:D009410
106|Retinoid-associated signaling which plays an  essential role in neurodevelopment appears to remain active in the adult central  nervous system (CNS), thus assuming a high significance in the context of neurodegeneration, and indeed retinoid analogs are thought to be promising therapeutic agents for the treatment of neurodegenerative disorders|neurodegeneration|neurodegeneration|disease|202|mesh:D009410|neurodegenerative disorders|neurodegenerative disorders|disease|317|mesh:D019636
106|Retinoid-associated signaling which plays an  essential role in neurodevelopment appears to remain active in the adult central  nervous system (CNS), thus assuming a high significance in the context of neurodegeneration, and indeed retinoid analogs are thought to be promising therapeutic agents for the treatment of neurodegenerative disorders|retinoid|retinoid|compound|232|CHEBI:4913|neurodegenerative disorders|neurodegenerative disorders|disease|317|mesh:D019636
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|retinoids|retinoids|compound|16|mesh:D012176|amyloid|amyloid|disease|64|mesh:D000686
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|retinoids|retinoids|compound|16|mesh:D012176|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|retinoids|retinoids|compound|16|mesh:D012176|tau|tau|gene|134|NCBIGene:4137
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|retinoids|retinoids|compound|16|mesh:D012176|IL6|IL6|gene|170|NCBIGene:3569
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|retinoids|retinoids|compound|16|mesh:D012176|neuroinflammation|neuroinflammation|disease|189|mesh:D020078
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|retinoids|retinoids|compound|16|mesh:D012176|cognitive deficits|cognitive deficits|disease|262|mesh:D003072
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|retinoids|retinoids|compound|16|mesh:D012176|Alzheimer's disease|Alzheimer's disease|disease|301|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|retinoids|retinoids|compound|16|mesh:D012176|AD|AD|disease|322|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|retinoids|retinoids|compound|16|mesh:D012176|Block Specimens|inhibit|anatomy|56|C1533157
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|retinoids|retinoids|compound|16|mesh:D012176|Hippocampus (Brain)|hippocampal|anatomy|233|C0019564
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|amyloid|amyloid|disease|64|mesh:D000686
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|IL6|IL6|gene|170|NCBIGene:3569|amyloid|amyloid|disease|64|mesh:D000686
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid|amyloid|disease|64|mesh:D000686|neuroinflammation|neuroinflammation|disease|189|mesh:D020078
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid|amyloid|disease|64|mesh:D000686|cognitive deficits|cognitive deficits|disease|262|mesh:D003072
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid|amyloid|disease|64|mesh:D000686|Alzheimer's disease|Alzheimer's disease|disease|301|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid|amyloid|disease|64|mesh:D000686|AD|AD|disease|322|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid|amyloid|disease|64|mesh:D000686|Block Specimens|inhibit|anatomy|56|C1533157
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid|amyloid|disease|64|mesh:D000686|Hippocampus (Brain)|hippocampal|anatomy|233|C0019564
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|tau|tau|gene|134|NCBIGene:4137
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|IL6|IL6|gene|170|NCBIGene:3569
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|neuroinflammation|neuroinflammation|disease|189|mesh:D020078
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|cognitive deficits|cognitive deficits|disease|262|mesh:D003072
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|Alzheimer's disease|Alzheimer's disease|disease|301|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|AD|AD|disease|322|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|Antioxidant Effect|antioxidant effects|physiology|35|C3179302
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|Exertion|exert|physiology|29|C0015264
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|Block Specimens|inhibit|anatomy|56|C1533157
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|interleukin-6 production|IL6 production|physiology|174|C1819459
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|Ability|ability|physiology|4|C0085732
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|amyloid- (A)|amyloid- (A)|gene|64|NCBIGene:6288|Hippocampus (Brain)|hippocampal|anatomy|233|C0019564
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|IL6|IL6|gene|170|NCBIGene:3569
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|neuroinflammation|neuroinflammation|disease|189|mesh:D020078
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|cognitive deficits|cognitive deficits|disease|262|mesh:D003072
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|Alzheimer's disease|Alzheimer's disease|disease|301|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|AD|AD|disease|322|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|Antioxidant Effect|antioxidant effects|physiology|35|C3179302
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|Exertion|exert|physiology|29|C0015264
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|Block Specimens|inhibit|anatomy|56|C1533157
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|interleukin-6 production|IL6 production|physiology|174|C1819459
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|Ability|ability|physiology|4|C0085732
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|tau|tau|gene|134|NCBIGene:4137|Hippocampus (Brain)|hippocampal|anatomy|233|C0019564
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|IL6|IL6|gene|170|NCBIGene:3569|neuroinflammation|neuroinflammation|disease|189|mesh:D020078
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|IL6|IL6|gene|170|NCBIGene:3569|cognitive deficits|cognitive deficits|disease|262|mesh:D003072
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|IL6|IL6|gene|170|NCBIGene:3569|Alzheimer's disease|Alzheimer's disease|disease|301|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|IL6|IL6|gene|170|NCBIGene:3569|AD|AD|disease|322|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|IL6|IL6|gene|170|NCBIGene:3569|Antioxidant Effect|antioxidant effects|physiology|35|C3179302
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|IL6|IL6|gene|170|NCBIGene:3569|Exertion|exert|physiology|29|C0015264
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|IL6|IL6|gene|170|NCBIGene:3569|Block Specimens|inhibit|anatomy|56|C1533157
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|IL6|IL6|gene|170|NCBIGene:3569|interleukin-6 production|IL6 production|physiology|174|C1819459
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|IL6|IL6|gene|170|NCBIGene:3569|Ability|ability|physiology|4|C0085732
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|IL6|IL6|gene|170|NCBIGene:3569|Hippocampus (Brain)|hippocampal|anatomy|233|C0019564
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|neuroinflammation|neuroinflammation|disease|189|mesh:D020078|cognitive deficits|cognitive deficits|disease|262|mesh:D003072
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|neuroinflammation|neuroinflammation|disease|189|mesh:D020078|Alzheimer's disease|Alzheimer's disease|disease|301|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|neuroinflammation|neuroinflammation|disease|189|mesh:D020078|AD|AD|disease|322|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|neuroinflammation|neuroinflammation|disease|189|mesh:D020078|Block Specimens|inhibit|anatomy|56|C1533157
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|neuroinflammation|neuroinflammation|disease|189|mesh:D020078|Hippocampus (Brain)|hippocampal|anatomy|233|C0019564
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|cognitive deficits|cognitive deficits|disease|262|mesh:D003072|Alzheimer's disease|Alzheimer's disease|disease|301|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|cognitive deficits|cognitive deficits|disease|262|mesh:D003072|AD|AD|disease|322|mesh:D000544
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|cognitive deficits|cognitive deficits|disease|262|mesh:D003072|Block Specimens|inhibit|anatomy|56|C1533157
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|cognitive deficits|cognitive deficits|disease|262|mesh:D003072|Hippocampus (Brain)|hippocampal|anatomy|233|C0019564
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|Alzheimer's disease|Alzheimer's disease|disease|301|mesh:D000544|Block Specimens|inhibit|anatomy|56|C1533157
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|Alzheimer's disease|Alzheimer's disease|disease|301|mesh:D000544|Hippocampus (Brain)|hippocampal|anatomy|233|C0019564
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|AD|AD|disease|322|mesh:D000544|Block Specimens|inhibit|anatomy|56|C1533157
106|The ability  of retinoids to exert antioxidant effects, inhibit amyloid-β (Aβ) deposits and likely Aβ-induced mitochondrial dysfunction, tau hyperphosphorylation, Aβ-induced IL6 production and neuroinflammation, increase survival in hippocampal neurons, and reverse cognitive deficits in animal models of Alzheimer's disease (AD) is discussed|AD|AD|disease|322|mesh:D000544|Hippocampus (Brain)|hippocampal|anatomy|233|C0019564
106|Although retinoids with their multi-target activity are revealing to be promising for management of AD which is a multifaceted biochemical phenomenon, timing as well as appropriate dosage and safety remain, however, a challenge|retinoids|retinoids|compound|9|mesh:D012176|AD|AD|disease|100|mesh:D000544
106|The end-stage lesions, namely senile plaques and neurofibrillary tangles, are, at present, considered an adaptive response to oxidative stress underlying AD, thus  paradoxically late administration of retinoids could even suppress a protective mechanism by inhibiting Aβ deposits|retinoids|retinoids|compound|201|mesh:D012176|AD|AD|disease|154|mesh:D000544
107|Mitochondrial dysfunction (MtD) and abnormal brain bioenergetics have been implicated in autism, suggesting possible candidate genes in the electron transport chain (ETC)|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|0|mesh:D028361|MtD|MtD|disease|27|omim:239100
107|Mitochondrial dysfunction (MtD) and abnormal brain bioenergetics have been implicated in autism, suggesting possible candidate genes in the electron transport chain (ETC)|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|0|mesh:D028361|autism|autism|disease|89|omim:209850
107|Mitochondrial dysfunction (MtD) and abnormal brain bioenergetics have been implicated in autism, suggesting possible candidate genes in the electron transport chain (ETC)|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|0|mesh:D028361|Brain|brain|anatomy|45|C0006104
107|Mitochondrial dysfunction (MtD) and abnormal brain bioenergetics have been implicated in autism, suggesting possible candidate genes in the electron transport chain (ETC)|MtD|MtD|disease|27|omim:239100|autism|autism|disease|89|omim:209850
107|Mitochondrial dysfunction (MtD) and abnormal brain bioenergetics have been implicated in autism, suggesting possible candidate genes in the electron transport chain (ETC)|MtD|MtD|disease|27|omim:239100|Brain|brain|anatomy|45|C0006104
107|Mitochondrial dysfunction (MtD) and abnormal brain bioenergetics have been implicated in autism, suggesting possible candidate genes in the electron transport chain (ETC)|autism|autism|disease|89|omim:209850|Brain|brain|anatomy|45|C0006104
107|We compared the expression of 84 ETC genes in the post-mortem brains of autism patients and controls|ETC genes|ETC genes|gene|33|NCBIGene:4846|autism|autism|disease|72|omim:209850
107|We compared the expression of 84 ETC genes in the post-mortem brains of autism patients and controls|ETC genes|ETC genes|gene|33|NCBIGene:4846|Brain|brains|anatomy|62|C0006104
107|We compared the expression of 84 ETC genes in the post-mortem brains of autism patients and controls|autism|autism|disease|72|omim:209850|Brain|brains|anatomy|62|C0006104
107|Brain tissues from the anterior cingulate gyrus, motor cortex, and thalamus of autism patients (n = 8) and controls (n = 10) were obtained from Autism Tissue Program, USA|autism|autism|disease|79|omim:209850|Motor Cortex|motor cortex|anatomy|49|C0026607
107|Brain tissues from the anterior cingulate gyrus, motor cortex, and thalamus of autism patients (n = 8) and controls (n = 10) were obtained from Autism Tissue Program, USA|autism|autism|disease|79|omim:209850|brain tissue surgical material|Brain tissues|anatomy|0|C0440746
107|Brain tissues from the anterior cingulate gyrus, motor cortex, and thalamus of autism patients (n = 8) and controls (n = 10) were obtained from Autism Tissue Program, USA|autism|autism|disease|79|omim:209850|Thalamic structure|thalamus|anatomy|67|C0039729
107|Brain tissues from the anterior cingulate gyrus, motor cortex, and thalamus of autism patients (n = 8) and controls (n = 10) were obtained from Autism Tissue Program, USA|autism|autism|disease|79|omim:209850|Body tissue|Tissue|anatomy|171|C0040300
107|Brain tissues from the anterior cingulate gyrus, motor cortex, and thalamus of autism patients (n = 8) and controls (n = 10) were obtained from Autism Tissue Program, USA|autism|autism|disease|79|omim:209850|Gyrus Cinguli|anterior cingulate gyrus|anatomy|23|C0018427
107|Brain tissues from the anterior cingulate gyrus, motor cortex, and thalamus of autism patients (n = 8) and controls (n = 10) were obtained from Autism Tissue Program, USA|Autism|Autism|disease|140|omim:209850|Motor Cortex|motor cortex|anatomy|49|C0026607
107|Brain tissues from the anterior cingulate gyrus, motor cortex, and thalamus of autism patients (n = 8) and controls (n = 10) were obtained from Autism Tissue Program, USA|Autism|Autism|disease|140|omim:209850|brain tissue surgical material|Brain tissues|anatomy|0|C0440746
107|Brain tissues from the anterior cingulate gyrus, motor cortex, and thalamus of autism patients (n = 8) and controls (n = 10) were obtained from Autism Tissue Program, USA|Autism|Autism|disease|140|omim:209850|Thalamic structure|thalamus|anatomy|67|C0039729
107|Brain tissues from the anterior cingulate gyrus, motor cortex, and thalamus of autism patients (n = 8) and controls (n = 10) were obtained from Autism Tissue Program, USA|Autism|Autism|disease|140|omim:209850|Body tissue|Tissue|anatomy|171|C0040300
107|Brain tissues from the anterior cingulate gyrus, motor cortex, and thalamus of autism patients (n = 8) and controls (n = 10) were obtained from Autism Tissue Program, USA|Autism|Autism|disease|140|omim:209850|Gyrus Cinguli|anterior cingulate gyrus|anatomy|23|C0018427
107|We observed reduced expression of several ETC genes in autism brains compared to controls|ETC genes|ETC genes|gene|42|NCBIGene:4846|autism|autism|disease|55|omim:209850
107|We observed reduced expression of several ETC genes in autism brains compared to controls|ETC genes|ETC genes|gene|42|NCBIGene:4846|Brain|brains|anatomy|62|C0006104
107|We observed reduced expression of several ETC genes in autism brains compared to controls|autism|autism|disease|55|omim:209850|Brain|brains|anatomy|62|C0006104
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex I|Complex I|gene|16|NCBIGene:4723|Complex III|Complex III|gene|46|NCBIGene:7384
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex I|Complex I|gene|16|NCBIGene:4723|Complex IV|Complex IV|gene|62|NCBIGene:1537
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex I|Complex I|gene|16|NCBIGene:4723|Complex V|Complex V|gene|93|NCBIGene:4540
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex I|Complex I|gene|16|NCBIGene:4723|autism|autism|disease|154|omim:209850
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex I|Complex I|gene|16|NCBIGene:4723|respiratory chain complex III location|Complex III|anatomy|46|C1167295
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex I|Complex I|gene|16|NCBIGene:4723|Brain region|brain region|anatomy|110|C1273723
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex III|Complex III|gene|46|NCBIGene:7384|Complex IV|Complex IV|gene|62|NCBIGene:1537
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex III|Complex III|gene|46|NCBIGene:7384|Complex V|Complex V|gene|93|NCBIGene:4540
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex III|Complex III|gene|46|NCBIGene:7384|autism|autism|disease|154|omim:209850
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex III|Complex III|gene|46|NCBIGene:7384|NADH dehydrogenase complex location|Complex I|anatomy|16|C2245017
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex III|Complex III|gene|46|NCBIGene:7384|Brain region|brain region|anatomy|110|C1273723
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex IV|Complex IV|gene|62|NCBIGene:1537|Complex V|Complex V|gene|93|NCBIGene:4540
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex IV|Complex IV|gene|62|NCBIGene:1537|autism|autism|disease|154|omim:209850
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex IV|Complex IV|gene|62|NCBIGene:1537|respiratory chain complex III location|Complex III|anatomy|46|C1167295
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex IV|Complex IV|gene|62|NCBIGene:1537|NADH dehydrogenase complex location|Complex I|anatomy|16|C2245017
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex IV|Complex IV|gene|62|NCBIGene:1537|Brain region|brain region|anatomy|110|C1273723
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex V|Complex V|gene|93|NCBIGene:4540|autism|autism|disease|154|omim:209850
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex V|Complex V|gene|93|NCBIGene:4540|respiratory chain complex III location|Complex III|anatomy|46|C1167295
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex V|Complex V|gene|93|NCBIGene:4540|NADH dehydrogenase complex location|Complex I|anatomy|16|C2245017
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|Complex V|Complex V|gene|93|NCBIGene:4540|Brain region|brain region|anatomy|110|C1273723
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|autism|autism|disease|154|omim:209850|respiratory chain complex III location|Complex III|anatomy|46|C1167295
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|autism|autism|disease|154|omim:209850|NADH dehydrogenase complex location|Complex I|anatomy|16|C2245017
107|Eleven genes of Complex I, five genes each of Complex III and Complex IV, and seven genes of Complex V showed brain region-specific reduced expression in autism|autism|autism|disease|154|omim:209850|Brain region|brain region|anatomy|110|C1273723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5A1|ATP5A1|gene|0|NCBIGene:498|Complex V|Complex V|gene|8|NCBIGene:4540
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5A1|ATP5A1|gene|0|NCBIGene:498|ATP5G3|ATP5G3|gene|20|NCBIGene:518
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5A1|ATP5A1|gene|0|NCBIGene:498|Complex V|Complex V|gene|28|NCBIGene:4540
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5A1|ATP5A1|gene|0|NCBIGene:498|NDUFA5|NDUFA5|gene|43|NCBIGene:4698
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5A1|ATP5A1|gene|0|NCBIGene:498|Complex I|Complex I|gene|51|NCBIGene:4723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5A1|ATP5A1|gene|0|NCBIGene:498|autism|autism|disease|129|omim:209850
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5A1|ATP5A1|gene|0|NCBIGene:498|NADH dehydrogenase complex location|Complex I|anatomy|51|C2245017
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5A1|ATP5A1|gene|0|NCBIGene:498|Brain region|brain regions|anatomy|112|C1273723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex V|Complex V|gene|8|NCBIGene:4540|ATP5G3|ATP5G3|gene|20|NCBIGene:518
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex V|Complex V|gene|8|NCBIGene:4540|NDUFA5|NDUFA5|gene|43|NCBIGene:4698
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex V|Complex V|gene|8|NCBIGene:4540|Complex I|Complex I|gene|51|NCBIGene:4723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex V|Complex V|gene|8|NCBIGene:4540|autism|autism|disease|129|omim:209850
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex V|Complex V|gene|8|NCBIGene:4540|NADH dehydrogenase complex location|Complex I|anatomy|51|C2245017
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex V|Complex V|gene|8|NCBIGene:4540|Brain region|brain regions|anatomy|112|C1273723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5G3|ATP5G3|gene|20|NCBIGene:518|Complex V|Complex V|gene|28|NCBIGene:4540
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5G3|ATP5G3|gene|20|NCBIGene:518|NDUFA5|NDUFA5|gene|43|NCBIGene:4698
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5G3|ATP5G3|gene|20|NCBIGene:518|Complex I|Complex I|gene|51|NCBIGene:4723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5G3|ATP5G3|gene|20|NCBIGene:518|autism|autism|disease|129|omim:209850
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5G3|ATP5G3|gene|20|NCBIGene:518|NADH dehydrogenase complex location|Complex I|anatomy|51|C2245017
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|ATP5G3|ATP5G3|gene|20|NCBIGene:518|Brain region|brain regions|anatomy|112|C1273723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex V|Complex V|gene|28|NCBIGene:4540|NDUFA5|NDUFA5|gene|43|NCBIGene:4698
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex V|Complex V|gene|28|NCBIGene:4540|Complex I|Complex I|gene|51|NCBIGene:4723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex V|Complex V|gene|28|NCBIGene:4540|autism|autism|disease|129|omim:209850
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex V|Complex V|gene|28|NCBIGene:4540|NADH dehydrogenase complex location|Complex I|anatomy|51|C2245017
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex V|Complex V|gene|28|NCBIGene:4540|Brain region|brain regions|anatomy|112|C1273723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|NDUFA5|NDUFA5|gene|43|NCBIGene:4698|Complex I|Complex I|gene|51|NCBIGene:4723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|NDUFA5|NDUFA5|gene|43|NCBIGene:4698|autism|autism|disease|129|omim:209850
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|NDUFA5|NDUFA5|gene|43|NCBIGene:4698|NADH dehydrogenase complex location|Complex I|anatomy|51|C2245017
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|NDUFA5|NDUFA5|gene|43|NCBIGene:4698|Brain region|brain regions|anatomy|112|C1273723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex I|Complex I|gene|51|NCBIGene:4723|autism|autism|disease|129|omim:209850
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|Complex I|Complex I|gene|51|NCBIGene:4723|Brain region|brain regions|anatomy|112|C1273723
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|autism|autism|disease|129|omim:209850|NADH dehydrogenase complex location|Complex I|anatomy|51|C2245017
107|ATP5A1 (Complex V), ATP5G3 (Complex V) and NDUFA5 (Complex I) showed consistently reduced expression in all the brain regions of autism patients|autism|autism|disease|129|omim:209850|Brain region|brain regions|anatomy|112|C1273723
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|ATP5A1|ATP5A1|gene|15|NCBIGene:498|mitogen-activated protein kinase 13|mitogen-activated protein kinase 13|gene|41|NCBIGene:5603
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|ATP5A1|ATP5A1|gene|15|NCBIGene:498|MAPK13|MAPK13|gene|78|NCBIGene:5603
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|ATP5A1|ATP5A1|gene|15|NCBIGene:498|p38 MAPK|p38 MAPK|gene|89|NCBIGene:1432
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|ATP5A1|ATP5A1|gene|15|NCBIGene:498|HEK293 Cells|HEK 293 cells|anatomy|147|C2936239
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|ATP5A1|ATP5A1|gene|15|NCBIGene:498|W stress|stress|physiology|112|C1718621
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|mitogen-activated protein kinase 13|mitogen-activated protein kinase 13|gene|41|NCBIGene:5603|p38 MAPK|p38 MAPK|gene|89|NCBIGene:1432
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|mitogen-activated protein kinase 13|mitogen-activated protein kinase 13|gene|41|NCBIGene:5603|HEK293 Cells|HEK 293 cells|anatomy|147|C2936239
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|mitogen-activated protein kinase 13|mitogen-activated protein kinase 13|gene|41|NCBIGene:5603|W stress|stress|physiology|112|C1718621
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|MAPK13|MAPK13|gene|78|NCBIGene:5603|p38 MAPK|p38 MAPK|gene|89|NCBIGene:1432
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|MAPK13|MAPK13|gene|78|NCBIGene:5603|HEK293 Cells|HEK 293 cells|anatomy|147|C2936239
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|MAPK13|MAPK13|gene|78|NCBIGene:5603|W stress|stress|physiology|112|C1718621
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|p38 MAPK|p38 MAPK|gene|89|NCBIGene:1432|HEK293 Cells|HEK 293 cells|anatomy|147|C2936239
107|Upon silencing ATP5A1, the expression of mitogen-activated protein kinase 13 (MAPK13), a p38 MAPK responsive to stress stimuli, was upregulated in HEK 293 cells|p38 MAPK|p38 MAPK|gene|89|NCBIGene:1432|W stress|stress|physiology|112|C1718621
107|We report new candidate genes involved in abnormal brain bioenergetics in autism, supporting the hypothesis that mitochondria, critical for neurodevelopment, may play a role in autism|autism|autism|disease|74|omim:209850|Mitochondria|mitochondria|anatomy|113|C0026237
107|We report new candidate genes involved in abnormal brain bioenergetics in autism, supporting the hypothesis that mitochondria, critical for neurodevelopment, may play a role in autism|autism|autism|disease|74|omim:209850|Brain|brain|anatomy|51|C0006104
107|We report new candidate genes involved in abnormal brain bioenergetics in autism, supporting the hypothesis that mitochondria, critical for neurodevelopment, may play a role in autism|autism|autism|disease|177|omim:209850|Mitochondria|mitochondria|anatomy|113|C0026237
107|We report new candidate genes involved in abnormal brain bioenergetics in autism, supporting the hypothesis that mitochondria, critical for neurodevelopment, may play a role in autism|autism|autism|disease|177|omim:209850|Brain|brain|anatomy|51|C0006104
108|METHODS: We exposed rats to daily ETS (300, 100, and 0 µg/m3 total suspended particulate) from postnatal day 8 (PD8) to PD23 and then assayed the response at  the behavioral, neuroproteomic, and cellular levels|PD23|PD23|compound|119|CHEBI:66847|Cells|cellular|anatomy|195|C0007634
108|Findings revealed a dose-dependent up-regulation of aerobic processes through the modification and increased translocation of Hk1 to the mitochondrion with corresponding heightened ATP synthase expression|ATP|ATP|compound|181|CHEBI:30616|Hk1|Hk1|gene|126|NCBIGene:3098
108|Findings revealed a dose-dependent up-regulation of aerobic processes through the modification and increased translocation of Hk1 to the mitochondrion with corresponding heightened ATP synthase expression|Hk1|Hk1|gene|126|NCBIGene:3098|ATP synthase|ATP synthase|gene|181|NCBIGene:1769
108|Findings revealed a dose-dependent up-regulation of aerobic processes through the modification and increased translocation of Hk1 to the mitochondrion with corresponding heightened ATP synthase expression|Hk1|Hk1|gene|126|NCBIGene:3098|Procedure findings:Finding:Point in time:^Patient:Narrative|Findings|physiology|0|C2926606
108|Findings revealed a dose-dependent up-regulation of aerobic processes through the modification and increased translocation of Hk1 to the mitochondrion with corresponding heightened ATP synthase expression|Hk1|Hk1|gene|126|NCBIGene:3098|Mitochondria|mitochondrion|anatomy|137|C0026237
108|Findings revealed a dose-dependent up-regulation of aerobic processes through the modification and increased translocation of Hk1 to the mitochondrion with corresponding heightened ATP synthase expression|ATP|ATP|compound|181|CHEBI:30616|Mitochondria|mitochondrion|anatomy|137|C0026237
108|Findings revealed a dose-dependent up-regulation of aerobic processes through the modification and increased translocation of Hk1 to the mitochondrion with corresponding heightened ATP synthase expression|ATP synthase|ATP synthase|gene|181|NCBIGene:1769|Procedure findings:Finding:Point in time:^Patient:Narrative|Findings|physiology|0|C2926606
108|Findings revealed a dose-dependent up-regulation of aerobic processes through the modification and increased translocation of Hk1 to the mitochondrion with corresponding heightened ATP synthase expression|ATP synthase|ATP synthase|gene|181|NCBIGene:1769|Mitochondria|mitochondrion|anatomy|137|C0026237
108|ETS exposure also induced a dose-dependent increase in total Dnm1l mitochondrial fission factor; although more active membrane-bound Dnm1l was found at the lower dose|Dnm1l mitochondrial fission factor|Dnm1l mitochondrial fission factor|gene|61|NCBIGene:10059|Membrane|membrane|anatomy|118|C0596901
108|ETS exposure also induced a dose-dependent increase in total Dnm1l mitochondrial fission factor; although more active membrane-bound Dnm1l was found at the lower dose|Dnm1l|Dnm1l|gene|133|NCBIGene:10059|Membrane|membrane|anatomy|118|C0596901
108|Dnm1l activation was associated with greater mitochondrial staining, particularly in the molecular layer, which was independent of stress-induced Bcl-2 family dynamics|Dnm1l|Dnm1l|gene|0|NCBIGene:10059|Bcl-2 family|Bcl-2 family|gene|146|NCBIGene:596
108|Dnm1l activation was associated with greater mitochondrial staining, particularly in the molecular layer, which was independent of stress-induced Bcl-2 family dynamics|Dnm1l|Dnm1l|gene|0|NCBIGene:10059|Mitochondria|mitochondrial|anatomy|45|C0026237
108|Dnm1l activation was associated with greater mitochondrial staining, particularly in the molecular layer, which was independent of stress-induced Bcl-2 family dynamics|Dnm1l|Dnm1l|gene|0|NCBIGene:10059|anatomical layer|layer|anatomy|99|C0934502
108|Dnm1l activation was associated with greater mitochondrial staining, particularly in the molecular layer, which was independent of stress-induced Bcl-2 family dynamics|Bcl-2 family|Bcl-2 family|gene|146|NCBIGene:596|Mitochondria|mitochondrial|anatomy|45|C0026237
108|Dnm1l activation was associated with greater mitochondrial staining, particularly in the molecular layer, which was independent of stress-induced Bcl-2 family dynamics|Bcl-2 family|Bcl-2 family|gene|146|NCBIGene:596|anatomical layer|layer|anatomy|99|C0934502
108|Further, electron microscopy associated Dnm1l-mediated mitochondrial fission with increased biogenesis, rather than fragmentation|Dnm1l|Dnm1l|gene|40|NCBIGene:10059|Mitochondrial Fission|mitochondrial fission|physiology|55|C0230871
108|The biological effect of ETS is underlain in part by a Dnm1l-mediated mitochondrial energetic response at a time of normally tight control|Dnm1l|Dnm1l|gene|55|NCBIGene:10059|Mitochondria|mitochondrial|anatomy|70|C0026237
109|Mitochondria are a major source of ROS,  and mechanisms to prevent elevated ROS during oxidative phosphorylation require super oxide dismutase (SOD) activity|super oxide|super oxide|compound|121|mesh:D013481|SOD|SOD|gene|144|NCBIGene:6647
109|Mitochondria are a major source of ROS,  and mechanisms to prevent elevated ROS during oxidative phosphorylation require super oxide dismutase (SOD) activity|super oxide|super oxide|compound|121|mesh:D013481|Mitochondria|Mitochondria|anatomy|0|C0026237
109|Mitochondria are a major source of ROS,  and mechanisms to prevent elevated ROS during oxidative phosphorylation require super oxide dismutase (SOD) activity|super oxide dismutase|super oxide dismutase|gene|121|NCBIGene:6647|Mitochondria|Mitochondria|anatomy|0|C0026237
109|Mitochondria are a major source of ROS,  and mechanisms to prevent elevated ROS during oxidative phosphorylation require super oxide dismutase (SOD) activity|super oxide dismutase|super oxide dismutase|gene|121|NCBIGene:6647|Oxidative Phosphorylation|oxidative phosphorylation|physiology|87|C0030013
109|Mitochondria are a major source of ROS,  and mechanisms to prevent elevated ROS during oxidative phosphorylation require super oxide dismutase (SOD) activity|SOD|SOD|gene|144|NCBIGene:6647|Mitochondria|Mitochondria|anatomy|0|C0026237
109|Mitochondria are a major source of ROS,  and mechanisms to prevent elevated ROS during oxidative phosphorylation require super oxide dismutase (SOD) activity|SOD|SOD|gene|144|NCBIGene:6647|Oxidative Phosphorylation|oxidative phosphorylation|physiology|87|C0030013
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|superoxides|superoxides|compound|110|mesh:D013481|SOD2|SOD2|gene|0|NCBIGene:6648
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|hydrogen peroxide|hydrogen peroxide|compound|125|mesh:D006861|SOD2|SOD2|gene|0|NCBIGene:6648
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|H(2)O|H(2)O|compound|178|CHEBI:33813|SOD2|SOD2|gene|0|NCBIGene:6648
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|oxygen|oxygen|compound|188|mesh:D010100|SOD2|SOD2|gene|0|NCBIGene:6648
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|SOD2|SOD2|gene|0|NCBIGene:6648|superoxide dismutase activity|MnSOD|physiology|20|C1151619
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|SOD2|SOD2|gene|0|NCBIGene:6648|Mitochondria|mitochondria|anatomy|42|C0026237
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|superoxides|superoxides|compound|110|mesh:D013481|MnSOD|MnSOD|gene|20|NCBIGene:6648
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|hydrogen peroxide|hydrogen peroxide|compound|125|mesh:D006861|MnSOD|MnSOD|gene|20|NCBIGene:6648
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|H(2)O|H(2)O|compound|178|CHEBI:33813|MnSOD|MnSOD|gene|20|NCBIGene:6648
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|oxygen|oxygen|compound|188|mesh:D010100|MnSOD|MnSOD|gene|20|NCBIGene:6648
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|MnSOD|MnSOD|gene|20|NCBIGene:6648|superoxide dismutase activity|SOD2|physiology|0|C1151619
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|MnSOD|MnSOD|gene|20|NCBIGene:6648|Mitochondria|mitochondria|anatomy|42|C0026237
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|superoxides|superoxides|compound|110|mesh:D013481|hydrogen peroxide|hydrogen peroxide|compound|125|mesh:D006861
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|superoxides|superoxides|compound|110|mesh:D013481|H(2)O|H(2)O|compound|178|CHEBI:33813
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|superoxides|superoxides|compound|110|mesh:D013481|oxygen|oxygen|compound|188|mesh:D010100
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|superoxides|superoxides|compound|110|mesh:D013481|Mitochondria|mitochondria|anatomy|42|C0026237
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|hydrogen peroxide|hydrogen peroxide|compound|125|mesh:D006861|H(2)O|H(2)O|compound|178|CHEBI:33813
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|hydrogen peroxide|hydrogen peroxide|compound|125|mesh:D006861|oxygen|oxygen|compound|188|mesh:D010100
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|hydrogen peroxide|hydrogen peroxide|compound|125|mesh:D006861|Mitochondria|mitochondria|anatomy|42|C0026237
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|H(2)O|H(2)O|compound|178|CHEBI:33813|oxygen|oxygen|compound|188|mesh:D010100
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|H(2)O|H(2)O|compound|178|CHEBI:33813|Mitochondria|mitochondria|anatomy|42|C0026237
109|SOD2, also known as MnSOD, is targeted to mitochondria and is instrumental in regulating ROS by conversion of superoxides to hydrogen peroxide, which is further broken down into H(2)O and oxygen|oxygen|oxygen|compound|188|mesh:D010100|Mitochondria|mitochondria|anatomy|42|C0026237
109|Here, we describe the identification of a novel mutation within the mitochondrial SOD2  enzyme in Drosophila that results in adults with an extremely shortened life span, sensitivity to hyperoxia, and neuropathology|mitochondrial SOD2  enzyme in|mitochondrial SOD2  enzyme in|gene|68|NCBIGene:6648|hyperoxia|hyperoxia|disease|186|mesh:D018496
109|Here, we describe the identification of a novel mutation within the mitochondrial SOD2  enzyme in Drosophila that results in adults with an extremely shortened life span, sensitivity to hyperoxia, and neuropathology|mitochondrial SOD2  enzyme in|mitochondrial SOD2  enzyme in|gene|68|NCBIGene:6648|neuropathology|neuropathology|disease|201|mesh:D001927
109|Here, we describe the identification of a novel mutation within the mitochondrial SOD2  enzyme in Drosophila that results in adults with an extremely shortened life span, sensitivity to hyperoxia, and neuropathology|mitochondrial SOD2  enzyme in|mitochondrial SOD2  enzyme in|gene|68|NCBIGene:6648|Identification (Psychology)|identification|physiology|22|C0020792
109|Here, we describe the identification of a novel mutation within the mitochondrial SOD2  enzyme in Drosophila that results in adults with an extremely shortened life span, sensitivity to hyperoxia, and neuropathology|hyperoxia|hyperoxia|disease|186|mesh:D018496|neuropathology|neuropathology|disease|201|mesh:D001927
109|Here, we describe the identification of a novel mutation within the mitochondrial SOD2  enzyme in Drosophila that results in adults with an extremely shortened life span, sensitivity to hyperoxia, and neuropathology|hyperoxia|hyperoxia|disease|186|mesh:D018496|Mitochondria|mitochondrial|anatomy|68|C0026237
109|Here, we describe the identification of a novel mutation within the mitochondrial SOD2  enzyme in Drosophila that results in adults with an extremely shortened life span, sensitivity to hyperoxia, and neuropathology|neuropathology|neuropathology|disease|201|mesh:D001927|Mitochondria|mitochondrial|anatomy|68|C0026237
109|Additional studies demonstrate that this novel mutant, SOD2(bewildered), exhibits abnormal brain morphology, suggesting a critical role for this protein in neurodevelopment|SOD2|SOD2|gene|55|NCBIGene:6648|neurodevelopment|neurodevelopment|physiology|156|C0599855
109|We investigated the basis of this neurodevelopmental defect and discovered an increase in aberrant axonal that could underlie the aberrant neurodevelopment and brain morphology defects|neurodevelopmental defect|neurodevelopmental defect|disease|34|mesh:D065886|brain morphology defects|brain morphology defects|disease|160|mesh:D001927
109|We investigated the basis of this neurodevelopmental defect and discovered an increase in aberrant axonal that could underlie the aberrant neurodevelopment and brain morphology defects|neurodevelopmental defect|neurodevelopmental defect|disease|34|mesh:D065886|Axon|axonal|anatomy|99|C0004461
109|We investigated the basis of this neurodevelopmental defect and discovered an increase in aberrant axonal that could underlie the aberrant neurodevelopment and brain morphology defects|brain morphology defects|brain morphology defects|disease|160|mesh:D001927|Axon|axonal|anatomy|99|C0004461
109|This novel allele, SOD2(bewildered), provides a unique  opportunity to study the effects of increased mitochondrial ROS on neural development, axonal targeting, and neural cell degeneration in vivo|SOD2(bewildered)|SOD2(bewildered)|gene|19|NCBIGene:6648|Neurogenesis|neural development|physiology|123|C0814002
109|This novel allele, SOD2(bewildered), provides a unique  opportunity to study the effects of increased mitochondrial ROS on neural development, axonal targeting, and neural cell degeneration in vivo|SOD2(bewildered)|SOD2(bewildered)|gene|19|NCBIGene:6648|Axon|axonal|anatomy|143|C0004461
109|This novel allele, SOD2(bewildered), provides a unique  opportunity to study the effects of increased mitochondrial ROS on neural development, axonal targeting, and neural cell degeneration in vivo|SOD2(bewildered)|SOD2(bewildered)|gene|19|NCBIGene:6648|Mitochondria|mitochondrial|anatomy|102|C0026237
110|Defects in the ubiquitin-proteasome system have been related to aging and the development of neurodegenerative disease, although the effects of deficient proteasome activity during early postnatal development are poorly understood|ubiquitin|ubiquitin|gene|15|NCBIGene:10537|neurodegenerative disease|neurodegenerative disease|disease|93|mesh:D019636
110|Defects in the ubiquitin-proteasome system have been related to aging and the development of neurodegenerative disease, although the effects of deficient proteasome activity during early postnatal development are poorly understood|ubiquitin|ubiquitin|gene|15|NCBIGene:10537|Comprehension|understood|physiology|220|C0162340
110|Defects in the ubiquitin-proteasome system have been related to aging and the development of neurodegenerative disease, although the effects of deficient proteasome activity during early postnatal development are poorly understood|ubiquitin|ubiquitin|gene|15|NCBIGene:10537|postnatal development|postnatal development|physiology|187|C1135598
110|Defects in the ubiquitin-proteasome system have been related to aging and the development of neurodegenerative disease, although the effects of deficient proteasome activity during early postnatal development are poorly understood|ubiquitin|ubiquitin|gene|15|NCBIGene:10537|Aging|aging|physiology|64|C0001811
110|Defects in the ubiquitin-proteasome system have been related to aging and the development of neurodegenerative disease, although the effects of deficient proteasome activity during early postnatal development are poorly understood|ubiquitin|ubiquitin|gene|15|NCBIGene:10537|proteasome activity|proteasome activity|physiology|154|C1622946
110|Defects in the ubiquitin-proteasome system have been related to aging and the development of neurodegenerative disease, although the effects of deficient proteasome activity during early postnatal development are poorly understood|ubiquitin|ubiquitin|gene|15|NCBIGene:10537|Proteasome Pathway|proteasome|physiology|25|C1752727
110|We found that this regime of exposure to the proteasome inhibitors MG132 or lactacystin did not produce significant behavioural or morphological changes in the first 15 days of  life|MG132|MG132|compound|67|mesh:C072553|lactacystin|lactacystin|compound|76|CHEBI:52722
110|On reaching adulthood, the memory of mice that were injected with proteasome inhibitors postnatally was impaired in hippocampal and amygdala-dependent tasks, and they suffered motor dysfunction and imbalance|motor dysfunction|motor dysfunction|disease|176|mesh:D000068079|Hippocampus (Brain)|hippocampal|anatomy|116|C0019564
110|On reaching adulthood, the memory of mice that were injected with proteasome inhibitors postnatally was impaired in hippocampal and amygdala-dependent tasks, and they suffered motor dysfunction and imbalance|motor dysfunction|motor dysfunction|disease|176|mesh:D000068079|Amygdaloid structure|amygdala|anatomy|132|C0002708
110|Accordingly, impairing proteasome activity at early postnatal ages appears to cause morphological and behavioural alterations in adult mice that resemble those associated with certain neurodegenerative diseases and/or syndromes of mental retardation|proteasome|proteasome|gene|23|NCBIGene:5694|neurodegenerative diseases|neurodegenerative diseases|disease|184|mesh:D019636
110|Accordingly, impairing proteasome activity at early postnatal ages appears to cause morphological and behavioural alterations in adult mice that resemble those associated with certain neurodegenerative diseases and/or syndromes of mental retardation|proteasome|proteasome|gene|23|NCBIGene:5694|mental retardation|mental retardation|disease|231|mesh:D008607
110|Accordingly, impairing proteasome activity at early postnatal ages appears to cause morphological and behavioural alterations in adult mice that resemble those associated with certain neurodegenerative diseases and/or syndromes of mental retardation|neurodegenerative diseases|neurodegenerative diseases|disease|184|mesh:D019636|mental retardation|mental retardation|disease|231|mesh:D008607
111|CONTEXT: Impaired mitochondrial function may influence processes highly dependent on energy, such as neurodevelopment, and contribute to autism|autism|autism|disease|137|omim:209850|bony process|processes|anatomy|55|C1184743
111|No studies have evaluated mitochondrial dysfunction and mitochondrial DNA (mtDNA) abnormalities in a well-defined population of children with autism|mitochondrial dysfunction|mitochondrial dysfunction|disease|26|mesh:D028361|autism|autism|disease|142|omim:209850
111|No studies have evaluated mitochondrial dysfunction and mitochondrial DNA (mtDNA) abnormalities in a well-defined population of children with autism|mitochondrial dysfunction|mitochondrial dysfunction|disease|26|mesh:D028361|mitochondrial DNA location|mitochondrial DNA|anatomy|56|C1819717
111|No studies have evaluated mitochondrial dysfunction and mitochondrial DNA (mtDNA) abnormalities in a well-defined population of children with autism|mitochondrial dysfunction|mitochondrial dysfunction|disease|26|mesh:D028361|mitochondrial DNA location|mtDNA|anatomy|75|C1819717
111|No studies have evaluated mitochondrial dysfunction and mitochondrial DNA (mtDNA) abnormalities in a well-defined population of children with autism|mitochondrial DNA (mtDNA) abnormalities|mitochondrial DNA (mtDNA) abnormalities|disease|56|mesh:D028361|autism|autism|disease|142|omim:209850
111|No studies have evaluated mitochondrial dysfunction and mitochondrial DNA (mtDNA) abnormalities in a well-defined population of children with autism|autism|autism|disease|142|omim:209850|mitochondrial DNA location|mitochondrial DNA|anatomy|56|C1819717
111|No studies have evaluated mitochondrial dysfunction and mitochondrial DNA (mtDNA) abnormalities in a well-defined population of children with autism|autism|autism|disease|142|omim:209850|mitochondrial DNA location|mtDNA|anatomy|75|C1819717
111|OBJECTIVE: To evaluate mitochondrial defects in children with autism|autism|autism|disease|62|omim:209850|Mitochondria|mitochondrial|anatomy|23|C0026237
111|Mitochondrial dysfunction and mtDNA abnormalities were evaluated in lymphocytes from 10 children with autism and 10 controls|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|0|mesh:D028361|autism|autism|disease|102|omim:209850
111|Mitochondrial dysfunction and mtDNA abnormalities were evaluated in lymphocytes from 10 children with autism and 10 controls|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|0|mesh:D028361|Lymphocyte|lymphocytes|anatomy|68|C0024264
111|Mitochondrial dysfunction and mtDNA abnormalities were evaluated in lymphocytes from 10 children with autism and 10 controls|Mitochondrial dysfunction|Mitochondrial dysfunction|disease|0|mesh:D028361|mitochondrial DNA location|mtDNA|anatomy|30|C1819717
111|Mitochondrial dysfunction and mtDNA abnormalities were evaluated in lymphocytes from 10 children with autism and 10 controls|mtDNA|mtDNA|disease|30|mesh:D028361|autism|autism|disease|102|omim:209850
111|Mitochondrial dysfunction and mtDNA abnormalities were evaluated in lymphocytes from 10 children with autism and 10 controls|mtDNA|mtDNA|disease|30|mesh:D028361|Lymphocyte|lymphocytes|anatomy|68|C0024264
111|Mitochondrial dysfunction and mtDNA abnormalities were evaluated in lymphocytes from 10 children with autism and 10 controls|autism|autism|disease|102|omim:209850|Lymphocyte|lymphocytes|anatomy|68|C0024264
111|Mitochondrial dysfunction and mtDNA abnormalities were evaluated in lymphocytes from 10 children with autism and 10 controls|autism|autism|disease|102|omim:209850|mitochondrial DNA location|mtDNA|anatomy|30|C1819717
111|MAIN OUTCOME MEASURES: Oxidative phosphorylation capacity, mtDNA copy number and  deletions, mitochondrial rate of hydrogen peroxide production, and plasma lactate and pyruvate|hydrogen peroxide|hydrogen peroxide|compound|115|mesh:D006861|lactate|lactate|compound|156|mesh:D019344
111|MAIN OUTCOME MEASURES: Oxidative phosphorylation capacity, mtDNA copy number and  deletions, mitochondrial rate of hydrogen peroxide production, and plasma lactate and pyruvate|hydrogen peroxide|hydrogen peroxide|compound|115|mesh:D006861|pyruvate|pyruvate|compound|168|mesh:D019289
111|MAIN OUTCOME MEASURES: Oxidative phosphorylation capacity, mtDNA copy number and  deletions, mitochondrial rate of hydrogen peroxide production, and plasma lactate and pyruvate|hydrogen peroxide|hydrogen peroxide|compound|115|mesh:D006861|Plasma|plasma|anatomy|149|C0032105
111|MAIN OUTCOME MEASURES: Oxidative phosphorylation capacity, mtDNA copy number and  deletions, mitochondrial rate of hydrogen peroxide production, and plasma lactate and pyruvate|hydrogen peroxide|hydrogen peroxide|compound|115|mesh:D006861|mitochondrial DNA location|mtDNA|anatomy|59|C1819717
111|MAIN OUTCOME MEASURES: Oxidative phosphorylation capacity, mtDNA copy number and  deletions, mitochondrial rate of hydrogen peroxide production, and plasma lactate and pyruvate|lactate|lactate|compound|156|mesh:D019344|pyruvate|pyruvate|compound|168|mesh:D019289
111|MAIN OUTCOME MEASURES: Oxidative phosphorylation capacity, mtDNA copy number and  deletions, mitochondrial rate of hydrogen peroxide production, and plasma lactate and pyruvate|lactate|lactate|compound|156|mesh:D019344|Plasma|plasma|anatomy|149|C0032105
111|MAIN OUTCOME MEASURES: Oxidative phosphorylation capacity, mtDNA copy number and  deletions, mitochondrial rate of hydrogen peroxide production, and plasma lactate and pyruvate|lactate|lactate|compound|156|mesh:D019344|mitochondrial DNA location|mtDNA|anatomy|59|C1819717
111|MAIN OUTCOME MEASURES: Oxidative phosphorylation capacity, mtDNA copy number and  deletions, mitochondrial rate of hydrogen peroxide production, and plasma lactate and pyruvate|pyruvate|pyruvate|compound|168|mesh:D019289|Plasma|plasma|anatomy|149|C0032105
111|MAIN OUTCOME MEASURES: Oxidative phosphorylation capacity, mtDNA copy number and  deletions, mitochondrial rate of hydrogen peroxide production, and plasma lactate and pyruvate|pyruvate|pyruvate|compound|168|mesh:D019289|mitochondrial DNA location|mtDNA|anatomy|59|C1819717
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide|nicotinamide adenine dinucleotide|compound|21|CHEBI:15846|NADH|NADH|compound|56|mesh:D009243
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide|nicotinamide adenine dinucleotide|compound|21|CHEBI:15846|citrate|citrate|compound|94|mesh:D019343
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide|nicotinamide adenine dinucleotide|compound|21|CHEBI:15846|citrate synthase|citrate synthase|gene|94|NCBIGene:1431
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide|nicotinamide adenine dinucleotide|compound|21|CHEBI:15846|autism|autism|disease|168|omim:209850
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide|nicotinamide adenine dinucleotide|compound|21|CHEBI:15846|Body Site Modifier - Lower|lower|anatomy|193|C1548802
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide|nicotinamide adenine dinucleotide|compound|21|CHEBI:15846|Mitochondria|mitochondria|anatomy|136|C0026237
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide|nicotinamide adenine dinucleotide|compound|21|CHEBI:15846|Lymphocyte|lymphocytic|anatomy|124|C0024264
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|citrate|citrate|compound|94|mesh:D019343|nicotinamide adenine dinucleotide (NADH) oxidase|nicotinamide adenine dinucleotide (NADH) oxidase|gene|21|NCBIGene:50506
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide (NADH) oxidase|nicotinamide adenine dinucleotide (NADH) oxidase|gene|21|NCBIGene:50506|citrate synthase|citrate synthase|gene|94|NCBIGene:1431
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide (NADH) oxidase|nicotinamide adenine dinucleotide (NADH) oxidase|gene|21|NCBIGene:50506|autism|autism|disease|168|omim:209850
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide (NADH) oxidase|nicotinamide adenine dinucleotide (NADH) oxidase|gene|21|NCBIGene:50506|citrate synthase activity|citrate synthase activity|physiology|94|C2258114
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide (NADH) oxidase|nicotinamide adenine dinucleotide (NADH) oxidase|gene|21|NCBIGene:50506|Body Site Modifier - Lower|lower|anatomy|193|C1548802
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide (NADH) oxidase|nicotinamide adenine dinucleotide (NADH) oxidase|gene|21|NCBIGene:50506|Mitochondria|mitochondria|anatomy|136|C0026237
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|nicotinamide adenine dinucleotide (NADH) oxidase|nicotinamide adenine dinucleotide (NADH) oxidase|gene|21|NCBIGene:50506|Lymphocyte|lymphocytic|anatomy|124|C0024264
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|NADH|NADH|compound|56|mesh:D009243|citrate|citrate|compound|94|mesh:D019343
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|NADH|NADH|compound|56|mesh:D009243|citrate synthase|citrate synthase|gene|94|NCBIGene:1431
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|NADH|NADH|compound|56|mesh:D009243|autism|autism|disease|168|omim:209850
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|NADH|NADH|compound|56|mesh:D009243|Body Site Modifier - Lower|lower|anatomy|193|C1548802
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|NADH|NADH|compound|56|mesh:D009243|Mitochondria|mitochondria|anatomy|136|C0026237
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|NADH|NADH|compound|56|mesh:D009243|Lymphocyte|lymphocytic|anatomy|124|C0024264
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|citrate|citrate|compound|94|mesh:D019343|autism|autism|disease|168|omim:209850
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|citrate|citrate|compound|94|mesh:D019343|Body Site Modifier - Lower|lower|anatomy|193|C1548802
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|citrate|citrate|compound|94|mesh:D019343|Mitochondria|mitochondria|anatomy|136|C0026237
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|citrate|citrate|compound|94|mesh:D019343|Lymphocyte|lymphocytic|anatomy|124|C0024264
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|citrate synthase|citrate synthase|gene|94|NCBIGene:1431|autism|autism|disease|168|omim:209850
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|citrate synthase|citrate synthase|gene|94|NCBIGene:1431|Body Site Modifier - Lower|lower|anatomy|193|C1548802
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|citrate synthase|citrate synthase|gene|94|NCBIGene:1431|Mitochondria|mitochondria|anatomy|136|C0026237
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|citrate synthase|citrate synthase|gene|94|NCBIGene:1431|Lymphocyte|lymphocytic|anatomy|124|C0024264
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|autism|autism|disease|168|omim:209850|Body Site Modifier - Lower|lower|anatomy|193|C1548802
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|autism|autism|disease|168|omim:209850|Mitochondria|mitochondria|anatomy|136|C0026237
111|RESULTS: The reduced nicotinamide adenine dinucleotide (NADH) oxidase activity (normalized to citrate synthase activity) in lymphocytic mitochondria from children with autism was significantly lower compared with controls (mean, 4|autism|autism|disease|168|omim:209850|Lymphocyte|lymphocytic|anatomy|124|C0024264
111|The majority of children with autism (6 of 10) had complex I activity below control range values|complex I|complex I|gene|51|NCBIGene:4723|autism|autism|disease|30|omim:209850
111|Higher plasma pyruvate levels were found in children  with autism compared with controls (0|pyruvate|pyruvate|compound|14|mesh:D019289|autism|autism|disease|59|omim:209850
111|Eight of 10 cases had higher pyruvate levels but only 2 cases had higher lactate levels compared with controls|pyruvate|pyruvate|compound|29|mesh:D019289|lactate|lactate|compound|73|mesh:D019344
111|These results were consistent with the lower pyruvate dehydrogenase activity observed in children with autism compared with controls (1|pyruvate|pyruvate|compound|45|mesh:D019289|autism|autism|disease|103|omim:209850
111|These results were consistent with the lower pyruvate dehydrogenase activity observed in children with autism compared with controls (1|pyruvate|pyruvate|compound|45|mesh:D019289|Body Site Modifier - Lower|lower|anatomy|39|C1548802
111|These results were consistent with the lower pyruvate dehydrogenase activity observed in children with autism compared with controls (1|pyruvate dehydrogenase|pyruvate dehydrogenase|gene|45|NCBIGene:5160|autism|autism|disease|103|omim:209850
111|These results were consistent with the lower pyruvate dehydrogenase activity observed in children with autism compared with controls (1|pyruvate dehydrogenase|pyruvate dehydrogenase|gene|45|NCBIGene:5160|Body Site Modifier - Lower|lower|anatomy|39|C1548802
111|These results were consistent with the lower pyruvate dehydrogenase activity observed in children with autism compared with controls (1|autism|autism|disease|103|omim:209850|Body Site Modifier - Lower|lower|anatomy|39|C1548802
111|Children with autism had higher mitochondrial rates of hydrogen peroxide production compared with controls (0|hydrogen peroxide|hydrogen peroxide|compound|55|mesh:D006861|autism|autism|disease|14|omim:209850
111|20]  nmol × [min × mg protein](-1) by complex III; P =|complex III|complex III|gene|36|NCBIGene:7384|P prime|P|physiology|51|C2603361
111|Deletions at the segment of cytochrome b were observed in 2 cases (ratio of cytochrome b to ND1: 0|cytochrome b|cytochrome b|gene|28|NCBIGene:4519|ND1|ND1|gene|92|NCBIGene:4535
111|Deletions at the segment of cytochrome b were observed in 2 cases (ratio of cytochrome b to ND1: 0|cytochrome b|cytochrome b|gene|76|NCBIGene:4519|ND1|ND1|gene|92|NCBIGene:4535
111|CONCLUSION: In this exploratory study, children with autism were more likely to have mitochondrial dysfunction, mtDNA overreplication, and mtDNA deletions than typically developing children|autism|autism|disease|53|omim:209850|mitochondrial dysfunction|mitochondrial dysfunction|disease|85|mesh:D028361
111|CONCLUSION: In this exploratory study, children with autism were more likely to have mitochondrial dysfunction, mtDNA overreplication, and mtDNA deletions than typically developing children|autism|autism|disease|53|omim:209850|mitochondrial DNA location|mtDNA|anatomy|112|C1819717
111|CONCLUSION: In this exploratory study, children with autism were more likely to have mitochondrial dysfunction, mtDNA overreplication, and mtDNA deletions than typically developing children|mitochondrial dysfunction|mitochondrial dysfunction|disease|85|mesh:D028361|mitochondrial DNA location|mtDNA|anatomy|112|C1819717
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|58|NCBIGene:3060|orexin receptors|orexin receptors|gene|128|NCBIGene:3061
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|58|NCBIGene:3060|OX1R|OX1R|gene|145|NCBIGene:3061
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|58|NCBIGene:3060|OX2R|OX2R|gene|153|NCBIGene:3062
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|58|NCBIGene:3060|cancer|cancer|disease|241|mesh:D009369
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|58|NCBIGene:3060|Apoptosis|apoptosis|physiology|174|C0162638
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|58|NCBIGene:3060|Cultured Cell Line|cell lines|anatomy|248|C0007600
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|58|NCBIGene:3060|Tumor cells, malignant|cancer cell|anatomy|241|C0334227
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|110|NCBIGene:3060|orexin receptors|orexin receptors|gene|128|NCBIGene:3061
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|110|NCBIGene:3060|OX1R|OX1R|gene|145|NCBIGene:3061
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|110|NCBIGene:3060|OX2R|OX2R|gene|153|NCBIGene:3062
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|110|NCBIGene:3060|cancer|cancer|disease|241|mesh:D009369
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|110|NCBIGene:3060|Apoptosis|apoptosis|physiology|174|C0162638
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|110|NCBIGene:3060|Cultured Cell Line|cell lines|anatomy|248|C0007600
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexins|orexins|gene|110|NCBIGene:3060|Tumor cells, malignant|cancer cell|anatomy|241|C0334227
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexin receptors|orexin receptors|gene|128|NCBIGene:3061|OX2R|OX2R|gene|153|NCBIGene:3062
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexin receptors|orexin receptors|gene|128|NCBIGene:3061|cancer|cancer|disease|241|mesh:D009369
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexin receptors|orexin receptors|gene|128|NCBIGene:3061|Apoptosis|apoptosis|physiology|174|C0162638
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexin receptors|orexin receptors|gene|128|NCBIGene:3061|Cultured Cell Line|cell lines|anatomy|248|C0007600
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|orexin receptors|orexin receptors|gene|128|NCBIGene:3061|Tumor cells, malignant|cancer cell|anatomy|241|C0334227
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|OX1R|OX1R|gene|145|NCBIGene:3061|OX2R|OX2R|gene|153|NCBIGene:3062
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|OX1R|OX1R|gene|145|NCBIGene:3061|cancer|cancer|disease|241|mesh:D009369
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|OX1R|OX1R|gene|145|NCBIGene:3061|Apoptosis|apoptosis|physiology|174|C0162638
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|OX1R|OX1R|gene|145|NCBIGene:3061|Cultured Cell Line|cell lines|anatomy|248|C0007600
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|OX1R|OX1R|gene|145|NCBIGene:3061|Tumor cells, malignant|cancer cell|anatomy|241|C0334227
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|OX2R|OX2R|gene|153|NCBIGene:3062|cancer|cancer|disease|241|mesh:D009369
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|OX2R|OX2R|gene|153|NCBIGene:3062|Apoptosis|apoptosis|physiology|174|C0162638
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|OX2R|OX2R|gene|153|NCBIGene:3062|Cultured Cell Line|cell lines|anatomy|248|C0007600
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|OX2R|OX2R|gene|153|NCBIGene:3062|Tumor cells, malignant|cancer cell|anatomy|241|C0334227
112|An unexpected and fascinating aspect of the neuropeptides orexins has recently emerged when it was shown that orexins acting at orexin receptors OX1R or OX2R induce dramatic apoptosis resulting in massive reduction in cell growth in various cancer cell lines|cancer|cancer|disease|241|mesh:D009369|Cultured Cell Line|cell lines|anatomy|248|C0007600
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|orexins|orexins|gene|101|NCBIGene:3060|GPCR|GPCR|gene|206|NCBIGene:441931
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|orexins|orexins|gene|101|NCBIGene:3060|OX1R|OX1R|gene|212|NCBIGene:3061
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|orexins|orexins|gene|101|NCBIGene:3060|Apoptosis|apoptosis|physiology|226|C0162638
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|orexins|orexins|gene|101|NCBIGene:3060|Precipitating Factors|triggers|physiology|217|C0032930
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|orexins|orexins|gene|101|NCBIGene:3060|Mini|mini|physiology|5|C0445542
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|orexins|orexins|gene|101|NCBIGene:3060|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|53|C2926606
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|GPCR|GPCR|gene|206|NCBIGene:441931|OX1R|OX1R|gene|212|NCBIGene:3061
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|GPCR|GPCR|gene|206|NCBIGene:441931|Apoptosis|apoptosis|physiology|226|C0162638
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|GPCR|GPCR|gene|206|NCBIGene:441931|Precipitating Factors|triggers|physiology|217|C0032930
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|GPCR|GPCR|gene|206|NCBIGene:441931|Mini|mini|physiology|5|C0445542
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|GPCR|GPCR|gene|206|NCBIGene:441931|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|53|C2926606
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|OX1R|OX1R|gene|212|NCBIGene:3061|Apoptosis|apoptosis|physiology|226|C0162638
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|OX1R|OX1R|gene|212|NCBIGene:3061|Precipitating Factors|triggers|physiology|217|C0032930
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|OX1R|OX1R|gene|212|NCBIGene:3061|Mini|mini|physiology|5|C0445542
112|This mini-review will provide the reader with recent findings related to the proapoptotic actions of orexins and the entirely novel mechanism whereby the seven membrane-spanning G-protein-coupled receptor (GPCR) OX1R triggers apoptosis|OX1R|OX1R|gene|212|NCBIGene:3061|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|53|C2926606
112|Recent data show that orexins induce tyrosine phosphorylation of the tyrosine-based motifs - immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif - in OX1R|tyrosine|tyrosine|compound|37|mesh:D014443|orexins|orexins|gene|22|NCBIGene:3060
112|Recent data show that orexins induce tyrosine phosphorylation of the tyrosine-based motifs - immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif - in OX1R|tyrosine|tyrosine|compound|69|mesh:D014443|orexins|orexins|gene|22|NCBIGene:3060
112|Recent data show that orexins induce tyrosine phosphorylation of the tyrosine-based motifs - immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif - in OX1R|tyrosine|tyrosine|compound|108|mesh:D014443|orexins|orexins|gene|22|NCBIGene:3060
112|Recent data show that orexins induce tyrosine phosphorylation of the tyrosine-based motifs - immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif - in OX1R|tyrosine|tyrosine|compound|159|mesh:D014443|orexins|orexins|gene|22|NCBIGene:3060
112|Recent data show that orexins induce tyrosine phosphorylation of the tyrosine-based motifs - immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif - in OX1R|orexins|orexins|gene|22|NCBIGene:3060|OX1R|OX1R|gene|192|NCBIGene:3061
112|Recent data show that orexins induce tyrosine phosphorylation of the tyrosine-based motifs - immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif - in OX1R|orexins|orexins|gene|22|NCBIGene:3060|Tyrosine Phosphorylation|tyrosine phosphorylation|physiology|37|C1519726
112|Recent data show that orexins induce tyrosine phosphorylation of the tyrosine-based motifs - immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif - in OX1R|tyrosine|tyrosine|compound|37|mesh:D014443|OX1R|OX1R|gene|192|NCBIGene:3061
112|Recent data show that orexins induce tyrosine phosphorylation of the tyrosine-based motifs - immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif - in OX1R|tyrosine|tyrosine|compound|69|mesh:D014443|OX1R|OX1R|gene|192|NCBIGene:3061
112|Recent data show that orexins induce tyrosine phosphorylation of the tyrosine-based motifs - immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif - in OX1R|tyrosine|tyrosine|compound|108|mesh:D014443|OX1R|OX1R|gene|192|NCBIGene:3061
112|Recent data show that orexins induce tyrosine phosphorylation of the tyrosine-based motifs - immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif - in OX1R|tyrosine|tyrosine|compound|159|mesh:D014443|OX1R|OX1R|gene|192|NCBIGene:3061
112|Recent data show that orexins induce tyrosine phosphorylation of the tyrosine-based motifs - immunoreceptor tyrosine-based inhibitory motif and immunoreceptor tyrosine-based switch motif - in OX1R|OX1R|OX1R|gene|192|NCBIGene:3061|Tyrosine Phosphorylation|tyrosine phosphorylation|physiology|37|C1519726
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|phosphotyrosine|phosphotyrosine|compound|72|mesh:D019000|SHP-2|SHP-2|gene|101|NCBIGene:5781
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|phosphotyrosine|phosphotyrosine|compound|72|mesh:D019000|cytochrome c|cytochrome c|gene|122|NCBIGene:54205
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|phosphotyrosine  phosphatase|phosphotyrosine  phosphatase|gene|72|NCBIGene:995|SHP-2|SHP-2|gene|101|NCBIGene:5781
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|phosphotyrosine  phosphatase|phosphotyrosine  phosphatase|gene|72|NCBIGene:995|cytochrome c|cytochrome c|gene|122|NCBIGene:54205
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|phosphotyrosine  phosphatase|phosphotyrosine  phosphatase|gene|72|NCBIGene:995|Phosphorylation|phosphorylations|physiology|7|C0031715
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|phosphotyrosine  phosphatase|phosphotyrosine  phosphatase|gene|72|NCBIGene:995|Apoptosis|apoptosis|physiology|158|C0162638
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|phosphotyrosine  phosphatase|phosphotyrosine  phosphatase|gene|72|NCBIGene:995|cytochrome c activity|cytochrome c|physiology|122|C1153524
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|SHP-2|SHP-2|gene|101|NCBIGene:5781|cytochrome c|cytochrome c|gene|122|NCBIGene:54205
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|SHP-2|SHP-2|gene|101|NCBIGene:5781|Phosphorylation|phosphorylations|physiology|7|C0031715
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|SHP-2|SHP-2|gene|101|NCBIGene:5781|Apoptosis|apoptosis|physiology|158|C0162638
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|SHP-2|SHP-2|gene|101|NCBIGene:5781|cytochrome c activity|cytochrome c|physiology|122|C1153524
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|cytochrome c|cytochrome c|gene|122|NCBIGene:54205|Phosphorylation|phosphorylations|physiology|7|C0031715
112|These  phosphorylations result in the recruitment and activation of the phosphotyrosine  phosphatase SHP-2 and subsequent cytochrome c-mediated mitochondrial apoptosis|cytochrome c|cytochrome c|gene|122|NCBIGene:54205|Apoptosis|apoptosis|physiology|158|C0162638
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|tyrosine|tyrosine|compound|82|mesh:D014443|GPCRs|GPCRs|gene|127|NCBIGene:8322
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|tyrosine|tyrosine|compound|82|mesh:D014443|orexin receptors|orexin receptors|gene|154|NCBIGene:3061
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|tyrosine|tyrosine|compound|82|mesh:D014443|cancer|cancer|disease|197|mesh:D009369
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|tyrosine|tyrosine|compound|82|mesh:D014443|orexin receptor|orexin receptor|gene|238|NCBIGene:3061
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|tyrosine|tyrosine|compound|82|mesh:D014443|neurodegenerative diseases|neurodegenerative diseases|disease|339|mesh:D019636
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|GPCRs|GPCRs|gene|127|NCBIGene:8322|orexin receptors|orexin receptors|gene|154|NCBIGene:3061
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|GPCRs|GPCRs|gene|127|NCBIGene:8322|cancer|cancer|disease|197|mesh:D009369
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|GPCRs|GPCRs|gene|127|NCBIGene:8322|orexin receptor|orexin receptor|gene|238|NCBIGene:3061
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|GPCRs|GPCRs|gene|127|NCBIGene:8322|neurodegenerative diseases|neurodegenerative diseases|disease|339|mesh:D019636
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|GPCRs|GPCRs|gene|127|NCBIGene:8322|neurodevelopment|neurodevelopment|physiology|321|C0599855
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|GPCRs|GPCRs|gene|127|NCBIGene:8322|physiological aspects|physiology|physiology|276|C0031843
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|GPCRs|GPCRs|gene|127|NCBIGene:8322|Mini|mini|physiology|14|C0445542
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|GPCRs|GPCRs|gene|127|NCBIGene:8322|Interested|interest|physiology|142|C0543488
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptors|orexin receptors|gene|154|NCBIGene:3061|cancer|cancer|disease|197|mesh:D009369
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptors|orexin receptors|gene|154|NCBIGene:3061|neurodegenerative diseases|neurodegenerative diseases|disease|339|mesh:D019636
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptors|orexin receptors|gene|154|NCBIGene:3061|neurodevelopment|neurodevelopment|physiology|321|C0599855
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptors|orexin receptors|gene|154|NCBIGene:3061|physiological aspects|physiology|physiology|276|C0031843
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptors|orexin receptors|gene|154|NCBIGene:3061|Mini|mini|physiology|14|C0445542
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptors|orexin receptors|gene|154|NCBIGene:3061|Interested|interest|physiology|142|C0543488
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptor|orexin receptor|gene|238|NCBIGene:3061|cancer|cancer|disease|197|mesh:D009369
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|cancer|cancer|disease|197|mesh:D009369|neurodegenerative diseases|neurodegenerative diseases|disease|339|mesh:D019636
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptor|orexin receptor|gene|238|NCBIGene:3061|neurodegenerative diseases|neurodegenerative diseases|disease|339|mesh:D019636
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptor|orexin receptor|gene|238|NCBIGene:3061|neurodevelopment|neurodevelopment|physiology|321|C0599855
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptor|orexin receptor|gene|238|NCBIGene:3061|physiological aspects|physiology|physiology|276|C0031843
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptor|orexin receptor|gene|238|NCBIGene:3061|Mini|mini|physiology|14|C0445542
112|Finally, this mini-review will also speculate on: (1) the potential importance of tyrosine-based motifs in the large family of GPCRs; (2) the interest of orexin receptors as therapeutic targets in cancer therapy; (3) the possible role of orexin receptor-mediated apoptosis in physiology and pathophysiology in the brain (neurodevelopment, neurodegenerative diseases) and in the periphery|orexin receptor|orexin receptor|gene|238|NCBIGene:3061|Interested|interest|physiology|142|C0543488
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|Disrupted-In-Schizophrenia-1|Disrupted-In-Schizophrenia-1|gene|0|NCBIGene:27185|schizophrenia|schizophrenia|disease|71|omim:181500
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|Disrupted-In-Schizophrenia-1|Disrupted-In-Schizophrenia-1|gene|0|NCBIGene:27185|SZ|SZ|disease|86|mesh:D012640
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|Disrupted-In-Schizophrenia-1|Disrupted-In-Schizophrenia-1|gene|0|NCBIGene:27185|bipolar disorder|bipolar disorder|disease|94|mesh:D001714
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|Disrupted-In-Schizophrenia-1|Disrupted-In-Schizophrenia-1|gene|0|NCBIGene:27185|BP|BP|disease|112|mesh:D006973
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|DISC1|DISC1|gene|30|NCBIGene:27185|schizophrenia|schizophrenia|disease|71|omim:181500
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|DISC1|DISC1|gene|30|NCBIGene:27185|SZ|SZ|disease|86|mesh:D012640
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|DISC1|DISC1|gene|30|NCBIGene:27185|bipolar disorder|bipolar disorder|disease|94|mesh:D001714
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|DISC1|DISC1|gene|30|NCBIGene:27185|BP|BP|disease|112|mesh:D006973
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|schizophrenia|schizophrenia|disease|71|omim:181500|SZ|SZ|disease|86|mesh:D012640
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|schizophrenia|schizophrenia|disease|71|omim:181500|bipolar disorder|bipolar disorder|disease|94|mesh:D001714
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|schizophrenia|schizophrenia|disease|71|omim:181500|BP|BP|disease|112|mesh:D006973
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|SZ|SZ|disease|86|mesh:D012640|bipolar disorder|bipolar disorder|disease|94|mesh:D001714
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|SZ|SZ|disease|86|mesh:D012640|BP|BP|disease|112|mesh:D006973
113|Disrupted-In-Schizophrenia-1 (DISC1) is a promising candidate gene for schizophrenia (SZ) and bipolar disorder (BP), but its basic biology remains to be elucidated|bipolar disorder|bipolar disorder|disease|94|mesh:D001714|BP|BP|disease|112|mesh:D006973
113|Accumulating genetic evidence supports that DISC1 is associated with  some aspects of cognitive functions relevant to SZ and BP|DISC1|DISC1|gene|44|NCBIGene:27185|SZ|SZ|disease|118|mesh:D012640
113|Accumulating genetic evidence supports that DISC1 is associated with  some aspects of cognitive functions relevant to SZ and BP|DISC1|DISC1|gene|44|NCBIGene:27185|BP|BP|disease|125|mesh:D006973
113|Accumulating genetic evidence supports that DISC1 is associated with  some aspects of cognitive functions relevant to SZ and BP|DISC1|DISC1|gene|44|NCBIGene:27185|Cognition|[|physiology|86|C0009240
113|Accumulating genetic evidence supports that DISC1 is associated with  some aspects of cognitive functions relevant to SZ and BP|SZ|SZ|disease|118|mesh:D012640|BP|BP|disease|125|mesh:D006973
113|Disrupted-In-Schizophrenia-1, preferentially expressed in the forebrain, has multiple isoforms with potential posttranslational modifications|Disrupted-In-Schizophrenia-1|Disrupted-In-Schizophrenia-1|gene|0|NCBIGene:27185|Prosencephalon|forebrain|anatomy|62|C0085140
113|Disrupted-In-Schizophrenia-1, preferentially expressed in the forebrain, has multiple isoforms with potential posttranslational modifications|Disrupted-In-Schizophrenia-1|Disrupted-In-Schizophrenia-1|gene|0|NCBIGene:27185|Post-Translational Protein Processing|posttranslational modifications|physiology|110|C0033666
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|Disrupted-In-Schizophrenia-1 protein|Disrupted-In-Schizophrenia-1 protein|gene|0|NCBIGene:27185|actin|actin|gene|159|NCBIGene:148709
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|Disrupted-In-Schizophrenia-1 protein|Disrupted-In-Schizophrenia-1 protein|gene|0|NCBIGene:27185|Cell Nucleus|nucleus|anatomy|215|C0007610
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|Disrupted-In-Schizophrenia-1 protein|Disrupted-In-Schizophrenia-1 protein|gene|0|NCBIGene:27185|Centrosome|centrosome|anatomy|100|C0242608
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|Disrupted-In-Schizophrenia-1 protein|Disrupted-In-Schizophrenia-1 protein|gene|0|NCBIGene:27185|Mitochondria|mitochondria|anatomy|193|C0026237
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|Disrupted-In-Schizophrenia-1 protein|Disrupted-In-Schizophrenia-1 protein|gene|0|NCBIGene:27185|Post-Synaptic Density|postsynaptic densities|anatomy|135|C1817671
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|Disrupted-In-Schizophrenia-1 protein|Disrupted-In-Schizophrenia-1 protein|gene|0|NCBIGene:27185|Microtubules|microtubule|anatomy|112|C0026046
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|Disrupted-In-Schizophrenia-1 protein|Disrupted-In-Schizophrenia-1 protein|gene|0|NCBIGene:27185|Cytoskeleton|cytoskeletal|anatomy|165|C0010853
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|actin|actin|gene|159|NCBIGene:148709|Cell Nucleus|nucleus|anatomy|215|C0007610
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|actin|actin|gene|159|NCBIGene:148709|Centrosome|centrosome|anatomy|100|C0242608
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|actin|actin|gene|159|NCBIGene:148709|Mitochondria|mitochondria|anatomy|193|C0026237
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|actin|actin|gene|159|NCBIGene:148709|Post-Synaptic Density|postsynaptic densities|anatomy|135|C1817671
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|actin|actin|gene|159|NCBIGene:148709|Microtubules|microtubule|anatomy|112|C0026046
113|Disrupted-In-Schizophrenia-1 protein occurs in multiple subcellular compartments, which include the centrosome, microtubule fractions, postsynaptic densities, actin cytoskeletal fractions, the mitochondria, and the nucleus|actin|actin|gene|159|NCBIGene:148709|Cytoskeleton|cytoskeletal|anatomy|165|C0010853
113|Recent studies have clarified that DISC1 mediates at least centrosome-dynein cascade and cyclic  adenosine monophosphate (cAMP) signaling|DISC1|DISC1|gene|35|NCBIGene:27185|dynein|dynein|gene|70|NCBIGene:1778
113|Recent studies have clarified that DISC1 mediates at least centrosome-dynein cascade and cyclic  adenosine monophosphate (cAMP) signaling|cyclic  adenosine monophosphate|cyclic  adenosine monophosphate|compound|89|mesh:D000242|DISC1|DISC1|gene|35|NCBIGene:27185
113|Recent studies have clarified that DISC1 mediates at least centrosome-dynein cascade and cyclic  adenosine monophosphate (cAMP) signaling|cAMP|cAMP|compound|122|mesh:D000242|DISC1|DISC1|gene|35|NCBIGene:27185
113|Recent studies have clarified that DISC1 mediates at least centrosome-dynein cascade and cyclic  adenosine monophosphate (cAMP) signaling|DISC1|DISC1|gene|35|NCBIGene:27185|Signal Transduction|signaling|physiology|128|C0037083
113|Recent studies have clarified that DISC1 mediates at least centrosome-dynein cascade and cyclic  adenosine monophosphate (cAMP) signaling|DISC1|DISC1|gene|35|NCBIGene:27185|dynein activity|dynein|physiology|70|C1622677
113|Recent studies have clarified that DISC1 mediates at least centrosome-dynein cascade and cyclic  adenosine monophosphate (cAMP) signaling|cyclic  adenosine monophosphate|cyclic  adenosine monophosphate|compound|89|mesh:D000242|dynein|dynein|gene|70|NCBIGene:1778
113|Recent studies have clarified that DISC1 mediates at least centrosome-dynein cascade and cyclic  adenosine monophosphate (cAMP) signaling|cAMP|cAMP|compound|122|mesh:D000242|dynein|dynein|gene|70|NCBIGene:1778
113|Recent studies have clarified that DISC1 mediates at least centrosome-dynein cascade and cyclic  adenosine monophosphate (cAMP) signaling|dynein|dynein|gene|70|NCBIGene:1778|Signal Transduction|signaling|physiology|128|C0037083
113|Furthermore, both cytogenetic and cell  biological studies consistently suggest that an overall loss of DISC1 function (either haploinsufficiency or dominant-negative, or both) may be associated with  SZ and BP|DISC1|DISC1|gene|104|NCBIGene:27185|haploinsufficiency|haploinsufficiency|disease|127|mesh:D030342
113|Furthermore, both cytogenetic and cell  biological studies consistently suggest that an overall loss of DISC1 function (either haploinsufficiency or dominant-negative, or both) may be associated with  SZ and BP|DISC1|DISC1|gene|104|NCBIGene:27185|SZ|SZ|disease|201|mesh:D012640
113|Furthermore, both cytogenetic and cell  biological studies consistently suggest that an overall loss of DISC1 function (either haploinsufficiency or dominant-negative, or both) may be associated with  SZ and BP|DISC1|DISC1|gene|104|NCBIGene:27185|BP|BP|disease|208|mesh:D006973
113|Furthermore, both cytogenetic and cell  biological studies consistently suggest that an overall loss of DISC1 function (either haploinsufficiency or dominant-negative, or both) may be associated with  SZ and BP|DISC1|DISC1|gene|104|NCBIGene:27185|Cells|cell|anatomy|34|C0007634
113|Furthermore, both cytogenetic and cell  biological studies consistently suggest that an overall loss of DISC1 function (either haploinsufficiency or dominant-negative, or both) may be associated with  SZ and BP|DISC1|DISC1|gene|104|NCBIGene:27185|Function Axis|function|physiology|110|C0700205
113|Furthermore, both cytogenetic and cell  biological studies consistently suggest that an overall loss of DISC1 function (either haploinsufficiency or dominant-negative, or both) may be associated with  SZ and BP|haploinsufficiency|haploinsufficiency|disease|127|mesh:D030342|SZ|SZ|disease|201|mesh:D012640
113|Furthermore, both cytogenetic and cell  biological studies consistently suggest that an overall loss of DISC1 function (either haploinsufficiency or dominant-negative, or both) may be associated with  SZ and BP|haploinsufficiency|haploinsufficiency|disease|127|mesh:D030342|BP|BP|disease|208|mesh:D006973
113|Furthermore, both cytogenetic and cell  biological studies consistently suggest that an overall loss of DISC1 function (either haploinsufficiency or dominant-negative, or both) may be associated with  SZ and BP|haploinsufficiency|haploinsufficiency|disease|127|mesh:D030342|Cells|cell|anatomy|34|C0007634
113|Furthermore, both cytogenetic and cell  biological studies consistently suggest that an overall loss of DISC1 function (either haploinsufficiency or dominant-negative, or both) may be associated with  SZ and BP|SZ|SZ|disease|201|mesh:D012640|BP|BP|disease|208|mesh:D006973
113|Furthermore, both cytogenetic and cell  biological studies consistently suggest that an overall loss of DISC1 function (either haploinsufficiency or dominant-negative, or both) may be associated with  SZ and BP|SZ|SZ|disease|201|mesh:D012640|Cells|cell|anatomy|34|C0007634
113|Furthermore, both cytogenetic and cell  biological studies consistently suggest that an overall loss of DISC1 function (either haploinsufficiency or dominant-negative, or both) may be associated with  SZ and BP|BP|BP|disease|208|mesh:D006973|Cells|cell|anatomy|34|C0007634
113|On the basis of these findings, production of DISC1 genetically engineered mice is proposed as a promising animal model for SZ and BP|DISC1|DISC1|gene|46|NCBIGene:27185|SZ|SZ|disease|124|mesh:D012640
113|On the basis of these findings, production of DISC1 genetically engineered mice is proposed as a promising animal model for SZ and BP|DISC1|DISC1|gene|46|NCBIGene:27185|BP|BP|disease|131|mesh:D006973
113|On the basis of these findings, production of DISC1 genetically engineered mice is proposed as a promising animal model for SZ and BP|DISC1|DISC1|gene|46|NCBIGene:27185|Procedure findings:Finding:Point in time:^Patient:Narrative|findings|physiology|22|C2926606
113|On the basis of these findings, production of DISC1 genetically engineered mice is proposed as a promising animal model for SZ and BP|SZ|SZ|disease|124|mesh:D012640|BP|BP|disease|131|mesh:D006973
115|Bax mediates cytochrome c release and apoptosis during neurodevelopment|Bax|Bax|gene|0|NCBIGene:581|cytochrome c|cytochrome c|gene|13|NCBIGene:54205
115|Bax mediates cytochrome c release and apoptosis during neurodevelopment|Bax|Bax|gene|0|NCBIGene:581|Apoptosis|apoptosis|physiology|38|C0162638
115|Bax mediates cytochrome c release and apoptosis during neurodevelopment|Bax|Bax|gene|0|NCBIGene:581|neurodevelopment|neurodevelopment|physiology|55|C0599855
115|Bax mediates cytochrome c release and apoptosis during neurodevelopment|cytochrome c|cytochrome c|gene|13|NCBIGene:54205|Apoptosis|apoptosis|physiology|38|C0162638
115|Bax mediates cytochrome c release and apoptosis during neurodevelopment|cytochrome c|cytochrome c|gene|13|NCBIGene:54205|neurodevelopment|neurodevelopment|physiology|55|C0599855
115|Brain mitochondria that were isolated from 8-day, 17-day, and adult rats displayed decreasing levels of mitochondrial Bax|mitochondrial Bax|mitochondrial Bax|gene|104|NCBIGene:581|Mitochondria|mitochondria|anatomy|6|C0026237
115|Brain mitochondria that were isolated from 8-day, 17-day, and adult rats displayed decreasing levels of mitochondrial Bax|mitochondrial Bax|mitochondrial Bax|gene|104|NCBIGene:581|Brain|Brain|anatomy|0|C0006104
115|The amount of cytochrome c released from  brain mitochondria by a peptide containing the BH3 cell death domain decreased with increasing age|cytochrome c|cytochrome c|gene|14|NCBIGene:54205|BH3 cell death domain|BH3 cell death domain|gene|89|NCBIGene:414899
115|The amount of cytochrome c released from  brain mitochondria by a peptide containing the BH3 cell death domain decreased with increasing age|cytochrome c|cytochrome c|gene|14|NCBIGene:54205|Age|age|physiology|137|C0001779
115|The amount of cytochrome c released from  brain mitochondria by a peptide containing the BH3 cell death domain decreased with increasing age|cytochrome c|cytochrome c|gene|14|NCBIGene:54205|Brain|brain|anatomy|42|C0006104
115|The amount of cytochrome c released from  brain mitochondria by a peptide containing the BH3 cell death domain decreased with increasing age|cytochrome c|cytochrome c|gene|14|NCBIGene:54205|Mitochondria|mitochondria|anatomy|48|C0026237
115|The amount of cytochrome c released from  brain mitochondria by a peptide containing the BH3 cell death domain decreased with increasing age|cytochrome c|cytochrome c|gene|14|NCBIGene:54205|Cell Death|cell death|physiology|93|C0007587
115|The amount of cytochrome c released from  brain mitochondria by a peptide containing the BH3 cell death domain decreased with increasing age|BH3 cell death domain|BH3 cell death domain|gene|89|NCBIGene:414899|Age|age|physiology|137|C0001779
115|The amount of cytochrome c released from  brain mitochondria by a peptide containing the BH3 cell death domain decreased with increasing age|BH3 cell death domain|BH3 cell death domain|gene|89|NCBIGene:414899|Brain|brain|anatomy|42|C0006104
115|The amount of cytochrome c released from  brain mitochondria by a peptide containing the BH3 cell death domain decreased with increasing age|BH3 cell death domain|BH3 cell death domain|gene|89|NCBIGene:414899|Mitochondria|mitochondria|anatomy|48|C0026237
115|The amount of cytochrome c released from  brain mitochondria by a peptide containing the BH3 cell death domain decreased with increasing age|BH3 cell death domain|BH3 cell death domain|gene|89|NCBIGene:414899|cytochrome c activity|cytochrome c|physiology|14|C1153524
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|BH3|BH3|compound|96|mesh:C006008|cytochrome c|cytochrome c|gene|30|NCBIGene:54205
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|cytochrome c|cytochrome c|gene|30|NCBIGene:54205|BH3 peptide|BH3 peptide|gene|96|NCBIGene:79680
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|cytochrome c|cytochrome c|gene|30|NCBIGene:54205|exogenous human recombinant Bax|exogenous human recombinant Bax|gene|127|NCBIGene:581
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|cytochrome c|cytochrome c|gene|30|NCBIGene:54205|Brain|brain|anatomy|52|C0006104
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|cytochrome c|cytochrome c|gene|30|NCBIGene:54205|Mitochondria|mitochondria|anatomy|58|C0026237
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|BH3|BH3|compound|96|mesh:C006008|exogenous human recombinant Bax|exogenous human recombinant Bax|gene|127|NCBIGene:581
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|BH3|BH3|compound|96|mesh:C006008|Brain|brain|anatomy|52|C0006104
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|BH3|BH3|compound|96|mesh:C006008|Mitochondria|mitochondria|anatomy|58|C0026237
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|BH3 peptide|BH3 peptide|gene|96|NCBIGene:79680|exogenous human recombinant Bax|exogenous human recombinant Bax|gene|127|NCBIGene:581
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|BH3 peptide|BH3 peptide|gene|96|NCBIGene:79680|Brain|brain|anatomy|52|C0006104
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|BH3 peptide|BH3 peptide|gene|96|NCBIGene:79680|Mitochondria|mitochondria|anatomy|58|C0026237
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|BH3 peptide|BH3 peptide|gene|96|NCBIGene:79680|cytochrome c activity|cytochrome c|physiology|30|C1153524
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|exogenous human recombinant Bax|exogenous human recombinant Bax|gene|127|NCBIGene:581|Brain|brain|anatomy|52|C0006104
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|exogenous human recombinant Bax|exogenous human recombinant Bax|gene|127|NCBIGene:581|Mitochondria|mitochondria|anatomy|58|C0026237
115|However, approximately 60% of cytochrome c in adult brain mitochondria could be released by the BH3 peptide in the presence of exogenous human recombinant Bax|exogenous human recombinant Bax|exogenous human recombinant Bax|gene|127|NCBIGene:581|cytochrome c activity|cytochrome c|physiology|30|C1153524
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|Mitochondrial Bax|Mitochondrial Bax|gene|0|NCBIGene:581|nerve growth factor|nerve growth factor|gene|79|NCBIGene:4803
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|Mitochondrial Bax|Mitochondrial Bax|gene|0|NCBIGene:581|BH3-peptide|BH3-peptide|gene|181|NCBIGene:79680
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|Mitochondrial Bax|Mitochondrial Bax|gene|0|NCBIGene:581|cytochrome|cytochrome|gene|201|NCBIGene:54205
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|Mitochondrial Bax|Mitochondrial Bax|gene|0|NCBIGene:581|Mitochondria|mitochondria|anatomy|104|C0026237
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|Mitochondrial Bax|Mitochondrial Bax|gene|0|NCBIGene:581|Neurons|neural cells|anatomy|45|C0027882
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|Mitochondrial Bax|Mitochondrial Bax|gene|0|NCBIGene:581|Cells|cells|anatomy|137|C0007634
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|nerve growth factor|nerve growth factor|gene|79|NCBIGene:4803|BH3-peptide|BH3-peptide|gene|181|NCBIGene:79680
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|nerve growth factor|nerve growth factor|gene|79|NCBIGene:4803|cytochrome|cytochrome|gene|201|NCBIGene:54205
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|nerve growth factor|nerve growth factor|gene|79|NCBIGene:4803|Mitochondria|mitochondria|anatomy|104|C0026237
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|nerve growth factor|nerve growth factor|gene|79|NCBIGene:4803|Mitochondria|Mitochondrial|anatomy|0|C0026237
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|nerve growth factor|nerve growth factor|gene|79|NCBIGene:4803|Neurons|neural cells|anatomy|45|C0027882
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|nerve growth factor|nerve growth factor|gene|79|NCBIGene:4803|Cells|cells|anatomy|137|C0007634
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|BH3-peptide|BH3-peptide|gene|181|NCBIGene:79680|cytochrome|cytochrome|gene|201|NCBIGene:54205
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|BH3-peptide|BH3-peptide|gene|181|NCBIGene:79680|Mitochondria|mitochondria|anatomy|104|C0026237
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|BH3-peptide|BH3-peptide|gene|181|NCBIGene:79680|Mitochondria|Mitochondrial|anatomy|0|C0026237
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|BH3-peptide|BH3-peptide|gene|181|NCBIGene:79680|Neurons|neural cells|anatomy|45|C0027882
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|BH3-peptide|BH3-peptide|gene|181|NCBIGene:79680|Cells|cells|anatomy|137|C0007634
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|cytochrome|cytochrome|gene|201|NCBIGene:54205|Mitochondria|mitochondria|anatomy|104|C0026237
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|cytochrome|cytochrome|gene|201|NCBIGene:54205|Mitochondria|Mitochondrial|anatomy|0|C0026237
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|cytochrome|cytochrome|gene|201|NCBIGene:54205|Neurons|neural cells|anatomy|45|C0027882
115|Mitochondrial Bax was downregulated in PC12S neural cells  differentiated with nerve growth factor, and mitochondria isolated from these cells demonstrated decreased sensitivity to BH3-peptide-induced cytochrome c release|cytochrome|cytochrome|gene|201|NCBIGene:54205|Cells|cells|anatomy|137|C0007634
115|These results demonstrate that immature brain mitochondria and mitochondria from undifferentiated neural cells are particularly sensitive to cytochrome c release mediated by endogenous Bax and a BH3 death domain peptide|cytochrome c|cytochrome c|gene|141|NCBIGene:54205|endogenous Bax|endogenous Bax|gene|174|NCBIGene:581
115|These results demonstrate that immature brain mitochondria and mitochondria from undifferentiated neural cells are particularly sensitive to cytochrome c release mediated by endogenous Bax and a BH3 death domain peptide|cytochrome c|cytochrome c|gene|141|NCBIGene:54205|BH3 death domain peptide|BH3 death domain peptide|gene|195|NCBIGene:637
115|These results demonstrate that immature brain mitochondria and mitochondria from undifferentiated neural cells are particularly sensitive to cytochrome c release mediated by endogenous Bax and a BH3 death domain peptide|cytochrome c|cytochrome c|gene|141|NCBIGene:54205|Brain|brain|anatomy|40|C0006104
115|These results demonstrate that immature brain mitochondria and mitochondria from undifferentiated neural cells are particularly sensitive to cytochrome c release mediated by endogenous Bax and a BH3 death domain peptide|cytochrome c|cytochrome c|gene|141|NCBIGene:54205|Neurons|neural cells|anatomy|98|C0027882
115|These results demonstrate that immature brain mitochondria and mitochondria from undifferentiated neural cells are particularly sensitive to cytochrome c release mediated by endogenous Bax and a BH3 death domain peptide|endogenous Bax|endogenous Bax|gene|174|NCBIGene:581|BH3 death domain peptide|BH3 death domain peptide|gene|195|NCBIGene:637
115|These results demonstrate that immature brain mitochondria and mitochondria from undifferentiated neural cells are particularly sensitive to cytochrome c release mediated by endogenous Bax and a BH3 death domain peptide|endogenous Bax|endogenous Bax|gene|174|NCBIGene:581|Brain|brain|anatomy|40|C0006104
115|These results demonstrate that immature brain mitochondria and mitochondria from undifferentiated neural cells are particularly sensitive to cytochrome c release mediated by endogenous Bax and a BH3 death domain peptide|endogenous Bax|endogenous Bax|gene|174|NCBIGene:581|cytochrome c activity|cytochrome c|physiology|141|C1153524
115|These results demonstrate that immature brain mitochondria and mitochondria from undifferentiated neural cells are particularly sensitive to cytochrome c release mediated by endogenous Bax and a BH3 death domain peptide|endogenous Bax|endogenous Bax|gene|174|NCBIGene:581|Neurons|neural cells|anatomy|98|C0027882
115|These results demonstrate that immature brain mitochondria and mitochondria from undifferentiated neural cells are particularly sensitive to cytochrome c release mediated by endogenous Bax and a BH3 death domain peptide|BH3 death domain peptide|BH3 death domain peptide|gene|195|NCBIGene:637|Brain|brain|anatomy|40|C0006104
115|These results demonstrate that immature brain mitochondria and mitochondria from undifferentiated neural cells are particularly sensitive to cytochrome c release mediated by endogenous Bax and a BH3 death domain peptide|BH3 death domain peptide|BH3 death domain peptide|gene|195|NCBIGene:637|cytochrome c activity|cytochrome c|physiology|141|C1153524
115|These results demonstrate that immature brain mitochondria and mitochondria from undifferentiated neural cells are particularly sensitive to cytochrome c release mediated by endogenous Bax and a BH3 death domain peptide|BH3 death domain peptide|BH3 death domain peptide|gene|195|NCBIGene:637|Neurons|neural cells|anatomy|98|C0027882
115|Postnatal developmental changes in mitochondrial Bax levels may contribute to the increased susceptibility of neurons to pathological apoptosis in immature animals|mitochondrial Bax|mitochondrial Bax|gene|35|NCBIGene:581|Apoptosis|apoptosis|physiology|134|C0162638
115|Postnatal developmental changes in mitochondrial Bax levels may contribute to the increased susceptibility of neurons to pathological apoptosis in immature animals|mitochondrial Bax|mitochondrial Bax|gene|35|NCBIGene:581|Biologic Development|developmental|physiology|10|C0678723
115|Postnatal developmental changes in mitochondrial Bax levels may contribute to the increased susceptibility of neurons to pathological apoptosis in immature animals|mitochondrial Bax|mitochondrial Bax|gene|35|NCBIGene:581|Disease susceptibility|susceptibility|physiology|92|C0012655
115|Postnatal developmental changes in mitochondrial Bax levels may contribute to the increased susceptibility of neurons to pathological apoptosis in immature animals|mitochondrial Bax|mitochondrial Bax|gene|35|NCBIGene:581|Neurons|neurons|anatomy|110|C0027882
115|Postnatal developmental changes in mitochondrial Bax levels may contribute to the increased susceptibility of neurons to pathological apoptosis in immature animals|mitochondrial Bax|mitochondrial Bax|gene|35|NCBIGene:581|immature animal|immature animals|physiology|147|C0596750
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|ortho|ortho|compound|0|mesh:C509516|PCBs|PCBs|compound|18|CHEBI:53156
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|ortho|ortho|compound|0|mesh:C509516|Ca2+|Ca2+|compound|32|CHEBI:29108
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|ortho|ortho|compound|0|mesh:C509516|FKBP12|FKBP12|gene|88|NCBIGene:2285
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|ortho|ortho|compound|0|mesh:C509516|RyR|RyR|gene|95|NCBIGene:6261
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|ortho|ortho|compound|0|mesh:C509516|Microsomes|microsomes|anatomy|57|C0026029
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|ortho|ortho|compound|0|mesh:C509516|ryanodine receptor complex location|RyR|anatomy|95|C3890160
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|ortho|ortho|compound|0|mesh:C509516|Brain|brain|anatomy|51|C0006104
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|PCBs|PCBs|compound|18|CHEBI:53156|Ca2+|Ca2+|compound|32|CHEBI:29108
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|PCBs|PCBs|compound|18|CHEBI:53156|FKBP12|FKBP12|gene|88|NCBIGene:2285
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|PCBs|PCBs|compound|18|CHEBI:53156|RyR|RyR|gene|95|NCBIGene:6261
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|PCBs|PCBs|compound|18|CHEBI:53156|Microsomes|microsomes|anatomy|57|C0026029
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|PCBs|PCBs|compound|18|CHEBI:53156|ryanodine receptor complex location|RyR|anatomy|95|C3890160
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|PCBs|PCBs|compound|18|CHEBI:53156|Brain|brain|anatomy|51|C0006104
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|Ca2+|Ca2+|compound|32|CHEBI:29108|FKBP12|FKBP12|gene|88|NCBIGene:2285
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|Ca2+|Ca2+|compound|32|CHEBI:29108|RyR|RyR|gene|95|NCBIGene:6261
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|Ca2+|Ca2+|compound|32|CHEBI:29108|Microsomes|microsomes|anatomy|57|C0026029
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|Ca2+|Ca2+|compound|32|CHEBI:29108|ryanodine receptor complex location|RyR|anatomy|95|C3890160
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|Ca2+|Ca2+|compound|32|CHEBI:29108|Brain|brain|anatomy|51|C0006104
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|FKBP12|FKBP12|gene|88|NCBIGene:2285|RyR|RyR|gene|95|NCBIGene:6261
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|FKBP12|FKBP12|gene|88|NCBIGene:2285|Microsomes|microsomes|anatomy|57|C0026029
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|FKBP12|FKBP12|gene|88|NCBIGene:2285|ryanodine receptor complex location|RyR|anatomy|95|C3890160
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|FKBP12|FKBP12|gene|88|NCBIGene:2285|Brain|brain|anatomy|51|C0006104
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|RyR|RyR|gene|95|NCBIGene:6261|Microsomes|microsomes|anatomy|57|C0026029
116|ortho-Substituted PCBs mobilize Ca2+ from isolated brain microsomes by interaction with FKBP12/RyR complexes|RyR|RyR|gene|95|NCBIGene:6261|Brain|brain|anatomy|51|C0006104
116|Investigation into the cellular importance of this mechanism was undertaken using PC12 cells by fluoroimaging the actions of specific PCB congeners on [Ca2+]i and pH|PCB|PCB|compound|134|CHEBI:47136|Ca2+|Ca2+|compound|152|CHEBI:29108
116|Investigation into the cellular importance of this mechanism was undertaken using PC12 cells by fluoroimaging the actions of specific PCB congeners on [Ca2+]i and pH|PCB|PCB|compound|134|CHEBI:47136|PC12 Cells|PC12 cells|anatomy|82|C0085262
116|Investigation into the cellular importance of this mechanism was undertaken using PC12 cells by fluoroimaging the actions of specific PCB congeners on [Ca2+]i and pH|Ca2+|Ca2+|compound|152|CHEBI:29108|PC12 Cells|PC12 cells|anatomy|82|C0085262
116|RyR and IP3R share a common intracellular Ca2+ store in PC12 cells|RyR|RyR|gene|0|NCBIGene:6261|IP3R|IP3R|gene|8|NCBIGene:3710
116|RyR and IP3R share a common intracellular Ca2+ store in PC12 cells|Ca2+|Ca2+|compound|42|CHEBI:29108|RyR|RyR|gene|0|NCBIGene:6261
116|RyR and IP3R share a common intracellular Ca2+ store in PC12 cells|RyR|RyR|gene|0|NCBIGene:6261|PC12 Cells|PC12 cells|anatomy|56|C0085262
116|RyR and IP3R share a common intracellular Ca2+ store in PC12 cells|RyR|RyR|gene|0|NCBIGene:6261|Protoplasm|intracellular|anatomy|28|C0175996
116|RyR and IP3R share a common intracellular Ca2+ store in PC12 cells|Ca2+|Ca2+|compound|42|CHEBI:29108|IP3R|IP3R|gene|8|NCBIGene:3710
116|RyR and IP3R share a common intracellular Ca2+ store in PC12 cells|IP3R|IP3R|gene|8|NCBIGene:3710|ryanodine receptor complex location|RyR|anatomy|0|C3890160
116|RyR and IP3R share a common intracellular Ca2+ store in PC12 cells|IP3R|IP3R|gene|8|NCBIGene:3710|PC12 Cells|PC12 cells|anatomy|56|C0085262
116|RyR and IP3R share a common intracellular Ca2+ store in PC12 cells|IP3R|IP3R|gene|8|NCBIGene:3710|Protoplasm|intracellular|anatomy|28|C0175996
116|RyR and IP3R share a common intracellular Ca2+ store in PC12 cells|Ca2+|Ca2+|compound|42|CHEBI:29108|ryanodine receptor complex location|RyR|anatomy|0|C3890160
116|RyR and IP3R share a common intracellular Ca2+ store in PC12 cells|Ca2+|Ca2+|compound|42|CHEBI:29108|PC12 Cells|PC12 cells|anatomy|56|C0085262
116|RyR and IP3R share a common intracellular Ca2+ store in PC12 cells|Ca2+|Ca2+|compound|42|CHEBI:29108|Protoplasm|intracellular|anatomy|28|C0175996
116|Perfusion of nM to low microM PCB95 caused a transient rise of [Ca2+]i that was not completely dependent on extracellular Ca2+|PCB95|PCB95|compound|30|mesh:C032904|Ca2+|Ca2+|compound|64|CHEBI:29108
116|Perfusion of nM to low microM PCB95 caused a transient rise of [Ca2+]i that was not completely dependent on extracellular Ca2+|PCB95|PCB95|compound|30|mesh:C032904|Ca2+|Ca2+|compound|122|CHEBI:29108
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|ryanodine|ryanodine|compound|33|mesh:D012433|FK506|FK506|compound|46|mesh:D016559
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|ryanodine|ryanodine|compound|33|mesh:D012433|PCB95|PCB95|compound|74|mesh:C032904
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|ryanodine|ryanodine|compound|33|mesh:D012433|FKPP12|FKPP12|gene|126|NCBIGene:2301
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|ryanodine|ryanodine|compound|33|mesh:D012433|RyR|RyR|gene|133|NCBIGene:6261
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|FK506|FK506|compound|46|mesh:D016559|PCB95|PCB95|compound|74|mesh:C032904
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|FK506|FK506|compound|46|mesh:D016559|FKPP12|FKPP12|gene|126|NCBIGene:2301
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|FK506|FK506|compound|46|mesh:D016559|RyR|RyR|gene|133|NCBIGene:6261
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|PCB95|PCB95|compound|74|mesh:C032904|FKPP12|FKPP12|gene|126|NCBIGene:2301
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|PCB95|PCB95|compound|74|mesh:C032904|RyR|RyR|gene|133|NCBIGene:6261
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|FKPP12|FKPP12|gene|126|NCBIGene:2301|RyR|RyR|gene|133|NCBIGene:6261
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|FKPP12|FKPP12|gene|126|NCBIGene:2301|Response process|responses|physiology|80|C0871261
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|FKPP12|FKPP12|gene|126|NCBIGene:2301|photoreactivating enzyme activity|Pre|physiology|0|C2257086
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|RyR|RyR|gene|133|NCBIGene:6261|Response process|responses|physiology|80|C0871261
116|Pre-incubation of the cells with ryanodine or FK506 completely eliminated PCB95 responses, suggesting a primary action on the FKPP12/RyR-sensitive store|RyR|RyR|gene|133|NCBIGene:6261|photoreactivating enzyme activity|Pre|physiology|0|C2257086
116|PCB95, but not PCB126, induced a gradual decrease in  cytosolic pH that could be completely eliminated by FK506 pre-incubation of the cells|PCB95|PCB95|compound|0|mesh:C032904|PCB126|PCB126|compound|15|mesh:C023035
116|PCB95, but not PCB126, induced a gradual decrease in  cytosolic pH that could be completely eliminated by FK506 pre-incubation of the cells|PCB95|PCB95|compound|0|mesh:C032904|FK506|FK506|compound|106|mesh:D016559
116|PCB95, but not PCB126, induced a gradual decrease in  cytosolic pH that could be completely eliminated by FK506 pre-incubation of the cells|PCB95|PCB95|compound|0|mesh:C032904|Cells|cells|anatomy|134|C0007634
116|PCB95, but not PCB126, induced a gradual decrease in  cytosolic pH that could be completely eliminated by FK506 pre-incubation of the cells|PCB126|PCB126|compound|15|mesh:C023035|FK506|FK506|compound|106|mesh:D016559
116|PCB95, but not PCB126, induced a gradual decrease in  cytosolic pH that could be completely eliminated by FK506 pre-incubation of the cells|PCB126|PCB126|compound|15|mesh:C023035|Cells|cells|anatomy|134|C0007634
116|PCB95, but not PCB126, induced a gradual decrease in  cytosolic pH that could be completely eliminated by FK506 pre-incubation of the cells|FK506|FK506|compound|106|mesh:D016559|Cells|cells|anatomy|134|C0007634
116|Direct respiration measurement using isolated brain mitochondria demonstrated that neither of the PCBs directly altered any stage of mitochondrial respiration|PCBs|PCBs|compound|98|CHEBI:53156|Mitochondria|mitochondria|anatomy|52|C0026237
116|Direct respiration measurement using isolated brain mitochondria demonstrated that neither of the PCBs directly altered any stage of mitochondrial respiration|PCBs|PCBs|compound|98|CHEBI:53156|Mitochondria|mitochondrial|anatomy|133|C0026237
116|Direct respiration measurement using isolated brain mitochondria demonstrated that neither of the PCBs directly altered any stage of mitochondrial respiration|PCBs|PCBs|compound|98|CHEBI:53156|Brain|brain|anatomy|46|C0006104
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|PCB95|PCB95|compound|28|mesh:C032904|Ca2+|Ca2+|compound|57|CHEBI:29108
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|PCB95|PCB95|compound|28|mesh:C032904|FKBP12|FKBP12|gene|110|NCBIGene:2285
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|PCB95|PCB95|compound|28|mesh:C032904|RyR|RyR|gene|117|NCBIGene:6261
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|PCB95|PCB95|compound|28|mesh:C032904|Mitochondria|mitochondria|anatomy|219|C0026237
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|Ca2+|Ca2+|compound|57|CHEBI:29108|FKBP12|FKBP12|gene|110|NCBIGene:2285
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|Ca2+|Ca2+|compound|57|CHEBI:29108|RyR|RyR|gene|117|NCBIGene:6261
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|Ca2+|Ca2+|compound|57|CHEBI:29108|Mitochondria|mitochondria|anatomy|219|C0026237
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|FKBP12|FKBP12|gene|110|NCBIGene:2285|RyR|RyR|gene|117|NCBIGene:6261
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|FKBP12|FKBP12|gene|110|NCBIGene:2285|Metabolic Process, Cellular|cellular metabolism|physiology|154|C1524026
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|FKBP12|FKBP12|gene|110|NCBIGene:2285|Mitochondria|mitochondria|anatomy|219|C0026237
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|FKBP12|FKBP12|gene|110|NCBIGene:2285|Signal Transduction|signaling|physiology|194|C0037083
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|RyR|RyR|gene|117|NCBIGene:6261|Metabolic Process, Cellular|cellular metabolism|physiology|154|C1524026
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|RyR|RyR|gene|117|NCBIGene:6261|Mitochondria|mitochondria|anatomy|219|C0026237
116|These results revealed that PCB95 disrupts intracellular Ca2+ signaling in PC12 cells by interaction with the FKBP12/RyR complex that in turn accelerated cellular metabolism, possibly affecting signaling between ER and mitochondria|RyR|RyR|gene|117|NCBIGene:6261|Signal Transduction|signaling|physiology|194|C0037083
116|Since ortho-substituted PCBs have been shown to be neurotoxic and may affect neurodevelopment, studies on the molecular mechanism by which they alter cellular signaling may provide valuable information on the physiological roles of FKPB12 and RyR on neuronal functions|ortho-substituted PCBs|ortho-substituted PCBs|compound|6|mesh:D011078|FKPB12|FKPB12|gene|232|NCBIGene:2301
116|Since ortho-substituted PCBs have been shown to be neurotoxic and may affect neurodevelopment, studies on the molecular mechanism by which they alter cellular signaling may provide valuable information on the physiological roles of FKPB12 and RyR on neuronal functions|ortho-substituted PCBs|ortho-substituted PCBs|compound|6|mesh:D011078|RyR|RyR|gene|243|NCBIGene:6261
116|Since ortho-substituted PCBs have been shown to be neurotoxic and may affect neurodevelopment, studies on the molecular mechanism by which they alter cellular signaling may provide valuable information on the physiological roles of FKPB12 and RyR on neuronal functions|ortho-substituted PCBs|ortho-substituted PCBs|compound|6|mesh:D011078|ryanodine receptor complex location|RyR|anatomy|243|C3890160
116|Since ortho-substituted PCBs have been shown to be neurotoxic and may affect neurodevelopment, studies on the molecular mechanism by which they alter cellular signaling may provide valuable information on the physiological roles of FKPB12 and RyR on neuronal functions|FKPB12|FKPB12|gene|232|NCBIGene:2301|RyR|RyR|gene|243|NCBIGene:6261
116|Since ortho-substituted PCBs have been shown to be neurotoxic and may affect neurodevelopment, studies on the molecular mechanism by which they alter cellular signaling may provide valuable information on the physiological roles of FKPB12 and RyR on neuronal functions|FKPB12|FKPB12|gene|232|NCBIGene:2301|Affect (mental function)|affect|physiology|70|C0001721
116|Since ortho-substituted PCBs have been shown to be neurotoxic and may affect neurodevelopment, studies on the molecular mechanism by which they alter cellular signaling may provide valuable information on the physiological roles of FKPB12 and RyR on neuronal functions|FKPB12|FKPB12|gene|232|NCBIGene:2301|Cellular signal transduction|cellular signaling|physiology|150|C3825288
116|Since ortho-substituted PCBs have been shown to be neurotoxic and may affect neurodevelopment, studies on the molecular mechanism by which they alter cellular signaling may provide valuable information on the physiological roles of FKPB12 and RyR on neuronal functions|FKPB12|FKPB12|gene|232|NCBIGene:2301|neurodevelopment|neurodevelopment|physiology|77|C0599855
116|Since ortho-substituted PCBs have been shown to be neurotoxic and may affect neurodevelopment, studies on the molecular mechanism by which they alter cellular signaling may provide valuable information on the physiological roles of FKPB12 and RyR on neuronal functions|FKPB12|FKPB12|gene|232|NCBIGene:2301|ryanodine receptor complex location|RyR|anatomy|243|C3890160
116|Since ortho-substituted PCBs have been shown to be neurotoxic and may affect neurodevelopment, studies on the molecular mechanism by which they alter cellular signaling may provide valuable information on the physiological roles of FKPB12 and RyR on neuronal functions|RyR|RyR|gene|243|NCBIGene:6261|Affect (mental function)|affect|physiology|70|C0001721
116|Since ortho-substituted PCBs have been shown to be neurotoxic and may affect neurodevelopment, studies on the molecular mechanism by which they alter cellular signaling may provide valuable information on the physiological roles of FKPB12 and RyR on neuronal functions|RyR|RyR|gene|243|NCBIGene:6261|Cellular signal transduction|cellular signaling|physiology|150|C3825288
116|Since ortho-substituted PCBs have been shown to be neurotoxic and may affect neurodevelopment, studies on the molecular mechanism by which they alter cellular signaling may provide valuable information on the physiological roles of FKPB12 and RyR on neuronal functions|RyR|RyR|gene|243|NCBIGene:6261|neurodevelopment|neurodevelopment|physiology|77|C0599855
